,0
halflife,67.64214046822742
cmax,62.87625418060201
eliminationhalflife,58.61204013377927
t12,58.36120401337793
tmax,57.859531772575245
clearance,52.59197324414716
bioavailability,52.4247491638796
auc,48.66220735785953
flowrate,46.23745819397993
volumeofdistribution,43.64548494983278
terminalhalflife,42.97658862876254
absolutebioavailability,37.37458193979933
halflive,34.86622073578595
oralbioavailability,34.86622073578595
recovery,31.93979933110368
ic50,31.187290969899667
peakplasmaconcentration,31.103678929765888
relativebioavailability,31.103678929765888
totalbodyclearance,29.180602006688964
eliminationhalflive,29.180602006688964
plasmaclearance,29.180602006688964
recoverie,28.428093645484946
plasmahalflife,28.093645484949832
apparentvolumeofdistribution,27.926421404682273
renalclearance,27.842809364548494
terminaleliminationhalflife,26.672240802675585
totalclearance,25.668896321070235
peakconcentration,25.585284280936456
cl,24.83277591973244
maximumconcentration,24.16387959866221
t12beta,23.494983277591974
mz,23.411371237458194
plasmaconcentration,23.327759197324415
auc0infinity,22.909698996655518
concentration,22.909698996655518
maximumplasmaconcentration,22.5752508361204
retentiontime,22.49163879598662
auc0t,22.40802675585284
eliminationhalflifet12,22.32441471571906
ki,21.48829431438127
meanresidencetime,21.48829431438127
halflifet12,21.40468227424749
areaunderthecurve,21.070234113712374
volumeofdistributionatsteadystate,20.986622073578594
systemicclearance,20.735785953177256
auc0,20.317725752508363
detectionlimit,20.234113712374583
areaunderthecurveauc,20.150501672240804
clf,20.066889632107024
runtime,19.732441471571907
vd,19.565217391304348
m,19.230769230769234
limitofdetection,19.230769230769234
ec50,19.147157190635454
oralclearance,18.729096989966553
maximumplasmaconcentrationcmax,18.645484949832774
totalruntime,18.561872909698995
steadystatevolumeofdistribution,17.05685618729097
auc024,16.387959866220736
totalplasmaclearance,15.802675585284282
urinaryexcretion,15.468227424749164
aucratio,15.301003344481606
km,15.217391304347828
extractionrecovery,15.050167224080269
t12alpha,14.96655518394649
ed50,14.79933110367893
plasmaproteinbinding,14.715719063545151
mrt,14.715719063545151
terminalhalflive,14.464882943143811
clearancecl,14.297658862876252
extractionrecoverie,14.297658862876252
maximumconcentrationcmax,13.795986622073578
plasmaeliminationhalflife,13.628762541806019
v,13.54515050167224
proteinbinding,13.461538461538462
zetapotential,13.043478260869565
areaundertheplasmaconcentrationtimecurve,12.792642140468228
apparentclearance,12.709030100334449
apparentoralclearance,12.62541806020067
troughconcentration,12.45819397993311
steadystateplasmaconcentration,12.37458193979933
meanresidencetimemrt,12.207357859531772
peaklevel,12.207357859531772
ka,12.123745819397994
steadystateconcentration,12.040133779264215
peak,11.956521739130435
f,11.872909698996656
peakplasmalevel,11.789297658862877
peakplasmaconcentrationcmax,11.705685618729097
lagtime,11.454849498327759
peakserumconcentration,11.454849498327759
distributionvolume,11.454849498327759
auc024h,11.37123745819398
vmax,11.2876254180602
eliminationrateconstant,11.20401337792642
areaundertheconcentrationtimecurve,11.120401337792641
mtd,10.451505016722408
areaundertheplasmaconcentrationtimecurveauc,10.367892976588628
areaundertheconcentrationtimecurveauc,10.28428093645485
distributionhalflife,10.200668896321071
systemicavailability,10.117056856187292
absorptionrateconstant,9.949832775919733
eliminationt12,9.949832775919733
excretion,9.866220735785953
absoluteoralbioavailability,9.782608695652174
cmin,9.782608695652174
clearancerate,9.782608695652174
apparenteliminationhalflife,9.698996655518394
emax,9.698996655518394
serumhalflife,9.615384615384617
biologicalhalflife,9.531772575250837
accumulationratio,9.364548494983277
terminalhalflifet12,9.364548494983277
bioavailabilitie,9.280936454849497
maximalplasmaconcentration,9.280936454849497
entrapmentefficiency,9.280936454849497
auc012,9.280936454849497
eliminationhalflifet12beta,9.197324414715718
troughlevel,8.946488294314381
volumeofdistributionvd,8.862876254180602
timetomaximumconcentration,8.862876254180602
peakconcentrationcmax,8.862876254180602
apparenthalflife,8.779264214046822
absoluterecovery,8.779264214046822
limitsofdetection,8.528428093645484
signaltonoiseratio,8.444816053511705
maximumtolerateddose,8.444816053511705
absorptionhalflife,8.444816053511705
aucinf,8.361204013377927
time,8.361204013377927
volumesofdistribution,8.277591973244148
maximalconcentration,8.193979933110368
plasma,8.110367892976589
v1,8.02675585284281
maximumserumconcentration,7.94314381270903
ratio,7.859531772575251
overallresponserate,7.859531772575251
timetocmaxtmax,7.775919732441472
t12z,7.775919732441472
halftime,7.775919732441472
serumconcentration,7.775919732441472
urinaryrecovery,7.6923076923076925
timetopeakconcentration,7.608695652173914
halflifeofelimination,7.608695652173914
systemicbioavailability,7.5250836120401345
trough,7.441471571906355
terminalt12,7.357859531772576
terminaleliminationhalflive,7.274247491638795
unboundfraction,7.274247491638795
plasmalevel,7.274247491638795
absorption,7.274247491638795
distribution,7.190635451505016
c,6.9397993311036785
vf,6.9397993311036785
vc,6.9397993311036785
auc0inf,6.856187290969899
apparentclearanceclf,6.856187290969899
plasmahalflive,6.856187290969899
v2,6.688963210702341
relativebioavailabilitie,6.688963210702341
terminalphasehalflife,6.605351170568562
totalchromatographicruntime,6.605351170568562
clr,6.605351170568562
progressionfreesurvival,6.605351170568562
overallsurvival,6.605351170568562
auclast,6.521739130434782
extractionratio,6.438127090301003
centralvolumeofdistribution,6.438127090301003
polydispersityindex,6.270903010033445
timetomaximumplasmaconcentration,6.270903010033445
solubility,6.270903010033445
maximumplasmaconcentrationscmax,6.270903010033445
freefraction,6.270903010033445
responserate,6.187290969899665
apparentvolumesofdistribution,6.187290969899665
binding,6.187290969899665
timetoreachcmaxtmax,6.103678929765886
timetocmax,6.103678929765886
vdf,6.103678929765886
timetomaximumconcentrationtmax,6.103678929765886
limitofdetectionlod,6.0200668896321075
sensitivity,6.0200668896321075
rateconstant,6.0200668896321075
plasmat12,6.0200668896321075
lod,5.936454849498328
alpha,5.936454849498328
total,5.936454849498328
heartrate,5.852842809364549
volumeofthecentralcompartment,5.769230769230769
absoluterecoverie,5.769230769230769
kel,5.769230769230769
plasmaauc,5.68561872909699
loq,5.68561872909699
concentrationratio,5.68561872909699
timetopeakplasmaconcentration,5.68561872909699
k,5.60200668896321
extractionefficiency,5.60200668896321
timetopeak,5.60200668896321
peakplasmaconcentrationscmax,5.518394648829431
bioavailabilityf,5.518394648829431
terminaleliminationhalflifet12,5.518394648829431
maximum,5.434782608695652
kd,5.434782608695652
pf,5.434782608695652
ee,5.434782608695652
volumeofdistributionatsteadystatevss,5.434782608695652
intercompartmentalclearance,5.2675585284280935
totalbodyclearancecl,5.2675585284280935
auc012h,5.183946488294314
peaktime,5.183946488294314
renalclearanceclr,5.183946488294314
nonrenalclearance,5.183946488294314
,5.1003344481605355
plasmacmax,5.1003344481605355
peakserumlevel,5.1003344481605355
timetoprogression,5.1003344481605355
ctrough,5.1003344481605355
terminalplasmahalflife,5.1003344481605355
ke,5.1003344481605355
absorptionrateconstantka,5.016722408026756
apparentoralclearanceclf,5.016722408026756
bodyclearance,4.933110367892977
metabolicclearancerate,4.933110367892977
survival,4.933110367892977
o,4.933110367892977
metabolicclearance,4.849498327759197
metabolicratio,4.765886287625419
volumeofdistributionv,4.765886287625419
oralclearanceclf,4.765886287625419
t12el,4.765886287625419
volumeofdistributionatsteadystatevdss,4.765886287625419
clearanceclf,4.682274247491638
beta,4.682274247491638
t12b,4.598662207357859
limitofquantification,4.598662207357859
objectiveresponserate,4.598662207357859
elimination,4.598662207357859
volumeofdistributionvss,4.51505016722408
exposure,4.51505016722408
absolutebioavailabilitie,4.431438127090301
totalvolumeofdistribution,4.431438127090301
peakvalue,4.431438127090301
cltot,4.3478260869565215
initial,4.3478260869565215
mic,4.3478260869565215
rate,4.3478260869565215
intrinsicclearance,4.264214046822742
renalexcretion,4.264214046822742
hepaticextractionratio,4.264214046822742
apparentvolumeofdistributionatsteadystate,4.264214046822742
particlesize,4.264214046822742
auct,4.1806020066889635
survivaltime,4.1806020066889635
steadystate,4.1806020066889635
k21,4.1806020066889635
c0,4.1806020066889635
apparentvolumeofdistributionvd,4.1806020066889635
plasmaclearancecl,4.1806020066889635
peripheralvolumeofdistribution,4.096989966555184
maximumconcentrationscmax,4.096989966555184
aucinfinity,4.096989966555184
cumulativeurinaryexcretion,4.096989966555184
steadystatevolumeofdistributionvss,4.096989966555184
steadystatelevel,4.096989966555184
plasmahalflifet12,4.096989966555184
auc048,4.096989966555184
renal,4.013377926421405
recoveryrate,4.013377926421405
troughplasmaconcentration,4.013377926421405
maximumtolerateddosemtd,4.013377926421405
sn,4.013377926421405
t,4.013377926421405
duration,4.013377926421405
apparentterminalhalflife,4.013377926421405
bloodclearance,3.9297658862876257
hepaticclearance,3.9297658862876257
meanabsorptiontime,3.9297658862876257
serumeliminationhalflife,3.9297658862876257
ld50,3.9297658862876257
bioavailable,3.8461538461538463
encapsulationefficiency,3.8461538461538463
cssmax,3.8461538461538463
q,3.8461538461538463
k12,3.8461538461538463
minimumconcentration,3.8461538461538463
maximalplasmaconcentrationcmax,3.7625418060200673
auc08,3.7625418060200673
maximal,3.7625418060200673
eliminationclearance,3.7625418060200673
kinact,3.7625418060200673
absolutebioavailabilityf,3.7625418060200673
relativeoralbioavailability,3.678929765886288
apparentdistributionvolume,3.678929765886288
t12gamma,3.678929765886288
progressionfreesurvivalpfs,3.678929765886288
mcr,3.678929765886288
infusionrate,3.678929765886288
limitofquantificationloq,3.595317725752508
durationofresponse,3.595317725752508
absorptionlagtime,3.595317725752508
halflifetime,3.511705685618729
t12a,3.511705685618729
betahalflife,3.511705685618729
initialhalflife,3.511705685618729
halflivest12,3.511705685618729
auc06,3.511705685618729
durationofaction,3.511705685618729
steadystateplasmalevel,3.511705685618729
oralbioavailabilityf,3.511705685618729
auc08h,3.511705685618729
auc0last,3.4280936454849495
biliaryexcretion,3.4280936454849495
auc06h,3.4280936454849495
maximumserumconcentrationcmax,3.4280936454849495
maximumlevel,3.4280936454849495
vdss,3.4280936454849495
inhibitionconstant,3.4280936454849495
areasunderthecurve,3.4280936454849495
fraction,3.3444816053511706
v3,3.3444816053511706
vdbeta,3.3444816053511706
timetomaximumplasmaconcentrationtmax,3.3444816053511706
vdarea,3.3444816053511706
serumclearance,3.260869565217391
central,3.260869565217391
totalplasmaclearancecl,3.260869565217391
clb,3.260869565217391
clt,3.260869565217391
hepaticextraction,3.260869565217391
50inhibitoryconcentration,3.260869565217391
timetoreachcmax,3.260869565217391
auctau,3.177257525083612
ch,3.177257525083612
formationclearance,3.177257525083612
p,3.177257525083612
apparentvolumeofdistributionvf,3.177257525083612
volume,3.0936454849498327
vss,3.0936454849498327
clint,3.0936454849498327
maximumplasmalevel,3.0936454849498327
systemicplasmaclearance,3.0936454849498327
flux,3.0936454849498327
absorptionrate,3.0936454849498327
maximalconcentrationcmax,3.0936454849498327
plasmaeliminationhalflive,3.0936454849498327
inhibitionconstantki,3.0100334448160537
timetopeakconcentrationtmax,3.0100334448160537
distributionhalflifet12alpha,3.0100334448160537
accumulationfactor,3.0100334448160537
apparentki,3.0100334448160537
timetoreachmaximumconcentrationtmax,3.0100334448160537
durationof,2.9264214046822743
totalauc,2.9264214046822743
areaundertheplasmaconcentrationtimecurveauc0infinity,2.9264214046822743
apparentt12,2.9264214046822743
apparentplasmaclearance,2.9264214046822743
areaundertheconcentrationversustimecurveauc,2.9264214046822743
pdi,2.9264214046822743
gamma,2.9264214046822743
drug,2.9264214046822743
brainplasmaratio,2.842809364548495
auc24,2.842809364548495
peakconcentrationscmax,2.842809364548495
50inhibitoryconcentrationic50,2.842809364548495
pka,2.842809364548495
totalrecovery,2.842809364548495
analyticalrecovery,2.7591973244147154
maximuminhibition,2.7591973244147154
plasmaeliminationhalflifet12,2.7591973244147154
effectivehalflife,2.7591973244147154
matrixeffect,2.7591973244147154
areaundertheplasmaconcentrationversustimecurveauc,2.7591973244147154
totalanalysistime,2.7591973244147154
analysistime,2.7591973244147154
specificactivity,2.7591973244147154
diseasecontrolrate,2.7591973244147154
steadystateserumconcentration,2.7591973244147154
cl1,2.6755852842809364
totalclearancecl,2.6755852842809364
hillcoefficient,2.6755852842809364
eliminationhalftime,2.6755852842809364
biologicalhalflive,2.6755852842809364
permeability,2.6755852842809364
releaserate,2.6755852842809364
penetration,2.6755852842809364
volumeofdistributionofthecentralcompartment,2.6755852842809364
eliminationhalflifet12b,2.6755852842809364
oralavailability,2.6755852842809364
serumproteinbinding,2.6755852842809364
polydispersityindexpdi,2.6755852842809364
timetoreachpeakconcentration,2.591973244147157
timetoreachmaximumconcentration,2.591973244147157
responseduration,2.591973244147157
volumeofdistributionvf,2.591973244147157
totalsystemicclearance,2.591973244147157
cmaxratio,2.591973244147157
area,2.591973244147157
occupancy,2.591973244147157
rsratio,2.508361204013378
k10,2.508361204013378
apparenttotalbodyclearance,2.508361204013378
urinary,2.508361204013378
cl2,2.508361204013378
en,2.508361204013378
constantflowrate,2.508361204013378
meanplasmaconcentration,2.508361204013378
apparenteliminationhalflifet12,2.508361204013378
areaundertheplasmaconcentrationversustimecurve,2.508361204013378
availability,2.508361204013378
overallresponserateorr,2.508361204013378
onsettime,2.508361204013378
halfmaximalinhibitoryconcentration,2.508361204013378
auc04h,2.508361204013378
intercompartmentalclearanceq,2.508361204013378
overallrecovery,2.4247491638795986
maximumdose,2.4247491638795986
effluxratio,2.4247491638795986
tlag,2.4247491638795986
timetoreachmaximumplasmaconcentration,2.4247491638795986
plasmaclearanceclp,2.4247491638795986
dose,2.4247491638795986
clcr,2.4247491638795986
in,2.4247491638795986
apparentbioavailability,2.4247491638795986
biologichalflife,2.4247491638795986
volumeofdistributionvdf,2.4247491638795986
totalplasmaconcentration,2.4247491638795986
areaunderthecurveratio,2.4247491638795986
apparentvolumeofdistributionvdf,2.4247491638795986
alphahalflife,2.4247491638795986
globulesize,2.4247491638795986
overallsurvivalos,2.4247491638795986
vz,2.341137123745819
relativerecovery,2.341137123745819
cumulativeexcretion,2.341137123745819
drugloading,2.341137123745819
oralplasmaclearance,2.341137123745819
urinaryrecoverie,2.341137123745819
systemicclearancecl,2.341137123745819
eliminationrateconstantkel,2.341137123745819
areaunderthecurveauc0,2.341137123745819
id50,2.341137123745819
cav,2.341137123745819
betaphasehalflife,2.341137123745819
plasmapeakconcentration,2.341137123745819
relativerecoverie,2.341137123745819
t12lz,2.25752508361204
cv,2.25752508361204
intercompartmentclearance,2.25752508361204
apparentkm,2.25752508361204
b,2.25752508361204
accumulationindex,2.25752508361204
volumesofdistributionatsteadystate,2.25752508361204
extractionefficiencie,2.25752508361204
minimumplasmaconcentration,2.25752508361204
volumeofdistributionvdss,2.25752508361204
mic90,2.25752508361204
a,2.25752508361204
ke0,2.25752508361204
au,2.25752508361204
plasmaclearancerate,2.25752508361204
overallrecoverie,2.25752508361204
areaundercurve,2.1739130434782608
plasmabinding,2.1739130434782608
excreted,2.1739130434782608
areaundercurveauc,2.1739130434782608
auc0tlast,2.1739130434782608
vbeta,2.1739130434782608
terminalphaset12,2.1739130434782608
centralcompartmentvolume,2.1739130434782608
eliminationhalflivest12,2.1739130434782608
areaundertheserumconcentrationtimecurve,2.1739130434782608
halfmaximalinhibitoryconcentrationic50,2.1739130434782608
bloodconcentration,2.1739130434782608
areaunderthetimeconcentrationcurve,2.1739130434782608
lineardynamic,2.1739130434782608
terminaleliminationhalflifet12beta,2.1739130434782608
timeofpeakconcentration,2.1739130434782608
cssmin,2.1739130434782608
auc04,2.1739130434782608
steadystatevolumeofdistributionvdss,2.1739130434782608
volumeofdistributionvz,2.0903010033444818
bloodflow,2.0903010033444818
peakserumconcentrationcmax,2.0903010033444818
areaundertheconcentrationversustimecurve,2.0903010033444818
t50,2.0903010033444818
eliminationphasehalflife,2.0903010033444818
auc0tau,2.0066889632107023
totalurinaryrecovery,2.0066889632107023
terminalhalflifet12beta,2.0066889632107023
activity,2.0066889632107023
volumeofdistributionvdarea,2.0066889632107023
totalanalyticalruntime,2.0066889632107023
cdratio,2.0066889632107023
totalbodyclearancetbc,2.0066889632107023
totalbodyclearanceclt,2.0066889632107023
nominalretentiontime,2.0066889632107023
areaundertheserumconcentrationtimecurveauc,2.0066889632107023
t12ke,2.0066889632107023
uptake,2.0066889632107023
particle,2.0066889632107023
eliminationconstant,2.0066889632107023
viscosity,2.0066889632107023
serumhalflive,2.0066889632107023
michaelismentenconstantkm,2.0066889632107023
minimumdetectableconcentration,2.0066889632107023
fu,2.0066889632107023
amount,2.0066889632107023
t12ka,2.0066889632107023
g,2.0066889632107023
clinicalbenefitrate,1.9230769230769231
cardiacoutput,1.9230769230769231
totalclearanceclt,1.9230769230769231
peff,1.9230769230769231
milkplasmaratio,1.9230769230769231
fractionunbound,1.9230769230769231
centralvolumeofdistributionv1,1.9230769230769231
keo,1.9230769230769231
vm,1.9230769230769231
vzf,1.9230769230769231
maximumeffect,1.9230769230769231
auc072h,1.9230769230769231
papp,1.9230769230769231
drugrelease,1.9230769230769231
maximumpeakplasmaconcentrationcmax,1.9230769230769231
clp,1.9230769230769231
distributionhalflive,1.9230769230769231
overallsurvivaltime,1.9230769230769231
fractionabsorbed,1.9230769230769231
auc048h,1.9230769230769231
absorptiont12,1.839464882943144
eliminationhalflifet12el,1.839464882943144
disintegrationtime,1.839464882943144
timetopeakplasmaconcentrationtmax,1.839464882943144
timetoreachmaximumplasmaconcentrationtmax,1.839464882943144
maximalserumconcentration,1.839464882943144
totaltime,1.839464882943144
vssf,1.839464882943144
recoverytime,1.839464882943144
f2,1.839464882943144
eliminationrateconstantke,1.839464882943144
maximumobservedplasmaconcentrationcmax,1.839464882943144
c50,1.839464882943144
flow,1.839464882943144
loadingcapacity,1.839464882943144
cl3,1.839464882943144
terminal,1.839464882943144
overallresponse,1.839464882943144
constantrate,1.839464882943144
totalurinaryexcretion,1.839464882943144
timeofmaximumconcentration,1.839464882943144
firstorderabsorptionrateconstant,1.839464882943144
productionrate,1.839464882943144
troughplasmalevel,1.839464882943144
t12ab,1.7558528428093645
partialmetabolicclearance,1.7558528428093645
unboundconcentration,1.7558528428093645
metabolicratiomr,1.7558528428093645
csf,1.7558528428093645
t1,1.7558528428093645
bindingconstant,1.7558528428093645
systemic,1.7558528428093645
plasmaterminalhalflife,1.7558528428093645
r,1.7558528428093645
totalamount,1.7558528428093645
bmax,1.7558528428093645
apparenthalflive,1.7558528428093645
maximalplasmalevel,1.7558528428093645
steadystatetroughconcentration,1.7558528428093645
peakbloodconcentration,1.7558528428093645
steadystatevolumesofdistribution,1.7558528428093645
apparenttotalclearance,1.7558528428093645
metabolicclearanceratemcr,1.7558528428093645
kp,1.7558528428093645
targetplasmaconcentration,1.7558528428093645
crrate,1.7558528428093645
partialclearance,1.6722408026755853
initialvolumeofdistribution,1.6722408026755853
systemicclearancecls,1.6722408026755853
durationofeffect,1.6722408026755853
maximumconcentrationinplasmacmax,1.6722408026755853
terminaldispositionhalflife,1.6722408026755853
totalexcretion,1.6722408026755853
timetomaximumserumconcentration,1.6722408026755853
hepaticbloodflow,1.6722408026755853
progressionfree,1.6722408026755853
michaelismentenconstant,1.6722408026755853
percentage,1.6722408026755853
steadystatecmax,1.6722408026755853
areaundertheconcentrationcurveauc,1.6722408026755853
completeresponserate,1.6722408026755853
diameter,1.6722408026755853
e0,1.6722408026755853
salivaplasmaconcentrationsratio,1.6722408026755853
partitioncoefficient,1.6722408026755853
distributionvolumeatsteadystate,1.6722408026755853
limitof,1.6722408026755853
totalserumclearance,1.6722408026755853
troughserumconcentration,1.6722408026755853
steadystateclearance,1.6722408026755853
mr,1.6722408026755853
absorptionhalftime,1.588628762541806
steadystatedistributionvolume,1.588628762541806
cp,1.588628762541806
areaunderthecurveauc0infinity,1.588628762541806
hepatic,1.588628762541806
areaundertheplasmaconcentrationcurve,1.588628762541806
ma,1.588628762541806
eliminationrate,1.588628762541806
pa2,1.588628762541806
totalapparentvolumeofdistribution,1.588628762541806
response,1.588628762541806
overall,1.588628762541806
apparentvolumeofthecentralcompartment,1.588628762541806
areaundertheconcentrationcurve,1.588628762541806
timetoreachsteadystate,1.588628762541806
limitsofdetectionlod,1.588628762541806
totalclearancecltot,1.588628762541806
unbound,1.588628762541806
re,1.588628762541806
drugloadingcapacity,1.588628762541806
absorptionconstantka,1.588628762541806
firstorderrateconstant,1.588628762541806
encapsulationefficiencyee,1.588628762541806
urinaryexcretionrate,1.588628762541806
co,1.588628762541806
relapserate,1.588628762541806
fecalexcretion,1.588628762541806
serum,1.588628762541806
cpmax,1.588628762541806
vp,1.588628762541806
24hour,1.588628762541806
permeabilitycoefficient,1.588628762541806
totalmetabolicclearance,1.5050167224080269
auc072,1.5050167224080269
auc0ratio,1.5050167224080269
biliaryclearance,1.5050167224080269
areaunderthetimeconcentrationcurveauc,1.5050167224080269
aucdose,1.5050167224080269
cavg,1.5050167224080269
dial,1.5050167224080269
centralvolume,1.5050167224080269
elutiontime,1.5050167224080269
peakbloodlevel,1.5050167224080269
bioavaila,1.5050167224080269
areasundertheplasmaconcentrationtimecurve,1.5050167224080269
imax,1.5050167224080269
peripheralvolumeofdistributionv2,1.5050167224080269
maximumobservedplasmaconcentration,1.5050167224080269
halflifet12beta,1.5050167224080269
terminaleliminationt12,1.5050167224080269
extraction,1.5050167224080269
totalbodyclearanceclb,1.5050167224080269
tc,1.5050167224080269
peakdrugconcentration,1.5050167224080269
accumulation,1.5050167224080269
overallmediansurvival,1.5050167224080269
effectsiteconcentration,1.5050167224080269
c2,1.5050167224080269
u,1.5050167224080269
firstorderabsorptionrateconstantka,1.5050167224080269
associationconstant,1.5050167224080269
maximalinhibition,1.5050167224080269
meanabsorptiontimemat,1.5050167224080269
z,1.5050167224080269
t12lambda1,1.5050167224080269
peakplasma,1.5050167224080269
oralabsolutebioavailability,1.5050167224080269
bleedingtime,1.4214046822742474
plasmadrugconcentration,1.4214046822742474
q2,1.4214046822742474
timeofmaximumconcentrationtmax,1.4214046822742474
oral,1.4214046822742474
kout,1.4214046822742474
absorptionhalflive,1.4214046822742474
maximumplasmadrugconcentrationcmax,1.4214046822742474
fe,1.4214046822742474
srratio,1.4214046822742474
timetopeakserumconcentration,1.4214046822742474
q3,1.4214046822742474
k1,1.4214046822742474
alphaphasehalflife,1.4214046822742474
peripheralvolume,1.4214046822742474
eh,1.4214046822742474
ba,1.4214046822742474
terminalphaseeliminationhalflife,1.4214046822742474
cloral,1.4214046822742474
auc036,1.4214046822742474
plasmaratio,1.4214046822742474
braintoplasmaratio,1.4214046822742474
d,1.4214046822742474
aucot,1.4214046822742474
plasmatmax,1.4214046822742474
clearanceratio,1.3377926421404682
absolutebioavailabilityab,1.3377926421404682
maximumeffectemax,1.3377926421404682
rsd,1.3377926421404682
mrt0t,1.3377926421404682
peritonealclearance,1.3377926421404682
volumeofcentralcompartment,1.3377926421404682
di,1.3377926421404682
tpeak,1.3377926421404682
nadir,1.3377926421404682
survivalrate,1.3377926421404682
maximumvalue,1.3377926421404682
timetotumorprogression,1.3377926421404682
injectionvolume,1.3377926421404682
auc24h,1.3377926421404682
minimuminhibitoryconcentrationmic,1.3377926421404682
kin,1.3377926421404682
entrapmentefficiencyee,1.3377926421404682
mw,1.3377926421404682
timestomaximumconcentration,1.3377926421404682
vcf,1.3377926421404682
timetosteadystate,1.3377926421404682
maximumbloodconcentration,1.3377926421404682
limitsofquantitation,1.3377926421404682
aucmicratio,1.3377926421404682
volumeofdistributionvdbeta,1.3377926421404682
distributionclearance,1.3377926421404682
csfplasmaratio,1.3377926421404682
mean,1.3377926421404682
oralabsorption,1.3377926421404682
curerate,1.3377926421404682
totalareaunderthecurve,1.3377926421404682
totalruntimeofanalysi,1.3377926421404682
residencetime,1.3377926421404682
mae,1.3377926421404682
occupancie,1.3377926421404682
effectiveconcentration,1.3377926421404682
max,1.3377926421404682
e,1.3377926421404682
timetodiseaseprogression,1.3377926421404682
timetotreatmentfailure,1.3377926421404682
t12lambdaz,1.3377926421404682
friability,1.3377926421404682
peaktimetmax,1.254180602006689
iontransition,1.254180602006689
fm,1.254180602006689
urinaryclearance,1.254180602006689
plasmaconcentrationratio,1.254180602006689
maximumobservedconcentration,1.254180602006689
areasundertheconcentrationtimecurve,1.254180602006689
terminaleliminationrateconstant,1.254180602006689
totalrecoveryofradioactivity,1.254180602006689
pkb,1.254180602006689
cltf,1.254180602006689
timetoresponse,1.254180602006689
steadystateplasmaconcentrationcss,1.254180602006689
qf,1.254180602006689
frel,1.254180602006689
flowrateofthemobilephase,1.254180602006689
timetoreachthemaximumplasmaconcentration,1.254180602006689
serumcmax,1.254180602006689
meantime,1.254180602006689
halflifetimet12,1.254180602006689
bloodtoplasmaratio,1.254180602006689
halflifeoftheeliminationphase,1.254180602006689
minimumquantifiableconcentration,1.254180602006689
recoveryof,1.254180602006689
maximumconcentrationofdruginserumcmax,1.254180602006689
resolutionfactor,1.254180602006689
t05,1.254180602006689
areaundertheplasmaconcentrationcurveauc,1.254180602006689
plateletnadir,1.254180602006689
shelflife,1.254180602006689
50inhibitionconcentrationic50,1.254180602006689
michaelisconstantkm,1.254180602006689
halflifeof,1.254180602006689
totaldrugclearance,1.254180602006689
csfplasmaconcentrationratio,1.254180602006689
cmax1,1.254180602006689
initialhalflive,1.254180602006689
inhibition,1.254180602006689
auc02h,1.254180602006689
apparentabsorptionhalflife,1.254180602006689
bodyclearanceclb,1.254180602006689
dl,1.254180602006689
detection,1.254180602006689
entrapment,1.254180602006689
overallbioavailability,1.254180602006689
bloodflowrate,1.254180602006689
timetoprogressionttp,1.254180602006689
halflifeofabsorption,1.254180602006689
size,1.254180602006689
fg,1.254180602006689
clnr,1.254180602006689
apparentterminalhalflive,1.254180602006689
minimumconcentrationcmin,1.254180602006689
steadystateauc,1.1705685618729096
areaundertheconcentrationtimecurveratio,1.1705685618729096
c24,1.1705685618729096
onsetofaction,1.1705685618729096
fio2,1.1705685618729096
apparenteliminationhalflive,1.1705685618729096
auc07,1.1705685618729096
respiratoryrate,1.1705685618729096
v2f,1.1705685618729096
apparentsteadystatevolumeofdistribution,1.1705685618729096
auc024ratio,1.1705685618729096
pki,1.1705685618729096
apparenteliminationt12,1.1705685618729096
kb,1.1705685618729096
cardiacindex,1.1705685618729096
lambdaem,1.1705685618729096
halflivesofelimination,1.1705685618729096
oralbioavailabilitie,1.1705685618729096
kinactkiratio,1.1705685618729096
betahalflive,1.1705685618729096
meantransittime,1.1705685618729096
ttp,1.1705685618729096
hepaticavailability,1.1705685618729096
steadystateflux,1.1705685618729096
elution,1.1705685618729096
inhibitoryconcentrationic50,1.1705685618729096
auc12,1.1705685618729096
aucss,1.1705685618729096
ce50,1.1705685618729096
cltb,1.1705685618729096
absorptionconstant,1.1705685618729096
maximalplasmaconcentrationscmax,1.1705685618729096
lambdaex,1.1705685618729096
areaundertheplasmaconcentrationvstimecurveauc,1.1705685618729096
ci,1.1705685618729096
minimumeffectivedose,1.1705685618729096
quantificationlimit,1.1705685618729096
terminalhalflifet12gamma,1.1705685618729096
timetopeaktmax,1.1705685618729096
penetrationratio,1.1705685618729096
effectivedoseed50,1.1705685618729096
fractionof,1.1705685618729096
maximalincrease,1.1705685618729096
parasiteclearancetime,1.1705685618729096
totalbodyclearancecltot,1.1705685618729096
timetoreachpeakconcentrationtmax,1.1705685618729096
maximaltolerateddose,1.1705685618729096
dosenormalizedcmax,1.1705685618729096
detectiontime,1.1705685618729096
limitofquantitationloq,1.1705685618729096
t12e,1.1705685618729096
clearancehalflife,1.1705685618729096
number,1.1705685618729096
mp,1.1705685618729096
totalareaundertheplasmaconcentrationtimecurve,1.1705685618729096
minimuminhibitoryconcentration,1.1705685618729096
accumulationhalflife,1.1705685618729096
maximaleffect,1.1705685618729096
apparentvolumeofdistributionofthecentralcompartment,1.1705685618729096
eliminationhalflivest12beta,1.1705685618729096
areaunderconcentrationtimecurveauc,1.0869565217391304
totalconcentration,1.0869565217391304
overallsurvivalrate,1.0869565217391304
i,1.0869565217391304
areaunderthecurveaucratio,1.0869565217391304
atsteadystate,1.0869565217391304
csubmaxsub,1.0869565217391304
t05beta,1.0869565217391304
excretionrate,1.0869565217391304
ed90,1.0869565217391304
absoluteoralbioavailabilityf,1.0869565217391304
relativebioavailabilityf,1.0869565217391304
occup,1.0869565217391304
distributiont12,1.0869565217391304
areasundertheserumconcentrationtimecurve,1.0869565217391304
wholebodyclearance,1.0869565217391304
vl,1.0869565217391304
c1,1.0869565217391304
plasmaunboundfraction,1.0869565217391304
plasmaeliminationhalflivest12,1.0869565217391304
steadystateconcentrationcss,1.0869565217391304
lowerdetectionlimit,1.0869565217391304
cmaxss,1.0869565217391304
permeation,1.0869565217391304
apparentterminaleliminationhalflife,1.0869565217391304
auc03,1.0869565217391304
mac,1.0869565217391304
dispositionhalflive,1.0869565217391304
peakplasmalevelcmax,1.0869565217391304
fractionunboundtoplasmaproteinsfu,1.0869565217391304
level,1.0869565217391304
timetopeaklevel,1.0869565217391304
timetoreachpeakplasmaconcentration,1.0869565217391304
braintoplasmaconcentrationratio,1.0869565217391304
totaldose,1.0869565217391304
hr,1.0869565217391304
cmax2,1.0869565217391304
t2,1.0869565217391304
terminalhalflivest12,1.0869565217391304
activationenergyea,1.0869565217391304
areaunderplasmaconcentrationtimecurve,1.0869565217391304
50effectiveconcentration,1.0869565217391304
eradicationrate,1.0869565217391304
targetconcentration,1.0869565217391304
paco2,1.0869565217391304
infusiontime,1.0869565217391304
masstransition,1.0869565217391304
mrt0,1.0869565217391304
bloodlevel,1.0869565217391304
release,1.0869565217391304
plasmaaucratio,1.0869565217391304
intrinsichepaticclearance,1.0869565217391304
biologicalhalflifet12,1.0869565217391304
timetomaximalplasmaconcentration,1.0869565217391304
minimalinhibitoryconcentration,1.0869565217391304
c12,1.0869565217391304
spratio,1.0869565217391304
minimum,1.0869565217391304
drugclearance,1.0869565217391304
tissuetoplasmaratio,1.0869565217391304
unboundclearance,1.0869565217391304
free,1.0869565217391304
cminss,1.0869565217391304
mic50,1.0869565217391304
limitofquantitation,1.0869565217391304
apparentplasmahalflife,1.0869565217391304
timerequired,1.0869565217391304
timeofpeakconcentrationtmax,1.0869565217391304
areaundertheconcentrationtimecurveauc024,1.0869565217391304
nonrenalclearanceclnr,1.0869565217391304
apparentvolumeofdistributionv,1.0869565217391304
gammahalflive,1.0869565217391304
totalradioactivityrecovered,1.0869565217391304
serumhalflifet12,1.0033444816053512
areaundertheplasmaconcentrationtimecurvefromtime0toinfinityauc0,1.0033444816053512
gastricresidencetime,1.0033444816053512
slope,1.0033444816053512
totalareaundertheplasmaconcentrationtimecurveauc,1.0033444816053512
tbc,1.0033444816053512
subcutaneousbioavailability,1.0033444816053512
n,1.0033444816053512
fh,1.0033444816053512
dosenormalizedauc,1.0033444816053512
quantificationloq,1.0033444816053512
sr,1.0033444816053512
aerodynamicdiameter,1.0033444816053512
eliminationofhalflife,1.0033444816053512
halflifeelimination,1.0033444816053512
maximumincrease,1.0033444816053512
clinicalduration,1.0033444816053512
terminalhalflifeofelimination,1.0033444816053512
tau,1.0033444816053512
maximumplasmaconcentrationcpmax,1.0033444816053512
potency,1.0033444816053512
specificactivitie,1.0033444816053512
kpuu,1.0033444816053512
timetoextubation,1.0033444816053512
fr,1.0033444816053512
cd50,1.0033444816053512
totalbioavailability,1.0033444816053512
timestoawakening,1.0033444816053512
apparentvolumeofdistributionatsteadystatevdss,1.0033444816053512
clo,1.0033444816053512
fev1,1.0033444816053512
intercompartmentclearanceq,1.0033444816053512
absolutesystemicavailability,1.0033444816053512
bloodhalflife,1.0033444816053512
apparent,1.0033444816053512
invivorecovery,1.0033444816053512
dropletsize,1.0033444816053512
apparentvolumeofdistributionvzf,1.0033444816053512
unboundplasmaconcentration,1.0033444816053512
mztransition,1.0033444816053512
peripheralvolumesofdistribution,1.0033444816053512
renalelimination,1.0033444816053512
peakdrugplasmaconcentrationcmax,1.0033444816053512
hillfactor,1.0033444816053512
totalresponserate,1.0033444816053512
totalbodyplasmaclearance,1.0033444816053512
retention,1.0033444816053512
er,1.0033444816053512
t12lambda,1.0033444816053512
invasionhalflife,1.0033444816053512
auc1,1.0033444816053512
halflifeofeliminationt12beta,1.0033444816053512
timetoreachthemaximumplasmaconcentrationtmax,1.0033444816053512
volumeofthecentralcompartmentv1,1.0033444816053512
serumt12,1.0033444816053512
zpotential,1.0033444816053512
timetomaximalconcentration,1.0033444816053512
inhibitoryconstant,1.0033444816053512
degradationrateconstant,1.0033444816053512
effectivedose,1.0033444816053512
sievingcoefficient,1.0033444816053512
serumlevel,1.0033444816053512
aucr,1.0033444816053512
systemicbioavailabilityf,1.0033444816053512
percentageof,1.0033444816053512
areaunderthebloodconcentrationtimecurveauc,1.0033444816053512
watersolubility,1.0033444816053512
cld,1.0033444816053512
pao2,1.0033444816053512
24h,1.0033444816053512
maximumsolubility,1.0033444816053512
loadingefficiency,1.0033444816053512
brainbloodratio,1.0033444816053512
ct,1.0033444816053512
plasmahalftime,1.0033444816053512
areaunderconcentrationtimecurve,1.0033444816053512
dialyticclearance,1.0033444816053512
betaphaset12,1.0033444816053512
peakcsfconcentration,1.0033444816053512
renalclearancerate,1.0033444816053512
totalbody,1.0033444816053512
cbf,1.0033444816053512
criticalmicelleconcentration,1.0033444816053512
areaunderthecurveauc024,1.0033444816053512
timetmax,1.0033444816053512
maximumobservedconcentrationcmax,1.0033444816053512
eliminationhalflifetime,1.0033444816053512
kiinhibitionconstant,0.919732441471572
t12keo,0.919732441471572
concentrationat1hc1h,0.919732441471572
maximumdrugconcentrationcmax,0.919732441471572
peakcmax,0.919732441471572
volumeofthecentralcompartmentvc,0.919732441471572
degradationhalflife,0.919732441471572
rd,0.919732441471572
fractionalexcretion,0.919732441471572
dissociationconstantkd,0.919732441471572
volumeofdistributionofcentralcompartment,0.919732441471572
urinerecovery,0.919732441471572
totalbodyclearancerate,0.919732441471572
predose,0.919732441471572
auc024mic,0.919732441471572
timetopeakplasmalevel,0.919732441471572
distributionhalflifet12a,0.919732441471572
cumulativeamount,0.919732441471572
limit,0.919732441471572
residualplasmaconcentration,0.919732441471572
bi,0.919732441471572
terminalphasehalflifet12,0.919732441471572
areaundertheconcentrationtimecurveaucratio,0.919732441471572
meanresidencetimesmrt,0.919732441471572
apparenteliminationrateconstant,0.919732441471572
fi,0.919732441471572
diseasefreesurvival,0.919732441471572
timestopeakconcentration,0.919732441471572
terminalhalflifet12z,0.919732441471572
varea,0.919732441471572
areaundertheconcentrationtimecurvefrom0to24hauc024,0.919732441471572
intestinalavailability,0.919732441471572
halflifeofdistribution,0.919732441471572
clearanceindex,0.919732441471572
urineconcentration,0.919732441471572
va,0.919732441471572
distributionphasehalflife,0.919732441471572
steadystateserumlevel,0.919732441471572
areaunderthecurveauc0t,0.919732441471572
apparentoralbioavailability,0.919732441471572
apparentcentralvolumeofdistribution,0.919732441471572
milkmaternalplasmaconcentrationratio,0.919732441471572
entrapmentefficiencie,0.919732441471572
apparenteffluxclearance,0.919732441471572
l,0.919732441471572
drugtargetingindex,0.919732441471572
orr,0.919732441471572
blood,0.919732441471572
auc0168h,0.919732441471572
serumpeak,0.919732441471572
affinity,0.919732441471572
uptakeclearance,0.919732441471572
disappearancehalflife,0.919732441471572
timetoreachthepeak,0.919732441471572
timeofpeak,0.919732441471572
rateof,0.919732441471572
plasmaeliminationhalflifet12beta,0.919732441471572
ec90,0.919732441471572
timetoreachmaximalplasmaconcentration,0.919732441471572
bloodtoplasmaconcentrationratio,0.919732441471572
aucmic,0.919732441471572
plasmafreefraction,0.919732441471572
areasundertheplasmaconcentrationtimecurveauc0infinity,0.919732441471572
tbeta12,0.919732441471572
halflivest12beta,0.919732441471572
auc01,0.919732441471572
qtc,0.919732441471572
halflifet12alpha,0.919732441471572
circulatinghalflife,0.919732441471572
percentrecovery,0.919732441471572
remissionrate,0.919732441471572
minimaldetectableconcentration,0.919732441471572
tmic,0.919732441471572
percent,0.8361204013377926
timetopeakplasmaconcentrationstmax,0.8361204013377926
timetoreachmaximumobservedplasmaconcentration,0.8361204013377926
50effectivedoseed50,0.8361204013377926
relative,0.8361204013377926
troughpeakratio,0.8361204013377926
areasundertheconcentrationtimecurveauc,0.8361204013377926
areasunderthecurveauc,0.8361204013377926
initialconcentration,0.8361204013377926
cmaxmic,0.8361204013377926
plasmasteadystateconcentration,0.8361204013377926
overallobjectiveresponserate,0.8361204013377926
timetothecmax,0.8361204013377926
distributionalclearance,0.8361204013377926
eliminationphasehalflive,0.8361204013377926
recoveryofradioactivity,0.8361204013377926
volumeofdistributionforthecentralcompartment,0.8361204013377926
lambdaz,0.8361204013377926
plasmatroughconcentration,0.8361204013377926
transport,0.8361204013377926
limitofsensitivity,0.8361204013377926
auec,0.8361204013377926
absolute,0.8361204013377926
kr,0.8361204013377926
areaunderthe,0.8361204013377926
css,0.8361204013377926
steadystateratio,0.8361204013377926
distributionvolumevd,0.8361204013377926
molarratio,0.8361204013377926
apparentplasmaclearanceclf,0.8361204013377926
faecalexcretion,0.8361204013377926
apparentclearancecl,0.8361204013377926
peakplasmadrugconcentrationcmax,0.8361204013377926
tensilestrength,0.8361204013377926
totalclearancerate,0.8361204013377926
k1e,0.8361204013377926
t12ke0,0.8361204013377926
steadystateareaundertheconcentrationtimecurve,0.8361204013377926
ddqtcf,0.8361204013377926
plasmaconcentrationcp,0.8361204013377926
timeofmaximalconcentrationtmax,0.8361204013377926
maximumserumlevel,0.8361204013377926
bindingto,0.8361204013377926
drugconcentration,0.8361204013377926
auc010h,0.8361204013377926
sodiumexcretion,0.8361204013377926
apparentvolumeofdistributionvdbeta,0.8361204013377926
auc0a,0.8361204013377926
vv,0.8361204013377926
apparenthalflifet12,0.8361204013377926
auc030min,0.8361204013377926
limitsof,0.8361204013377926
totaltimefor,0.8361204013377926
totalplasma,0.8361204013377926
feverclearancetime,0.8361204013377926
volumeofdistributionarea,0.8361204013377926
areaundertheconcentrationvstimecurve,0.8361204013377926
trainoffourratio,0.8361204013377926
bloodplasmaratio,0.8361204013377926
peakincrease,0.8361204013377926
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc,0.8361204013377926
eliminationhalflifeatsteadystate,0.8361204013377926
terminalexponentialhalflife,0.8361204013377926
areaundertheconcentrationtimecurveauc0t,0.8361204013377926
enhancementratio,0.8361204013377926
rf,0.8361204013377926
gastricph,0.8361204013377926
terminaleliminationhalflifet12z,0.8361204013377926
fafg,0.8361204013377926
relativebioavailabilityfrel,0.8361204013377926
eliminationrateconstantbeta,0.8361204013377926
metabolicstability,0.8361204013377926
finaleliminationhalflife,0.8361204013377926
timefor,0.8361204013377926
cumulativerenalexcretion,0.8361204013377926
areasundertheplasmaconcentrationversustimecurveauc,0.8361204013377926
brain,0.8361204013377926
drugloadingdl,0.8361204013377926
cmaxauc,0.8361204013377926
auctot,0.8361204013377926
drugtargetingefficiency,0.8361204013377926
urineoutput,0.8361204013377926
linear,0.8361204013377926
cltotal,0.8361204013377926
cli,0.8361204013377926
systemicexposure,0.8361204013377926
hepaticplasmaflow,0.8361204013377926
terminaleliminationhalflifet12b,0.8361204013377926
areaundertheplasmaconcentrationtimecurveratio,0.8361204013377926
maximumcsfconcentration,0.8361204013377926
tissueplasmaratio,0.8361204013377926
drugloadingefficiency,0.8361204013377926
timetoreachthepeakconcentration,0.8361204013377926
circulationhalflife,0.8361204013377926
lungdeposition,0.8361204013377926
apparentsystemicclearance,0.8361204013377926
affinitie,0.8361204013377926
potencyratio,0.8361204013377926
terminaldispositionhalflive,0.8361204013377926
lagphase,0.8361204013377926
limitofquant,0.8361204013377926
kt,0.8361204013377926
half,0.8361204013377926
me,0.8361204013377926
tumoruptake,0.8361204013377926
apparentterminalhalflifet12,0.8361204013377926
lloq,0.8361204013377926
totaldistributionvolume,0.7525083612040134
halftimeofelimination,0.7525083612040134
concentrationatsteadystate,0.7525083612040134
ka1,0.7525083612040134
c0h,0.7525083612040134
drugentrapmentefficiency,0.7525083612040134
eliminationhalflifetimet12,0.7525083612040134
areaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinity,0.7525083612040134
c24h,0.7525083612040134
activationentropyds,0.7525083612040134
delta,0.7525083612040134
aucss012,0.7525083612040134
absoluteoralavailability,0.7525083612040134
progressionfreesurvivalrate,0.7525083612040134
fractionalabsorption,0.7525083612040134
bindingrate,0.7525083612040134
areaundertheplasmaconcentrationtimecurveofpravastatinfrom0to10hoursauc010,0.7525083612040134
clclearance,0.7525083612040134
encapsulationefficiencie,0.7525083612040134
totalassaytime,0.7525083612040134
radiationabsorbeddose,0.7525083612040134
serumauc,0.7525083612040134
steady,0.7525083612040134
bloodlo,0.7525083612040134
gastricemptyingtime,0.7525083612040134
lineardynamicrange,0.7525083612040134
mrtinf,0.7525083612040134
target,0.7525083612040134
intramuscularbioavailability,0.7525083612040134
initialt12,0.7525083612040134
50inhibitoryconcentrationsic50,0.7525083612040134
metabolism,0.7525083612040134
totalamountof,0.7525083612040134
auc02,0.7525083612040134
completeresponsecrrate,0.7525083612040134
completeremissionrate,0.7525083612040134
maximumtolerated,0.7525083612040134
intrinsicclearanceclint,0.7525083612040134
durationsofaction,0.7525083612040134
residual,0.7525083612040134
transittime,0.7525083612040134
eliminationhalflifet12lz,0.7525083612040134
observedmaximumplasmaconcentrationcmax,0.7525083612040134
serumtroughconcentration,0.7525083612040134
vareaf,0.7525083612040134
overallruntime,0.7525083612040134
bindingpotentialbp,0.7525083612040134
proteinunboundfraction,0.7525083612040134
renalplasmaclearance,0.7525083612040134
lowerlimitofdetection,0.7525083612040134
volumeofdistributionofthecentralcompartmentv1,0.7525083612040134
areaundertheconcentrationtimecurveauc0infinity,0.7525083612040134
bloodplasmaconcentrationratio,0.7525083612040134
secondphaseeliminationhalflivest12beta,0.7525083612040134
auc036h,0.7525083612040134
plateaulevel,0.7525083612040134
bloodeliminationhalflife,0.7525083612040134
secretionrate,0.7525083612040134
saturation,0.7525083612040134
stability,0.7525083612040134
firstphaseeliminationhalflivest12alpha,0.7525083612040134
timetoreach,0.7525083612040134
centraldistributionvolume,0.7525083612040134
transdermalflux,0.7525083612040134
rmax,0.7525083612040134
maximaltolerateddosemtd,0.7525083612040134
apparentcl,0.7525083612040134
areaunderthecurveauc024h,0.7525083612040134
areasundertheplasmaconcentrationtimecurveauc,0.7525083612040134
troughlevelc0,0.7525083612040134
df,0.7525083612040134
ic90,0.7525083612040134
terminalphasehalflive,0.7525083612040134
systemicavailabilitie,0.7525083612040134
unboundki,0.7525083612040134
relativeattenuationratio,0.7525083612040134
peakplasmadrugconcentration,0.7525083612040134
eliminationhalftimet12,0.7525083612040134
concentrationdosecdratio,0.7525083612040134
clearancetime,0.7525083612040134
cin,0.7525083612040134
halflifeatbetaphase,0.7525083612040134
urinaryrecoveryrate,0.7525083612040134
recoveryindex,0.7525083612040134
apparentvolumeofdistributionatsteadystatevss,0.7525083612040134
apparentrenalclearance,0.7525083612040134
percentagerecovery,0.7525083612040134
bindingaffinity,0.7525083612040134
amplitude,0.7525083612040134
koff,0.7525083612040134
hepaticintrinsicclearance,0.7525083612040134
ratioof,0.7525083612040134
cssmusclec,0.7525083612040134
steadystateplasmalevelscss,0.7525083612040134
mbc,0.7525083612040134
minimumeffectiveconcentration,0.7525083612040134
latencyto,0.7525083612040134
eliminationhalflifet12e,0.7525083612040134
dialysance,0.7525083612040134
areaundertheplasmaconcentrationtimecurveauc024,0.7525083612040134
concentrationathalfmaximaleffect,0.7525083612040134
troughbloodlevel,0.7525083612040134
terminaleliminationhalfline,0.7525083612040134
fractionunboundfu,0.7525083612040134
unboundvolumeofdistribution,0.7525083612040134
excretionratio,0.7525083612040134
maxima,0.7525083612040134
nasalbioavailability,0.7525083612040134
absorptionhalflifet12ab,0.7525083612040134
urineexcretion,0.7525083612040134
metabolicclearanceratesmcr,0.7525083612040134
ed95,0.7525083612040134
areaundertheconcentrationtimecurveauctau,0.7525083612040134
latency,0.7525083612040134
conversionratio,0.7525083612040134
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityauc0infinity,0.7525083612040134
milkplasmaconcentrationratio,0.7525083612040134
equilibriumdissociationconstantkd,0.7525083612040134
timetomaximalconcentrationtmax,0.7525083612040134
auc060,0.7525083612040134
plasmaconcentrationscmax,0.7525083612040134
dissolutionrate,0.7525083612040134
mat,0.7525083612040134
totaloralclearance,0.7525083612040134
bioavibility,0.7525083612040134
intestinalextractionratio,0.7525083612040134
urinevolume,0.7525083612040134
auc12h,0.7525083612040134
areaundertheplasmaconcentrationtimecurvesauc,0.7525083612040134
hardne,0.7525083612040134
timetothesteadystate,0.7525083612040134
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc,0.7525083612040134
areasundertheplasmaconcentrationtimecurvesauc,0.7525083612040134
concentrationat12hc12h,0.7525083612040134
plasmatictarget,0.7525083612040134
areaunderthecurvefrom0to12hauc012h,0.7525083612040134
urineflowrate,0.7525083612040134
areaundertheconcentrationtimecurveauc0,0.6688963210702341
cmaxmicratio,0.6688963210702341
peaklevelcmax,0.6688963210702341
volumeofdistributionv1,0.6688963210702341
peakapixabanconcentration,0.6688963210702341
absorptionhalflifet12ka,0.6688963210702341
unboundplasmaclearance,0.6688963210702341
conversion,0.6688963210702341
accuracy,0.6688963210702341
logp,0.6688963210702341
auc8,0.6688963210702341
circulationtime,0.6688963210702341
dissociationhalflife,0.6688963210702341
jmax,0.6688963210702341
totalareaunderthecurveauc,0.6688963210702341
tmax1,0.6688963210702341
initiallagtime,0.6688963210702341
kab,0.6688963210702341
smallintestinaltransittime,0.6688963210702341
vgamma,0.6688963210702341
rateofabsorption,0.6688963210702341
betat12,0.6688963210702341
tsubmaxsub,0.6688963210702341
crossreactivitie,0.6688963210702341
volumeofdistributionsteadystate,0.6688963210702341
meanconcentration,0.6688963210702341
auctotal,0.6688963210702341
totalbloodclearance,0.6688963210702341
cpeak,0.6688963210702341
sc50,0.6688963210702341
steadystatepeak,0.6688963210702341
pro,0.6688963210702341
absolutesystemicbioavailability,0.6688963210702341
internationalnormalizedratio,0.6688963210702341
maximumbloodconcentrationscmax,0.6688963210702341
encap,0.6688963210702341
salivaplasmaconcentrationratio,0.6688963210702341
plasmaextractionrecovery,0.6688963210702341
vt,0.6688963210702341
timeofanalysi,0.6688963210702341
auc50,0.6688963210702341
lowestdetectableconcentration,0.6688963210702341
specificradioactivity,0.6688963210702341
peaktiter,0.6688963210702341
peakvitreousconcentration,0.6688963210702341
areaunderthecurvefrom0to24h,0.6688963210702341
minimuminhibitoryconcentrationsmics,0.6688963210702341
steadystatepeakplasmaconcentration,0.6688963210702341
salivatoplasmaratio,0.6688963210702341
intestinalclearance,0.6688963210702341
distributioncoefficient,0.6688963210702341
ft3,0.6688963210702341
equilibriumdissociationconstant,0.6688963210702341
bindingenergy,0.6688963210702341
dispositionhalflife,0.6688963210702341
receptorbinding,0.6688963210702341
proteinbindingfraction,0.6688963210702341
maximumvelocity,0.6688963210702341
csftoplasmaratio,0.6688963210702341
steadystateplasmaalpra,0.6688963210702341
areaundertheconcentrationvstimecurveauc,0.6688963210702341
arterialplasmaconcentration,0.6688963210702341
weight,0.6688963210702341
peaktotalreversingconcentration,0.6688963210702341
terminalphasevolumeofdistribution,0.6688963210702341
concentrationscmax,0.6688963210702341
unboundfractionfu,0.6688963210702341
pr,0.6688963210702341
caverage,0.6688963210702341
absorptionrateka,0.6688963210702341
orallybioavailable,0.6688963210702341
oraldoseclearance,0.6688963210702341
apparentdistributionvolumevf,0.6688963210702341
maximalconcentrationscmax,0.6688963210702341
tissueplasmaconcentrationratio,0.6688963210702341
mse,0.6688963210702341
wholebloodclearance,0.6688963210702341
selectivityratio,0.6688963210702341
totalrecoverie,0.6688963210702341
peakbloodethanolconcentration,0.6688963210702341
transmittance,0.6688963210702341
residualconcentration,0.6688963210702341
percentunbound,0.6688963210702341
timerequiredtoreachpeakplasmalevelstmax,0.6688963210702341
renalclearanceofunbounddrug,0.6688963210702341
milktoplasmaratio,0.6688963210702341
aucsrratio,0.6688963210702341
maximumsuppression,0.6688963210702341
auic,0.6688963210702341
steadystateapparentvolumeofdistribution,0.6688963210702341
production,0.6688963210702341
aucoinfinity,0.6688963210702341
fabs,0.6688963210702341
systemicabsorption,0.6688963210702341
nausea,0.6688963210702341
cssav,0.6688963210702341
receptor,0.6688963210702341
relativebioavailabilityfr,0.6688963210702341
cd,0.6688963210702341
vdc,0.6688963210702341
areaundertheconcentrationversustimecurveauc0infinity,0.6688963210702341
halfmaximaleffectiveconcentrationec50,0.6688963210702341
lowdetectionlimit,0.6688963210702341
maximalbloodconcentration,0.6688963210702341
maximumserumconcentrationscmax,0.6688963210702341
intrinsicclearancerate,0.6688963210702341
t05alpha,0.6688963210702341
bp,0.6688963210702341
aciddissociationconstantpka,0.6688963210702341
extractionyield,0.6688963210702341
eliminationphase,0.6688963210702341
fcmax,0.6688963210702341
serumeliminationhalflive,0.6688963210702341
terminaleliminationhalflifet12lz,0.6688963210702341
csfconcentration,0.6688963210702341
twentyfourhour,0.6688963210702341
areaundertheconcentrationtimecurvefrom0to12hauc012,0.6688963210702341
peaksalicylateconcentration,0.6688963210702341
clin,0.6688963210702341
j,0.6688963210702341
octanolwaterpartitioncoefficient,0.6688963210702341
criticalmicelleconcentrationcmc,0.6688963210702341
systemicbioavailabilitie,0.6688963210702341
maximaleffectemax,0.6688963210702341
troughbloodconcentration,0.6688963210702341
firstpassmetabolism,0.6688963210702341
confirmedresponserate,0.6688963210702341
peripheraldistributionvolume,0.6688963210702341
conversionrate,0.6688963210702341
k31,0.6688963210702341
ratiooftheauc,0.6688963210702341
liver,0.6688963210702341
ed30,0.6688963210702341
ad50,0.6688963210702341
ratioofauc,0.6688963210702341
c12h,0.6688963210702341
progressionfreesurvivalpfsrate,0.6688963210702341
extubation,0.6688963210702341
minimaleffectivedose,0.6688963210702341
onset,0.6688963210702341
hospitalstay,0.6688963210702341
halflifet05,0.6688963210702341
v1f,0.6688963210702341
areaundertheplasmaconcentrationvstimecurve,0.6688963210702341
t12pi,0.6688963210702341
freeconcentration,0.6688963210702341
systemicclearancerate,0.6688963210702341
finalhalflife,0.6688963210702341
volumeofdistributionofthecentralcompartmentvc,0.6688963210702341
v3f,0.6688963210702341
k13,0.6688963210702341
halflifebetaphase,0.6688963210702341
auc09,0.5852842809364548
overalldiseasecontrolrate,0.5852842809364548
lungconcentration,0.5852842809364548
sedationscore,0.5852842809364548
timetoobservedmaximumplasmaconcentrationtmax,0.5852842809364548
peakmeanconcentration,0.5852842809364548
targetplasmaconcentrationtpc,0.5852842809364548
valpha,0.5852842809364548
excretionconstant,0.5852842809364548
clintugt,0.5852842809364548
cumulativerelease,0.5852842809364548
absorptionfraction,0.5852842809364548
halflivesofdistribution,0.5852842809364548
apparentvolume,0.5852842809364548
volumeofdistributionatsteadystatevd,0.5852842809364548
systemicclearanceofunbounddrugclu,0.5852842809364548
rateofclearance,0.5852842809364548
kdeg,0.5852842809364548
meanabsorptiontimesmat,0.5852842809364548
terminalphaseeliminationhalflive,0.5852842809364548
aucauc,0.5852842809364548
progressionfreesurvivaltime,0.5852842809364548
maximuminhibitoryrate,0.5852842809364548
serumfreefraction,0.5852842809364548
plasmapeak,0.5852842809364548
objectiveresponse,0.5852842809364548
timestocmaxtmax,0.5852842809364548
serumpeakconcentrationcmax,0.5852842809364548
t0,0.5852842809364548
areaundertheconcentrationtimecurveauc08,0.5852842809364548
steadystatemean,0.5852842809364548
areaunderthecurvefromzerotoinfinityauc0,0.5852842809364548
apparentvolumeofdistributionvdarea,0.5852842809364548
maximumdrugconcentration,0.5852842809364548
maximumwhealsuppression,0.5852842809364548
areaundertheconcentrationtimecurveauc012h,0.5852842809364548
areaunderthecurvefromtimezerotoinfinity,0.5852842809364548
auc024micratio,0.5852842809364548
t12elimination,0.5852842809364548
terminalrateconstant,0.5852842809364548
aucsub0tsub,0.5852842809364548
ocularbioavailability,0.5852842809364548
volumedistribution,0.5852842809364548
t12ofdistribution,0.5852842809364548
terminalserumhalflife,0.5852842809364548
eliminationhalflifet12gamma,0.5852842809364548
eliminationclearancefromthecsf,0.5852842809364548
percentpenetration,0.5852842809364548
cumulativeauc,0.5852842809364548
volumeofcentralcompartmentv1,0.5852842809364548
limitsofdetectionlods,0.5852842809364548
dissolution,0.5852842809364548
halflifeofthedistributionphase,0.5852842809364548
cmaxtmax,0.5852842809364548
maximallevel,0.5852842809364548
oralclearancecl,0.5852842809364548
imprecision,0.5852842809364548
areaundertheconcentrationtimecurveauc0tlast,0.5852842809364548
t1t0,0.5852842809364548
meantransittimetau,0.5852842809364548
ldr,0.5852842809364548
volumeofdistributioninthecentralcompartment,0.5852842809364548
pfstime,0.5852842809364548
areaunderthecurvefromtime0toinfinityauc0infinity,0.5852842809364548
csfpenetration,0.5852842809364548
fluxe,0.5852842809364548
secondpeak,0.5852842809364548
gi50,0.5852842809364548
logd,0.5852842809364548
peakeffect,0.5852842809364548
fractionbound,0.5852842809364548
completeresponse,0.5852842809364548
effectivehalflifet12eff,0.5852842809364548
timetoreachpeaktmax,0.5852842809364548
excre,0.5852842809364548
kal,0.5852842809364548
firstordereliminationhalflife,0.5852842809364548
relativebioavailabilityba,0.5852842809364548
apparentpa2,0.5852842809364548
anti,0.5852842809364548
totalradioactivity,0.5852842809364548
percentageentrapmentefficiencyee,0.5852842809364548
maximumqtc,0.5852842809364548
timetoancrecovery,0.5852842809364548
systemicavailabilityf,0.5852842809364548
lagtimetlag,0.5852842809364548
cp50,0.5852842809364548
centralcompartmentvolumesofdistribution,0.5852842809364548
dwelltime,0.5852842809364548
peakserumconcentrationscmax,0.5852842809364548
faucmic,0.5852842809364548
receptoroccupancy,0.5852842809364548
timelag,0.5852842809364548
fecalrecoverie,0.5852842809364548
concentrationmaximum,0.5852842809364548
si,0.5852842809364548
totalareaundertheserumconcentrationtimecurveauc0infinity,0.5852842809364548
extractionrecoveryrate,0.5852842809364548
ubt,0.5852842809364548
first,0.5852842809364548
totalareasunderthecurveauc0,0.5852842809364548
to,0.5852842809364548
halflifeperiod,0.5852842809364548
c60,0.5852842809364548
liverbloodflow,0.5852842809364548
observedaccumulationratio,0.5852842809364548
maximumipa,0.5852842809364548
areaunderthemethylprednisoloneconcentrationtimecurve,0.5852842809364548
bioavailabilityba,0.5852842809364548
ne,0.5852842809364548
plasmaauc024,0.5852842809364548
timetoplateletrecovery,0.5852842809364548
tmaxtimetoreachcmax,0.5852842809364548
steadystateconcentrationscss,0.5852842809364548
turnoverhalflife,0.5852842809364548
terminaldispositionhalflifet12,0.5852842809364548
minimal,0.5852842809364548
reactiontime,0.5852842809364548
halflifeoftheterminaleliminationphase,0.5852842809364548
durationofgrade4neutropenia,0.5852842809364548
plasmadrugclearance,0.5852842809364548
absorptionlag,0.5852842809364548
peakserumifc,0.5852842809364548
selectivityindex,0.5852842809364548
t3,0.5852842809364548
totalbodyexposure,0.5852842809364548
ce,0.5852842809364548
minimumeffectivedosemed,0.5852842809364548
kiapp,0.5852842809364548
t12lambda2,0.5852842809364548
timetmaxtoreachcmax,0.5852842809364548
entrapmentefficacy,0.5852842809364548
auclevel,0.5852842809364548
faucmicratio,0.5852842809364548
neteffluxratio,0.5852842809364548
plateautime,0.5852842809364548
areaunderplasmaconcentrationtimecurveauc,0.5852842809364548
auct0264,0.5852842809364548
resolution,0.5852842809364548
apparentvolumeofdistributionvdssf,0.5852842809364548
eliminationt12beta,0.5852842809364548
apparentsystemicclearancecl,0.5852842809364548
meandissolutiontime,0.5852842809364548
masstochargeratiomz,0.5852842809364548
la,0.5852842809364548
timestopeakplasmaconcentration,0.5852842809364548
areaundertheplasmadrugconcentrationtimecurve,0.5852842809364548
ph,0.5852842809364548
50effectivedose,0.5852842809364548
crcl,0.5852842809364548
k2,0.5852842809364548
absorptionhalflifet12a,0.5852842809364548
maximumbloodlevel,0.5852842809364548
areaunderthecurvesauc024,0.5852842809364548
renalclearanceclren,0.5852842809364548
doseadjusted,0.5852842809364548
maximumdailydosage,0.5852842809364548
plasmatargetconcentration,0.5852842809364548
hepatocellularity,0.5852842809364548
auc010,0.5852842809364548
bioavailablefraction,0.5852842809364548
clearancebioavailability,0.5852842809364548
effectiveplasmaconcentration,0.5852842809364548
eliminationrateconstantk,0.5852842809364548
initialhalflifet12alpha,0.5852842809364548
volumesofthecentralcompartment,0.5852842809364548
terminalplasmahalflifet12,0.5852842809364548
polydispersity,0.5852842809364548
overallclearance,0.5852842809364548
minimaleffectiveconcentration,0.5852842809364548
kon,0.5852842809364548
oralrelativebioavailability,0.5852842809364548
michaelisconstant,0.5852842809364548
cumulative,0.5852842809364548
rateofbioavailability,0.5852842809364548
halflifeforabsorption,0.5852842809364548
ic50ratio,0.5852842809364548
pec50,0.5852842809364548
cmaxatsteadystate,0.5852842809364548
chromatographicruntime,0.5852842809364548
aucfromtimezerotoinfinity,0.5852842809364548
distributiont12alpha,0.5852842809364548
eliminationhalflifet12z,0.5852842809364548
milktoplasmaconcentrationratio,0.5852842809364548
oralclearanceclo,0.5852842809364548
liverextractionratio,0.5852842809364548
dlt,0.5852842809364548
overallextractionrecovery,0.5852842809364548
totalareaundertheplasmazolpidemconcentrationtimecurve,0.5852842809364548
apparentintrinsicclearance,0.5852842809364548
runningtime,0.5852842809364548
distributionphase,0.5852842809364548
50inhibitionic50,0.5852842809364548
kob,0.5852842809364548
permeationflux,0.5852842809364548
apparentpermeability,0.5852842809364548
auc09h,0.5852842809364548
peaktroughratio,0.5852842809364548
steadystatevolume,0.5852842809364548
eliminationcapacity,0.5852842809364548
enhancementratioer,0.5852842809364548
halftimeofabsorption,0.5852842809364548
neteffluxbaab,0.5852842809364548
gradientflowrate,0.5852842809364548
inactivationconstantki,0.5852842809364548
plasmaterminalhalflifet12,0.5852842809364548
encapsulationrate,0.5852842809364548
serumconcentrationratio,0.5852842809364548
apparenttotalclearanceclf,0.5852842809364548
oralsystemicbioavailability,0.5852842809364548
timetoabsoluteneutrophilcountancrecovery,0.5852842809364548
tissuehalflife,0.5852842809364548
transplacentaltransfer,0.5852842809364548
auc0infinityratio,0.5852842809364548
surfacearea,0.5852842809364548
areaunderthecurveauc012h,0.5852842809364548
totalcdratio,0.5852842809364548
ka2,0.5852842809364548
eliminationphaset12beta,0.5852842809364548
tmax2,0.5852842809364548
percentrecoverie,0.5852842809364548
eliminationclearancecl,0.5852842809364548
eliminationconstantkel,0.5852842809364548
terminalhalflifetime,0.5852842809364548
apparentvolumeofdistributionvz,0.5852842809364548
serumtroughlevel,0.5852842809364548
residenttime,0.5852842809364548
eliminationhalftimet12beta,0.5852842809364548
tl,0.5852842809364548
populationclearance,0.5852842809364548
tab,0.5852842809364548
diffusioncoefficient,0.5852842809364548
enrichmentfactor,0.5852842809364548
areasundertheconcentrationtimecurveaucs,0.5852842809364548
radioactivity,0.5852842809364548
stabilityconstant,0.5852842809364548
areaundertheplasmaconcentrationtimecurveauc024h,0.5852842809364548
pra,0.5016722408026756
totalapparentvolumeofdistributionvdf,0.5016722408026756
peakserum,0.5016722408026756
percentageofproteinbinding,0.5016722408026756
tissueserumratio,0.5016722408026756
plateauconcentration,0.5016722408026756
k3,0.5016722408026756
reabsorption,0.5016722408026756
areaunderthecurveauc012,0.5016722408026756
whealarea,0.5016722408026756
um,0.5016722408026756
plasmaauc096h,0.5016722408026756
peripheralcompartmentvolume,0.5016722408026756
urinaryelimination,0.5016722408026756
timeofpeakplasmadrugconcentration,0.5016722408026756
intestinalextraction,0.5016722408026756
cmaxmic90ratio,0.5016722408026756
areaunderthecurvetoinfinity,0.5016722408026756
flarearea,0.5016722408026756
steadystatebloodconcentration,0.5016722408026756
cmaxdose,0.5016722408026756
apparentvolumesofdistributionvd,0.5016722408026756
halflivesof,0.5016722408026756
method,0.5016722408026756
halflifeforelimination,0.5016722408026756
areaunderthebloodconcentrationversustimecurve,0.5016722408026756
fractionalclearance,0.5016722408026756
ccr,0.5016722408026756
volumeofdistributioninthecentralcompartmentv1,0.5016722408026756
areaundertheconcentrationtimecurvefromtimezerotoinfinityauc0,0.5016722408026756
timeabovethe,0.5016722408026756
areaundertheconcentrationtimecurveauc48,0.5016722408026756
initialrate,0.5016722408026756
auciv,0.5016722408026756
totalgasflow,0.5016722408026756
freeclearance,0.5016722408026756
cerebrospinalfluidtoserumratio,0.5016722408026756
maximumcmax,0.5016722408026756
areaundercurveauc0infinity,0.5016722408026756
basal,0.5016722408026756
effectcompartmentconcentrationat50block,0.5016722408026756
processefficiency,0.5016722408026756
overallvolumeofdistribution,0.5016722408026756
timeaftertransplantation,0.5016722408026756
fab,0.5016722408026756
terminalplasmaeliminationhalflife,0.5016722408026756
areaundertheconcentrationtimecurveauc24,0.5016722408026756
morningtroughconcentration,0.5016722408026756
minimumoptimalc1trough,0.5016722408026756
areaundertheplasmaconcentrationtimecurvefrom0to12hoursauc012,0.5016722408026756
biliaryelimination,0.5016722408026756
plasmaareaunderthecurve,0.5016722408026756
mst,0.5016722408026756
safetythreshold,0.5016722408026756
survivaltimemst,0.5016722408026756
ctroughlevel,0.5016722408026756
turnovertime,0.5016722408026756
areaundertheplasmaconcentrationtimecurveauc0t,0.5016722408026756
clearancehalftime,0.5016722408026756
durationofanalgesia,0.5016722408026756
overallefficacyrate,0.5016722408026756
auc8h,0.5016722408026756
antixaactivity,0.5016722408026756
minimumdetectablelimit,0.5016722408026756
maximalrate,0.5016722408026756
ae,0.5016722408026756
penetrationrate,0.5016722408026756
vpf,0.5016722408026756
log,0.5016722408026756
oxygensaturation,0.5016722408026756
dosetroughconcentrationratio,0.5016722408026756
areaundercurveauc012,0.5016722408026756
dissociationconstant,0.5016722408026756
terminalhalflifet12lz,0.5016722408026756
halflifeoftheterminalphase,0.5016722408026756
apparenthalftime,0.5016722408026756
apparentvolumeofdistributionvbeta,0.5016722408026756
serumeliminationt12,0.5016722408026756
rateofdisappearance,0.5016722408026756
peakplasmadoxlevel,0.5016722408026756
plasmahalflivest12,0.5016722408026756
subjectiveresponse,0.5016722408026756
tubularsecretion,0.5016722408026756
weightnormalizedclearance,0.5016722408026756
meac,0.5016722408026756
metabolicrate,0.5016722408026756
halfmaximalinhibition,0.5016722408026756
areaunderthecurveoveradosingintervalauc,0.5016722408026756
metabolitetoparentratio,0.5016722408026756
peakd2receptoroccupancy,0.5016722408026756
timeinterval,0.5016722408026756
toxicity,0.5016722408026756
maximumchange,0.5016722408026756
ld,0.5016722408026756
salivaplasmaratio,0.5016722408026756
apparentdistributionvolumevdf,0.5016722408026756
timeofmaximumplasmaconcentrationtmax,0.5016722408026756
volumeoftheperipheralcompartment,0.5016722408026756
apparentkidose,0.5016722408026756
peakremifentanilconcentration,0.5016722408026756
hillconstant,0.5016722408026756
relativesystemicavailability,0.5016722408026756
clearanceatsteadystate,0.5016722408026756
totalcumulativeurinaryexcretion,0.5016722408026756
partitioncoefficientkp,0.5016722408026756
ad,0.5016722408026756
areaundertheplasmaconcentrationtimecurvefromtime0to12hauc012,0.5016722408026756
fractionfd,0.5016722408026756
steadystateplasmaconcentrationcssratio,0.5016722408026756
totalbodyclearanceci,0.5016722408026756
withdrawaltime,0.5016722408026756
s,0.5016722408026756
peakghconcentration,0.5016722408026756
brainplasmaaucratio,0.5016722408026756
maximumdoxcellularconcentration,0.5016722408026756
firstpasseffect,0.5016722408026756
clearanceofredituxtm,0.5016722408026756
clmax,0.5016722408026756
apparentcentraldistributionvolume,0.5016722408026756
clfkg,0.5016722408026756
c1trough,0.5016722408026756
fractionalendtidalalveolarconcentrationfa,0.5016722408026756
timetoneutrophilengraftment,0.5016722408026756
centralvolumeofdistributionvcf,0.5016722408026756
urinarysodiumexcretion,0.5016722408026756
apparentperipheralvolumeofdistribution,0.5016722408026756
maximumclearance,0.5016722408026756
formationrateconstant,0.5016722408026756
specificclearance,0.5016722408026756
rp2d,0.5016722408026756
livertoplasmaratio,0.5016722408026756
synovialfluidconcentration,0.5016722408026756
plasmaradioactivity,0.5016722408026756
failurerate,0.5016722408026756
negativity,0.5016722408026756
peakcodeineplasmaconcentration,0.5016722408026756
auc24mic,0.5016722408026756
steadystatepredosebloodconcentration,0.5016722408026756
inhibitionrate,0.5016722408026756
clh,0.5016722408026756
0to24hour,0.5016722408026756
encapsulation,0.5016722408026756
troughconcentrationscmin,0.5016722408026756
ec50u,0.5016722408026756
areaundertheconcentrationtimecurvefrom0to24h,0.5016722408026756
plasmaexposure,0.5016722408026756
cumulativebiliaryexcretion,0.5016722408026756
ft4,0.5016722408026756
overalleliminationhalflife,0.5016722408026756
peakaqueoushumorconcentration,0.5016722408026756
km1,0.5016722408026756
sensitivitie,0.5016722408026756
h,0.5016722408026756
apparentabsorption,0.5016722408026756
timetoreachmaximumconcentrationcmax,0.5016722408026756
apparentvmax,0.5016722408026756
peakvenousplasmaconcentration,0.5016722408026756
hydroxylationindex,0.5016722408026756
urinaryoutput,0.5016722408026756
dosecorrected,0.5016722408026756
deltaauc,0.5016722408026756
areaunderthecurveauc06,0.5016722408026756
responseraterr,0.5016722408026756
distributionrateconstant,0.5016722408026756
cls,0.5016722408026756
relapse,0.5016722408026756
absolutebioavailabilityba,0.5016722408026756
micro,0.5016722408026756
volumeofdistributionbyarea,0.5016722408026756
maximalserumconcentrationcmax,0.5016722408026756
troughconcentrationctrough,0.5016722408026756
centralvolumeofdistributionvc,0.5016722408026756
fa,0.5016722408026756
centralcompartmentvolumev1,0.5016722408026756
pulmonaryextraction,0.5016722408026756
dynamic,0.5016722408026756
plasmaclearancecltot,0.5016722408026756
apparentvolumeof,0.5016722408026756
c2h,0.5016722408026756
eliminationrateconstantk10,0.5016722408026756
auco,0.5016722408026756
diseasefreeinterval,0.5016722408026756
rptd,0.5016722408026756
vfemale,0.5016722408026756
volumeofdistributionvbeta,0.5016722408026756
entra,0.5016722408026756
areasundertheserumconcentrationcurve,0.5016722408026756
halflifeofthebetaphase,0.5016722408026756
vmale,0.5016722408026756
milkserumratio,0.5016722408026756
lengthofhospitalstay,0.5016722408026756
maturationhalftime,0.5016722408026756
peripheralcompartment,0.5016722408026756
bt,0.5016722408026756
absorbeddose,0.5016722408026756
encapsulationratio,0.5016722408026756
tissueconcentration,0.5016722408026756
auc071hratio,0.5016722408026756
meanresidencetimesmrts,0.5016722408026756
durationsofresponse,0.5016722408026756
auc024hr,0.5016722408026756
auc0180,0.5016722408026756
apparentdissociationconstant,0.5016722408026756
percentexcretedunchanged,0.5016722408026756
troughdaclizumablevel,0.5016722408026756
effect,0.5016722408026756
cc50,0.5016722408026756
rateofabsorptionka,0.5016722408026756
timeconstant,0.5016722408026756
cumulativeurinaryrecovery,0.5016722408026756
aucd,0.5016722408026756
latelo,0.5016722408026756
tmaxss,0.5016722408026756
precision,0.5016722408026756
durationofremission,0.5016722408026756
residualvariability,0.5016722408026756
maximuminactivationrateconstant,0.5016722408026756
2h,0.5016722408026756
steadystatebloodlevel,0.5016722408026756
ana,0.5016722408026756
lagtimeinabsorption,0.5016722408026756
painscore,0.5016722408026756
apparentplasmaeliminationhalflife,0.5016722408026756
observed,0.5016722408026756
absorptionhalflifetabs,0.5016722408026756
apparentpermeabilitycoefficient,0.5016722408026756
maximalresponse,0.5016722408026756
halfdisappearancetime,0.5016722408026756
totalchromatographytime,0.5016722408026756
serumpeakconcentration,0.5016722408026756
plasmaosmolality,0.5016722408026756
auc016h,0.5016722408026756
vascularcardiaceffectratio,0.5016722408026756
apparentvd,0.5016722408026756
betaphase,0.5016722408026756
maximummeanconcentration,0.5016722408026756
plasmaticconcentration,0.5016722408026756
intestinalelimination,0.5016722408026756
clearancefromthecentralcompartment,0.5016722408026756
peakheight,0.5016722408026756
50inhibitionconcentration,0.5016722408026756
timeatwhichpeakconcentrationsoccurred,0.5016722408026756
peakplasmalevelscmax,0.5016722408026756
ve,0.5016722408026756
maximumtimetmax,0.5016722408026756
icr,0.5016722408026756
maximuminspiredconcentration,0.5016722408026756
steadystatedistributionvolumevdss,0.5016722408026756
percutaneousabsorption,0.5016722408026756
relativeabsorption,0.5016722408026756
drugrecovery,0.5016722408026756
overallextractionrecoverie,0.5016722408026756
absoluteavailability,0.5016722408026756
analyticalrecoverie,0.5016722408026756
ece50,0.5016722408026756
plasmatroughlevel,0.5016722408026756
celltomediumconcentrationratio,0.5016722408026756
pic50,0.5016722408026756
f1,0.5016722408026756
timeofmaximumplasmaconcentration,0.5016722408026756
cumulativepermeation,0.5016722408026756
deliveryrate,0.5016722408026756
rateconstantk,0.5016722408026756
turnaroundtime,0.5016722408026756
areaxtime,0.5016722408026756
directtransportpercentage,0.5016722408026756
pulserate,0.5016722408026756
ri,0.5016722408026756
relativeclearance,0.5016722408026756
plasmaterminaleliminationhalflive,0.5016722408026756
apparentterminalhalflifet12beta,0.5016722408026756
refractiveindex,0.5016722408026756
oralareaundertheserumconcentrationtimecurveauc,0.5016722408026756
peakulcer,0.5016722408026756
wholebloodtoplasmaratio,0.5016722408026756
bpratio,0.5016722408026756
dauc,0.5016722408026756
associationconstantka,0.5016722408026756
glucuronidation,0.5016722408026756
glucuronidationrate,0.5016722408026756
peakresolution,0.5016722408026756
latencie,0.5016722408026756
timetorecovery,0.5016722408026756
diseasefree,0.5016722408026756
membranepermeability,0.5016722408026756
volumeofdistributionintheperipheralcompartmentvp,0.5016722408026756
initialplasmaconcentration,0.5016722408026756
foral,0.5016722408026756
areaundertheconcentrationtimecurveauc012,0.5016722408026756
tid20,0.5016722408026756
totalbodyclearancesclt,0.5016722408026756
apparentvolumeofdistributionvssf,0.5016722408026756
plasmahalflifet12beta,0.5016722408026756
redistributionhalflife,0.5016722408026756
clinicalcurerate,0.5016722408026756
rapid,0.5016722408026756
t12term,0.5016722408026756
cmean,0.5016722408026756
volumeofdistributionvcf,0.5016722408026756
perme,0.5016722408026756
volumeofdistributioninthecentralcompartmentvc,0.5016722408026756
metabolitetoparentdrugratio,0.5016722408026756
metabolic,0.5016722408026756
emulsificationtime,0.5016722408026756
transferhalflife,0.5016722408026756
complete,0.5016722408026756
qainterval,0.5016722408026756
productionrateconstant,0.5016722408026756
auc022h,0.5016722408026756
maximumheartrate,0.5016722408026756
timetopeakapaptmax,0.4180602006688963
pd20,0.4180602006688963
forcedexpiratoryvolumein1second,0.4180602006688963
areaunderthereceiveroperatingcharacteristiccurveauc08,0.4180602006688963
auc1224,0.4180602006688963
occupancyhalflife,0.4180602006688963
oralbioavailabilityba,0.4180602006688963
areaundertheserummtxconcentrationtimecurveauc,0.4180602006688963
timetoonset,0.4180602006688963
maximuminactivationrateconstantkinact,0.4180602006688963
plasmadisappearancehalftime,0.4180602006688963
apparentmtxclearanceci,0.4180602006688963
maximumapapconcentrationapapmax,0.4180602006688963
areaunderthecurvefrom0to24hauc024,0.4180602006688963
apparentcentral,0.4180602006688963
appearancehalflife,0.4180602006688963
volumeofdistributionatsteadystatev,0.4180602006688963
systemicvascularresistance,0.4180602006688963
t12elim,0.4180602006688963
terminalhalftime,0.4180602006688963
tailflicklatencie,0.4180602006688963
kmkiratio,0.4180602006688963
areasunderthecurveauc0infinity,0.4180602006688963
crossmembranepermeabilitypm,0.4180602006688963
fractionmetabolizedtodoxolfm,0.4180602006688963
apparentmeanvolumeofdistribution,0.4180602006688963
vdkg,0.4180602006688963
maximumbupivacaineplasmaconcentration,0.4180602006688963
rateofabsorptiontmax,0.4180602006688963
drugtargetingindexdti,0.4180602006688963
lifetime,0.4180602006688963
conversiontooc,0.4180602006688963
transporterindependent,0.4180602006688963
aucoral,0.4180602006688963
eauc50,0.4180602006688963
plasmamidazolamconcentration,0.4180602006688963
fct,0.4180602006688963
killrate,0.4180602006688963
kpapp,0.4180602006688963
pct,0.4180602006688963
apparentabsolutebioavailability,0.4180602006688963
maximalaggregation,0.4180602006688963
micsusceptibilitybreakpoint,0.4180602006688963
circulatinghalflive,0.4180602006688963
plasmaareaunderthetimecurve0toinfinity,0.4180602006688963
halflifebeta,0.4180602006688963
drugentrapment,0.4180602006688963
volumeoftheperipheralcompartmentv2,0.4180602006688963
apparentspecificvolumeofdistribution,0.4180602006688963
t12ratio,0.4180602006688963
aucsr,0.4180602006688963
cssplasmaconcentration,0.4180602006688963
halflifetimet05,0.4180602006688963
occurrenceprobabilitie,0.4180602006688963
ktr,0.4180602006688963
auc096,0.4180602006688963
coefficient,0.4180602006688963
halflifeintheeliminationphase,0.4180602006688963
constant,0.4180602006688963
synovialfluidexitrateconstant,0.4180602006688963
saturationlevel,0.4180602006688963
apparentvolumeofdistributionarea,0.4180602006688963
percentinhibition,0.4180602006688963
plasmacortisolconcentration,0.4180602006688963
timetomaximumvenousconcentration,0.4180602006688963
centralvolumevc,0.4180602006688963
timetoreachthecmaxtmax,0.4180602006688963
maximumvenousconcentration,0.4180602006688963
limitsofq,0.4180602006688963
biodisponibility,0.4180602006688963
overallauc,0.4180602006688963
peaktherapeuticserumconcentration,0.4180602006688963
totalexposure,0.4180602006688963
totalabsorption,0.4180602006688963
auclastratio,0.4180602006688963
terminalplasmat12,0.4180602006688963
linearclearance,0.4180602006688963
totalsystemicexposure,0.4180602006688963
terminalslope,0.4180602006688963
halfmaximaleffect,0.4180602006688963
cxt,0.4180602006688963
wholebloodconcentration,0.4180602006688963
loading,0.4180602006688963
absoluteextractionrecovery,0.4180602006688963
observedclearanceclf,0.4180602006688963
relativesystemicbioavailability,0.4180602006688963
concentrationcmax,0.4180602006688963
areaundertheplasmaconcentrationtimecurvedextrapolatedtoinfinity,0.4180602006688963
areaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc,0.4180602006688963
biliaryexcretionindex,0.4180602006688963
peripheraltocentralk21,0.4180602006688963
areasundertheplasmaconcentrationcurve,0.4180602006688963
distributionvolumesatsteadystate,0.4180602006688963
kiinhibitorconstant,0.4180602006688963
activationenergy,0.4180602006688963
acrophase,0.4180602006688963
dem,0.4180602006688963
vssratio,0.4180602006688963
halflivesforelimination,0.4180602006688963
arterialpco2,0.4180602006688963
extra,0.4180602006688963
apparentvolumeofdistributionvdss,0.4180602006688963
timetomaximumplasmaconcentrationcmax,0.4180602006688963
plasmareninactivity,0.4180602006688963
vasscore,0.4180602006688963
t12halflife,0.4180602006688963
snratio,0.4180602006688963
timeofmaximalconcentration,0.4180602006688963
vssvolumeofdistributionatsteadystate,0.4180602006688963
auc024hratio,0.4180602006688963
clearanceci,0.4180602006688963
rateofmetabolism,0.4180602006688963
12hour,0.4180602006688963
maximalmeanplasmaconcentration,0.4180602006688963
renalexcretionduring24hour,0.4180602006688963
maximalpeakconcentration,0.4180602006688963
rateofdegradation,0.4180602006688963
distributionrateconstantscentraltoperipheralcompartmentk12,0.4180602006688963
halflifeatalphaphase,0.4180602006688963
cluptake,0.4180602006688963
terminalserumeliminationhalflife,0.4180602006688963
fractionofdepositeddose,0.4180602006688963
aucprostate,0.4180602006688963
urinaryexcretionratio,0.4180602006688963
maximumavratio,0.4180602006688963
ic,0.4180602006688963
bloodserumconcentration,0.4180602006688963
areaunderthecurveaucinfinity,0.4180602006688963
aqueoushumorconcentration,0.4180602006688963
rateofincreaseintwitchtension,0.4180602006688963
timetoplateau,0.4180602006688963
timeatwhich,0.4180602006688963
steadystatevolumeofdistributionv,0.4180602006688963
unbounddrug,0.4180602006688963
timetomaximalactivity,0.4180602006688963
freefractioninserum,0.4180602006688963
volumeof,0.4180602006688963
distributionclearancecld,0.4180602006688963
pulmonaryextractionratio,0.4180602006688963
clsf,0.4180602006688963
pulmonaryclearance,0.4180602006688963
bioavailabilityauc,0.4180602006688963
sc,0.4180602006688963
auic24,0.4180602006688963
headacheresponserate,0.4180602006688963
recoveryratefromurine,0.4180602006688963
timetomaximalserumlevel,0.4180602006688963
systemicclearancecl1,0.4180602006688963
systemictemperature,0.4180602006688963
eliminationhalflifeduringthecpbphaset12cpb,0.4180602006688963
totaldurationofneuromuscularblockade,0.4180602006688963
tr,0.4180602006688963
responderrate,0.4180602006688963
tofratio,0.4180602006688963
liverextraction,0.4180602006688963
degradationrate,0.4180602006688963
mtdrd,0.4180602006688963
concentrationat50blockcpss50,0.4180602006688963
concentrationratiouvmv,0.4180602006688963
maximumdepressionofthefirsttwitch,0.4180602006688963
timesto90,0.4180602006688963
steadystateplasma,0.4180602006688963
q12h,0.4180602006688963
totalrunningtime,0.4180602006688963
525recoverytime,0.4180602006688963
apparenteliminationrateconstantlz,0.4180602006688963
uptakeratio,0.4180602006688963
apparentinfluxclearance,0.4180602006688963
volumesofdistributionatsteadystatevdss,0.4180602006688963
analyticalruntime,0.4180602006688963
halftimeoftheapparentfirstorderdeclineofplasmaconcentration,0.4180602006688963
rateofeliminationk10,0.4180602006688963
competitiveki,0.4180602006688963
capacityfactor,0.4180602006688963
timetoreachthemaximumconcentration,0.4180602006688963
totalapparentoralclearance,0.4180602006688963
id50concentration,0.4180602006688963
mrt024,0.4180602006688963
2575recoverytime,0.4180602006688963
rateofrenalclearance,0.4180602006688963
t75,0.4180602006688963
cs50,0.4180602006688963
totalbodyelimination,0.4180602006688963
maximumbloodconcentrationcmax,0.4180602006688963
areaunderthecurvefrom0to72hauc072,0.4180602006688963
bioavailabilityfactor,0.4180602006688963
areasunderthecurvesauc,0.4180602006688963
peakconcentrationsinplasmacmax,0.4180602006688963
totalhepaticbloodflow,0.4180602006688963
timestorecovery,0.4180602006688963
timetofullalertne,0.4180602006688963
plasmaradioactivityhalflife,0.4180602006688963
bindingpercentage,0.4180602006688963
biliary,0.4180602006688963
timeofonset,0.4180602006688963
overallpenetrationintoinflammatoryfluid,0.4180602006688963
areaundertheplasmaconcentrationtimecurveaucratio,0.4180602006688963
maximumdrugplasmaconcentrationscmax,0.4180602006688963
percentrelativebioavailability,0.4180602006688963
volumeofperipheralcompartment,0.4180602006688963
apparentic50,0.4180602006688963
noncompartmentalclearance,0.4180602006688963
relativeoralintramuscularbioavailability,0.4180602006688963
clplasma,0.4180602006688963
k0,0.4180602006688963
nonrenal,0.4180602006688963
halflifet12eff,0.4180602006688963
eliminationhalflivest12alpha,0.4180602006688963
biologicalhalftime,0.4180602006688963
spreadability,0.4180602006688963
volumevf,0.4180602006688963
totaltlevel,0.4180602006688963
clinical,0.4180602006688963
toplasmaaucratio,0.4180602006688963
aucfrom0to6h,0.4180602006688963
doseratecsstroughratio,0.4180602006688963
totaldurationof,0.4180602006688963
effectcompartmentconcentration,0.4180602006688963
timetorecoverto50ofmaximaltwitchdepression,0.4180602006688963
em,0.4180602006688963
distributionvolumevf,0.4180602006688963
vdareaf,0.4180602006688963
cthrough,0.4180602006688963
residualvolume,0.4180602006688963
liverwaterpartitionratio,0.4180602006688963
respiration,0.4180602006688963
therapeuticwindow,0.4180602006688963
lifespan,0.4180602006688963
gammahl,0.4180602006688963
troughlevelsc0,0.4180602006688963
rateofappearance,0.4180602006688963
cmaxcminratio,0.4180602006688963
maximalglucoseinfusionrate,0.4180602006688963
fast,0.4180602006688963
troughevrlevel,0.4180602006688963
troughsirolimusconcentration,0.4180602006688963
lossindex,0.4180602006688963
auc0alpha,0.4180602006688963
therapeuticplasmaconcentration,0.4180602006688963
durationofstabledisease,0.4180602006688963
lambda2,0.4180602006688963
intrinsicclbiliary,0.4180602006688963
areaundertheconcentrationtimecurvefrom0to24hour,0.4180602006688963
clc,0.4180602006688963
mic80,0.4180602006688963
alphat12,0.4180602006688963
steadystateplasmatpaclearance,0.4180602006688963
initialplasmahalflife,0.4180602006688963
tissue,0.4180602006688963
ttr,0.4180602006688963
rc,0.4180602006688963
cmaxdn10mg,0.4180602006688963
areaundertheconcentrationtimecurvefromzerotoinfinity,0.4180602006688963
majorresponseratecrmr,0.4180602006688963
ld90,0.4180602006688963
lc50,0.4180602006688963
aptt,0.4180602006688963
lambda,0.4180602006688963
inhibitoryconstantski,0.4180602006688963
vdssf,0.4180602006688963
clearancescl,0.4180602006688963
extentofabsorption,0.4180602006688963
extrarenalclearance,0.4180602006688963
fp,0.4180602006688963
totalvolumeofdistributionvd,0.4180602006688963
apparenteliminationhalflifet12beta,0.4180602006688963
auc48,0.4180602006688963
aucinfinity0,0.4180602006688963
m1,0.4180602006688963
maximumconcentrationinserumcmax,0.4180602006688963
excitationemissionwavelength,0.4180602006688963
initialreleaserate,0.4180602006688963
auco24,0.4180602006688963
auc0tratio,0.4180602006688963
efficacy,0.4180602006688963
orrate,0.4180602006688963
parasiteclearancetimepct,0.4180602006688963
feverclearancetimefct,0.4180602006688963
steadystatebiliaryclearance,0.4180602006688963
tumortomuscleratiotm,0.4180602006688963
minimalconcentration,0.4180602006688963
distributionvolumevdf,0.4180602006688963
totalareaundertheplasmaz,0.4180602006688963
urinaryrecoveryofunchangeddrug,0.4180602006688963
apparenttotalclearancecltf,0.4180602006688963
invivorecoverie,0.4180602006688963
clearancerateclf,0.4180602006688963
firstorderdegradationhalflive,0.4180602006688963
from,0.4180602006688963
areaundertheserumconcentrationtimecurvefromtime0toinfinityauc0infinity,0.4180602006688963
apparentvolumeatsteadystate,0.4180602006688963
apparentvolumeoftherapidperipheralcompartment,0.4180602006688963
auc0tauss,0.4180602006688963
auccsfaucplasmaratio,0.4180602006688963
observedmaximumplasmaconcentration,0.4180602006688963
steadystatevolumeofdistributionvd,0.4180602006688963
tclor,0.4180602006688963
reductionratio,0.4180602006688963
totalareaundertheplasmabuspironeconcentrationtimecurve,0.4180602006688963
timetopeakbloodconcentration,0.4180602006688963
halflivest12s,0.4180602006688963
areaunderthecurve0toinfinity,0.4180602006688963
areaunderthecurve024,0.4180602006688963
clren,0.4180602006688963
centralcompartmentvolumeofdistribution,0.4180602006688963
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityaucinfinity,0.4180602006688963
aucareaunderthecurve,0.4180602006688963
maximumcorrectedqtqtcinterval,0.4180602006688963
auc0144,0.4180602006688963
index,0.4180602006688963
totalcumulativedose,0.4180602006688963
totalareasunderthecurveauctot,0.4180602006688963
biologicalhalflifet12beta,0.4180602006688963
concentrationproducing50inhibitionic50,0.4180602006688963
renaldigoxinclearance,0.4180602006688963
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityaucinfinity,0.4180602006688963
inhibitionratio,0.4180602006688963
apparentplasmahalflive,0.4180602006688963
ced,0.4180602006688963
tumorresponserate,0.4180602006688963
sleepingtime,0.4180602006688963
apparenttotalplasmaclearance,0.4180602006688963
specificsurfacearea,0.4180602006688963
steadystatetroughlevel,0.4180602006688963
inductiontime,0.4180602006688963
cerebrospinalfluidconcentration,0.4180602006688963
totalsystemicavailability,0.4180602006688963
fauc024micratio,0.4180602006688963
drugplasmaconcentration,0.4180602006688963
transportratio,0.4180602006688963
ro,0.4180602006688963
pk,0.4180602006688963
vmax1,0.4180602006688963
steadystatebrainconcentration,0.4180602006688963
cluint,0.4180602006688963
maximalinactivationrateconstantskinact,0.4180602006688963
troughfev1,0.4180602006688963
t90,0.4180602006688963
fractionofdoseabsorbed,0.4180602006688963
plateletcount,0.4180602006688963
objectiveresponserateorr,0.4180602006688963
equilibriumhalflife,0.4180602006688963
halflifeofeffectdelay,0.4180602006688963
peakfev1,0.4180602006688963
dosenormalizedauclast,0.4180602006688963
apparentbodyclearance,0.4180602006688963
timeto50recoveryofeffectt12offset,0.4180602006688963
tp,0.4180602006688963
t12offset,0.4180602006688963
recoveryhalflife,0.4180602006688963
tmaxtimetomaximalplasmaconcentration,0.4180602006688963
relativedoseintensity,0.4180602006688963
totalpathologiccompleteresponserate,0.4180602006688963
bpcrrate,0.4180602006688963
brainplasmaconcentrationratio,0.4180602006688963
totalplasmaclearancecltot,0.4180602006688963
maximallytolerateddosemtd,0.4180602006688963
aucss024,0.4180602006688963
glucose,0.4180602006688963
doserequiredtoproducehalfmaximaleffected50,0.4180602006688963
km2,0.4180602006688963
extentof,0.4180602006688963
c0mpalevel,0.4180602006688963
milkplasmaaucratio,0.4180602006688963
diffusion,0.4180602006688963
shelflive,0.4180602006688963
timeofpeaklevel,0.4180602006688963
fmax,0.4180602006688963
steadystateauc0,0.4180602006688963
steadystatetmax,0.4180602006688963
leukocytenadir,0.4180602006688963
biliaryrecoverie,0.4180602006688963
sampleanalysistime,0.4180602006688963
totalareaundertheplasmazolpidemconcentrationtimecurveauc0infinity,0.4180602006688963
fmax1b,0.4180602006688963
timetofirstresponse,0.4180602006688963
concentrationc0h,0.4180602006688963
clinicalresponserate,0.4180602006688963
unboundrenalclearance,0.4180602006688963
ks,0.4180602006688963
percentageaucratio,0.4180602006688963
concentrationtodoseratio,0.4180602006688963
apparentvolumeofdistributionavd,0.4180602006688963
kip,0.4180602006688963
tc01,0.4180602006688963
areasundertheplasmaconcentrationtimecurveaucvalues,0.4180602006688963
terminaleliminationphasehalflife,0.4180602006688963
cle,0.4180602006688963
areaunderthebloodconcentrationtimecurve,0.4180602006688963
precursorproducttransitionsmz,0.4180602006688963
massratio,0.4180602006688963
proteinbindingtoserumalbumin,0.4180602006688963
lengthofstay,0.4180602006688963
peakantixa,0.4180602006688963
maximumratevm,0.4180602006688963
areaundertheconcentrationtimecurvefrom0to12hour,0.4180602006688963
onsettimeofmaximumeffect,0.4180602006688963
terminaleliminationhalflifeinblood,0.4180602006688963
kapp,0.4180602006688963
bloodtroughlevel,0.4180602006688963
timeoftheconversion,0.4180602006688963
tn,0.4180602006688963
t01,0.4180602006688963
tmaxtimetocmax,0.4180602006688963
aucfrom0to12hoursauc12,0.4180602006688963
requirement,0.4180602006688963
areaunderthecurvesaucs,0.4180602006688963
dosenormalizedc0,0.4180602006688963
a2,0.4180602006688963
plasmaauc0infinity,0.4180602006688963
transferrateconstant,0.4180602006688963
survivingfraction,0.4180602006688963
auc0360,0.4180602006688963
totalch,0.4180602006688963
minimumeffectivecsfclonidineconcentration,0.4180602006688963
initialvolumeofdistributionv1,0.4180602006688963
pa,0.4180602006688963
halflifeincirculation,0.4180602006688963
solubilitie,0.4180602006688963
totalmsruntime,0.4180602006688963
aucbrain,0.4180602006688963
timetoreachmaximum,0.4180602006688963
areaundertheconcentrationtimecurvefrom0to48h,0.4180602006688963
troughantifactorxaactivity,0.4180602006688963
minutevolume,0.4180602006688963
distributionclearanceq,0.4180602006688963
activatedpartialthromboplastintime,0.4180602006688963
volumeofdistributionvzf,0.4180602006688963
plasmaip,0.4180602006688963
renalextractionratio,0.4180602006688963
durationofsurgery,0.4180602006688963
hepaticavailabilityfh,0.4180602006688963
timetoreachthemaximum,0.4180602006688963
totalamountofteriflunomideremoved,0.4180602006688963
timetomaximumconcentrationofdruginserumtmax,0.4180602006688963
areaundertheconcentrationcurvefrom0to12hauc012,0.4180602006688963
timetopsaprogression,0.4180602006688963
timetoseizuretermination,0.4180602006688963
aucsstau,0.4180602006688963
biologichalflive,0.4180602006688963
areaunderthecurvesauc,0.4180602006688963
relativeaucratio,0.4180602006688963
rateofremoval,0.4180602006688963
secondorderrateconstant,0.4180602006688963
areaunderthetimeconcentrationcurvesaucs,0.4180602006688963
troughplasmaticagrelor,0.4180602006688963
clap,0.4180602006688963
areaundertheconcentrationtimecurvesaucs,0.4180602006688963
areaundertheplasmaconcentrationtimecurvefromtime0to8hoursauc8,0.4180602006688963
areaundertheplasmatimecurve,0.4180602006688963
apparentvolumeofdistributionvarea,0.4180602006688963
bindingcapacity,0.4180602006688963
intercompartmentalclearanceqf,0.4180602006688963
inhibitorconstantki,0.4180602006688963
halftimeoftheterminalphase,0.4180602006688963
apparentclearancesclf,0.4180602006688963
absoluterecoveryrate,0.4180602006688963
tm,0.4180602006688963
peakarterialconcentration,0.4180602006688963
toplasmaratio,0.4180602006688963
timestomaximalplasmaconcentrationtmax,0.4180602006688963
oralauc,0.4180602006688963
50effectiveconcentrationec50,0.4180602006688963
placentaltransferrate,0.4180602006688963
auc01h,0.4180602006688963
minimumalveolarconcentration,0.4180602006688963
kd1,0.4180602006688963
loadingcontent,0.4180602006688963
areaunderthecurvefrom0to2hoursauc02,0.4180602006688963
salivaryconcentration,0.4180602006688963
bloodbrain,0.4180602006688963
halftimeofblockade,0.4180602006688963
aucp,0.4180602006688963
totaldailydose,0.4180602006688963
el,0.4180602006688963
c30,0.4180602006688963
absolutegran,0.4180602006688963
areaundertheplasmaconcentrationtimecurveauc0,0.4180602006688963
dltrate,0.4180602006688963
areaunderthecurve012,0.4180602006688963
25recoveryt1t0,0.4180602006688963
halflivesofaccumulation,0.4180602006688963
emaxec50,0.4180602006688963
apparentsteadystateplasmaconcentration,0.4180602006688963
maximumcortisolreleaserate,0.4180602006688963
vesiclesize,0.4180602006688963
biliaryexcretionclearance,0.4180602006688963
effectcompartmentconcentrationcorrespondingto50,0.4180602006688963
inhibitionconstantski,0.4180602006688963
vo2max,0.4180602006688963
second,0.4180602006688963
75recovery,0.4180602006688963
robs,0.4180602006688963
log10,0.4180602006688963
apparentvolumeofdistributionofthecentralcompartmentvc,0.4180602006688963
12h,0.4180602006688963
50recoveryt1t0,0.4180602006688963
average,0.4180602006688963
directtransportpercentagedtp,0.4180602006688963
timetothisnadir,0.4180602006688963
maximumdiltiazemconcentration,0.4180602006688963
concentrationdoseratio,0.4180602006688963
apparentvolumeofdistributionofatgvd,0.4180602006688963
auctratio,0.4180602006688963
steadystatemaximumconcentration,0.4180602006688963
vmaxkm,0.4180602006688963
eliminationhalflifet05e,0.4180602006688963
recoveryoft4t1,0.4180602006688963
mzratio,0.4180602006688963
auc015,0.4180602006688963
mpf,0.4180602006688963
reversibility,0.4180602006688963
lagtimeofabsorption,0.4180602006688963
clsec,0.4180602006688963
progressionfreeratepfr,0.4180602006688963
td,0.4180602006688963
ra,0.4180602006688963
peakbronchodilatoreffect,0.4180602006688963
maximummean,0.4180602006688963
meanretentiontime,0.4180602006688963
tumorplasmaratio,0.4180602006688963
areaundertheconcentrationtimecurveinhibitoryratio,0.4180602006688963
vesi,0.4180602006688963
1,0.4180602006688963
totalbodyclearancecltb,0.4180602006688963
totaltroughconcentration,0.4180602006688963
maximumplasmalevelcmax,0.4180602006688963
ft,0.4180602006688963
plasmaunboundconcentration,0.4180602006688963
unboundauc012,0.4180602006688963
kf,0.4180602006688963
plasmaconcentrationatsteadystate,0.4180602006688963
betaphasehalflifeofelimination,0.4180602006688963
oralmidazolam,0.4180602006688963
t12kel,0.4180602006688963
volumeofdistributionofthecentralcompartmentafteroraladministrationv1f,0.4180602006688963
terminalhalflivesofelimination,0.4180602006688963
eliminationt12zhalflive,0.4180602006688963
percentagerelativebioavailability,0.4180602006688963
exitrateconstantfor,0.4180602006688963
maximumrhil3serumconcentration,0.4180602006688963
maximaleliminationratevmax,0.4180602006688963
areasundertheconcentrationcurve,0.4180602006688963
ic50u,0.4180602006688963
sirauc,0.4180602006688963
redistribution,0.4180602006688963
peakplasmaepinephrineconcentration,0.4180602006688963
areaunderthebloodconcentrationtimecurvefromtimezeroto12hoursauc12,0.4180602006688963
fecalrecovery,0.4180602006688963
apparentsystemicplasmaclearance,0.4180602006688963
insulinsensitivity,0.4180602006688963
plasmaconcentrationsatsteadystate,0.4180602006688963
maximumis5mnplasmaconcentration,0.4180602006688963
apparentterminaleliminationhalflifet12,0.33444816053511706
serumbioavailability,0.33444816053511706
pef,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefrom0to24hour,0.33444816053511706
throughconcentration,0.33444816053511706
ie,0.33444816053511706
maximumtolerabledose,0.33444816053511706
corneal,0.33444816053511706
fractionofdoseexcretedinurine,0.33444816053511706
timetocr,0.33444816053511706
totalapparentvolumeofdistributionatsteadystate,0.33444816053511706
ggt,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefromzeroto24hoursauc24,0.33444816053511706
serumterminalhalflife,0.33444816053511706
initialserumconcentrationco,0.33444816053511706
influxclearance,0.33444816053511706
systemicclearanceclf,0.33444816053511706
lo,0.33444816053511706
krbc,0.33444816053511706
steadystateauc024,0.33444816053511706
initialpeak,0.33444816053511706
clpf,0.33444816053511706
minimumserumconcentration,0.33444816053511706
apparenttotalbodyclearanceclf,0.33444816053511706
ratiosofareaundertheconcentrationtimecurveauctothemic,0.33444816053511706
rateofelimination,0.33444816053511706
pseudosteadystatelevel,0.33444816053511706
effectiveplasmalevel,0.33444816053511706
totalmcd,0.33444816053511706
recoveryof14c,0.33444816053511706
auc08hr,0.33444816053511706
durationuntil,0.33444816053511706
maximumnatriureticeffect,0.33444816053511706
percentagecumulativerelease,0.33444816053511706
totaleliminationconstantk10,0.33444816053511706
totalareasundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc,0.33444816053511706
steadystatecerebrospinalfluidplasmaratio,0.33444816053511706
tumorinhibitoryrate,0.33444816053511706
biologicalhalflifebetaphase,0.33444816053511706
volumeofdistributionbasedonarea,0.33444816053511706
plasmadialysisclearance,0.33444816053511706
timetofirstincreaseindose,0.33444816053511706
onsettimeuntilmaximumblock,0.33444816053511706
plasmaconcentrationat25recoveryofthetwitchheight,0.33444816053511706
plasmamaximumconcentrationcmax,0.33444816053511706
apparentvolumeofdistributionatequilibrium,0.33444816053511706
end,0.33444816053511706
drugrequirement,0.33444816053511706
fractionalconversion,0.33444816053511706
bioavailablity,0.33444816053511706
peaktocainideconcentration,0.33444816053511706
totalsamplingtime,0.33444816053511706
dosecorrectedauc,0.33444816053511706
signaltonoiseratiosn,0.33444816053511706
meanresidencetimemrtinf,0.33444816053511706
distributionvolumev,0.33444816053511706
distributionhalflifet12lambda1,0.33444816053511706
mpratio,0.33444816053511706
msratio,0.33444816053511706
clearanceofunbound,0.33444816053511706
partialresponseduration,0.33444816053511706
timeofcmax,0.33444816053511706
serumpeaklevel,0.33444816053511706
percentagepenetrationintoblisterfluid,0.33444816053511706
systemicclearancecltot,0.33444816053511706
clearanceclb,0.33444816053511706
diuresisatsteadystate,0.33444816053511706
morning,0.33444816053511706
peakdifference,0.33444816053511706
freedrugclearance,0.33444816053511706
25recoveryoftwitchheight,0.33444816053511706
vo,0.33444816053511706
areaundertheconcentrationtimecurvefrom0to4h,0.33444816053511706
volumeofdistributionoftheperipheralcompartmentv2,0.33444816053511706
spectraldissociationconstantks,0.33444816053511706
apparentunboundclearance,0.33444816053511706
plasmaaucmicratio,0.33444816053511706
areasundertheserumlevelcurve,0.33444816053511706
productionratepr,0.33444816053511706
intrinsicactivity,0.33444816053511706
serumconcentrationpeak,0.33444816053511706
survivaltimesmsts,0.33444816053511706
cpss95,0.33444816053511706
halflivest12alpha,0.33444816053511706
volumeofdistributionduringtheterminalphase,0.33444816053511706
dmax,0.33444816053511706
distributionalhalflife,0.33444816053511706
fetaltomaternal,0.33444816053511706
peaktotroughratio,0.33444816053511706
50inhibitoryconcentrationsic50s,0.33444816053511706
concentrationsrequiredfor50inhibitionec50,0.33444816053511706
d50,0.33444816053511706
alphaphase,0.33444816053511706
clearancebioavailabilityclf,0.33444816053511706
feversubsidencetime,0.33444816053511706
totalanalysisruntime,0.33444816053511706
volumeofthecentralcompartmentbioavailability,0.33444816053511706
timetopainrelief,0.33444816053511706
deformabilityindex,0.33444816053511706
normalizedareaundertheplasmaconcentrationtimecurvefrom0to45minute,0.33444816053511706
eliminationhalflifet12lambda2,0.33444816053511706
volumeoftheperipheralcompartmentbioavailabilityvpf,0.33444816053511706
serumtmax,0.33444816053511706
celllossratedelta,0.33444816053511706
areaundertheplasmaconcentrationtimecurveaucfromtimezerotoinfinityaucinfinity,0.33444816053511706
urineph,0.33444816053511706
timeatmaximalconcentration,0.33444816053511706
maximumpercentageinhibition,0.33444816053511706
totalclearancefromtheblood,0.33444816053511706
enzymaticactivity,0.33444816053511706
timetopeakinsulinconcentration,0.33444816053511706
maximumflaresuppression,0.33444816053511706
troughserumquinidineconcentrationsqc,0.33444816053511706
micfor90,0.33444816053511706
t12d,0.33444816053511706
latebiologicalhalflifeplasma,0.33444816053511706
clpo,0.33444816053511706
latebiologicalhalflife,0.33444816053511706
nka,0.33444816053511706
steadystateminimumconcentrationcmin,0.33444816053511706
halflifeforclearance,0.33444816053511706
cmaxfor,0.33444816053511706
tmigr,0.33444816053511706
cmaxmaximumplasmaconcentrationratio,0.33444816053511706
milkconcentration,0.33444816053511706
ratesofsurvival,0.33444816053511706
inhibitionfractionofkin,0.33444816053511706
inputratekin,0.33444816053511706
clrfu,0.33444816053511706
p50,0.33444816053511706
timetoreachittmax,0.33444816053511706
halflifeofthesecondphase,0.33444816053511706
emit,0.33444816053511706
auctauratio,0.33444816053511706
terminaleliminationhalflifet12g,0.33444816053511706
dosecorrectedauc012,0.33444816053511706
earlytroughlevel,0.33444816053511706
halflifeinbrain,0.33444816053511706
mmconstantkm,0.33444816053511706
doseadjustedauc012,0.33444816053511706
terminaleliminationphase,0.33444816053511706
timetostanding,0.33444816053511706
partitioningcoefficient,0.33444816053511706
aerodynamic,0.33444816053511706
parasite,0.33444816053511706
liveruptake,0.33444816053511706
ratesofinsulinrise,0.33444816053511706
maximalchbtomaximalcbratio,0.33444816053511706
chb,0.33444816053511706
areaunderthecurvebetween012hoursauc012,0.33444816053511706
accumulationtime,0.33444816053511706
twentyfourhoururinevolume,0.33444816053511706
serumhalflike,0.33444816053511706
timerequiredfor50recoveryofbeta,0.33444816053511706
maximumforcedexpiratoryvolume,0.33444816053511706
areaundertheconcentrationcurveauc03h,0.33444816053511706
salivatoplasmaconcentrationratio,0.33444816053511706
steadystatepeakconcentration,0.33444816053511706
forcedexpiratoryvolumein1secfev1,0.33444816053511706
extrathoracicdeposition,0.33444816053511706
cpratio,0.33444816053511706
plasmaclearancescl,0.33444816053511706
mpc,0.33444816053511706
eliminationhalflifetbeta12,0.33444816053511706
totalareaundertheplasmaconcentrationcurveauc,0.33444816053511706
halflivesoftheexcretion,0.33444816053511706
fauc024mic,0.33444816053511706
betaphaseeliminationhalflive,0.33444816053511706
unboundbloodfraction,0.33444816053511706
bodysurfaceareanormalizedapparentclearance,0.33444816053511706
steadystateoralclearance,0.33444816053511706
totalperipheralresistance,0.33444816053511706
halftimefortransfer,0.33444816053511706
daytime,0.33444816053511706
aucfrom0to30minutesauc30min,0.33444816053511706
sustainedvirologicalresponserate,0.33444816053511706
terminalphaseplasmahalflife,0.33444816053511706
systemicclearanceci,0.33444816053511706
peakfev1change,0.33444816053511706
areaundertheconcentrationtimecurvefrom0to3hour,0.33444816053511706
aucpo,0.33444816053511706
eliminationphasehalflifet12beta,0.33444816053511706
maximalviralloadvl,0.33444816053511706
areaunderthecurvefrom6to12hoursauc612,0.33444816053511706
c0dose,0.33444816053511706
halflifestabilizationtime,0.33444816053511706
apparentdistributionvolumev,0.33444816053511706
sideeffect,0.33444816053511706
amountofradioactivity,0.33444816053511706
eliminationhalflifet05beta,0.33444816053511706
inspiratoryflowrate,0.33444816053511706
fever,0.33444816053511706
amountofdrugtransported,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefromtime0to12hour,0.33444816053511706
apparentvolumeofdistributionoftheplasmacompartmentvc,0.33444816053511706
apparentc,0.33444816053511706
areaundertheeffecttimecurve,0.33444816053511706
ratesofprogressionfreesurvival,0.33444816053511706
effectiveconcentrationec50,0.33444816053511706
timetoreachmaximalconcentrationtmax,0.33444816053511706
inhibitoryconcentrationof50,0.33444816053511706
intracellularconcentration,0.33444816053511706
initialdistributionphaset12pi,0.33444816053511706
freefractionin,0.33444816053511706
volumesofdistributionv1,0.33444816053511706
pseudosteadystateconcentration,0.33444816053511706
intermediatedistributionphaset12alpha,0.33444816053511706
t12ofelimination,0.33444816053511706
overallresponseproportion,0.33444816053511706
areasundertheconcentrationversustimecurvechangesaucr,0.33444816053511706
kidneytoplasmaconcentrationratio,0.33444816053511706
systemicportalaucratio,0.33444816053511706
mammaryuptake,0.33444816053511706
formation,0.33444816053511706
activationenergie,0.33444816053511706
peakeffectemax,0.33444816053511706
effectcompartmentconcentrationat50blockec50,0.33444816053511706
recoveryto25ofbaselinetwitchheight,0.33444816053511706
mpe,0.33444816053511706
mape,0.33444816053511706
2575recoveryindex,0.33444816053511706
act,0.33444816053511706
bioactivity,0.33444816053511706
areaundertheeffectcurve,0.33444816053511706
mobilephaseflowrate,0.33444816053511706
smax,0.33444816053511706
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinity,0.33444816053511706
osrate,0.33444816053511706
halflivesofdistributiont12alpha,0.33444816053511706
effluxintrinsicclearance,0.33444816053511706
perfusionrate,0.33444816053511706
terminaleliminationrateconstantbeta,0.33444816053511706
passivediffusion,0.33444816053511706
areaundertheplasmaconcentrationtimecurvesfrom0toinfinityaucinfinity,0.33444816053511706
flowgradient,0.33444816053511706
ceilingconcentration,0.33444816053511706
centralvolumev1,0.33444816053511706
hillcoefficienth,0.33444816053511706
peakantixaactivity,0.33444816053511706
cmaxmic90,0.33444816053511706
eliminationhalflifetl2,0.33444816053511706
pru,0.33444816053511706
tearconcentration,0.33444816053511706
d2,0.33444816053511706
activatedpartialth,0.33444816053511706
peakserumdabigatranlevel,0.33444816053511706
gammahalflife,0.33444816053511706
aucperitonealaucplasma,0.33444816053511706
saturationduration,0.33444816053511706
antixa,0.33444816053511706
tcpmax,0.33444816053511706
cpu,0.33444816053511706
rateconstantkeo,0.33444816053511706
lymphaticclearance,0.33444816053511706
concentrationsrequiredtoachieve50ofmaximumneuromuscularblockec50,0.33444816053511706
areaundertheconcentrationtimecurveaucmic,0.33444816053511706
tabslate,0.33444816053511706
cumulativedose,0.33444816053511706
aucbileaucvhratio,0.33444816053511706
timetomaximumconcentrationtcpmax,0.33444816053511706
cbucpu,0.33444816053511706
bindingki,0.33444816053511706
absoluteconcentration,0.33444816053511706
halflifeofdrug,0.33444816053511706
adhesiontime,0.33444816053511706
clcrea,0.33444816053511706
timetmaxtopeakconcentrationcmax,0.33444816053511706
meanretentiontimemrt,0.33444816053511706
bileconcentration,0.33444816053511706
cmaxmaximumplasmaconcentration,0.33444816053511706
unbounddrugfraction,0.33444816053511706
plasmalidoc,0.33444816053511706
auc0336,0.33444816053511706
basalrate,0.33444816053511706
demanddose,0.33444816053511706
halfvalueduration,0.33444816053511706
logpoct,0.33444816053511706
tumortomuscleratio,0.33444816053511706
mrtiv,0.33444816053511706
oralld50,0.33444816053511706
maximumamount,0.33444816053511706
areaundertheplasmaconcentrationversustimecurvesauc,0.33444816053511706
oraltotalclearance,0.33444816053511706
renalextraction,0.33444816053511706
completeresponsecrunconfirmedcrrate,0.33444816053511706
peaktheophyllinelevel,0.33444816053511706
overallun,0.33444816053511706
confirmedcompleteresponserate,0.33444816053511706
durationofanal,0.33444816053511706
apparentrateconstant,0.33444816053511706
totalbodyresidencetime,0.33444816053511706
influxclearanceintothebrain,0.33444816053511706
troughserumlevel,0.33444816053511706
timetoonsetofanalgesia,0.33444816053511706
areaunderthebloodcsaconcentrationtimecurve,0.33444816053511706
initialclearance,0.33444816053511706
effectivejejunalpermeability,0.33444816053511706
aucratioaucperitonealfluidaucplasma,0.33444816053511706
initialwholebloodconcentration,0.33444816053511706
terminalvolumeofdistributionatsteadystate,0.33444816053511706
numberofbindingsite,0.33444816053511706
tumouruptake,0.33444816053511706
apparentabsorptionrateconstantintothesystemiccirculation,0.33444816053511706
vuf,0.33444816053511706
ftmic,0.33444816053511706
csslevel,0.33444816053511706
peakplasmalevelscssmax,0.33444816053511706
timestopeak,0.33444816053511706
tissuelevelbloodlevelratio,0.33444816053511706
tu,0.33444816053511706
passivediffusionclearance,0.33444816053511706
terminaleliminationrate,0.33444816053511706
totaloralplasmaclearance,0.33444816053511706
fetalmaternal,0.33444816053511706
freeplasmaconcentration,0.33444816053511706
latehalflife,0.33444816053511706
baseline,0.33444816053511706
totalareaundertheplasmaconcentrationcurve,0.33444816053511706
drugcontent,0.33444816053511706
clu,0.33444816053511706
absoluteneutrophilcountanc,0.33444816053511706
areaundertheconcentrationtimecurvefromtime0toinfinity,0.33444816053511706
nauseabehaviourscore,0.33444816053511706
areaundertheplasmaleveltimecurveauctau,0.33444816053511706
auc0480,0.33444816053511706
totalapparentclearance,0.33444816053511706
red,0.33444816053511706
cpss90,0.33444816053511706
cluf,0.33444816053511706
areaundertheplasmaconcentrationtimecurveto1h,0.33444816053511706
timetosteadystateplasmalevel,0.33444816053511706
drugloadingcontent,0.33444816053511706
clearancefactorctrough0180,0.33444816053511706
onsetto90paralysi,0.33444816053511706
responseareaunderthecurve,0.33444816053511706
timetakentoreachthepeaktmax,0.33444816053511706
maximumbinding,0.33444816053511706
meantransittimemtt,0.33444816053511706
areaundertheconcentrationtimecurvefrom0to360minauc0t,0.33444816053511706
secretorytransport,0.33444816053511706
mrt0infinity,0.33444816053511706
determinationlimit,0.33444816053511706
swellingindex,0.33444816053511706
auc0360min,0.33444816053511706
meandissolutiontimemdt,0.33444816053511706
extubationtime,0.33444816053511706
halftimeofeliminationt12,0.33444816053511706
timetofirstanalgesicrequest,0.33444816053511706
0to6hoursauc06,0.33444816053511706
durationofabsorption,0.33444816053511706
space,0.33444816053511706
relativerectalbioavailability,0.33444816053511706
maximaleelevel,0.33444816053511706
peritonealplasmaaucratio,0.33444816053511706
areasundertheplasmaconcentrationtimecurvesaucsover12h,0.33444816053511706
progressionfreeinterval,0.33444816053511706
plasmaconcentrationofmpaatsteadystate,0.33444816053511706
percentageofrecovery,0.33444816053511706
auc03h,0.33444816053511706
drugextractionratio,0.33444816053511706
areaundertheplasmalevelvstimecurveauc,0.33444816053511706
areasunderthealkaloidconcentrationtimecurvefrom0toinfinity,0.33444816053511706
drugaccumulationsite,0.33444816053511706
areaundertheplasmaconcentrationversustimecurvefrom0to6hoursauc06,0.33444816053511706
systemicbloodclearance,0.33444816053511706
relativeba,0.33444816053511706
nonplacentalclearance,0.33444816053511706
totalplasmaclearanceclt,0.33444816053511706
maximalloading,0.33444816053511706
steadystateplasmaconcentrationscss,0.33444816053511706
totalaverageexcretion,0.33444816053511706
areaunderthetimeconcentrationcurveat0to90minutesauc090,0.33444816053511706
aucrsratio,0.33444816053511706
plasmaflow,0.33444816053511706
totalcl,0.33444816053511706
freedrug,0.33444816053511706
vcvalpha,0.33444816053511706
apparentpulmonarytissuevolume,0.33444816053511706
areaundertheplasmadrugconcentrationtimecurve012hoursauc012,0.33444816053511706
bispectralindex,0.33444816053511706
plasmaeliminationclearance,0.33444816053511706
peaksugammadexconcentration,0.33444816053511706
onsetofneuromuscularblockingeffect,0.33444816053511706
centralclearance,0.33444816053511706
areaunderthecurveofplasmaconcentration,0.33444816053511706
maximumclearanceclmax,0.33444816053511706
recoveryefficiencie,0.33444816053511706
totalaucmicratio,0.33444816053511706
maximalrateofeliminationvmax,0.33444816053511706
bloodclearanceclb,0.33444816053511706
areaundertheconcentrationtimecurveaucmicratio,0.33444816053511706
serumhalftime,0.33444816053511706
maximumdrugplasmaconcentration,0.33444816053511706
skinfluxe,0.33444816053511706
totalflowrate,0.33444816053511706
timetosputumcultureconversion,0.33444816053511706
peakfleroxacinconcentration,0.33444816053511706
excretionintourine,0.33444816053511706
timeuptothemaximumserumconcentration,0.33444816053511706
linearclearancecl,0.33444816053511706
volumeofdistributionbioavailability,0.33444816053511706
areasunderthepruritusintensitytimecurve,0.33444816053511706
analysistimeof,0.33444816053511706
absoluteneutrophilcount,0.33444816053511706
timespan,0.33444816053511706
placentalclearance,0.33444816053511706
t24,0.33444816053511706
flowrateofmobilephase,0.33444816053511706
peakplasmacaffeineconcentration,0.33444816053511706
areaundertheconcentrationtimecurvefor0to12hoursaftertreatmentauc012,0.33444816053511706
ratioatc0,0.33444816053511706
halflifet12ofelimination,0.33444816053511706
areaunderconcentration,0.33444816053511706
concentrationatwhichtheeliminationwashalfmaximalkm,0.33444816053511706
dosenormalizedareaundertheplasmaconcentrationtimecurvefromtimezerotoinfinitetime,0.33444816053511706
minimuminhibitoryconcentrationmic90,0.33444816053511706
clearanceratecl,0.33444816053511706
fetaltomaternalratio,0.33444816053511706
auc0oo,0.33444816053511706
timeofpeakingtmax,0.33444816053511706
electroconvulsivethreshold,0.33444816053511706
lmax,0.33444816053511706
plasmahalflifet12alpha,0.33444816053511706
recoverytimesoft4t1ratio,0.33444816053511706
t4t1ratio,0.33444816053511706
centralcompartmentconcentration,0.33444816053511706
totalmidazolamdose,0.33444816053511706
totalsufen,0.33444816053511706
t125tot175recoveryindex,0.33444816053511706
recoverytimestot1,0.33444816053511706
percenttime,0.33444816053511706
vmax2,0.33444816053511706
maximalreduction,0.33444816053511706
ontime,0.33444816053511706
auc012hh,0.33444816053511706
timetocultureconversion,0.33444816053511706
cu50,0.33444816053511706
areaundercurveauc0t,0.33444816053511706
cmc,0.33444816053511706
excretedamount,0.33444816053511706
overallmeanrecovery,0.33444816053511706
inhibitionconstantkiratio,0.33444816053511706
unboundsteadystatevpaconcentration,0.33444816053511706
ikiratio,0.33444816053511706
biologicavailability,0.33444816053511706
peakpaco2,0.33444816053511706
mature,0.33444816053511706
areaundertheconcentrationtimecurvefromtimezeroextrapolatedtoinfinityauc0,0.33444816053511706
hydrodynamicparticlesize,0.33444816053511706
molarextinctioncoefficient,0.33444816053511706
steadystatetotalconcentration,0.33444816053511706
ventilatoryfrequency,0.33444816053511706
aucmic90ratio,0.33444816053511706
ratecharacteristic,0.33444816053511706
maximummilkconcentration,0.33444816053511706
durationofinfusion,0.33444816053511706
serumsteadystateconcentrationscss,0.33444816053511706
clearancefromthecsf,0.33444816053511706
cldoc,0.33444816053511706
md,0.33444816053511706
centralvolumeofdistributionvdc,0.33444816053511706
timeformaximalconcentrationstmax,0.33444816053511706
totalareaunderthecurveauc0infinity,0.33444816053511706
plasmafnrconcentration,0.33444816053511706
peakrise,0.33444816053511706
steadystateplasmaconcentrationc,0.33444816053511706
plasmaconcentrationat2minute,0.33444816053511706
ratiosoftheareaunderthecurveaucovera24hdosingintervalauc24tothemic,0.33444816053511706
timeabovetherapeuticlevel,0.33444816053511706
bloodhalflive,0.33444816053511706
maximummeanconcentrationinplasmacmax,0.33444816053511706
arterialpropranololconcentration,0.33444816053511706
sodiumshift,0.33444816053511706
24,0.33444816053511706
arterialtovenousavconcentrationratio,0.33444816053511706
ahalflife,0.33444816053511706
eliminationhalflifet12y,0.33444816053511706
metabolicclearancecl1,0.33444816053511706
terminaleliminationratelambda,0.33444816053511706
intrinsicactivityemax,0.33444816053511706
timetothemaximumconcentration,0.33444816053511706
mcrrate,0.33444816053511706
auc0120min,0.33444816053511706
unboundprednisoloneclearance,0.33444816053511706
areasunderthecurveaucsfor,0.33444816053511706
plasmabnconcentration,0.33444816053511706
troughtiter,0.33444816053511706
intestinalavailabilityfg,0.33444816053511706
hairconcentration,0.33444816053511706
peakheartbinding,0.33444816053511706
maximumexcretionrate,0.33444816053511706
rateconstantofspecificclearancedecay,0.33444816053511706
halfic50,0.33444816053511706
centralcompartmentvolumeofdistributionv1,0.33444816053511706
peakcetirizinelevel,0.33444816053511706
tissuetobloodratio,0.33444816053511706
impedance,0.33444816053511706
plasmaconcentrationsof,0.33444816053511706
maximumobservedconcentrationscmax,0.33444816053511706
wholebloodtoplasmaconcentrationratio,0.33444816053511706
ttf,0.33444816053511706
am,0.33444816053511706
peakhydroxyzinelevel,0.33444816053511706
peakserummethylprednisoneconcentration,0.33444816053511706
wettingtime,0.33444816053511706
timetoreachpeakplasmaconcentrationtmax,0.33444816053511706
boundfraction,0.33444816053511706
timetoanabsoluteneutrophilcountof,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefromtimezerototimetauct,0.33444816053511706
timerequiredtoreachthemaximumplasmadrugconcentrationtmax,0.33444816053511706
sensitivitylimit,0.33444816053511706
absorptionratio,0.33444816053511706
apparentoralmdzclearance,0.33444816053511706
aucslcmsm,0.33444816053511706
vrc,0.33444816053511706
plasmarenalclearance,0.33444816053511706
netultrafiltrationuf,0.33444816053511706
plasmat12alpha,0.33444816053511706
normal,0.33444816053511706
urate,0.33444816053511706
clearanceperfractionabsorbed,0.33444816053511706
timetoreachthatmaximum,0.33444816053511706
50inhibitionconstant,0.33444816053511706
fractional,0.33444816053511706
terminaleliminationphaset12,0.33444816053511706
maximalipa,0.33444816053511706
timetotof,0.33444816053511706
passivepermeation,0.33444816053511706
apparentvolumebeingdistribution,0.33444816053511706
plasmaeliminationhalflifeintheterminalphase,0.33444816053511706
ddqtci,0.33444816053511706
plasmaec50,0.33444816053511706
troughlevelconcentrationsc12h,0.33444816053511706
inulinclearance,0.33444816053511706
clintu,0.33444816053511706
serumhalflifetime,0.33444816053511706
apparentvolumeofdistributionduringtheterminalphaseafteroraladministrationvzf,0.33444816053511706
excretionhalflife,0.33444816053511706
peakplasmapczlevel,0.33444816053511706
pla,0.33444816053511706
areaunderthetimeversusconcentrationcurveauc,0.33444816053511706
volumesofdistributionvbeta,0.33444816053511706
apparentliverbloodflow,0.33444816053511706
dosecorrectedauc06h,0.33444816053511706
loadingcapacitylc,0.33444816053511706
areasundertheconcentrationtimeprofile,0.33444816053511706
firstordereliminationke,0.33444816053511706
peakdrugplasmaconcentrationscmax,0.33444816053511706
samplingtime,0.33444816053511706
auc0h24h,0.33444816053511706
maximumdruglevel,0.33444816053511706
timetoachievemaximalsystemicconcentrationstmax,0.33444816053511706
maximumconcentrationtimetmax,0.33444816053511706
tumornecrosisratio,0.33444816053511706
peaktumorconcentration,0.33444816053511706
doselevelsdls,0.33444816053511706
areaundertheenzymeactivitytimecurveaec,0.33444816053511706
auc0240,0.33444816053511706
deltadeltaqtc,0.33444816053511706
minimalinhibitoryconcentrationmic,0.33444816053511706
volumeofthecentral,0.33444816053511706
totalareaundertheplasmamethylprednisoloneconcentrationtimecurve,0.33444816053511706
cycletime,0.33444816053511706
aucauc04h,0.33444816053511706
clrfgfr,0.33444816053511706
c1h2h,0.33444816053511706
dtp,0.33444816053511706
drugloadingamount,0.33444816053511706
concentrationsat30minutesc05h,0.33444816053511706
serumconcentrationsc0,0.33444816053511706
gt,0.33444816053511706
massmedianaerodynamicdiameter,0.33444816053511706
alphaphaset12,0.33444816053511706
timetoreachthatconcentration,0.33444816053511706
affinityconstant,0.33444816053511706
maximalvelocityvmax,0.33444816053511706
localbioavailability,0.33444816053511706
areaundertheconcentrationtimecurvefromtimezerotoinfinity,0.33444816053511706
areaundertheconcentrationtimecurvefrom0to8hauc08,0.33444816053511706
steadystatedexplasmaconcentration,0.33444816053511706
aucc03h,0.33444816053511706
so,0.33444816053511706
plasmapeaklevel,0.33444816053511706
ic50vmax,0.33444816053511706
depletionrateconstantkdep,0.33444816053511706
kdep,0.33444816053511706
t2beta,0.33444816053511706
therapeuticconcentration,0.33444816053511706
terminaldispositionrateconstant,0.33444816053511706
initialsteadystateconcentration,0.33444816053511706
maximumplasmaconcentrationofmycophenolicacid,0.33444816053511706
length,0.33444816053511706
auc024hour,0.33444816053511706
bloodgaspartitioncoefficient,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefromtimezeroextrapolatedtoinfinityaucinfinity,0.33444816053511706
antixaantiiiaratio,0.33444816053511706
ratepressureproduct,0.33444816053511706
timetmaxtoreachthe,0.33444816053511706
base,0.33444816053511706
areaunderthecurvefromtime0toinfinity,0.33444816053511706
areaunderthetimeconcentrationcurvesauc,0.33444816053511706
timefromdiagnosistohct,0.33444816053511706
linearity,0.33444816053511706
eliminationhalftimetbeta12,0.33444816053511706
initialmidazolam,0.33444816053511706
radioactivityrecovery,0.33444816053511706
circulationhalflive,0.33444816053511706
bloodethanoldisappearancerate,0.33444816053511706
percentageabsorption,0.33444816053511706
peakincrement,0.33444816053511706
effectiveconcentration50,0.33444816053511706
need,0.33444816053511706
needfor,0.33444816053511706
concentrationatthesecondhourc2,0.33444816053511706
adsorption,0.33444816053511706
csftoplasmaconcentrationratio,0.33444816053511706
steadystateplasmaepinephrineconcentration,0.33444816053511706
vascularperoxynitrite,0.33444816053511706
lambdamax,0.33444816053511706
areaundertheplasmaconcentrationtimecurveauc012,0.33444816053511706
areaunderthebloodconcentrationtimecurveauc08,0.33444816053511706
synthesisrate,0.33444816053511706
minimumdetectablelevel,0.33444816053511706
t12frompeak,0.33444816053511706
peakserumcalcitriolconcentrationcmax,0.33444816053511706
uptakekm,0.33444816053511706
plasmametabolicclearancerate,0.33444816053511706
unboundplasmadrugic50ic50u,0.33444816053511706
totalplasmaclearanceclp,0.33444816053511706
content,0.33444816053511706
areaunderthecurvefromzerotoinfinity,0.33444816053511706
concentrationsc0,0.33444816053511706
pc20,0.33444816053511706
fractionofnonproteinbound,0.33444816053511706
loadingefficiencie,0.33444816053511706
bloodethanol,0.33444816053511706
maximuminactivationratekinact,0.33444816053511706
amountexcreted,0.33444816053511706
halflifeofeliminationphase,0.33444816053511706
vcl,0.33444816053511706
effecthalftime,0.33444816053511706
plasmaoxycodoneconcentrationsmec,0.33444816053511706
bloodeliminationhalflive,0.33444816053511706
tissuetoplasmaconcentrationratio,0.33444816053511706
t12p,0.33444816053511706
peakdetachmentforce,0.33444816053511706
druginteractionprobabilityscore,0.33444816053511706
plasmahalflifebeta,0.33444816053511706
emergencetimesfromsedation,0.33444816053511706
fractionofthedoseabsorbed,0.33444816053511706
workofadhesion,0.33444816053511706
molarratioofdailyproductionrate,0.33444816053511706
effectclearancesclmiosis,0.33444816053511706
biologicalavailability,0.33444816053511706
timetopeaklevelstmax,0.33444816053511706
initialdeliveryrate,0.33444816053511706
apparentinactivationconstant,0.33444816053511706
apparentabsorptionrateconstant,0.33444816053511706
steadystatelevodopaconcentration,0.33444816053511706
clapp,0.33444816053511706
steadystatebraintoplasmaunboundconcentrationratio,0.33444816053511706
areaunderconcentrationtimecurveaucbrainaucplasmaratio,0.33444816053511706
steadystatetroughplasmaconcentration,0.33444816053511706
auecinfinity,0.33444816053511706
plasmabioavailability,0.33444816053511706
unboundauc,0.33444816053511706
peakplasmaexemestaneconcentration,0.33444816053511706
durationofthemotorresponse,0.33444816053511706
sleeptime,0.33444816053511706
troughwholebloodlevel,0.33444816053511706
ab50,0.33444816053511706
cerebrospinalfluidserumratio,0.33444816053511706
auc0tz,0.33444816053511706
bioavailabilityforal,0.33444816053511706
maximumindividualcmax,0.33444816053511706
renalbloodflow,0.33444816053511706
timestoextubation,0.33444816053511706
standardcurve,0.33444816053511706
effectivebloodconcentration,0.33444816053511706
auc024hss,0.33444816053511706
overallextractionefficiencie,0.33444816053511706
steadystateexposure,0.33444816053511706
limitsofquantification,0.33444816053511706
brainrecoverie,0.33444816053511706
clic,0.33444816053511706
dailyexcretion,0.33444816053511706
renalexcretionofunchangeddrug,0.33444816053511706
hepaticextractioneh,0.33444816053511706
auc012ratio,0.33444816053511706
cmaxmicmaximumplasmaconcentrationminimuminhibitoryconcentrationratio,0.33444816053511706
tgi,0.33444816053511706
halflivesofthedistributionphase,0.33444816053511706
c0d,0.33444816053511706
maximumsteadystateconcentration,0.33444816053511706
peakplasmamethconcentration,0.33444816053511706
peakapapconcentration,0.33444816053511706
aucaccumulationratio,0.33444816053511706
durationofmotorresponse,0.33444816053511706
timetomaximum,0.33444816053511706
q1,0.33444816053511706
peripheralvolumeofdistributionvp,0.33444816053511706
braintoplasmapartitioncoefficient,0.33444816053511706
cistransratio,0.33444816053511706
massof,0.33444816053511706
interburstinterval,0.33444816053511706
centraldistributionvolumevc,0.33444816053511706
maximumbrainconcentration,0.33444816053511706
areasunderthecurveaucs,0.33444816053511706
peak1hourplasmalevel,0.33444816053511706
durationofneutropenia,0.33444816053511706
distributionvolumevss,0.33444816053511706
apparentsteadystatevolumeofdistributionvdss,0.33444816053511706
maximalurinaryosmolality,0.33444816053511706
minimalfreewaterclearance,0.33444816053511706
brainserumratio,0.33444816053511706
cmaxec90ratio,0.33444816053511706
minimumdetectabledose,0.33444816053511706
completeremission,0.33444816053511706
auctss,0.33444816053511706
areaunderthecurveauc072,0.33444816053511706
eventfreesurvivalrate,0.33444816053511706
elf,0.33444816053511706
vd1,0.33444816053511706
intrinsichepaticclearanceclintlv,0.33444816053511706
fena,0.33444816053511706
steadystatec,0.33444816053511706
volumeofdistributionatsteadystateperbodyweightvdssbw,0.33444816053511706
peritonealconcentration,0.33444816053511706
infusionrequirement,0.33444816053511706
basallevel,0.33444816053511706
halfmaximaleffectiveconcentration,0.33444816053511706
h1r,0.33444816053511706
mpa,0.33444816053511706
peaklevocetirizineconcentration,0.33444816053511706
tumorvolume,0.33444816053511706
extractioneffect,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc0infinity,0.33444816053511706
detectionlimitssnof3,0.33444816053511706
intrinsicdissolutionrate,0.33444816053511706
minimumlungintracellulartnconcentration,0.33444816053511706
basplasmaconcentrationratio,0.33444816053511706
areaundertheconcentrationversustimecurveuptothelastmeasuredpointintimeauc0t,0.33444816053511706
intrinsicrenalclearanceclintkd,0.33444816053511706
apparentsteadystatevolume,0.33444816053511706
firstpassextraction,0.33444816053511706
concentrationxtimeproductscxts,0.33444816053511706
areaundertheplasmamidazolamconcentrationtimecurveauc0infinity,0.33444816053511706
cmaxlevel,0.33444816053511706
auc0infratio,0.33444816053511706
percentagerecoverie,0.33444816053511706
peakplasmamelphalanconcentration,0.33444816053511706
plasmaconcentrationtodailydoseratiocd,0.33444816053511706
plasmacxtratio,0.33444816053511706
apparentvolumeofdistributionafteroraladministrationvdf,0.33444816053511706
peritonealfluidplasmaaucratio,0.33444816053511706
lymphplasmaaucratio,0.33444816053511706
troughaqueoushumorlevel,0.33444816053511706
aucsub0sub,0.33444816053511706
halflifetimesoftheeliminationphase,0.33444816053511706
apparentdistributionvolumesofthecentralcompartment,0.33444816053511706
releasetime,0.33444816053511706
timetoreturntobaseline,0.33444816053511706
auc0600,0.33444816053511706
maximumbindingcapacity,0.33444816053511706
areaunderthecurveforconcentrationvstimeuntil600minfromdrugadministrationauc0600,0.33444816053511706
auc0inifinity,0.33444816053511706
oralclearancecif,0.33444816053511706
aft,0.33444816053511706
systemicextraction,0.33444816053511706
maximumdrugsolubility,0.33444816053511706
distributioncoefficientalpha,0.33444816053511706
signalnoise,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefrom0to3hoursauc03hr,0.33444816053511706
plasmaconcentrationat30minc30min,0.33444816053511706
painintensity,0.33444816053511706
transferhalflifet12t,0.33444816053511706
clearanceclp,0.33444816053511706
intracellularhalflife,0.33444816053511706
ic2xlt,0.33444816053511706
evltroughlevel,0.33444816053511706
metabolicresponserate,0.33444816053511706
peakumax,0.33444816053511706
dosenormalizedserumconcentration,0.33444816053511706
timeuntilacommandwasfollowed,0.33444816053511706
css90,0.33444816053511706
similarityfactorf2,0.33444816053511706
timeofcmaxtmax,0.33444816053511706
absolutebioavailabilityfabs,0.33444816053511706
dialysateflowrate,0.33444816053511706
unboundpartitioningkpuu,0.33444816053511706
biovailability,0.33444816053511706
effecthalflife,0.33444816053511706
uave,0.33444816053511706
apparentbloodclearance,0.33444816053511706
aucipsapironeauc1ppratio,0.33444816053511706
cpbtime,0.33444816053511706
constantplasmaconcentration,0.33444816053511706
relativeauc012ratio,0.33444816053511706
aucbasedaccumulationfactor,0.33444816053511706
initialtrougheverolimu,0.33444816053511706
auecrtauc,0.33444816053511706
areaundertheconcentrationversustimecurvefrom0to6hauc06,0.33444816053511706
concentrationsteadystatecss,0.33444816053511706
conversionfactor,0.33444816053511706
ischemictime,0.33444816053511706
scitrcitratio,0.33444816053511706
cf,0.33444816053511706
totalelutiontime,0.33444816053511706
endtidalconcentrationfa,0.33444816053511706
extractrecovery,0.33444816053511706
biliaryexcretionindexbei,0.33444816053511706
ng,0.33444816053511706
apparentvolumeofdistributionatsteadystatevssf,0.33444816053511706
gcr,0.33444816053511706
durationofinsulinactiontrlast,0.33444816053511706
oralvolumeofdistribution,0.33444816053511706
isoflurane,0.33444816053511706
aucfrom0to12h,0.33444816053511706
girmax,0.33444816053511706
troughvaluec0,0.33444816053511706
tissuetoplasmaauc0ratio,0.33444816053511706
areasundertheplasmaconcentrationcurvesauc024h,0.33444816053511706
peakplasmaeeconcentration,0.33444816053511706
peakplasmalnconcentration,0.33444816053511706
cockcroftcalculatedclearance,0.33444816053511706
overallexposureauc0,0.33444816053511706
cerebraldistributionvolume,0.33444816053511706
frl,0.33444816053511706
clearancevia,0.33444816053511706
terminalhalflifet12k10,0.33444816053511706
timetoachievemaximumconcentration,0.33444816053511706
apparentdistributionvolumeforphasebeta,0.33444816053511706
areaunderthetimeversusconcentrationcurve,0.33444816053511706
intrinsic,0.33444816053511706
concentrationsof,0.33444816053511706
moleratio,0.33444816053511706
tbil,0.33444816053511706
apparentsystemicclearanceclf,0.33444816053511706
kei,0.33444816053511706
auc72h,0.33444816053511706
prostaticserumantigen,0.33444816053511706
infusionraterequirementstoachieve90musclerelaxation,0.33444816053511706
steadystateplasmacsalevel,0.33444816053511706
cvec,0.33444816053511706
sampleruntime,0.33444816053511706
peakresponse,0.33444816053511706
rateofformation,0.33444816053511706
plasmatroughconcentrationc0,0.33444816053511706
vdfkg,0.33444816053511706
pth,0.33444816053511706
maximumtolerateddosage,0.33444816053511706
evl,0.33444816053511706
cde,0.33444816053511706
timetoreturnto90,0.33444816053511706
peakdruglevel,0.33444816053511706
targettroughlevel,0.33444816053511706
clearanceof,0.33444816053511706
dkrd,0.33444816053511706
radiocarbonrecovery,0.33444816053511706
areaunderthecurve032h,0.33444816053511706
dkd,0.33444816053511706
separationtime,0.33444816053511706
t12k,0.33444816053511706
rateofreachingpeakplasmaconcentrationcmaxdividedbytheareaundertheconcentrationtimecurveauc,0.33444816053511706
troughlevelctrough,0.33444816053511706
areaunderthereceiveroperatingcharacteristiccurveauc,0.33444816053511706
peakparacetamolconcentration,0.33444816053511706
fractionalurinaryexcretion,0.33444816053511706
dosecorrectedcmax,0.33444816053511706
criticalflickerfusionthreshold,0.33444816053511706
h1ro,0.33444816053511706
unboundc,0.33444816053511706
receptoroccupancylevel,0.33444816053511706
maximumkill,0.33444816053511706
ce10m,0.33444816053511706
apparentintestinalextraction,0.33444816053511706
apparentintestinal,0.33444816053511706
pumpflow,0.33444816053511706
dosenormalizedmp,0.33444816053511706
mec,0.33444816053511706
exposureratio,0.33444816053511706
retentionrate,0.33444816053511706
timeofthepeakconcentrationtmax,0.33444816053511706
doseturnoverrate,0.33444816053511706
pot,0.33444816053511706
tclctrough,0.33444816053511706
freeauc06,0.33444816053511706
timeonstudy,0.33444816053511706
vdl,0.33444816053511706
peakexposurecmax,0.33444816053511706
salivaconcentration,0.33444816053511706
timetopeakmexi,0.33444816053511706
timeto10ofgirmaxgirmaxt10,0.33444816053511706
aucbuspironeauc1ppratio,0.33444816053511706
apparentsolubility,0.33444816053511706
troughspecificlevel,0.33444816053511706
mrt0last,0.33444816053511706
minimalalveolarconcentration,0.33444816053511706
se,0.33444816053511706
totalsystemicclearanceclb,0.33444816053511706
peakparacetamolplasmaconcentration,0.33444816053511706
samplethroughput,0.33444816053511706
aucoaucpcsf,0.33444816053511706
oralclearancecloral,0.33444816053511706
cpeptide,0.33444816053511706
hepaticfirstpasseffect,0.33444816053511706
tt,0.33444816053511706
totalnitrazepamclearance,0.33444816053511706
urinaryexcretionhalflife,0.33444816053511706
hepaticclearanceclh,0.33444816053511706
bioavilaibility,0.33444816053511706
areaundertheglucoseinfusionrategircurveinthefirst30minaucgir030min,0.33444816053511706
apparentph,0.33444816053511706
renalsecretion,0.33444816053511706
maximumtimestocmaxtmax,0.33444816053511706
terminalplasmahalflive,0.33444816053511706
areaunderthecurveforplasmaconcentrationofdrugxtimeauc,0.33444816053511706
totalplasmaauc0720min,0.33444816053511706
ratesofclearance,0.33444816053511706
waitingtimefor,0.33444816053511706
ivclearance,0.33444816053511706
aucoaucpplasma,0.33444816053511706
centralcompartmentvolumevc,0.33444816053511706
maximumconcentrationofthedruginplasmacmax,0.33444816053511706
cssavg,0.33444816053511706
timeofonsetofaction,0.33444816053511706
areasunderthecurvempaauc012h,0.33444816053511706
peakplasmaoxaprozinconcentration,0.33444816053511706
qtinterval,0.33444816053511706
aumc0t,0.33444816053511706
areaundercurveratio,0.33444816053511706
timetopeakserumconcentrationtmax,0.33444816053511706
timetoreachmaximumserumconcentrationtmax,0.33444816053511706
timetothemaximumserumconcentration,0.33444816053511706
timetoreachumaxtmax,0.33444816053511706
k23,0.33444816053511706
effectsiteconcentrationce,0.33444816053511706
terminalhalflifet12lambdaz,0.33444816053511706
cm,0.33444816053511706
fractionsof,0.33444816053511706
labelingefficiency,0.33444816053511706
k14,0.33444816053511706
steadystateplasmatheophyllineconcentration,0.33444816053511706
braintargetingefficiency,0.33444816053511706
braintoserumconcentrationratio,0.33444816053511706
peakconcentrationachieved,0.33444816053511706
fractionalsurvival,0.33444816053511706
exposureauc048h,0.33444816053511706
plasmapeakconcentrationscmax,0.33444816053511706
growthvelocity,0.33444816053511706
biliaryexcretionrateconstant,0.33444816053511706
peakexposure,0.33444816053511706
peakmaximumconcentrationcmax,0.33444816053511706
intracellularaccumulation,0.33444816053511706
compliancerate,0.33444816053511706
areaundertheplasmaconcentrationtimecurvefromzerotoinfinity,0.33444816053511706
apparentplasmaterminalhalflive,0.33444816053511706
areaunderthecurveauc08,0.33444816053511706
peaktotroughplasmaconcentrationratio,0.33444816053511706
kiiv,0.33444816053511706
minimumeffectiveconcentrationmec,0.33444816053511706
gtot,0.33444816053511706
maximumppbg,0.33444816053511706
ratioofk12k21,0.33444816053511706
aucovera24hourdosingintervalauctau,0.33444816053511706
plasmacl,0.2508361204013378
peakratio,0.2508361204013378
ratetmax,0.2508361204013378
apparentoralmidazolamclearance,0.2508361204013378
ttag,0.2508361204013378
arterialconcentration,0.2508361204013378
peakobservedconcentrationsintheblood,0.2508361204013378
wholebloodsteadystateconcentration,0.2508361204013378
c0concentration,0.2508361204013378
maximumtestosteronelevel,0.2508361204013378
faca,0.2508361204013378
totalremoval,0.2508361204013378
aucfrom0to24hoursauc24h,0.2508361204013378
areaunderthecurveover48hauc048,0.2508361204013378
eliminationhalflifetimest12,0.2508361204013378
aucs048h,0.2508361204013378
basalmcr,0.2508361204013378
maximumeffectovertheentiresamplingphaseemax,0.2508361204013378
areaundertheeffecttimecurveauec01,0.2508361204013378
relativeuptakeratere,0.2508361204013378
timetoattainthepeakconcentration,0.2508361204013378
finalclearancerate,0.2508361204013378
sa,0.2508361204013378
aucepo,0.2508361204013378
averageplasmaconcentration,0.2508361204013378
ptr,0.2508361204013378
urinaryexcretionofunchanged,0.2508361204013378
clearancevaluescl,0.2508361204013378
observedhalflife,0.2508361204013378
maximumarterialconcentrationscmax,0.2508361204013378
renalclearanceratio,0.2508361204013378
drugclearanceclf,0.2508361204013378
erectbp,0.2508361204013378
maximumunboundconcentration,0.2508361204013378
peakserumibuprofenconcentration,0.2508361204013378
maximumrelease,0.2508361204013378
peakprogesteronelevel,0.2508361204013378
tissuetoplasma,0.2508361204013378
timetoachievemaximumconcentrationtmax,0.2508361204013378
areaundertheplasmaconcentrationversustimecurvefromtime0hourto96hour,0.2508361204013378
peaktheophyllinebloodlevel,0.2508361204013378
initialplasmat12,0.2508361204013378
initialdistributionhalftime,0.2508361204013378
t12oftheterminaldeclineinplasmaconcentration,0.2508361204013378
correctedbrainbloodratiobbrcorr,0.2508361204013378
observedmaximumplasmadrugconcentration,0.2508361204013378
minimalbasallevel,0.2508361204013378
functionalhalflife,0.2508361204013378
urineflow,0.2508361204013378
maximumrateofmetabolismvmax,0.2508361204013378
cumulativeurinaryexcretionrate,0.2508361204013378
troughplasmaphenytoinconcentration,0.2508361204013378
capsuleactivationtime,0.2508361204013378
timestomaximumcy,0.2508361204013378
ktapp,0.2508361204013378
maximalbinding,0.2508361204013378
totaleliminationrateconstant,0.2508361204013378
ld10,0.2508361204013378
braineliminationhalflivest12,0.2508361204013378
areaundertheplasmaleveltimecurveaucinfinity,0.2508361204013378
maximalpeakactivity,0.2508361204013378
plasmaic50,0.2508361204013378
coefficientofdistributionk,0.2508361204013378
permeationrate,0.2508361204013378
concentrationmaximumcmax,0.2508361204013378
peakcd4saturation,0.2508361204013378
percentageofunbound,0.2508361204013378
apparentoralclearancedoseauc,0.2508361204013378
dd,0.2508361204013378
populationeliminationhalflive,0.2508361204013378
amnioticfluidplasmaconcentrationratio,0.2508361204013378
bindingaffinitie,0.2508361204013378
apparentvolumeofthecentralcompartmentvcf,0.2508361204013378
troughwholeblood,0.2508361204013378
maximaloralabsorptionratevmax,0.2508361204013378
totalrecoveredradioactivity,0.2508361204013378
areaundertheconcentrationtimeforetoposidecurve,0.2508361204013378
auccsfauc,0.2508361204013378
c112,0.2508361204013378
cmaxssratio,0.2508361204013378
disappearancetime,0.2508361204013378
media,0.2508361204013378
timetoattainmentofseizurecontrol,0.2508361204013378
totaldoxorubicinclearance,0.2508361204013378
maximumflux,0.2508361204013378
bbrcorr,0.2508361204013378
controlhalflife,0.2508361204013378
tumortonormaltissueratio,0.2508361204013378
halftimeofdisappearance,0.2508361204013378
maximumbrainplasmaratio,0.2508361204013378
neutralisingcapacity,0.2508361204013378
kah1,0.2508361204013378
zeroorderrateconstant,0.2508361204013378
fiftypercentinhibitoryconcentrationsic50,0.2508361204013378
logmetabolicratio,0.2508361204013378
ecf,0.2508361204013378
volumeofdistributionofthedrugatsteadystate,0.2508361204013378
pd2,0.2508361204013378
afxa,0.2508361204013378
peakexpiratoryflowratepefr,0.2508361204013378
timeintervaltospontaneousrecovery,0.2508361204013378
serumtrough,0.2508361204013378
apparentplateauphasesteadystate,0.2508361204013378
firstordereliminationrateconstant,0.2508361204013378
cthalflife,0.2508361204013378
aucatsteadystateauctau,0.2508361204013378
doublingtime,0.2508361204013378
centralvenouspressure,0.2508361204013378
penetrationindex,0.2508361204013378
halflifet2,0.2508361204013378
dosenormalizedpeakplasmaconcentrationcmax,0.2508361204013378
minimumdetectionlimit,0.2508361204013378
troughitraconazolelevel,0.2508361204013378
cmaxcmin,0.2508361204013378
epoxidetoparentratio,0.2508361204013378
p450,0.2508361204013378
aucextrapolatedtoinfinityaucinfinity,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefrom0to24hoursauc24h,0.2508361204013378
clearancef,0.2508361204013378
tto,0.2508361204013378
peakphtplasmaconcentration,0.2508361204013378
troughhydroxy,0.2508361204013378
pasi,0.2508361204013378
steadystatemidazolamconcentration,0.2508361204013378
k1k2,0.2508361204013378
maximumeffectec50,0.2508361204013378
areaunderthetimeactivitycurve,0.2508361204013378
maximalplasmaconcentrationofsacmax,0.2508361204013378
competitiveinhibitionconstant,0.2508361204013378
areaundertheplasmanifedipineconcentrationtimecurveauc0alpha,0.2508361204013378
areaunderthebloodconcentrationtimecurveto24hauc024h,0.2508361204013378
totalplasmaclearanceofnifedipineclf,0.2508361204013378
tpt,0.2508361204013378
aumcinfinity,0.2508361204013378
metabolicclearanceclm,0.2508361204013378
neutrophilcount,0.2508361204013378
breakthroughresponse,0.2508361204013378
terminaldispositionhalftime,0.2508361204013378
steadystateaverageconcentration,0.2508361204013378
plasmaantixaactivity,0.2508361204013378
aucdividedbydosinginterval,0.2508361204013378
hepaticbioavailability1hepaticextractionratio,0.2508361204013378
timetocastratesuppression,0.2508361204013378
mrtinfinity,0.2508361204013378
auctlast,0.2508361204013378
bodyweightnormalizedapparentoralclearance,0.2508361204013378
maximumrateofsecretorytransporttm,0.2508361204013378
fvc,0.2508361204013378
areaundertheserumconcentrationtimecurvefromzeroto35daysauc035days,0.2508361204013378
clearancesdoseauc,0.2508361204013378
td50,0.2508361204013378
daparatio,0.2508361204013378
pdif,0.2508361204013378
troughlevelcmin,0.2508361204013378
keliminationrateconstant,0.2508361204013378
plasmalevelpeak,0.2508361204013378
pefr,0.2508361204013378
activityhalflife,0.2508361204013378
steadystateserum,0.2508361204013378
timetopeakfev1response,0.2508361204013378
areaundertheresponsetimecurvefrom0to12h,0.2508361204013378
nonglomerularclearance,0.2508361204013378
tissueperfusionliquidratio,0.2508361204013378
areaundertheplasmaconcentrationversustimecurveauc024h,0.2508361204013378
peakbupivacainelevel,0.2508361204013378
ed501,0.2508361204013378
maximummeanplasmaconcentrationcmax,0.2508361204013378
timetomaximumobservedplasmaconcentrationtmax,0.2508361204013378
urinarymetabolicratiomr,0.2508361204013378
apparentvolumeofdistributioninthecentralcompartment,0.2508361204013378
eliminationlambdaz,0.2508361204013378
areaunderthetheophyllineconcentrationtimecurve,0.2508361204013378
absolutebioavailabilityafteroraladministrationf,0.2508361204013378
nagg,0.2508361204013378
heightvelocity,0.2508361204013378
terminalbetahalflife,0.2508361204013378
plasmaactivity,0.2508361204013378
proth,0.2508361204013378
ag,0.2508361204013378
bloodcirculationhalflife,0.2508361204013378
netrenalclearancebytubularsecretion,0.2508361204013378
intraperitonealbioavailability,0.2508361204013378
areaundertheantifxaactivitycurvefrom012h,0.2508361204013378
gastrointestinaluptake,0.2508361204013378
apparentplasmaclearancecl,0.2508361204013378
serumtroughradio,0.2508361204013378
plasmaaucinfinity,0.2508361204013378
runcycletime,0.2508361204013378
initialhalflifet12,0.2508361204013378
areasunderthecurveauc024h,0.2508361204013378
recoveredamount,0.2508361204013378
t12absorption,0.2508361204013378
peakplasma125d3concentrationscpmax,0.2508361204013378
apparentfirstorderdistributionlambda1,0.2508361204013378
systemicclearanceclt,0.2508361204013378
troughpriortovblinjection,0.2508361204013378
peakwholebloodcsalevel,0.2508361204013378
areaunderthecurveatsteadystate,0.2508361204013378
maximalhumanplasmaconcentration,0.2508361204013378
effectivedosesed50,0.2508361204013378
areasundertheplasmaconcentrationtimecurvetothelastquantifiabletimepoint,0.2508361204013378
cumulativerecovery,0.2508361204013378
timerequiredtoreachmaximalconcentration,0.2508361204013378
auci,0.2508361204013378
basolateraltransport,0.2508361204013378
areaundertheconcentrationtimecurvefrom0toinfinity,0.2508361204013378
absorptiontimelag,0.2508361204013378
maximalplasmasalicylateconcentrationcpmax,0.2508361204013378
auc0168,0.2508361204013378
rh,0.2508361204013378
minimalplasmaconcentration,0.2508361204013378
plasmaeliminationt12,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefromtime0totimeoffinalquantifiablesampleaucs,0.2508361204013378
absolutesystemicavailabilityf,0.2508361204013378
igfi,0.2508361204013378
peakmiosi,0.2508361204013378
percentbioavailability,0.2508361204013378
selectivityindice,0.2508361204013378
overallhalflife,0.2508361204013378
biletoblooddistributionratioaucbileaucblood,0.2508361204013378
halflifet12b,0.2508361204013378
peakplasmamefloquineconcentration,0.2508361204013378
partitionratio,0.2508361204013378
steadystatetheophyllineconcentration,0.2508361204013378
totalcumulativeexcretion,0.2508361204013378
peakmidazolamconcentration,0.2508361204013378
activityhalflive,0.2508361204013378
rateconstantka,0.2508361204013378
auc05hr,0.2508361204013378
timeneededtoachieve,0.2508361204013378
aucsublastsub,0.2508361204013378
timetothepeakconcentration,0.2508361204013378
effectivepermeabilitypeff,0.2508361204013378
volumeofditributionatbetaphase,0.2508361204013378
betaphasehalflive,0.2508361204013378
cu50r,0.2508361204013378
612,0.2508361204013378
apparentabsorptionhalftimet12abs,0.2508361204013378
e2,0.2508361204013378
peakw554serumlevel,0.2508361204013378
totalapparentvolumesofdistribution,0.2508361204013378
maximummeasuredplasmaconcentration,0.2508361204013378
terminaleliminationhalflivest12,0.2508361204013378
drugdeliveryrate,0.2508361204013378
activationratio,0.2508361204013378
halflivesalpha,0.2508361204013378
peakinhibition,0.2508361204013378
salivaplasmaaucratio,0.2508361204013378
aucalb,0.2508361204013378
apparentchronicreleaserateacrr,0.2508361204013378
maximumend,0.2508361204013378
maximumrelaxation,0.2508361204013378
absorptionconstantrate,0.2508361204013378
therapeuticrate,0.2508361204013378
areaundertheconcentrationtimecurvefromtimezerotoinfinityauc0infinity,0.2508361204013378
partialresponse,0.2508361204013378
auc0540min,0.2508361204013378
clzf,0.2508361204013378
areaundertheplasmaconcentrationversustimecurvefromtimeofdosingtotimeoflastdetectableconcentrationauc0t,0.2508361204013378
ph4holdingtimeratio,0.2508361204013378
auccsftoaucplasmaratio,0.2508361204013378
tmaxtmaxss,0.2508361204013378
apparentoralglibenclamideclearance,0.2508361204013378
valleyconcentration,0.2508361204013378
actionperiod,0.2508361204013378
absorptionlagtimealag,0.2508361204013378
maximumconcentrationatsteadystate,0.2508361204013378
plasmaclss,0.2508361204013378
removalrate,0.2508361204013378
areasundertheconcentrationvstimecurveaucmg,0.2508361204013378
steadystatefuraconcentration,0.2508361204013378
areasundertheconcentrationvtimecurveauc,0.2508361204013378
mtx,0.2508361204013378
peakaztplasmaconcentration,0.2508361204013378
volumeofthecentralv1f,0.2508361204013378
eliminationrateconstantlambdaz,0.2508361204013378
peripheralv2f,0.2508361204013378
intercompartmentclearanceqf,0.2508361204013378
areaunderplasmaconcentrationtimecurveextrapolatedtoinfinityauc0infinity,0.2508361204013378
auec112,0.2508361204013378
steadystateplasmaconcentrationcpss,0.2508361204013378
michaelismenten,0.2508361204013378
folatelevel,0.2508361204013378
perceiveddissolvetime,0.2508361204013378
tfirst,0.2508361204013378
cl0,0.2508361204013378
peakmeanplasmaconcentration,0.2508361204013378
areaundertheplasmaconcentrationtimecurvesfrom0to12hauc012,0.2508361204013378
uge06h,0.2508361204013378
peripheralvolumesofdistributionv2,0.2508361204013378
macbar,0.2508361204013378
ratiooftheaucmic,0.2508361204013378
fafi,0.2508361204013378
fractionexcretedinurine,0.2508361204013378
equivalentsteadystateplasmaconcentration,0.2508361204013378
peakplasmaconcentrationoffentanylcmax,0.2508361204013378
fafa0,0.2508361204013378
endtidalisofluraneconcentration,0.2508361204013378
lossterm,0.2508361204013378
maximumdailydose,0.2508361204013378
drugaccumulation,0.2508361204013378
releasingrate,0.2508361204013378
clpl,0.2508361204013378
vapp,0.2508361204013378
areaunderthecurvefromzerotoinfinitumauc0infinity,0.2508361204013378
ultrafiltrate,0.2508361204013378
biliaryclearanceratio,0.2508361204013378
minimumalveolarconcentrationmac,0.2508361204013378
oilgaspartitioncoefficient,0.2508361204013378
trainoffourratiotoreturnspontaneously,0.2508361204013378
sm2,0.2508361204013378
timetothemaximumobservedconcentration,0.2508361204013378
peritonealtoplasmaaucratio,0.2508361204013378
troughmethadoneconcentration,0.2508361204013378
areaundercurvefor0to24h,0.2508361204013378
areaundertheserumdoxtimeconcentrationcurveauc024h,0.2508361204013378
quantification,0.2508361204013378
relativebioavailabilitiesfrel,0.2508361204013378
im,0.2508361204013378
auc0th,0.2508361204013378
oralcecaltransittime,0.2508361204013378
transportclearancefrom,0.2508361204013378
logd74,0.2508361204013378
timesofdisintegration,0.2508361204013378
sm1,0.2508361204013378
volumeofdistributionvdgamma,0.2508361204013378
totalaucra,0.2508361204013378
onsettimeformaximumblock,0.2508361204013378
durationofclinicalrelaxationdur25,0.2508361204013378
amountremoved,0.2508361204013378
areaunderthecurvefromtimezerotoinfinityauc0,0.2508361204013378
minimaldetectablelevel,0.2508361204013378
areasundertheplasmaconcentrationversustimecurves0toinfinity,0.2508361204013378
permeabilitysurfaceareaproduct,0.2508361204013378
efflux,0.2508361204013378
ratioofmeta,0.2508361204013378
peako6bgcsfconcentration,0.2508361204013378
oralcmax,0.2508361204013378
t4absorption,0.2508361204013378
totalt4absorption,0.2508361204013378
auccmax,0.2508361204013378
areaundertheplasmaconcentrationtimecurveauc012h,0.2508361204013378
formationratio,0.2508361204013378
residualtimemrt,0.2508361204013378
unboundcl,0.2508361204013378
tetrahy,0.2508361204013378
maximumtopotecanlactoneauc,0.2508361204013378
crossreactivity,0.2508361204013378
plasmaareaundertheconcentrationtimecurveauc,0.2508361204013378
areaundertheplasmaconcentrationcurveauc000,0.2508361204013378
therapeutichalflife,0.2508361204013378
indirect,0.2508361204013378
eliminationhalflifet12elimination,0.2508361204013378
distributionhalflifet12distribution,0.2508361204013378
centralvolumeofdistributionvcentral,0.2508361204013378
plasmaclearanceclf,0.2508361204013378
betaeliminationhalflifet12beta,0.2508361204013378
maximaletoposideplasmaconcentration,0.2508361204013378
olt12,0.2508361204013378
maximumplasmacurcuminconcentration,0.2508361204013378
overallmediansurvivaltime,0.2508361204013378
absoluteneutrophilcountnadir,0.2508361204013378
aucper6h,0.2508361204013378
degradationhalflive,0.2508361204013378
aucforal,0.2508361204013378
peripheralvolumedistributionvperipheral,0.2508361204013378
maximumreduction,0.2508361204013378
criticalconcentration,0.2508361204013378
peripheralvolumevp,0.2508361204013378
distributionalclq,0.2508361204013378
betaphasehalflifet12beta,0.2508361204013378
tclr,0.2508361204013378
rclr,0.2508361204013378
steadystatetrough,0.2508361204013378
timetoplatelet,0.2508361204013378
timetobloodneutrophil,0.2508361204013378
clobserved,0.2508361204013378
auc24ratio,0.2508361204013378
halfsaturationconcentration,0.2508361204013378
availabilitypa,0.2508361204013378
formationclearanceclf,0.2508361204013378
areaundertheinsulintimecurve,0.2508361204013378
four,0.2508361204013378
halflifetimeofthealphaphase,0.2508361204013378
peakplasmaconcentrationlevelscmax,0.2508361204013378
tumourresponse,0.2508361204013378
kpuuliver,0.2508361204013378
basalspacing,0.2508361204013378
dosecorrectedauc24h,0.2508361204013378
troughdrugconcentrationatsteadystatecssmin,0.2508361204013378
minimumabsorption,0.2508361204013378
matrixfactor,0.2508361204013378
areaunderthecurveover24hauc024,0.2508361204013378
tissuetoplasmatpratio,0.2508361204013378
peakitraconazoleconcentration,0.2508361204013378
detectionpotential,0.2508361204013378
metabolicclearancecld,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefrom0to24hauc024,0.2508361204013378
aucnt,0.2508361204013378
peakplasmamen10755level,0.2508361204013378
cmaxconcentration,0.2508361204013378
correctedqtqtc,0.2508361204013378
areaundertheplasmaconcentrationversustimecurveaucratio,0.2508361204013378
areaundertheplasmaconcentrationtimecurveauc08,0.2508361204013378
percentdistribution,0.2508361204013378
plasmaclearanceofunboundcisplatinclfree,0.2508361204013378
bsa,0.2508361204013378
aucor,0.2508361204013378
areaundertheplasmaimatinibconcentrationversustimecurveauc,0.2508361204013378
maximumplasmaconcentrationofacitretincmax,0.2508361204013378
apparenttotalvolumeofdistributionatsteadystate,0.2508361204013378
maximumurineconcentration,0.2508361204013378
centralcompartmentofdistribution,0.2508361204013378
rl,0.2508361204013378
apparentabsorptionfirstorderhalftimest12ka,0.2508361204013378
timeelapsinguntilappearanceoffirstorderdrugabsorption,0.2508361204013378
oraled50,0.2508361204013378
concentrationquotient,0.2508361204013378
plasmahalflifetbeta,0.2508361204013378
clearanceclforal,0.2508361204013378
volumeofdistributionvforal,0.2508361204013378
excretoryefficiency,0.2508361204013378
floatingduration,0.2508361204013378
aniongap,0.2508361204013378
zetapotentialzp,0.2508361204013378
totalchromatographicanalysistime,0.2508361204013378
cumulativerecoverie,0.2508361204013378
cmaxauc0,0.2508361204013378
x1,0.2508361204013378
drugtotroughratio,0.2508361204013378
x2,0.2508361204013378
drugretentionrate,0.2508361204013378
x3,0.2508361204013378
peaktroughterbutalineplasmaconcentrationsratio,0.2508361204013378
volumeofdistributionintheperipheralcompartmentv2,0.2508361204013378
peakmtxpdxconcentration,0.2508361204013378
maximumdurationofaction,0.2508361204013378
levl,0.2508361204013378
terminalvolumeofdistribution,0.2508361204013378
percentageextractionrecoverie,0.2508361204013378
antibody,0.2508361204013378
apparentoralabsorption,0.2508361204013378
nox,0.2508361204013378
maximalpeak,0.2508361204013378
apparentinvitropartitioningratio,0.2508361204013378
areaundertheprednisoloneconcentrationtimecurve,0.2508361204013378
apparenthepaticbloodclearance,0.2508361204013378
healthassessmentquestionnairedisabilityindex,0.2508361204013378
clearanceoverbioavailabilityclf,0.2508361204013378
maximuminfusionrate,0.2508361204013378
maximumclf,0.2508361204013378
rbc,0.2508361204013378
oraluptake,0.2508361204013378
maximumworkload,0.2508361204013378
passivepermeability,0.2508361204013378
finallevel,0.2508361204013378
penetrationrateconstant,0.2508361204013378
denitrationrate,0.2508361204013378
maximumplasmalevelscmax,0.2508361204013378
areaunderthecurveofplasmaconcentrationt,0.2508361204013378
plasmaproteinbindingdegree,0.2508361204013378
steadystatebioavailability,0.2508361204013378
highestobservedconcentration,0.2508361204013378
totalifx,0.2508361204013378
clearancebyultrafiltration,0.2508361204013378
maximumdrspconcentration,0.2508361204013378
firstordertransitabsorptionrateconstant,0.2508361204013378
timetomaximumimprovement,0.2508361204013378
timetotrsscoremaximumeffect,0.2508361204013378
timetoonsetofdyskinesia,0.2508361204013378
cmaxmaximalldopaconcentrationreached,0.2508361204013378
c10min,0.2508361204013378
t12halflifetime,0.2508361204013378
peakplasmadopaconcentration,0.2508361204013378
firstordereliminationbioavailability,0.2508361204013378
concentrationat50effect,0.2508361204013378
totaldailyofftime,0.2508361204013378
maximumratio,0.2508361204013378
maximumcomtinhibitionemax,0.2508361204013378
apparentvolumeofthecentralcompartmentvc,0.2508361204013378
peakic,0.2508361204013378
timetopeakplasmalevodopaconcentration,0.2508361204013378
areaunderthetimecurvefromzerotoinfinity,0.2508361204013378
cavgss,0.2508361204013378
peakplasmaldconcentrationcmax,0.2508361204013378
firstmaximumtime,0.2508361204013378
c30min,0.2508361204013378
halflifeoftheabsorptionphase,0.2508361204013378
gastricresidualvolume,0.2508361204013378
gamma2,0.2508361204013378
breastmilkversusserumconcentrationratio,0.2508361204013378
ratioofauc048h,0.2508361204013378
t12f,0.2508361204013378
vd2,0.2508361204013378
washouthalflife,0.2508361204013378
activatedclottingtime,0.2508361204013378
peakserumtopiramatelevel,0.2508361204013378
timetopeaklevodopaconcentration,0.2508361204013378
timeofonsetin,0.2508361204013378
meanresidencetimeofabsorption,0.2508361204013378
onsetofmaximalclinicalimprovement,0.2508361204013378
peakplasmaldopalevel,0.2508361204013378
onsetofeffect,0.2508361204013378
timetoonsetofabsorption,0.2508361204013378
024h,0.2508361204013378
plasmabetahalflife,0.2508361204013378
areaunderthebloodconcentrationtimecurveupto4hauc4hr,0.2508361204013378
drugloadingefficiencydle,0.2508361204013378
initialplasmaclearance,0.2508361204013378
areaunderthebloodethanolcurveauc,0.2508361204013378
apparenthalflivesofelimination,0.2508361204013378
halfmaximalresponse,0.2508361204013378
dlc,0.2508361204013378
percentagedrugrelease,0.2508361204013378
fractionalpotassiumreabsorption,0.2508361204013378
peakserummtx,0.2508361204013378
effectivehalflifeforaccumulation,0.2508361204013378
areaundertheserumconcentrationtimecurveauc0120h,0.2508361204013378
peaklisinoprilserumconcentration,0.2508361204013378
timetopeaklisinoprilserumconcentration,0.2508361204013378
areaunderthetimecoursecurveauc024h,0.2508361204013378
volumeofdistributionperkilo,0.2508361204013378
tmaxtimetofirstoccurrenceofcmax,0.2508361204013378
auc0infareaundertheplasmaconcentrationtimecurvefromtimezerotoinfinity,0.2508361204013378
freebindingenergy,0.2508361204013378
pc,0.2508361204013378
viability,0.2508361204013378
maximumserum,0.2508361204013378
areaunderthecurveaucat0120min,0.2508361204013378
freepercentage,0.2508361204013378
maximumobservedserumconcentration,0.2508361204013378
oralsystemicavailability,0.2508361204013378
doseinducinghalfmaximalresponse,0.2508361204013378
csfdrugpenetration,0.2508361204013378
recoveryscore,0.2508361204013378
tumortoipsilateralbrainratio,0.2508361204013378
maximumbloodethanolconcentrationcmax,0.2508361204013378
maximumpeakplasmadrugconcentrationcmax,0.2508361204013378
durationofclinicalrelaxationt125,0.2508361204013378
timefortofratioto,0.2508361204013378
areaundertheserumconcentrationvstimecurve,0.2508361204013378
areaunderconcentrationtimecurveauc0t,0.2508361204013378
degree,0.2508361204013378
peakpczplasmalevel,0.2508361204013378
areasundertheplasmaconcentrationtimecurveoverthedosingintervalauc024,0.2508361204013378
fractionofunboundepia,0.2508361204013378
maximumentrapmentefficiency,0.2508361204013378
maximumtime,0.2508361204013378
percentfree,0.2508361204013378
gasflowrate,0.2508361204013378
totalrenalexcretion,0.2508361204013378
peakplasmapczconcentration,0.2508361204013378
bindingratio,0.2508361204013378
objectiveresponsefrequency,0.2508361204013378
initialextractionratio,0.2508361204013378
netfluxe,0.2508361204013378
urinaryexcretionof,0.2508361204013378
aucs0infinity,0.2508361204013378
fractionofalfentanilunboundinserumfu,0.2508361204013378
maximumconcentrationreached,0.2508361204013378
eliminationt12betahalflive,0.2508361204013378
areaunderthecurveconcentration,0.2508361204013378
sthiop,0.2508361204013378
timesto50recoveryoftwitch,0.2508361204013378
plasmaareaunderthecurveauc,0.2508361204013378
effective,0.2508361204013378
centralvolumeofdistributionvd,0.2508361204013378
apparenttherapeuticrange,0.2508361204013378
bindingconstantkd,0.2508361204013378
rateconstantke0,0.2508361204013378
areaundertheserumconcentrationversustimecurve,0.2508361204013378
onsetofneuromuscularblockade,0.2508361204013378
recoveryofthe,0.2508361204013378
apparentfinalvolumeofdistribution,0.2508361204013378
aortatoplasmaratio,0.2508361204013378
rac,0.2508361204013378
totaleliminationclearance,0.2508361204013378
serumclearancecl,0.2508361204013378
hvd,0.2508361204013378
peakchlormezanoneplasmalevel,0.2508361204013378
timeto90emptying,0.2508361204013378
clm,0.2508361204013378
timeofpeakexcretionrate,0.2508361204013378
pulse,0.2508361204013378
fractionsunbound,0.2508361204013378
cxtconcentrationxtimeratio,0.2508361204013378
particlesizesd50,0.2508361204013378
2,0.2508361204013378
fractionsofdrugremoved,0.2508361204013378
steadystatetargetconcentration,0.2508361204013378
prenin,0.2508361204013378
paldo,0.2508361204013378
renalexcretionrateconstant,0.2508361204013378
overallic50,0.2508361204013378
auc0to24hours,0.2508361204013378
ofpratio,0.2508361204013378
timetopeakeffect,0.2508361204013378
peakmeloxicamconcentration,0.2508361204013378
meanresidencetimeinperipheraltissuesmrtp,0.2508361204013378
totalpercentageofadministeredradioactivedoserecovered,0.2508361204013378
halflivesforserumelimination,0.2508361204013378
peakdrugconcentrationcmax,0.2508361204013378
apparenthalflifeofelimination,0.2508361204013378
hourlyeliminationratess60,0.2508361204013378
hourlyeliminationratebeta60,0.2508361204013378
terminalserumhalflive,0.2508361204013378
micsinhibiting50,0.2508361204013378
mic90m,0.2508361204013378
cltotf,0.2508361204013378
finalhalflive,0.2508361204013378
areaundertheinhibitorycurve,0.2508361204013378
areaundertheconcentrationtimecurvefrom0to10h,0.2508361204013378
fiftypercenteffectivedosesed50s,0.2508361204013378
timetoseveredyspnoea,0.2508361204013378
areaundertheinhibitorycurveover24hauic24,0.2508361204013378
seruminhibitorytitre,0.2508361204013378
minimumauic,0.2508361204013378
hourlyeliminationrate,0.2508361204013378
ratesofexcretion,0.2508361204013378
durationsuntil25twitchrecovery,0.2508361204013378
timetorecoveryoft1t0,0.2508361204013378
firstpassuptake,0.2508361204013378
cmax024hratio,0.2508361204013378
areaunderthecurvefrom0to24hoursauc,0.2508361204013378
areasunderthedrugconcentrationcurvesauc,0.2508361204013378
volumeofdistributionoftheperipheralcompartment,0.2508361204013378
steadystatedistributionvolumevss,0.2508361204013378
steadystatehalflife,0.2508361204013378
mdt,0.2508361204013378
areaunderthecurvefromtimezerotoinfinityauc,0.2508361204013378
totalserumlevel,0.2508361204013378
dailyrelease,0.2508361204013378
spontaneousrecoveryoft1t0,0.2508361204013378
maximummeanserumconcentrationscmax,0.2508361204013378
maximumee2,0.2508361204013378
areaundertheplasmaconcentrationversustimecurveauc0infinity,0.2508361204013378
areaunderthecurveauc0180min,0.2508361204013378
t4t1,0.2508361204013378
recoverytot1t0,0.2508361204013378
vmaxc,0.2508361204013378
timestorecoveryoft4t1to,0.2508361204013378
t12h,0.2508361204013378
auc0approximatelyinfinity,0.2508361204013378
steadystateg3139concentration,0.2508361204013378
50protectivedose,0.2508361204013378
urinaryconcentration,0.2508361204013378
rateofpenetration,0.2508361204013378
lz,0.2508361204013378
maximumconcentrationofdrug,0.2508361204013378
transdermalabsorption,0.2508361204013378
auc24micratio,0.2508361204013378
maximaltoleratedauc,0.2508361204013378
timesto999killing,0.2508361204013378
areaundertheinhibitorycurvemicratioaucmic,0.2508361204013378
clinicalbenefitresponserate,0.2508361204013378
maximumauc,0.2508361204013378
basalconcentration,0.2508361204013378
peaksynovialfluidconcentration,0.2508361204013378
initialdistributionhalflife,0.2508361204013378
tounboundplasmadrugconcentrationratio,0.2508361204013378
maximummeasuredlevel,0.2508361204013378
cumulativelevelofrenalexcretion,0.2508361204013378
tissueplasmapartitioncoefficientkpuu,0.2508361204013378
t50cmax,0.2508361204013378
heartbloodconcentration,0.2508361204013378
eliminationhalflifet05b,0.2508361204013378
absorptionhalflifet05ab,0.2508361204013378
durationofabsorptiond1,0.2508361204013378
yield,0.2508361204013378
distributionvolumesv0,0.2508361204013378
absoluteextractionefficiencie,0.2508361204013378
eliminationclearancecle,0.2508361204013378
areaundertheconcentrationtimecurvefrom0to24hauc0tau,0.2508361204013378
saturatedsolubility,0.2508361204013378
steadystateplasmadrugconcentration,0.2508361204013378
percentsurvival,0.2508361204013378
areaundertheserumconcentrationvstimecurveauc,0.2508361204013378
minimumtherapeuticplasmaconcentration,0.2508361204013378
timetoonsetofbronchodilation,0.2508361204013378
resolutionfactorrs,0.2508361204013378
areaunderthecurveaucmicratio,0.2508361204013378
bioaccessibility,0.2508361204013378
plasmaalfentanilconcentration,0.2508361204013378
peakconcentrationinplasmacmax,0.2508361204013378
maximumindividualconcentration,0.2508361204013378
weightnormalizedplasmaclearance,0.2508361204013378
clearancesofproduction,0.2508361204013378
penetrationintolung,0.2508361204013378
peaklungconcentration,0.2508361204013378
heartratenadir,0.2508361204013378
apparentdistributionvolumevd,0.2508361204013378
minimumdetectionrange,0.2508361204013378
timetoattainmentoftargetconcentration,0.2508361204013378
organclearance,0.2508361204013378
auczeroinfinity,0.2508361204013378
leadintime,0.2508361204013378
recoveryphasehalflife,0.2508361204013378
pc50sgawamp,0.2508361204013378
medianrecoverytime,0.2508361204013378
constanttargetplasmaalfentanilconcentration,0.2508361204013378
timetospontaneousrecovery,0.2508361204013378
deltaunav,0.2508361204013378
urinarysodiumexcretionunav,0.2508361204013378
ece95,0.2508361204013378
areaunderthecurvefrom0toinfinityoftheophyllineauc0infinity,0.2508361204013378
betadecay,0.2508361204013378
steadystatevd,0.2508361204013378
recoveryperiod,0.2508361204013378
netfluorideexcretion,0.2508361204013378
unboundareaundertheconcentrationcurve,0.2508361204013378
residueconcentration,0.2508361204013378
rateofbiophaseequilibrationke0,0.2508361204013378
areaunderthecurvefromtime0to120min,0.2508361204013378
volumeofdistributionbytheareamethodvdarea,0.2508361204013378
maximumobservedard07concentrationrelativetodoseadministrationcmax,0.2508361204013378
areaunderthecurvefor0to24hour,0.2508361204013378
na,0.2508361204013378
maximumfreeplasmaconcentration,0.2508361204013378
apparentoralvolumeofdistributionvf,0.2508361204013378
effectcompartmentconcentrationscorresponding,0.2508361204013378
areasundertheconcentrationtimecurvefromtime0extrapolatedtoinfinityauczeroinfinity,0.2508361204013378
aucconcentration,0.2508361204013378
onsetof,0.2508361204013378
steadystateplasmaareaundertheconcentrationtimecurveauc,0.2508361204013378
basalbileflowrate,0.2508361204013378
highestconcentration,0.2508361204013378
fractionofdruginthecentralcompartment,0.2508361204013378
minimalplasmadiazepamconcentration,0.2508361204013378
t12bterminalhalflife,0.2508361204013378
timetomaximalplasmaconcentrationtmax,0.2508361204013378
unboundbrainconcentration,0.2508361204013378
ce50na,0.2508361204013378
hfip,0.2508361204013378
apparentrenalfluoride,0.2508361204013378
peakfleroxacin,0.2508361204013378
poolsize,0.2508361204013378
distributionvolumeatsteadystatevdss,0.2508361204013378
terminalphaset12beta,0.2508361204013378
redistributionhalflifet12gamma,0.2508361204013378
centralcompartmentdistributionvolumev1,0.2508361204013378
vtihr,0.2508361204013378
vti,0.2508361204013378
bloodke,0.2508361204013378
abscessfluidconcentration,0.2508361204013378
mbc50,0.2508361204013378
cmaxcfcmaxefratio,0.2508361204013378
auc0tcfauc0tefratio,0.2508361204013378
bhalflife,0.2508361204013378
plasmaclearanceplcl,0.2508361204013378
ce95,0.2508361204013378
cleared,0.2508361204013378
biliaryrecovery,0.2508361204013378
initialserumconcentration,0.2508361204013378
mbc50tomic50ratio,0.2508361204013378
mbc90,0.2508361204013378
concentrationathalfmaximumeffectec50,0.2508361204013378
volumesofdistributionatsteadystatevss,0.2508361204013378
brainuptakeclearanceclup,0.2508361204013378
timetoachievearecoveryoftrainoffourratio,0.2508361204013378
anae,0.2508361204013378
relativeextentsofabsorptionfrel,0.2508361204013378
pp,0.2508361204013378
ce50wa,0.2508361204013378
timesto,0.2508361204013378
antifactorxaactivitie,0.2508361204013378
tg,0.2508361204013378
mb,0.2508361204013378
sedationsuccessrate,0.2508361204013378
v2l,0.2508361204013378
amax,0.2508361204013378
inhibitorytiter,0.2508361204013378
v1l,0.2508361204013378
timetoc,0.2508361204013378
volumeofdistributionintheeliminationphase,0.2508361204013378
plasmaantifactorxalevel,0.2508361204013378
tsub12sub,0.2508361204013378
bindingdistance,0.2508361204013378
elutionatflowrate,0.2508361204013378
areaundertheplasmaleveltimecurve,0.2508361204013378
maximummiosi,0.2508361204013378
k24,0.2508361204013378
dissociationconstantkd1,0.2508361204013378
dissociationkoff,0.2508361204013378
halflifeofoccupancydisappearance,0.2508361204013378
peakoccupancie,0.2508361204013378
t2alpha,0.2508361204013378
kmu,0.2508361204013378
miosi,0.2508361204013378
fractionalurinaryrecovery,0.2508361204013378
halfmaximumeffectec50,0.2508361204013378
maximalobservedconcentration,0.2508361204013378
t2gamma,0.2508361204013378
plcl,0.2508361204013378
mon,0.2508361204013378
metabolicaucratioauclast,0.2508361204013378
recoveryinurine,0.2508361204013378
peakpharmacodynamiceffect,0.2508361204013378
overalleliminationhalflifemtxt12,0.2508361204013378
logpe,0.2508361204013378
fmcyp2d6,0.2508361204013378
aucincreaseratio,0.2508361204013378
oralclearanceclsf,0.2508361204013378
peakplasmaconcentrationatthesteadystate,0.2508361204013378
biovailabilityf,0.2508361204013378
capacity,0.2508361204013378
areaundertheplasmaeeversustimecurve,0.2508361204013378
urinarytofecalexcretionratio,0.2508361204013378
auc048hour,0.2508361204013378
unboundpercent,0.2508361204013378
peakimipraminebloodlevel,0.2508361204013378
steadystatetotalserumconcentration,0.2508361204013378
dlratio,0.2508361204013378
peakurinarydrugconcentration,0.2508361204013378
peakplasmatheophyllineconcentration,0.2508361204013378
apparenteliminationclearance,0.2508361204013378
50effectiveconvulsantdose,0.2508361204013378
50effectiveanticonvulsantdose,0.2508361204013378
cerebralauc0infinityplasmaticauc0infinityratio,0.2508361204013378
aucadriamycinolaucadriamycinratio,0.2508361204013378
concentrationmultipliedbytimeareaundercurve,0.2508361204013378
doserecoverypercent,0.2508361204013378
durationofcompleteresponse,0.2508361204013378
maximumsensitivity,0.2508361204013378
platelet,0.2508361204013378
decayhalflife,0.2508361204013378
invivobindingrate,0.2508361204013378
peaksynovialconcentration,0.2508361204013378
volumesofdistributionofthecentralcompartment,0.2508361204013378
availabilityinserum,0.2508361204013378
cmaxratiodoxepi,0.2508361204013378
maximumalendronateplasmaconcentrationcmax,0.2508361204013378
aggregation,0.2508361204013378
intestinalabsorption,0.2508361204013378
overallresponsecompleteresponsecrpartialresponseprrate,0.2508361204013378
cumulativeurinaryrecoveryrate,0.2508361204013378
totalclearanceofdrug,0.2508361204013378
shedding,0.2508361204013378
vlzf,0.2508361204013378
areaunderthetimeeffectcurveauec,0.2508361204013378
maximalantiplateleteffectemax,0.2508361204013378
growthinhibitionrate,0.2508361204013378
auc0obs,0.2508361204013378
tumor,0.2508361204013378
protein,0.2508361204013378
apparentsteadystateclearance,0.2508361204013378
idml,0.2508361204013378
apparentassociationconstant,0.2508361204013378
turnover,0.2508361204013378
totalplasmatmtxclearance,0.2508361204013378
areaundertheconcentrationtimecurvetothelastsamplingtimeauc012,0.2508361204013378
peakcontent,0.2508361204013378
peakserumlevelscmax,0.2508361204013378
sloweliminationphase,0.2508361204013378
associationrateconstant,0.2508361204013378
areaunderthecurvefrom36to48hour,0.2508361204013378
concentrationtodosecdratio,0.2508361204013378
peakbec,0.2508361204013378
keq,0.2508361204013378
droplet,0.2508361204013378
effluentrate,0.2508361204013378
urinaryeliminationhalflife,0.2508361204013378
quantificationlimitloq,0.2508361204013378
apparentoverallvolumeofdistribution,0.2508361204013378
mrtmeanretentiontime,0.2508361204013378
efficacie,0.2508361204013378
dosenormalizedsteadystateconcentration,0.2508361204013378
auc24hmic,0.2508361204013378
minimumtargetconcentration,0.2508361204013378
tda,0.2508361204013378
c2micratio,0.2508361204013378
prostaticfluidplasmaratio,0.2508361204013378
maxmic90ratio,0.2508361204013378
ratiosoffauc024hmic90,0.2508361204013378
auc0tmic,0.2508361204013378
aucnorm,0.2508361204013378
mpcsmicmpc,0.2508361204013378
ratiosofareaundertheplasmaconcentrationtimecurveover24htominimuminhibitoryconcentrationauc024mic,0.2508361204013378
auc024hrmic,0.2508361204013378
areaundertheconcentrationtimecurveover24hour,0.2508361204013378
cmaxblood,0.2508361204013378
peakpleuralfluidlevelcmax,0.2508361204013378
peakbloodconcentrationcmaxblood,0.2508361204013378
timetomaximumpleuralfluidconcentrationtmaxpf,0.2508361204013378
peakpleuralfluidconcentrationcmaxpf,0.2508361204013378
nominaloraldose,0.2508361204013378
clearancecirate,0.2508361204013378
timeto,0.2508361204013378
timesto999kill,0.2508361204013378
totalkill,0.2508361204013378
micthreshold,0.2508361204013378
urinaryflowrate,0.2508361204013378
aucmic24,0.2508361204013378
bodyclearancecl,0.2508361204013378
timetoreachthemaximumconcentrationtmax,0.2508361204013378
brainconcentration,0.2508361204013378
maximumresiduelimit,0.2508361204013378
zeroordereliminationrate,0.2508361204013378
ratioaucbau,0.2508361204013378
maximalduration,0.2508361204013378
totalapparentvolumeofdistributionatequilibrium,0.2508361204013378
terminalhalflifephaseofelimination,0.2508361204013378
detectionlimitsn3,0.2508361204013378
renalclearancecl,0.2508361204013378
areaundertheplasmaconcentrationversustimecurveauc024,0.2508361204013378
prrate,0.2508361204013378
aubt,0.2508361204013378
gitransittime,0.2508361204013378
gastricresidence,0.2508361204013378
cumulativedistribution,0.2508361204013378
breastmilklevel,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefrom0toinfinityauc0,0.2508361204013378
apparentfirstorderterminaleliminationhalflife,0.2508361204013378
areaovertheegpcurve,0.2508361204013378
durationoftheblockade,0.2508361204013378
onsettimeofsensoryblock,0.2508361204013378
peakmaconcentration,0.2508361204013378
timeafteringestiontopeakconcentration,0.2508361204013378
tgirmax,0.2508361204013378
timetomaximalserumglucoseconcentrationtmax,0.2508361204013378
maximumserumglucoseconcentrationcmax,0.2508361204013378
maximumarterialplasmaconcentration,0.2508361204013378
affinityka,0.2508361204013378
timetoconversion,0.2508361204013378
baselinee0,0.2508361204013378
efficacytau,0.2508361204013378
affinitykb,0.2508361204013378
normalized,0.2508361204013378
cmaxcmax,0.2508361204013378
aucaucnorm,0.2508361204013378
drugdoserequiredfor90inhibitionofcfu,0.2508361204013378
plasmasteadystatelevel,0.2508361204013378
accumulativedrugrelease,0.2508361204013378
maximalvenouslevobupivacaineconcentration,0.2508361204013378
circulationt12,0.2508361204013378
timetoreachthem,0.2508361204013378
peakmicratio,0.2508361204013378
areaundertheconcentrationtimecurveover24hinthesteadystatedividedbythemic,0.2508361204013378
centraldistributionvolumev1,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityaucinfinity,0.2508361204013378
placentaltransfer,0.2508361204013378
highestplasmaconcentration,0.2508361204013378
progressionfreesurvivalduration,0.2508361204013378
timetopeakconcerntrationtmax,0.2508361204013378
consumption,0.2508361204013378
maximumarteriallevobupivacaineconcentration,0.2508361204013378
lag,0.2508361204013378
peakmean,0.2508361204013378
brainuptakeclearance,0.2508361204013378
maximaltoleratedoraldose,0.2508361204013378
eliminationphasehalflifet12alpha,0.2508361204013378
terminaleliminationphasehalflifet12beta,0.2508361204013378
residualradioactivity,0.2508361204013378
maximumglucoseinfusionrategirmax,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefromzeroto48hoursauc048,0.2508361204013378
basalendogenousreleaserateclearancex,0.2508361204013378
clrenal,0.2508361204013378
post,0.2508361204013378
timeto10of,0.2508361204013378
areaunderthecurvegirauc,0.2508361204013378
maximumseruminsulinconcentrationcmax,0.2508361204013378
areaunderthebaselinecorrectedserumconcentrationversustimecurvefromtime0to24hauc024,0.2508361204013378
urinaryrecoveryurxf,0.2508361204013378
urxf,0.2508361204013378
timetohalfmaximumconcentrationt50max,0.2508361204013378
auc120,0.2508361204013378
rootmean,0.2508361204013378
timeto10,0.2508361204013378
cpeptideconcentration,0.2508361204013378
maximumlngconcentration,0.2508361204013378
serumconcentrationcmax,0.2508361204013378
fractionsbound,0.2508361204013378
tmin,0.2508361204013378
glucoseconcentration,0.2508361204013378
areaunderthecurve0t,0.2508361204013378
aucin,0.2508361204013378
timetoreperfusion,0.2508361204013378
maximalpostinsulinbolusconcentration,0.2508361204013378
peakestradiolconcentration,0.2508361204013378
eliminationhalflivest12el,0.2508361204013378
plasmaconcentrationtimecurveaucelimination,0.2508361204013378
washintimetop50,0.2508361204013378
p90,0.2508361204013378
areaundertheket,0.2508361204013378
cumulativeurinaryexcretionpercentage,0.2508361204013378
per,0.2508361204013378
troughpef,0.2508361204013378
dominanthalflife,0.2508361204013378
appearanceratera,0.2508361204013378
activityratio,0.2508361204013378
iauct90,0.2508361204013378
topeakconcentration,0.2508361204013378
steadystateplasmailoprostconcentration,0.2508361204013378
initialdistributionvolume,0.2508361204013378
troughfsi,0.2508361204013378
timetomaximuminsulinconcentration,0.2508361204013378
areaundercurveauc0clampend,0.2508361204013378
maximalinsulinconcentration,0.2508361204013378
timetoreachgirmax,0.2508361204013378
aucfreefattyacids024h,0.2508361204013378
timetoreachthismaximumtmax,0.2508361204013378
carryover,0.2508361204013378
tumortoplasmaratio,0.2508361204013378
mz1,0.2508361204013378
apparentoralsteadystatevolumeofdistribution,0.2508361204013378
t12kle,0.2508361204013378
urineproduction,0.2508361204013378
inflammationscore,0.2508361204013378
absorptionhalflivest12a,0.2508361204013378
oralbiodisponibility,0.2508361204013378
wholebloodvolumeofdistribution,0.2508361204013378
metabolichalflife,0.2508361204013378
aucfororalabsorption,0.2508361204013378
integratedacthresponse,0.2508361204013378
areaundertheplasmatriazolamconcentrationtimecurve,0.2508361204013378
ratioofintrinsicformationclearance,0.2508361204013378
centralvolumeofdistributionv2f,0.2508361204013378
peritoneal,0.2508361204013378
aucareaundertheplasmaconcentrationtimecurve,0.2508361204013378
intercompartmentalcl,0.2508361204013378
cmintroughlevel,0.2508361204013378
timereceivingdrug,0.2508361204013378
timeofendofaction,0.2508361204013378
exudateplasmaconcentrationratio,0.2508361204013378
areaundertheplasmaconcentrationtimecurveoverthedosingintervalofdurationt,0.2508361204013378
maximumoralequivalentdose,0.2508361204013378
areaunderthecurveauc0endofgir,0.2508361204013378
timetoonsetofaction,0.2508361204013378
areaunderthecurve0168h,0.2508361204013378
steadystateconcentrationcss48168h,0.2508361204013378
timetomaximumdrugconcentrationtmax,0.2508361204013378
areaundertheserumconcentrationtimecurveauc096h,0.2508361204013378
auc24mic90ratio,0.2508361204013378
acuterejectionrate,0.2508361204013378
inversionratio,0.2508361204013378
relativebiopotency,0.2508361204013378
apparentoralbloodclearance,0.2508361204013378
serumtroughconcentrationctrough,0.2508361204013378
areaunderthebloodconcentrationtimecurveto12hauc012h,0.2508361204013378
partitioninginto,0.2508361204013378
steadystatectrough,0.2508361204013378
objectiveresponseraterr,0.2508361204013378
mrm,0.2508361204013378
maximumeffectauc50,0.2508361204013378
transferrate,0.2508361204013378
halflifeofrecovery,0.2508361204013378
auc0336h,0.2508361204013378
beta1beta2selectivity,0.2508361204013378
volumeofdistributionvlambda,0.2508361204013378
alphahalflive,0.2508361204013378
effectiveconcentrationat50ofmaximumec50,0.2508361204013378
ratioofformationabsorptionrateconstant,0.2508361204013378
areaundertheplasmaconcentrationtimeprofilefromtime0to24h,0.2508361204013378
systemicextractionratio,0.2508361204013378
csi,0.2508361204013378
plasmaglucoseconcentration,0.2508361204013378
kihigh,0.2508361204013378
kilow,0.2508361204013378
da,0.2508361204013378
steadystatetroughconcentrationcminss,0.2508361204013378
contribution,0.2508361204013378
peakplasmappalevel,0.2508361204013378
initialdetectiontime,0.2508361204013378
vmaxxv,0.2508361204013378
lactate,0.2508361204013378
permeationcoefficient,0.2508361204013378
mz281,0.2508361204013378
striatalposteriorbrainratio,0.2508361204013378
eliminationtl2,0.2508361204013378
timetopeakdatoccupancy,0.2508361204013378
plasmalevodopaconcentration,0.2508361204013378
minimaltoxicconcentration,0.2508361204013378
offset,0.2508361204013378
contextsensitivehalftime,0.2508361204013378
apparentpkb,0.2508361204013378
halflivesofequilibrium,0.2508361204013378
halflifeofwashout,0.2508361204013378
receptoroccupancyhalflife,0.2508361204013378
halflifevaluest12,0.2508361204013378
maintenanceinfusionrate,0.2508361204013378
conjugatedfreeratio,0.2508361204013378
effectiveconcentrationfor50maximaleffect,0.2508361204013378
maximalplasmaconcentrationofldopacmax,0.2508361204013378
durationofexamination,0.2508361204013378
studyduration,0.2508361204013378
d23,0.2508361204013378
peakuptake,0.2508361204013378
halftimeforclearancefrompeakuptake,0.2508361204013378
steadystatebrainextracellularfluidplasmaunboundconcentrationratio,0.2508361204013378
areaundertheresponsecurve,0.2508361204013378
50inhibitory,0.2508361204013378
mtt,0.2508361204013378
returnauc,0.2508361204013378
suppressionratio,0.2508361204013378
concentrationproducingthehalfmaximumeffect,0.2508361204013378
total24heffectareaauetc,0.2508361204013378
suppressionhalflife,0.2508361204013378
areaunderthecurveauccret,0.2508361204013378
cauc12,0.2508361204013378
eo,0.2508361204013378
totalvolumeofdistributionvss,0.2508361204013378
suppressiont12,0.2508361204013378
maximumalemtuzumabconcentration,0.2508361204013378
troughconcentrationsc0,0.2508361204013378
maximumtoleratedplasmaconcentration,0.2508361204013378
saturationconcentration,0.2508361204013378
maximumpercentageofinhibition,0.2508361204013378
totalcortisol,0.2508361204013378
peakintracellularconcentration,0.2508361204013378
cellularelimination,0.2508361204013378
terminalrateofeliminationt12,0.2508361204013378
eliminationrateconstantofplasma5fuk40,0.2508361204013378
bloodtoplasmapartitionratio,0.2508361204013378
clearancehalflive,0.2508361204013378
totaldrugcontent,0.2508361204013378
kiz,0.2508361204013378
lagtimetl,0.2508361204013378
refractoryperiod,0.2508361204013378
auc0120,0.2508361204013378
tissuelevel,0.2508361204013378
maximumdosage,0.2508361204013378
t15,0.2508361204013378
t30,0.2508361204013378
t60,0.2508361204013378
t120,0.2508361204013378
retentionvolume,0.2508361204013378
signaltonoise,0.2508361204013378
clcl10,0.2508361204013378
eliminationrateconstantk34,0.2508361204013378
ramsaysedationscore,0.2508361204013378
iv,0.2508361204013378
maciso,0.2508361204013378
meanresidencetimeafteroraladministrationmrtpo,0.2508361204013378
timeforconcentrationstodecrease50frommaximal,0.2508361204013378
wobble,0.2508361204013378
durationofsedation,0.2508361204013378
tcp02,0.2508361204013378
frequenciesofspontaneousresistance,0.2508361204013378
hepaticextractioncoefficient,0.2508361204013378
localabsorptiontimeta,0.2508361204013378
areaundertheconcentrationauc0infinity,0.2508361204013378
percentcumulativeurinaryexcretionin024hour,0.2508361204013378
areasundertheconcentrationtimecurvesaucs,0.2508361204013378
overallcmin,0.2508361204013378
adipose,0.2508361204013378
pka1,0.2508361204013378
pka2,0.2508361204013378
areaundertheserumconcentrationtimecurveauc0,0.2508361204013378
mucosalconcentration,0.2508361204013378
serumauc024,0.2508361204013378
stationarygrowthphaseminimalbactericidalconcentration,0.2508361204013378
tsb,0.2508361204013378
plasmasufentanilconcentration,0.2508361204013378
areasundertheconcentrationtimecurvefromtimezeroto24hatsteadystate,0.2508361204013378
rateofventilation,0.2508361204013378
survivorship,0.2508361204013378
relativeinfantdose,0.2508361204013378
areaunderthecaffeineconcentrationtimecurve,0.2508361204013378
halflifet12el,0.2508361204013378
abundance,0.2508361204013378
ae024h,0.2508361204013378
timetoeyeopening,0.2508361204013378
t12mrt,0.2508361204013378
maximalmedianconcentrationsofplasma,0.2508361204013378
auc090min,0.2508361204013378
biological,0.2508361204013378
secondcompartmentvolume,0.2508361204013378
thirdcompartmentvolume,0.2508361204013378
cl1eliminationclearance,0.2508361204013378
cl2distributionclearance,0.2508361204013378
cl3distributionclearance,0.2508361204013378
timetomaximumnaloxoneconcentrationtmax,0.2508361204013378
maximumnaloxoneconcentrationcmax,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefromtime0toinfinity,0.2508361204013378
totalplasmaclearanceclf,0.2508361204013378
maximumconcentrationinserum,0.2508361204013378
peakserumdigoxinconcentration,0.2508361204013378
pappblap,0.2508361204013378
peakarearatio,0.2508361204013378
apparentreactionrateconstant,0.2508361204013378
cmaxtotal,0.2508361204013378
clratio,0.2508361204013378
maximalrelativeefficacyemax,0.2508361204013378
clearanceclratio,0.2508361204013378
ckseffluxratio,0.2508361204013378
ktvurea,0.2508361204013378
faecalbloodlo,0.2508361204013378
draineddialysatevolume,0.2508361204013378
absorptivetransport,0.2508361204013378
netefflux,0.2508361204013378
ptf,0.2508361204013378
maximalpq,0.2508361204013378
ver,0.2508361204013378
steadystatecmin,0.2508361204013378
auc0r,0.2508361204013378
intestinal,0.2508361204013378
inletconcentration,0.2508361204013378
apparentrecoveryrate,0.2508361204013378
apparenteliminationrateconstantlambdaz,0.2508361204013378
lambda1,0.2508361204013378
fauc,0.2508361204013378
cmaxs,0.2508361204013378
timetakentoreachpeak,0.2508361204013378
aucinfinityratio,0.2508361204013378
peakplasmacortisolconcentration,0.2508361204013378
peakplasmaprogesteroneconcentration,0.2508361204013378
lengthofthelutealphase,0.2508361204013378
overallremissionrate,0.2508361204013378
methodrecovery,0.2508361204013378
durationsof,0.2508361204013378
steadystateserumghconcentration,0.2508361204013378
normalizedmcr,0.2508361204013378
peakserumghconcentration,0.2508361204013378
extractiverecovery,0.2508361204013378
areaunderthecurveauc04h,0.2508361204013378
influxrateconstantk1,0.2508361204013378
timestothemaximumconcentration,0.2508361204013378
maximumcaffeineconcentration,0.2508361204013378
plasmaconcentrationcpt,0.2508361204013378
tissuedistributionv,0.2508361204013378
drugconcentrationathalfmaximaleffectec50,0.2508361204013378
maximumpotentialamount,0.2508361204013378
k01,0.2508361204013378
relativesystemicbioavailabilitie,0.2508361204013378
dosecorrectedsystemicavailability,0.2508361204013378
0toinfinity,0.2508361204013378
unboundsr,0.2508361204013378
aucss08,0.2508361204013378
peakbrompheniramineconcentration,0.2508361204013378
oralclearanceclpo,0.2508361204013378
timetoreachmaximumplasmadrugconcentrationtmax,0.2508361204013378
areaunderthedrugconcentrationtimecurvefromtime0toinfinityaucinfinity,0.2508361204013378
apparentterminaleliminationhalflifet12beta,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefor24hour,0.2508361204013378
areaundertheconcentrationtimecurvetothelastmeasurabletimepoint,0.2508361204013378
steadystated,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefromtimezerototimeoflastmeasurableconcentrationauclast,0.2508361204013378
cgmaxss,0.2508361204013378
firstorderrateconstantkeohalflife,0.2508361204013378
clearanceofunbounddrug,0.2508361204013378
aucyen,0.2508361204013378
acute,0.2508361204013378
effectsiteconcentrationcet,0.2508361204013378
targetconcentrationct,0.2508361204013378
peakbloodconcentrationcmax,0.2508361204013378
diuresi,0.2508361204013378
ec99,0.2508361204013378
halflifefortheeliminationphase,0.2508361204013378
maximumplasmadrugconcentration,0.2508361204013378
betahalftime,0.2508361204013378
totalapparentvolumeofdistributionvd,0.2508361204013378
apparentvolumeofthecentralcompartmentv1,0.2508361204013378
durationofzeroorderabsorption,0.2508361204013378
eliminationplasmahalflife,0.2508361204013378
areaundertheplasmamidazolamconcentrationtimecurve,0.2508361204013378
peaktissuelevel,0.2508361204013378
areaundertheconcentrationtimecurveaucfromtime0tothelastquantifiabletimepointauc0t,0.2508361204013378
basedeficit,0.2508361204013378
uosm,0.2508361204013378
secretoryrate,0.2508361204013378
augtau,0.2508361204013378
troughlevelsc24h,0.2508361204013378
peaktotroughratioscmaxc24h,0.2508361204013378
peakplasmaconcentrationmicratio,0.2508361204013378
withdrawalrate,0.2508361204013378
cbt,0.2508361204013378
plasmaareaunderthecurveauc024,0.2508361204013378
steadystatesspeaks,0.2508361204013378
sstroughs,0.2508361204013378
areaunderthecurveminimuminhibitoryconcentration,0.2508361204013378
epc,0.2508361204013378
iuc,0.2508361204013378
peaksalivaryconcentration,0.2508361204013378
incre,0.2508361204013378
percentageexhalation,0.2508361204013378
exhalationrate,0.2508361204013378
eliminationcoefficient,0.2508361204013378
halflifeofdevelopment,0.2508361204013378
mrp,0.2508361204013378
apparentelimination,0.2508361204013378
peaksalivarycaffeineconcentration,0.2508361204013378
peakcaf,0.2508361204013378
newsteadystate,0.2508361204013378
maximumvaluecmax,0.2508361204013378
uvealtractconcentration,0.2508361204013378
steadystatevolumesofdistributionvss,0.2508361204013378
cacrclearanceratio,0.2508361204013378
d3,0.2508361204013378
gastricemptying,0.2508361204013378
milkeliminationhalflife,0.2508361204013378
factor,0.2508361204013378
serumbinding,0.2508361204013378
annual,0.2508361204013378
areaunderthecurve024h,0.2508361204013378
secondary,0.2508361204013378
steadystatespeed,0.2508361204013378
drugtargetingefficiencydte,0.2508361204013378
hemofiltrationclearance,0.2508361204013378
an,0.2508361204013378
msob,0.2508361204013378
unboundsystemicclearancecisu,0.2508361204013378
ti,0.2508361204013378
wholebody,0.2508361204013378
totalurinaryrecoverie,0.2508361204013378
zeroordereliminationratek0,0.2508361204013378
percentageofplasmaproteinbinding,0.2508361204013378
d30,0.2508361204013378
peakheartrate,0.2508361204013378
apparentsteadystatebloodpropofolconcentration,0.2508361204013378
effectivepermeability,0.2508361204013378
clearancefromcsf,0.2508361204013378
normalizedareaunderthecurveaucd,0.2508361204013378
durationofanalgesiamesor,0.2508361204013378
mechanicalthreshold,0.2508361204013378
thermallatencie,0.2508361204013378
maximumreversal,0.2508361204013378
onsetofanalgesia,0.2508361204013378
minimumeffectiveanalgesicconcentration,0.2508361204013378
clearanceperbioavailability,0.2508361204013378
fty720,0.2508361204013378
twelvehour,0.2508361204013378
troughmpalevel,0.2508361204013378
vcfvcumpagf,0.2508361204013378
areaundertheconcentrationtimecurvefrom0to12hoursauc012,0.2508361204013378
distributionvolumevz,0.2508361204013378
peaksystolicbloodpressure,0.2508361204013378
serumdrugconcentrationatsteadystate,0.2508361204013378
areaunderthedrugconcentrationtimecurveoveradosingintervalauc,0.2508361204013378
durationofpainrelief,0.2508361204013378
peakurineconcentration,0.2508361204013378
oralabsorptionrateconstant,0.2508361204013378
absoluteoralbioavailabilitie,0.2508361204013378
serumhalflifet12beta,0.2508361204013378
timetoachievemaximumplasmacodeineconcentration,0.2508361204013378
brainserumconcentrationratio,0.2508361204013378
apparentpartitioncoefficient,0.2508361204013378
volumeofdistributionintheterminalphase,0.2508361204013378
percentofdailydoseexcreted,0.2508361204013378
overallsystemicbioavailability,0.2508361204013378
volumeofthefirstbraincompartment,0.2508361204013378
halflifeofequilibrium,0.2508361204013378
deepcerebraldistributionvolume,0.2508361204013378
drugretentionin,0.2508361204013378
apparentoralcentralvolumeofdistribution,0.2508361204013378
apparentorallinearclearance,0.2508361204013378
totalamountofmorphineexcretedinurine,0.2508361204013378
areaundertheplasmamorphineconcentrationtimecurvefrom024hauc024,0.2508361204013378
predosedrugconcentrationc0,0.2508361204013378
icustay,0.2508361204013378
percentmaximuminhibition,0.2508361204013378
auc024hthreshold,0.2508361204013378
c12hratio,0.2508361204013378
timetomyeloid,0.2508361204013378
ec50concentrationrequiredfor50inhibition,0.2508361204013378
eliminationconstantke,0.2508361204013378
maximummpaplasmaconcentration,0.2508361204013378
steadystateareaundertheplasmaconcentrationversustimecurveauc012,0.2508361204013378
cumulativeoccurrencerateofadverseevent,0.2508361204013378
areaunderthecuveauc612,0.2508361204013378
areaunderthecurveaucfrom0to6hour,0.2508361204013378
areasunderthetimeconcentrationcurvebetween0and12hoursauc012h,0.2508361204013378
unboundaucfrom0to12hour,0.2508361204013378
maximummpaconcentration,0.2508361204013378
rateofgastricemptying,0.2508361204013378
areaundertheconcentrationtimecurvefrom012hoursauc012,0.2508361204013378
totalareaundertheobservedplasmaconcentrationtimecurveauc012,0.2508361204013378
areaunderconcentrationtimecurveauc012,0.2508361204013378
v4f,0.2508361204013378
cl2f,0.2508361204013378
troughconcentrationsc12h,0.2508361204013378
minimalclearance,0.2508361204013378
areaundertheconcentrationtimecurveauc012hours,0.2508361204013378
maximummeanplasmaconcentration,0.2508361204013378
auc012hours,0.2508361204013378
areasundertheconcentrationtimecurvesauc0,0.2508361204013378
totalauc012,0.2508361204013378
overalleliminationrateconstant,0.2508361204013378
areasunderthetimeconcentrationcurvesauc,0.2508361204013378
areaunderthecurveaucfrom0to12h,0.2508361204013378
timetothemaximumplasmaconcentration,0.2508361204013378
areaunderthetimeconcentrationcurveauc012,0.2508361204013378
drg,0.2508361204013378
apparentplasmat12,0.2508361204013378
c0mpa,0.2508361204013378
aec012,0.2508361204013378
unbounddrugconcentration,0.2508361204013378
timeforittoreachpeaktmax,0.2508361204013378
steadystateauc012hplasmalevel,0.2508361204013378
volumeofdistributionvarea,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefromzeroto12hoursauc012,0.2508361204013378
auc09level,0.2508361204013378
terminaleliminationofhalflife,0.2508361204013378
aucglucoselevel,0.2508361204013378
apparentmeanhalflife,0.2508361204013378
phint,0.2508361204013378
haireliminationhalflive,0.2508361204013378
overalldruglikingmaximumeffect,0.2508361204013378
auccsfaucserum0120minconcentrationratio,0.2508361204013378
timetoreachthemedianmaximumserumconcentration,0.2508361204013378
infectedcelllossrate,0.2508361204013378
lumbarcsflevel,0.2508361204013378
areaunderthecurveover2h,0.2508361204013378
viraldecline,0.2508361204013378
relativebioavailabilityauc0infinityratio,0.2508361204013378
maximumhydromorphoneplasmaconcentrationcmax,0.2508361204013378
peakheroinconcentration,0.2508361204013378
peaksalivacocaineconcentration,0.2508361204013378
peakplasmacocaineconcentration,0.2508361204013378
peaksalivaaemeconcentration,0.2508361204013378
apparentterminaleliminationt12,0.2508361204013378
latencyofonsettoclinicaleffect,0.2508361204013378
maximumserumconcentrationofmorphinecmax,0.2508361204013378
areaundertheplasmaconcentrationversustimecurvefromtimezerotoinfinityaucinfinity,0.2508361204013378
kep,0.2508361204013378
responserange,0.2508361204013378
absorptiontransittime,0.2508361204013378
maximumpeakplasmaconcentration,0.2508361204013378
areaundertheconcentrationtimecurvefromtimezerotoinfinityauc,0.2508361204013378
minimumplasmaconcentrationcmin,0.2508361204013378
troughplasmaconcentrationctrough,0.2508361204013378
auc17dratio,0.2508361204013378
areaundertheconcentrationtimecurvefromtimezerotoinfinityafterfirstdoseaucinf,0.2508361204013378
qtcinterval,0.2508361204013378
tsc,0.2508361204013378
plasmahalflifet12b,0.2508361204013378
timefrom,0.2508361204013378
maximumsystemicconcentration,0.2508361204013378
brainlevel,0.2508361204013378
absorbedfraction,0.2508361204013378
bioavailabledose,0.2508361204013378
amountof,0.2508361204013378
aucfoldchange,0.2508361204013378
maximumserumdrugconcentrationcmax,0.2508361204013378
dor,0.2508361204013378
maximumcotinineconcentration,0.2508361204013378
maximumobservedplasmahydrocodoneconcentrationcmax,0.2508361204013378
areaundertheplasmahydrocodoneconcentrationversustimecurvefromtime0toinfinityauc0,0.2508361204013378
detectionlimit3sigma,0.2508361204013378
plasmaconcentrationofo,0.2508361204013378
combinationkillslope,0.2508361204013378
areaundertheconcentrationtimecurvefrom0to24hauc024mic,0.2508361204013378
maturationhalflife,0.2508361204013378
abusequotientcmaxtmax,0.2508361204013378
steadystateplasmaconcentrationratio,0.2508361204013378
minimumtherapeuticconcentration,0.2508361204013378
absorptionrateconstantkacr,0.2508361204013378
kasol,0.2508361204013378
morcod,0.2508361204013378
auc07h,0.2508361204013378
morcodratio,0.2508361204013378
apparentsteadystatevolumeofdistributionvss,0.2508361204013378
clearancecls,0.2508361204013378
pain,0.2508361204013378
aucchange,0.2508361204013378
aic,0.2508361204013378
tcmax,0.2508361204013378
durationofseverepain,0.2508361204013378
areasundertheplasmaconcentrationvstimecurve,0.2508361204013378
biliaryexcretionrate,0.2508361204013378
scoreatpainflare,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefrom0to12hoursatsteadystate,0.2508361204013378
plasmaed50,0.2508361204013378
volumeofdistributionperfractionabsorbed,0.2508361204013378
midazolam,0.2508361204013378
timetoreach50completematuremidaz,0.2508361204013378
apparentplasmaterminalhalflife,0.2508361204013378
centralcompartmentv1,0.2508361204013378
centralcompartment,0.2508361204013378
timetoreachthemaximumserumconcentration,0.2508361204013378
maximumbupivacaineconcentration,0.2508361204013378
arterialclearance,0.2508361204013378
analgesicpotency,0.2508361204013378
halftimeatsteadystate,0.2508361204013378
painlevel,0.2508361204013378
timetopatientcomfort,0.2508361204013378
halfthemaximaleffectec50,0.2508361204013378
redbloodcellplasmawaterpartitioncoefficient,0.2508361204013378
maximumplasmaoxycodoneconcentration,0.2508361204013378
cna,0.2508361204013378
il2,0.2508361204013378
timetosubtherapeuticlevel,0.2508361204013378
absorptionrateconstantska,0.2508361204013378
peakconcentrationsofunboundplasmaconcentration,0.2508361204013378
clexcretion,0.2508361204013378
clottobloodratio,0.2508361204013378
areaunderthecurveau,0.2508361204013378
rpredob,0.2508361204013378
steadystatecsaconcentration,0.2508361204013378
aucfrom0to25hour,0.2508361204013378
poststeadystateapparentt12,0.2508361204013378
lagtimet0,0.2508361204013378
urinarymetabolicratio,0.2508361204013378
totalchroma,0.2508361204013378
serumtroughrifampinconcentration,0.2508361204013378
steadystateareaunderthecurveauctau,0.2508361204013378
timetomaximumpt,0.2508361204013378
timewhen,0.2508361204013378
24hourrecoverie,0.2508361204013378
mauc0inf,0.2508361204013378
areaundertheplasmaconcentrationtimecurvemauc0inf,0.2508361204013378
pulmonaryretention,0.2508361204013378
clearanceofmidazolamcyp3a,0.2508361204013378
totalrenalexcretiontue,0.2508361204013378
fractionalchloridedelivery,0.2508361204013378
renalo,0.2508361204013378
fot,0.2508361204013378
f0infinity,0.2508361204013378
cue,0.2508361204013378
ai,0.2508361204013378
cumulativeamountexcretedunchanged,0.2508361204013378
fluctuationindexfi,0.2508361204013378
gastrointestinalabsorption,0.2508361204013378
meta,0.2508361204013378
molarauc048,0.2508361204013378
steadystatemaximumplasmaconcentrationcssmax,0.2508361204013378
fetomaternalratio,0.2508361204013378
mucoadhesion,0.2508361204013378
plasmaactivemoietylevel,0.2508361204013378
intrinsicoralclearance,0.2508361204013378
turnoverhalflive,0.2508361204013378
apparenttotaloralclearance,0.2508361204013378
peakexpiratoryflow,0.2508361204013378
potencyic50,0.2508361204013378
percentageofurinaryrecovery,0.2508361204013378
totalfaecalrecovery,0.2508361204013378
apparentrelativevolumesofdrugdistribution,0.2508361204013378
migrationtime,0.2508361204013378
areaunderserumconcentrationtimecurve,0.2508361204013378
cytotoxicity50inhibitoryconcentration,0.2508361204013378
paraaminohippurateclearancecpah,0.2508361204013378
cpre,0.2508361204013378
areaundertheplasmaconcentrationtimecurveuptothelastquantifiabletime,0.2508361204013378
excretionofradioactivity,0.2508361204013378
totalclearanceclf,0.2508361204013378
morninglevel,0.2508361204013378
areaundertheeffecttimecurveover8h,0.2508361204013378
alphat12alpha,0.2508361204013378
betat12beta,0.2508361204013378
areaunderthedxmplasmaconcentrationcurveauc,0.2508361204013378
eveningtomorningratio,0.2508361204013378
volumeofdistributioninthesteadystate,0.2508361204013378
repeatabilitycoefficient,0.2508361204013378
areaundertheplasmaconcentrationcurveauc0infinity,0.2508361204013378
steadystatemaximumplasmaconcentration,0.2508361204013378
csfserumratio,0.2508361204013378
50,0.2508361204013378
dissociationconstantski,0.2508361204013378
waterreabsorption,0.2508361204013378
steadystateplasma5fuconcentration,0.2508361204013378
fractionallithiumexcretion,0.2508361204013378
spinlatticerelaxationtime,0.2508361204013378
slow,0.2508361204013378
dispositionrateconstantbeta,0.2508361204013378
tl2,0.2508361204013378
lateproximaltfpli,0.2508361204013378
areaunderthecurveauc144168h,0.2508361204013378
steadystateplasmaconcentrationcp,0.2508361204013378
livertoserumratio,0.2508361204013378
totalamountexcreted,0.2508361204013378
reten,0.2508361204013378
reab,0.2508361204013378
deltan,0.2508361204013378
glucosetolipidsratio,0.2508361204013378
absolutesodiumexcretion,0.2508361204013378
auc0yen,0.2508361204013378
tue,0.2508361204013378
totalrecoveryfromurine,0.2508361204013378
ma68,0.2508361204013378
kelcorrectedrelativebioavailabilitie,0.2508361204013378
steadystateplasmaexposure,0.2508361204013378
curssigma,0.2508361204013378
cltpt,0.2508361204013378
absoluteba,0.2508361204013378
era,0.2508361204013378
encapsulationpercentage,0.2508361204013378
inhibitoryconcentration50ic50,0.2508361204013378
oralmidazolamclearance,0.2508361204013378
bioavailabilityratio,0.2508361204013378
nonprogressionrate,0.2508361204013378
concentrationc0,0.2508361204013378
absolutegranulocytecount,0.2508361204013378
hepaticbioavailability,0.2508361204013378
dosenormalizedauc012,0.2508361204013378
massmedianaerodynamicdiametermmad,0.2508361204013378
apparentpermeabilitycoefficientpapp,0.2508361204013378
lowerlimitofdetectionlod,0.2508361204013378
partialresponserate,0.2508361204013378
relativebioavailabilityrb,0.2508361204013378
timetomaximumpimasertibconcentration,0.2508361204013378
drcsstrough,0.2508361204013378
combinationindex,0.2508361204013378
biliaryexcretionhalflife,0.2508361204013378
plasmsclearance,0.2508361204013378
auc096h,0.2508361204013378
neutrophilnadir,0.2508361204013378
tumorinhibitionrate,0.2508361204013378
latencytoeffect,0.2508361204013378
totalfecalexcretion,0.2508361204013378
auc5,0.2508361204013378
cumulativedrugreleaserate,0.2508361204013378
enhancementratiosers,0.2508361204013378
q24,0.2508361204013378
aucplasma,0.2508361204013378
drugpayload,0.2508361204013378
selectivity,0.2508361204013378
lethaldoseld50,0.2508361204013378
selfdiffusioncoefficientd,0.2508361204013378
peakperitonealconcentration,0.2508361204013378
peritonealconcentrationat24hour,0.2508361204013378
arterial,0.2508361204013378
unboundpaclitaxelclearance,0.2508361204013378
plasmaauc012h,0.2508361204013378
urinerecoveryrate,0.2508361204013378
rapidvirologicresponserate,0.2508361204013378
90effectiveconcentrationec90,0.2508361204013378
overallinhibitionconstantki,0.2508361204013378
tmaxcmax,0.2508361204013378
residence,0.2508361204013378
areasundertheplasmaconcentrationtimecurveoveroneadministrationintervalof12hoursauctau,0.2508361204013378
halflifet12z,0.2508361204013378
areaundertheplasmaconcentrationtimecurvefromtimezerotothetimeofthelastmeasurableconcentrationauclast,0.2508361204013378
fractionalcatabolicratefcr,0.2508361204013378
timetoprogressionordeath,0.2508361204013378
irreversibleeliminationclearance,0.2508361204013378
cl10,0.2508361204013378
cl20,0.2508361204013378
cl12,0.2508361204013378
cl21,0.2508361204013378
recycledfraction,0.2508361204013378
volumeofdistributionatsteadystatevssreal,0.2508361204013378
ic5,0.2508361204013378
sustainedv,0.2508361204013378
washouthalflive,0.2508361204013378
precursor,0.2508361204013378
rvr,0.2508361204013378
tumorinhibitionratio,0.2508361204013378
observedrecovery,0.2508361204013378
effluxrateconstantkout,0.2508361204013378
eliminationrateconstantkbe,0.2508361204013378
influxrateconstantkin,0.2508361204013378
kcp,0.2508361204013378
kpc,0.2508361204013378
percentagetransmittance,0.2508361204013378
timetotumourprogression,0.2508361204013378
overall50,0.2508361204013378
halflifeofdisposition,0.2508361204013378
halflifeofrenalexcretion,0.2508361204013378
volumesofdistributionvss,0.2508361204013378
areaundertheplasmaconcentrationtimecurveauc072,0.2508361204013378
maximumdecline,0.2508361204013378
cevr,0.2508361204013378
hcl,0.2508361204013378
areaundertheeffectversustimecurve,0.2508361204013378
areaundertheplasmalevelcurve,0.2508361204013378
extractrecoverie,0.2508361204013378
fractionalextraction,0.2508361204013378
plasmaconcentrationyielding50inhibitionc50,0.2508361204013378
aucsthe,0.2508361204013378
aumc,0.2508361204013378
concentrationpeak,0.2508361204013378
peakarterialplasmalidocaineconcentration,0.2508361204013378
dtl,0.2508361204013378
peakfelbamateconcentration,0.2508361204013378
percentagesofunbound,0.2508361204013378
perfusionpressure,0.2508361204013378
clearancet12,0.2508361204013378
racc,0.2508361204013378
wetdryratio,0.2508361204013378
areaundertheplasmadrugconcentrationversustimecurveauc,0.2508361204013378
timeofpeaknifedipineconcentration,0.2508361204013378
areaundertheheartrateresponsetimecurve,0.2508361204013378
clearanceclt,0.2508361204013378
terminalphaserateconstant,0.2508361204013378
uptakerate,0.2508361204013378
cp50bar,0.2508361204013378
brainplasmauptakeratio,0.2508361204013378
areaundertheplasmaconcentrationversustimecurvefromtimezerototimeinfinity,0.2508361204013378
highaffinity,0.2508361204013378
aucsfromtime0totheendofthedosingintervaltauauc0tau,0.2508361204013378
epilevel,0.2508361204013378
areaundertheplasmaconcentrationtimecurveaucfromtime024hauc24,0.2508361204013378
aeazo,0.2508361204013378
gcrba,0.2508361204013378
areaunderthecurvefor08h,0.2508361204013378
areaunderthecurvefor04h,0.2508361204013378
totalhplcruntime,0.2508361204013378
ratord,0.2508361204013378
or,0.2508361204013378
saturationsolubility,0.2508361204013378
lungretentiont12,0.2508361204013378
oralclearanceratio,0.2508361204013378
eliminationplasmahalflifet12,0.2508361204013378
pd12,0.2508361204013378
meanresidencetimeinthebodymrt,0.2508361204013378
activitie,0.2508361204013378
maximumserumcetirizineconcentration,0.2508361204013378
areaundercurve0,0.2508361204013378
residuallevel,0.2508361204013378
terminaldispositionphasehalflife,0.2508361204013378
majormolecularresponserate,0.2508361204013378
vb,0.2508361204013378
systemicprednisoloneclearance,0.2508361204013378
maximalttratio,0.2508361204013378
maximumprothrombintime,0.2508361204013378
steadystateconcentrationratiocssmcss,0.2508361204013378
terminalhalflifeterminalt12,0.2508361204013378
ic50ki,0.2508361204013378
areaundertheplasmaconcentrationversustimecurvefromtime0to72hauc072h,0.2508361204013378
totalg,0.2508361204013378
90inhibitoryconcentration,0.2508361204013378
massmedian,0.2508361204013378
maximalconcentrationsinplasmacmax,0.2508361204013378
peakreachingtimetmax,0.2508361204013378
bio,0.2508361204013378
clssf,0.2508361204013378
auc15360min,0.2508361204013378
auc15180min,0.2508361204013378
completecytogeneticresponserate,0.2508361204013378
areaunderthemidazolamconcentrationtimecurve,0.2508361204013378
dosenormalizedareaundertheplasmaconcentrationtimecurveduringthe24hourdosingintervalatsteadystateauc24ssd,0.2508361204013378
peakserumbromazepamconcentration,0.2508361204013378
peakcetirizineconcentration,0.2508361204013378
bte,0.2508361204013378
totalsodiumnaexcretion,0.2508361204013378
auc05h,0.2508361204013378
cumulativemexcretion,0.2508361204013378
apparentoralclearancesclor,0.2508361204013378
th,0.2508361204013378
totalbiliaryexcretion,0.2508361204013378
areasundertheplasmaconcentrationtimecurvesaucs,0.2508361204013378
inputrate,0.2508361204013378
oralvolumeofdistributionvf,0.2508361204013378
decreasehalflife,0.2508361204013378
auc24ssd,0.2508361204013378
adherence,0.2508361204013378
maximumconcentrationachievedcmax,0.2508361204013378
areasundertheplasmaconcentrationtimecurvesauc0leadsto12,0.2508361204013378
permeationhalflife,0.2508361204013378
effectiveplasmahalflife,0.2508361204013378
peakrd,0.2508361204013378
entrapmentratio,0.2508361204013378
rateofcsfbulkflow,0.2508361204013378
injectionflow,0.2508361204013378
timetorelapse,0.2508361204013378
pseudosteadystatec,0.2508361204013378
arrivaltime,0.2508361204013378
areaundertheserumcurveauc,0.2508361204013378
apparenttopotecanclearance,0.2508361204013378
rateconstantk3ki,0.2508361204013378
serumt,0.2508361204013378
peaktshresponse,0.2508361204013378
areaundertheplasmaconcentrationvstimecurveauc0infinity,0.2508361204013378
peakserumpropranololconcentration,0.2508361204013378
reserve,0.2508361204013378
maximumtolerableplasmasteadystateconcentration,0.2508361204013378
fpf,0.2508361204013378
plasmaconcentrationinterval,0.2508361204013378
peakexcretiontime,0.2508361204013378
braintumortissueconcentration,0.2508361204013378
areaunderthe48hrplasmaconcentrationcurve,0.2508361204013378
fractionofthedoseexcreteda,0.2508361204013378
lunguptake,0.2508361204013378
baroreflexsensitivity,0.2508361204013378
zaveragediameter,0.2508361204013378
vbetaf,0.2508361204013378
gammaphasehalflife,0.2508361204013378
maximumdailymaintenancedose,0.2508361204013378
minimumdetectionlevel,0.2508361204013378
renalclearanceofdrug,0.2508361204013378
morningtrough,0.2508361204013378
cldf,0.2508361204013378
peakserumcetirizineconcentration,0.2508361204013378
tumorgrowthinhibitiontgi,0.2508361204013378
turnovert12,0.2508361204013378
areasofplasmahydroxyzineconcentrationversustimeareaunderthecurveaucs,0.2508361204013378
apparentvolumeofdistributionvss,0.2508361204013378
pbf,0.2508361204013378
boundfractionof,0.2508361204013378
apparentoralbodyclearance,0.2508361204013378
plasmak,0.2508361204013378
ultrafiltrationflowrate,0.2508361204013378
totalareaundertheconcentrationtimecurveauc,0.2508361204013378
dissociationrateconstant,0.2508361204013378
initialpainintensity,0.2508361204013378
areaundertheplasmaconcentrationtimecurveaucfromadministrationtothelastobservedconcentrationtimetauct,0.2508361204013378
areaunderplasmaconcentrationcurve,0.2508361204013378
maxconcentration,0.2508361204013378
50ofmaximaleffectec50,0.2508361204013378
maximumplasmaantixaactivityamax,0.2508361204013378
receptorreactivity,0.2508361204013378
cmaxmaximumconcentration,0.2508361204013378
mzmh,0.2508361204013378
aucduringthetimeintervaltbetweentwoconsecutivedosesatsteadystateauct,0.2508361204013378
areaundertheplasmaactivereninversustimecurve0to24hours,0.2508361204013378
totaldrugtroughconcentration,0.2508361204013378
steadystateplasmacimetidineconcentration,0.2508361204013378
aucfrom0to72hoursauc72h,0.2508361204013378
e50,0.2508361204013378
intercept,0.2508361204013378
maximumvenousplasmaconcentration,0.2508361204013378
totalnonspecificbindingratio,0.2508361204013378
maximalnordiazepamconcentration,0.2508361204013378
completerenalresponserate,0.2508361204013378
initialdistributionhalflifeinitialt12,0.2508361204013378
recoveryratio,0.2508361204013378
minimalinhibitoryconcentrationsmics,0.2508361204013378
peakplasmatriazolamconcentrationcmax,0.2508361204013378
relativebindingaffinitie,0.2508361204013378
areaundertheconcentrationtimecurveatsteadystate,0.2508361204013378
peakmeasuredconcentration,0.2508361204013378
maximumplasmaantiiiaactivity,0.2508361204013378
timetomaximumbloodconcentration,0.2508361204013378
tissueretentionhalflive,0.2508361204013378
vesiclesizevs,0.2508361204013378
halflivesofeliminationt12alpha,0.2508361204013378
timetofirstoccurrence,0.2508361204013378
stablemid,0.16722408026755853
inhaledflowrate,0.16722408026755853
timefor75tobereleasedt75,0.16722408026755853
maximumdurationofeffect,0.16722408026755853
netexposure,0.16722408026755853
effectivehalflifetsub12accsub,0.16722408026755853
cmaxcl,0.16722408026755853
unboundcmax,0.16722408026755853
mid,0.16722408026755853
absolutep,0.16722408026755853
constantflow,0.16722408026755853
apparentdistributionvolumeofthecentralcompartmentv1,0.16722408026755853
relativeaffinity,0.16722408026755853
timeofattainmenttmax,0.16722408026755853
clearanceclfpm,0.16722408026755853
filtratevolume,0.16722408026755853
plasmatotalclearance,0.16722408026755853
volumeofdistributionvfpm,0.16722408026755853
circulatingt12,0.16722408026755853
extractione,0.16722408026755853
current,0.16722408026755853
coefficientofrbc,0.16722408026755853
maximumquantity,0.16722408026755853
apparentdistributionvolumeoftheperipheralcompartmentv2,0.16722408026755853
auc0400min,0.16722408026755853
renalplasmaflowrpf,0.16722408026755853
plasmaratiors,0.16722408026755853
maximumaccumulation,0.16722408026755853
porevolume,0.16722408026755853
rateofeliminationkelim,0.16722408026755853
median,0.16722408026755853
maximalspecificbindingcapacitybmax,0.16722408026755853
bindingdissociationconstantkd,0.16722408026755853
halflifeoftheinitialphase,0.16722408026755853
timetomaximumabsorptiontmax,0.16722408026755853
remissionduration,0.16722408026755853
areasunderthetimeversusconcentrationcurve,0.16722408026755853
steadystateeliminationhalflife,0.16722408026755853
molecular,0.16722408026755853
t12km,0.16722408026755853
t12kappa,0.16722408026755853
vesiclessize,0.16722408026755853
plasmaeffectiveconcentrationec50,0.16722408026755853
bioavailabilityfm,0.16722408026755853
t12kappam,0.16722408026755853
effective24hrenalplasmaflowerpf,0.16722408026755853
d1,0.16722408026755853
totalnumberof,0.16722408026755853
polydispersitypdi,0.16722408026755853
areaunderthecsfconcentrationfrom0to24h,0.16722408026755853
pe,0.16722408026755853
areaundertheplasmaconcentrationfrom0to24h,0.16722408026755853
tissuetoplasmadistributioncoefficientkp,0.16722408026755853
plasmaslowhalflifet12,0.16722408026755853
maximalsorafenibconcentration,0.16722408026755853
plasmaconcentrationsatsteadystatecpss,0.16722408026755853
intracellularinitialhalflife,0.16722408026755853
auccsfaucplasma,0.16722408026755853
volumesofdistributionforthecentralcompartment,0.16722408026755853
initialhalftime,0.16722408026755853
ca199,0.16722408026755853
maximalrateoflysi,0.16722408026755853
halftimefordisappearance,0.16722408026755853
maximallysi,0.16722408026755853
catabolichalflife,0.16722408026755853
atpconcentration,0.16722408026755853
t12phase,0.16722408026755853
bioconversiont12,0.16722408026755853
vdinthecentralcompartmentv1,0.16722408026755853
vdintheperipheralcompartmentv2,0.16722408026755853
initialphasehalflifet12alpha,0.16722408026755853
troughinfliximabconcentration,0.16722408026755853
inhibitoryactivitiesic50,0.16722408026755853
volumeofdistributionofthecentralv1,0.16722408026755853
peripheralv2compartment,0.16722408026755853
partialthromboplastintimeprolongation,0.16722408026755853
oralhalflife,0.16722408026755853
ket,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to36hauc036,0.16722408026755853
minimumplasmasaconcentration,0.16722408026755853
selectivitie,0.16722408026755853
select,0.16722408026755853
halflifeofdisappearancefromserum,0.16722408026755853
serumunboundfractionfs,0.16722408026755853
terminaleliminationhalftimet12beta,0.16722408026755853
extractionrecoverypercentage,0.16722408026755853
plasmaproteinbindinglevel,0.16722408026755853
terminalbetaphasehalflife,0.16722408026755853
apparentsteadystatedistributionvolume,0.16722408026755853
areaundercurveconcentration,0.16722408026755853
pulmonaryconcentration,0.16722408026755853
bloodcelltoplasmapartitioningratio,0.16722408026755853
intrinsicsteadystatepotency,0.16722408026755853
cellulart12time,0.16722408026755853
peakplasmaddnmconcentration,0.16722408026755853
halflifeperiodofthebetaphase,0.16722408026755853
peaktotaldoxorubicinconcentration,0.16722408026755853
apparentvolumeofdistributionvmfm,0.16722408026755853
plasmatotalbodyclearance,0.16722408026755853
correctedeffluxratio,0.16722408026755853
apparentclearanceclmfm,0.16722408026755853
troughdrugconcentration,0.16722408026755853
ionsuppression,0.16722408026755853
areaunderthecurveauc0tldc,0.16722408026755853
maximumsteadystatedoxorubicinconcentration,0.16722408026755853
bindingaffinityconstantki,0.16722408026755853
achlevel,0.16722408026755853
potencyed50,0.16722408026755853
firstcomponenthalflife,0.16722408026755853
enrichmentfactoref,0.16722408026755853
kpf,0.16722408026755853
concentrationtimecurve,0.16722408026755853
secondcomponenthalflife,0.16722408026755853
absorptiontimetmax,0.16722408026755853
areaunderthecurvefromtimezerotoinfinityauc0alpha,0.16722408026755853
troughtopeakratiosatsteadystate,0.16722408026755853
50maximumplasmaconcentration,0.16722408026755853
timetostopseizure,0.16722408026755853
cssratio,0.16722408026755853
areaunderthecurvefrom0hto10hauc010,0.16722408026755853
apparentequilibriumbindingconstantkivalue,0.16722408026755853
timeuntilmaximumconcentrationtmax,0.16722408026755853
halftimeofbloodbrain,0.16722408026755853
quantitation,0.16722408026755853
releasepercentage,0.16722408026755853
areaundertheplasmaconcentrationtimecurveoverdosingintervalt,0.16722408026755853
apparentvolumeoftheperipheralcompartmentofad,0.16722408026755853
volumevss,0.16722408026755853
lethaldose,0.16722408026755853
oralclearanceofthesolutiondose,0.16722408026755853
plasmaconcentrationpeak,0.16722408026755853
areaunderthecurveauc0tau,0.16722408026755853
kidneyplasmapartitioncoefficient,0.16722408026755853
peakrateofabsorption,0.16722408026755853
aucextrapolatedtoinfinity,0.16722408026755853
timetopeakabsorptionrate,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0tolastmeasuredtimeauct,0.16722408026755853
areaunderthecurveinfaucinf,0.16722408026755853
meanresidencetimeinfmrtinf,0.16722408026755853
maximumalmitrineconcentration,0.16722408026755853
maximumapparentsteadystatealmitrinelevel,0.16722408026755853
clbsalh1m2,0.16722408026755853
auc0dose,0.16722408026755853
concentrationtime,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtimezeroto480minauc0480,0.16722408026755853
surfaceratio,0.16722408026755853
survivalspan,0.16722408026755853
percenttumornecrosi,0.16722408026755853
tumortonormalliverdoxratio,0.16722408026755853
tumordrugconcentration,0.16722408026755853
aucperfusateaucplasmaratio,0.16722408026755853
steadystatepeakplasmaalmitrinelevel,0.16722408026755853
mucoadhesiveforce,0.16722408026755853
transferof,0.16722408026755853
fullruntime,0.16722408026755853
concentrationat24hcmin,0.16722408026755853
peaktumorlevel,0.16722408026755853
aucratiosaucperitonealfluidaucblood,0.16722408026755853
halflifeofdistributiont12alpha,0.16722408026755853
criticalflickerfusion,0.16722408026755853
maximumcumulativeamountpermeatedin24hoursq24,0.16722408026755853
aucliver,0.16722408026755853
peakofmeanplasmaconcentration,0.16722408026755853
aucfromtimezerotoinfinityauc,0.16722408026755853
terminaldisappearancet12,0.16722408026755853
steadystatemcpflux,0.16722408026755853
fullrate,0.16722408026755853
constantcurrent,0.16722408026755853
maximumplasmaconcentrationstmax,0.16722408026755853
peakmeanlevel,0.16722408026755853
interpulseinterval,0.16722408026755853
peakmaximumcmax,0.16722408026755853
totalareaunderthecurveauct,0.16722408026755853
minimumsteadystateserumlevel,0.16722408026755853
steadystatedrugflux,0.16722408026755853
peakwidthfwhm,0.16722408026755853
halflivesofhydrolysi,0.16722408026755853
maximumisdnconcentration,0.16722408026755853
areaunderthebloodplasmaconcentrationtimecurveauc,0.16722408026755853
molarnitrateconcentration,0.16722408026755853
peakplasma5ismnconcentration,0.16722408026755853
brainplasmapartitioncoefficient,0.16722408026755853
maximumminimumconcentration,0.16722408026755853
maximumpeak,0.16722408026755853
steadystatefluxj,0.16722408026755853
ea,0.16722408026755853
amplitudeof,0.16722408026755853
plasmaapparenteliminationhalflife,0.16722408026755853
arearatio,0.16722408026755853
terminalhalflifet12betaor,0.16722408026755853
tmaxmedian,0.16722408026755853
peakplasmaisosorbide5mononitrateconcentration,0.16722408026755853
areasunderthecurveauc012,0.16722408026755853
lossofbioavailability,0.16722408026755853
t024h,0.16722408026755853
areasunderthecurveauc06,0.16722408026755853
kg2,0.16722408026755853
areaunder,0.16722408026755853
kg1,0.16722408026755853
renalclrclearance,0.16722408026755853
maximumalmitrineplasmaconcentrationcmax,0.16722408026755853
totalbodyclearanceoverfractionofdoseabsorbed,0.16722408026755853
timetoreachpeakserumconcentrationtmax,0.16722408026755853
d90,0.16722408026755853
steadystateskinpermeationrate,0.16722408026755853
steadystatetransdermaltznconcentration,0.16722408026755853
bloodcl,0.16722408026755853
eliminationratehalflife,0.16722408026755853
absorptionratehalflife,0.16722408026755853
areaunderthecurvefromtime0to480minutesauc0480,0.16722408026755853
serumhalflifet05beta,0.16722408026755853
plasmaproteinbindingrate,0.16722408026755853
timerequiredtoreachthecmax,0.16722408026755853
areasunder,0.16722408026755853
braindrugconcentration,0.16722408026755853
areaundertheplasmaconcentrationtimecurveoverthedosingintervalt,0.16722408026755853
timetoobservedmaximumplasmaconcentration,0.16722408026755853
constantkm,0.16722408026755853
totalareasunderthecurveauc,0.16722408026755853
unboundfractionofms275fu,0.16722408026755853
timetoequilibrium,0.16722408026755853
firstorderabsorptionrateka,0.16722408026755853
timerequiredtoreachthepeakconcentration,0.16722408026755853
michaelsmenten,0.16722408026755853
diccic,0.16722408026755853
humanhalflife,0.16722408026755853
feedingrate,0.16722408026755853
peakmeanplasmadrugconcentration,0.16722408026755853
unboundplasmalevel,0.16722408026755853
terminalclearancehalflife,0.16722408026755853
plasmaproteinbindingfreefraction,0.16722408026755853
biletoplasmaaucratio,0.16722408026755853
auc07d,0.16722408026755853
wholebloodclearancebioavailability,0.16722408026755853
noxideratio,0.16722408026755853
grt,0.16722408026755853
maximumconcentrationofparacetamolcmax,0.16722408026755853
timetakentoreachthepeakconcentration,0.16722408026755853
serumtconcentration,0.16722408026755853
totaltareaunderthecurve,0.16722408026755853
txb2,0.16722408026755853
maximalt,0.16722408026755853
intercompartmentrateconstantsk12,0.16722408026755853
timetocompletedisintegration,0.16722408026755853
peakplasmaconcentrationscpmax,0.16722408026755853
maximumplasmaparacetamolconcentration,0.16722408026755853
areaundertheplasmaparacetamolconcentrationtimecurvefrom0to180min,0.16722408026755853
timetoachievethismaximumconcentrationtmax,0.16722408026755853
druginhibitoryconstantki,0.16722408026755853
timetoachieve,0.16722408026755853
unboundpeakconcentration,0.16722408026755853
troughtak385concentration,0.16722408026755853
betaphaseeliminationhalflife,0.16722408026755853
timeuntil50,0.16722408026755853
areaunderthecurveduringthefirst60minauc60,0.16722408026755853
auc60,0.16722408026755853
areaundertheteverelixplasmaconcentrationtimecoursefromzerototimeofthelastquantifiableplasmaconcentrationaucotlast,0.16722408026755853
areaundertheconcentrationtimecurvefor0toinfinityauc0infinity,0.16722408026755853
clearancewith,0.16722408026755853
areaundercurveauc060,0.16722408026755853
maximalserumsaconcentration,0.16722408026755853
totaloralbodyclearance,0.16722408026755853
halflifeteq,0.16722408026755853
maximalserumlevel,0.16722408026755853
terminaleliminationt12beta,0.16722408026755853
areasunderthetimeserumsalicylateconcentrationcurveover6hour,0.16722408026755853
auc012ss,0.16722408026755853
vvratio,0.16722408026755853
peripheral,0.16722408026755853
cmaxtmaxratio,0.16722408026755853
oct,0.16722408026755853
hydrolysishalflife,0.16722408026755853
teq,0.16722408026755853
noxidemetaboliteratio,0.16722408026755853
slowhalflife,0.16722408026755853
maximalconcentrationintheserumcmax,0.16722408026755853
areaundertheindomethacinplasmaconcentrationcurveauc0alpha,0.16722408026755853
rateofexcretion,0.16722408026755853
apparentfetalplasmahalflife,0.16722408026755853
halfmaximalproductionp50,0.16722408026755853
areaunderthe24hoursconcentrationtimecurve,0.16722408026755853
timeofpeakplasmaconcentration,0.16722408026755853
fbio,0.16722408026755853
maximumbloodplasmalevel,0.16722408026755853
overallextractionefficiency,0.16722408026755853
apparentbiologicalhalflife,0.16722408026755853
lesionsscore,0.16722408026755853
maximalconcentrationofdruginplasmacmax,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezerotothelastsamplingtimepointauc0t,0.16722408026755853
timeneededtoattainthepeakconcentration,0.16722408026755853
safetymarginratio,0.16722408026755853
peakplaceboeffect,0.16722408026755853
peakacetaminophenconcentration,0.16722408026755853
meanplasmalevel,0.16722408026755853
halfforelimination,0.16722408026755853
timetomaximumacetaminophenconcentration,0.16722408026755853
areaundertheacetam,0.16722408026755853
highestserumconcentration,0.16722408026755853
bioactivation,0.16722408026755853
peakplasmasalevel,0.16722408026755853
clformation,0.16722408026755853
vu,0.16722408026755853
peripheralvd,0.16722408026755853
totalcentral,0.16722408026755853
totalsystemicnormalizedclearance,0.16722408026755853
peakplasmaasalevel,0.16722408026755853
halflifeofdistributionthroughthecirculation,0.16722408026755853
auc240min,0.16722408026755853
btt12,0.16722408026755853
peakserumaspartateaminotransferaselevel,0.16722408026755853
plasmaconcentrationpeakedcmax,0.16722408026755853
inductiondeliverytime,0.16722408026755853
areaundertheplasmaconcentrationtimefrom0to48hoursauc048,0.16722408026755853
peaksteroidconcentration,0.16722408026755853
excretionofradio,0.16722408026755853
volumeoftheinnercompartment,0.16722408026755853
plasmaconcentrationsat10,0.16722408026755853
50recovery,0.16722408026755853
peakinhibitionimax,0.16722408026755853
percentof,0.16722408026755853
proteinbound,0.16722408026755853
auco72,0.16722408026755853
timeofmaximumserumconcentration,0.16722408026755853
halflifeofacheinhibitionti12,0.16722408026755853
alt,0.16722408026755853
biletoplasmaratio,0.16722408026755853
zetapotentialz,0.16722408026755853
areaundertheconcentrationtimecurveauc0tau,0.16722408026755853
peakplasmatotaltconcentration,0.16722408026755853
limitofq,0.16722408026755853
deltacbfdeltapaco2,0.16722408026755853
auc2,0.16722408026755853
timetoreachmaximumlisinoprilconcentration,0.16722408026755853
maximumrecovery,0.16722408026755853
inhibitorybindingaffinitie,0.16722408026755853
inhibitorybindingaffinity,0.16722408026755853
peakmaximumplasmaconcentrationcmax,0.16722408026755853
timeaveragedrenalclearanceclr,0.16722408026755853
recoveriesofextraction,0.16722408026755853
clearancefromtheperfusatecl,0.16722408026755853
plasmaclearancec1,0.16722408026755853
plasmaavailabilitie,0.16722408026755853
kmiu,0.16722408026755853
vmaxi,0.16722408026755853
auciauc,0.16722408026755853
volumeofanti,0.16722408026755853
radioactivityconcentrationratio,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityaucinf,0.16722408026755853
dissolutionnumberdn,0.16722408026755853
aucxo,0.16722408026755853
cave,0.16722408026755853
bioavailabilityaucoralauc,0.16722408026755853
concentrationathalfthemaximumvelocityofmetabolismvmax,0.16722408026755853
leveldoseratiold,0.16722408026755853
peakofmeanconcentration,0.16722408026755853
t100,0.16722408026755853
concentrationpeaktime,0.16722408026755853
pcr,0.16722408026755853
halflifeoftherapid,0.16722408026755853
vssvc,0.16722408026755853
milktobloodratio,0.16722408026755853
areaunderthecurvefor24hauc024,0.16722408026755853
dispersion,0.16722408026755853
amountofdrugabsorbed,0.16722408026755853
halflifeofclearance,0.16722408026755853
peakteverilixplasmaconcentration,0.16722408026755853
steadystateminimumconcentration,0.16722408026755853
timetomaximumtemperaturedecrease,0.16722408026755853
firstorderoralclearance,0.16722408026755853
csubmax,0.16722408026755853
mcrt,0.16722408026755853
pcra,0.16722408026755853
steadystateplasmaglucose,0.16722408026755853
mcrdht,0.16722408026755853
timetomaximalconcentrationofradio,0.16722408026755853
kpl,0.16722408026755853
apparentmeanoralclearance,0.16722408026755853
terminalhalflifeofdisposition,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0totimeofthelastmeasurableconcentrationauc0t,0.16722408026755853
timecorrectedauc,0.16722408026755853
plasmaeliminationhalftime,0.16722408026755853
faa,0.16722408026755853
aucsubtsssub,0.16722408026755853
maximaldailydosetobeclearedvmax,0.16722408026755853
concentrationgiving,0.16722408026755853
halfmaximalclearanceamichaelismentenconstant,0.16722408026755853
overallabsoluteoralbioavailability,0.16722408026755853
timetomaximumparacetamolconcentration,0.16722408026755853
maximumparacetamolconcentration,0.16722408026755853
volumeatsteadystate,0.16722408026755853
areaunderthecurveto24hauc024h,0.16722408026755853
maximumprednisoneconcentration,0.16722408026755853
fractionofunboundprednisolone,0.16722408026755853
inactivationrate,0.16722408026755853
areaunderthecurve010h,0.16722408026755853
areaunderthecurvefrom0to24hour,0.16722408026755853
mcr0,0.16722408026755853
mcr2,0.16722408026755853
massaerodynamicdiameter,0.16722408026755853
ser,0.16722408026755853
peakplasmadiazepamconcentration,0.16722408026755853
oraldoseplasmaclearance,0.16722408026755853
maximumprednisoloneplasmalevel,0.16722408026755853
areaundertheplasmaconcentrationbytimecurve,0.16722408026755853
maximumareaundertheconcentrationtimecurvefrom012h,0.16722408026755853
aucfromtime0toinfinity,0.16722408026755853
fractionalrenalclearance,0.16722408026755853
halfmaximalkinactki,0.16722408026755853
50inhibitoryconcentrationforinhibitionof,0.16722408026755853
totalsystemicabsorption,0.16722408026755853
apparentoraldiazepamclearance,0.16722408026755853
oralec50,0.16722408026755853
concentrationareaunderthecurveauc,0.16722408026755853
splitratio,0.16722408026755853
timetaken,0.16722408026755853
areaundertheconcentrationtimecurveauc018hoursratio,0.16722408026755853
clearanceofhemodiafiltration,0.16722408026755853
maximumloadability,0.16722408026755853
maximaltherapeuticdosage,0.16722408026755853
auc012hr,0.16722408026755853
troughconcentrationc0d,0.16722408026755853
volumedistributionofsteadystate,0.16722408026755853
areaunderthecurveauc240,0.16722408026755853
clearancefromserum,0.16722408026755853
eliminationrateconstantk2,0.16722408026755853
nonrenalclearancerate,0.16722408026755853
firstpasslo,0.16722408026755853
availablefraction,0.16722408026755853
unboundplasmaprednisoloneclearance,0.16722408026755853
areaundertheplasmaconcentrationtimeprofile,0.16722408026755853
undertheplasmaconcentrationtimecurvefrom0to8hauc08h,0.16722408026755853
vk1,0.16722408026755853
oralclearanceofmidazolam,0.16722408026755853
maximalrelaxation,0.16722408026755853
c50s,0.16722408026755853
emaxcontrol,0.16722408026755853
compliance,0.16722408026755853
eliminationcoefficientkbeta,0.16722408026755853
rateofsystemicclearance,0.16722408026755853
halftimet12keo,0.16722408026755853
maximumsorafenibconcentrationstmax,0.16722408026755853
aucnoxide,0.16722408026755853
timetogallbladderemptying,0.16722408026755853
auc012hoursatsteadystate,0.16722408026755853
circulatingplasmac,0.16722408026755853
steadystatekd,0.16722408026755853
totalplasmaprednisolonelevel,0.16722408026755853
halflifetimeofelimination,0.16722408026755853
concentrationcss,0.16722408026755853
disappearancehalftime,0.16722408026755853
absorptiontmax,0.16722408026755853
areaundercurveaucu,0.16722408026755853
apparenttissuebinding,0.16722408026755853
clearancecorrectedforbioavailability,0.16722408026755853
peakdmdzlevel,0.16722408026755853
apparentpercentage,0.16722408026755853
peakmeanplasmacysteamineconcentration,0.16722408026755853
totalkidneyclearancecit,0.16722408026755853
areaunderthecurveaucwithin72hauc072h,0.16722408026755853
clfatsteadystate,0.16722408026755853
maximumprednisoloneconcentration,0.16722408026755853
relativeavailability,0.16722408026755853
auc0tareaunderthecurve,0.16722408026755853
areasunderthecurveauc010,0.16722408026755853
vdssvolumeofdistributionatsteadystate,0.16722408026755853
gastric,0.16722408026755853
csfplasmapartitioncoefficient,0.16722408026755853
t1relaxivity,0.16722408026755853
halflivesoftheterminalphase,0.16722408026755853
apparentdistributionvolumevbeta,0.16722408026755853
maximumenzymeinhibitionec50,0.16722408026755853
uptakeefficiency,0.16722408026755853
rateofurinaryelimination,0.16722408026755853
halftimeofdisappearancefromtheserum,0.16722408026755853
serumn,0.16722408026755853
biliarytransportmaximum,0.16722408026755853
terminalplasmahalflivest12,0.16722408026755853
ofp,0.16722408026755853
basiclevel,0.16722408026755853
ratioofintrinsictransportclearancedividedbydiffusionclearance,0.16722408026755853
100,0.16722408026755853
maximummdmaconcentrationscmax,0.16722408026755853
percentdoseexcreted,0.16722408026755853
basalplasmaconcentration,0.16722408026755853
steadystatesaconcentration,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0tothelastmeasurableplasmaconcentration,0.16722408026755853
targetingfactor,0.16722408026755853
transdermaleliminationhalflife,0.16722408026755853
velocity,0.16722408026755853
maximumsaconcentrationcmax,0.16722408026755853
receptorequilibriumdissociationconstant,0.16722408026755853
inputratekinput,0.16722408026755853
ctrpmin,0.16722408026755853
areaundercurvefromtimezeroto24hoursauc024,0.16722408026755853
transportrate,0.16722408026755853
areaundertheconcentrationtimecurve0168hours,0.16722408026755853
timeelapsedtoachievemaximumplasmaconcentrationsin,0.16722408026755853
areaunderthesalivaflowtimecurve,0.16722408026755853
halflifeofterminalphase,0.16722408026755853
stablediseaseresponserate,0.16722408026755853
vmaxspg,0.16722408026755853
vmaxsu,0.16722408026755853
parasiteclearancehalflife,0.16722408026755853
plasmaaccumulationratio,0.16722408026755853
peakserumasaconcentrationscmax,0.16722408026755853
input,0.16722408026755853
auto,0.16722408026755853
k203,0.16722408026755853
timetocompleteremissioncr,0.16722408026755853
k027,0.16722408026755853
standarduptakevaluessuvs,0.16722408026755853
peakconcentrationcp,0.16722408026755853
lodlimitofdetection,0.16722408026755853
inhibitoryconcentration50,0.16722408026755853
rsratioofauc0,0.16722408026755853
resistanceindex,0.16722408026755853
steadystatepenetrationrate,0.16722408026755853
intrinsicmetabolicclearance,0.16722408026755853
plasmaitc,0.16722408026755853
betaphaseeliminationhalftime,0.16722408026755853
mortality,0.16722408026755853
maximumfd4concentration,0.16722408026755853
totalradioactivityrecovery,0.16722408026755853
releaset12,0.16722408026755853
disintegrationdissolutiontime,0.16722408026755853
halflifeoftheterminalphaseofthecurve,0.16722408026755853
highestobservedplasmaconcentrationcmax,0.16722408026755853
tsublagsub,0.16722408026755853
durationofcompleteremission,0.16722408026755853
timetomaximumplasmaconcentrationstmax,0.16722408026755853
totalurinary,0.16722408026755853
plasmaresidencetime,0.16722408026755853
dermistoplasmacmaxratio,0.16722408026755853
maximumrabeprazoleconcentration,0.16722408026755853
maximumrateofoxidativedesulfurization,0.16722408026755853
halflifefortheelimination,0.16722408026755853
ic50insulin,0.16722408026755853
hepatobiliarytransportmaximum,0.16722408026755853
concentrationathalfmaximumeffectsec50,0.16722408026755853
apparenteliminationphasehalflife,0.16722408026755853
dosenormalizedcmin,0.16722408026755853
maximumplasmatrazodoneconcentration,0.16722408026755853
steadystatetumourplasmaratio,0.16722408026755853
enhancingratioer,0.16722408026755853
plateaulevelmaxima,0.16722408026755853
troughplasmatheophyllinelevel,0.16722408026755853
sct,0.16722408026755853
totalcompartmentclearance,0.16722408026755853
absoluteclearance,0.16722408026755853
peakflowratepfr,0.16722408026755853
rateconstantkd,0.16722408026755853
serumpeakconcentrationsc,0.16722408026755853
auec0t,0.16722408026755853
partialformationclearance,0.16722408026755853
captureefficiency,0.16722408026755853
plasmalevelmaxima,0.16722408026755853
releasehalflife,0.16722408026755853
troughcminday28concentration,0.16722408026755853
wholebloodresidencetime,0.16722408026755853
peakserumifnlevel,0.16722408026755853
fractionoftheadministereddoseabsorbedthrough,0.16722408026755853
fus,0.16722408026755853
areaundertheplasmaalphaifnconcentrationtimecurve,0.16722408026755853
maximalincreaseininsulinsecretion,0.16722408026755853
areasundertheconcentrationcurvesauc,0.16722408026755853
timeneededtoreachthi,0.16722408026755853
vcmax,0.16722408026755853
timerequiredtoreachmaximumplasmaconcentration,0.16722408026755853
masstransitionionpairsmz,0.16722408026755853
thrombintime,0.16722408026755853
peakflavopiridolconcentration,0.16722408026755853
apparenttheophyllineclearance,0.16722408026755853
areaundertheplasmaconcentrationversustimecurveauc0last,0.16722408026755853
timeatwhichcmaxoccurredtmax,0.16722408026755853
urinaryrecoveryofunchangedsubstance,0.16722408026755853
partitioncoefficientslogp,0.16722408026755853
aucf,0.16722408026755853
auc091,0.16722408026755853
durationofcr,0.16722408026755853
totalclearanceratescltol,0.16722408026755853
retentiontimemrt,0.16722408026755853
bloodpoolhalflife,0.16722408026755853
relativetotalclearance,0.16722408026755853
onsetofappearance,0.16722408026755853
spontaneou,0.16722408026755853
fur,0.16722408026755853
fv,0.16722408026755853
areasunderthecurveauc028days,0.16722408026755853
plasmamcr6mp,0.16722408026755853
steadystateinfusionconcentration,0.16722408026755853
plasmasteadystatempconcentration,0.16722408026755853
viabilityrate,0.16722408026755853
apoptosisindex,0.16722408026755853
compressibility,0.16722408026755853
auczerolastratio,0.16722408026755853
systemicclearanceclsys,0.16722408026755853
areaunderthetimeversusradioactivitycurve,0.16722408026755853
auczero24,0.16722408026755853
peaktheophyllineplasmaconcentrationcmax,0.16722408026755853
tumorstandardizeduptake,0.16722408026755853
f8h,0.16722408026755853
timeforreturntoo,0.16722408026755853
initialdrugclearance,0.16722408026755853
auc1224h,0.16722408026755853
peakexcretionrate,0.16722408026755853
areaundercurveabovefastingdeltaaucglucose,0.16722408026755853
troughcminday28,0.16722408026755853
timetofirstnadirglucose,0.16722408026755853
timetopeakactiontpeak,0.16722408026755853
durationofactiontdur,0.16722408026755853
atsteadystateplasmaconcentration,0.16722408026755853
recoveryofunchangeddrug,0.16722408026755853
apparentconcentration,0.16722408026755853
apparentvolumeofdrugdistribution,0.16722408026755853
maximalrateofformationofmetabolitevmax,0.16722408026755853
halflifeoftheabsorptionproce,0.16722408026755853
areasundertheplasmaconcentrationtimecurvesauc0infinity,0.16722408026755853
peakcocaineplasmalevel,0.16722408026755853
tmaxobservedtimetomaximumconcentration,0.16722408026755853
totalplasmatheophyllineclearance,0.16722408026755853
plasmawholebloodconcentrationratio,0.16722408026755853
relativepercentagebioavailabilitie,0.16722408026755853
generalplasmaconcentrationlevel,0.16722408026755853
alveolarhalflife,0.16722408026755853
timeatwhichthemaximumpeak,0.16722408026755853
mrtpo,0.16722408026755853
ktran,0.16722408026755853
clearanceinthedistributionphaseofdrugdispositioncld,0.16722408026755853
areaunderthecurveover24hauc24,0.16722408026755853
concentrationfor50growthinhibition,0.16722408026755853
clearanceat100bioavailability,0.16722408026755853
areaunderthesildenafilplasmaconcentrationtimecurvefromtimezerotoinfinityauc0infinity,0.16722408026755853
apparentq,0.16722408026755853
peaka771726concentration,0.16722408026755853
apparentv2i,0.16722408026755853
totalamountabsorbed,0.16722408026755853
netsecretion,0.16722408026755853
tnratio,0.16722408026755853
vdpaa,0.16722408026755853
apparentv1i,0.16722408026755853
overallhistologicresponserate,0.16722408026755853
vdssiv,0.16722408026755853
steadystateplasmaa771726concentration,0.16722408026755853
plasmaflowrate,0.16722408026755853
ratiosofexcretion,0.16722408026755853
retardationfactor,0.16722408026755853
ratioofauc024,0.16722408026755853
cib,0.16722408026755853
areaundertheunbounddrugconcentrationtimecurvetominimuminhibitoryconcentrationratiofaucmic,0.16722408026755853
volumeinthecentralcompartment,0.16722408026755853
auc024mictarget,0.16722408026755853
maximumpeakplasmaconcentrationppc,0.16722408026755853
urinetofecesratio,0.16722408026755853
maximuma771726concentrationecmax,0.16722408026755853
plasmahalflifeofeliminationt12beta,0.16722408026755853
lengthoftreatment,0.16722408026755853
timetopeakplasmadrugconcentration,0.16722408026755853
clearanceclobs,0.16722408026755853
concentrationthatinhibited50lymphocytesec50,0.16722408026755853
firstorderabsorptionrate,0.16722408026755853
firstorderabsorptionconstantka,0.16722408026755853
halflifeinblood,0.16722408026755853
vdpa,0.16722408026755853
peripheralcompartmentvolumev2,0.16722408026755853
plasmaclearanceci,0.16722408026755853
finaleliminationhalflifet12elim,0.16722408026755853
halflifeatgammaphaset12gamma,0.16722408026755853
halflifeatbetaphaset12beta,0.16722408026755853
halflifeatalphaphaset12alpha,0.16722408026755853
couplingratio,0.16722408026755853
antifactorxaantithrombinratio,0.16722408026755853
antiiiaactivity,0.16722408026755853
peakpercentage,0.16722408026755853
peaklevodopalevel,0.16722408026755853
plasmaactivitie,0.16722408026755853
peakstc,0.16722408026755853
plasmaantixaactivitie,0.16722408026755853
maximuminhibitoryeffect,0.16722408026755853
troughpeak,0.16722408026755853
peaktheophyllineplasmaconcentration,0.16722408026755853
steadystateantifactorxaactivitie,0.16722408026755853
maximalantifactorxaantixaactivity,0.16722408026755853
areaundertheconcentrationtimecurveoverthedosageintervalauctau,0.16722408026755853
areasundertheplasmaconcentrationversustimecurveaucinfinity,0.16722408026755853
aucsinfinity,0.16722408026755853
clearanceratek1,0.16722408026755853
clearanceq,0.16722408026755853
recoveryinurinaryexcretion,0.16722408026755853
residualvar,0.16722408026755853
plasmaactivereninconcentration,0.16722408026755853
overalltimestodiseaseprogression,0.16722408026755853
peaksystemiclevel,0.16722408026755853
freefractionfreetotalconcentrationratio,0.16722408026755853
retentionhalflive,0.16722408026755853
dialysisclearance,0.16722408026755853
tissueconcentrationofdoxorubicintisscdox,0.16722408026755853
totalradioactivityexhaled,0.16722408026755853
cpmaxivcpmaxihep,0.16722408026755853
totalfractioneliminated,0.16722408026755853
areaundertheplasmaconcentrationversustimecurvefromtime0to72hauc72h,0.16722408026755853
areaundertheplasma5fuconcentrationversusthetimecurve,0.16722408026755853
timeto50ofmaximumconcentrationtearly50cmax,0.16722408026755853
dx,0.16722408026755853
peffcms,0.16722408026755853
printerval,0.16722408026755853
mad,0.16722408026755853
fvalue,0.16722408026755853
dqtcf,0.16722408026755853
apparentvolumeofdistributionvcf,0.16722408026755853
maximumpeakconcentrationcmax,0.16722408026755853
unboundhydroxylationclearancerate,0.16722408026755853
peakmic,0.16722408026755853
smallintestinetransittime,0.16722408026755853
steadystatefuraplasmaconcentration,0.16722408026755853
apparentformationclearance,0.16722408026755853
ed95t,0.16722408026755853
peakdetectionperiod,0.16722408026755853
earliest,0.16722408026755853
maximumobservedserumtrovafloxacinconcentration,0.16722408026755853
knorketamine,0.16722408026755853
depressionofskeletalmuscletwitchheighted95t,0.16722408026755853
maximumplasmanicotinamideconcentration,0.16722408026755853
ccimgfr,0.16722408026755853
tubularsecretionclearance,0.16722408026755853
totalareaunderthetotalplasmaconcentrationtimecurveauc012,0.16722408026755853
rerr,0.16722408026755853
peakinsulinconcentration,0.16722408026755853
plasmaconcentrationcausinghalfmaximaleffect,0.16722408026755853
areaundertheplasmaethanolconcentrationtimecurveauc0t,0.16722408026755853
aqueoussolubility,0.16722408026755853
timetoreach50maximumconcentration,0.16722408026755853
areaundertheserumfamotidineconcentrationtimecurveupto10hour,0.16722408026755853
ratioofsodiumchlorideexcretion,0.16722408026755853
timetoreach50maximumglucoseinfusionrate,0.16722408026755853
ratioofaucphtoaucdrugconcentration012hour,0.16722408026755853
relativebiologicaleffectivene,0.16722408026755853
maximumunboundplasmadrugconcentrationcmaxuic50,0.16722408026755853
peakinsulin,0.16722408026755853
concentrationofdrugproducing50inhibitionic50,0.16722408026755853
timeatwhichthemaximumconcentrationoccurred,0.16722408026755853
kdehydronorketamine,0.16722408026755853
areaunderthecurvefromtimezerotoinfinityauc0infinity,0.16722408026755853
resistance,0.16722408026755853
prothrombintime,0.16722408026755853
50lethaldose,0.16722408026755853
areaunderthetimeconcentrationcurveauc08,0.16722408026755853
perfusion,0.16722408026755853
effluxrateconstantsratio,0.16722408026755853
livertissuetoplasmaconcentrationratiokpliver,0.16722408026755853
areaundertheconcentrationtimecurveratioaucr,0.16722408026755853
ssowrate,0.16722408026755853
maximummeasuredplasmaconcentrationcmax,0.16722408026755853
areaundertheplasmaconcentrationcurveaucbetween0to8hour,0.16722408026755853
lungmeanabsorptiontime,0.16722408026755853
metabolicclearancebasedonunbounddrug,0.16722408026755853
timefor90absorption,0.16722408026755853
timefor90tobeabsorbedt90,0.16722408026755853
halflifeofpulmonaryretention,0.16722408026755853
percentageunbounddrugintheplasma,0.16722408026755853
absorptionemissionwavelengthlabsem,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to8hour,0.16722408026755853
areaunderthezidovudineconcentrationtimecurveauc,0.16722408026755853
fractionalexcretionfe,0.16722408026755853
areaundertheexcretionratecurve,0.16722408026755853
bioavailabilityenhancement,0.16722408026755853
overallhealingrate,0.16722408026755853
total12h,0.16722408026755853
apparentcmax,0.16722408026755853
timeatwhichitoccurredtmax,0.16722408026755853
gastricresidencetimegrt,0.16722408026755853
apparentpostpseudodistributionvolumeofdistributionvdbeta,0.16722408026755853
halflifeofdissociation,0.16722408026755853
renaltubularclearanceclt,0.16722408026755853
minimumplasmalevel,0.16722408026755853
halflifeperiodofantipyrinet50,0.16722408026755853
auctothelastmeasurableconcentrationattimet,0.16722408026755853
partialapparentmetabolicclearance,0.16722408026755853
maximumabzsxconcentrationcmax,0.16722408026755853
timetopeakdoxepinplasmaconcentration,0.16722408026755853
totalapparentclearancesclf,0.16722408026755853
timetomaximalgir,0.16722408026755853
fractionoftheoraldoseabsorbed,0.16722408026755853
areaundercurveauc0,0.16722408026755853
betaeliminationhalflife,0.16722408026755853
areaunderthecurveaucinfinity0,0.16722408026755853
atbf,0.16722408026755853
timetopeakplasmainsulinaspartconcentration,0.16722408026755853
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc0infinity,0.16722408026755853
tinsmax,0.16722408026755853
totalglucosedisposal,0.16722408026755853
areaundertheglucoseconcentrationtimecurvefor0240min,0.16722408026755853
maximumplasmainsulinaspartconcentration,0.16722408026755853
areaunderthecurveperdoseaucd,0.16722408026755853
halftimet12beta,0.16722408026755853
areaundertheinsulinaspartvstimecurve,0.16722408026755853
peaktheophyllineconcentration,0.16722408026755853
timeofpeaktheophyllineconcentration,0.16722408026755853
apparentspecificvolumeofdistributionvdarea,0.16722408026755853
auc021d,0.16722408026755853
areaunderthecurveauc360min,0.16722408026755853
timetosteadystatetss,0.16722408026755853
timeadvantage,0.16722408026755853
ib,0.16722408026755853
kel3mx,0.16722408026755853
timetomaximumseruminsulinconcentrationtmax,0.16722408026755853
maximuminsulinconcentrationcmax,0.16722408026755853
aucinsulinlevel,0.16722408026755853
areaunderthetimeconcentrationcurveaucfromzerotoinfinity,0.16722408026755853
areaunderthecurveauctratio,0.16722408026755853
maximuminsulinconcentrationinblood,0.16722408026755853
minimumserumtheophyllineconcentrationsatsteadystate,0.16722408026755853
t48,0.16722408026755853
steadystateminimumconcentrationcmeas,0.16722408026755853
nearsteadystateserumconcentration,0.16722408026755853
timetopeakinsulinlevel,0.16722408026755853
maximuminsulinconcentration,0.16722408026755853
timetopeakoftheplasmaconcentrationcurve,0.16722408026755853
maximumseruminsulincmaxins,0.16722408026755853
tmaxin,0.16722408026755853
cpred,0.16722408026755853
serumconcentrationcp,0.16722408026755853
timecourseofabsorption,0.16722408026755853
apparentvolumeofdistributionfortheophyllinevf,0.16722408026755853
eliminationhalfline,0.16722408026755853
volumeofdistributionforthe,0.16722408026755853
contacttime,0.16722408026755853
timetomaximumtmax,0.16722408026755853
urinaryglucoseexcretion,0.16722408026755853
maximumhydroxychloroquinebloodconcentrationcmax,0.16722408026755853
timetoreachmaximuminsulinactiontgirmax,0.16722408026755853
toreach50maximumactiont50girmax,0.16722408026755853
encapsulatingefficiency,0.16722408026755853
totalbodyclearancedosecss,0.16722408026755853
auc120360,0.16722408026755853
timeuntilpeakplasmainsulinlevel,0.16722408026755853
timefor50absorption,0.16722408026755853
maximumtolerancedose,0.16722408026755853
lagtimebeforeabsorptioncommenced,0.16722408026755853
renalclearancefromblood,0.16722408026755853
bloodconcentrationratiors,0.16722408026755853
incorporationrateconstant,0.16722408026755853
apparentdistributionvolumevzf,0.16722408026755853
pharmacologicalavailability,0.16722408026755853
apparentspecificvolumeofcentralcompartment,0.16722408026755853
rateofinsulinaction,0.16722408026755853
tconcentration,0.16722408026755853
aucgir010h,0.16722408026755853
glucoseauc06h,0.16722408026755853
water,0.16722408026755853
effectsiteconcentrationcausing50ofemax,0.16722408026755853
peakexpiratoryflowrate,0.16722408026755853
insc,0.16722408026755853
plasmaconcentrationec50,0.16722408026755853
glucoseuptake,0.16722408026755853
oralformationclearance,0.16722408026755853
peaktroughdifference,0.16722408026755853
areaundertheigf1concentrationcurveauc,0.16722408026755853
peakserumdyphyllineconcentration,0.16722408026755853
timeoftheplasmaconcentrationpeak,0.16722408026755853
arterialbloodph,0.16722408026755853
mn,0.16722408026755853
totalsystemicplasmaclearancecl,0.16722408026755853
plasmaareaunderthecurveaucratio,0.16722408026755853
completeresponsecrincompletecountrecoverycrirate,0.16722408026755853
m2,0.16722408026755853
systemicserumclearance,0.16722408026755853
plasmasteadystateconcentrationratio,0.16722408026755853
meandispositionresidencetimemdrt,0.16722408026755853
areaundertheserumconcentrationcurveauc,0.16722408026755853
successfuldose,0.16722408026755853
volumeofdistributionofnflxgaatsteadystatevdss,0.16722408026755853
tumourfoci,0.16722408026755853
timetoreachdischargecriteria,0.16722408026755853
temperaturecoefficient,0.16722408026755853
timestosternal,0.16722408026755853
albuminsolution,0.16722408026755853
serummidazolamconcentration,0.16722408026755853
totalreleaserate,0.16722408026755853
maximumdiameter,0.16722408026755853
relapsefreesurvival,0.16722408026755853
inactivationrateconstant,0.16722408026755853
halflethaldose,0.16722408026755853
bacterialeradicationrate,0.16722408026755853
permeationcharacteristic,0.16722408026755853
volumedoublingtimevdt,0.16722408026755853
t12oftheterminalsteadystateeliminationphase,0.16722408026755853
initialclearancehalftime,0.16722408026755853
residencehalflife,0.16722408026755853
extractionfraction,0.16722408026755853
totaluptake,0.16722408026755853
tumortonontumorratio,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0to4hour,0.16722408026755853
t12ofthefirstdistributionphase,0.16722408026755853
absorptiont12ka,0.16722408026755853
effectivene,0.16722408026755853
kalpha,0.16722408026755853
sievingcoefficients,0.16722408026755853
tumourarea,0.16722408026755853
maximalabsorptionconcentrationcmax,0.16722408026755853
minimumdiameter,0.16722408026755853
her,0.16722408026755853
areaundertheglucoseconcentrationtimecurve,0.16722408026755853
minimumdetectablequantity,0.16722408026755853
areaunderthetimeconcentrationcurveauc090min,0.16722408026755853
apparentinhibitionconstantki,0.16722408026755853
plasmapeakconcentrationcmax,0.16722408026755853
qa,0.16722408026755853
maximalbloodglucose,0.16722408026755853
areaundertheconcentrationtimecurvefrom024hour,0.16722408026755853
timetoreach75ofthereleaseplateaulevel,0.16722408026755853
perfusateplasmaareaunderthecurveratio,0.16722408026755853
perfusiontime,0.16722408026755853
ftr,0.16722408026755853
centralvolumeofdistributionatsteadystate,0.16722408026755853
tumorconcurrentplasmaratio,0.16722408026755853
totalplasmaticclearance,0.16722408026755853
acirculationhalflife,0.16722408026755853
peaksitagliptinconcentration,0.16722408026755853
tumoraccumulationefficiencyauctumoraucplasma,0.16722408026755853
060min,0.16722408026755853
maximumcrosssection,0.16722408026755853
timetoclearresponsetoverbalcommand,0.16722408026755853
timeforreachingthehalfmaximumeffect,0.16722408026755853
plasmamidazolam,0.16722408026755853
areasunderthetimeconcentrationcurve,0.16722408026755853
volatilecontent,0.16722408026755853
halflifeoflabel,0.16722408026755853
midazolamconcentration,0.16722408026755853
areaundertheconcentrationtimecurveextrapolatedtoinfinity,0.16722408026755853
intrinsicassociationconstant,0.16722408026755853
durationoffirstremission,0.16722408026755853
fetaltransferrate,0.16722408026755853
effluxrateconstant,0.16722408026755853
placentaltissueplasmaconcentrationratio,0.16722408026755853
transportfractiontf,0.16722408026755853
overallobjectiveresponse,0.16722408026755853
maximumplasmaconcentrationofdo,0.16722408026755853
apparentvolumedistributioninterminalphase,0.16722408026755853
tissuemediumratioatequilibrium,0.16722408026755853
interassayrecoverie,0.16722408026755853
oralclearancevaluesclf,0.16722408026755853
apparentconstantplasmalevel,0.16722408026755853
rateconstantsbeta,0.16722408026755853
serumstability,0.16722408026755853
plasmaticclearance,0.16722408026755853
heartconcentration,0.16722408026755853
areaundertheplasmaconcentrationxtimecurveauc,0.16722408026755853
peakghlevel,0.16722408026755853
bloodcirculationtime,0.16722408026755853
tumourdoxorubicin,0.16722408026755853
distributionhalflifetalpha12,0.16722408026755853
apparentec50,0.16722408026755853
steadystateconcentrationattheendofthedosingintervalctau,0.16722408026755853
apparentsteadystatevolumedistribution,0.16722408026755853
oralabsolutebioavailabilityf,0.16722408026755853
auc054h,0.16722408026755853
50growthinhibitoryconcentrationic50,0.16722408026755853
maximumplasmamidazolamconcentration,0.16722408026755853
peakserumketoconazoleconcentration,0.16722408026755853
areaundertheconcentrationtimecurveoveradosingintervalauc0tau,0.16722408026755853
tumormuscleconcentrationratio,0.16722408026755853
peakdeliveredamount,0.16722408026755853
halflifeofthefirstdispositionphaset12alpha,0.16722408026755853
loqsn,0.16722408026755853
tumorskinconcentrationratio,0.16722408026755853
timetomaximumplasmatrazodoneconcentration,0.16722408026755853
liverextractionratioaucliveraucplasma,0.16722408026755853
aucintrahepaticaucintraarterialratio,0.16722408026755853
aucintrahepaticaucintravenousratio,0.16722408026755853
terminaleliminationhalflifet12gamma,0.16722408026755853
desirability,0.16722408026755853
timetopeakplasmaconcentrationcmax,0.16722408026755853
tntratio,0.16722408026755853
tissueabsorbeddose,0.16722408026755853
maximaltelithromycinconcentrationatsteadystatecmaxss,0.16722408026755853
steadystateareaundertheplasmaconcentrationtimecurvefromtimezeroto24hoursauc024hss,0.16722408026755853
deltaqtc,0.16722408026755853
art,0.16722408026755853
arterialcarbondioxidetensionpaco2,0.16722408026755853
endometrial,0.16722408026755853
relativesurvivalratescmaxs,0.16722408026755853
areaunderthelumiracoxibplasmaconcentrationtimecurvesauc0infinity,0.16722408026755853
firstorderabsorptionksr,0.16722408026755853
areaunderthecurvefrom0to12hoursauc012,0.16722408026755853
serumclearancecls,0.16722408026755853
cumulativeurinaryexcretionamount,0.16722408026755853
peakplasmaadmconcentration,0.16722408026755853
vfratio,0.16722408026755853
limitedabsorptiontime,0.16722408026755853
firstorderabsorptionkir,0.16722408026755853
clearance1h,0.16722408026755853
relativesurvivalratesmaximalconcentrationscmaxs,0.16722408026755853
tumourtobloodratio,0.16722408026755853
coext,0.16722408026755853
arterialportalaucratio,0.16722408026755853
ratioofic50,0.16722408026755853
undertheplasmaconcentrationtimecurvefromtime0to12hourspostdoseauc012,0.16722408026755853
areaundertheadrconcentrationtimecurveauc,0.16722408026755853
cumulativeurinaryelimination,0.16722408026755853
completeremissioncrrate,0.16722408026755853
maximumintravascularconcentration,0.16722408026755853
eliminationpercentage,0.16722408026755853
salivatoplasmaratioofinhconcentration,0.16722408026755853
relativecellsurvivalrate,0.16722408026755853
freefractionff,0.16722408026755853
totaladequivalent,0.16722408026755853
totalurineexcretion,0.16722408026755853
dissociationequilibriumconstant,0.16722408026755853
clinicalresponseratecrpr,0.16722408026755853
peakobservedconcentration,0.16722408026755853
totalclerance,0.16722408026755853
timeforreachingmaximumconcentration,0.16722408026755853
peakketconcentration,0.16722408026755853
areaundertheconcentrationtimecurvefrom0htoinfinityauc0infinity,0.16722408026755853
peakradioactivityplasmalevel,0.16722408026755853
maximumsalivaconcentrationcsmax,0.16722408026755853
absorptionhalflifet12alpha,0.16722408026755853
wholebodyvolumeofdistribution,0.16722408026755853
maximumtauro,0.16722408026755853
hepaticfirstpassextractionratio,0.16722408026755853
lung,0.16722408026755853
contentuniformity,0.16722408026755853
dispersiontime,0.16722408026755853
clbsa,0.16722408026755853
tumourtoheartauc024ratio,0.16722408026755853
areaunderthetumourleveltimecurve,0.16722408026755853
intracellularpeakconcentration,0.16722408026755853
maximalbioavailability,0.16722408026755853
redispersedtime,0.16722408026755853
dosenormalizedplasmaconcentration,0.16722408026755853
fauc24mic,0.16722408026755853
areaundertheplasmaversusconcentrationtimecurve,0.16722408026755853
withdrawalvolume,0.16722408026755853
concentrationatsteadystatecss,0.16722408026755853
areaundercurvefromzerotoinfinity,0.16722408026755853
peakleftventriculartissueconcentration,0.16722408026755853
eliminationrateke,0.16722408026755853
totalclearancecltotf,0.16722408026755853
terminalhalftimet12,0.16722408026755853
effectiveexposureindex,0.16722408026755853
treatmentrelatedcomplicationrate,0.16722408026755853
maximumobservedserumgolimumabconcentrationcmax,0.16722408026755853
steadystatetissueconcentration,0.16722408026755853
tissuepenetrationratiostissuefaucplasmafauc,0.16722408026755853
serumlevelpeak,0.16722408026755853
aspectratio,0.16722408026755853
areaundertheplasmaconcentrationtimecurveduringadosageintervalauct,0.16722408026755853
minimuminhibitoryconcentrationsminimumbactericidalconcentrationsmicsmbcs,0.16722408026755853
abbc,0.16722408026755853
transferconstantktran,0.16722408026755853
areaundertheconcentrationversustimecurvesfromtimezerotoinfinityauc0infinity,0.16722408026755853
t12alpha1,0.16722408026755853
t12alpha2,0.16722408026755853
susceptibilityrate,0.16722408026755853
auc012hxvmicratio,0.16722408026755853
troughsynovialfluidminocyclineconcentration,0.16722408026755853
secondaryhalflive,0.16722408026755853
ahconcentration,0.16722408026755853
ratiooftumourtissuetonormalliveruptake,0.16722408026755853
peakplasmadoxorubicinconcentration,0.16722408026755853
areaundertheadmconcentrationstimecurveauc,0.16722408026755853
areaunderthebiliaryexcretionratetimecurveauc,0.16722408026755853
fauc024mictauc024mic,0.16722408026755853
halfmaximalactivity,0.16722408026755853
bonetoserumratio,0.16722408026755853
areaunderthecurveabovethemicfaucmic,0.16722408026755853
permeabilityarea,0.16722408026755853
microbialkill,0.16722408026755853
biliaryexcretionk,0.16722408026755853
extentofdrugboundtoplasmaprotein,0.16722408026755853
ratioofareaundertheconcentrationtimecurveminimuminhibitoryconcentrationaucmic,0.16722408026755853
imprecisioncv,0.16722408026755853
fecalelimination,0.16722408026755853
0tot,0.16722408026755853
areaunderthefirstmomentofcurvefrom0tot,0.16722408026755853
heatproduction,0.16722408026755853
lunglevel,0.16722408026755853
areasundertheconcentrationtimecurvefrom0to24h,0.16722408026755853
fcmaxconcentration,0.16722408026755853
halfclearancetime,0.16722408026755853
overallclinicalcurerate,0.16722408026755853
absorptionhalflivest12ka,0.16722408026755853
efficiencyofabsorption,0.16722408026755853
concentrationsatsteadystate,0.16722408026755853
areaundertheconcentrationtimecurve012hour,0.16722408026755853
areaundertheconcentrationtimecurveaucfromtimezeroto24hpostdosingauc024,0.16722408026755853
timetoreachpeakserumconcentration,0.16722408026755853
ratioauciaolaolauci,0.16722408026755853
aucfromtimezeroto12hpostdosingauc012,0.16722408026755853
fatratio,0.16722408026755853
cumulativepriordose,0.16722408026755853
intraabdominalfatvolume,0.16722408026755853
concentrationproducing50inhibitionofcontrolenzymeactivityic50,0.16722408026755853
areaundertheconcentrationcurvefor08hauc08h,0.16722408026755853
eliminationhalflivest12ke,0.16722408026755853
totalclearanceclbf,0.16722408026755853
ratiooftheareaundertheconcentrationtimecurveauctothemicaucmicratio,0.16722408026755853
percentageabsorbed,0.16722408026755853
fractionofthedoseeliminated,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to24hfauc024,0.16722408026755853
aucbileaucvp,0.16722408026755853
peakmefloquineconcentration,0.16722408026755853
delaytime,0.16722408026755853
decaytime,0.16722408026755853
gammaeliminationhalflive,0.16722408026755853
rateofdelivery,0.16722408026755853
areaundertheconcentrationtimecurve048hauc,0.16722408026755853
bloodcirculationtimet12,0.16722408026755853
eliminationhalftimet12gamma,0.16722408026755853
inductionfactor,0.16722408026755853
lowinhibitoryconcentrationic50,0.16722408026755853
timetoreachserumfentanylconcentration,0.16722408026755853
percentagetumorcelldeath,0.16722408026755853
areaundertheconcentrationtimeprofile,0.16722408026755853
reversionmultiple,0.16722408026755853
aucfromzerotimetoinfinity,0.16722408026755853
zetaelectricalpotential,0.16722408026755853
apparentda,0.16722408026755853
minimaltherapeuticconcentration,0.16722408026755853
eliminationhalflifetfrac12,0.16722408026755853
auat,0.16722408026755853
capillarybloodconcentration,0.16722408026755853
maximumadmlevelcmax,0.16722408026755853
intrahepaticconcentration,0.16722408026755853
apparenthalflifeofabsorption,0.16722408026755853
transferclearance,0.16722408026755853
lcretentiontime,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtimezeroto12h,0.16722408026755853
concentrationathalfmaximuminhibitionic50,0.16722408026755853
releasingduration,0.16722408026755853
placentalpartitioncoefficient,0.16722408026755853
maximaplasmaconcentration,0.16722408026755853
volumeofdistributionofthemetabolitecompartment,0.16722408026755853
terminalhalflifevaluest12beta,0.16722408026755853
aucfromzerotimeto7day,0.16722408026755853
timestofeverclearance,0.16722408026755853
peaklevelofdrugconcentrationin,0.16722408026755853
tissuedrugconcentration,0.16722408026755853
ebf,0.16722408026755853
mbf,0.16722408026755853
plasmafen,0.16722408026755853
024mic,0.16722408026755853
apparentinitialvolumeofdistribution,0.16722408026755853
auc0negativeinfinity,0.16722408026755853
clearanceofantixaactivity,0.16722408026755853
areaundertheconcentrationtimecurvebetweenzeroandthelastsamplingpointauc0t,0.16722408026755853
extracellularph,0.16722408026755853
eliminationhalflivesatbetaphase,0.16722408026755853
aucelf,0.16722408026755853
entrappedefficiency,0.16722408026755853
ebfmbfratio,0.16722408026755853
auc0mictarget,0.16722408026755853
80,0.16722408026755853
effectiveexposure,0.16722408026755853
deltab,0.16722408026755853
stasisexposureindex,0.16722408026755853
overalleliminationconstant,0.16722408026755853
apparentvc,0.16722408026755853
aeaz0,0.16722408026755853
auc0negativeinfinitydosebsa,0.16722408026755853
peakplasmatolvaptanconcentration,0.16722408026755853
accumulative,0.16722408026755853
maximummeanplasmafenconcentrationcmax,0.16722408026755853
intrinsicactivityalpha,0.16722408026755853
tissuedistributiontime,0.16722408026755853
maximumwholebloodmefloquineconcentration,0.16722408026755853
maximumintracellulartumordrugconcentration,0.16722408026755853
serumconcentrationtodosecdratio,0.16722408026755853
portalclearance,0.16722408026755853
areaundertheconcentrationtimecurveextrapolatedtoinfinityaucinf,0.16722408026755853
exposuretime,0.16722408026755853
plasmacirculationhalflife,0.16722408026755853
cavitybloodratio,0.16722408026755853
totalbodyclearanceofdigitoxincltot,0.16722408026755853
cumulativeexcretionof,0.16722408026755853
peaktolvaptanconcentration,0.16722408026755853
steadystatecsfplasmaconcentrationratio,0.16722408026755853
analytical,0.16722408026755853
nonspecificclearance,0.16722408026755853
incorporationcapacity,0.16722408026755853
tolerance,0.16722408026755853
ratioofaqueoushumourserumconcentration,0.16722408026755853
productionratecalcidiolratio,0.16722408026755853
salivaversusserumconcentrationratio,0.16722408026755853
distributionphaseplasmahalflife,0.16722408026755853
totalurinarycalciumexcretionrate,0.16722408026755853
bileliverunboundconcentrationratio,0.16722408026755853
calciumexcretion,0.16722408026755853
maximalbh4concentration,0.16722408026755853
volumeofdistributionatbetaphase,0.16722408026755853
liverplasmaunboundconcentrationratiokpu,0.16722408026755853
internalvolume,0.16722408026755853
auct032,0.16722408026755853
strokevolume,0.16722408026755853
natriuresi,0.16722408026755853
auccsf,0.16722408026755853
clbeta,0.16722408026755853
terminalserumhalftimet12,0.16722408026755853
peakpulmonarythromboxaneb2txb2concentration,0.16722408026755853
highestachievedconcentration,0.16722408026755853
urinaryeliminationhalflive,0.16722408026755853
timeofthepeakplasmaconcentration,0.16722408026755853
spontaneousabr,0.16722408026755853
halflifeinthecirculation,0.16722408026755853
formateclearancerate,0.16722408026755853
ratiosclvcrclvsli,0.16722408026755853
totalbodywater,0.16722408026755853
peakplasmaethanolconcentration,0.16722408026755853
loadingdose,0.16722408026755853
troughfixlevel,0.16722408026755853
clrate,0.16722408026755853
incrementalrecovery,0.16722408026755853
integrated4hplasmaethanolconcentration,0.16722408026755853
steadystateghconcentration,0.16722408026755853
ratetoreachsteadystate,0.16722408026755853
accumulationpermeationpercentage,0.16722408026755853
timetakentoreachmaximumplasmaconcentration,0.16722408026755853
pulmonarycapillarywedgepressure,0.16722408026755853
steadystatefviiiactivitytroughlevel,0.16722408026755853
fbl,0.16722408026755853
qretention,0.16722408026755853
biologicalhalflifet12el,0.16722408026755853
qn,0.16722408026755853
rect,0.16722408026755853
volumeofdistributionofflunarizineperfractionofthedoseabsorbedvdf,0.16722408026755853
totalplasmaclearanceofflunarizineperfractionofthedoseabsorbedclpf,0.16722408026755853
troughplasmaperhexilineconcentration,0.16722408026755853
durationofanalgesiceffect,0.16722408026755853
reconstitutiontime,0.16722408026755853
concentrationofthefirstpeakcpeak1,0.16722408026755853
eliminationrateconstantkc1,0.16722408026755853
tissuedistributionvz,0.16722408026755853
minimumeffective,0.16722408026755853
plasmat12beta,0.16722408026755853
peakibuprofenplasmaconcentration,0.16722408026755853
chiralinversion,0.16722408026755853
volumeofdistributionper,0.16722408026755853
ce50bi,0.16722408026755853
oralbiologicalavailability,0.16722408026755853
peakserumtriprolidineconcentration,0.16722408026755853
extrarenal,0.16722408026755853
percentagestime,0.16722408026755853
ic80,0.16722408026755853
timetomaintaingastricph4,0.16722408026755853
weightcorrelatedapparenttotalbodyclearance,0.16722408026755853
mpt,0.16722408026755853
percentagetime,0.16722408026755853
apparenthalftimeofelimination,0.16722408026755853
maximumconcentrationofdruginplasmacmax,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinity,0.16722408026755853
steadystatedrugconcentration,0.16722408026755853
bodysurfaceareaatsteadystate,0.16722408026755853
pea,0.16722408026755853
peakscmax,0.16722408026755853
areaundertheplasmaconcentrationtimecurveduringthedosingintervalauctau,0.16722408026755853
bac,0.16722408026755853
incrementalrecoverie,0.16722408026755853
closurerate,0.16722408026755853
bec,0.16722408026755853
apparentavailability,0.16722408026755853
aucminimuminhibitoryconcentrationmic,0.16722408026755853
peakethanolconcentration,0.16722408026755853
fauc24hmic,0.16722408026755853
maximummeasuredyohimbineplasmaconcentration,0.16722408026755853
cumulativeurineexcretionratio,0.16722408026755853
ratesofethanolelimination,0.16722408026755853
steadytargetbloodconcentration,0.16722408026755853
residualdrug,0.16722408026755853
chemicalplasmahalflife,0.16722408026755853
areaundertheconcentrationtimecurvefromzeroto8hrauc08hr,0.16722408026755853
maximalplasmaconcentrationofketoprofencmax,0.16722408026755853
accumulationcoefficient,0.16722408026755853
totalareasundertheplasmaconcentrationcurve,0.16722408026755853
peakplasmadiazepamlevel,0.16722408026755853
ethanol,0.16722408026755853
meanresidencetime0,0.16722408026755853
plasmaclearanceofunbound,0.16722408026755853
ratioofcmax,0.16722408026755853
oralt12,0.16722408026755853
maximumdmphplasmaconcentrationcmax,0.16722408026755853
peakurinaryconcentrations015h,0.16722408026755853
tissuecluptake,0.16722408026755853
timetoattainthepeak,0.16722408026755853
totalsystemicplasmaclearance,0.16722408026755853
prostatictissueserumratio,0.16722408026755853
inhibitionpercentage,0.16722408026755853
ktv,0.16722408026755853
totalamountofofloxacinexcretedinurine,0.16722408026755853
ic50tetraeth,0.16722408026755853
aqueoustoplasmaratio,0.16722408026755853
totaldermalabsorption,0.16722408026755853
saconcentration,0.16722408026755853
logdseddsreleasemedium,0.16722408026755853
aucbrainaucplasmaratio,0.16722408026755853
areaunderthecurvebetween0and24hauc024,0.16722408026755853
cumulativefractionoffauc024mic,0.16722408026755853
secondphaset12,0.16722408026755853
timetoreachpeakheartrate,0.16722408026755853
invivorecoveryivr,0.16722408026755853
excretionof,0.16722408026755853
influxclin,0.16722408026755853
thl,0.16722408026755853
totaldurationoflrr,0.16722408026755853
onsetoflossofrightingreflexlrr,0.16722408026755853
maximummeasureddetomidineconcentration,0.16722408026755853
halflivesforclearance,0.16722408026755853
tissuelevelscmax,0.16722408026755853
activitylevel,0.16722408026755853
effluxcloutpermeability,0.16722408026755853
normalizedclearancerate,0.16722408026755853
normalizedrate,0.16722408026755853
totalbioaccessibility,0.16722408026755853
apparentequilibriumdissociationconstantkd,0.16722408026755853
bioaccessible,0.16722408026755853
stimulationconstant,0.16722408026755853
salivatoplasmaconcentrationratiospratio,0.16722408026755853
salivatoplasmadrugconcentrationratiosspratio,0.16722408026755853
concentrationpeakcmax,0.16722408026755853
circulatingconcentration,0.16722408026755853
completiontime,0.16722408026755853
disappearancerate,0.16722408026755853
t12dist,0.16722408026755853
t12forthisproce,0.16722408026755853
volumeinthesteadystate,0.16722408026755853
timetosinussterilization,0.16722408026755853
timetoresolution,0.16722408026755853
volumeofthereferencecompartment,0.16722408026755853
particlesizedistribution,0.16722408026755853
timerequiredto,0.16722408026755853
overallsuccessrate,0.16722408026755853
areaunderthecurvefor24hauc24,0.16722408026755853
bactericidalindex,0.16722408026755853
bactericidalindexe,0.16722408026755853
aucfromtimezerotoinfinityauc0,0.16722408026755853
overallclosurerate,0.16722408026755853
correctedtransfer,0.16722408026755853
oralvolumeofdistributionvdf,0.16722408026755853
steadystaterelease,0.16722408026755853
areaundertheserumconcentrationtimecurveauc024h,0.16722408026755853
peakamitriptylineplasmaconcentration,0.16722408026755853
aucnt0infinity,0.16722408026755853
areaundertheplasmaconcentrationtimecurveaucat,0.16722408026755853
fine,0.16722408026755853
targetratio,0.16722408026755853
rateconstantforintermediatecompartment,0.16722408026755853
longterminaleliminationhalflife,0.16722408026755853
volumeofdistributionatthesteadystatevdss,0.16722408026755853
areaundertheconcentrationtimecurveover12hauc012h,0.16722408026755853
oralbloodclearance,0.16722408026755853
ddtci,0.16722408026755853
apparentexcretoryhalflife,0.16722408026755853
fetalmaternalplasmaconcentrationratio,0.16722408026755853
ddqtcib,0.16722408026755853
extractedrecoveryefficiency,0.16722408026755853
netfluidlo,0.16722408026755853
auc024mic90ratio,0.16722408026755853
l1,0.16722408026755853
maximalinfusionrate,0.16722408026755853
immunoreactivefraction,0.16722408026755853
maximaldose,0.16722408026755853
bioavailabilityfactorf,0.16722408026755853
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityauc,0.16722408026755853
absoluteoralbioavalabilityf,0.16722408026755853
restingheartrate,0.16722408026755853
biologict12,0.16722408026755853
csftoplasmapartitioncoefficient,0.16722408026755853
peakserumrcd4iggconcentration,0.16722408026755853
appearanceclearance,0.16722408026755853
cd4cd8ratio,0.16722408026755853
recurrencerate,0.16722408026755853
clearanceofpermeation,0.16722408026755853
rateofplasmaclearance,0.16722408026755853
accumulatedamountatsteadystate,0.16722408026755853
meanserumconcentration,0.16722408026755853
tumorabsorbeddose,0.16722408026755853
meanresidencetimemrt0t,0.16722408026755853
auc02524h,0.16722408026755853
sketorolacconcentration,0.16722408026755853
c6hr,0.16722408026755853
ipf,0.16722408026755853
c2hr,0.16722408026755853
eliminationhalflifebt12,0.16722408026755853
maximumdrugeffectemax,0.16722408026755853
adsorptioncapacitie,0.16722408026755853
apparentvolumeofdistributionofsteadystate,0.16722408026755853
intracranialresponserate,0.16722408026755853
auc084h,0.16722408026755853
auc024hminimuminhibitoryconcentrationratio,0.16722408026755853
colonicarrivaltime,0.16722408026755853
t12eliminationt12el,0.16722408026755853
cmax24h,0.16722408026755853
areaunderthecurvefrom012hauc012h,0.16722408026755853
dissolutionefficiency,0.16722408026755853
initialdissolutionrate,0.16722408026755853
cumulativepercentdrugrelease,0.16722408026755853
absorptionhalflifet12abs,0.16722408026755853
maximumplasma,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0tolastmeasurabletime,0.16722408026755853
degradationhalflifet12,0.16722408026755853
objectivetumourresponserate,0.16722408026755853
plasmaauc06,0.16722408026755853
areaunderthetimeconcentrationcurveupto6hafterdoseauc06,0.16722408026755853
pta,0.16722408026755853
faucmictarget,0.16722408026755853
timetotumorprogressionttp,0.16722408026755853
steadystateplasmatroughconcentration,0.16722408026755853
midazola,0.16722408026755853
plasmaproteinbindingratio,0.16722408026755853
cssminc1min,0.16722408026755853
maximumobserveddrugconcentrationcmax,0.16722408026755853
peritonealadvantageaucperitonealaucplasma,0.16722408026755853
maximumnifedipineplasmaconcentration,0.16722408026755853
cd25saturation,0.16722408026755853
areaunderthecurveaucfrom0to4h,0.16722408026755853
halflifeofcortisoldisappearance,0.16722408026755853
interpulsevalleyconcentration,0.16722408026755853
prepeaknadirconcentration,0.16722408026755853
maximumconcentrationofdruginthebraincmax,0.16722408026755853
maximumrateofpermeationcoefficient,0.16722408026755853
completionrate,0.16722408026755853
halflifeofcort,0.16722408026755853
polydispersionindexpi,0.16722408026755853
milktoserumratio,0.16722408026755853
cumulativefaecalexcretion,0.16722408026755853
abz,0.16722408026755853
bodysurfaceareanormalizedareaunderthecurve,0.16722408026755853
compartmentalhalflife,0.16722408026755853
titer,0.16722408026755853
kiub,0.16722408026755853
plasmaareaundertheplasmaconcentrationtimecurveauc,0.16722408026755853
totalmedianclearance,0.16722408026755853
ic50concentration,0.16722408026755853
drugtargetingpotential,0.16722408026755853
peakamplitude,0.16722408026755853
peakserumtt4concentration,0.16722408026755853
detectedplasmaconcentration,0.16722408026755853
timetoreachthi,0.16722408026755853
halftimeforlnclearancetc12,0.16722408026755853
logauc,0.16722408026755853
t12abs,0.16722408026755853
logclearance,0.16722408026755853
areaundertheconcentrationxtimecurvefrom0toinfinityauc0infinity,0.16722408026755853
tsh2tsh1ratio,0.16722408026755853
totalexposureauc012h,0.16722408026755853
wholeanalysistime,0.16722408026755853
effectivedetectionlimit,0.16722408026755853
mage,0.16722408026755853
areaundertheplasmaconcentrationversustimecurvefromtime0hto12hauc012,0.16722408026755853
t12zterminalphasehalflife,0.16722408026755853
auc28d,0.16722408026755853
auc0tn,0.16722408026755853
eliminationhalflifet12ke,0.16722408026755853
urinelevel,0.16722408026755853
clz,0.16722408026755853
steadystateplasmabaconcentration,0.16722408026755853
firstorderabsorptionka,0.16722408026755853
watercontent,0.16722408026755853
peakplasmacannabidiolconcentration,0.16722408026755853
maximumplasmaconcentrationtmax,0.16722408026755853
plasmaclo,0.16722408026755853
weightcorrecteddose,0.16722408026755853
acuteeliminationhalflife,0.16722408026755853
maximalplasmaamitriptylineconcentrationcmax,0.16722408026755853
halflifeofdegradation,0.16722408026755853
detectablelevelsduration,0.16722408026755853
hydroxylationratio,0.16722408026755853
serumtroughto,0.16722408026755853
areaunderthehrversustimecurveauec,0.16722408026755853
metabolicratiosmr,0.16722408026755853
auc020,0.16722408026755853
minimumserumlevetiracetamconcentration,0.16722408026755853
maximumserumlevetiracetamconcentration,0.16722408026755853
aucgas24,0.16722408026755853
peatstime,0.16722408026755853
overallclinicaldrugefficacie,0.16722408026755853
volumeofdistributionatasteadystate,0.16722408026755853
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityaucoinfinity,0.16722408026755853
maximumconcentrationofepminplasmacmax,0.16722408026755853
maximumconcentrationcmaxfit,0.16722408026755853
mrl,0.16722408026755853
areaunderthecurveauclast,0.16722408026755853
observedpeakplasmaconcentrationcmax,0.16722408026755853
terminalphasehalflivest12,0.16722408026755853
cmaxfit,0.16722408026755853
terminalphase,0.16722408026755853
maximalflecainide,0.16722408026755853
areaundertheconcentrationtimecurveauc0loq,0.16722408026755853
saliva,0.16722408026755853
terminalplasmahalflifet12beta,0.16722408026755853
areasundertheconcentrationtimecurvefrom0to24hauc024,0.16722408026755853
areaunderthecurveareaunderthecurve0,0.16722408026755853
ratioofaucmic,0.16722408026755853
peakplasma6tuconcentration,0.16722408026755853
peakplasma6mplevel,0.16722408026755853
cmaxminimuminhibitoryconcentrationmic,0.16722408026755853
halflifeinthebetaphase,0.16722408026755853
fcmaxmic,0.16722408026755853
ratioofthetotalclearancebioavailability,0.16722408026755853
volumesofthecentralcompartmentv,0.16722408026755853
concentrationmicratio,0.16722408026755853
volumesofdistributionatequilibriumvr,0.16722408026755853
areaunderthebloodconcentrationtimecurveauc024,0.16722408026755853
renalurateclearance,0.16722408026755853
aucpancreasaucblood,0.16722408026755853
tbl,0.16722408026755853
constantct,0.16722408026755853
steadystateplasmaoxypurinolconcentration,0.16722408026755853
resolutionrate,0.16722408026755853
maximumconcentrationofthedrugcmaxmic,0.16722408026755853
peakconcentrationsisinflammatoryfluid,0.16722408026755853
ribonucleotidetioguanineratio,0.16722408026755853
halflivesofthecentral,0.16722408026755853
areaunderthefreeconcentrationtimecurvefauc,0.16722408026755853
dg,0.16722408026755853
dh,0.16722408026755853
concentrationcausinghalfofthemaximaleffect,0.16722408026755853
ds,0.16722408026755853
cldistribution,0.16722408026755853
maximaldrugcontent,0.16722408026755853
overallclinicalsuccessrate,0.16722408026755853
plasmaclearancecltar,0.16722408026755853
initialeffectsiteconcentration,0.16722408026755853
areaunderthetimeconcentrationcurveauc0t,0.16722408026755853
intercompartmentaldistributionrateconstant,0.16722408026755853
k41,0.16722408026755853
apparentvolumeofdistributionatasteadystatevdss,0.16722408026755853
maximumplasmaconcentrationcmaxmic,0.16722408026755853
maximumfreeplasmalevofloxacinconcentrationfcmaxss,0.16722408026755853
totalbodymetabolicclearance,0.16722408026755853
durationofthemotorblock,0.16722408026755853
clfm,0.16722408026755853
volumeofsteadystate,0.16722408026755853
v3l,0.16722408026755853
peripheraltocentralcompartment,0.16722408026755853
halftimeofeliminationforthefirstrapidphaset12alpha,0.16722408026755853
mucosatoplasmaratio,0.16722408026755853
sodiumoutput,0.16722408026755853
accumulatingeliminationrate,0.16722408026755853
sensitivitysc50,0.16722408026755853
minimumconcentrationdruginserumcmin,0.16722408026755853
timetotheonsetofmotorblock,0.16722408026755853
areaundertheplasmatimeconcentrationcurvefrom0to24hoursauc024,0.16722408026755853
aucfortissueauctissue,0.16722408026755853
unboundauctissuemic,0.16722408026755853
meanabsorptiontransittime,0.16722408026755853
maturationhalftimetm50,0.16722408026755853
effectivedosefor50,0.16722408026755853
totalnumberoftransitcompartment,0.16722408026755853
intercompartmentalclearanceconstantsfromcentraltoperipheral,0.16722408026755853
cockcroftgaultcrea,0.16722408026755853
tounboundplasmaaucconcentrationratio,0.16722408026755853
cblood,0.16722408026755853
cmaxpeak,0.16722408026755853
renaloxypurinolclearance,0.16722408026755853
effectsiteconcentrationforhalfmaximumeffect,0.16722408026755853
maximumpropofolconcentration,0.16722408026755853
maximalenzymeactivity,0.16722408026755853
fractionalremoval,0.16722408026755853
ppc,0.16722408026755853
areaundertheconcentrationtimecurvewithextrapolationtoinfinityauc0inf,0.16722408026755853
maximal6mpplasmaconcentrationcmax,0.16722408026755853
maximumralevel,0.16722408026755853
alveolarmacrophage,0.16722408026755853
penetrationelfplasmaratio,0.16722408026755853
haemofiltrationclearance,0.16722408026755853
boneuptaket12,0.16722408026755853
tounboundplasmaaucratio,0.16722408026755853
bindingstoichiometry,0.16722408026755853
apparentterminalplasmahalflife,0.16722408026755853
volumeofdistributiondividedbybioavailabilityvdf,0.16722408026755853
totaloxazepamclearance,0.16722408026755853
maximaldiazepamconcentration,0.16722408026755853
minimallyeffectiveplasmaconcentration,0.16722408026755853
bloodclearancerateofcortisolbcr,0.16722408026755853
volumeofdistributionvssd,0.16722408026755853
areaunderthecurveaucinf,0.16722408026755853
icg,0.16722408026755853
timerequiredtoachievesteadystateconcentration,0.16722408026755853
bioavailabilityrate,0.16722408026755853
areaunderthetissueconcentrationversustimecurveauc,0.16722408026755853
kinactivationki,0.16722408026755853
cmaxauc0t,0.16722408026755853
maximumconsumption,0.16722408026755853
globule,0.16722408026755853
gasflow,0.16722408026755853
activationhalflife,0.16722408026755853
macbarsevo,0.16722408026755853
signaltonoisebaselineratiosn,0.16722408026755853
apparentextent,0.16722408026755853
peakrbtconcentration,0.16722408026755853
maximumm2concentrationscmax,0.16722408026755853
apparentantimode,0.16722408026755853
relativelylo,0.16722408026755853
mlz,0.16722408026755853
braintoplasmaratioatsteadystate,0.16722408026755853
troughlevelnaproxenconcentrationsatsteadystate,0.16722408026755853
slowestrate,0.16722408026755853
apparentabsoluteoralbioavailability,0.16722408026755853
braineliminationhalflife,0.16722408026755853
braintoplasmahalfliferatio,0.16722408026755853
mz310,0.16722408026755853
unboundkm,0.16722408026755853
areasunderthecurvefromtimezerotoinfinity,0.16722408026755853
timeatwhichtheplasmaconcentrationwasmaximaltmax,0.16722408026755853
steadystatemaximalplasmaconcentrationscmax,0.16722408026755853
aucmetaboliteparentratio,0.16722408026755853
clearancedrug,0.16722408026755853
firststageeliminationhalflifet12beta,0.16722408026755853
t12betaaftersteadystate,0.16722408026755853
relativeinvivorecoverie,0.16722408026755853
flowofinfusion,0.16722408026755853
minimalmeanconcentration,0.16722408026755853
minimalmeanconcentrationsat,0.16722408026755853
biophaseconcentration,0.16722408026755853
timeforextubation,0.16722408026755853
peaknorfloxacinplasmalevel,0.16722408026755853
formulaseetext,0.16722408026755853
ke21,0.16722408026755853
apparentoralvolumeofdistribution,0.16722408026755853
ke12,0.16722408026755853
timetakentoreachmaximumconcentration,0.16722408026755853
distributionhalflifet12lambda2,0.16722408026755853
specificvolumeofdistribution,0.16722408026755853
maximumplasmaprobenecidconcentration,0.16722408026755853
kiratio,0.16722408026755853
aucazt,0.16722408026755853
nasalbioavailabilitie,0.16722408026755853
michaelistypeconstant,0.16722408026755853
midazolamclearance,0.16722408026755853
hospitaldischargetime,0.16722408026755853
masschlorideexcretion,0.16722408026755853
reversaltime,0.16722408026755853
tolerateddose,0.16722408026755853
concentrationathalfmaximumeffect,0.16722408026755853
totalclearanceafteroraladministrationclf,0.16722408026755853
ke0model,0.16722408026755853
t95,0.16722408026755853
volumeofdistributionafteroraladministrationvdf,0.16722408026755853
t25,0.16722408026755853
absorptioncoefficient,0.16722408026755853
maximumabsorptioncmax,0.16722408026755853
timeofmaximumabsorptiontmax,0.16722408026755853
bloodvolume,0.16722408026755853
volumeofperipheralcompartmentv2,0.16722408026755853
halflifet12l2,0.16722408026755853
emergencetime,0.16722408026755853
capacitysmax,0.16722408026755853
reabsorptionratior,0.16722408026755853
metaboliccapacityvmaxc,0.16722408026755853
areaundertheserumconcentrationtimecurvefrom0to6hoursauc6,0.16722408026755853
areaundertheserumconcentrationtimecurvefrom024hoursauc024,0.16722408026755853
peakplasmassalevel,0.16722408026755853
nh,0.16722408026755853
timeatwhichmaximumconcentration,0.16722408026755853
t80clearance,0.16722408026755853
t50clearance,0.16722408026755853
targetattainmentratesofaucmic,0.16722408026755853
timeofmaximalurinaryexcretionrate,0.16722408026755853
targetattainmentratesofaucmic125,0.16722408026755853
peakserumtriazolamlevel,0.16722408026755853
constantplasmaalcoholconcentration,0.16722408026755853
ubtsaubts,0.16722408026755853
distributionatsteadystatevdss,0.16722408026755853
peakbloodtceconcentration,0.16722408026755853
fecalexcretionrateconstant,0.16722408026755853
dispositiondistributionhalflife,0.16722408026755853
intrinsicclearancevmaxkm,0.16722408026755853
minimumserumconcentrationscmax,0.16722408026755853
dispositioneliminationhalflife,0.16722408026755853
percentagereleased,0.16722408026755853
nonspecificbinding,0.16722408026755853
dhalflife,0.16722408026755853
ehalflife,0.16722408026755853
unboundauc0,0.16722408026755853
daily,0.16722408026755853
aucdistribution,0.16722408026755853
v3fuprostate,0.16722408026755853
timetocontrol,0.16722408026755853
areaundertheconcentrationtimecurvefor24hauc24,0.16722408026755853
areaunderthecurveminimuminhibitoryconcentrationratio,0.16722408026755853
tof,0.16722408026755853
aucelfexposure,0.16722408026755853
inhibitordissociationconstantskivalues,0.16722408026755853
v2fl,0.16722408026755853
urinaryexcretionrateconstant,0.16722408026755853
osmolalgap,0.16722408026755853
areaundertheconcentrationtimecurveminimuminhibitoryconcentrationmic,0.16722408026755853
permeated,0.16722408026755853
breakpoint,0.16722408026755853
concentrationinserumcmax,0.16722408026755853
cavitaryconcentration,0.16722408026755853
visco,0.16722408026755853
residenttimemrt,0.16722408026755853
cavitaryserumlevofloxacinratio,0.16722408026755853
peaklevofloxacinexposure,0.16722408026755853
transdermalcmax,0.16722408026755853
ratesoflivermetabolism,0.16722408026755853
penetrationratioelfplasma,0.16722408026755853
maximalcoronarydilation,0.16722408026755853
cumic,0.16722408026755853
timeto50emptying,0.16722408026755853
auc24humic,0.16722408026755853
overallrenalexcretion,0.16722408026755853
areaundertheplasmaconcentrationvstimecurvefrom012hauc012,0.16722408026755853
slowerphaset12,0.16722408026755853
bioadhesivestrength,0.16722408026755853
totalelimination,0.16722408026755853
maximumdrugencapsulationefficiency,0.16722408026755853
frequencie,0.16722408026755853
numberofsce,0.16722408026755853
sceper,0.16722408026755853
ecmax,0.16722408026755853
fecal,0.16722408026755853
apparentethanolvmax,0.16722408026755853
peakplasmaalcoholconcentration,0.16722408026755853
ecmaxminimuminhibitoryconcentrationmic,0.16722408026755853
peakplasmaradioactivity,0.16722408026755853
steadystatet,0.16722408026755853
auctissueplasmaratio,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtimezerotolastsamplingtimeauc0t,0.16722408026755853
portalvenousflow,0.16722408026755853
rapidphaset12,0.16722408026755853
charge,0.16722408026755853
lungtrovafloxacinlevel,0.16722408026755853
aucs028,0.16722408026755853
areaunderplasmaconcentrationversustimecurve,0.16722408026755853
maximumencapsulationefficiency,0.16722408026755853
conversionlevel,0.16722408026755853
mode,0.16722408026755853
equilibriumdistributionvolume,0.16722408026755853
biophasedistributionrateconstant,0.16722408026755853
renalclearanceof,0.16722408026755853
population,0.16722408026755853
ratesofserum,0.16722408026755853
plasmaunboundinhibitionconstant,0.16722408026755853
areaundertheserumconcentrationtimecurveauc028,0.16722408026755853
totaloraldiltiazemclearance,0.16722408026755853
peakplasmameanconcentrationcmax,0.16722408026755853
keff,0.16722408026755853
bioconcentrationfactorbcf,0.16722408026755853
peaktriazolamconcentration,0.16722408026755853
areaunderthetriazolamconcentrationtimecurve,0.16722408026755853
effluxclearanceclout,0.16722408026755853
mrtim,0.16722408026755853
timetotofratio,0.16722408026755853
halftimeteq,0.16722408026755853
timestoloc,0.16722408026755853
fgluc,0.16722408026755853
apparentdistributionvolumeofperipheralcompartmentvsubpsubf,0.16722408026755853
peakconcentrationoflevofloxacinatsteadystatecmaxss,0.16722408026755853
areasundertheconcentrationtimecurvesduringthe12hdosingintervalauc0taus,0.16722408026755853
ultrafiltrateflow,0.16722408026755853
plasmaurateconcentration,0.16722408026755853
rateconstantfromtheperipheralcompartmenttothecentralcompartmentkpc,0.16722408026755853
csfplasmasteadystateaztconcentrationratio,0.16722408026755853
absorptionrateconstantksubasub,0.16722408026755853
apparentdistributionvolumeofcentralcompartmentvsubcsubf,0.16722408026755853
clearancefromthecentralcompartmentclc,0.16722408026755853
vt0,0.16722408026755853
effectsitetarget,0.16722408026755853
epec,0.16722408026755853
steadystateapparentoralclearance,0.16722408026755853
steadystateconcentrationathalfvmaxkm,0.16722408026755853
maximumtransportcapacity,0.16722408026755853
areaundertheconcentrationtimecurveatsteadystatefrom0to24hafterdoseadministrationaucss024,0.16722408026755853
unboundpeakplasmaconcentration,0.16722408026755853
removalhalflife,0.16722408026755853
plasmaauc08,0.16722408026755853
unboundpeakcsfconcentration,0.16722408026755853
auccsf08,0.16722408026755853
areasunderthemetronidazoleplasmaconcentrationtimecurveauc024,0.16722408026755853
auc024micall,0.16722408026755853
apparentoraleliminationclearance,0.16722408026755853
areaundertheplasmaconcentrationtimecurve024h,0.16722408026755853
drugdeliveryefficiency,0.16722408026755853
penetrationdepth,0.16722408026755853
eng,0.16722408026755853
steadystatedepletion,0.16722408026755853
maximaltimetmax,0.16722408026755853
targetattainmentpotential,0.16722408026755853
maximumfulvestrantconcentration,0.16722408026755853
aucoinf,0.16722408026755853
maximumurineconcentrationcumax,0.16722408026755853
proteinbindingpercentage,0.16722408026755853
10v,0.16722408026755853
concentrationatsteadystateathalfvmaxkm,0.16722408026755853
maximaldoseratevmax,0.16722408026755853
totallineareliminationclearancefromcsf,0.16722408026755853
effectivepermeabilitycoefficient,0.16722408026755853
areaunderthemesentericbloodtimecurve,0.16722408026755853
peaklevofloxacinconcentration,0.16722408026755853
pulmonarypercentagepenetration,0.16722408026755853
minimummeasurableconcentration,0.16722408026755853
peakconcentrationtominimuminhibitoryconcentrationratio,0.16722408026755853
braintoplasmaeffluxrateconstant,0.16722408026755853
areaunderconcentrationtimecurvetominimalinhibitoryconcentrationratio,0.16722408026755853
minimuminhibitoryconcentrationsfor90,0.16722408026755853
constantbloodflowrate,0.16722408026755853
substitutionflowrate,0.16722408026755853
extracorporealclearance,0.16722408026755853
terminalhalflivesofeliminationt12beta,0.16722408026755853
volumesofdistributionofthecentralcompartmentvc,0.16722408026755853
atsteadystatevss,0.16722408026755853
csftoplasmaaucratio,0.16722408026755853
overallpfs6,0.16722408026755853
intraextracellularratio,0.16722408026755853
netoutput,0.16722408026755853
auc0192,0.16722408026755853
tissuetoplasmapartitioncoefficient,0.16722408026755853
clearanceratetbc,0.16722408026755853
totalapparentvolumeofdistributionvdss,0.16722408026755853
brainecftoplasmaaucratio,0.16722408026755853
areaundertheprothrombintimevstimecurve,0.16722408026755853
peakmilkconcentration,0.16722408026755853
brainecf,0.16722408026755853
firstdistributionhalflife,0.16722408026755853
percentextractionefficiency,0.16722408026755853
kelco2eliminationrateconstantofco2,0.16722408026755853
cumulativeurineexcretion,0.16722408026755853
peakplasmaleuprorelinconcentrationscmax,0.16722408026755853
steadystatemedian,0.16722408026755853
steadystateimatinibplasmaconcentration,0.16722408026755853
peakstimulatedlhconcentration,0.16722408026755853
auccsfaucpratio,0.16722408026755853
aud,0.16722408026755853
apparentinvivodissociationconstant,0.16722408026755853
endoftreatmentresponserate,0.16722408026755853
areaunderthechangeindiastolicbloodpressurecurve,0.16722408026755853
clast,0.16722408026755853
durationofadequateanalgesia,0.16722408026755853
progressionfreesurvivalperiod,0.16722408026755853
timetomaximumserumconcentrationtmax,0.16722408026755853
bestoverallresponse,0.16722408026755853
livertumoruptakeratio,0.16722408026755853
relativenasalbioavailability,0.16722408026755853
min,0.16722408026755853
totalclearancesclt,0.16722408026755853
payloadcapacity,0.16722408026755853
eliminationhalflifeofalfentanilt12beta,0.16722408026755853
continuousdrugconcentration,0.16722408026755853
t12ke0halftime,0.16722408026755853
subcutaneousabsolutebioavailability,0.16722408026755853
ta,0.16722408026755853
positiveatretentiontime,0.16722408026755853
solub,0.16722408026755853
lloqlod,0.16722408026755853
auctmax,0.16722408026755853
percentageunbound,0.16722408026755853
timetomaximumresponse,0.16722408026755853
plasmaapparenthalflife,0.16722408026755853
steadystateplasmaacetyl5aminosalicylicacidconcentration,0.16722408026755853
t12fast,0.16722408026755853
relativepercentageof,0.16722408026755853
rectalabsorption,0.16722408026755853
systemicrelativebioavailability,0.16722408026755853
bioavailibility,0.16722408026755853
plasmaticauc,0.16722408026755853
bloodplasmapartitioningbpratio,0.16722408026755853
areaunderconcentrationtimecurve0720min,0.16722408026755853
micx8,0.16722408026755853
micx4,0.16722408026755853
freefractionf,0.16722408026755853
peakconcentrationininflammatoryfluid,0.16722408026755853
t12slow,0.16722408026755853
peakdiazepamconcentrationcmax,0.16722408026755853
peakalfentanilconcentration,0.16722408026755853
fattissuelevel,0.16722408026755853
minimumvalue,0.16722408026755853
steadystatebraintoserumconcentrationratiokpbrain,0.16722408026755853
serumareaundercurveauc,0.16722408026755853
initialeffectsitetargetconcentration,0.16722408026755853
faecalwaterconcentration,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0to12hauc012h,0.16722408026755853
tumornecrosi,0.16722408026755853
areaundertheplasmaconcentrationtimecurvetoinfinity,0.16722408026755853
iri,0.16722408026755853
objectivetumorresponserate,0.16722408026755853
treatmentfailure,0.16722408026755853
peakconcentrationtime,0.16722408026755853
auc6,0.16722408026755853
keeliminationrateconstant,0.16722408026755853
zeroorderkineticfr,0.16722408026755853
highestmeasuredconcentrationcmax,0.16722408026755853
timetothehighestconcentrationtmax,0.16722408026755853
blooddialysateflowrate,0.16722408026755853
formationrateconstantkf,0.16722408026755853
maximumheartrateincreaseemax,0.16722408026755853
maximumheartrateec50,0.16722408026755853
tk0,0.16722408026755853
meanresidencetimemrtiv,0.16722408026755853
50recoverytime,0.16722408026755853
steadystatecmins,0.16722408026755853
braintoplasmaexposureratio,0.16722408026755853
maximumextentofinhibition,0.16722408026755853
apparentoralclearancecloratio,0.16722408026755853
steadystateauc012,0.16722408026755853
vascularcardiacefficacyquotient,0.16722408026755853
effectiveplasmaconcentrationsat50recoveryofthetwitchheight,0.16722408026755853
forceofdetachment,0.16722408026755853
apparentperipheralvolumeofdistributionvpf,0.16722408026755853
maximalin,0.16722408026755853
timetothemaximumconcentrationtmax,0.16722408026755853
limitsofdetectionslod,0.16722408026755853
vdfcentral,0.16722408026755853
redistributionrateconstant,0.16722408026755853
peakserumbrompheniramineconcentration,0.16722408026755853
terminalhalflivest11,0.16722408026755853
hepaticbloodextractionratio,0.16722408026755853
imcmin,0.16722408026755853
cndi,0.16722408026755853
cim,0.16722408026755853
doseadjustedconcentration,0.16722408026755853
oralabsolutebioavailabilitie,0.16722408026755853
areaunderthecurveuptothelastconcentrationauc0t,0.16722408026755853
toinfinityauc0oo,0.16722408026755853
maximumconcentrationcpmax,0.16722408026755853
apparentintercompartmentclearanceqf,0.16722408026755853
recoveryrateth2575,0.16722408026755853
particlesizesz,0.16722408026755853
intrinsicclearanceclintratio,0.16722408026755853
peakintoxication,0.16722408026755853
detectionwindow,0.16722408026755853
pre,0.16722408026755853
apparentt12lambdaz,0.16722408026755853
molarpercentageofdose,0.16722408026755853
urinaryterminaleliminationhalflive,0.16722408026755853
peakheartratechange,0.16722408026755853
apparentterminalvolumeofdistribution,0.16722408026755853
t12betaatsteadystate,0.16722408026755853
halfthekinactkiapp,0.16722408026755853
ratioofmilktoplasmaauc,0.16722408026755853
wholebloodtoplasmadistributionratio,0.16722408026755853
timetoreachmaximalinhibitiontmax,0.16722408026755853
equilibriumdissociationrateconstantkd,0.16722408026755853
clastt,0.16722408026755853
cmaxtmaximumconcentration,0.16722408026755853
oobr,0.16722408026755853
peakaragconcentration,0.16722408026755853
oralfluidplasmameth,0.16722408026755853
peakplasmaimatinibconcentration,0.16722408026755853
csfplasmaareaundertheplasmaconcentrationversustimecurveratio,0.16722408026755853
steadystateim,0.16722408026755853
distributionhalflifet12,0.16722408026755853
clearanceofultrafiltration,0.16722408026755853
volumeofdistributionof,0.16722408026755853
percentageentrapmentefficiency,0.16722408026755853
firstordereliminationconstant,0.16722408026755853
areaundertheconcentrationtimecurveauc024h,0.16722408026755853
zeta,0.16722408026755853
minimumtherapeuticimconcentration,0.16722408026755853
plasmathresholdlevel,0.16722408026755853
dosenormalizedareasundertheplasmaconcentrationtimecurvefromtime0toinfinityauc0infinity,0.16722408026755853
biologicalhalflifeofthealphaphasetalpha12,0.16722408026755853
faecaltourinaryexcretionratio,0.16722408026755853
intestinalpermeability,0.16722408026755853
audrc,0.16722408026755853
auc7276,0.16722408026755853
ratioaucperitoneum,0.16722408026755853
clearanceratecls,0.16722408026755853
peakex,0.16722408026755853
peakplasmafolateconcentration,0.16722408026755853
fbal,0.16722408026755853
areasunderthecurvefromthetimeofdosingtothelastmeasurableconcentrationauc0t,0.16722408026755853
timetoadministration,0.16722408026755853
drugtargetindexdti,0.16722408026755853
fe04ss,0.16722408026755853
liverclearance,0.16722408026755853
normalizedclearance,0.16722408026755853
apparenterlotinibclearance,0.16722408026755853
uh2uratio,0.16722408026755853
plasmaultrafiltratecmax,0.16722408026755853
timetomaximumlevel,0.16722408026755853
areaundertheinterstitialfluidconcentrationtimecurve,0.16722408026755853
apparentvolumeofdistributioninsteadystatevdiss,0.16722408026755853
halftimes,0.16722408026755853
targetedbloodflow,0.16722408026755853
distributionspace,0.16722408026755853
totalactivefolateconcentration,0.16722408026755853
apparentvolumesofdistributionvf,0.16722408026755853
areasundertheplasmaconcentrationcurvesauc,0.16722408026755853
apparentdistributionhalflifet12alpha,0.16722408026755853
fractionofdoseabsorbedfa,0.16722408026755853
troughfe,0.16722408026755853
areaundertheconcentrationversustimecurveauc06h,0.16722408026755853
parkplasmaconcentrationcmax,0.16722408026755853
apparentterminalphasevolumeofdistribution,0.16722408026755853
timeofprogression,0.16722408026755853
protectivetime,0.16722408026755853
eliminationclearanceoftheperipheralcompartmentcl2,0.16722408026755853
disappearancehalflive,0.16722408026755853
eliminationt12alpha,0.16722408026755853
steadystateaucmtx,0.16722408026755853
areaunderthecurve03h,0.16722408026755853
molecularweightmw,0.16722408026755853
timetoobtain,0.16722408026755853
braintumortoplasmasteadystatetmzconcentrationssctcpratio,0.16722408026755853
maximumpeaklevel,0.16722408026755853
apparentifngammaclearance,0.16722408026755853
basalzeroorderproductionrateofglucosekgprod,0.16722408026755853
90effectiveconcentration,0.16722408026755853
areaundertheplasmaconcentrationtimecurveaucho,0.16722408026755853
peakmeanx,0.16722408026755853
percentcumulativedrugrelease,0.16722408026755853
equilibriumplasmatobloodcellspartitionratio,0.16722408026755853
unabsorbedfraction,0.16722408026755853
maximumrelativebioavailability,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromzeroto48hauc048,0.16722408026755853
uppertherapeuticplasmaconcentration,0.16722408026755853
areaundertheconcentrationtimecurvefromt0tothelasttime,0.16722408026755853
alphahalflifet12alpha,0.16722408026755853
drop,0.16722408026755853
cytochromep450content,0.16722408026755853
accumulativebileexcretion,0.16722408026755853
steadystatetroughplasmaconcentrationcpss,0.16722408026755853
cpss,0.16722408026755853
minimumeffectiveserumconcentration,0.16722408026755853
eliminationt12ehalflive,0.16722408026755853
clearanceclsf,0.16722408026755853
ratiooftheauc010h,0.16722408026755853
maximalplasmahippurate,0.16722408026755853
extrahepaticclearance,0.16722408026755853
biochemicalhalflife,0.16722408026755853
drugloadingcapacitydl,0.16722408026755853
cirttp,0.16722408026755853
areaundertheconcentrationxtimecurveauc,0.16722408026755853
timeofconcentrationpeak,0.16722408026755853
kfc,0.16722408026755853
effectivebloodhalflife,0.16722408026755853
ureasynthesisrate,0.16722408026755853
braintissueletrozole,0.16722408026755853
areaunderthecurvefrom024hour,0.16722408026755853
relativeclearancerate,0.16722408026755853
absorptiont12partialdifferential,0.16722408026755853
areaunderthecurveauc010h,0.16722408026755853
relativelungbioavailability,0.16722408026755853
plasmaperitonealfluidconcentrationratio,0.16722408026755853
initialslopededc,0.16722408026755853
tumorconcentration,0.16722408026755853
peakplasmalignocaineconcentration,0.16722408026755853
peakmethotrexateconcentration,0.16722408026755853
timetomtxclearance,0.16722408026755853
plasmadialysisclearanceclp,0.16722408026755853
peakfuraconcentration,0.16722408026755853
totalexposureaucinfinity,0.16722408026755853
tissueconcentrationplasmaconcentrationratio,0.16722408026755853
halflifeofplasmaelimination,0.16722408026755853
areaunderfev1,0.16722408026755853
cellviability,0.16722408026755853
lastmeasurabletime,0.16722408026755853
greatestconcentration,0.16722408026755853
percentageofdoseabsorbed,0.16722408026755853
uctotalplatinumratio,0.16722408026755853
totalplatinumhalflife,0.16722408026755853
unboundcsffraction,0.16722408026755853
areasunderthecurveatinfinity,0.16722408026755853
correctedrenalclearance,0.16722408026755853
areasundertheplasmaconcentrationtimecurveupto2h,0.16722408026755853
distributionvolumeatsteadystatev,0.16722408026755853
maximumnimodipineplasmaconcentrationscmax,0.16722408026755853
grade34toxicity,0.16722408026755853
steadystatecerebralarterialconcentration,0.16722408026755853
steadystatemtxconcentration,0.16722408026755853
cumulativedrugrelease,0.16722408026755853
totalduration,0.16722408026755853
steadystatemtxplasmaconcentration,0.16722408026755853
kc,0.16722408026755853
timeofdistributiont12alpha,0.16722408026755853
v1v1m,0.16722408026755853
tbaf,0.16722408026755853
peaklevelscmax,0.16722408026755853
halfsaturatingplasmaconcentration,0.16722408026755853
maximumrateofelimination,0.16722408026755853
steadystatecmaxcssmax,0.16722408026755853
plasmahalftimeofelimination,0.16722408026755853
halflifeoftheterminalpartofthe,0.16722408026755853
halflifeoftherapidphase,0.16722408026755853
areaunderthemomentcurveaumc,0.16722408026755853
90,0.16722408026755853
eliminationhalflifet12ss,0.16722408026755853
curve,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0tothelasttimepoint,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0to1hour,0.16722408026755853
aucareaunderthecurveratio,0.16722408026755853
timetoreachimaxtmax,0.16722408026755853
maximuminhibitionimax,0.16722408026755853
lowestplasmaconcentrationsatsteadystate,0.16722408026755853
normalizedcl,0.16722408026755853
plasmatichalflifet12,0.16722408026755853
durationofsurvival,0.16722408026755853
disposition,0.16722408026755853
peakabsorptionrate,0.16722408026755853
peritonealfluid,0.16722408026755853
executiontime,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to6hauc06,0.16722408026755853
serumultrafiltrateconcentration,0.16722408026755853
plasmaamt,0.16722408026755853
material,0.16722408026755853
singletonoiseratio,0.16722408026755853
clearanceclhd,0.16722408026755853
steadystatetotalplasmareducedfolateconcentration,0.16722408026755853
extractionratioer,0.16722408026755853
fc,0.16722408026755853
ratiosoffolinicacidtomtx,0.16722408026755853
systemicmtxclearance,0.16722408026755853
cerebrospinalfluidplasmaratio,0.16722408026755853
minimalplasmalevel,0.16722408026755853
freetotaldipyridamoleratio,0.16722408026755853
cerebrospinalfluidtoplasmaratio,0.16722408026755853
plasmatroughatevirdineconcentration,0.16722408026755853
cmaxtocminratio,0.16722408026755853
areaundertheconcentrationtimecurveat0to8hoursauc08,0.16722408026755853
areaundertheconcentrationtimecurvesfrom024hour,0.16722408026755853
percentcminchange,0.16722408026755853
detectableantifxaconcentration,0.16722408026755853
zeroorderinput,0.16722408026755853
terminalplasmaeliminationhalflifet12,0.16722408026755853
aucsub0tlastsub,0.16722408026755853
peakplasmaantifxaactivitycmax,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0to12h,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0to2hoursauc02h,0.16722408026755853
overallinfectionrate,0.16722408026755853
acuteseriousbacterialinfectionrate,0.16722408026755853
aucid,0.16722408026755853
steadystateaucaucss,0.16722408026755853
braintoplasmaratiokp,0.16722408026755853
fastingcpeptide,0.16722408026755853
peakmousebloodlevel,0.16722408026755853
slowabsorptionhalflife,0.16722408026755853
maximumobserved,0.16722408026755853
steadystatefluxe,0.16722408026755853
timetopeakoflisproabsorptiontmax,0.16722408026755853
milkplasmadistributionratio,0.16722408026755853
tw,0.16722408026755853
visibledetection,0.16722408026755853
sqc,0.16722408026755853
surfaceunderthethrombingenerationcurve,0.16722408026755853
eliminationrateconstantlz,0.16722408026755853
areaunderplasmaconcentrationtimecurveauct,0.16722408026755853
meltingpoint,0.16722408026755853
totalareaundertheplasmaconcentrationtimecurvefromtimezerotothelastmeasuredtime48h,0.16722408026755853
totalareaunderthecurveauc0t,0.16722408026755853
auc0144h,0.16722408026755853
areaundertheplasmarosiglitazoneconcentrationtimecurvefromtime0toinfinityauc0infinity,0.16722408026755853
cmaxaucfromtime0tothelastavailablemeasurementauclast,0.16722408026755853
quantitativelimit,0.16722408026755853
unboundoralclearance,0.16722408026755853
aucfrom0toinfinityauc0infinity,0.16722408026755853
digitalcompressiontime,0.16722408026755853
apparentlivervolume,0.16722408026755853
plasmaeliminationhalflifetime,0.16722408026755853
maximumgranisetronplasmaconcentration,0.16722408026755853
troughconcentrationcmin,0.16722408026755853
steadystatemaximum,0.16722408026755853
k50,0.16722408026755853
distributionvolumeatsteadystatevss,0.16722408026755853
peakplasmaglucagonlevel,0.16722408026755853
descent,0.16722408026755853
peakplasmafreeinsulinlevel,0.16722408026755853
timetomaximalinsulinconcentration,0.16722408026755853
timetomaximalmetaboliceffect,0.16722408026755853
absorptionfromdosingto30minutesauc30,0.16722408026755853
overallmetaboliceffect,0.16722408026755853
maximaldeltadeltaqtcf,0.16722408026755853
fasteliminationphaset12beta,0.16722408026755853
activatedpartialthromboplastintimeratio,0.16722408026755853
k30,0.16722408026755853
initialphaset12alpha,0.16722408026755853
k45,0.16722408026755853
k35,0.16722408026755853
clearancecltyp,0.16722408026755853
volumecorrectedbyrealbodyweightvsskg1,0.16722408026755853
terminalslowphaset12gamma,0.16722408026755853
vsskg1,0.16722408026755853
venousvolume,0.16722408026755853
secondbetahalflife,0.16722408026755853
timetomaximumantixaactivity,0.16722408026755853
peakafxalevel,0.16722408026755853
areaundertheconcentrationtimecurvefromtime0to24hmeasurableconcentrationauc024h,0.16722408026755853
initialalphahalflife,0.16722408026755853
troughafxa,0.16722408026755853
fractionofdrugexcretedunchangedfu,0.16722408026755853
firstorderrateconstantofabsorption,0.16722408026755853
intrinsicclearanceclin,0.16722408026755853
maximalantixaactivity,0.16722408026755853
peakantifactorxa,0.16722408026755853
peripheralresistance,0.16722408026755853
dti,0.16722408026755853
standardizedmaximumconcentrationcmaxd,0.16722408026755853
plasmaconcentrationsduringsteadystatecondition,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0tothelastmeasurementauc0t,0.16722408026755853
drugloadinginto,0.16722408026755853
kddistributionrateconstant,0.16722408026755853
urinaryosmolality,0.16722408026755853
ffractionabsorbed,0.16722408026755853
activityresponseatpeaklevel,0.16722408026755853
maximalplasmaantixaactivitie,0.16722408026755853
biologicalhalflifeintheterminalphaset12beta,0.16722408026755853
areasauc,0.16722408026755853
terminalhalflifeofeliminationt12,0.16722408026755853
urineosmolality,0.16722408026755853
halflifeofeliminationt12,0.16722408026755853
timesuntilpeakinsulinconcentration,0.16722408026755853
totalsc,0.16722408026755853
tmaxtimetomaximumplasmaconcentration,0.16722408026755853
maximumglucoseinfusionrate,0.16722408026755853
timesformaximalmetaboliceffect,0.16722408026755853
peaknighttimeacylatedghrelinconcentration,0.16722408026755853
peaknighttimeproductionrate,0.16722408026755853
glucoseinfusionrategir,0.16722408026755853
ionmassspectrum,0.16722408026755853
cmaxc0,0.16722408026755853
painintensityscore,0.16722408026755853
cumulativeareaundertheplasmaconcentrationtimecurve,0.16722408026755853
urinaryclearancerate,0.16722408026755853
excretedwaterfraction,0.16722408026755853
amountexcretedinurine,0.16722408026755853
ratiourineosmolalityplasmaosmolality,0.16722408026755853
auc024hssmic,0.16722408026755853
mi,0.16722408026755853
troughplasmalevelctrough,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to24hoursauc024hauc024hss,0.16722408026755853
peakddqtcf,0.16722408026755853
maximumexposure,0.16722408026755853
cp0,0.16722408026755853
urineaccumulatedexcretoryrate,0.16722408026755853
maximummeanurineosmolalitie,0.16722408026755853
timetocmaxatsteadystate,0.16722408026755853
areaundertheplasmaconcentrationtimecurveoverthedosingintervalatsteadystate,0.16722408026755853
timesuntilgirmax,0.16722408026755853
metabolict12,0.16722408026755853
slowdisappearancehalflive,0.16722408026755853
steadystateantixaconcentrationcss,0.16722408026755853
canaliculareffluxclearanceclintbile,0.16722408026755853
auc1824h,0.16722408026755853
maximalserumghconcentration,0.16722408026755853
serumpeakghconcentration,0.16722408026755853
plasmahalflifetime,0.16722408026755853
peakghresponse,0.16722408026755853
hepaticuptakeclearancecluptake,0.16722408026755853
criticalcytotoxicconcentration,0.16722408026755853
totalglucoseinfused,0.16722408026755853
peakdacconcentration,0.16722408026755853
eliminationphasebeta,0.16722408026755853
peakantixalevel,0.16722408026755853
intrinsickm,0.16722408026755853
antixalevel,0.16722408026755853
halflifematching,0.16722408026755853
csfclearance,0.16722408026755853
insulinaction,0.16722408026755853
antixaactivitie,0.16722408026755853
plasmadistributionhalflife,0.16722408026755853
peakplasmaconcentrationcmax090min,0.16722408026755853
peakantixaactivitie,0.16722408026755853
halfofthemaximumdrugeffectisobservedec50,0.16722408026755853
plateauheightcplateau2112d,0.16722408026755853
antifactorxa,0.16722408026755853
areaunderthepercentinhibitiontimecurveover72hour,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0to72hour,0.16722408026755853
peakplasmainsulinlevel,0.16722408026755853
durationdeltaplateau,0.16722408026755853
integratedconcentrationtimecurveauc0112d,0.16722408026755853
maximumgir,0.16722408026755853
timetoglucosenadir,0.16722408026755853
concentrationcavg,0.16722408026755853
hv,0.16722408026755853
holmanindex,0.16722408026755853
areasundertheinsulincurve,0.16722408026755853
volumeofdistributionvtyp,0.16722408026755853
minimumantixalevel,0.16722408026755853
terminalplasmaeliminationhalflifebetaphase,0.16722408026755853
halflifeoftotalradioactivity,0.16722408026755853
maximalrateoftransport,0.16722408026755853
fractionabsorbedf1,0.16722408026755853
extentofaccumulationro,0.16722408026755853
observedmaximumconcentrationscmax,0.16722408026755853
boundconcentration,0.16722408026755853
vdatsteadystatevss,0.16722408026755853
areaunderthecurveaucss0t,0.16722408026755853
plasmahalflifebetaphase,0.16722408026755853
xu024h,0.16722408026755853
intermediatephasehalflife,0.16722408026755853
peakbreathalcoholconcentrationbrac,0.16722408026755853
clearanceclpred,0.16722408026755853
peakcocainelevel,0.16722408026755853
freemaximumplasmalevobupivacaine,0.16722408026755853
areaunderthecurveaucpred,0.16722408026755853
peakplasmacocainelevel,0.16722408026755853
transportconstant,0.16722408026755853
maximalencapsulation,0.16722408026755853
freefractionatthetimeofpeakplasmaconcentration,0.16722408026755853
salivaplasmamhdratio,0.16722408026755853
differentialtransportrate,0.16722408026755853
timetoclearance,0.16722408026755853
timetoserummethotrexatelevel,0.16722408026755853
apparentrateofformation,0.16722408026755853
corpuscularvolume,0.16722408026755853
fataldose,0.16722408026755853
steadystateritonavirconcentration,0.16722408026755853
totallevelsoftststot,0.16722408026755853
areaundertheconcentrationversustimecurveauc04hour,0.16722408026755853
plasmamtx,0.16722408026755853
plasmaareaundercurve,0.16722408026755853
serumt1druglevel,0.16722408026755853
fracti,0.16722408026755853
totalbodyclearanc,0.16722408026755853
absorptionhalflifet12a1,0.16722408026755853
maximumtt,0.16722408026755853
timerequiredtoreachthemaximalconcentration,0.16722408026755853
auc08hratio,0.16722408026755853
fractionboundtoplasmaprotein,0.16722408026755853
permeationcoefficientpapp,0.16722408026755853
hight,0.16722408026755853
cumulativeexcretedradioactivity,0.16722408026755853
bloodtoplasmaradioactivityaucinfratio,0.16722408026755853
halflifeofdrugremoval,0.16722408026755853
maximumserumhydroxyzineconcentration,0.16722408026755853
areaunderthecurvetothelastmeasurableconcentrationauc036,0.16722408026755853
initialtroughconcentration,0.16722408026755853
totalmphexcreted,0.16722408026755853
concentrationsatsteadystatecss,0.16722408026755853
ipc,0.16722408026755853
emaxmaximumeffectoninputrate,0.16722408026755853
kininputrate,0.16722408026755853
v3volumeofperipheralcompartment,0.16722408026755853
v2volumeofcentralcompartment,0.16722408026755853
troughimatinibconcentration,0.16722408026755853
areaundertheconcentrationtimecurveaucfromdosingtoinfinity,0.16722408026755853
cauc,0.16722408026755853
peakserumhydroxyzineconcentration,0.16722408026755853
timetomaximalplasmaclopidogrelconcentrationtmax,0.16722408026755853
maximumtoleratedauc,0.16722408026755853
efficiency,0.16722408026755853
auc06areaundertheplasmaconcentrationsvstimecurve,0.16722408026755853
ratiooftheareaunderthecurve,0.16722408026755853
apparenteliminationrate,0.16722408026755853
areaundertheplasmatransretinoicacidconcentrationvstimecurve,0.16722408026755853
seauc,0.16722408026755853
totalcourseauc,0.16722408026755853
cumulativeareaunderthecurvecauc,0.16722408026755853
c05h,0.16722408026755853
transformationefficiency,0.16722408026755853
timetolastmeasurableradioactivity,0.16722408026755853
totallevobupivacaineconcentration,0.16722408026755853
maximaldrugconcentration,0.16722408026755853
heartrateincrease,0.16722408026755853
timetoanabsoluteneutrophilcount,0.16722408026755853
timetoaplateletcount,0.16722408026755853
absolutesubcutaneousbioavailability,0.16722408026755853
maximummeasurableconcentration,0.16722408026755853
timetosensoryblock,0.16722408026755853
timetolisproplasmapeaktmax,0.16722408026755853
cumulativerecoveryofradioactivity,0.16722408026755853
unboundvenouslevobupivacaine,0.16722408026755853
steadystatetransdermalabsorptionrate,0.16722408026755853
timetogirmax,0.16722408026755853
secondphasehalfdisappearancetime,0.16722408026755853
totalvenouslevobupivacaineplasmaconcentration,0.16722408026755853
maximumserumconcentrationtotroughconcentrationratio,0.16722408026755853
auc24ssratio,0.16722408026755853
absorptionhalflifetabsfree,0.16722408026755853
volumeofdistributionvfree,0.16722408026755853
auc480,0.16722408026755853
transfercoefficient,0.16722408026755853
relativedrugrecovery,0.16722408026755853
initialeliminationhalflife,0.16722408026755853
timeofreturntobaseline,0.16722408026755853
insulintmax,0.16722408026755853
areaunderthefentanylplasmaconcentrationtimecurvefrom0to18h,0.16722408026755853
latet50,0.16722408026755853
halflifeofbiophasedistribution,0.16722408026755853
peaktotrough,0.16722408026755853
rateconstantsofreceptorassociationkon,0.16722408026755853
steadystatevdss,0.16722408026755853
timetoearlyhalfmaximalactivity,0.16722408026755853
aucglucoseinfusionrategir0120min,0.16722408026755853
maximumplasmafentanylconcentration,0.16722408026755853
aucgir0120min,0.16722408026755853
totalbodybloodclearance,0.16722408026755853
durationofthe,0.16722408026755853
percentageofplasmaextraction,0.16722408026755853
earlyhalfmaximal,0.16722408026755853
timetolatehalfmaximal,0.16722408026755853
glucoseutilization,0.16722408026755853
timetomaximumconcentrationstmax,0.16722408026755853
timetoreachthepeakplasmalevel,0.16722408026755853
distributionvolumevbeta,0.16722408026755853
areaundertheplasmafpconcentrationtimecurveauctoinfinitetimeaucinfinity,0.16722408026755853
venouscapillaryplasmaconcentrationratio,0.16722408026755853
volumeofdistributionvt,0.16722408026755853
zaverageparticlesize,0.16722408026755853
timeofnadir,0.16722408026755853
areaunderthefreemtxconcentrationvstimecurve,0.16722408026755853
tserum,0.16722408026755853
areaunderthetotalmtxconcentrationvstimecurve,0.16722408026755853
auc300mininfinity,0.16722408026755853
serumenrichment,0.16722408026755853
timetomethotrexateclearance,0.16722408026755853
peakventricularconcentration,0.16722408026755853
auc0168h0336h,0.16722408026755853
fluidplasmaconcentrationratio,0.16722408026755853
timetoappearanceofantidrugantibodie,0.16722408026755853
peakmediantriamcinoloneconcentration,0.16722408026755853
areaundertheserumconcentrationtimecurveaccumulationratio,0.16722408026755853
maximumplasmafpconcentration,0.16722408026755853
clearanceclfree,0.16722408026755853
eliminationcoefficientke,0.16722408026755853
t12out,0.16722408026755853
maximumplasmafpconcentrationcmax,0.16722408026755853
steadystatelevelscss,0.16722408026755853
aucupto12hoursauc12h,0.16722408026755853
steadystatetosingledoseaccumulationratio,0.16722408026755853
seriousadverseeventfrequencie,0.16722408026755853
fractionalrateconversion,0.16722408026755853
timefromfirstoccurrenceofaresponsetofirstoccurrenceofanonresponse,0.16722408026755853
unboundhydro,0.16722408026755853
steadystateserumadalimumabtroughconcentration,0.16722408026755853
timetoreachaclinical,0.16722408026755853
peritonealclearancerate,0.16722408026755853
timetoreach200nmoll,0.16722408026755853
peakexpiratoryflowpef,0.16722408026755853
steadystateemtx,0.16722408026755853
dosenormalizedareaundertheserumconcentrationtimecurve,0.16722408026755853
totalrelease,0.16722408026755853
apparentoralsystemicclearance,0.16722408026755853
oralfluiddetectiontime,0.16722408026755853
halflifeofnicotineelimination,0.16722408026755853
detectionlimitsn,0.16722408026755853
limitofqualificationloq,0.16722408026755853
fmao,0.16722408026755853
proberecovery,0.16722408026755853
mzq1q3,0.16722408026755853
tmaxmodel,0.16722408026755853
peripheralcompartmentvolumeofdistribution,0.16722408026755853
cmaxb,0.16722408026755853
rateofuptake,0.16722408026755853
maximalmithramycinplasmaconcentration,0.16722408026755853
maximumhydro,0.16722408026755853
maximumdexamethasoneconcentration,0.16722408026755853
50crossreactivity,0.16722408026755853
t12k10,0.16722408026755853
bloodtroughconcentration,0.16722408026755853
micatwhich80ofisolatesareinhibitedmic80,0.16722408026755853
alag,0.16722408026755853
ratioofintercompartmentalrateconstantsk12k21,0.16722408026755853
infractsize,0.16722408026755853
areaundertheconcentrationtimecurvefrom06hour,0.16722408026755853
peakchemiluminescenceresponse,0.16722408026755853
infarctsize,0.16722408026755853
doseweighttoreachthetargettroughconcentrationc0,0.16722408026755853
minimumsteadystateconcentration,0.16722408026755853
eliminationhalflifeoftiv12,0.16722408026755853
rateconstantoflambdaiv1,0.16722408026755853
clearanceofpinacidilclp,0.16722408026755853
apparentsteadystateoralavailabilitie,0.16722408026755853
bioavailabilityauc0t,0.16722408026755853
biliaryexcretionratiofb,0.16722408026755853
inhibitoryconstantki,0.16722408026755853
cer20min,0.16722408026755853
aucb,0.16722408026755853
apparentterminalplasmahalflive,0.16722408026755853
plasmaunboundconcentrationofc10c10f,0.16722408026755853
limitofdetectability,0.16722408026755853
drugdeliveryindex,0.16722408026755853
apparentpartialclearance,0.16722408026755853
iki,0.16722408026755853
brainhalflive,0.16722408026755853
idg,0.16722408026755853
plasmaconcentrationsc10,0.16722408026755853
biologichalflifet12,0.16722408026755853
unboundquinidineconcentration,0.16722408026755853
freefattyacidconcentration,0.16722408026755853
effectiverefractoryperiod,0.16722408026755853
rateconstantforthetransferbetweenplasmaandeffectcompartmentke0,0.16722408026755853
inhibitoryeffect,0.16722408026755853
areaunderthetimeversusdeltaqtccurve,0.16722408026755853
braintoserumratio,0.16722408026755853
aucall,0.16722408026755853
maximumplasmastconcentration,0.16722408026755853
areasundertheplasmastconcentrationversustimecurvesauc,0.16722408026755853
areaunderplasmaconcentrationtimecurvefromtimezerototimeinfinityauc,0.16722408026755853
minimumbactericidalconcentrationmbc,0.16722408026755853
serumpeakconcentrationscmax,0.16722408026755853
percentbound,0.16722408026755853
halflifetimeoftheterminalphase,0.16722408026755853
totalencapsulationefficiency,0.16722408026755853
availabilitie,0.16722408026755853
totalareaundertheplasmatriazolamconcentrationtimecurve,0.16722408026755853
plasmaturnover,0.16722408026755853
mo,0.16722408026755853
timeofwithdrawal,0.16722408026755853
clfim,0.16722408026755853
oralabsorptionconstant,0.16722408026755853
transdermalbioavailability,0.16722408026755853
tb,0.16722408026755853
kineticassociationrateconstantkon,0.16722408026755853
totalamountofdrugrecovered,0.16722408026755853
timeneeded,0.16722408026755853
intraoculartissueavailability,0.16722408026755853
tmaxratio,0.16722408026755853
faecalelimination,0.16722408026755853
areaunderthepropranololconcentrationtimecurvefrom0to24hours,0.16722408026755853
timetoreachmaximumpropranololconcentration,0.16722408026755853
oralintravenousavailabilityratio,0.16722408026755853
steadystatevolumeofpentobarbitaldistribution,0.16722408026755853
biologicalhalflifet12b,0.16722408026755853
totalbodyclearancecltf,0.16722408026755853
clrf,0.16722408026755853
volumeofdistributionve,0.16722408026755853
unbound3h,0.16722408026755853
cumulativefractionexcretedunchanged,0.16722408026755853
ivhalflife,0.16722408026755853
fl,0.16722408026755853
eliminationhalflifet12yz,0.16722408026755853
dmean,0.16722408026755853
aucmaucp,0.16722408026755853
milkcmax,0.16722408026755853
aucratioaucmaucp,0.16722408026755853
troughsteadystateconcentration,0.16722408026755853
plasmaspconcentration,0.16722408026755853
eliminationhalflifet12lambdaz,0.16722408026755853
volumeofdistributionperabsorption,0.16722408026755853
halflifeofplasmadisappearance,0.16722408026755853
systemicclearanceperabsorption,0.16722408026755853
areaunderthepropranololconcentrationtimecurve,0.16722408026755853
maximumplasmadetomidineconcentration,0.16722408026755853
areasunderthepropranololconcentrationtimecurve,0.16722408026755853
progressfreesurvival,0.16722408026755853
peaknimodipineplasmaconcentration,0.16722408026755853
phasesystemicplasmaclearance,0.16722408026755853
initialclearancefrombloodtotissuek1,0.16722408026755853
effectcompartmentconcentrationat50ofmaximalobservedeffectec50,0.16722408026755853
inratio,0.16722408026755853
kineticdissociationrateconstantkoff,0.16722408026755853
cumulativepercentagerelease,0.16722408026755853
least,0.16722408026755853
activatedpartialthromboplastintimeaptt,0.16722408026755853
radiochemicalpurity,0.16722408026755853
terminaleliminationhalflivest12beta,0.16722408026755853
axa,0.16722408026755853
prothrombintimept,0.16722408026755853
centralcompartmentvolumeofdistributionvc,0.16722408026755853
steadystatecnsfreeplasmaratio,0.16722408026755853
steadystatecnstotalplasmaconcentrationratio,0.16722408026755853
ctroughratio,0.16722408026755853
peakplasmaconcentrationcpmax,0.16722408026755853
steadystatecerebrospinalfluidconcentration,0.16722408026755853
peakpcthreshold,0.16722408026755853
timetodeath,0.16722408026755853
totalserumbileacidconcentration,0.16722408026755853
liverplasmaflow,0.16722408026755853
steadystateclearanceclss,0.16722408026755853
maximalrateofmetabolismvm,0.16722408026755853
intraportalintrinsicclearance,0.16722408026755853
apparentmeanresidencetime,0.16722408026755853
unboundfractionsfu,0.16722408026755853
apparentsteadystateconcentration,0.16722408026755853
peaktaconcentration,0.16722408026755853
maximumta,0.16722408026755853
totalclearanceofracemicmirtazapineclf,0.16722408026755853
doseweightadjustedauc0infinity,0.16722408026755853
peakpc,0.16722408026755853
areaunderthetimeplasmaquinidineconcentrationcurve,0.16722408026755853
aucvstime,0.16722408026755853
redcellplasmapartitionratio,0.16722408026755853
vascularabsorptiont12abs,0.16722408026755853
percentreductionratio,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezeroto48hauc48,0.16722408026755853
aucfromtimezeroextrapolatedtoinfinityauc,0.16722408026755853
steadystatecmaxcmaxss,0.16722408026755853
steadystateaucattimetaucsst,0.16722408026755853
steadystateplasmadrugconcentrationduringmultipledoseadministrationcavss,0.16722408026755853
maximummeanconcentrationcpmax,0.16722408026755853
levelatsteadystate,0.16722408026755853
burstrelease,0.16722408026755853
minimumdosage,0.16722408026755853
maximumsafedosage,0.16722408026755853
brainblooduptakeratio,0.16722408026755853
pco2gradient,0.16722408026755853
tgel,0.16722408026755853
halfmaximaleffectpec50,0.16722408026755853
degradationt12,0.16722408026755853
bloodvolumeslost,0.16722408026755853
maximumallowedtime,0.16722408026755853
apparentaffinityka,0.16722408026755853
ic100,0.16722408026755853
timeofobservedmaximumdrugconcentration,0.16722408026755853
totalclearancecltotal,0.16722408026755853
areasundertheplasmaconcentrationtimecurvesduringthedosingintervalauct,0.16722408026755853
aucinfinity5hmt,0.16722408026755853
apparentvolumeofdistributiondividedbybioavailabilityvdf,0.16722408026755853
troughconcentrationsctrough,0.16722408026755853
clearancedividedbybioavailabilityclf,0.16722408026755853
timeofingestion,0.16722408026755853
maximumtissuepressure,0.16722408026755853
areaunderthecurvefromtimezerotolastdatapoint,0.16722408026755853
kcat,0.16722408026755853
peakplasmavenousconcentration,0.16722408026755853
peakwholebloodarterialbupivacaine,0.16722408026755853
qtintervalqtc,0.16722408026755853
totalamountofunchanged,0.16722408026755853
pulmonaryspillover,0.16722408026755853
pulmonaryfractionalextraction,0.16722408026755853
spilloverrateintoplasma,0.16722408026755853
areasundertheserumconcentrationtimecurvesfrom024hoursauc024,0.16722408026755853
ne2,0.16722408026755853
nereleaseintotheextravascularcompartmentne2,0.16722408026755853
productionrateofdhpgkin,0.16722408026755853
arterialbloodflow,0.16722408026755853
peakplasmabupivacaineconcentration,0.16722408026755853
timetofirstmorphinedose,0.16722408026755853
aucss0t,0.16722408026755853
timetoreachmaximumplasmacodeineconcentrations,0.16722408026755853
cssmm,0.16722408026755853
methodologicrecovery,0.16722408026755853
totalamountofunchangeddrugexcreted,0.16722408026755853
totalplasmaepinephrine,0.16722408026755853
pulmonaryarterialsystemicarterialextractionratio,0.16722408026755853
apparentnicotineclearance,0.16722408026755853
mortalityrate,0.16722408026755853
cumulativesurvival,0.16722408026755853
dosecorrectedamlevel,0.16722408026755853
areaunderthecurvefromday0to2auc02day,0.16722408026755853
maximumblood,0.16722408026755853
peakexogenousepinephrineconcentration,0.16722408026755853
apparentserumeliminationhalflife,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc0,0.16722408026755853
totalcaduration,0.16722408026755853
auc0to12hour,0.16722408026755853
peakplasmalidocainelevel,0.16722408026755853
peakarterialplasmaconcentration,0.16722408026755853
steadystateplasmabupivacaineconcentration,0.16722408026755853
coronaryperfusionpressure,0.16722408026755853
constantredcellbufferpartitionratio,0.16722408026755853
intrinsicclearanceofunbounddesipramine,0.16722408026755853
maximalbrainconcentrationscmax,0.16722408026755853
eliminationconstantratek,0.16722408026755853
prostatetoseminalvesiclesconcentrationratio,0.16722408026755853
halftimesofelimination,0.16722408026755853
cumulativeamountofdrugpermeated,0.16722408026755853
maximaldrugabsorption,0.16722408026755853
bioavailabilitylsmeansratio,0.16722408026755853
timetorosc,0.16722408026755853
flowratethroughthesystem,0.16722408026755853
absoluteoral,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezerotoinfinityratio,0.16722408026755853
clrcg,0.16722408026755853
intracerebral,0.16722408026755853
nasalresidencetime,0.16722408026755853
timetopeakimipramineconcentration,0.16722408026755853
timestocmax,0.16722408026755853
windowoccupancy,0.16722408026755853
haloperidolhaloperidolratio,0.16722408026755853
areaundercurvefrom0to24hauc024,0.16722408026755853
dosenormalizedauc024,0.16722408026755853
altalto,0.16722408026755853
totalareaundertheplasmaconcentrationtimecurvesauc,0.16722408026755853
areunderthecurve,0.16722408026755853
peakconcentrationsofnicotineinplasmacmax,0.16722408026755853
maximumhydrocortisonelevel,0.16722408026755853
exposureauc,0.16722408026755853
peakbac,0.16722408026755853
halflifefortotalelimination,0.16722408026755853
clrugfrratio,0.16722408026755853
dmr,0.16722408026755853
peakbrainconcentration,0.16722408026755853
totalactivecompound,0.16722408026755853
unboundtadalafil,0.16722408026755853
steadystateauct,0.16722408026755853
instillationabsorptionrate,0.16722408026755853
maximumtotalplasmaconcentration,0.16722408026755853
halflifeofreceptoroccupancy,0.16722408026755853
maximumarterial,0.16722408026755853
venousconcentration,0.16722408026755853
systemicvenousplasmaclearance,0.16722408026755853
bodyresidencetime,0.16722408026755853
stabilizedconcentration,0.16722408026755853
totalmaternalbodyclearance,0.16722408026755853
timetoreachpeaklidocaineconcentration,0.16722408026755853
timetakentoreachthemaximumconcentration,0.16722408026755853
peakofplasmaconcentration,0.16722408026755853
arterialplasmame,0.16722408026755853
peaklidocaineserumconcentration,0.16722408026755853
aucof,0.16722408026755853
spreadof,0.16722408026755853
auc0tauauc0infinityratio,0.16722408026755853
regressionof,0.16722408026755853
timetoplacement,0.16722408026755853
areaundertheatovaquoneplasmaconcentrationtimecurvecalculatedfrom0to24hafterthelastdoseauc024h,0.16722408026755853
areaunderserumdrugconcentrationauc02h,0.16722408026755853
totalbupivacaine,0.16722408026755853
peakplasmaneostxconcentration,0.16722408026755853
timetonearcompleterecovery,0.16722408026755853
aucareaunderplasmaconcentrationtimecurve,0.16722408026755853
mmad,0.16722408026755853
para,0.16722408026755853
partialintrinsicclearance,0.16722408026755853
overallurinaryrecovery,0.16722408026755853
maximumplasmachlorproguanilconcentration,0.16722408026755853
clmfm,0.16722408026755853
nadirneutrophilcount,0.16722408026755853
unboundcisplatinplasmaconcentration,0.16722408026755853
totaldrugexposuretime,0.16722408026755853
timetoreachcssmaxtmax,0.16722408026755853
halfmaximumprueffect,0.16722408026755853
maximumprueffect,0.16722408026755853
timetomaximumconcentrationcmaxtmax,0.16722408026755853
timestosufficientplateletinhibition,0.16722408026755853
areaundertheplasmaconcentrationcurvefromtimezerotoinfinityauc0,0.16722408026755853
reactivityindex,0.16722408026755853
arterialumbilicalcordtomaternalconcentrationratio,0.16722408026755853
lagtimeofrelease,0.16722408026755853
venousumbilicalcordtomaternalconcentrationratio,0.16722408026755853
arterialtovenousplasmaconcentrationratio,0.16722408026755853
contactangle,0.16722408026755853
areaunderthecurvevaluesauc,0.16722408026755853
floatingability,0.16722408026755853
percentdrugentrapment,0.16722408026755853
plasmavolume,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtimezeroto1hauc1,0.16722408026755853
timetmaxtoreachmaximumplasmaconcentrationcmax,0.16722408026755853
ratioofradioactivity,0.16722408026755853
unboundvolumeofdistributionatsteadystatevssu,0.16722408026755853
peakserumlithiumlevel,0.16722408026755853
peakdigoxinlevel,0.16722408026755853
secretion,0.16722408026755853
apparentturnoverrate,0.16722408026755853
percentageoftime,0.16722408026755853
areaundertheconcentrationtimecurveauctruncatedat2daysauc2,0.16722408026755853
aucfromtime0toinfinityauc0infinity,0.16722408026755853
areavolumeofdistribution,0.16722408026755853
gastricionconcentration,0.16722408026755853
coefficientofelimination,0.16722408026755853
maintenanceconcentration,0.16722408026755853
halflifeofgastricfoodremoval,0.16722408026755853
fractionmetabolism,0.16722408026755853
passiveuptakeclearance,0.16722408026755853
activehepaticuptake,0.16722408026755853
centralvolumeofdistributionv2,0.16722408026755853
areaundertheconcentrationtimecurvesfrom0htoinfinity,0.16722408026755853
totalsum,0.16722408026755853
maximumconcentrationscmaxs,0.16722408026755853
areasundertheconcentrationtimecurvefromtimezerotoinfinityauc0infinitys,0.16722408026755853
maximumconcentrationsofdrugcmax,0.16722408026755853
minimumfungicidalconcentration,0.16722408026755853
troughplasmaitraconazoleconcentration,0.16722408026755853
troughitraconazoleconcentration,0.16722408026755853
plasmasteadystatetroughconcentration,0.16722408026755853
cminitra,0.16722408026755853
ohitra,0.16722408026755853
areaundertheconcentrationtimecurvesaucfrom0hto24h,0.16722408026755853
therapeutictroughconcentration,0.16722408026755853
peakliverconcentration,0.16722408026755853
nailplasmaratio,0.16722408026755853
slowdispositionphaserateconstant,0.16722408026755853
timetoreacheffectiveconcentration,0.16722408026755853
peakconcentrationofdruginplasmacmax,0.16722408026755853
metabolicratiosauc,0.16722408026755853
permeationamount,0.16722408026755853
steadystatedrugplasmaconcentration,0.16722408026755853
maximalqtprolongation,0.16722408026755853
efficacyimax,0.16722408026755853
unboundbraintoplasmaaucratio,0.16722408026755853
boneagechronologicalageratio,0.16722408026755853
areaundertheplasmaconcentrationversustimecurveauclast,0.16722408026755853
normalizedaucssnorm,0.16722408026755853
minimumlevelofdetection,0.16722408026755853
deconjugationclearance,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromtime0toinfinityauc0infinity,0.16722408026755853
effluxrateconstantk2,0.16722408026755853
timetoachievethemaximumconcentrationtmax,0.16722408026755853
maximumlungtissueconcentration,0.16722408026755853
disappearancet12,0.16722408026755853
chlorideexcretion,0.16722408026755853
bothrenalclearance,0.16722408026755853
effectiverenalplasmaflow,0.16722408026755853
timestmax,0.16722408026755853
areasundertheplasmacurveauc024,0.16722408026755853
plasmahalflife12,0.16722408026755853
proteinboundfraction,0.16722408026755853
maximumachievedconcentrationcmax,0.16722408026755853
plasmalevelatsteadystate,0.16722408026755853
apparentclearanceclf1,0.16722408026755853
apparentvolumeofdistributionvzf1,0.16722408026755853
maximumtenoxicamconcentrationcmax,0.16722408026755853
plasmasalivaconcentrationratio,0.16722408026755853
areaundertheisoxicamplasmaconcentrationtimecurveaucinfinity,0.16722408026755853
concentrationsinducinghalfmaximaleffect,0.16722408026755853
percentdrugreleased,0.16722408026755853
halflifeforaccumulation,0.16722408026755853
timeforpeakplasmadruglevel,0.16722408026755853
aucwithinadosingintervalatsteadystate,0.16722408026755853
plasmaconcentrationat24hoursafterdosingcmin,0.16722408026755853
immunoactivity,0.16722408026755853
troughpeakdbpratio,0.16722408026755853
totaldrugrecovery,0.16722408026755853
absoluteurinaryexcretionofsodium,0.16722408026755853
halflifefortheterminalphase,0.16722408026755853
absorptionbioavailability,0.16722408026755853
apparentfirstorderregression,0.16722408026755853
meanresidencetimeofdrug,0.16722408026755853
deltaaucmin,0.16722408026755853
glucoseeliminationratek,0.16722408026755853
glucosedeltaauc,0.16722408026755853
highsensitivitytroponinconcentration,0.16722408026755853
timetoreach50ofarterialsteadystateconcentration,0.16722408026755853
washin,0.16722408026755853
sodiumclearance,0.16722408026755853
eliminationhalflifebeta,0.16722408026755853
areaundertheconcentrationtimecurveaucatsteadystate,0.16722408026755853
limitofdetermination,0.16722408026755853
secondorderenzymeinactivationconstant,0.16722408026755853
timeelapsedtopeakconcentrationtmax,0.16722408026755853
aucverapamilauc,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezerotoinfinityaucinfinity,0.16722408026755853
aucfrom0to12hauc012,0.16722408026755853
auc024s,0.16722408026755853
areaundertheplasmaconcentrationtimecurveaucfromtimezerototimeoflastmeasurableconcentration,0.16722408026755853
eliminationrateconstantfromthecentralcompartment,0.16722408026755853
minimumdeterminableconcentration,0.16722408026755853
eiso,0.16722408026755853
maximumtwitchdepression,0.16722408026755853
timetoachievethislevel,0.16722408026755853
tissuetoplasmadrugconcentrationgradient,0.16722408026755853
recoverytimestotwitchheight,0.16722408026755853
peakhalfclearance,0.16722408026755853
dpdt,0.16722408026755853
arterialpropofolconcentration,0.16722408026755853
arterialph,0.16722408026755853
peakplasmainorganicfluorideconcentration,0.16722408026755853
timefromcomplementarydoseto25recovery,0.16722408026755853
equilibriumrateconstanttotheeffectcompartmentkco,0.16722408026755853
areaundertheconcentrationversustimecurvefromzerotoinfinity,0.16722408026755853
50probabilityofmovement,0.16722408026755853
timetorecoveryof25neuromusculartransmissiont25,0.16722408026755853
endtidalconcentration,0.16722408026755853
timetoattain100twitchdepressiononsettime,0.16722408026755853
timetothereappearanceoftwitchresponse,0.16722408026755853
peakserumitraconazoleconcentration,0.16722408026755853
maximalratesofdruginducedkilling,0.16722408026755853
leukocyterecovery,0.16722408026755853
tumorbloodratio,0.16722408026755853
fractionofunboundetofu,0.16722408026755853
k2max,0.16722408026755853
timerequiredtoreachthemaximumplasmaetoposideconcentration,0.16722408026755853
maximumplasmaetoposidelevel,0.16722408026755853
peakgl331concentration,0.16722408026755853
freeauc,0.16722408026755853
systemicexposureof,0.16722408026755853
fractionalsodiumexcretion,0.16722408026755853
residualplasmalevel,0.16722408026755853
maximalplasmaurodilatinlevel,0.16722408026755853
apparentdistributionvolumeoftheperipheralcompartmentv3f,0.16722408026755853
otr,0.16722408026755853
halflifefororalabsorption,0.16722408026755853
apparentdistributionvolumeofthecentralcompartmentv2f,0.16722408026755853
effectivepermeabilitycoefficientpeff,0.16722408026755853
peakpleuralfluiddruglevel,0.16722408026755853
zatapotential,0.16722408026755853
meansize,0.16722408026755853
durationofcompleteresponsecr,0.16722408026755853
c24trough,0.16722408026755853
peakplasmaverapamilconcentration,0.16722408026755853
peritonealplasmapeakratio,0.16722408026755853
percentageoftumorgrowthsuppressionratetc,0.16722408026755853
eliminationt05elphase,0.16722408026755853
biologicalhalflivesoftheabsorption,0.16722408026755853
cbefore,0.16722408026755853
areaundertheconcentrationsversustimeauc0infinity,0.16722408026755853
cafter,0.16722408026755853
renalclearanceclrclclh,0.16722408026755853
sf,0.16722408026755853
peripheralcompartmentvolumevp,0.16722408026755853
peakplasmavp16concentration,0.16722408026755853
licmax,0.16722408026755853
aucat72hour,0.16722408026755853
tauc,0.16722408026755853
halflifeofdisappearance,0.16722408026755853
plasmatotalclearancecltot,0.16722408026755853
dwellingtime,0.16722408026755853
serumclearancehalflife,0.16722408026755853
persistentplasmalevel,0.16722408026755853
equilibriumaqueoussolubility,0.16722408026755853
diseasefreesurvivalrate,0.16722408026755853
tumorsuppressionratetsr,0.16722408026755853
timefromdiagnosistoinclusion,0.16722408026755853
plateletcountnadir,0.16722408026755853
areaundertheserumconcentrationversustimecurvetauc,0.16722408026755853
renaltobodyclearanceratio,0.16722408026755853
peaksplasmaconcentrationcmax,0.16722408026755853
gfr,0.16722408026755853
peakplasmaetoposideconcentration,0.16722408026755853
plasmagaconcentration,0.16722408026755853
totalareasundertheconcentrationtimecurve,0.16722408026755853
proximalabsolutereabsorptionoffluid,0.16722408026755853
eliminationtime,0.16722408026755853
areaunderthedrugplasmaconcentrationvstimecurveauc,0.16722408026755853
bioavailabilty,0.16722408026755853
distalabsolutereabsorptionofsodium,0.16722408026755853
areaundertheetoposideplasmaconcentrationtimecurveauc,0.16722408026755853
intrinsicclearanceoftotaldrugclint,0.16722408026755853
volumeofthemetabolitecompartment,0.16722408026755853
plasmaeliminationofhalflife,0.16722408026755853
shelflifet09,0.16722408026755853
areaunderthecurveofconcentrationversustimefromzerotothelasttimepoint,0.16722408026755853
areaunderthetotalplasmaplatinumconcentrationsversustimecurveaucpt0120,0.16722408026755853
aucpt0120,0.16722408026755853
dar,0.16722408026755853
minimalurinesodiumconcentration,0.16722408026755853
areaundertheconcentrationtimecurveover24hoursauc24,0.16722408026755853
intrinsicclearanceof,0.16722408026755853
plasmaticauc024h,0.16722408026755853
mrt024h,0.16722408026755853
maximummetabolicreactionvelocityvmax,0.16722408026755853
liverconcentration,0.16722408026755853
dosenormalizedrelativebioavailability,0.16722408026755853
clpc,0.16722408026755853
proteolyticdegradationclearance,0.16722408026755853
timetoabsoluteneutrophilcount,0.16722408026755853
areaundertheetoposideserumconcentrationtimecurveauc,0.16722408026755853
relativef,0.16722408026755853
freeaucpo,0.16722408026755853
plasmaconcentrationtime,0.16722408026755853
ratioofaccumulation,0.16722408026755853
cittotalclearance,0.16722408026755853
apparentclearanceclitraconazole,0.16722408026755853
apparentvolumeofdistributionvditraconazole,0.16722408026755853
clearanceclffm,0.16722408026755853
minimumtherapeutictroughplasmaconcentration,0.16722408026755853
maximalitraconazoleconcentration,0.16722408026755853
troughtargetconcentration,0.16722408026755853
aucsfor024h,0.16722408026755853
hepaticdrugextractionratio,0.16722408026755853
bloodctroughlevel,0.16722408026755853
areaunderplasmaconcentrationversustimecurveauc012h,0.16722408026755853
equilibriumplasmabloodcellsconcentrationratio,0.16722408026755853
tstoratio,0.16722408026755853
aucaumc,0.16722408026755853
percentagecumulativeexcretion,0.16722408026755853
residualcamphor,0.16722408026755853
aucfrom0to8h,0.16722408026755853
steadystatetroughplasmaitraconazoleconcentration,0.16722408026755853
areaundertheethanolconcentrationversustimecurve,0.16722408026755853
24hoururinevolume,0.16722408026755853
apparentterminalplasmat12,0.16722408026755853
peakplasmaaracconcentration,0.16722408026755853
maximumplasmaetoposideconcentration,0.16722408026755853
limitsofdetectionsn,0.16722408026755853
apparentpermeabilitypapp,0.16722408026755853
peakplasmalevelsppl,0.16722408026755853
ppl,0.16722408026755853
steadystatevp16concentration,0.16722408026755853
relativebioavailabilityfrb,0.16722408026755853
cpeekpeakplasmaconcentration,0.16722408026755853
urinaryexcretionuefractionofunchanged,0.16722408026755853
absolutebioavailabilityfab,0.16722408026755853
peritonealtoplasmaratioofunbound,0.16722408026755853
peritonealhalflive,0.16722408026755853
peritonealplasmaareaundercurveaucratio,0.16722408026755853
vvm,0.16722408026755853
infusionrateko,0.16722408026755853
atsteadystatecss,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0to12hauc012h,0.16722408026755853
cellulartoextracellularconcentrationratio,0.16722408026755853
totalsystemicclearancecl,0.16722408026755853
intrinsicbiliaryclearance,0.16722408026755853
plasmatobloodcellconcentrationratio,0.16722408026755853
ecp,0.16722408026755853
bloodtoplasma,0.16722408026755853
leaching,0.16722408026755853
overallduration,0.16722408026755853
medianconcentration,0.16722408026755853
areaundertheconcentrationversustimecurveofetoposideoverthetreatmentperiodtotalauc,0.16722408026755853
areaundertheplasmaconcentrationtimecurveauc24h,0.16722408026755853
aucinfareaundertheconcentrationvstimecurvefromzerotoinfinity,0.16722408026755853
timetotreatmentresponse,0.16722408026755853
spillover,0.16722408026755853
metaboliteratio,0.16722408026755853
adsorptioncapacity,0.16722408026755853
enteralabsorption,0.16722408026755853
uca,0.16722408026755853
efficiencie,0.16722408026755853
alphapeakfractionalabsorptionh,0.16722408026755853
areaunderthedrugconcentrationtimecurveratio,0.16722408026755853
samplecollectiontime,0.16722408026755853
dialysateplasmaconcentrationratio,0.16722408026755853
cfucount,0.16722408026755853
minima,0.16722408026755853
progressionfreesurvivalmpfs,0.16722408026755853
steadystateplasmapaclitaxelconcentration,0.16722408026755853
renalclearancecre,0.16722408026755853
absorptionlagtimetlag,0.16722408026755853
ratioofmaximumtominimumplasmalevel,0.16722408026755853
peakhaircodeineconcentration,0.16722408026755853
urinarycalciumexcretionuca,0.16722408026755853
peakcalcitriollevel,0.16722408026755853
renalsynthesi,0.16722408026755853
initialbrainconcentration,0.16722408026755853
auc051,0.16722408026755853
auc005,0.16722408026755853
apparentplasmacl,0.16722408026755853
minimumtime,0.16722408026755853
totaltreatmentresponse,0.16722408026755853
sputumtoplasmaratio,0.16722408026755853
limitsofquantificationloq,0.16722408026755853
areaundertheconcentrationcurveaucratio,0.16722408026755853
clearanceintothebrain,0.16722408026755853
extravascularpenetration,0.16722408026755853
ultrafiltrationrate,0.16722408026755853
tmor,0.16722408026755853
peakconcentrationofdruginserumcmax,0.16722408026755853
peakclonidineconcentration,0.16722408026755853
deliveryefficiency,0.16722408026755853
totaluop,0.16722408026755853
noncompartmentalclearancecl1min,0.16722408026755853
timetomaximalneuromuscularblock,0.16722408026755853
peaklaudanosineconcentration,0.16722408026755853
timeto25recovery,0.16722408026755853
maximumtransportnmaxvecf,0.16722408026755853
clinicaleffectivedurationofaction,0.16722408026755853
maximumplasmatargetconcentration,0.16722408026755853
areaunderthecurve0to72h,0.16722408026755853
timetoabsorb95,0.16722408026755853
freeunboundfraction,0.16722408026755853
apparentsteadystate,0.16722408026755853
totalclearancesclccl,0.16722408026755853
slopefactorg,0.16722408026755853
steadystateapparentvolumesofdistributionv1vdss,0.16722408026755853
timetothemaximalneuromuscularblockingeffect,0.16722408026755853
activeeffluxrateconstant,0.16722408026755853
passivediffusionrateconstant,0.16722408026755853
recoverytimesfrommaximumblockto50recovery,0.16722408026755853
onsettimetomaximalneuromuscularblock,0.16722408026755853
bioavailabilitytrueabsorption,0.16722408026755853
interstitial,0.16722408026755853
cellulardistributionvolume,0.16722408026755853
permeabilitysurfaceareaps,0.16722408026755853
permeationclearancesclpi,0.16722408026755853
preliminaryresponserate,0.16722408026755853
areaundertheplasmaconcentrationtimeprofilesauc0last,0.16722408026755853
auc0were,0.16722408026755853
inter,0.16722408026755853
maximalconcentrationinserumcmax,0.16722408026755853
peakplasmafentanylconcentrationsfmax,0.16722408026755853
ratepulse,0.16722408026755853
timepulse,0.16722408026755853
percentofheroinexcretedintourinea,0.16722408026755853
troughbloodconcentrationtbc,0.16722408026755853
meanresidencetimemrt0,0.16722408026755853
oralfluidtoplasmaratio,0.16722408026755853
wholeblood,0.16722408026755853
durationoftime,0.16722408026755853
totalareaundertheconcentrationtimecurveduringoraladministrationaucpo,0.16722408026755853
peakcodeineconcentration,0.16722408026755853
ab,0.16722408026755853
timetothepeakbloodciclosporinconcentrationatsteadystatetmaxss,0.16722408026755853
detectionwavelength,0.16722408026755853
steadystatepaclitaxelconcentrationscss,0.16722408026755853
leakage,0.16722408026755853
areaunderthebloodlevelcurveauc,0.16722408026755853
hydrodynamicradiu,0.16722408026755853
radiusofgyration,0.16722408026755853
glucuronide,0.16722408026755853
volumesofdistributionvd,0.16722408026755853
relativeoralbioavailabilityfr,0.16722408026755853
throughlevel,0.16722408026755853
effluxratiobaab,0.16722408026755853
totalbodyclearancebioavailability,0.16722408026755853
maximumserumconcentrationnormalizedfordosecmaxd,0.16722408026755853
areaunderthekillingandregrowthcurvefrom0to48haubc048,0.16722408026755853
areabetweenthecontrolgrowthcurveandthekillingandregrowthcurvefrom0to48h,0.16722408026755853
abbc048,0.16722408026755853
areaunderthebloodcyclosporinconcentrationtimecurveafteroraladministrationaucpo,0.16722408026755853
plasmavolumeofdistribution,0.16722408026755853
steadystatemolarratio,0.16722408026755853
troughc,0.16722408026755853
troughcsaconcentration,0.16722408026755853
renalclearancecr,0.16722408026755853
cea,0.16722408026755853
peakplasmapaclitaxelconcentration,0.16722408026755853
areaunderthefreedrugplasmaconcentrationtimecurve,0.16722408026755853
volumeofdistributionvdbetaf,0.16722408026755853
cumulativereleaserate,0.16722408026755853
areaundertheplasmaconcentrationtimecurveoverthedosingintervalauc06,0.16722408026755853
maximumnonlinearclearancevmaxkm,0.16722408026755853
pae,0.16722408026755853
eliminationrateconstantb,0.16722408026755853
absolutepercentbioavailabilitie,0.16722408026755853
timetolastpositive,0.16722408026755853
areaunderthecurve24hours,0.16722408026755853
postantibioticeffectspaes,0.16722408026755853
peakfmorconcentration,0.16722408026755853
minimumconcentrationofdrug,0.16722408026755853
phaseclearance,0.16722408026755853
timetolastpositivesample,0.16722408026755853
areaundertheconcentrationtimecurveat2324hr,0.16722408026755853
50effectiveconcentrationsec50s,0.16722408026755853
percentagepenetration,0.16722408026755853
areasundertheserumcurve,0.16722408026755853
fcr,0.16722408026755853
loadingrate,0.16722408026755853
peakplasmacremophorconcentration,0.16722408026755853
totaltimethattheplasmaconcentration,0.16722408026755853
totaltimethatthe,0.16722408026755853
timethat,0.16722408026755853
detectionlimitslod,0.16722408026755853
fractionofunbound,0.16722408026755853
aucpd06h,0.16722408026755853
cotac,0.16722408026755853
steadystateauc024h,0.16722408026755853
ureaclearance,0.16722408026755853
fractionofelimination,0.16722408026755853
auctissueaucserumratio,0.16722408026755853
steadystateplasmatopotecanlactoneconcentration,0.16722408026755853
le,0.16722408026755853
timeforthetofratio,0.16722408026755853
effectcompartmentconcentrationresultingin,0.16722408026755853
timeoftransferringfromcentraltoeffectcompartment,0.16722408026755853
totaltrough,0.16722408026755853
populationclearanceclf,0.16722408026755853
troughmpaconcentration,0.16722408026755853
apparentnonrenalclearanceclnrf,0.16722408026755853
apparentrenalclearanceclrf,0.16722408026755853
auc014h,0.16722408026755853
unboundtrough,0.16722408026755853
unboundtroughconcentration,0.16722408026755853
totalc0,0.16722408026755853
pumprate,0.16722408026755853
maximumplasmamycophenolicacidconcentration,0.16722408026755853
serumcmin,0.16722408026755853
areaundertheplasmamycophenolicacidconcentrationversustimecurvesauc012,0.16722408026755853
areaunderconcentrationtimecurveauc012h,0.16722408026755853
individualplasmaconcentration,0.16722408026755853
plasmadisappearancehalflifet12alpha,0.16722408026755853
totalropivacaine,0.16722408026755853
plasmaconcentrationofunboundropivacaine,0.16722408026755853
timetofirstsupplementaryanalgesic,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to12hauc12,0.16722408026755853
troughmmflevel,0.16722408026755853
steadystateplasmaconcentrationelicitinghalfofthemaximumresponse,0.16722408026755853
c0threshold,0.16722408026755853
maximumpercentinhibitionsimax,0.16722408026755853
aucthreshold,0.16722408026755853
timeofoccurrenceformaximumdrugconcentration,0.16722408026755853
ic50the,0.16722408026755853
timetofourthseizure,0.16722408026755853
troughplasmampalevel,0.16722408026755853
auctargetattainment,0.16722408026755853
c120,0.16722408026755853
maximalrateofelimination,0.16722408026755853
c510h,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0to14hour,0.16722408026755853
t9,0.16722408026755853
bw,0.16722408026755853
plasmafreefractionfreetotalconcentrationratio,0.16722408026755853
serumsteadystateconcentration,0.16722408026755853
totalareaundertheplasmaconcentrationtimecurveaucinfinity,0.16722408026755853
areaunderthefirstmomentcurve,0.16722408026755853
auc612,0.16722408026755853
areaunderconcentrationtimecurveaucfrom0to12hour,0.16722408026755853
screa,0.16722408026755853
totalmpaareaunderthecurveforhours0to12auc012,0.16722408026755853
1halflife,0.16722408026755853
apparentoralmpaclearanceclf,0.16722408026755853
dosebwratio,0.16722408026755853
acuteld50,0.16722408026755853
clearancescl1,0.16722408026755853
minimumcmax,0.16722408026755853
plasmaunboundphenytoinconcentration,0.16722408026755853
timestoreachthemaximumconcentration,0.16722408026755853
dosenormalisedauc04h,0.16722408026755853
maximumdrugeffectec50,0.16722408026755853
unbound24h,0.16722408026755853
dosauc,0.16722408026755853
steadystatefreephenytoinconcentration,0.16722408026755853
metabolicratiompagaucmpaauc,0.16722408026755853
csstarget,0.16722408026755853
aucvaluefrom0to12hauc012h,0.16722408026755853
zeroorderabsorptionduration,0.16722408026755853
peakropivacaineconcentration,0.16722408026755853
fractionoffree,0.16722408026755853
t10,0.16722408026755853
t9t10,0.16722408026755853
peakunboundropivacaineconcentration,0.16722408026755853
apparentvolumeofdistributionofthecentralcompartmentv1f,0.16722408026755853
mrtstoplast,0.16722408026755853
timetomaximumblock,0.16722408026755853
peakunboundphenytoinconcentrationscmax,0.16722408026755853
timetoattainpeakplasmaconcentration,0.16722408026755853
constantvolume,0.16722408026755853
systemictoxic,0.16722408026755853
highestunboundropivacaineconcentrationcumax,0.16722408026755853
highestropivacaine,0.16722408026755853
areaundertheplasmaunboundphenytoinconcentrationtimecurveauc0infinity,0.16722408026755853
peripheralclearance,0.16722408026755853
areaundertheplasmamycophenolicacid,0.16722408026755853
areaundertheconcentrationtimecurveauc0last,0.16722408026755853
asc,0.16722408026755853
freeplasmafraction,0.16722408026755853
totalphenytoinclearance,0.16722408026755853
totalsteadystateconcentration,0.16722408026755853
areaundertheplasmamexiletineconcentrationtimecurve,0.16722408026755853
ratiosofclearance,0.16722408026755853
volumeofcsfdistribution,0.16722408026755853
maximumtotalplasmaropivacaineconcentration,0.16722408026755853
timetomaximumtotalplasmaropivacaineconcentration,0.16722408026755853
maximumtotaldosage,0.16722408026755853
areaundertheplasmaconcentrationtimecurve0toinfinity,0.16722408026755853
maximummetabolicvelocity,0.16722408026755853
steadystateplasmamorphineconcentration,0.16722408026755853
rateofinfusion,0.16722408026755853
maximumeliminationrate,0.16722408026755853
totalrecoveredamount,0.16722408026755853
areaunderthebloodconcentrationtimecurvefrom0to24hr,0.16722408026755853
synovialfluidserumareaundercurveaucratio,0.16722408026755853
apparentpaclitaxelclearance,0.16722408026755853
synovialfluidserumaucratio,0.16722408026755853
maximumbusulfanconcentration,0.16722408026755853
concentrationatfirstdose,0.16722408026755853
freeserumconcentration,0.16722408026755853
totalcmax,0.16722408026755853
constantoftransportrateofspeedk10,0.16722408026755853
totali,0.16722408026755853
onsetofsensory,0.16722408026755853
cmaxauc036,0.16722408026755853
sspc,0.16722408026755853
auc0loqh,0.16722408026755853
durationofsensoryblock,0.16722408026755853
cl1f,0.16722408026755853
maximalunboundplasmaconcentration,0.16722408026755853
totalmeanscore,0.16722408026755853
totalropivacaineplasmaconcentration,0.16722408026755853
areaunderthecurvelimitofquantificationauc0loqh,0.16722408026755853
fractionsabsorbed,0.16722408026755853
dosenormalizedtotalc0,0.16722408026755853
areaundertheplasmaconcentrationcurveauc012h,0.16722408026755853
baselineactivitiese0,0.16722408026755853
plasmatoerythrocyteconcentrationratio,0.16722408026755853
un,0.16722408026755853
timetorenalresponse,0.16722408026755853
conversionhalflifet12,0.16722408026755853
t12inversion,0.16722408026755853
volumeofdistributionperbioavailability,0.16722408026755853
timestopeakplasmaconcentrationtmax,0.16722408026755853
therapeuticserumconcentration,0.16722408026755853
peakwholebloodlevel,0.16722408026755853
areaundertheplasmadrugconcentrationversustimecurveauc024,0.16722408026755853
conversionhalflive,0.16722408026755853
areasundertheconcentrationtimecurveauc0tn,0.16722408026755853
troughplasmaconcentrationatsteadystate,0.16722408026755853
conversionhalflife,0.16722408026755853
apparentbioavailabilitie,0.16722408026755853
peaktotalropivacaineconcentration,0.16722408026755853
nn,0.16722408026755853
peakconcentrationcpeak,0.16722408026755853
survivalduration,0.16722408026755853
volumeofcudistribution,0.16722408026755853
peaksofmeanconcentration,0.16722408026755853
cbr,0.16722408026755853
extractionrecoveryr,0.16722408026755853
insulinogenicindex,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0to12hoursauc12,0.16722408026755853
pd50,0.16722408026755853
bioconversion,0.16722408026755853
drugreleaserate,0.16722408026755853
areaundertheserumconcentrationversustimecurveauc,0.16722408026755853
gastricretentionperiod,0.16722408026755853
minimumgluconcentration,0.16722408026755853
steadyplasmaconcentration,0.16722408026755853
aucabovethemic,0.16722408026755853
limitofdetectionsn31,0.16722408026755853
timetoachievethatmaximum,0.16722408026755853
maximumcalculatedeffectsitemorphineconcentration,0.16722408026755853
plasmabrainratio,0.16722408026755853
hydrolysishalflive,0.16722408026755853
kobs,0.16722408026755853
timestosustainedresponse,0.16722408026755853
plasmaeffectsitetransferrateconstantke0,0.16722408026755853
timetosustainedresponse,0.16722408026755853
ic50value,0.16722408026755853
timestoreachpeakplasmaconcentrationstmax,0.16722408026755853
hyperforinconcentration,0.16722408026755853
sampleextractrecoverie,0.16722408026755853
timetoreachthepeakconcentrationtmax,0.16722408026755853
processextractionefficiency,0.16722408026755853
selectivityfactoralpha,0.16722408026755853
areaunderthemiosistimecurve,0.16722408026755853
areaundertheplasmamorphineconcentrationversustimecurve,0.16722408026755853
polydispersibilityindex,0.16722408026755853
peakconcentrationmicratio,0.16722408026755853
totalbodyclearanceclf,0.16722408026755853
zerotimeconcentration,0.16722408026755853
apparentclearanceclapp,0.16722408026755853
maximalmorphineconcentration,0.16722408026755853
peakplasmalevelsofradioactivity,0.16722408026755853
areasundertheconcentrationtimecurvesauc,0.16722408026755853
aucelftoaucuplasmaratio,0.16722408026755853
rsplasmaconcentrationratio,0.16722408026755853
totalruntimeneeded,0.16722408026755853
troughmarimastatlevel,0.16722408026755853
initialvolumeofdistributionincsf,0.16722408026755853
maximumcsfmorphineconcentration,0.16722408026755853
elasticity,0.16722408026755853
plasmaclearancet12,0.16722408026755853
tissuetoserumaucratio,0.16722408026755853
volumeofdistributionatsteadystatevdssf,0.16722408026755853
volumeofdistributionvbetaf,0.16722408026755853
zpotentialzp,0.16722408026755853
maximumplasmamorphineconcentration,0.16722408026755853
plasmahalflifeofelimination,0.16722408026755853
inhalationtime,0.16722408026755853
boundratio,0.16722408026755853
aerodynamicdiametermmda,0.16722408026755853
auc120hr,0.16722408026755853
micofcimicci,0.16722408026755853
mictr,0.16722408026755853
apparentformationt12,0.16722408026755853
dispositiont12,0.16722408026755853
micci,0.16722408026755853
apparentvolumeofdistributionvc,0.16722408026755853
aucmicbreakpoint,0.16722408026755853
maximumdrugloading,0.16722408026755853
amnioticfluidconcentration,0.16722408026755853
areaunderthecurveuptothetimecorrespondingtothelastmeasurableconcentrationauc0tlast,0.16722408026755853
clearancehalflifeoffibrinolyticactivity,0.16722408026755853
timetoreachmaximumfentanylplasmaconcentration,0.16722408026755853
auctissueaucplasmaratio,0.16722408026755853
halflifeoftheterminalphaseofelimination,0.16722408026755853
totalreleaseof,0.16722408026755853
timetoreachmaximumserumconcentration,0.16722408026755853
areaundertherlpccurve,0.16722408026755853
timetoonsetofrelief,0.16722408026755853
transmit,0.16722408026755853
maximummeanincrease,0.16722408026755853
withdrawalperiod,0.16722408026755853
bioavailabilityfraction,0.16722408026755853
oralclearanceoftheophyllineatsteadystateclf,0.16722408026755853
rateofspillover,0.16722408026755853
halftimeoftherapidremovalphaset112,0.16722408026755853
fauc024,0.16722408026755853
areasunderplasmaconcentrationtimecurve,0.16722408026755853
areaunderthebactericidalcurveaubc,0.16722408026755853
aubc,0.16722408026755853
peakplasmasmvconcentration,0.16722408026755853
drugloadingrate,0.16722408026755853
areaundertimeversusconcentrationcurvefrom0to10hoursauc010,0.16722408026755853
solubilizingcapacity,0.16722408026755853
maximumconcentrationofdrugcmax,0.16722408026755853
maximumenzymeinhibitionic50,0.16722408026755853
bindingability,0.16722408026755853
timeatwhichthismaximumconcentrationofdrugtmax,0.16722408026755853
0mz,0.16722408026755853
serumareaundertheconcentrationtimecurvemic,0.16722408026755853
volumeofdistributioninthecentralcompartmentvcf,0.16722408026755853
siwv,0.16722408026755853
clearanceofheroinfromthebloodatapparentsteadystate,0.16722408026755853
totalmeanrecovery,0.16722408026755853
effluxclearance,0.16722408026755853
timerequiredtoreachthecmaxtmax,0.16722408026755853
halftimeofthesecondexponentialt212,0.16722408026755853
sojourntime,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezeroto24hoursauc024,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to24hauc024h,0.16722408026755853
relativebioavailabilityrf,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezeroto24hoursafterthedoseauc024,0.16722408026755853
percentin,0.16722408026755853
mrt0inf,0.16722408026755853
c01havg,0.16722408026755853
steadystateareasundertheconcentrationtimecurve,0.16722408026755853
minimalinhibitoryconcentrationsmic90,0.16722408026755853
areaundertheconcentrationtimecurveaucinfinity,0.16722408026755853
lcratio,0.16722408026755853
absorptionhalflivest12ab,0.16722408026755853
spaceofdistribution,0.16722408026755853
areasunderthewholebloodconcentrationtimeprofile,0.16722408026755853
initialdisappearancetimet12,0.16722408026755853
cbratio,0.16722408026755853
hepaticintestinalspilloverrate,0.16722408026755853
paintolerance,0.16722408026755853
appearancerate,0.16722408026755853
csfflux,0.16722408026755853
toxicconcentration,0.16722408026755853
earlyhalflifeincsf,0.16722408026755853
apparentvolumeofdistributionvdlambdaz,0.16722408026755853
totalproteincontent,0.16722408026755853
mini,0.16722408026755853
peakplasmamorphineconcentration,0.16722408026755853
overallappearancerate,0.16722408026755853
basalplasma,0.16722408026755853
tumortoplasmapartitioncoefficient,0.16722408026755853
ratiosofareaundertheconcentrationtimecurveauctomic,0.16722408026755853
deacylationhalflife,0.16722408026755853
timeofmaximalplasmaconcentration,0.16722408026755853
cytroughlevel,0.16722408026755853
criticalmicellarconcentration,0.16722408026755853
c1h,0.16722408026755853
arterialhalflive,0.16722408026755853
c25,0.16722408026755853
steadystatedistributionvolumevd,0.16722408026755853
eliminationhalflifeattheterminaleliminationphaset12beta,0.16722408026755853
volumeoftheinitialdistributionspacev1,0.16722408026755853
surfacetension,0.16722408026755853
eliminationt12b,0.16722408026755853
intrinsicaqueoussolubility,0.16722408026755853
sievingcoefficientsc,0.16722408026755853
sap,0.16722408026755853
areaunderthecurveuntil,0.16722408026755853
halflifeatbetaeliminationphase,0.16722408026755853
plasmahydromorphone,0.16722408026755853
serumbactericidalactivitytiter,0.16722408026755853
durationofreceptorsaturation,0.16722408026755853
serummaximumconcentrationcmax,0.16722408026755853
skinliverratio,0.16722408026755853
skinbloodratio,0.16722408026755853
localization,0.16722408026755853
renalvascularresistance,0.16722408026755853
dbp,0.16722408026755853
sbp,0.16722408026755853
peakcisternalcsfmorphineconcentration,0.16722408026755853
dosenormalizedauc024h,0.16722408026755853
absolutereactiontime,0.16722408026755853
dissociationconstantskd,0.16722408026755853
cumulativefecalexcretion,0.16722408026755853
areaundertheplasmadrugconcentrationtimecurvefromtime0tothelastmeasurableconcentration,0.16722408026755853
peaksba,0.16722408026755853
cumulativepercentrelease,0.16722408026755853
plasmaaucmic,0.16722408026755853
overallvolumesofdistribution,0.16722408026755853
peakplasmacodeineconcentration,0.16722408026755853
kideltakimu,0.16722408026755853
localregionalcontrolrate,0.16722408026755853
timeabovethethresholdconcentration,0.16722408026755853
bioavailabilitiesf,0.16722408026755853
neointimaarea,0.16722408026755853
areaunderthetimeconcentration,0.16722408026755853
apparentdistributionvolumesvdarea,0.16722408026755853
bloodconcentrationatsteadystate,0.16722408026755853
unboundcol,0.16722408026755853
centralvolumesofdistribution,0.16722408026755853
auc024hmic,0.16722408026755853
troughlevelcminratiocyatacofcmin,0.16722408026755853
areaundertheconcentrationtimecurveaucratiocyatacofauc,0.16722408026755853
weightnormalizedclf,0.16722408026755853
areaunderthecurveofbloodcsaversustimeauciv,0.16722408026755853
timerequiredtoachievegoodpaincontrol,0.16722408026755853
percentcoefficient,0.16722408026755853
apparentdissociationhalflive,0.16722408026755853
initialinfusionrate,0.16722408026755853
finalrate,0.16722408026755853
terminalphasehalflifeofeliminationfromserum,0.16722408026755853
halfsaturationconstantkd,0.16722408026755853
permeationinfluxrate,0.16722408026755853
braintobloodcoefficientofdistribution,0.16722408026755853
bbb,0.16722408026755853
drugloadingcontentdl,0.16722408026755853
apparentmeanvolumesofdistributionatsteadystate,0.16722408026755853
minimumquantifiablelevel,0.16722408026755853
50inhibition,0.16722408026755853
aucuptoinfinity,0.16722408026755853
troughconcentrationc0,0.16722408026755853
polydispersityindexpi,0.16722408026755853
biletoblooddistributionratiosaucbileaucblood,0.16722408026755853
totalsingleruntime,0.16722408026755853
timetotmax,0.16722408026755853
maximumparacetamolconcentrationcmax,0.16722408026755853
hepaticextractionratioher,0.16722408026755853
peaksitetoserumratio,0.16722408026755853
csfavailability,0.16722408026755853
systemictotalbodyclearancecl,0.16722408026755853
apparenteliminationhalflifet12lz,0.16722408026755853
sequentialhalflive,0.16722408026755853
livertoblooddistributionratiosaucliveraucblood,0.16722408026755853
timetoreachmaximumpeakplasmaconcentrationtmax,0.16722408026755853
areaundertheblooddrugconcentrationtimecurve,0.16722408026755853
erpf,0.16722408026755853
acutecellularrejectionrate,0.16722408026755853
c2level,0.16722408026755853
overalleliminationhalflifet12,0.16722408026755853
timetoparacetamolcmax,0.16722408026755853
areaunderthebloodconcentrationnutimecurve,0.16722408026755853
timetoreachmaximumcsfconcentration,0.16722408026755853
minimumcmin,0.16722408026755853
totalimprecision,0.16722408026755853
peakcsfopioidconcentration,0.16722408026755853
apparentmaximalconcentrationkm,0.16722408026755853
maximumbloodmorphineconcentration,0.16722408026755853
peakconcentrationcpmax,0.16722408026755853
areaunderthekillcurveaukc,0.16722408026755853
plasmaultrafiltrate,0.16722408026755853
washouttime,0.16722408026755853
kidney,0.16722408026755853
areaunderthecurvetoinfinityauc0infinity,0.16722408026755853
bonemarrow,0.16722408026755853
microsomalmetabolism,0.16722408026755853
areaundertheconcentrationcurveauc0,0.16722408026755853
eliminationrateconstantof,0.16722408026755853
cre,0.16722408026755853
tpratio,0.16722408026755853
fwr,0.16722408026755853
extendedtoimmediatereleasebioavailability,0.16722408026755853
ratioofaucmorphineauccodeine,0.16722408026755853
weightnormalizedvolumeofdistributionofvdarea,0.16722408026755853
weightcorrected,0.16722408026755853
logbeta1,0.16722408026755853
logbeta2,0.16722408026755853
aucovertheentire12hdosageintervalauc012,0.16722408026755853
areaunderthetimeconcentrationcurveaucoverthefirst4hofthe12hdosageintervalauc04,0.16722408026755853
clwh,0.16722408026755853
clwr,0.16722408026755853
clsr,0.16722408026755853
totalrenalclearance,0.16722408026755853
vaspainscore,0.16722408026755853
fwh,0.16722408026755853
firstdosetimeatwhichmaximalconcentrationisreachedtmax,0.16722408026755853
auc012hd,0.16722408026755853
trohalflife,0.16722408026755853
areaundertheconcentrationtimecurveauctomicratio,0.16722408026755853
morphineaucblood,0.16722408026755853
unboundaucblood,0.16722408026755853
cssratioofbraintoblood,0.16722408026755853
aucratiosofbraintoblood,0.16722408026755853
peritonealfluidconcentration,0.16722408026755853
maximumwholebloodconcentrationcmax,0.16722408026755853
distributionratio,0.16722408026755853
peakchange,0.16722408026755853
formula,0.16722408026755853
oralf,0.16722408026755853
terminaleliminationhalflifet12lambdaz,0.16722408026755853
of,0.16722408026755853
fecalfatexcretion,0.16722408026755853
peakserum5asaconcentration,0.16722408026755853
apparentdose,0.16722408026755853
totalnumberofrotation,0.16722408026755853
auc0tmax,0.16722408026755853
aucfromtime0to1hour,0.16722408026755853
fractionofdoseexcretedthrough,0.16722408026755853
plasmacurve,0.16722408026755853
terminalphaseplasmarateconstant,0.16722408026755853
semenplasmadrugconcentrationratio,0.16722408026755853
aucfromtime0totmax,0.16722408026755853
vfc,0.16722408026755853
serumhalflifeduringtheeliminationphase,0.16722408026755853
aetaccumulatedexcretionamount,0.16722408026755853
umaxmaximalexcretionrate,0.16722408026755853
auc060h,0.16722408026755853
lungedemaclearance,0.16722408026755853
eliminationhalflifetl2beta,0.16722408026755853
maximumvelocitie,0.16722408026755853
effectcompartmentexposure,0.16722408026755853
knal,0.16722408026755853
99invitroinhibitoryconcentrationec99,0.16722408026755853
cerebrospinalfluidtroughconcentration,0.16722408026755853
maximumracsalmeterolurineconcentration,0.16722408026755853
lowconcentration,0.16722408026755853
ic50saturation,0.16722408026755853
ic50desaturation,0.16722408026755853
plasmaauc0,0.16722408026755853
specificradioactivitie,0.16722408026755853
initialdispositionhalflifet12alpha,0.16722408026755853
cmaxdn,0.16722408026755853
maximalplasmaapomorphineconcentration,0.16722408026755853
timetakentoreachcmaxtmax,0.16722408026755853
cfcm,0.16722408026755853
cfucmu,0.16722408026755853
braintounboundplasmaconcentrationratio,0.16722408026755853
tounboundplasmaconcentrationratio,0.16722408026755853
cfcmratio,0.16722408026755853
apparentvdvdapp,0.16722408026755853
apparenthalflivest12app,0.16722408026755853
fractionsmetabolizedfm,0.16722408026755853
fractionsexcretedunchangedfe,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefromthetimeofdosingto12hourspostdoseauc12,0.16722408026755853
timeintervalsfromdosingtocmaxtmax,0.16722408026755853
centralnervoussystempenetration,0.16722408026755853
maximalventricularcsfapomorphineconcentration,0.16722408026755853
bioavailabilityeba,0.16722408026755853
timetonormalizationof,0.16722408026755853
areaundertheparasiteclearancecurve,0.16722408026755853
aulot,0.16722408026755853
areaunderthatcurve,0.16722408026755853
kdforbinding,0.16722408026755853
peakd2occupancy,0.16722408026755853
eliminationrateconstantbetaofbetaphase,0.16722408026755853
centralcompartmentapparentvolumeofdistribution,0.16722408026755853
distributionalhalflifet12lambda1,0.16722408026755853
elutionprofile,0.16722408026755853
t12t,0.16722408026755853
areaunderthecurveauc0to48hours,0.16722408026755853
peakplasmaquinineconcentration,0.16722408026755853
distributionhalflifet12d,0.16722408026755853
plasmahalflifeoftheterminalphase,0.16722408026755853
fractionalexcretionofparaquatfepq,0.16722408026755853
timestoachieve50reduction,0.16722408026755853
firstcmaxpeakcmax04,0.16722408026755853
x,0.16722408026755853
clearancerelativetobioavailability,0.16722408026755853
areaunderthecurveauc028,0.16722408026755853
totalbileproduction,0.16722408026755853
cmax410,0.16722408026755853
apparentconversion,0.16722408026755853
peripheralvolumeofdistributionv2f,0.16722408026755853
fractionalturnoverratekt3,0.16722408026755853
percentproteinbinding,0.16722408026755853
steadystateareasunderthecurve,0.16722408026755853
relativeoralfastedbioavailability,0.16722408026755853
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityaucinf,0.16722408026755853
peakplasmamilrinoneconcentration,0.16722408026755853
adequateplasmaconcentration,0.16722408026755853
plasmaconcentrationatsteadystatecssavg,0.16722408026755853
timeofinfusion,0.16722408026755853
peakmilrinoneconcentration,0.16722408026755853
ofclearance,0.16722408026755853
halfeffectiveplasmaconcentration,0.16722408026755853
timetoatrainoffourratio,0.16722408026755853
595recoveryindexe,0.16722408026755853
2575,0.16722408026755853
totalbrainuptake,0.16722408026755853
t3distributionspace,0.16722408026755853
serumt3concentration,0.16722408026755853
t3clearance,0.16722408026755853
t3productionrate,0.16722408026755853
ratiooft3to,0.16722408026755853
ft4level,0.16722408026755853
raiu,0.16722408026755853
freet3level,0.16722408026755853
peakfreet3,0.16722408026755853
degradation,0.16722408026755853
time0tsh,0.16722408026755853
valley,0.16722408026755853
serumconcentrationj14,0.16722408026755853
brainecfplasmaareaunderthecurveratio,0.16722408026755853
maximumconcentrationintheplasmacmax,0.16722408026755853
minimum12hourplasmaconcentration,0.16722408026755853
betaeliminationhalflive,0.16722408026755853
skinplasmaconcentrationratio,0.16722408026755853
shedantigen,0.16722408026755853
minimalsteadystateplasmaconcentration,0.16722408026755853
timetoreachmaximumplasmadrugconcentration,0.16722408026755853
areasundertheconcentrationversustimecurve,0.16722408026755853
sba,0.16722408026755853
timeforthebeginningof,0.16722408026755853
absoluterectalbioavailability,0.16722408026755853
vg,0.16722408026755853
dissolutionratio,0.16722408026755853
peakplasmalorazepamconcentration,0.16722408026755853
timestoreachcmax,0.16722408026755853
mz321,0.16722408026755853
maximumpapp,0.16722408026755853
apparentpermeabilitycoefficientspapp,0.16722408026755853
extrudability,0.16722408026755853
peakcortisollevel,0.16722408026755853
clearanceto,0.16722408026755853
apparentcomposite1orderrateconstantsalpha,0.16722408026755853
k0d,0.16722408026755853
rateconstantk1m,0.16722408026755853
initialclearanceoffdopatostriatumk1d,0.16722408026755853
areaunderthecurveofmetforminauc0540min,0.16722408026755853
plasmapeakdrugconcentration,0.16722408026755853
intradialyticclearance,0.16722408026755853
equilibriumdistributionvolumeved,0.16722408026755853
equilibriumdistributionvolumevem,0.16722408026755853
maximalfelodipineplasmaconcentration,0.16722408026755853
steadystateserumtroughminimumconcentrationcminss,0.16722408026755853
rateconstantoffdop,0.16722408026755853
rateconstantk11,0.16722408026755853
bloodbrainclearance,0.16722408026755853
troughtopeakratiostp,0.16722408026755853
peakcortisolcmax,0.16722408026755853
tubularsegmentalreabsorptionrate,0.16722408026755853
maximummedianplasmaconcentration,0.16722408026755853
auectracking,0.16722408026755853
degreeofplasmaproteinbinding,0.16722408026755853
auc240,0.16722408026755853
tmaxthetimetoreachmaximumconcentration,0.16722408026755853
auc024areaundertheconcentrationtimecurvefromtime0hto24h,0.16722408026755853
t12terminalhalflife,0.16722408026755853
carrsindex,0.16722408026755853
relativebasrbas,0.16722408026755853
rba,0.16722408026755853
apparentvolumeoftheperipheralcompartment,0.16722408026755853
metabolicstabilityt12,0.16722408026755853
oralauc08h,0.16722408026755853
radialcrushingstrength,0.16722408026755853
apparentcentralcompartmentvolumeofdistributionafteroraladministrationv1f,0.16722408026755853
apparentperipheralcompartmentvolumeofdistributionafteroraladministrationv2f,0.16722408026755853
apparenttotalclearanceofatorvastatinlactoneclmf,0.16722408026755853
apparentintercompartmentalclearanceofatorvastatinlactoneqmf,0.16722408026755853
apparentvolumeofdistributionof,0.16722408026755853
vmf,0.16722408026755853
clcreat,0.16722408026755853
bioavaiability,0.16722408026755853
apparentplasmaterbutalineclearance,0.16722408026755853
overallprogressionfreesurvival,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to21day,0.16722408026755853
ultrafiltrationclearance,0.16722408026755853
absorptiontime,0.16722408026755853
plasmasteadystateconcentrationcss,0.16722408026755853
accumulationindice,0.16722408026755853
vdz,0.16722408026755853
interactionenergy,0.16722408026755853
durationofeffectiveplasmaconcentration,0.16722408026755853
intrinsicclearancecli,0.16722408026755853
hepaticperfusaterate,0.16722408026755853
samplepreparationtime,0.16722408026755853
minimaleffectiveconcentrationmec,0.16722408026755853
unboundapparentoralclearance,0.16722408026755853
absolutepulmonarybioavailibility,0.16722408026755853
timeto90ofsteadystate,0.16722408026755853
clearancefractionofquinineconverted,0.16722408026755853
aucuptothelastmeasurableconcentrationauc0t,0.16722408026755853
plasmadistributionratio,0.16722408026755853
bloodclearancet12a,0.16722408026755853
plasmadisappearancehalflife,0.16722408026755853
braintoplasmaaucratio,0.16722408026755853
lungbioavailability,0.16722408026755853
timeofmaximum,0.16722408026755853
relativedistributionvolume,0.16722408026755853
maximumcumulativepercentageofdrugrelease,0.16722408026755853
steadystateplasmapanipenemconcentration,0.16722408026755853
elasticmodulu,0.16722408026755853
bindingpotential,0.16722408026755853
ae0168h,0.16722408026755853
fractionmetabolized,0.16722408026755853
apparentterminalt12,0.16722408026755853
peakquininelevel,0.16722408026755853
plasmaacetaminophenclearance,0.16722408026755853
areaundertheconcentrationtimecurvefrom3to7day,0.16722408026755853
peakcortisonecmax,0.16722408026755853
areaundertheconcentrationtimecurvefromtime0extrapolatedtoinfinityauc0inf,0.16722408026755853
maximumplasmadamphetamineconcentration,0.16722408026755853
uvwavelength,0.16722408026755853
areaunderplasmaconcentrationtimecurveauc0infinity,0.16722408026755853
unboundclearancecluf,0.16722408026755853
ter,0.16722408026755853
distributionhalftime,0.16722408026755853
inhibitionconcentration50ic50,0.16722408026755853
areaundertheplasmadrugconcentrationtimecurvetoday7auc07,0.16722408026755853
overallmetabolicratioatsteadystate,0.16722408026755853
alphaphaserateconstant,0.16722408026755853
steadystatefelbamateconcentration,0.16722408026755853
parasitaemia,0.16722408026755853
terminaleliminationhalftime,0.16722408026755853
peakbloodpbconcentration,0.16722408026755853
peakplasmadipipanoneconcentration,0.16722408026755853
maximumdegreeofinhibition,0.16722408026755853
troughplasmaconcentrationcs,0.16722408026755853
basalpower,0.16722408026755853
c10,0.16722408026755853
minimumparasiticidalconcentration,0.16722408026755853
rateofperfusion,0.16722408026755853
apparentfirstorderterminaleliminationrateconstantbeta,0.16722408026755853
maximumplasmamilrinoneconcentration,0.16722408026755853
maximumsimulated,0.16722408026755853
clbf,0.16722408026755853
maximalrateofinactivationkinact,0.16722408026755853
halfvaluedurationhvd,0.16722408026755853
timeofpeakplasmaconcentrationtmax,0.16722408026755853
effectivedoseof50thrombolysised50,0.16722408026755853
chesttubeoutput,0.16722408026755853
degreeofpenetration,0.16722408026755853
apparentmr,0.16722408026755853
tumortissuedrugconcentration,0.16722408026755853
transplacentalpassage,0.16722408026755853
fmratio,0.16722408026755853
vdzf,0.16722408026755853
42,0.16722408026755853
antigen,0.16722408026755853
meanresidencetimemrt048,0.16722408026755853
troughconcentrationctroughatsteadystate,0.16722408026755853
tfpi,0.16722408026755853
areaunderplasmaconcentrationtimecurve0to12hour,0.16722408026755853
areaundertheconcentrationtimecurvewithinadosingintervaloftauct,0.16722408026755853
apparentsystemicmetforminclearanceclf,0.16722408026755853
renalmetforminclearance,0.16722408026755853
areaundertheconcentrationversustimecurveauc024,0.16722408026755853
troughlevelbeforethedosec0,0.16722408026755853
timeafterdose,0.16722408026755853
maximumobservedeverolimusbloodconcentrationscmax,0.16722408026755853
halfmaximalinactivationki,0.16722408026755853
areaunderplasmaconcentrationtimecurveextrapolatedtoinfinityauc0,0.16722408026755853
tissuetowholebloodratio,0.16722408026755853
civi,0.16722408026755853
ironbioavailability,0.16722408026755853
peakghplasmaconcentration,0.16722408026755853
precursorproducttransition,0.16722408026755853
eliminationhalflifept12,0.16722408026755853
apparentvolumeofdistributioninthepostdistributivephasevdbetaf,0.16722408026755853
systemicclearancecltsf,0.16722408026755853
venousplasmaconcentration,0.16722408026755853
ld25,0.16722408026755853
areaunderthe24hconcentrationtimecurve,0.16722408026755853
apparentdistributionvolumevz,0.16722408026755853
plasmacentrationtimecurveauc0t,0.16722408026755853
fatmilkconcentration,0.16722408026755853
milkproteinconcentration,0.16722408026755853
transferinfantdose,0.16722408026755853
maximalplasmaexposure,0.16722408026755853
pc20metha,0.16722408026755853
tidalvolumevt,0.16722408026755853
cnstoplasmaratio,0.16722408026755853
signaltonoisesn,0.16722408026755853
recoveryquality,0.16722408026755853
masstochargetransition,0.16722408026755853
timestostand,0.16722408026755853
percentagebioavailability,0.16722408026755853
rateofacutecellularrejection,0.16722408026755853
sir,0.16722408026755853
timeittakestoreachpeakserumconcentrationtmax,0.16722408026755853
percentageconjugation,0.16722408026755853
totalurinaryd,0.16722408026755853
areaundertheplasmaconcentrationtimecurvefrom0htoinfinityauc0infinity,0.16722408026755853
areaundertheconcentrationtimecurvefromzerotoinfinityaucinfinity,0.16722408026755853
ultrafilterability,0.16722408026755853
fecalciprofloxacin,0.16722408026755853
removalhalflifefirstcompartment,0.16722408026755853
tel,0.16722408026755853
fractionalbioavailability,0.16722408026755853
glucoseauc,0.16722408026755853
steadystateatovaquoneconcentration,0.16722408026755853
day1,0.16722408026755853
t12terminalhalflifeinplasmaatsteadystate,0.16722408026755853
partialauc290,0.16722408026755853
peakmeloxicam,0.16722408026755853
apparentoralplasmaclearance,0.16722408026755853
absorptionhalflifetime,0.16722408026755853
steadystatealprenololconcentration,0.16722408026755853
apparentoralclearancerate,0.16722408026755853
ratesofinfusion,0.16722408026755853
areaundertheprocainamideplasmaconcentrationtimecurve,0.16722408026755853
areaundertheace,0.16722408026755853
auc96hmic,0.16722408026755853
wholebloodplasmaratio,0.16722408026755853
urine,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezeroto24hauc24,0.16722408026755853
peakplasmaphelnaaratio,0.16722408026755853
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityauc90infinity,0.16722408026755853
aucdosebsa,0.16722408026755853
accretion,0.16722408026755853
bphase,0.16722408026755853
aphase,0.16722408026755853
specificamidolyticactivity,0.16722408026755853
ddimer,0.16722408026755853
catalyticefficienciesforp,0.16722408026755853
drugtoantibodyratiodar,0.16722408026755853
maximumlysi,0.16722408026755853
halflivesoft12alpha,0.16722408026755853
totalsystemicclearanceclt,0.16722408026755853
clearanceantigen,0.16722408026755853
totaldrugdose,0.16722408026755853
srl,0.16722408026755853
srlwb,0.16722408026755853
timeofhalflifeofeliminationphaset12,0.16722408026755853
meansurvivaltimemst,0.16722408026755853
timetoreachamaximumconcentration,0.16722408026755853
concentrationtimeareaunderthecurveaucfrom0toinfinity,0.16722408026755853
maximumplasmaphelnaaratio,0.16722408026755853
peakplasmalphenylalanineconcentration,0.16722408026755853
peakplasmaphenylalaninelevel,0.16722408026755853
areaunderthefourhourplasmaphenylalanineconcentrationtimecurve,0.16722408026755853
peakplasmaaspartateconcentration,0.16722408026755853
iron,0.16722408026755853
epratio,0.16722408026755853
pulmonaryarteryocclusionpressure,0.16722408026755853
oralbioavailabilitycoefficient,0.16722408026755853
areaundertheconcentrationtimecurvefrom0to144hour,0.16722408026755853
braindirectdrugtransportpercentage,0.16722408026755853
vslope,0.16722408026755853
plasmaproteinboundfraction,0.16722408026755853
maximaloccupancie,0.16722408026755853
ec95,0.16722408026755853
fractionremovedbydial,0.16722408026755853
steadystatefluxjss,0.16722408026755853
areaundercurveauc06h,0.16722408026755853
maximumnimesulideconcentration,0.16722408026755853
maximumseminalfluidbloodplasmaratio,0.16722408026755853
maximumnimesulideplasmaconcentration,0.16722408026755853
totaltumordose,0.16722408026755853
de,0.16722408026755853
dispositionrateconstant,0.16722408026755853
icgpdr,0.16722408026755853
maximumminimumratioofplasmaconcentration,0.16722408026755853
initialmaximalrenalclearance,0.16722408026755853
concentrationsathalfmaximalinhibition,0.16722408026755853
totalfecalba,0.16722408026755853
hillexponent,0.16722408026755853
areaunderthetimeconcentrationcurvebetweentimezeroand32hauc032h,0.16722408026755853
steadystateplasmafenoldopamconcentration,0.16722408026755853
steadystateinputrate,0.16722408026755853
intercompartmentdistributionclearance,0.16722408026755853
volumeofdistributionofthecentralcompartmentv2,0.16722408026755853
timestoattaina,0.16722408026755853
steadystate90blockoft1,0.16722408026755853
ultrafiltrationdrugclearance,0.16722408026755853
steadystatetherapeuticconcentration,0.16722408026755853
timestoreachpeaklevel,0.16722408026755853
peaktimeacrophase,0.16722408026755853
timerequiredtoreachmaximumplasmaconcentrationtmax,0.16722408026755853
areaundertheplasmanorethindroneversustimecurve,0.16722408026755853
frenal,0.16722408026755853
absolutebioavailabilty,0.16722408026755853
centralvolumeofdistributionv1f,0.16722408026755853
bileplasmaconcentrationratio,0.16722408026755853
timeatwhichmaximumserumconcentrationswerereachedtmax,0.16722408026755853
renalclearanceofthedrug,0.16722408026755853
auc0480min,0.16722408026755853
vdintheperipheralcompartmentv3,0.16722408026755853
infusionclearance,0.16722408026755853
totalfictivevolumeofdistribution,0.16722408026755853
toxicityscore,0.16722408026755853
steadystatevinblastineconcentration,0.16722408026755853
cytotoxicityratioshcr,0.16722408026755853
weightnormalizeddistributionalclearance,0.16722408026755853
weightnormalizedcentralcompartmentvolume,0.16722408026755853
weightnormalizedvolumeofdistributionatsteadystate,0.16722408026755853
volumeofdistributionatequilibrium,0.16722408026755853
qtcmax,0.16722408026755853
intrinsicclearanceclintvmaxkm,0.16722408026755853
fractionalcaabsorption,0.16722408026755853
fractionofmsmetabolized,0.16722408026755853
futp,0.16722408026755853
areaunderthefutpconcentrationtimecurve,0.16722408026755853
timetofirstresult,0.16722408026755853
circ0,0.16722408026755853
apparentprednisoloneclearance,0.16722408026755853
percentagedrugreleased,0.16722408026755853
rateofrelativebioavailability,0.16722408026755853
inputrateconstant,0.16722408026755853
timetoeuthanasia,0.16722408026755853
maximumvelocityofelimination,0.16722408026755853
wholebodyclearancecltot,0.16722408026755853
timeofhalfmaximalincreaseinclt50,0.16722408026755853
urinarycumulativeexcretion,0.16722408026755853
gammahillcoefficient,0.16722408026755853
sct12,0.16722408026755853
transfer,0.16722408026755853
maximummeasuredplasmampaconcentration,0.16722408026755853
pathologicalcompleteresponse,0.16722408026755853
auctablet,0.16722408026755853
plasmacsfratio,0.16722408026755853
disappearance,0.16722408026755853
areaundertheplasmaconcentrationtimecurveauc0inf,0.16722408026755853
bioavailabilityvssf,0.16722408026755853
appearancehalflive,0.16722408026755853
t12eliv,0.16722408026755853
t12elin,0.16722408026755853
diffusionexponent,0.16722408026755853
maximalplasmacobalaminconcentrationcmax,0.16722408026755853
thydht,0.16722408026755853
bioaccumulation,0.16722408026755853
cytotoxicityratio,0.16722408026755853
overallurinaryexcretion,0.16722408026755853
antifxaactivity,0.16722408026755853
standardizeduptake,0.16722408026755853
peakplasmaheparinactivity,0.16722408026755853
maximumheparinactivity,0.16722408026755853
plasmaterminalhalflifet50,0.16722408026755853
adjusted,0.16722408026755853
maximumantixaactivity,0.16722408026755853
troughantixalevel,0.16722408026755853
troughantixa,0.16722408026755853
maximumplasmaheparinactivitiescmax,0.16722408026755853
unitimpulseresponsefunction,0.16722408026755853
maintainplasmaconcentration,0.16722408026755853
impulseresponsefunction,0.16722408026755853
seconddistributionclearance,0.16722408026755853
cytotoxicityselectivityindice,0.16722408026755853
deltap,0.16722408026755853
areaunderthecurveauc0220min,0.16722408026755853
apparentvolumeofdistributioncentralcompartment,0.16722408026755853
maximalsbpresponsesemax,0.16722408026755853
cmaxthemaximumconcentration,0.16722408026755853
maximumplasmamycophenolicacidconcentrationcmax,0.16722408026755853
conversionindex,0.16722408026755853
ec50concentration,0.16722408026755853
betadistributionhalflive,0.16722408026755853
timetopeakcsfsufentanilconcentration,0.16722408026755853
steadystatetroughpeakconcentration,0.16722408026755853
steadystateareaundertheplasmaconcentrationtimecurve,0.16722408026755853
fractionalsodiumexcretionfena,0.16722408026755853
terminaleliminationbetahalflife,0.16722408026755853
steadystatetarget,0.16722408026755853
timesofmaximumbloodconcentration,0.16722408026755853
troughvpaconcentration,0.16722408026755853
tciduration,0.16722408026755853
sna,0.16722408026755853
timetoneutrophilreconstitution,0.16722408026755853
cp21stday,0.16722408026755853
timetomaximumpeakplasmaconcentrationcmax,0.16722408026755853
ultrafilterable,0.16722408026755853
timestoreachpeakhaemodynamiceffect,0.16722408026755853
halflifeofeliminationfromthebody,0.16722408026755853
totalbodyclearanceofunbounddrug,0.16722408026755853
plasmafentanyl,0.16722408026755853
areaundertheserumconcentrationtimecurvesauc,0.16722408026755853
peakaverageconcentration,0.16722408026755853
synovialfluidplasmaratio,0.16722408026755853
timetorecoverytoanabsoluteneutrophilcount,0.16722408026755853
timefrompeakplasmaconcentrationto50ofpeakconcentration,0.16722408026755853
dnox,0.16722408026755853
apparentintrinsicmetabolicclearance,0.16722408026755853
rateofchangeinvolumeofdistributionatzerotime,0.16722408026755853
t12appin,0.16722408026755853
clearanceclo,0.16722408026755853
timetoonsetofresponse,0.16722408026755853
dosecorrectedconcentration,0.16722408026755853
totalplasmaoralclearance,0.16722408026755853
areaundertheconcentrationtimecurvefromtimezerotothelastquantifiableconcentrationauc0t,0.16722408026755853
aucs015min,0.16722408026755853
reabsorptionrateconstantka,0.16722408026755853
maximumanc,0.16722408026755853
measurable,0.16722408026755853
totalbodyclearancesclf,0.16722408026755853
volumesofdistributionvf,0.16722408026755853
acidoutput,0.16722408026755853
nocturnal,0.16722408026755853
areaundertheanc,0.16722408026755853
basalsecretion,0.16722408026755853
acidsecretion,0.16722408026755853
areaundertheplasmaconcentrationtimecurveaucinf,0.16722408026755853
totalapparentcaffeineclearancecl,0.16722408026755853
renalclearanceae024hauc024h,0.16722408026755853
totalareaundertheplasmaparacetamolconcentrationtimecurvefrom0to180min,0.16722408026755853
rapidlyeffectiveplasmaconcentration,0.16722408026755853
concentrationcausing50ofmaximumresponse,0.16722408026755853
transdermalfluxe,0.16722408026755853
distributionalpha,0.16722408026755853
mf,0.16722408026755853
areaunderthecurvefrom0to6h,0.16722408026755853
volumesofthecentralcompartmentvc,0.16722408026755853
v1vd,0.16722408026755853
apparentsystemicavailability,0.16722408026755853
auctoinfinity,0.16722408026755853
benefitindex,0.16722408026755853
fractionalclearanceofc,0.16722408026755853
eliminationbetahalflive,0.16722408026755853
latencyperiod,0.16722408026755853
eax,0.16722408026755853
apparentltgoralclearance,0.16722408026755853
systemichalflive,0.16722408026755853
unboundfractionsofdrug,0.16722408026755853
maximumplateaulevel,0.16722408026755853
mcfb,0.16722408026755853
maximallengthofeffectiveanalgesia,0.16722408026755853
terminalelimination,0.16722408026755853
oraleliminationt12,0.16722408026755853
apparentbetaphasehalflife,0.16722408026755853
timetorecoveryfromanesthesia,0.16722408026755853
terminalphaseplasmat12,0.16722408026755853
areaundertheplasmadrugconcentrationtimecurveauc,0.16722408026755853
minimumplasmatroughtenoxicamconcentrationcmin,0.16722408026755853
cp50asleep,0.16722408026755853
dissociationrateconstantkoff,0.16722408026755853
timetopatientextubation,0.16722408026755853
distributionphasealphahalflife,0.16722408026755853
maximumbloodthiopentoneconcentration,0.16722408026755853
de30,0.16722408026755853
eliminationphasebetahalflife,0.16722408026755853
areaunderthecurvefromtimezerotothelastsamplingtime,0.16722408026755853
detectable,0.16722408026755853
sssmin,0.16722408026755853
fractionallithiumexcretionfeli,0.16722408026755853
absoluteneutrophilnadir,0.16722408026755853
highestmeasuredconcentration,0.16722408026755853
slowphasehalflife,0.16722408026755853
terminaleliminationconstant,0.16722408026755853
cmincmaxratio,0.16722408026755853
areaundertheserumconcentrationcurvetoinfinityauc,0.16722408026755853
areasunderthecurveauc0t,0.16722408026755853
plasmacbz,0.16722408026755853
renalclearancevr,0.16722408026755853
survivalfraction,0.16722408026755853
distributionhalflivest12alpha,0.16722408026755853
areaundertheplasmaconcentrationtimecurveforlamotrigineaucoinfinity,0.16722408026755853
plasmaconcentrationofropivacaineattheendofepiduralinfusionc48h,0.16722408026755853
maximumtenoxicamplasmaconcentrationcmax,0.16722408026755853
fractionofdoseexcreted,0.16722408026755853
vdbetaf,0.16722408026755853
unboundvolumesofdistribution,0.16722408026755853
peakextracellularlevel,0.16722408026755853
volumeofdistributionratiovdcvdt,0.16722408026755853
maximumdrugdissolutionrate,0.16722408026755853
lengthofeffectiveanalgesia,0.16722408026755853
tssmax,0.16722408026755853
areaundertheplasmaconcentrationcurveauc060,0.16722408026755853
accumulationt12,0.16722408026755853
finalconcentration,0.16722408026755853
absolutetransnasalbioavailability,0.16722408026755853
areaundertheplasmaconcentrationtimecurveaucfromtime0toinfinity,0.16722408026755853
fractionalabsorbance,0.16722408026755853
oralcltotf,0.16722408026755853
apparentphysiologicalvolumev,0.08361204013377926
ao,0.08361204013377926
maximumplasmalidocaineconcentrationsatsteadystate,0.08361204013377926
cit,0.08361204013377926
volumeofseminalplasma,0.08361204013377926
formationhalflife,0.08361204013377926
percentageofdoseexcreted,0.08361204013377926
peakslc,0.08361204013377926
d2occupancie,0.08361204013377926
clearancecltb,0.08361204013377926
ettot,0.08361204013377926
plasmaareaundertheplasmaconcentrationtimecurve,0.08361204013377926
areaundertheserumconcentrationtimecurvesauc0infinity,0.08361204013377926
areaundertheplasmaconcentrationtimecurveofo,0.08361204013377926
nh3output,0.08361204013377926
areaundertheconcentrationtimecurvefromtime0,0.08361204013377926
clbloodclearance,0.08361204013377926
apparentterminalphasehalflife,0.08361204013377926
aucgg,0.08361204013377926
aucgz,0.08361204013377926
hi,0.08361204013377926
areaundertheplasmaconcentrationtimecurvesfrom0to24hoursauc,0.08361204013377926
partitioningratio,0.08361204013377926
detectiontimeadvice,0.08361204013377926
peakplasmaconcentrationofomeprazolecmax,0.08361204013377926
latenttime,0.08361204013377926
fractionoforaldoseabsorbed,0.08361204013377926
concentrationscss,0.08361204013377926
concentrationsat,0.08361204013377926
secondorderassociationrateconstantskome,0.08361204013377926
absolutebioavailabilityforal,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefrom0to24hoursauc024h,0.08361204013377926
apparentdelayedterminalphaset12,0.08361204013377926
areaunderthetimeversusplasmaconcentrationcurve,0.08361204013377926
apparentturnoverrateconstantoftheenzymekout,0.08361204013377926
timeofph5,0.08361204013377926
bloodlevelafterdosingc2peaklevel,0.08361204013377926
halflifeofinhibitionofacidsecretorycapacity,0.08361204013377926
kome,0.08361204013377926
bloodtobile,0.08361204013377926
maximumvelocityofeliminationvmax,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to8h,0.08361204013377926
concentrationleadingto50occupancy,0.08361204013377926
bloodtobraincoefficientofdistribution,0.08361204013377926
areaundertheconcentrationcurveauc0180,0.08361204013377926
troughconcentrationsc24h,0.08361204013377926
peakplasmaconcentrationwascmax,0.08361204013377926
electrophoreticmobility,0.08361204013377926
maximumantibioticgastricjuiceconcentration,0.08361204013377926
tumorcumulatedactivity,0.08361204013377926
auc0metabolicratiomr,0.08361204013377926
serumbetahalflife,0.08361204013377926
buccalbioavailability,0.08361204013377926
terminalhalflivet12,0.08361204013377926
extent,0.08361204013377926
timetoreachmaximalserumconcentrationtmax,0.08361204013377926
ratecmax,0.08361204013377926
peaksteadystateserumconcentration,0.08361204013377926
tumorweightinhibitionrate,0.08361204013377926
preparationtime,0.08361204013377926
ivybleedingtime,0.08361204013377926
precipitationtime,0.08361204013377926
peakpaclitaxelplasmaconcentration,0.08361204013377926
treatmentresponserate,0.08361204013377926
relativetumorgrowthrate,0.08361204013377926
timestoprogression,0.08361204013377926
peakefatutazonebloodlevel,0.08361204013377926
neointimalarea,0.08361204013377926
relativetumorgrowthratetc,0.08361204013377926
tumorresponse,0.08361204013377926
overallresponseratesorr,0.08361204013377926
ratiooflethalityld50ld1,0.08361204013377926
maximumenergy,0.08361204013377926
totalclearancect,0.08361204013377926
bulkflowrate,0.08361204013377926
timeperiodabove,0.08361204013377926
effluxtransportclearancepsbbbeff,0.08361204013377926
permeabilityclearancepsbbb,0.08361204013377926
areaunderthemabplasmaconcentrationtimecurveauc07d,0.08361204013377926
effluxtransportclearancepscsfeff,0.08361204013377926
permeabilityclearancepscsf,0.08361204013377926
maximumtoleratedsystemicexposuremtse,0.08361204013377926
relativetissuedistributionratio,0.08361204013377926
aucareaundertheplotofconcentrationagainsttime,0.08361204013377926
maximumadministered,0.08361204013377926
areaunderthecsfconcentrationtimecurve,0.08361204013377926
steadystatemaximumobservedplasmaconcentrationcssmax,0.08361204013377926
minimalviralinhibitoryconcentration,0.08361204013377926
finalphasehalflifet12beta,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityratio,0.08361204013377926
peakconcentrationofpaclitaxelcmax,0.08361204013377926
releaseefficiency,0.08361204013377926
areaundertheserumconcentrationtimeprofile,0.08361204013377926
generalexcretion,0.08361204013377926
peakplasmabupropionlevel,0.08361204013377926
peakbupropionbreastmilkconcentration,0.08361204013377926
auchyd,0.08361204013377926
areaundertheconcentrationtimecurvefromtime0extrapolatedtoinfinityauc0infinity,0.08361204013377926
ptxtc,0.08361204013377926
ratioofhydro,0.08361204013377926
ratiocsskc50,0.08361204013377926
proteinbindingrate,0.08361204013377926
auctoplasmaaucratio,0.08361204013377926
ratiobetweenplasmaclearanceand,0.08361204013377926
steadystateserumultrafiltrate,0.08361204013377926
renalplasmaflow,0.08361204013377926
timetofailure,0.08361204013377926
plasmauptake,0.08361204013377926
bbbeff,0.08361204013377926
effusiondrainagerate,0.08361204013377926
plasmaeliminationhalflifetimet12b,0.08361204013377926
plasmadistributionhalflifetimet12a,0.08361204013377926
auctarget,0.08361204013377926
plasmamaximalpeakconcentrationcpmax,0.08361204013377926
p24antigen,0.08361204013377926
timetoabsoluteneutrophilcountrecovery,0.08361204013377926
drugplasmamaximalconcentrationcpmax,0.08361204013377926
systemclearancecls,0.08361204013377926
transfusionindependentplateletcountrecovery,0.08361204013377926
betat12eliminationorbetaphasehalflife,0.08361204013377926
apparentdistributionvolumevc,0.08361204013377926
plasmadistributionhalftimet12alpha,0.08361204013377926
timetopeakconcentrationtp,0.08361204013377926
cumulatedurinerecoverie,0.08361204013377926
plasmamaximalconcentrationcpmax,0.08361204013377926
areaundertheconcentrationtimecurvefrom0,0.08361204013377926
maximaltyrosinaemia,0.08361204013377926
lsstime,0.08361204013377926
halflifeofthedistributionphasealpha,0.08361204013377926
mtdlevel,0.08361204013377926
steadystateminimalplasmaconcentration,0.08361204013377926
entrydistributionvolumevc,0.08361204013377926
areaundercurveauc0tofconcentrationtime,0.08361204013377926
cd4cellcount,0.08361204013377926
peakbloodconcn,0.08361204013377926
csfeff,0.08361204013377926
aucsoauc,0.08361204013377926
vmfkm,0.08361204013377926
clmfkm,0.08361204013377926
maximumtransportcapacitytmax,0.08361204013377926
area1,0.08361204013377926
fractionofthedrugunboundinplasma,0.08361204013377926
aucration,0.08361204013377926
solubilityratio,0.08361204013377926
renalbloodclearance,0.08361204013377926
minimalsteadystateplasmadrugconcentrationcssmin,0.08361204013377926
biologict12betaphase,0.08361204013377926
fb,0.08361204013377926
unboundsecretoryintrinsicclearanceclusint,0.08361204013377926
steadystateddcplasmaconcentration,0.08361204013377926
percentagesof,0.08361204013377926
sensitivityfactor,0.08361204013377926
areaundertheconcentrationtimestimecurveauc024,0.08361204013377926
timetoprogressttp,0.08361204013377926
painreliefrate,0.08361204013377926
aucs4h,0.08361204013377926
peakplasmaeacaconcentration,0.08361204013377926
peripheralcompartmentdistributionvolume,0.08361204013377926
populationclearancecl,0.08361204013377926
metaboliteclearance,0.08361204013377926
timetoinfluenzasymptomresolution,0.08361204013377926
bodyweightnormalizedoralclearance,0.08361204013377926
endofinfusionplasmaconcentration,0.08361204013377926
tmaxtime,0.08361204013377926
apparentplasmaclearancedoauc,0.08361204013377926
extractionof,0.08361204013377926
areaunderthebloodconcentrationtimecurveauc0infinity,0.08361204013377926
maximumtacrolimusbloodconcentrationcmax,0.08361204013377926
cdw,0.08361204013377926
codratio,0.08361204013377926
areaundertheplasmaconcentrationtimecurvesforthe12hourdosingintervalauc012,0.08361204013377926
concentrationratiosincsfserum,0.08361204013377926
venousplasma,0.08361204013377926
volumeatsteadystatev,0.08361204013377926
auc042,0.08361204013377926
012hauc,0.08361204013377926
probability,0.08361204013377926
c0atasteadystate,0.08361204013377926
c0todoseratio,0.08361204013377926
timetocessationof,0.08361204013377926
tissuebloodconcentrationsratio,0.08361204013377926
influx,0.08361204013377926
lymphabsorptionrate,0.08361204013377926
troughocconcentration,0.08361204013377926
areaunderthebloodconcentrationtimecurves012hours,0.08361204013377926
areaundertheconcentrationtimecurveforthedosingintervalauc0t,0.08361204013377926
timetonormalizationofrespiratoryfunction,0.08361204013377926
areaunderthetacrolimusconcentrationtimecurveauc024h,0.08361204013377926
maximalresidence,0.08361204013377926
cl14096h,0.08361204013377926
maximumfineparticlefractionfpf,0.08361204013377926
entrappingefficiency,0.08361204013377926
apparentoralvolumeofdistributionatsteadystate,0.08361204013377926
clf415,0.08361204013377926
clf03,0.08361204013377926
auctauatsteadystate,0.08361204013377926
lagtimealag,0.08361204013377926
peakserumconcentrationcmaxofsystemicabsorption,0.08361204013377926
acd4,0.08361204013377926
ptl,0.08361204013377926
timeofpomaximumbloodconcentration,0.08361204013377926
mothertofetustransferratio,0.08361204013377926
terminalexponentialvolumeofdistribution,0.08361204013377926
couplingmolarratio,0.08361204013377926
tac,0.08361204013377926
sustainedvirologicresponserate,0.08361204013377926
weightnormalizedoralclearanceclfclfweight70,0.08361204013377926
relativedoseintensityrdi,0.08361204013377926
initialclearancelevel,0.08361204013377926
abclevel,0.08361204013377926
timetoalleviation,0.08361204013377926
distributionvolumeof,0.08361204013377926
distributionvolumeofthecentralroom,0.08361204013377926
apparentvolumeofdistributionbased,0.08361204013377926
cmaxmd,0.08361204013377926
apparentvolumeofdistributionbasedon,0.08361204013377926
auctaumd,0.08361204013377926
cmaxsd,0.08361204013377926
auctausd,0.08361204013377926
aucmilktoaucserumratio,0.08361204013377926
vrl,0.08361204013377926
steadystateareaunderthecurve,0.08361204013377926
tumorhalflive,0.08361204013377926
halflifealpha,0.08361204013377926
apparentserumt12beta,0.08361204013377926
areaundertheplasmaconcentrationtimecurve012h,0.08361204013377926
terminalt12beta,0.08361204013377926
concentrationxtimeproductstoachieve50inhibitioniauc50,0.08361204013377926
t12alphaalpha,0.08361204013377926
minimumobservedplasmatroughconcentrationctrough,0.08361204013377926
cmaxpeakplasmaconcentration,0.08361204013377926
t12betaeliminationhalflife,0.08361204013377926
plateauplasmalevel,0.08361204013377926
airflowrate,0.08361204013377926
netperitonealdialysisclearance,0.08361204013377926
cumulativereleasepercentage,0.08361204013377926
vdpf,0.08361204013377926
t1212,0.08361204013377926
maximumbloodplasmaratio,0.08361204013377926
maximumqrsdurationemax,0.08361204013377926
drugencapsulationefficiency,0.08361204013377926
troughoclevel,0.08361204013377926
peaktroughconcentration,0.08361204013377926
omaxec50,0.08361204013377926
timetotherapeuticta,0.08361204013377926
treatmentcost,0.08361204013377926
steadystateperfusateconcentrationproducinghalftheeffectc50,0.08361204013377926
apparentdistributionvolumesv,0.08361204013377926
areaunderthecurveofbrainconcentration,0.08361204013377926
tcl50,0.08361204013377926
absorptiondurationta,0.08361204013377926
peakipplasmaratio,0.08361204013377926
areaunderthecurveaucfrom0to24hoursauc024,0.08361204013377926
my,0.08361204013377926
troughbloodconcentrationcmin,0.08361204013377926
overallefficacyfailurerate,0.08361204013377926
peaktransplantedlungconcentration,0.08361204013377926
peakarterialwallpaclitaxellevel,0.08361204013377926
fineparticlefractionfpf,0.08361204013377926
t1221,0.08361204013377926
timetoreachthetargetconcentration,0.08361204013377926
volumeofdistributionofcompartment,0.08361204013377926
ratesofcd4changeacd4,0.08361204013377926
arterialoxygentensionpao2,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to120h,0.08361204013377926
peakaprepitantplasmaconcentration,0.08361204013377926
areaunderthedocetaxelcurveauc0t,0.08361204013377926
occupancyrate,0.08361204013377926
jss,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc0120,0.08361204013377926
120h,0.08361204013377926
maximumconcentrationincmax,0.08361204013377926
minimumtotalvolume,0.08361204013377926
plasmaconcentrationat12hc12h,0.08361204013377926
urinaryrecoveryratewithin,0.08361204013377926
maximummeanserumlevel,0.08361204013377926
aucfromtime0toinfinityauc0inf,0.08361204013377926
areaunderthecurveaucfromtime0totimeoflastmeasurableplasmaconcentrationauc0t,0.08361204013377926
human,0.08361204013377926
troughserumdrugconcentration,0.08361204013377926
absorptionfirstorderrate,0.08361204013377926
maximumbloodclearance,0.08361204013377926
apparentvolumesofthecentralcompartment,0.08361204013377926
distributionvolumeatthesteadystatevdss,0.08361204013377926
areaundertheconcentrationtimecurvebetween0and12husingthetrapezoidalruleauc012,0.08361204013377926
areaundertheconcentrationcurvefor12hoursauc012,0.08361204013377926
timetoreachmaximumbloodconcentration,0.08361204013377926
aucfrom0to24hourspostdoseauc024,0.08361204013377926
cl1753h,0.08361204013377926
viralload,0.08361204013377926
masstochargemz,0.08361204013377926
cl1353h,0.08361204013377926
fractionallithiumclearanceclicin,0.08361204013377926
minimumlopinavirconcentration,0.08361204013377926
areaundertheconcentrationtimecurve08,0.08361204013377926
auc1auctotratio,0.08361204013377926
auc024hresponse,0.08361204013377926
aucfromtimezerohourstothetimeofthelastmeasurabletiotropiumconcentrationauct,0.08361204013377926
areaundertheconcentrationtimecurveaucfromtimezerohourstoinfinityaucinf,0.08361204013377926
overallsystemicavailability,0.08361204013377926
maximumaverageplasmaclonazepamconcentration,0.08361204013377926
metabolicformationrateconstant,0.08361204013377926
tmaxt12beta,0.08361204013377926
terminaleliminationhalflifet05betaor,0.08361204013377926
steadystateconcentrationcs,0.08361204013377926
metabolitesdrugratio,0.08361204013377926
total14cdoserecoverie,0.08361204013377926
terminaleliminationphasezido,0.08361204013377926
skinreleaserateconstantkr,0.08361204013377926
overallplasmaclearance,0.08361204013377926
braincsfpartitioncoefficient,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0to24hour,0.08361204013377926
s50,0.08361204013377926
areaunderthecurveauctometaboliteaucratio,0.08361204013377926
volumeofdistributionduringtheterminalexponentialphaseofdrugeliminationvdbeta,0.08361204013377926
plasmaind,0.08361204013377926
areaunderthetimeconcentrationcurveaucfromtime0totimeofthelastconcentration,0.08361204013377926
bodyweightnormalizeddistributionvolume,0.08361204013377926
oralclearancerate,0.08361204013377926
maximumlidocainelevel,0.08361204013377926
dntc,0.08361204013377926
dosenormalizedtroughconcentrationdntc,0.08361204013377926
totalareaunderthebloodconcentrationtimecurvefromtimezerototimeinfinity,0.08361204013377926
peakmaximalconcentration,0.08361204013377926
peakplasmasch39304concentration,0.08361204013377926
apparenthalflifeoftacrolimust12z,0.08361204013377926
apparentperipheraldistributionvolumev3f,0.08361204013377926
dosenormalizedareaunderthecurve012h,0.08361204013377926
areasundertheplasmaconcentrationversustimecurvefrom0to24h,0.08361204013377926
apparentdrugavailability,0.08361204013377926
troughcmin,0.08361204013377926
solubilisation,0.08361204013377926
ci17524h,0.08361204013377926
ldratio,0.08361204013377926
concentrationtoreach50ofkinactki,0.08361204013377926
troughconcentrationdoseratio,0.08361204013377926
firstbloodtroughlevel,0.08361204013377926
maximumbloodlevelcmax,0.08361204013377926
doseadjustedtroughlevel,0.08361204013377926
bloodtroughconcentrationc0,0.08361204013377926
lit12,0.08361204013377926
maximallidocaineplasmaconcentration,0.08361204013377926
delaysinceg,0.08361204013377926
areaundertheplasmaconcentrationvstimecurveatsteadystate,0.08361204013377926
grwr,0.08361204013377926
timetofirstacuterejection,0.08361204013377926
postdoseconcentrationclast,0.08361204013377926
percentageofdoserecovered,0.08361204013377926
totalmolarquantity,0.08361204013377926
summatedrecoveryrate,0.08361204013377926
maximummetabolizingcapacity,0.08361204013377926
initialdilutionspace,0.08361204013377926
systemicclearanceof,0.08361204013377926
areasunderthedrugconcentrationtimecurveauc0d,0.08361204013377926
maximumdrugconcentrationscmaxd,0.08361204013377926
percenturinaryelimination,0.08361204013377926
averageconcentrationcavg,0.08361204013377926
firstorderrate,0.08361204013377926
timetotherapeutictacrolimusconcentration,0.08361204013377926
percentfecalelimination,0.08361204013377926
troughcna,0.08361204013377926
areaunderthecnaversustimecurve,0.08361204013377926
areaunderthetacconcentrationtimecurve,0.08361204013377926
totalplasmaclearancecltp,0.08361204013377926
halflivesofabsorption,0.08361204013377926
dosenormalized,0.08361204013377926
areaundertheeffecttimecurvefrom0to24hoursaue024h,0.08361204013377926
clearanceclbioavailabilityf,0.08361204013377926
timetopeaklid,0.08361204013377926
durationofbolusactivity,0.08361204013377926
normalizedtotalnortriptylineconcentration,0.08361204013377926
volumeofdistributionintheterminalphasevbeta,0.08361204013377926
cordbloodmaternalplasmaconcentrationratio,0.08361204013377926
peaksteadystateazimilideconcentration,0.08361204013377926
24hourauc,0.08361204013377926
ratiobetweenplateaulevel,0.08361204013377926
recoveryfromplasma,0.08361204013377926
t12pla,0.08361204013377926
maximumserumconcentrationcmaxss,0.08361204013377926
peakglp2level,0.08361204013377926
bloodbrainbarrierclearance,0.08361204013377926
icnb,0.08361204013377926
aucfromtime0to30hour,0.08361204013377926
cumulativetransportedamount,0.08361204013377926
kcsf,0.08361204013377926
eliminationconstantratemax,0.08361204013377926
clpla,0.08361204013377926
steadystatedoripenemcsfconcentration,0.08361204013377926
be50,0.08361204013377926
initialantigenlevel,0.08361204013377926
humanoralbioavailability,0.08361204013377926
removalrateconstant,0.08361204013377926
absorptionlatencytime,0.08361204013377926
apparentclearancef,0.08361204013377926
plasmaclearanceclpl,0.08361204013377926
apparentvolumeofdistributionmax,0.08361204013377926
washoutt12,0.08361204013377926
minimumcminconcentration,0.08361204013377926
troughsteadystateazimilideconcentration,0.08361204013377926
po2,0.08361204013377926
peakantigenlevel,0.08361204013377926
terminalhalflifet12m,0.08361204013377926
aucamt,0.08361204013377926
salivaserumratio,0.08361204013377926
maximumazmconcentration,0.08361204013377926
ic95,0.08361204013377926
plasmaterminaleliminationt12,0.08361204013377926
mrto50,0.08361204013377926
timetoreocclusion,0.08361204013377926
timetolysi,0.08361204013377926
halfmaximalconcentrationic50,0.08361204013377926
glucoseproduction,0.08361204013377926
flung,0.08361204013377926
inhaled,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0to24h,0.08361204013377926
peaklidocaineplasmaconcentration,0.08361204013377926
biliaryclbclearance,0.08361204013377926
steadystateserumlithiumconcentration,0.08361204013377926
minimumsteadystateserumconcentration,0.08361204013377926
apparentmeantotalclearanceclt,0.08361204013377926
vdip,0.08361204013377926
meltpa,0.08361204013377926
alphahalflifet12,0.08361204013377926
concentrationneededtoattainonehalfemax,0.08361204013377926
meanresidencetimesmrt024h,0.08361204013377926
vdpla,0.08361204013377926
peakarahconcentration,0.08361204013377926
topicalabsorption,0.08361204013377926
eliminationhalftimet12b,0.08361204013377926
delayedreleasetimetlag,0.08361204013377926
pulsedreleasetimet0102,0.08361204013377926
aqueouslosscoefficient,0.08361204013377926
delayedreleasetimet01,0.08361204013377926
terminaleliminationrateconstantlz,0.08361204013377926
minimumparticlesizeps,0.08361204013377926
terminaldrughalflife,0.08361204013377926
peakplasmadiclofenaclevel,0.08361204013377926
peaktriamtereneconcentration,0.08361204013377926
skinsurfaceresidue,0.08361204013377926
meanabsorptiontimesmats,0.08361204013377926
distributionphaseconstantalpha,0.08361204013377926
timeto90cumulativeinput,0.08361204013377926
cmaxarithm,0.08361204013377926
peakurineelimination,0.08361204013377926
toxicthresholdconcentration,0.08361204013377926
maxim,0.08361204013377926
thresholdconcentration,0.08361204013377926
peakcortisolconcentration,0.08361204013377926
totalamountsexcreted,0.08361204013377926
meanabsorptiontimeta,0.08361204013377926
steadystadeconcentration,0.08361204013377926
absorptionratiofa,0.08361204013377926
auc012hratio,0.08361204013377926
first24hour,0.08361204013377926
ko,0.08361204013377926
areaundertheconcentrationcurveauc012,0.08361204013377926
coefficientof,0.08361204013377926
eliminationphaseconstantbeta,0.08361204013377926
volumeofthecentralcompartmentvcf,0.08361204013377926
rateofdecrease,0.08361204013377926
maximalipversusplasmaconcentrationratio,0.08361204013377926
totalclearanceofunbound,0.08361204013377926
excretedunchangedin,0.08361204013377926
bloodconcentrationsafter8hour,0.08361204013377926
volumeofthebodycompartmentvareaf,0.08361204013377926
rateconstantofabsorptionka,0.08361204013377926
peakbloodconcentrationscmaxs,0.08361204013377926
apparentexcretion,0.08361204013377926
eliminativehalftime,0.08361204013377926
quicklyreachedpeakconcentration,0.08361204013377926
csflevel,0.08361204013377926
distributionvolumesofthecentralcompartment,0.08361204013377926
reocclusiontime,0.08361204013377926
bacteriologicaleradicationrate,0.08361204013377926
biliaryrecoveryrate,0.08361204013377926
losscoefficient,0.08361204013377926
50effectivedosesed50,0.08361204013377926
overalleradicationrate,0.08361204013377926
auc312,0.08361204013377926
fractionaleffluxrateconstantfromthecentralcompartment,0.08361204013377926
fractionalcatabolicrateconstant,0.08361204013377926
apparentsteadystatevolumesofdistribution,0.08361204013377926
halflivesofserumlevel,0.08361204013377926
auc01440min,0.08361204013377926
overallpregnancyrate,0.08361204013377926
auc0240min,0.08361204013377926
auc0720min,0.08361204013377926
volumeofdistributionvda,0.08361204013377926
areaundercurveauc024,0.08361204013377926
peakplasmalngconcentration,0.08361204013377926
timetoreachthemaximalconcentrationstmax,0.08361204013377926
peripheralvolumev3,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimezerotothetimeofthelastmeasurableconcentrationauc0t,0.08361204013377926
numberofbleedingday,0.08361204013377926
dosenormalizedsteadystateplasmalevel,0.08361204013377926
gastrichalfemptyingtime,0.08361204013377926
plasmaunbounddrugconcentration,0.08361204013377926
inhibitorylevel,0.08361204013377926
minimumsteadystateplasmaconcentration,0.08361204013377926
ratiosofauc024,0.08361204013377926
tissueplasmaratioof,0.08361204013377926
dissolutiontime,0.08361204013377926
noobservedadverseeffectlevel,0.08361204013377926
areaunderthecurveexposurefromt0tot8hoursauc08,0.08361204013377926
pltc,0.08361204013377926
troughforcedexpiratoryvolumein1second,0.08361204013377926
volumeofdistributionofthecentral,0.08361204013377926
plasmareninactivitypra,0.08361204013377926
endogenouseliminationhalflife,0.08361204013377926
tmec,0.08361204013377926
serummethanol,0.08361204013377926
serumhalflifeoftheterminalslope,0.08361204013377926
brainecfplasma,0.08361204013377926
fetaltomaternalplasmaratio,0.08361204013377926
kineticsoftumorcelldeathk1,0.08361204013377926
t4t8ratio,0.08361204013377926
ktm208,0.08361204013377926
peritonealtoplasmaareaunderthecurveratio,0.08361204013377926
kng,0.08361204013377926
clearancebytotalefflux,0.08361204013377926
timeforfloatation,0.08361204013377926
plasmaliconcentrationattimezero,0.08361204013377926
clactive,0.08361204013377926
centralvolumev2,0.08361204013377926
areaundercurvefrom0to24hoursauc024hr,0.08361204013377926
areaundercurvefrom0hourtoinfinityauc0hr,0.08361204013377926
pearlindex,0.08361204013377926
clbulk,0.08361204013377926
ec50nh,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimezero,0.08361204013377926
ratesofconcentrationdecline,0.08361204013377926
clse,0.08361204013377926
peakplasmaqtconcentration,0.08361204013377926
peakformatelevel,0.08361204013377926
apparentvolumeoftheperipheralcompartmentvpf,0.08361204013377926
distributionalclearanceqf,0.08361204013377926
areaunderthecurvefromtime0tothelastmeasurableconcentrationauc0t,0.08361204013377926
breakability,0.08361204013377926
m8ratio,0.08361204013377926
dominanthalflifet12a,0.08361204013377926
2ppex,0.08361204013377926
amnioticfluidtoplasmaratio,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefrom0to32hauc032h,0.08361204013377926
areaunderthecurveauc036h,0.08361204013377926
gexmax,0.08361204013377926
maximumserumurapidillevel,0.08361204013377926
areaunderthecurvebreakpoint,0.08361204013377926
aucex4,0.08361204013377926
hepaticclearancefraction,0.08361204013377926
extractableradioactivity,0.08361204013377926
halflivesinthebetaphase,0.08361204013377926
hepatictissueuptake,0.08361204013377926
90inhibitoryconcentrationic90,0.08361204013377926
rectalsystemicavailability,0.08361204013377926
liverperfusateclearance,0.08361204013377926
peakplasmacpibconcentration,0.08361204013377926
cellpermeability,0.08361204013377926
specificmaximalbindingcapacitybmax,0.08361204013377926
geometricmedian,0.08361204013377926
peakzidovudinelevel,0.08361204013377926
pool,0.08361204013377926
amnioticfluidtomaternalplasmaratio,0.08361204013377926
similarityfactorsf2,0.08361204013377926
milkserum,0.08361204013377926
k51,0.08361204013377926
minimumconcentrationmic,0.08361204013377926
tp2,0.08361204013377926
ttrough,0.08361204013377926
tp1,0.08361204013377926
peakplasmalnglevel,0.08361204013377926
troughserumlngconcentration,0.08361204013377926
percentagerelativebioavailabilityf,0.08361204013377926
steadystateplasmaconcentrationsc,0.08361204013377926
totalcontent,0.08361204013377926
recoveryefficiency,0.08361204013377926
percentfractionunboundfu,0.08361204013377926
c0infinity,0.08361204013377926
intracellularhalflifet12,0.08361204013377926
k32,0.08361204013377926
volumeofdistributionduringtheeliminationbetaphase,0.08361204013377926
k42,0.08361204013377926
k15,0.08361204013377926
maximumseruminsulinlevelcmax,0.08361204013377926
timetomaximumglucoseinfusionratetrmax,0.08361204013377926
fecalexcretionrate,0.08361204013377926
maximumglucoseinfusionratermax,0.08361204013377926
apparentvolumeofdistributionofthecentralcompartmentvf,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefrom0toinfiniteauc0infinity,0.08361204013377926
recirculationtimetc,0.08361204013377926
recirculationratiofc,0.08361204013377926
hepaticextractionratioin,0.08361204013377926
etea,0.08361204013377926
tsub12,0.08361204013377926
absolutef,0.08361204013377926
minimumdoserequiredformaximumcalciumloweringdminmax,0.08361204013377926
apparentvolumesofdistributionavd,0.08361204013377926
plasmaultrafiltrateaucofccpufauc,0.08361204013377926
apparentdrugconcentration,0.08361204013377926
timeabove01micro,0.08361204013377926
durationofdrugconcentration,0.08361204013377926
50cytotoxicdose,0.08361204013377926
saturatedattachmentratio,0.08361204013377926
tissuetoplasmatpconcentrationratio,0.08361204013377926
extractionfractionse,0.08361204013377926
ww,0.08361204013377926
highestobservedconcentrationinplasmacmax,0.08361204013377926
absoluteproximalreabsorptionoffluid,0.08361204013377926
peakplasmafirocoxibconcentrationscmax,0.08361204013377926
accumulationindexr,0.08361204013377926
alphaphasedistributionhalflife,0.08361204013377926
fractionexcretedrenally,0.08361204013377926
aucsublast,0.08361204013377926
plasmadrugconcentrationcmax,0.08361204013377926
renalexcretionratio,0.08361204013377926
fractionalzincabsorption,0.08361204013377926
timetomaximumplasmatelmisartanconcentration,0.08361204013377926
aucsub,0.08361204013377926
immunoreactivesecretinconcentration,0.08361204013377926
immunoreactiveinsulinconcentration,0.08361204013377926
pt,0.08361204013377926
maximallidocaineconcentration,0.08361204013377926
arterialwallconcentration,0.08361204013377926
distributionvolumevdext,0.08361204013377926
maximalradioactivity,0.08361204013377926
peakduration,0.08361204013377926
totaldurationofsecretoryactivity,0.08361204013377926
effectduration,0.08361204013377926
braintissuetoplasmaratio,0.08361204013377926
numberofpeak,0.08361204013377926
intracellularauc,0.08361204013377926
percentageexcreted,0.08361204013377926
plasmaconcentrationcmax,0.08361204013377926
cliv,0.08361204013377926
clpv,0.08361204013377926
totalliverbloodflow,0.08361204013377926
steadystatepaclitaxelconcentrationcss,0.08361204013377926
maximalintraperitonealpaclitaxelconcentration,0.08361204013377926
apparentextrarenalclearance,0.08361204013377926
90effectivedose,0.08361204013377926
halflifetsub12,0.08361204013377926
peritonealfluidversusplasmaaucratio,0.08361204013377926
atsteadystatevdss,0.08361204013377926
recurrencefree,0.08361204013377926
areaundertheeffectcurveauec,0.08361204013377926
maximalbloodlevel,0.08361204013377926
areaundertheserumdigoxinconcentrationcurve,0.08361204013377926
ecrcl,0.08361204013377926
areaunderthecurvet0inf,0.08361204013377926
minimumlevel,0.08361204013377926
dheartrate,0.08361204013377926
drugloadingcoefficient,0.08361204013377926
terminalcatabolichalflife,0.08361204013377926
areaundertheconcentrationversustimecurveauc01,0.08361204013377926
aucif,0.08361204013377926
normalizedfreeplasmaconcentration,0.08361204013377926
mitochondrialhalflive,0.08361204013377926
survivetime,0.08361204013377926
overallabsolute,0.08361204013377926
bioavailabilityki,0.08361204013377926
a2aa1,0.08361204013377926
radioactivityratio,0.08361204013377926
clearanceratescl,0.08361204013377926
muscle,0.08361204013377926
maximumplasmaconcentrationtimetmax,0.08361204013377926
areaundercurveaucratio,0.08361204013377926
intercompartmentaltransportclearance,0.08361204013377926
leveldoseldratio,0.08361204013377926
kant0,0.08361204013377926
masstochargemzratio,0.08361204013377926
halfmaximalin,0.08361204013377926
c6h,0.08361204013377926
systemicclearancescl,0.08361204013377926
areaundertheplasmapropafenoneconcentrationtimecurve,0.08361204013377926
terminaleliminationhalflifevaluest12,0.08361204013377926
timestoreachpeakserumconcentration,0.08361204013377926
trueabsorption,0.08361204013377926
timetoapproachsteadystatetissuelevel,0.08361204013377926
halflifeofmyocardialuptaket12d,0.08361204013377926
serumdigoxinconcentration,0.08361204013377926
aucfinalaucinitialratio,0.08361204013377926
metabolicratios,0.08361204013377926
drugconcentrationratio,0.08361204013377926
areaundertheplasmaticdigoxinconcentrationcurveauc12h,0.08361204013377926
ratiooftheauc0180,0.08361204013377926
steadystateblood,0.08361204013377926
centralvdkg,0.08361204013377926
distributionvd,0.08361204013377926
areaunderplasmaconcentrationtimecurveauc036,0.08361204013377926
aur,0.08361204013377926
steadystatemeanconcentration,0.08361204013377926
plasmabindingunboundfraction,0.08361204013377926
aucloinfinity,0.08361204013377926
partitioningtoerythrocyte,0.08361204013377926
eliminationhalflifev0,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc0tn,0.08361204013377926
unboundtumortoplasmapartitioncoefficientkptuu,0.08361204013377926
plasmaareaundertheconcentrationtimecurve,0.08361204013377926
timeabovethresholdconcentration,0.08361204013377926
remissiontime,0.08361204013377926
timetoachievepeakplasmaconcentration,0.08361204013377926
peakprl,0.08361204013377926
drugfluxe,0.08361204013377926
timetoattainpeakserumconcentration,0.08361204013377926
linearscope,0.08361204013377926
terminalt12lambda,0.08361204013377926
timetoperformancestatusworsening,0.08361204013377926
timetofirstpeakcortisol,0.08361204013377926
minimumabsoluterecoverypercentage,0.08361204013377926
aucsfrom0toinfinityauc0,0.08361204013377926
peakgh,0.08361204013377926
mtctrate,0.08361204013377926
peakarterialwholebloodconcentration,0.08361204013377926
areasunderthecurvefrom0tolastmeasurabletimepointauc0t,0.08361204013377926
distributionvolumeofcortisolatsteadystatevdss,0.08361204013377926
timeoftheconcentrationmaximumtmax,0.08361204013377926
timeatwhich632,0.08361204013377926
aqueoushumorconcentrationpeak,0.08361204013377926
distributionplasmahalflife,0.08361204013377926
aucoralauc,0.08361204013377926
ionizationconstantspkas,0.08361204013377926
areaundercurvefor08hrauc08hr,0.08361204013377926
auc0g,0.08361204013377926
auc026h,0.08361204013377926
areaundertheplasmadrugconcentrationtimecurvefora012hintervalauc,0.08361204013377926
dissociationt12,0.08361204013377926
areaundertheconcentrationtimecurveover12h,0.08361204013377926
areaundertheplasmaconcentrationtimecurvesauc0t,0.08361204013377926
oralmedianlethaldoseld50,0.08361204013377926
secondpeakcortisol,0.08361204013377926
cordbloodmaternalplasmaratio,0.08361204013377926
peakserumtotalcortisolconcentration,0.08361204013377926
reperfusiontime,0.08361204013377926
clm6b,0.08361204013377926
latehalflifet12beta,0.08361204013377926
selectivityindicesefficacytoxicityratio,0.08361204013377926
progressionfreesurvivalpsf,0.08361204013377926
aucdeaqauc,0.08361204013377926
plasmaterminalhalflifeofelimination,0.08361204013377926
plasmatissueplasminogenactivatortpa,0.08361204013377926
settlingvelocity,0.08361204013377926
lowflowrate,0.08361204013377926
meanclearancetime,0.08361204013377926
areaundertheconcentrationtimecurvefromzerotothelastmeasurabletimepoint,0.08361204013377926
terminaleliminationhalflifetimest12beta,0.08361204013377926
auctmaxrefratio,0.08361204013377926
auctmaxref,0.08361204013377926
wetweight,0.08361204013377926
residualthrombu,0.08361204013377926
paincontroltime,0.08361204013377926
bileexcretionratio,0.08361204013377926
troughcortisollevelcmin,0.08361204013377926
firstpeakcortisol,0.08361204013377926
plateautimeofconcentrationsaboveminimumeffectiveconcentrationsmec,0.08361204013377926
vmaxkmratio,0.08361204013377926
peakrtpaconcentration,0.08361204013377926
areaunderthecurvetothelastmeasurableconcentrationauc048,0.08361204013377926
unboundcsfunboundplasmaconcentrationratio,0.08361204013377926
intracellularhalflive,0.08361204013377926
systemicclearancesofdrug,0.08361204013377926
mtdrp2d,0.08361204013377926
50toxicitylevel,0.08361204013377926
diseasecontrolratedcr,0.08361204013377926
totalliclearance,0.08361204013377926
saturabletransportwashalfmaximal,0.08361204013377926
areaunderplasmaconcentrationtimecurvefrom0to24hauc024,0.08361204013377926
halfinhibitoryconcentration,0.08361204013377926
volumeofdistributionduringsteadystatevdbeta,0.08361204013377926
minimumgastricph,0.08361204013377926
halftimeoftheshowphaseofelimination,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc048,0.08361204013377926
aucauc50,0.08361204013377926
plasmaticpeak,0.08361204013377926
maximumplasmalidocaineconcentration,0.08361204013377926
hepaticextractionofdrug,0.08361204013377926
ion,0.08361204013377926
steadystatelidocaineplasmaconcentration,0.08361204013377926
areaunderthedrugconcentrationtimecurveaucratio,0.08361204013377926
peakserumliconcentration,0.08361204013377926
absorptionenhancementratio,0.08361204013377926
volumeofdistributionvdssor,0.08361204013377926
timestoreachthreshold,0.08361204013377926
fcl,0.08361204013377926
areaunderthecurveextrapolatedtoinfinityauc0infinity,0.08361204013377926
cmax024,0.08361204013377926
cmax1224,0.08361204013377926
cmax012,0.08361204013377926
chemicalhalflife,0.08361204013377926
steadystateantigenconcentration,0.08361204013377926
stabilitie,0.08361204013377926
timetoobtainthepeakplasmaconcentrationtmax,0.08361204013377926
arterialoxygensaturation,0.08361204013377926
bioavailabilityofthe,0.08361204013377926
maximumeffectsatsteadystateplasmaconcentration,0.08361204013377926
maximumrateforsaturabledistribution,0.08361204013377926
saturableelimination,0.08361204013377926
rafio,0.08361204013377926
peakreachtime,0.08361204013377926
intercompartmentalclearancebetweencentralandperipheralcompartmentsq12,0.08361204013377926
cltp,0.08361204013377926
q13,0.08361204013377926
concentrationathalfvmaxkm,0.08361204013377926
unbounddrugcl,0.08361204013377926
oralcl,0.08361204013377926
vdtp,0.08361204013377926
concentrationinblood,0.08361204013377926
systemicoralclearancerate,0.08361204013377926
areaundertheconcentrationversustimecurvefromzerotoinfinityauc0,0.08361204013377926
dl50,0.08361204013377926
areabelowthecurveconcentrationtimeauc,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefrom0toinfinityauc0infinity,0.08361204013377926
cmintxb2,0.08361204013377926
timeforsa,0.08361204013377926
totalbodyhalflive,0.08361204013377926
timerequiredafterdrugadministrationtoreachpeakconcentration,0.08361204013377926
rateofentry,0.08361204013377926
fractionalelimination,0.08361204013377926
timetoachievemaximumaspirinconcentration,0.08361204013377926
partialpressureofoxygenathalfsaturation,0.08361204013377926
serumeliminationhalflivest12,0.08361204013377926
areaunderthecurveoftheconcentrationtimeprofilefromtimezerotoinfinityauc0,0.08361204013377926
rateconstantsofdegradation,0.08361204013377926
timestoreachthepeakmaximum,0.08361204013377926
areaundertheplasmaconcentrationtimecurveforthe12hourdosingintervalauc012,0.08361204013377926
timeaveragedtrough,0.08361204013377926
totalexcretedurinarymetabolite,0.08361204013377926
mzion,0.08361204013377926
maximumsemaximibplasmaconcentration,0.08361204013377926
apparentvolumesofdistributionvdssf,0.08361204013377926
areasunderthecurveof,0.08361204013377926
maximumacetylcholinesteraseinhibitionimax,0.08361204013377926
totalbodyretention,0.08361204013377926
cloralf,0.08361204013377926
urinaryhalflive,0.08361204013377926
halflivesterminalphases,0.08361204013377926
absolutebioavailabledose,0.08361204013377926
peaknitrazepamplasmaconcentration,0.08361204013377926
apparentvolumeofdistributionduringthebetaphase,0.08361204013377926
halflivesofabsorptiont12dis,0.08361204013377926
areaundertheconcentrationtimecurveaucfromtimezerotothelastquantifiableconcentrationauc0tlqc,0.08361204013377926
weightnormalisedrenalclearance,0.08361204013377926
apparentvolumeofdistributionv2f,0.08361204013377926
apparentk11,0.08361204013377926
areasunderthecurveauc0,0.08361204013377926
areaunderplasmaconcentrationtimecurveaucratio,0.08361204013377926
areaunderthetimeserumconcentrationcurveauc,0.08361204013377926
peakserummiconazoleconcentration,0.08361204013377926
overallbioavailabilityf,0.08361204013377926
areaundertheplasmaconcentrationtimecurvesto8hauc08,0.08361204013377926
cumulativepercentreleasesigmar24ratio,0.08361204013377926
auclinfinity,0.08361204013377926
firstordert12,0.08361204013377926
halfmaximaldiuresi,0.08361204013377926
maximaldiuresi,0.08361204013377926
timeinwhich,0.08361204013377926
stoolexcretion,0.08361204013377926
auc0mrt,0.08361204013377926
halflifeatlphaset12l,0.08361204013377926
areaundertheconcentrationtimecurvein0auc0,0.08361204013377926
totalbodyt12,0.08361204013377926
areaundertheconcentrationcurveratio,0.08361204013377926
totalbinding,0.08361204013377926
betahalflifebiologicalhalflifeforterminalslope,0.08361204013377926
peakfreeoxaprozinserumlevel,0.08361204013377926
halftimeofcholinesteraserecovery,0.08361204013377926
gutbloodbarrierpermeability,0.08361204013377926
steadystatecpnecessary,0.08361204013377926
distributionpseudoequilbriumhalftimet12alpha,0.08361204013377926
fractionofthedoseexcretedunchangedinurine,0.08361204013377926
auc0264h,0.08361204013377926
t0concentration,0.08361204013377926
v88duofunbounddrug,0.08361204013377926
timeofonsetof,0.08361204013377926
meanresidencetimet,0.08361204013377926
centralvolumeofdistributionv,0.08361204013377926
partitioncoefficientinoctanolwaterlogp,0.08361204013377926
peakplasmaaaconcentration,0.08361204013377926
maximumfeasibledose,0.08361204013377926
totalturnover,0.08361204013377926
c1a,0.08361204013377926
clinicalcure,0.08361204013377926
eliminationratio,0.08361204013377926
urineelimination,0.08361204013377926
biosynthesi,0.08361204013377926
apparentrenal,0.08361204013377926
esaindex,0.08361204013377926
milktoplasmampconcentrationratio,0.08361204013377926
incorporation,0.08361204013377926
ammonia,0.08361204013377926
effectiveplasmaconcentrationsfor50paralysisecp50,0.08361204013377926
emg,0.08361204013377926
voralf,0.08361204013377926
nethb,0.08361204013377926
maximumplasmacholinesteraseinhibition,0.08361204013377926
volumeofdistributionbasedontotalarea,0.08361204013377926
inhibitionhalflife,0.08361204013377926
urinaryeliminationrateconstantku,0.08361204013377926
cumulativepercentofradioactivityexcreted,0.08361204013377926
cho,0.08361204013377926
concentrationinbrain,0.08361204013377926
phy,0.08361204013377926
clearancec1,0.08361204013377926
serumtobileratio,0.08361204013377926
halflifeofthesecondeliminationphase,0.08361204013377926
observedtimetoreachmaximumconcentration,0.08361204013377926
apparentvolumeofdistributionduringtheterminaleliminationphase,0.08361204013377926
apparentdrugclearanceclffromthecentralcompartment,0.08361204013377926
totalcumulativerecovery,0.08361204013377926
percentremaining,0.08361204013377926
cumulativebiliarygoldexcretion,0.08361204013377926
organretention,0.08361204013377926
distributionvolumeoftheterminalphasevz,0.08361204013377926
ironutilizationrate,0.08361204013377926
bodypoolsize,0.08361204013377926
entryrate,0.08361204013377926
peakplasmavitamincconcentration,0.08361204013377926
areaundertheconcentrationversustimecurvefromthelastdosetoinfinity,0.08361204013377926
timestosteadystatemaximumplasmaconcentration,0.08361204013377926
steadystatetroughplasmadigoxinconcentration,0.08361204013377926
eliminationhalflifest12s,0.08361204013377926
dosenormalizedconcentration,0.08361204013377926
tissuehalflifet12,0.08361204013377926
tissuet12,0.08361204013377926
aucsratio,0.08361204013377926
troughcp,0.08361204013377926
troughsteadystateplasmaamantadineconcentrationcp,0.08361204013377926
maximumirinotecanplasmaconcentration,0.08361204013377926
peakcbzplasmalevel,0.08361204013377926
steadystatetroughserumcbzconcentration,0.08361204013377926
14,0.08361204013377926
meantransittimeintheperipheraltissuesmttt,0.08361204013377926
seizurerate,0.08361204013377926
percentdrugcontentdissolved,0.08361204013377926
gradientelutionflow,0.08361204013377926
plasmareleasehalflive,0.08361204013377926
plasmareleasehalflife,0.08361204013377926
poststeadystatehalflife,0.08361204013377926
maximumnasalmucusdrugconcentration,0.08361204013377926
areaunderthecurveirinotecanareaunderthecurveratio,0.08361204013377926
molarratiooftheareaundertheconcentrationcurveauc,0.08361204013377926
maximumserumcarbamazepineconcentration,0.08361204013377926
matrix,0.08361204013377926
zaverage,0.08361204013377926
peakclearance,0.08361204013377926
ratioofthe,0.08361204013377926
oilcarryingcapacity,0.08361204013377926
halflifeofinterconversion,0.08361204013377926
clpof,0.08361204013377926
vlvolumeofdistributionofcentralcompartment,0.08361204013377926
michaelisconstantfor,0.08361204013377926
maximalsafeplasmaconcentration,0.08361204013377926
availabilitytothesystemiccirculationf,0.08361204013377926
totalquantityofdrugremoved,0.08361204013377926
biliaryindexe,0.08361204013377926
peakcsflactoneconcentration,0.08361204013377926
steadystatecbzserumlevel,0.08361204013377926
clearancedividedbyformationfractionfm,0.08361204013377926
vssfm,0.08361204013377926
tumorinhibitoryratetir,0.08361204013377926
biliaryindex,0.08361204013377926
drugantibodyratiodar,0.08361204013377926
maternalmilkserumconcentrationratio,0.08361204013377926
diffusionalcoefficient,0.08361204013377926
areaundertheplasmaconcentrationversusthetimecurveauc,0.08361204013377926
dosenormalizedareaundertheplasmaconcentrationtimecurve,0.08361204013377926
timetomtd,0.08361204013377926
urinaryexcretiont12,0.08361204013377926
timeofdiseasecontrol,0.08361204013377926
overallsurvivalpfsos,0.08361204013377926
maximumconjugationyield,0.08361204013377926
cbz,0.08361204013377926
maximumcbzconcentrationscmax,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezerototimeinfinityaucinf,0.08361204013377926
vi,0.08361204013377926
bioadhesiveforce,0.08361204013377926
fdet,0.08361204013377926
oadh,0.08361204013377926
ied,0.08361204013377926
percentdrugcontent,0.08361204013377926
ic50inhibitoryconcentration50,0.08361204013377926
areaunderthecurvefromzerotoinfinityauc0infinity,0.08361204013377926
areaundertheserumcbzconcentrationtimecurve,0.08361204013377926
vunb,0.08361204013377926
maximalplasmalevelcmax,0.08361204013377926
timeto50maturation,0.08361204013377926
pfserumratio,0.08361204013377926
aucalpha,0.08361204013377926
kacka,0.08361204013377926
arterialtovenousplasmapirenzepineratio,0.08361204013377926
cpsst,0.08361204013377926
refractivepoint,0.08361204013377926
areaundertheplasmarosiglitazoneconcentrationversustimecurve,0.08361204013377926
steadystateareaundertheconcentrationtimecurveover24hour,0.08361204013377926
steadystatetroughserumconcentrationscpsst,0.08361204013377926
percentagebinding,0.08361204013377926
areaundertheplasmaalprazolamconcentrationversustimecurve,0.08361204013377926
timetopeakconcentrationcmaxor,0.08361204013377926
aparameter,0.08361204013377926
serumdrugconcentration,0.08361204013377926
conjugationratio,0.08361204013377926
apparentmetabolicclearance,0.08361204013377926
areaundertheconcentrationtimecurveauc06,0.08361204013377926
apparentvolumesofdistributionsaliva,0.08361204013377926
serumareaundertheconcentrationtimecurve024h,0.08361204013377926
fcsf,0.08361204013377926
percentageofadministereddoseexcretedunchanged,0.08361204013377926
areaundertheplasmaconcentrationcurveaucfrom0to96hour,0.08361204013377926
dosenormalisedaucratio,0.08361204013377926
totaltransittime,0.08361204013377926
steadypeakconcentration,0.08361204013377926
peakserumcbzconcentration,0.08361204013377926
volumeofcentralcompartmentv3,0.08361204013377926
firstordereliminationrateconstantk30,0.08361204013377926
auc030h,0.08361204013377926
firstordereliminationrateconstantk10,0.08361204013377926
auc48h,0.08361204013377926
aucfrom0toinfinity,0.08361204013377926
dnaadductformation,0.08361204013377926
percenturinaryexcretionofdoseue,0.08361204013377926
metabolicratioof,0.08361204013377926
volumeratiosofantisolventtosolvent,0.08361204013377926
apparentrenalclearanceoftheactiveantipsychoticfraction,0.08361204013377926
peaktroughcarbamazepineserumlevelratio,0.08361204013377926
peakmeantroughcarbamazepineserumconcentrationratio,0.08361204013377926
fractionaldegradation,0.08361204013377926
percentagepermeatedamount,0.08361204013377926
areaundertheunboundplasmaconcentrationtimeprofileofflurbiprofenaucu,0.08361204013377926
portion,0.08361204013377926
structuralmeltingtemperaturetm,0.08361204013377926
halflifeofbetaelimination,0.08361204013377926
auc24hr,0.08361204013377926
dnadecline,0.08361204013377926
timetotheonsetofsleep,0.08361204013377926
plasmahepaticclearance,0.08361204013377926
highaffinityconstant,0.08361204013377926
oralsystemic,0.08361204013377926
totalintracellularconcentration,0.08361204013377926
maximumplasmamethohexitalconcentration,0.08361204013377926
relativebioavailiability,0.08361204013377926
halflifet12lambda1,0.08361204013377926
baa,0.08361204013377926
eliminationconstantratekel,0.08361204013377926
areaundertheconcentrationtimecurvefrom2to5hauc25,0.08361204013377926
timeafterdrugadministrationtoreachcmaxtmax,0.08361204013377926
numberoftransitcompartment,0.08361204013377926
maximumdrugconcentrationinbloodserumcmax,0.08361204013377926
vdprocainamide,0.08361204013377926
accumulationaccumulationrate,0.08361204013377926
oralapparentvolumeofdistributionatsteadystatevssf,0.08361204013377926
desorptionkd,0.08361204013377926
oralsystemicclearanceclf,0.08361204013377926
kcatkm,0.08361204013377926
excretedintourine,0.08361204013377926
peakabt751concentration,0.08361204013377926
vdn,0.08361204013377926
areaundertheserumdigoxincurve,0.08361204013377926
relativeextent,0.08361204013377926
metabolicclearancerateundersteadystatecondition,0.08361204013377926
targetplasmaconcentrationcpt,0.08361204013377926
biliaryconcentration,0.08361204013377926
clearancecl1,0.08361204013377926
maximalbileplasmaconcentrationratio,0.08361204013377926
apparentabsorptiont12,0.08361204013377926
ratioofareaundertheplasmaconcentrationtimecurvesaucr,0.08361204013377926
meanplasmaconcentrationsat30minute,0.08361204013377926
initialdispositionphasehalflife,0.08361204013377926
auc014day,0.08361204013377926
plasmaauc014day,0.08361204013377926
maximumintravenousinfusionrate,0.08361204013377926
relativetargetingefficiency,0.08361204013377926
c20tmic,0.08361204013377926
clinicalbenefitratecbr,0.08361204013377926
systemicpeakconcentration,0.08361204013377926
metabolicto,0.08361204013377926
auc024pge2,0.08361204013377926
lossinurine,0.08361204013377926
theoreticalmaximumserumconcentration,0.08361204013377926
brmmpratio,0.08361204013377926
bloodbrainbarrierpermeabilitysurfacearea,0.08361204013377926
apparentoralclearancecl,0.08361204013377926
bloodretention,0.08361204013377926
characteristictime,0.08361204013377926
minimumrelease,0.08361204013377926
taumax,0.08361204013377926
apparentlinearclearance,0.08361204013377926
timeatwhichthisconcentrationwasattainedtpeak,0.08361204013377926
maximumpercenteffect,0.08361204013377926
hillslope,0.08361204013377926
rateofredcellcountertransport,0.08361204013377926
renalfractionallithiumclearance,0.08361204013377926
terminaleliminationhalflifebetat12,0.08361204013377926
apparentmeanserumhalflife,0.08361204013377926
iscl,0.08361204013377926
timetoreachthemaximalplasmaconcentration,0.08361204013377926
terminalphaseplasmahalflifet12b,0.08361204013377926
pseudoequilibriumplasmaconcentration,0.08361204013377926
elimination12,0.08361204013377926
initialclearancet12a,0.08361204013377926
areaunderconcentrationtimecurveauc024h,0.08361204013377926
distributionhalflifealphat12,0.08361204013377926
cor,0.08361204013377926
oralbioavailabilityobav,0.08361204013377926
metabolicclearancecim,0.08361204013377926
t12zeta,0.08361204013377926
areaundertheci941plasmaconcentrationxtimecurveauc,0.08361204013377926
nonrenalclearence,0.08361204013377926
halflifeofthedistributionalphaphase,0.08361204013377926
apparentspecificvolumeofdistributionofthecentralcompartmentvc,0.08361204013377926
durationofprogressionfreesurvival,0.08361204013377926
serumvalue,0.08361204013377926
dna,0.08361204013377926
clsfn,0.08361204013377926
volumeofthecentralcompartmentvl,0.08361204013377926
feli,0.08361204013377926
apparenttotalcolchicineclearance,0.08361204013377926
relativeoral,0.08361204013377926
tumourtoplasmaratio,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc1auc3,0.08361204013377926
auc3,0.08361204013377926
clsfp,0.08361204013377926
volumeatsteadystatevdss,0.08361204013377926
urinetoplasmaconcentrationratiosup,0.08361204013377926
apparentvolumeofdistributionisvd,0.08361204013377926
totalamountexcretedinurine,0.08361204013377926
timesatmaximumconcentration,0.08361204013377926
clearanceiscl,0.08361204013377926
availabilityf,0.08361204013377926
doseauc,0.08361204013377926
aque,0.08361204013377926
plasmaterminalhalflive,0.08361204013377926
plasmahalflifeduringthebetaphase,0.08361204013377926
clearanceofnapacld,0.08361204013377926
octt,0.08361204013377926
volumeofdistributionatthesteadystate,0.08361204013377926
ocularbioavailabilitie,0.08361204013377926
totalpaclearance,0.08361204013377926
percentdissolved,0.08361204013377926
halftimefor50release,0.08361204013377926
predosepeakrange,0.08361204013377926
peakextrapol,0.08361204013377926
ar,0.08361204013377926
part,0.08361204013377926
urinaryexcretionofsodium,0.08361204013377926
metabolitemilkplasmaauc012ratio,0.08361204013377926
vascularresistance,0.08361204013377926
criv,0.08361204013377926
lateraldiffusion,0.08361204013377926
peakheighttmc50,0.08361204013377926
urinaryurate,0.08361204013377926
plasmaurate,0.08361204013377926
timeatwhichmaximalconcentration,0.08361204013377926
cerebrospinalfluidcsflevel,0.08361204013377926
lungtoplasmaratio,0.08361204013377926
distaltubularresorptionofsodium,0.08361204013377926
clearanceoflithiumclli,0.08361204013377926
fractionexcretion,0.08361204013377926
mrmtransition,0.08361204013377926
rbclo,0.08361204013377926
plasmahalflifet12lambda2,0.08361204013377926
timetoreachtheconcentrationpeak,0.08361204013377926
kbobeta,0.08361204013377926
halflifeintheblood,0.08361204013377926
timeatwhichpeakprocainamideplasmaconcentrationsoccurred,0.08361204013377926
aqueoushumoreliminationhalflife,0.08361204013377926
oculardistributionhalflive,0.08361204013377926
adverseeventrate,0.08361204013377926
maximumconcentrationsofthensaidinplasmacmax,0.08361204013377926
transdermalpermeationrate,0.08361204013377926
peaknapaconcentration,0.08361204013377926
peakplasmaflurbiprofenconcentration,0.08361204013377926
thcl,0.08361204013377926
thvd,0.08361204013377926
thke,0.08361204013377926
aucsaucr,0.08361204013377926
maximumpercentedemainhibition,0.08361204013377926
cbcfratio,0.08361204013377926
ratiooftheareaunderfreedrugplasmaconcentrationtimecurveover24hfauctomic90faucmic,0.08361204013377926
micsu,0.08361204013377926
percutaneousabsorptionratio,0.08361204013377926
halflifeforsedationt12ke0,0.08361204013377926
rbcplasmaratio,0.08361204013377926
timetothemeanobservedpeakserumlithiumconcentration,0.08361204013377926
bodypool,0.08361204013377926
1h,0.08361204013377926
ratioatsteadystate,0.08361204013377926
observedpeakserumlithiumconcentration,0.08361204013377926
peakserumpaconcentration,0.08361204013377926
linearconcentration,0.08361204013377926
recoveryofthetofratio,0.08361204013377926
timetoreachtherapeuticconcentration,0.08361204013377926
diffusionalclearance,0.08361204013377926
minimumeffectivelevel,0.08361204013377926
timeabovetheminimumeffectiveconcentrationtmec,0.08361204013377926
administereddose,0.08361204013377926
concentrationintheeffectcompartmentat50block,0.08361204013377926
s0,0.08361204013377926
effectivedose95,0.08361204013377926
bloodtransfusion,0.08361204013377926
c0hd,0.08361204013377926
areaundertheconcentrationtimecurvefromtime0toinfinityauc0,0.08361204013377926
areaundertheconcentrationtimecurvefromtime0tothelasttimepointwithbloodsamplecollectionauc0t,0.08361204013377926
permeabilitycoefficientpapp,0.08361204013377926
overallbacterialeradicationrate,0.08361204013377926
timesfromadministrationoflastincrementaldoseuntil25offirstresponseoftrainoffourtofrecovery,0.08361204013377926
urinaryexcretionofradio,0.08361204013377926
0,0.08361204013377926
trainoffour,0.08361204013377926
diffusionaltimeconstant,0.08361204013377926
apparentpermeabilitysurfaceareaproduct,0.08361204013377926
halflifeoftransport,0.08361204013377926
noobservableadverseeffectlevelnoael,0.08361204013377926
maximumblock,0.08361204013377926
concentrationintheeffectcompartmentassociatedwitha50drugeffectec50,0.08361204013377926
spontaneousrecoverytime,0.08361204013377926
systemicexposureauc06,0.08361204013377926
areaundertheplasmaleveltimecurveauc,0.08361204013377926
cta,0.08361204013377926
distalsodiumreabsorption,0.08361204013377926
vlambdazf,0.08361204013377926
fractionalproximalreabsorptionfpr,0.08361204013377926
clearancecli,0.08361204013377926
totalwartarea,0.08361204013377926
multipledoseaccumulationratio,0.08361204013377926
peakserumimiquimodconcentration,0.08361204013377926
completeclearancerate,0.08361204013377926
auc044,0.08361204013377926
ec,0.08361204013377926
urinaryexcretionfraction,0.08361204013377926
volumeofthesecondcompartment,0.08361204013377926
timefromsugammadextorecoverytotrainoffourt4t1ratio,0.08361204013377926
timefromsugammadextorecoverytot4t1ratio09,0.08361204013377926
t12serum,0.08361204013377926
24hourrecovery,0.08361204013377926
plasmadialysance,0.08361204013377926
aucoe,0.08361204013377926
h0,0.08361204013377926
du,0.08361204013377926
areaunderthecurvefordrugconcentration,0.08361204013377926
cla,0.08361204013377926
steadystatetxaplasmaconcentration,0.08361204013377926
integraloftheareaundertheconcentrationtimecurveauc0t,0.08361204013377926
concentrationdeterminedatsteadystate,0.08361204013377926
plasmahalflifest12s,0.08361204013377926
tic50,0.08361204013377926
aucic50,0.08361204013377926
cmaxic50,0.08361204013377926
tissueplasmaareaundertheconcentrationtimecurveratio,0.08361204013377926
redcellconcentration,0.08361204013377926
peakplasmalidocaineconcentration,0.08361204013377926
clcvvh,0.08361204013377926
halflifet12oftheeliminationphase,0.08361204013377926
halflifeofplasmaeliminationduringbetaphase,0.08361204013377926
steadystatelidocaineconcentration,0.08361204013377926
oralterminalexponentialvolumeofdistribution,0.08361204013377926
interstitialfluidspace,0.08361204013377926
timetoreachpeakplasmaleveltmax,0.08361204013377926
durationofclinicalbenefit,0.08361204013377926
overallresponderrate,0.08361204013377926
ventricularrate,0.08361204013377926
effectivehalflifet12,0.08361204013377926
ctroughplasmaconcentration,0.08361204013377926
tmaxtimetomaximumconcentrationofdruginserum,0.08361204013377926
responseratecrpr,0.08361204013377926
dosenormalizedplasmaauc012h,0.08361204013377926
maximallytolerateddose,0.08361204013377926
zeroordersynthesisrate,0.08361204013377926
peakwholebrainuptake,0.08361204013377926
timetoreachit,0.08361204013377926
dosenormalizedaucratio,0.08361204013377926
troughc8h,0.08361204013377926
auc011,0.08361204013377926
nettubularsecretion,0.08361204013377926
density,0.08361204013377926
ke1h,0.08361204013377926
aucpop,0.08361204013377926
meanresidencetimeinthebodymrtiv,0.08361204013377926
effectiveanalgesicconcentrationdurationseacds,0.08361204013377926
maximumnalbuphineconcentrationscmax,0.08361204013377926
timetoachievethemaximumplasmaconcentrationcmax,0.08361204013377926
nettubularreabsorption,0.08361204013377926
areaundertheconcentrationtimecurvefrom0hto12h,0.08361204013377926
hepaticclearanceclhpre,0.08361204013377926
clptotal,0.08361204013377926
totalplasmaclearanceclptotal,0.08361204013377926
plasmaconcentrationatsteadystatecss,0.08361204013377926
percentageinhibitioniss,0.08361204013377926
areaunderthecurveauc0inf,0.08361204013377926
degreeofaccumulationra,0.08361204013377926
maximumpercentageinhibitionimax,0.08361204013377926
vlambdazfatsteadystate,0.08361204013377926
volumeofdistributioninthesteadystatevdssf,0.08361204013377926
flowtime,0.08361204013377926
maximalacheinhibitionemax,0.08361204013377926
absorptionauc0,0.08361204013377926
totalhepaticmetaboliteconcentration,0.08361204013377926
conversiontime,0.08361204013377926
timefort110,0.08361204013377926
polydispersitie,0.08361204013377926
particlesized50,0.08361204013377926
eliminationhalflivest12lz,0.08361204013377926
overallsystemicexposure,0.08361204013377926
fastphasehalflife,0.08361204013377926
048h,0.08361204013377926
positiveresponserate,0.08361204013377926
permanentclosurerate,0.08361204013377926
surfaceunderthecurveaucolead,0.08361204013377926
eliminationhalflifeofindomethacint12beta,0.08361204013377926
volumeofdrugdistribution,0.08361204013377926
fastedstateabsolutebioavailabilityf,0.08361204013377926
nadircount,0.08361204013377926
peakabsolutemonocytecount,0.08361204013377926
drugbioavailability,0.08361204013377926
volumeduringeliminationphase,0.08361204013377926
activationenergyofthermaldegradation,0.08361204013377926
totalmetabolicclearancecltbw,0.08361204013377926
distributionvolumevdbw,0.08361204013377926
initialplasmaconcentrationco,0.08361204013377926
steadystateplasmaconcentrationscssp,0.08361204013377926
areaundertheconcentrationtimecurveover24h,0.08361204013377926
timetoachievemaximumplasmaconcentrationtmax,0.08361204013377926
lagtimebetweendosingandfirstappearance,0.08361204013377926
apparentinhibitionconstant,0.08361204013377926
maximumplasmaindometacinconcentration,0.08361204013377926
numberoftreatmentscycle,0.08361204013377926
areaundertheplasmaindometacinconcentrationtimecurve,0.08361204013377926
balconcentration,0.08361204013377926
terminalt12washout,0.08361204013377926
ctthreshold,0.08361204013377926
totalcycletime,0.08361204013377926
peakribavirinlevel,0.08361204013377926
plasmacthroughlevel,0.08361204013377926
areaundertheconcentrationtimecurveauclast,0.08361204013377926
cumulativeamountofdrugrelease,0.08361204013377926
disco,0.08361204013377926
sustainedvirologicalresponseratessvr,0.08361204013377926
troughconcentrationc24,0.08361204013377926
hazardratio,0.08361204013377926
bia5961,0.08361204013377926
highestflux,0.08361204013377926
folding,0.08361204013377926
vft,0.08361204013377926
firstorderdecayconstant,0.08361204013377926
areaundertheserumconcentrationtimecurvefromtimezerotoinfinityaucinf,0.08361204013377926
fatplasmaconcentrationratio,0.08361204013377926
serumunboundfraction,0.08361204013377926
terminalhalflifetimeofplasmaconcentration,0.08361204013377926
ratiooftotaltocentraldistributionvolume,0.08361204013377926
maximalplasmabiperidenconcentration,0.08361204013377926
plasmaterminalhalflifet112,0.08361204013377926
timeformaximumplasmaconcentrationtmax,0.08361204013377926
placentalclearanceclpl,0.08361204013377926
eliminationfromthecentralcompartment,0.08361204013377926
areaunderthefreeplasmaconcentrationversustimecurveauc,0.08361204013377926
aucnapa,0.08361204013377926
distributionalclearanceattheterminalphase,0.08361204013377926
absoluteclearancecl,0.08361204013377926
cellularuptaket12,0.08361204013377926
bloodhalflifetime,0.08361204013377926
netrespiratoryuptake,0.08361204013377926
halflifeofdecay,0.08361204013377926
gammat12ghalflive,0.08361204013377926
betat12b,0.08361204013377926
excretionfractionintheurine,0.08361204013377926
kineticconstant,0.08361204013377926
alphaphasehalflive,0.08361204013377926
rateconstantoftransport,0.08361204013377926
halflivesofexcretion,0.08361204013377926
peakpaclitaxelconcentration,0.08361204013377926
durationofeffectfrom,0.08361204013377926
percutaneouspermeabilitycoefficientkp,0.08361204013377926
concentrationsperdose,0.08361204013377926
areaunderthecurvewindow,0.08361204013377926
t12terminaleliminationhalflife,0.08361204013377926
alphat12a,0.08361204013377926
drugreleaserateconstant,0.08361204013377926
peakserumlidocaineconcentration,0.08361204013377926
peakplasmamifepristoneconcentration,0.08361204013377926
populationabsorptionrateconstant,0.08361204013377926
totalretention,0.08361204013377926
maximalcontent,0.08361204013377926
overallcompletepluspartialresponserate,0.08361204013377926
maximumobtainablereceptoroccupancyomax,0.08361204013377926
bu,0.08361204013377926
fractionofunboundlidocainein,0.08361204013377926
steadystatedistribution,0.08361204013377926
med,0.08361204013377926
clearancevolume,0.08361204013377926
aucauc8,0.08361204013377926
95,0.08361204013377926
peakwidth,0.08361204013377926
areasundertheconcentrationcurvesaucs024h,0.08361204013377926
maximumpaclitaxelplasmaconcentration,0.08361204013377926
areaundertheserumconcentrationtimecurvefor72hauc072,0.08361204013377926
rapidphasehalflife,0.08361204013377926
areaundertheconcentrationtimecurveuntil24hour,0.08361204013377926
areaundertheplasmacurvefromtimezerotoinfinity,0.08361204013377926
serumconcentrationauc0120h,0.08361204013377926
rateofcontinuousdripinfusion,0.08361204013377926
halfmaximuminhibitoryconcentration,0.08361204013377926
k12k21,0.08361204013377926
eliminationphasehalflifest12,0.08361204013377926
peakconcentrationsinbile,0.08361204013377926
peakplasmaplatinumpt,0.08361204013377926
firstorderrateconstantofeliminationke,0.08361204013377926
steadystaterecoverytime,0.08361204013377926
firstdosesteadystateconcentration,0.08361204013377926
secondorderratesofreaction,0.08361204013377926
maximumplasmaconcentrationatsteadystatecmax,0.08361204013377926
meanresidencetimet12,0.08361204013377926
firstorder,0.08361204013377926
freedomfromprogression,0.08361204013377926
timeabovepaclitaxelplasmaconcentration,0.08361204013377926
areaunderthefreeplatinumplasmaconcentrationtimecurveaucfp,0.08361204013377926
maximumplasmasodiumdichloroacetateconcentration,0.08361204013377926
aucfp,0.08361204013377926
volumeoffluidremainingin,0.08361204013377926
concentrationattheendof24hdosingintervalcmin,0.08361204013377926
eliminationmicroconstantske,0.08361204013377926
maximumplasmaconcentrationscmaxatsteadystatecmaxss,0.08361204013377926
kelim,0.08361204013377926
zeroorderelimination,0.08361204013377926
areaundertheplasmaconcentrationtimecurveoveradosingintervalatthesteadystateaucss,0.08361204013377926
avb,0.08361204013377926
plasmanaconcentration,0.08361204013377926
venouslactateconcentration,0.08361204013377926
peakpostinfusionlevel,0.08361204013377926
solubilizationefficiency,0.08361204013377926
plasmaantioxidantcapacity,0.08361204013377926
releasepercent,0.08361204013377926
maximalmetabolicratevmax,0.08361204013377926
tumourresponserate,0.08361204013377926
kgst,0.08361204013377926
maximumdepletion,0.08361204013377926
halflifefor,0.08361204013377926
hepaticuptakeclearance,0.08361204013377926
clearancecorrectedbybioavailability,0.08361204013377926
aucinfareaunderthetimevsconcentrationcurvefrom0toinfinity,0.08361204013377926
seroquel,0.08361204013377926
milkplasmadrugconcentrationratio,0.08361204013377926
percentagediffusion,0.08361204013377926
tumourbloodratio,0.08361204013377926
il8,0.08361204013377926
minimumparticlesize,0.08361204013377926
concentrationefficiency,0.08361204013377926
molarpercentage,0.08361204013377926
firstorderrateconstantsfor,0.08361204013377926
transitfromcentraltoperipheralcompartmentskcp,0.08361204013377926
maximalrateofeliminationvm10,0.08361204013377926
volumefraction,0.08361204013377926
halftimesforelimination,0.08361204013377926
timestoreachthecmax,0.08361204013377926
peakfreedaconcentration,0.08361204013377926
aucsubtsub,0.08361204013377926
timeabovethreshold,0.08361204013377926
firstordergshconjugation,0.08361204013377926
csubmin,0.08361204013377926
chromatographicanalysistime,0.08361204013377926
cmaxplasmalevel,0.08361204013377926
peaktriamcinoloneconcentration,0.08361204013377926
srratioofauc,0.08361204013377926
terminaleliminationrateconstantlambdaz,0.08361204013377926
clearanceclcr,0.08361204013377926
nitcontent,0.08361204013377926
ratiooftheaucoinfinity,0.08361204013377926
fractionunboundinserum,0.08361204013377926
dosenormal,0.08361204013377926
durationofthisplateau,0.08361204013377926
zeroorderinvitrorelease,0.08361204013377926
timeformaximumconcentrationtmax,0.08361204013377926
vbetavolumeofdistributionofeliminationphase,0.08361204013377926
maximalplasmaatenololconcentration,0.08361204013377926
ten,0.08361204013377926
constantpartitionratio,0.08361204013377926
fractionofabsorbed,0.08361204013377926
unboundvolumeofdistributioninbrainvubrain,0.08361204013377926
entrapmentefficiencypercentage,0.08361204013377926
unboundfractionfubrain,0.08361204013377926
amountexcretedunchangedinurine,0.08361204013377926
bloodbrainbarrierpenetratingpotential,0.08361204013377926
maximumheartrateduringexercise,0.08361204013377926
systemicdoseabsorbed,0.08361204013377926
injectionrate,0.08361204013377926
mfdratio,0.08361204013377926
wetting,0.08361204013377926
areasundertheplasmaconcentrationtimecurvesauc016,0.08361204013377926
areaunderbloodconcentrationtimecurveauc,0.08361204013377926
troughplasmaatenololconcentration,0.08361204013377926
netacidexcretion,0.08361204013377926
timeforhalfofthebioavailabledosetobeabsorbed,0.08361204013377926
alphadistributionrateconstant,0.08361204013377926
renalsalbutamolclearance,0.08361204013377926
apparenthalflifeofeliminationofphasebeta,0.08361204013377926
initialpihalflife,0.08361204013377926
terminalvolumesofdistribution,0.08361204013377926
mobilityratio,0.08361204013377926
deltah,0.08361204013377926
urinaryexcretionamount,0.08361204013377926
emitteddose,0.08361204013377926
deltag,0.08361204013377926
bindingconstantkb,0.08361204013377926
maximumsalbutamolplasmaconcentration,0.08361204013377926
initialclearancerateconstantki,0.08361204013377926
terminalclearancerateconstantkt,0.08361204013377926
timeuntilpeakplasmaconcentration,0.08361204013377926
normalizedsteadystateplasmaconcentration,0.08361204013377926
peaklevelsofradioactivity,0.08361204013377926
dosingrate,0.08361204013377926
skinpermeation,0.08361204013377926
tmpigfr,0.08361204013377926
auc028,0.08361204013377926
volumeofdistributionplasma,0.08361204013377926
auv0infinity,0.08361204013377926
timetomeanmaximumplasmaconcentration,0.08361204013377926
absolutivebioavailability,0.08361204013377926
maximumogtaconcentration,0.08361204013377926
maximumplasmasalbutamolconcentration,0.08361204013377926
drughalflife,0.08361204013377926
kappahalflife,0.08361204013377926
maximumliexcretion,0.08361204013377926
permeabilityconstantforthetransscleraldiffusionktrans,0.08361204013377926
maximumdurationofitseffect,0.08361204013377926
maximumtaconcentration,0.08361204013377926
clearancecoefficient,0.08361204013377926
absorptionpercentage,0.08361204013377926
peakurinarytconcentration,0.08361204013377926
maximumtriamcinoloneacetonidelevel,0.08361204013377926
peakplasmatriamcinoloneacetonideconcentrationscmax,0.08361204013377926
centrallunglevel,0.08361204013377926
limitofdetectionsn,0.08361204013377926
plasmaterminaleliminationhalflife,0.08361204013377926
maximummeasuredplasmataconcentration,0.08361204013377926
unboundvegflevel,0.08361204013377926
systemicplasmacl,0.08361204013377926
unboundvegfconcentration,0.08361204013377926
areaunderthecurvefromtime0toinfinityauc0inf,0.08361204013377926
buccalflux,0.08361204013377926
totalserumdruglevel,0.08361204013377926
minimumsputumconcentrationcmin,0.08361204013377926
halflivesassociated,0.08361204013377926
peaklidocaineconcentration,0.08361204013377926
receptordensity,0.08361204013377926
areaunderthecurveat010h,0.08361204013377926
aucoptimized,0.08361204013377926
maximummeaninhibition,0.08361204013377926
amountexcretedunchanged,0.08361204013377926
urinaryconcentrationscmax,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to180minute,0.08361204013377926
aucratioofradioactivity,0.08361204013377926
tissueratioofradioactivity,0.08361204013377926
surfaceroughnessra,0.08361204013377926
rootmeansquareroughnessrq,0.08361204013377926
eliminationphasehalflivet12beta,0.08361204013377926
aucareaunderconcentrationtimecurveratio,0.08361204013377926
percentofdoseexcretedinurine,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezerototimetauc0t,0.08361204013377926
patchstrength,0.08361204013377926
peaktotroughfluctuationratio,0.08361204013377926
totalserumclearancecl,0.08361204013377926
steadystateserumprllevel,0.08361204013377926
totalstudytime,0.08361204013377926
concentrationsdosecds,0.08361204013377926
highestmeasuredplasmaconcentration,0.08361204013377926
ratiotosystemicunboundconcentration,0.08361204013377926
ratioofsystemicunboundconcentration,0.08361204013377926
peakghbplasmaconcentration,0.08361204013377926
maximumghbconcentration,0.08361204013377926
steadystatefetalarterialplasmaindometacinconcentration,0.08361204013377926
salbutamol,0.08361204013377926
areaunderthecurveauc030,0.08361204013377926
rinaryrecoverie,0.08361204013377926
maximummegxconcentration,0.08361204013377926
plasmadopamineconcentration,0.08361204013377926
peakindomethacinplasmaconcentration,0.08361204013377926
latencytime,0.08361204013377926
usal05,0.08361204013377926
overalldrugtargetingefficiencyte,0.08361204013377926
fetalmaternalratio,0.08361204013377926
relativedrugexposurere,0.08361204013377926
maximalbloodlevelscmax,0.08361204013377926
od,0.08361204013377926
detectablelimit,0.08361204013377926
zero,0.08361204013377926
maximumlidocaineconcentration,0.08361204013377926
troughconcentrationsatsteadystate,0.08361204013377926
medianplasmaconcentration,0.08361204013377926
initiallagperiod,0.08361204013377926
forcedexpiratoryvolumeinoneminutefev1,0.08361204013377926
plasmaelimination,0.08361204013377926
timetoreachthemaximalconcentrationtimetomaximumconcentration,0.08361204013377926
areaundercurvesauc,0.08361204013377926
peakbupivacaineconcentration,0.08361204013377926
auc31h,0.08361204013377926
striatumtofrontalcortexcountratio1stfc1,0.08361204013377926
maximumpossibleeffect,0.08361204013377926
ratioofrenalclearancetoplasmaclearance,0.08361204013377926
timetotreatmentdiscontinuation,0.08361204013377926
areaunderthecurvefromtime0tothelastquantifiableconcentration,0.08361204013377926
areaundertheplasmaconcentrationstimecurveauc0infinity,0.08361204013377926
24hplasmaconcentration,0.08361204013377926
unboundldpl,0.08361204013377926
eliminationserumhalflife,0.08361204013377926
apparentclearanceatsteadystate,0.08361204013377926
areaundertheplasmaconcentrationversustimecurveatsteadystateaucss,0.08361204013377926
steadystateapparentclearanceclfssratio,0.08361204013377926
plasmai,0.08361204013377926
peakgentamicinplasmaconcentration,0.08361204013377926
kagi,0.08361204013377926
apparenteliminationhalflivest12,0.08361204013377926
areaundertheconcentrationtimecurvefrom0mintoinfinity,0.08361204013377926
kalung,0.08361204013377926
clcf,0.08361204013377926
attainedmaximumlevelscmax,0.08361204013377926
relativebiologicavailability,0.08361204013377926
initialhalflifeofelimination,0.08361204013377926
steadystatedopamineconcentration,0.08361204013377926
metabolicratioaucdmiaucindomethacin,0.08361204013377926
steadystateapparentoralclearanceclfss,0.08361204013377926
steadystatemeancmax,0.08361204013377926
dc50,0.08361204013377926
peakvenousserumconcentrationscmax,0.08361204013377926
michaelismentenconstantforrenalreabsorptionkmr,0.08361204013377926
clodv,0.08361204013377926
liverplasmapartitioncoefficient,0.08361204013377926
recoverycoefficient,0.08361204013377926
vven,0.08361204013377926
freefractiondeterminationf1,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefrom0to9hour,0.08361204013377926
ratior,0.08361204013377926
percentaucratio,0.08361204013377926
auctheareaunderthecurve,0.08361204013377926
minimumurineph,0.08361204013377926
betaexcretionrateconstant,0.08361204013377926
finaleliminationphasehalflife,0.08361204013377926
greatestplasmaconcentration,0.08361204013377926
percentageurinaryrecovery,0.08361204013377926
totalaresunderthebloodconcentrationtimecurve,0.08361204013377926
dosenormalizedareaunderthecurveaucdnauc24h,0.08361204013377926
steadystateplasmacmax,0.08361204013377926
drugloadingcapacitie,0.08361204013377926
pulsesimilarly,0.08361204013377926
ghb,0.08361204013377926
cmax48,0.08361204013377926
cmax04,0.08361204013377926
cloralclf,0.08361204013377926
brainplasmapartitioning,0.08361204013377926
vodv,0.08361204013377926
incorporationefficiency,0.08361204013377926
peakbupivacaineplasmalevel,0.08361204013377926
areaundersalbutamolplasmaconcentrationsasafunctionoftimeauc07h,0.08361204013377926
maximumbupivacaineplasmalevel,0.08361204013377926
maximaldecrement,0.08361204013377926
concentrationratiosfm,0.08361204013377926
auc0033h,0.08361204013377926
swellingratio,0.08361204013377926
aerosolrateofoutput,0.08361204013377926
totalplasmabupivacaineconcentration,0.08361204013377926
timetoachievemaximalplasmaconcentration,0.08361204013377926
maximumsafeplasmaconcentration,0.08361204013377926
maximumplasmabupivacaineconcentration,0.08361204013377926
durationofmotorblockade,0.08361204013377926
steadystatematernalplasmalidocaineconcentration,0.08361204013377926
timetoopioidrescue,0.08361204013377926
auc020min,0.08361204013377926
maximumurinesalbutamolconcentration,0.08361204013377926
maximummeasuredconcentration,0.08361204013377926
totalplasmabupivacainelevel,0.08361204013377926
areaunderthebloodconcentrationtimecurve0,0.08361204013377926
peakplasmarhtnflevel,0.08361204013377926
areaunderthebloodconcentrationtimecurve0t,0.08361204013377926
plasmadopamine,0.08361204013377926
lengthoftime,0.08361204013377926
pseudosteadystateplasmaconcentration,0.08361204013377926
csfplasmasteadystateconcentrationratio,0.08361204013377926
totalbodycime,0.08361204013377926
timeto50copie,0.08361204013377926
steadystateritodrineconcentration,0.08361204013377926
maximumqtcprolongationemax,0.08361204013377926
plasmaconcentrationassociatedwithhalfthemaximumeffectec50,0.08361204013377926
maximumdailyqtcinterval,0.08361204013377926
timetomaximumqtc,0.08361204013377926
peakritodrineconcentration,0.08361204013377926
maximumritodrinelevel,0.08361204013377926
cumulationt12,0.08361204013377926
fetalnonplacentalclearance,0.08361204013377926
omasalabsorption,0.08361204013377926
cumulativerelativefractionofdoseabsorbed,0.08361204013377926
stableplasmaconcentration,0.08361204013377926
maximalketamineconcentrationcmax,0.08361204013377926
volumeoftheperipheralcompartmentvt,0.08361204013377926
cl2m,0.08361204013377926
unboundbrainunboundplasmalevel,0.08361204013377926
halflifeofdrugeliminationduringtheterminalphaset12,0.08361204013377926
radioactivitydose,0.08361204013377926
totalbindingconstant,0.08361204013377926
humanclearance,0.08361204013377926
timetomaximumicatibantconcentration,0.08361204013377926
apparentplateauinplasmaconcentration,0.08361204013377926
tlu,0.08361204013377926
volumeofthecentralcompartmentofthetwo,0.08361204013377926
injectiontoinjectionrunningtime,0.08361204013377926
apparentvolumeofdistributionatsteadystatevd,0.08361204013377926
plasmaclearancerateclp,0.08361204013377926
totalplasmalevel,0.08361204013377926
peakplasmasuraminconcentration,0.08361204013377926
totalurinearsenicoutput,0.08361204013377926
averaged,0.08361204013377926
sustainedpeakplasmaconcentration,0.08361204013377926
timetotargetlevel,0.08361204013377926
maximumdanazolexposure,0.08361204013377926
timetoonsetofsymptomrelief,0.08361204013377926
tosr,0.08361204013377926
hepaticclearanceclparallel,0.08361204013377926
returnofrightingreflex,0.08361204013377926
ld50r1,0.08361204013377926
totalpharmacokineticflow,0.08361204013377926
fractionofarmbloodflow,0.08361204013377926
sslope,0.08361204013377926
percentageofabsorptionfor,0.08361204013377926
percentageabsorptionfrom,0.08361204013377926
serumcorrectedcalciumcca,0.08361204013377926
bloodclearancet12,0.08361204013377926
peakplasmaptconcentration,0.08361204013377926
timestopeakplasma,0.08361204013377926
auc9,0.08361204013377926
concentrationpeakinblood,0.08361204013377926
localconcentration,0.08361204013377926
meanresidencetimemrtab,0.08361204013377926
mrtab,0.08361204013377926
peakplasmahmbconcentration,0.08361204013377926
liquidpassagefrom,0.08361204013377926
linkrateconstant,0.08361204013377926
lengthtodetector,0.08361204013377926
onsetoffsethalflife,0.08361204013377926
eliminationclearanceclm,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefrombaselineto8hoursratio,0.08361204013377926
apparentuptakerateconstant,0.08361204013377926
areaundertheconcentrationstimecurveratio,0.08361204013377926
maximumhairconcentrationscmax,0.08361204013377926
plasmat12b,0.08361204013377926
plasmasteadystatevolumeofdistribution,0.08361204013377926
aucmilktoaucplasmaratio,0.08361204013377926
apparentincorporationconstantka,0.08361204013377926
volumeofdistributioninthecentral,0.08361204013377926
orientationrecoverytime,0.08361204013377926
minimumanestheticconcentration,0.08361204013377926
waterexcretion,0.08361204013377926
extentofplasmaproteinbinding,0.08361204013377926
clother,0.08361204013377926
formationclearancecl2m,0.08361204013377926
steadystatecp,0.08361204013377926
steadystatedtcconcentration,0.08361204013377926
unboundcentralvolumeofdistribution,0.08361204013377926
maximumbloodconccmax,0.08361204013377926
excretionfraction,0.08361204013377926
overallamountexcreted,0.08361204013377926
fluidabsorption,0.08361204013377926
naexcretion,0.08361204013377926
maximumbloodradioactivityconcentration,0.08361204013377926
hepaticfirstpasseliminationhfpe,0.08361204013377926
operativeapparentvolumeofdistributionvdf,0.08361204013377926
weightcorrectedclearance,0.08361204013377926
fclearance,0.08361204013377926
eliminationhalflifeoff,0.08361204013377926
halflifeofradio,0.08361204013377926
totalurinaryrecoveryoflabel,0.08361204013377926
nonrenalclearanceratiocrnr,0.08361204013377926
oraldoseabsorbed,0.08361204013377926
timetocpmax,0.08361204013377926
glasstransitiontemperature,0.08361204013377926
systemicbioavailablity,0.08361204013377926
oe,0.08361204013377926
maximumexternalexposurerate,0.08361204013377926
apparenthalftimeofabsorption,0.08361204013377926
apparenthalfliferemoval,0.08361204013377926
totalexposureauc0inf,0.08361204013377926
c90,0.08361204013377926
timetofirsttreatmentfailure,0.08361204013377926
bioavalability,0.08361204013377926
bloodtoplasmaconcentrationratioof,0.08361204013377926
maximumvaluescmax,0.08361204013377926
serumclearanceoffurosemidecls,0.08361204013377926
maximumadditionalexcretionrateofsodium,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0to8h,0.08361204013377926
urineoutputper,0.08361204013377926
equilibriumplasmabloodcellconcentrationratio,0.08361204013377926
gammaphasehalflive,0.08361204013377926
sodium,0.08361204013377926
cumulativeexcretoryrate,0.08361204013377926
deltae,0.08361204013377926
steadystatedtcplasmaconcentration,0.08361204013377926
areaundertheplasmaconcentrationtimecurvesoffurosemidefromtimezeroto4hauc04h,0.08361204013377926
plasmamangiferinconcentration,0.08361204013377926
flipangle,0.08361204013377926
snr,0.08361204013377926
tissueuptake,0.08361204013377926
liverretention,0.08361204013377926
ratioofauc024h,0.08361204013377926
halflifeforaccumulationt12acc,0.08361204013377926
maximumaceinhibition,0.08361204013377926
halflivesofeachphase,0.08361204013377926
accumulationratiosr,0.08361204013377926
maximalbindingcapacity,0.08361204013377926
equilibriumconstantofdissociationkd,0.08361204013377926
areaundertheplasmacurveauc096h,0.08361204013377926
observedplasmacmax,0.08361204013377926
peakmicrodialysatefenlevel,0.08361204013377926
abosrption,0.08361204013377926
volumeofdistributuion,0.08361204013377926
fexcretion,0.08361204013377926
stimulusrequiredforhalfmaximalresponse,0.08361204013377926
timerequiredtoreachthepeak,0.08361204013377926
peakplasmaplatinumconcentration,0.08361204013377926
peakconcentrationofunboundplatinum,0.08361204013377926
additionalremoval,0.08361204013377926
lagtimebeforeappearance,0.08361204013377926
fractionrecovered,0.08361204013377926
metabolicclearancec1m,0.08361204013377926
rateofurinaryexcretion,0.08361204013377926
rateofexcretionofsodium,0.08361204013377926
oralbioavailibility,0.08361204013377926
asciticfluidvolume,0.08361204013377926
integralradioactivityratio,0.08361204013377926
fractionoftheintratra,0.08361204013377926
halfmaximumeffect,0.08361204013377926
unboundsecretoryclearance,0.08361204013377926
ruminalescape,0.08361204013377926
totalrecoveryof,0.08361204013377926
steadystatebleomycinconcentration,0.08361204013377926
decompositionhalflive,0.08361204013377926
areasundertheserumconcentrationversustimecurvesaucs,0.08361204013377926
timeofoccurrence,0.08361204013377926
auc0infinityareaundertheconcentrationtimecurve,0.08361204013377926
cumulativeradioactivityexcretedvia,0.08361204013377926
extentofbiologicalavailabilityeba,0.08361204013377926
fractionalrate,0.08361204013377926
fractionalexchangeratebetweencompartment,0.08361204013377926
lke,0.08361204013377926
urinaryoxalateexcretion,0.08361204013377926
intrinsicclearanceper,0.08361204013377926
clearancebasedonunbounddrugconcentration,0.08361204013377926
maximumofplasmaconcentrationcmax,0.08361204013377926
tolbutamide,0.08361204013377926
ec40,0.08361204013377926
auc060iri,0.08361204013377926
peakglycaemia,0.08361204013377926
peaklhresponse,0.08361204013377926
halflifeofbuserelinrelease,0.08361204013377926
maximumconcentrationofdalarelininthebloodcmax,0.08361204013377926
eliminationkinetic,0.08361204013377926
totaldrugclearancefrom,0.08361204013377926
cumula,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimezeroto120hauc0120,0.08361204013377926
typical,0.08361204013377926
absorptiontimedelay,0.08361204013377926
weightgain,0.08361204013377926
areaunderthecurvefrom0to24hauc240,0.08361204013377926
auc240ria,0.08361204013377926
cmaxriagcmsratio,0.08361204013377926
halflivesforthefirstcompartment,0.08361204013377926
apparentplasmadisappearancet12,0.08361204013377926
bioavailabilitylevel,0.08361204013377926
peakimmunoreactivebuserelinlevel,0.08361204013377926
maximalnasalabsorption,0.08361204013377926
firsthalflive,0.08361204013377926
peakiri,0.08361204013377926
timetopeakglycaemia,0.08361204013377926
halflifeoftransfer,0.08361204013377926
areaundertheoxipurinolplasmaconcentrationtimecurveauc,0.08361204013377926
terminalbetaserumhalflife,0.08361204013377926
aucsub0tlast,0.08361204013377926
aucsub0,0.08361204013377926
volumeofthecentralcompartmentv,0.08361204013377926
initialconcentrationc0,0.08361204013377926
specificvolumevd,0.08361204013377926
absorptionrateconstantkab,0.08361204013377926
volumeofdistributioncorrectedbythefractionofdoseabsorbedvdf,0.08361204013377926
timetoreachmaximumconcentrationafterdrugadministrationtmax,0.08361204013377926
residualintracerebrospinalfluidconcentration,0.08361204013377926
vztf,0.08361204013377926
t12app,0.08361204013377926
auc050,0.08361204013377926
permeabilityareaproductpa,0.08361204013377926
steadystateplasmaconcentrationscav,0.08361204013377926
sua,0.08361204013377926
fractionalperoralbioavailability,0.08361204013377926
terminaleliminationhalflifeatsteadystate,0.08361204013377926
auc7day,0.08361204013377926
injectedactivity,0.08361204013377926
maximumafatinibplasmaconcentration,0.08361204013377926
maximumtroughplasmaconcentration,0.08361204013377926
peaktumoruptake,0.08361204013377926
tumoridg,0.08361204013377926
conversionyield,0.08361204013377926
tumortobloodratio,0.08361204013377926
areaunderthecurveofplasmadrugconcentrationauc,0.08361204013377926
steadystateplasmaconcentrationcssavg,0.08361204013377926
maximumtumoralconcentration,0.08361204013377926
recyclingeventtime,0.08361204013377926
timestomaximumplasmaconcentration,0.08361204013377926
troughnomacconcentrationcav,0.08361204013377926
peaknomacconcentrationcmax,0.08361204013377926
gradient,0.08361204013377926
centralcompartmentexcretionhalflife,0.08361204013377926
octanolpartitioncoefficient,0.08361204013377926
slop,0.08361204013377926
accumulationratiosrauc,0.08361204013377926
ratioofconjugationdeconjugationrateconstant,0.08361204013377926
maximumresponseemax,0.08361204013377926
potencyparameter,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezeroextrapolatedtoinfinityauc0infinity,0.08361204013377926
invivobinding,0.08361204013377926
areaundertheconcentrationtimecurvefrom0htoinfinityaucinfinity,0.08361204013377926
timetoachieve90steadystatepre,0.08361204013377926
peakcitrateconcentration,0.08361204013377926
citrateclearance,0.08361204013377926
timetoreachthemaximummabserumconcentrationtmax,0.08361204013377926
areaundertheplasmaconcentrationtimecurve0270min,0.08361204013377926
maximumcircuitconcentrationscmax,0.08361204013377926
qb,0.08361204013377926
qd,0.08361204013377926
aucover,0.08361204013377926
widthintimeathalfmaximalintensity,0.08361204013377926
areaundertheplasmaconcentrationcurveaucfromtimezeroto72h,0.08361204013377926
distributionvolumeduringtheeliminationphase,0.08361204013377926
ec20,0.08361204013377926
normalizedareaunderthephosphatevstimecurve,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefromtime0hto96hauc096,0.08361204013377926
peakplasmalanthanumconcentration,0.08361204013377926
calciumretention,0.08361204013377926
zinccontent,0.08361204013377926
relativeironbioavailabilitie,0.08361204013377926
c24hour,0.08361204013377926
timefor80drugreleaset80,0.08361204013377926
cooperativityconstanta,0.08361204013377926
extractionefficacy,0.08361204013377926
totalplatinumconcentration,0.08361204013377926
timeafterdosingwhencmaxoccurred,0.08361204013377926
volumeofdistributionvdss12,0.08361204013377926
intrinsicsolubilitys0,0.08361204013377926
polydispersityin,0.08361204013377926
areaunderthekemserumconcentrationcurve,0.08361204013377926
effectivehalflifet12acc,0.08361204013377926
slopeofthelinearconcentrationresponserelationship,0.08361204013377926
halflifeoftheterminalphaset12beta,0.08361204013377926
bioavailabilityextenteba,0.08361204013377926
volumesofdistributionbioavailabilityv1f,0.08361204013377926
clearancesbioavailabilitycl1f,0.08361204013377926
peakplasmadigoxinconcentration,0.08361204013377926
terminalhalflivest12beta,0.08361204013377926
totalclearanceof1,0.08361204013377926
systemicexposureauct,0.08361204013377926
nondecaycorrectedcumulativeurinaryexcretion,0.08361204013377926
multiple,0.08361204013377926
peakdabigatranconcentration,0.08361204013377926
apparentvolumeofdistributionduringtheterminalphasevzf,0.08361204013377926
apparenttotalclearanceafteroraladministrationcltotf,0.08361204013377926
areaundertheeffectauecabove212,0.08361204013377926
totalexposurei,0.08361204013377926
concentrationneededtoattain50ofmaximumeffectec50,0.08361204013377926
timeforreachingthem,0.08361204013377926
absoluteiodide,0.08361204013377926
eliminationhalflifet1,0.08361204013377926
terminaldispositionhalflifet12gamma,0.08361204013377926
timetoreachmaximalplasmaconcentrationtmax,0.08361204013377926
iic50,0.08361204013377926
i2ic50,0.08361204013377926
terminalhalflivest12gamma,0.08361204013377926
timetmaxtocmax,0.08361204013377926
maximaldesethylamiodaroneconcentration,0.08361204013377926
fatbloodconcentrationratio,0.08361204013377926
peakserumdigoxinlevelscmax,0.08361204013377926
myocardialplasmaamiodaroneratio,0.08361204013377926
terminalhalflifet12el,0.08361204013377926
apparenttel,0.08361204013377926
apparentt12el,0.08361204013377926
maximalplasmaamiodaronedesethylamiodaroneconcentrationratio,0.08361204013377926
peakplasmadesethylamiodaroneconcentration,0.08361204013377926
peakplasmaamiodaroneconcentration,0.08361204013377926
drugloadingefficacydl,0.08361204013377926
halflifeinurine,0.08361204013377926
hepaticrecurrencefreetime,0.08361204013377926
95unbound,0.08361204013377926
timeabovetheminimuminhibitoryconcentration,0.08361204013377926
vdssbw,0.08361204013377926
unboundfractionofcefazolininplasmafp,0.08361204013377926
peakaverageserumconcentration,0.08361204013377926
valleyserumconcentration,0.08361204013377926
totalcefazolinclearance,0.08361204013377926
peakofserumconcentration,0.08361204013377926
minimumobservedtotalplasmaconcentration,0.08361204013377926
recoveryofdruginurine,0.08361204013377926
minimumobservedunboundisfconcentration,0.08361204013377926
totalurinerecovery,0.08361204013377926
totalbodycl,0.08361204013377926
volumeofdistributionincentralcompartment,0.08361204013377926
peakvalueofserumconcentration,0.08361204013377926
minimumobservedunboundconcentration,0.08361204013377926
penetrationofunbounddrug,0.08361204013377926
timeabovethesu,0.08361204013377926
percentageoftotaladministereddoserecovered,0.08361204013377926
instrument,0.08361204013377926
systemicvolumeofdistribution,0.08361204013377926
lem,0.08361204013377926
areaundertheconcentrationtimecurveaucfromtimezerotoinfinityhour,0.08361204013377926
aucfromtimezerotothelastmeasurableplasmaamilorideconcentration,0.08361204013377926
effectivetimeuntilreturnto50deltapdet50,0.08361204013377926
ratesofmucociliaryclearance,0.08361204013377926
conductance,0.08361204013377926
meaninputtimemit,0.08361204013377926
fractionofdoseexcretedunchangedin,0.08361204013377926
timetopeakimilevel,0.08361204013377926
peakimiconcentration,0.08361204013377926
peakbileconcentration,0.08361204013377926
lowest,0.08361204013377926
timeaboveminimalinhibitoryconcentration,0.08361204013377926
serumeliminationrateconstant,0.08361204013377926
totalcefazolinbodyclearance,0.08361204013377926
unboundcfzfraction,0.08361204013377926
unboundcfzfractionatthepeakconcentration,0.08361204013377926
areaundertheconcentrationaucvstimeratio,0.08361204013377926
tcmicratio,0.08361204013377926
hepaticcystpenetration,0.08361204013377926
steadystatetroughserumcefazolin,0.08361204013377926
renalclearancecl012h,0.08361204013377926
areaundertheplasmaconcentrationtimecurveclr,0.08361204013377926
centralhipjointcapsulecompartmentclearanceq,0.08361204013377926
volumeofdistributioninthehipjointcapsulecompartmentvjc,0.08361204013377926
maximumaqueoushumorlevel,0.08361204013377926
biologicalhalflifeofgammaphase,0.08361204013377926
resistancebreakpoint,0.08361204013377926
percentagesofpenetration,0.08361204013377926
microbiologicallyactiveconcentration,0.08361204013377926
maximumproteinbindingbmax,0.08361204013377926
freeareaunderthecurvefrom0to8hfauc08,0.08361204013377926
tissuepenetrationratiotissueserumfaucratio,0.08361204013377926
minimalinhibitoryconcentrationfor90mic90,0.08361204013377926
plasmaunboundcefazolin,0.08361204013377926
qbl,0.08361204013377926
micdistributionfrequency,0.08361204013377926
rateofeffectivene,0.08361204013377926
adiposeconcentration,0.08361204013377926
baselineclearancecl,0.08361204013377926
constantoftheprocessrate,0.08361204013377926
bonehalflife,0.08361204013377926
troughtotalplasmaantibioticconcentration,0.08361204013377926
peakcefazolin,0.08361204013377926
releaseconstant,0.08361204013377926
peakserumgentamicinlevel,0.08361204013377926
plasmalevelsatpeak,0.08361204013377926
wounddrainageconcentrationspeak,0.08361204013377926
lipophilicitylogkw,0.08361204013377926
interdialysisclearance,0.08361204013377926
intradialysisclearance,0.08361204013377926
percentageremoval,0.08361204013377926
totalserumdrugconcentration,0.08361204013377926
lex,0.08361204013377926
cumulativepercentageofdrugreleased,0.08361204013377926
oralclf,0.08361204013377926
tumourenhancementratio,0.08361204013377926
areaundertheconcentrationtimecurveaucfromtime0htoinfinityaucinf,0.08361204013377926
aucfromtimezerohtothetimeofthelastmeasurableabirateroneacetateconcentrationsauct,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucfrom0tothelastmeasurableplasmaconcentrationauc0last,0.08361204013377926
nonrenalbloodclearance,0.08361204013377926
areasundertheconcentrationtimecurvesfrom0to24hoursauc024,0.08361204013377926
totalsteadystateclearanceclf,0.08361204013377926
inductionhalflife,0.08361204013377926
accessibleplasmalevel,0.08361204013377926
halflivesofurinaryexcretion,0.08361204013377926
totalmeanradioactivityrecovery,0.08361204013377926
auc0ttotalauc0t,0.08361204013377926
concentrationapparentinhibitionconstantkiratio,0.08361204013377926
50ofthemaximumeffect,0.08361204013377926
maximumobservedplasmaconcentrationratio,0.08361204013377926
maximalresponsecave50,0.08361204013377926
maximumrecordedplasmalevel,0.08361204013377926
apparentt12beta,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezerotothetimeofthelastquantifiableconcentrationauclast,0.08361204013377926
absoluteplasmalevel,0.08361204013377926
totaltransit,0.08361204013377926
timetoreachaveragesteadystateconcentrationscss,0.08361204013377926
kipl,0.08361204013377926
transferconstantbetweencentralandperipheralcompartmentskcp,0.08361204013377926
apparenttotalsystemicclearancecl,0.08361204013377926
timeofcpeak,0.08361204013377926
thermalhalflife,0.08361204013377926
dissociationconstantki,0.08361204013377926
dynamicresidencetimekoff,0.08361204013377926
tubularmaximumtm,0.08361204013377926
inblinratio,0.08361204013377926
bloodniklevel,0.08361204013377926
oraldoseequaling50occupancy,0.08361204013377926
absolutepeakconcentration,0.08361204013377926
timetakentopeakconcentration,0.08361204013377926
totalcave50,0.08361204013377926
percententrapmentefficiency,0.08361204013377926
steadystatetrougherlotinibplasmaconcentration,0.08361204013377926
peakendof,0.08361204013377926
plasmafreefractionspercentunbound,0.08361204013377926
areaundertheradioactivityconcentrationtimecurvesauc0infinity,0.08361204013377926
totalbloodclearanceclb,0.08361204013377926
colonarrivaltime,0.08361204013377926
releasetimespread,0.08361204013377926
cerebrospinalfluidpenetrationrate,0.08361204013377926
totallcanalysistimeperinjection,0.08361204013377926
plasmaconcentrationcap,0.08361204013377926
maximumsteadystatecsfconcentration,0.08361204013377926
troughconcentrationcminss,0.08361204013377926
pfs6,0.08361204013377926
kbio,0.08361204013377926
percentageofpenetration,0.08361204013377926
areaunderthedrugconcentrationtimecurve,0.08361204013377926
pbrain,0.08361204013377926
timetmaxtoreachmaximalraltitrexedconcentration,0.08361204013377926
auc0tldc,0.08361204013377926
totaldrugrelease,0.08361204013377926
peakplasmaactivereninarconcentration,0.08361204013377926
injectionpain,0.08361204013377926
tla,0.08361204013377926
upc,0.08361204013377926
steadystateadalimumabserumconcentration,0.08361204013377926
remission,0.08361204013377926
troughlevelstls,0.08361204013377926
inputkin,0.08361204013377926
kinc50,0.08361204013377926
steadystatemaximalconcentrationcmaxss,0.08361204013377926
maximalbeta1receptoroccupancy,0.08361204013377926
peakprinterval,0.08361204013377926
vepsilon,0.08361204013377926
c21min,0.08361204013377926
alphadistributionhalflife,0.08361204013377926
drugconcentrationpeaked,0.08361204013377926
unboundplasmacefazolinconcentration,0.08361204013377926
volumeofdistributionbytheareamethod,0.08361204013377926
totalplasmaclt,0.08361204013377926
tumoroversubcutisratio,0.08361204013377926
meanoralabsorptiontime,0.08361204013377926
alclearance,0.08361204013377926
renalalexcretion,0.08361204013377926
renalalclearance,0.08361204013377926
gastrointestinalabsorptionquotient,0.08361204013377926
totalalload,0.08361204013377926
interdialytichalflife,0.08361204013377926
timetomaximumserum,0.08361204013377926
penetrationratiofauctissuefaucplasma,0.08361204013377926
peakserumaluminium,0.08361204013377926
absorbeddosetotumor,0.08361204013377926
timetoreachthepeakplasmaconcentrationtmax,0.08361204013377926
fractionabsorbedorally,0.08361204013377926
unbounddistribution,0.08361204013377926
fractionalexcretionof,0.08361204013377926
absorbeddosetothekidney,0.08361204013377926
be,0.08361204013377926
liverrecovery,0.08361204013377926
alconcentration,0.08361204013377926
depthofnecrosi,0.08361204013377926
volumeofdistributionduringthebetaphasevbeta,0.08361204013377926
inflammatoryfluidlevel,0.08361204013377926
overallpenetration,0.08361204013377926
distributingvolume,0.08361204013377926
auicoinfinity,0.08361204013377926
troughplasmaimipenemconcentration,0.08361204013377926
troughplasmacilastatinconcentration,0.08361204013377926
aucssareaundertheconcentrationtimecurveoveradosageintervalatsteadystate,0.08361204013377926
stabledose,0.08361204013377926
subliminaldose,0.08361204013377926
apparentdepositionfraction,0.08361204013377926
maximumobservedlevel,0.08361204013377926
apparenturinaryhalflife,0.08361204013377926
meanarrivaltime,0.08361204013377926
brainbloodration,0.08361204013377926
26alexcretion,0.08361204013377926
fractionalintestinalabsorption,0.08361204013377926
ic50avb6,0.08361204013377926
cordtomaternalplasmaconcentrationratio,0.08361204013377926
noobservedeffectlevelnoel,0.08361204013377926
lactateplasmaconcentration,0.08361204013377926
invasionconstant,0.08361204013377926
totalclearanceof14cactivity,0.08361204013377926
ratioofcldegtocl,0.08361204013377926
peaksignaltonoiseratio,0.08361204013377926
concentrating,0.08361204013377926
betahalflifet12beta,0.08361204013377926
totalbodyclearanceratec1b,0.08361204013377926
renalclearanceratec1r,0.08361204013377926
totalplasmaaucareaundertheplasmadecaycurve,0.08361204013377926
total6day,0.08361204013377926
peakbleomycinplasmalevel,0.08361204013377926
peakperitonealplasmaconcentrationratio,0.08361204013377926
peritonealfluidhalflife,0.08361204013377926
terminaleliminationplasmahalflive,0.08361204013377926
totalcsfconcentration,0.08361204013377926
ic50avb3,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to24hours,0.08361204013377926
maximumcefiximeconcentration,0.08361204013377926
areaundertheserumconcentrationtimecurveextrapolatedtoinfinity,0.08361204013377926
apparentvolumeofdistributionforthecentralcompartment,0.08361204013377926
salivatowholebloodratiosb,0.08361204013377926
totalpermeation,0.08361204013377926
intestinalsecretion,0.08361204013377926
totalbodyclearancect,0.08361204013377926
areaundertheplasmarepaglinideconcentrationtimecurvefromtime0toinfinityauc0infinity,0.08361204013377926
payloaddrugtoantibodyratio,0.08361204013377926
enterohepaticcirculation,0.08361204013377926
cordbloodmaternalconcentrationratio,0.08361204013377926
ec90concentration,0.08361204013377926
spplasmaratio,0.08361204013377926
plasmaapparentclearance,0.08361204013377926
ctroughauc,0.08361204013377926
micsmic,0.08361204013377926
drainageflowrate,0.08361204013377926
total6hour,0.08361204013377926
uptakeatpeak,0.08361204013377926
tlast,0.08361204013377926
maternalresidencetime,0.08361204013377926
totalareasundertheconcentrationversustimecurvesaucs,0.08361204013377926
ed,0.08361204013377926
steadystatecocaineconcentration,0.08361204013377926
areaunderthecocaineconcentrationversustimecurveauc,0.08361204013377926
areasundertheconcentrationversustimecurveauc,0.08361204013377926
observedmaximalconcentration,0.08361204013377926
apparentcocaineeliminationhalflife,0.08361204013377926
functionaleliminationhalflife,0.08361204013377926
fractionabsorbedthrough,0.08361204013377926
halftimeforbzformation,0.08361204013377926
excretionhalftime,0.08361204013377926
peakcocaineplasmaconcentration,0.08361204013377926
coc,0.08361204013377926
effectt12,0.08361204013377926
halfpeakclearance,0.08361204013377926
globalt12,0.08361204013377926
satietythreshold,0.08361204013377926
tl201clearance,0.08361204013377926
finaldecayconstantlambda2,0.08361204013377926
bloodlambda3,0.08361204013377926
aucfrom0to4hour,0.08361204013377926
aucfrom0to24hour,0.08361204013377926
areaunderthedipyridamoleconcentrationtimecurvefrom04hour,0.08361204013377926
dispositionrateconstantsbeta,0.08361204013377926
intrinsicclearancesclint,0.08361204013377926
peritonealhalflife,0.08361204013377926
plasmaareaundertheconcentrationversustimecurve,0.08361204013377926
firstpassretentionfraction,0.08361204013377926
maximumcocconcentration,0.08361204013377926
urineconcentrationratio,0.08361204013377926
cmro2,0.08361204013377926
rateofdeclineofresponse,0.08361204013377926
milkbloodratio,0.08361204013377926
mrttime,0.08361204013377926
terminalexcretionhalflife,0.08361204013377926
trough55,0.08361204013377926
timeinvariantpartitioncoefficient,0.08361204013377926
auc0360plasmaauc0360ratio,0.08361204013377926
plasmaauc0360,0.08361204013377926
trough6hr,0.08361204013377926
clhf,0.08361204013377926
ha,0.08361204013377926
ct50,0.08361204013377926
peakserumimipenemconcentration,0.08361204013377926
maximumpdfconcentration,0.08361204013377926
peakconcentrationinbilefluid,0.08361204013377926
peaklevelinbilefluid,0.08361204013377926
halflifeinbile,0.08361204013377926
areaundertheconcentrationtimecurvefromzerohourtoinfinity,0.08361204013377926
totalareasundertheimipenemserumconcentrationcurvesaucstoinfinity,0.08361204013377926
distributionvolumevdbeta,0.08361204013377926
peakbactericidaltiter,0.08361204013377926
arterialdrugconcentration,0.08361204013377926
steadystateplasmaamrinoneconcentration,0.08361204013377926
venou,0.08361204013377926
apparentfirstordereliminationt12,0.08361204013377926
injectioninterval,0.08361204013377926
nonrenalnonhemofiltrationclearance,0.08361204013377926
aucskinwindowaucserumratio,0.08361204013377926
susceptibilitydistribution,0.08361204013377926
peakofthedistribution,0.08361204013377926
clinicaleffectivenessratio,0.08361204013377926
volumesofdistributionv,0.08361204013377926
areaundertheconcentrationtimecurveforthefreeunboundfractionofthedrugfauc,0.08361204013377926
limitsofreliabledetection,0.08361204013377926
clinicalefficacyrate,0.08361204013377926
lengthsoftreatment,0.08361204013377926
areasundertheconcentrationtimecurvefromtimezerotoinfinity,0.08361204013377926
renalclearancesper,0.08361204013377926
peakimipenemconcentration,0.08361204013377926
cumulativeurineexcretionpercentage,0.08361204013377926
acrophasepeaktime,0.08361204013377926
areaundertheplasmaconcentrationtimecurveoverthedosingintervaltauauctau,0.08361204013377926
oralnooveralladverseeffectlevelnoael,0.08361204013377926
wholebodyclearancectot,0.08361204013377926
ctot,0.08361204013377926
nefa,0.08361204013377926
fractionabsorbedfa,0.08361204013377926
fractionescapinggutwalleliminationfg,0.08361204013377926
volumeofdistributionduringsteadystate,0.08361204013377926
volumeofthebodyfluidspaceexpanded,0.08361204013377926
passiveinfluxintokin,0.08361204013377926
bmr,0.08361204013377926
effluxfromtheshallowbraincompartmentkout,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc072h,0.08361204013377926
signaltonoisesnratio,0.08361204013377926
brainvolumeofdistribution,0.08361204013377926
absoluteinfantdose,0.08361204013377926
totalmethodcycletime,0.08361204013377926
freefractionsfu,0.08361204013377926
systemicbodyclearancecls,0.08361204013377926
steadystateapparentvolumeofdistributionvss,0.08361204013377926
cerebrospinalfluidplasmaconcentrationratio,0.08361204013377926
maximalserumplasmaconcentration,0.08361204013377926
orallethaldose50ld50,0.08361204013377926
eliminationofhalflive,0.08361204013377926
vssn,0.08361204013377926
vgamman,0.08361204013377926
passivemembranepermeabilitypapp,0.08361204013377926
centralvc,0.08361204013377926
steadystatevss,0.08361204013377926
halflifet12time,0.08361204013377926
ninetyminuteplasmaretention,0.08361204013377926
systemicbodyclearance,0.08361204013377926
apparentvolumeofdistributioninthesecondcompartmentv2,0.08361204013377926
overallsynthesistime,0.08361204013377926
absorptiveclearance,0.08361204013377926
maximalbrainconcentration,0.08361204013377926
aer,0.08361204013377926
unboundclearanceclu,0.08361204013377926
unboundaucaucu,0.08361204013377926
betaphaserateconstant,0.08361204013377926
plasmahalflifeeliminationtime,0.08361204013377926
logka,0.08361204013377926
relaxivity,0.08361204013377926
mweff,0.08361204013377926
ktrans,0.08361204013377926
totalgadoliniumclearance,0.08361204013377926
trte,0.08361204013377926
relativepeakenhancement,0.08361204013377926
maximaluptakeratevmax,0.08361204013377926
areaunderthecurve090,0.08361204013377926
hct,0.08361204013377926
relaxationrateconstant,0.08361204013377926
transverserelaxationrateconstant,0.08361204013377926
r1,0.08361204013377926
r2,0.08361204013377926
ratioofld50toeffectivedose,0.08361204013377926
dynamicrange,0.08361204013377926
attenuationosmoticratio,0.08361204013377926
gammaphaserateconstant,0.08361204013377926
areaunderthecurvebetween0and30minute,0.08361204013377926
ostime,0.08361204013377926
overallsurvivall,0.08361204013377926
selectivityratioeffectiveconcentrationec50,0.08361204013377926
ec80,0.08361204013377926
auctatsteadystate,0.08361204013377926
ceratio,0.08361204013377926
washoutratio,0.08361204013377926
cumulativeamountof,0.08361204013377926
excreteddose,0.08361204013377926
distributiontime,0.08361204013377926
totaltumornecrosi,0.08361204013377926
logkcond,0.08361204013377926
initialenhancementrateer,0.08361204013377926
fvp,0.08361204013377926
cnr,0.08361204013377926
peakeffectsatsteadystate,0.08361204013377926
halflivesofplasmalevel,0.08361204013377926
fractionbioavailability,0.08361204013377926
apparentvolumeofdistributionvdareaf,0.08361204013377926
levelofdetection,0.08361204013377926
feedrate,0.08361204013377926
recoveryfrom,0.08361204013377926
dissolutionreleasetimesmdt,0.08361204013377926
c05hour,0.08361204013377926
timesofmaximumplasmaconcentrationtmax,0.08361204013377926
earlyplasmahalflife,0.08361204013377926
maximalplasmaketoprofenconcentration,0.08361204013377926
totalclearancecltf,0.08361204013377926
stor,0.08361204013377926
distributionphaset12alpha,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromzero0hourstoinfinityauc0,0.08361204013377926
peakplasmaketoprofenconcentration,0.08361204013377926
invitrorecovery,0.08361204013377926
highestobservedplasmaketoprofenconcentration,0.08361204013377926
tminimuminhibitoryconcentrationmic,0.08361204013377926
terminaleliminationhalflifet12yz,0.08361204013377926
totalanalyticaltime,0.08361204013377926
timeaveragedplasmaketoprofenconcentration,0.08361204013377926
auc0x,0.08361204013377926
apparentplateau,0.08361204013377926
oralmaximumplasmaconcentrationcmax,0.08361204013377926
ketoprofenconjugatesrratio,0.08361204013377926
timetopeakcmax,0.08361204013377926
emaxobservedauce,0.08361204013377926
bioavailabilityclf,0.08361204013377926
bloodclf,0.08361204013377926
ic50cox1ic50cox2ratio,0.08361204013377926
volumeoftissuecompartment,0.08361204013377926
areasunderthecurvetoinfinityauc,0.08361204013377926
volumesofdistributionarea,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityauc0,0.08361204013377926
areaunderthefirstmomentcurvefromzerotothetimeofinfinityaumc0,0.08361204013377926
volumeofdistributionareamethodvdarea,0.08361204013377926
apparentketoprofeneliminationhalflive,0.08361204013377926
fractionalinversionfinv,0.08361204013377926
fsr,0.08361204013377926
percentageofabsoluterecovery,0.08361204013377926
ratioofmilktoplasmaradioactivity,0.08361204013377926
absolutebioavailabilityfauc,0.08361204013377926
biliarytransittime50retentiontime,0.08361204013377926
maximumattainableconcentrationcmax,0.08361204013377926
associationconstantk,0.08361204013377926
numberofbindingsitesn,0.08361204013377926
plasmamaximumconcentration,0.08361204013377926
steadystaterenalextractionratio,0.08361204013377926
apparentrenalextractionratioexcretionrateformationrate,0.08361204013377926
tubulartransportmaximumtm,0.08361204013377926
michaelmentenconstantofthetubularsecretionmechanismkt,0.08361204013377926
bloodtoplasmatotalradioactivityconcentrationratio,0.08361204013377926
recoverypercentage,0.08361204013377926
tissuebloodratiosofradioactivityconcentration,0.08361204013377926
maximalplasmaconcentrationsoftotalradioactivity,0.08361204013377926
minimumsteadystateconcentrationcssmin,0.08361204013377926
tmbp,0.08361204013377926
completebioavailability,0.08361204013377926
vlambdau,0.08361204013377926
constantreleaserate,0.08361204013377926
recirculationratio,0.08361204013377926
biliaryexcretionration,0.08361204013377926
maximumsketoprofenconcentration,0.08361204013377926
equilibriumtime,0.08361204013377926
halflifefordrugrelease,0.08361204013377926
areaunderthetimeresponsecurveaur,0.08361204013377926
absoluteretentiontime,0.08361204013377926
overalldegradationrateconstant,0.08361204013377926
bloodproductionrate,0.08361204013377926
clearanceforelimination,0.08361204013377926
fractionofdrugexcretedinurine,0.08361204013377926
hcg,0.08361204013377926
timewhencmaxisobserved,0.08361204013377926
longterminalhalflife,0.08361204013377926
percentbiliaryexcretion,0.08361204013377926
renalclearance072h,0.08361204013377926
areaunderthecurveauc0x,0.08361204013377926
weightadjusted,0.08361204013377926
c0level,0.08361204013377926
ttdr,0.08361204013377926
peakplasmasunitinibconcentration,0.08361204013377926
peakhydralazineconcentrationcp,0.08361204013377926
aucoraldose,0.08361204013377926
dosenormalizedareaundertheconcentrationtimecurveauc,0.08361204013377926
dosenormalizedpeakconcentration,0.08361204013377926
bileserum,0.08361204013377926
peakliverenhancement,0.08361204013377926
systembioavailability,0.08361204013377926
ventilation,0.08361204013377926
ve50,0.08361204013377926
onsethalftime,0.08361204013377926
cb50,0.08361204013377926
steadystateremifentanilconcentration,0.08361204013377926
centralclearanceclc,0.08361204013377926
abratio,0.08361204013377926
totalsunitinibconcentration,0.08361204013377926
totaltroughlevelttl,0.08361204013377926
ctrough8a,0.08361204013377926
terminalplasmahalftime,0.08361204013377926
maximumbloodserumnadololconcentration,0.08361204013377926
peroralclearance,0.08361204013377926
kineticdistributionvolume,0.08361204013377926
timeofachievementofmaximumbloodserumnadololconcentration,0.08361204013377926
steadystateauctau,0.08361204013377926
ted90,0.08361204013377926
dosefractionexcretedunchanged,0.08361204013377926
timeontreatment,0.08361204013377926
sumplasmatroughconcentrationctrough,0.08361204013377926
timeofoverallsurvivalos,0.08361204013377926
plasmaauc0t,0.08361204013377926
cerebrospinalauc0t,0.08361204013377926
ctrough1,0.08361204013377926
ctrough6,0.08361204013377926
effectcompartmentrateconstantke0,0.08361204013377926
relativefreeconcentration,0.08361204013377926
concentrationatwhich50,0.08361204013377926
steadystateplasmainsulinconcentration,0.08361204013377926
gastrointestinalbioavailability,0.08361204013377926
halflifeofg,0.08361204013377926
postdistributionphasevolume,0.08361204013377926
totalchromatographicrunningtime,0.08361204013377926
bg,0.08361204013377926
areaunderthecurveextrapolatedtoinfinityauci,0.08361204013377926
oralclearancebioavailabilityclf,0.08361204013377926
volumeofdistributionbioavailabilityvf,0.08361204013377926
auc04glucose,0.08361204013377926
aucsub024h,0.08361204013377926
mpauc,0.08361204013377926
overalltreatmentresponserate,0.08361204013377926
accumulationindexaucday19aucday1at,0.08361204013377926
severityofillne,0.08361204013377926
t1z2,0.08361204013377926
areaundertheserumconcentrationtimecurvefromzeroto4hoursforglucoseauc04glucose,0.08361204013377926
totalinsulinresponse,0.08361204013377926
intercompartmentclearancescl2,0.08361204013377926
renalthresholdforglucosertg,0.08361204013377926
volumeofdistributionvdc,0.08361204013377926
centralv1,0.08361204013377926
peripheralvolumev2,0.08361204013377926
wholebodyclearancecl,0.08361204013377926
eliminationrateconstantofproteinunbounddrugke,0.08361204013377926
systemicplasmalevel,0.08361204013377926
logcount,0.08361204013377926
lateeliminationhalflife,0.08361204013377926
urinerecovery24h,0.08361204013377926
masstransitionpair,0.08361204013377926
cordtomaternalratio,0.08361204013377926
maximalresponseec50,0.08361204013377926
cumulativeradioactivityrecovery,0.08361204013377926
renalglucosethreshold,0.08361204013377926
uge,0.08361204013377926
ratioofaucssaucsd,0.08361204013377926
peaknadololconcentration,0.08361204013377926
distributionphaset12,0.08361204013377926
khkd,0.08361204013377926
areaundertheplasmaconcentrationagainsttimecurve,0.08361204013377926
permeationrateconstant,0.08361204013377926
mesorconcentration,0.08361204013377926
eliminationfractionef,0.08361204013377926
areaundertheconcentrationtimecurve012h,0.08361204013377926
halflifeeliminationoft12el,0.08361204013377926
observedtimetomaximumplasmaconcentrationtmax,0.08361204013377926
steadystateranitidineconcentration,0.08361204013377926
systemicplasmaclearancecltp,0.08361204013377926
aucinfinitymeanratio,0.08361204013377926
peakserumranitidineconcentration,0.08361204013377926
observedpeakafter,0.08361204013377926
oralapparentclearance,0.08361204013377926
plasmaicgclearance,0.08361204013377926
filtrateflowrate,0.08361204013377926
minimallyeffectiveserumconcentration,0.08361204013377926
minimumconcentrationofdetection,0.08361204013377926
renalranitidineclearance,0.08361204013377926
areasundertheplasmatimeconcentrationcurveauc,0.08361204013377926
perfusionratekp,0.08361204013377926
extrarenalelimination,0.08361204013377926
hclgda,0.08361204013377926
t21,0.08361204013377926
temporalresolution,0.08361204013377926
vesseldensity,0.08361204013377926
vesselarea,0.08361204013377926
upsilone,0.08361204013377926
maximalcellularuptake,0.08361204013377926
maximumabsorption,0.08361204013377926
isocraticflow,0.08361204013377926
rapidruntime,0.08361204013377926
absorptionconstantk1,0.08361204013377926
eliminationconstantfromtheplasmakelim,0.08361204013377926
apparentvolumeofdistributionofscgvdbeta,0.08361204013377926
amountofdrugremoved,0.08361204013377926
steadystateconcentrationcmss,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefrom0to25hoursauc025,0.08361204013377926
dnf,0.08361204013377926
biologicwholebodyretentionhalflife,0.08361204013377926
dmpef,0.08361204013377926
timeforabsorptionof50,0.08361204013377926
biologichalflifet12b,0.08361204013377926
timeofthepeakconcentration,0.08361204013377926
fetaltomaternalplasmaconcentrationratio,0.08361204013377926
peakcisaprideconcentrationc0,0.08361204013377926
apparentrenalclearanceclr,0.08361204013377926
plasmaclearanceclt,0.08361204013377926
qtmax,0.08361204013377926
qtmin,0.08361204013377926
qtd,0.08361204013377926
correctedqtqtcinterval,0.08361204013377926
kaabsorptionrateconstant,0.08361204013377926
timetothepeakplasmaconcentration,0.08361204013377926
targetrelease,0.08361204013377926
maximumtumorsuv,0.08361204013377926
steadystateconcentrationcfss,0.08361204013377926
drugtoantibodyratio,0.08361204013377926
cmaxst,0.08361204013377926
aucst,0.08361204013377926
volumeoftheinitialdilutionspace,0.08361204013377926
correctedclearance,0.08361204013377926
cumulativeurinaryrecoveryof,0.08361204013377926
maximumplasmatrovafloxacinconcentration,0.08361204013377926
bileserumratio,0.08361204013377926
lungt12,0.08361204013377926
lungbacterialconcentration,0.08361204013377926
peaktrovafloxacinconcentration,0.08361204013377926
maximumcolonictissueconcentration,0.08361204013377926
colonictissueserumconcentrationratio,0.08361204013377926
areaundertheplasmafpconcentrationtimecurveuptothelastquantifiableconcentrationauclast,0.08361204013377926
fpc,0.08361204013377926
cumulativesystemiceffectparameter,0.08361204013377926
volumesofdistributionvi,0.08361204013377926
ud50,0.08361204013377926
clmean,0.08361204013377926
areaundertheconcentrationtimecurveof5fuauc5fu,0.08361204013377926
halfsaturatingconcentrationkm,0.08361204013377926
auc014,0.08361204013377926
peakplasmaptauconcentrationscmax,0.08361204013377926
plasmapeakplatinumconcentrationscmax,0.08361204013377926
areasunderthecurvefortotalplatinumconcentrationversustimeauc,0.08361204013377926
vascularavailability,0.08361204013377926
coefficientofpartition,0.08361204013377926
auc5fu,0.08361204013377926
c1max,0.08361204013377926
peakconcentrationc,0.08361204013377926
clrenr,0.08361204013377926
clrens,0.08361204013377926
areaundertheconcentrationversustimecurvesratio,0.08361204013377926
timetopeakwholebloodconcentration,0.08361204013377926
peakwholebloodconcentration,0.08361204013377926
plasmawindow,0.08361204013377926
criticaltoxicsteadystatefuraplasmaconcentration,0.08361204013377926
concentrationofthemetabolite5fuatsteadystatecssaver,0.08361204013377926
areaundertheconcentrationversustimecurveauc08h,0.08361204013377926
apparenteliminationhalflifetl2beta,0.08361204013377926
steadystateplasmauridinelevel,0.08361204013377926
therapeuticindexld50ed50,0.08361204013377926
furconcentrationsic50s,0.08361204013377926
plasmaareaunderthecurveauc0105h,0.08361204013377926
leukocytetransittime,0.08361204013377926
maximumstandardizeduptake,0.08361204013377926
totalrtdose,0.08361204013377926
areaunderthecurvefromtoto4h,0.08361204013377926
maximumtolerateddosesmtds,0.08361204013377926
fdumpdumpratio,0.08361204013377926
frna,0.08361204013377926
rateofencap,0.08361204013377926
ic70,0.08361204013377926
concentrationin,0.08361204013377926
maximum5fuconcentrationscpmax,0.08361204013377926
maximumparasitekillingrate,0.08361204013377926
parasitereductionratio,0.08361204013377926
tmaxinsaliva,0.08361204013377926
maximumpeakofexcretion,0.08361204013377926
peaktissueplasmaconcentrationratio,0.08361204013377926
pct99,0.08361204013377926
ratioofconcentration,0.08361204013377926
peakgametocytaemia,0.08361204013377926
timetopeakgamelocytaemia,0.08361204013377926
halflifeofgametocytaemia,0.08361204013377926
50efficientdoseed50,0.08361204013377926
peakchloroquinebloodlevel,0.08361204013377926
areaunderthechloroquinewholebloodconcentrationtimecurvenormalizedtobodyweightauc024hbw,0.08361204013377926
auc024hbw,0.08361204013377926
salivatotalplasmaconcentrationsspratio,0.08361204013377926
apparenthalftimeofdrugconcentrationdecay,0.08361204013377926
halflifeinthedistributionphase,0.08361204013377926
slowtransferrateconstant,0.08361204013377926
semenplasmaratio,0.08361204013377926
timeofthatpeak,0.08361204013377926
doseexcreted,0.08361204013377926
cscp,0.08361204013377926
plasmaareaunderthesubstrateconcentrationtimecurveauc0infinity,0.08361204013377926
rbctoplasmaratio,0.08361204013377926
volumeofdistributionvssratio,0.08361204013377926
minimalbactericidalconcentration,0.08361204013377926
auc028d,0.08361204013377926
peakplasmachloroquineconcentration,0.08361204013377926
peakchloroquineconcentration,0.08361204013377926
peakplasmadesethylchloroquineconcentration,0.08361204013377926
internalizationrateconstantkint,0.08361204013377926
redcelltoplasmaratio,0.08361204013377926
lagtimeofabsorptionalag,0.08361204013377926
apparentcentralvolumeofdistributionv2f,0.08361204013377926
apparentdistributionclearanceqf,0.08361204013377926
volumeofdistributionofperipheralcompartmentq3f,0.08361204013377926
nf54,0.08361204013377926
ic50k1,0.08361204013377926
peakventricular5fuconcentration,0.08361204013377926
steadystateofc,0.08361204013377926
plasmabetahalflive,0.08361204013377926
doseper,0.08361204013377926
maximumvolumevmax,0.08361204013377926
localabsorptionratiofa,0.08361204013377926
localabsorptionratiosfma,0.08361204013377926
fma,0.08361204013377926
survivalperiod,0.08361204013377926
drugtolipidratio,0.08361204013377926
steadystate5fuconcentration,0.08361204013377926
maximalareasundertheconcentrationtimecurve,0.08361204013377926
totalptconcentration,0.08361204013377926
minimumtroughserumconcentration,0.08361204013377926
peakplasma5fuconcentration,0.08361204013377926
cumulativeauc5wk,0.08361204013377926
portalbloodflowrate,0.08361204013377926
hepaticextractionratiofh,0.08361204013377926
ratesof,0.08361204013377926
dosenormalizedareaunderthecurveauc,0.08361204013377926
halflifeoftheterminalelimination,0.08361204013377926
crosslinktime,0.08361204013377926
slopesoftheterminalphasek10,0.08361204013377926
ctntratio,0.08361204013377926
kg,0.08361204013377926
transmembranephgradient,0.08361204013377926
drugabsorption,0.08361204013377926
aerasunderthecurveauc,0.08361204013377926
aucperitonealfluidplasmaratio,0.08361204013377926
ft207,0.08361204013377926
extractionrate,0.08361204013377926
fractioneliminatedwithin,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefrom0to9h,0.08361204013377926
peaki,0.08361204013377926
maximumvitrealconcentration,0.08361204013377926
plasmapelvictosystemicexposureratio,0.08361204013377926
tumourgrowthdelaytime,0.08361204013377926
timetodoubleinvolume,0.08361204013377926
ratesoffuraformation,0.08361204013377926
overallsurvivalperiod,0.08361204013377926
mesor,0.08361204013377926
freeptconcentrationptfree,0.08361204013377926
totalexcretedfraction,0.08361204013377926
totalsampleprocessingtime,0.08361204013377926
cumulativesurvivalrate,0.08361204013377926
steadystatearteriallevel,0.08361204013377926
clearanceduringfirstorderelimination,0.08361204013377926
firstorderclearance,0.08361204013377926
hepaticflow,0.08361204013377926
auc060min,0.08361204013377926
maximumdrugloadingefficiency,0.08361204013377926
rateofcumulativelocalrecurrence,0.08361204013377926
distantrecurrencerate,0.08361204013377926
liverregenerationrate,0.08361204013377926
villousheight,0.08361204013377926
specificreleaserateconstant,0.08361204013377926
hepaticclearanceduringfirstorderelimination,0.08361204013377926
maximumsurvivaltime,0.08361204013377926
totalplatinumptconcentrationpttotal,0.08361204013377926
growthinhibitionrateir,0.08361204013377926
ultrafiltrateplasmaplatinumconcentration,0.08361204013377926
timeaveraged,0.08361204013377926
percentagesofremainingperitonealfluidvolume,0.08361204013377926
peak5fuconcentrationcmax,0.08361204013377926
loadingcapacitie,0.08361204013377926
thalf,0.08361204013377926
maximumplasmalevelscpmax,0.08361204013377926
totallungfudr,0.08361204013377926
fudr,0.08361204013377926
relativetissueefficiencie,0.08361204013377926
ratioofperitonealfluidauctoserumauc,0.08361204013377926
apparentvolumeofdistributionvdsf,0.08361204013377926
clearanceintheperitonealcavityclp,0.08361204013377926
aucfurd,0.08361204013377926
aucfdurd,0.08361204013377926
peaktotal,0.08361204013377926
mucositisscore,0.08361204013377926
c2max,0.08361204013377926
volumeofdistributionattheterminalphasesvdlambdaz,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezeroto24h,0.08361204013377926
distributionofthekineticvolume,0.08361204013377926
peakrifampinconcentration,0.08361204013377926
minimumrecommendedconcentration,0.08361204013377926
milkserumultrafiltrateconcentrationsratio,0.08361204013377926
aucatsteadystate,0.08361204013377926
exposureover24hauc024,0.08361204013377926
concentrationc24,0.08361204013377926
productratio,0.08361204013377926
c3max,0.08361204013377926
areaundertherifapentineplasmaconcentrationtimecurveauc0infinity,0.08361204013377926
areaundertheconcentrationtimecurveaucfromtimezeroto6hauc6,0.08361204013377926
em50,0.08361204013377926
lagperiod,0.08361204013377926
bioavailabilityfractionalabsorption,0.08361204013377926
peakplasmarifampinconcentration,0.08361204013377926
cultureconversionrate,0.08361204013377926
areaundertheconcentrationtimecurveover24hauc024,0.08361204013377926
releasekinetic,0.08361204013377926
maximumrifampinconcentrationscmax,0.08361204013377926
eba,0.08361204013377926
lagtimeintheabsorptionphasetlag,0.08361204013377926
earlybactericidalactivity,0.08361204013377926
boneconcentrationmic,0.08361204013377926
maximalcmin,0.08361204013377926
areaundertheconcentrationauctimecurvetothelastmeasurableconcentrationauc012h,0.08361204013377926
aucuptotimeinfinityauc0,0.08361204013377926
penetrationcoefficient,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to6h,0.08361204013377926
timetoreachtheseconcentration,0.08361204013377926
areasundertheplasmaconcentrationtimecurve072h,0.08361204013377926
t12betaserum,0.08361204013377926
boneplasmapenetrationratio,0.08361204013377926
areaunderthecurve0to6hour,0.08361204013377926
peakserumrifampinconcentration,0.08361204013377926
unboundserumrifampinconcentration,0.08361204013377926
peakserumrifampinlevelcmax,0.08361204013377926
areaunderthecurvefrom06hoursauc06,0.08361204013377926
areaundertheconcentrationtimecurvefrom024hauc024,0.08361204013377926
totalbodyclearancecorrectedforweightclw,0.08361204013377926
dol,0.08361204013377926
centralcompartmentclearanceclcf,0.08361204013377926
areaundertheconcentrationversustimecurveupto24hafterthedose,0.08361204013377926
bioavailabilityindicescmax,0.08361204013377926
maximumplasmagabapentinconcentration,0.08361204013377926
numberofseizure,0.08361204013377926
mtmd,0.08361204013377926
detectionlimitlod,0.08361204013377926
oralterminalhalflife,0.08361204013377926
maximumgabapentinplasmaconcentration,0.08361204013377926
dissociaterateconstant,0.08361204013377926
eliminationhalflifetv2lz,0.08361204013377926
cumulativeexcretedfraction,0.08361204013377926
excretedfraction,0.08361204013377926
terminalhalflivest12lambdaz,0.08361204013377926
maximaldrug,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityaucinf,0.08361204013377926
maximumantibioticconcentration,0.08361204013377926
auc06mic,0.08361204013377926
peakrifampinconcentrationcmax,0.08361204013377926
areaunderthedrugconcentrationversustimecurveauc08,0.08361204013377926
timetopositivity,0.08361204013377926
serumdisappearancerate,0.08361204013377926
areaundertheconcentrationtimecurvefor12hoursafterthedoseauc012,0.08361204013377926
peakrmpconcentrationcmax,0.08361204013377926
areasundertheconcentrationtimecurvesfrom0to8hauc08,0.08361204013377926
absorptionmeantransittime,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0to12hauc024h,0.08361204013377926
proteinunboundexposure,0.08361204013377926
halfmaximal50inhibitoryconcentrationic50,0.08361204013377926
drugdeposition,0.08361204013377926
totalexposureauc024,0.08361204013377926
chigh,0.08361204013377926
chighmic,0.08361204013377926
relativebioavailabilityfa,0.08361204013377926
absorptionrateconstantkaa,0.08361204013377926
troughlevelc12,0.08361204013377926
tmaxins,0.08361204013377926
mrtins,0.08361204013377926
timetomaximalmetabolicactivity,0.08361204013377926
areaundertheplasmadrugconcentrationtimecurvefromtimezerotoinfinity,0.08361204013377926
timetothepeakplasmadrugconcentration,0.08361204013377926
peakdaptomycinlevel,0.08361204013377926
plasmaconcentrationat12hc12,0.08361204013377926
aucupto12h,0.08361204013377926
totalrecoveryofradioactivedose,0.08361204013377926
zeroorderdrugreleasekinetic,0.08361204013377926
totalauc024,0.08361204013377926
unboundauc024,0.08361204013377926
zeroorderabsorption,0.08361204013377926
timeofmaximumconcentrationsofdrugsinplasmatmax,0.08361204013377926
elfplasmaratio,0.08361204013377926
alveolarcellconcentration,0.08361204013377926
cmaxins,0.08361204013377926
inhibitionemax,0.08361204013377926
peakrifampicinconcentration,0.08361204013377926
modedose,0.08361204013377926
apparentwr1065clearance,0.08361204013377926
lungclearancerate,0.08361204013377926
areaundercurveauc04h,0.08361204013377926
wr1065,0.08361204013377926
ld5030,0.08361204013377926
dv50,0.08361204013377926
timeofoccurrenceofobservedmaximumdrugplasmaconcentration,0.08361204013377926
areaunderthecurveauc028day,0.08361204013377926
fractionoftheabsorbeddosef3,0.08361204013377926
maximumabsorptionrateconstantka1max,0.08361204013377926
kamt150,0.08361204013377926
hillfactorg,0.08361204013377926
maximumabsorptionrateconstantka3max,0.08361204013377926
halfofthemaximumabsorptionratewasachieved,0.08361204013377926
kamt350,0.08361204013377926
c25h,0.08361204013377926
firstpassextractionratio,0.08361204013377926
aciddegradation,0.08361204013377926
timetoachievemaximumconcentrationstmax,0.08361204013377926
areaunderserumconcentrationcurveauc08hour,0.08361204013377926
auc07hour,0.08361204013377926
minimumconcentrationscmin,0.08361204013377926
areaundertheconcentrationtimecurveaucss,0.08361204013377926
maximalkillmaximumeffectemax,0.08361204013377926
killrateconstant,0.08361204013377926
bioavailabilityindice,0.08361204013377926
timetoattainundetectablehivvl,0.08361204013377926
concentrationofdruginserumat12hc12h,0.08361204013377926
ratiosofareaundertheplasmaconcentrationtimecurveduringanadministrationintervalof24hauc024hto,0.08361204013377926
meanresidencetimebasedontimezerotolastsampletimemrtlast,0.08361204013377926
meanresidencetimebasedontimezeroextrapolatedtoinfinitymrtinfobs,0.08361204013377926
gm,0.08361204013377926
halflifefordistributionplasmatocsf,0.08361204013377926
dissolutionefficiencie,0.08361204013377926
terminalhalflifeeliminationt12,0.08361204013377926
areaunderthecurvefrom0to24hauc0,0.08361204013377926
areaundertheconcentrationtimecurveauc024hour,0.08361204013377926
concentrationcd7,0.08361204013377926
cfu,0.08361204013377926
auc0mic,0.08361204013377926
areaundertheconcentrationversustimecurvefrom0to12hour,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to24hforthefreeunboundfractionofadrugfauc024micratio,0.08361204013377926
serumpeakvalue,0.08361204013377926
areaundertheserumconcentrationcurvefrom0toinfinity,0.08361204013377926
intracellularplasmaratio,0.08361204013377926
plasmaauc024hr,0.08361204013377926
fractionalinhibitoryconcentrationindex,0.08361204013377926
drugencapsulationefficiencie,0.08361204013377926
pericardialtoserumratio,0.08361204013377926
percentageunboundto,0.08361204013377926
riv,0.08361204013377926
rpo,0.08361204013377926
ratesoftargetattainmentforcmaxmic,0.08361204013377926
timetoarrivalinthecolon,0.08361204013377926
initialzeroorderreleaserate,0.08361204013377926
drugavailability,0.08361204013377926
analgeticconcentration,0.08361204013377926
maximumplasmaotcconcentration,0.08361204013377926
withholdingperiod,0.08361204013377926
dispositionalhalflive,0.08361204013377926
kbi,0.08361204013377926
volumesofdistributionvdarea,0.08361204013377926
acuteoraltoxicitiesld50,0.08361204013377926
peakplasmaotcconcentration,0.08361204013377926
areaundertheconcentration0to24hrcurveauc024,0.08361204013377926
meanabsorptiontimemat0infinity,0.08361204013377926
volumeofdistributiontvv,0.08361204013377926
csfplasmaconcentrationgradient,0.08361204013377926
fauc012,0.08361204013377926
eliminationconstantsbeta,0.08361204013377926
cpmin,0.08361204013377926
sedimentationrate,0.08361204013377926
lungserumratio,0.08361204013377926
maximumplasmaconcentrationofotccmax,0.08361204013377926
ratesofdecay,0.08361204013377926
t12ofrapiddistribution,0.08361204013377926
serumhalflivesinthebetaeliminationphase,0.08361204013377926
halflifest12ke0,0.08361204013377926
peakdoxycyclineconcentration,0.08361204013377926
percentageurinaryrecoverie,0.08361204013377926
depletionhalflife,0.08361204013377926
peakmuscleconcentrationscmax,0.08361204013377926
areasundertheplasmaconcentrationtimecurvesauc000,0.08361204013377926
netextraction,0.08361204013377926
concentrationratioat,0.08361204013377926
percentageofunchanged,0.08361204013377926
steadyrateserummorphineconcentration,0.08361204013377926
collectiontime,0.08361204013377926
plasmatogenitaltissueratio,0.08361204013377926
renalmetabolicclearance,0.08361204013377926
betae,0.08361204013377926
minimumeffectiveserumdoxycyclineconcentration,0.08361204013377926
muscleserum,0.08361204013377926
micratio,0.08361204013377926
auctotal024hmictargetattainment,0.08361204013377926
minimalplasmaconcentrationcmin,0.08361204013377926
areaundertheconcentrationtimecurvefrom0htoinfinityauc0,0.08361204013377926
sputumplasmaconcentrationratio,0.08361204013377926
absolutebioavailabilitiesf,0.08361204013377926
maximummilkotcconcentration,0.08361204013377926
peakmilkotcconcentration,0.08361204013377926
milkproteinbinding,0.08361204013377926
halflifeofslowspace,0.08361204013377926
detectionthreshold,0.08361204013377926
peakbiletoplasmaotcconcentrationratio,0.08361204013377926
peaktimetomaximumconcentration,0.08361204013377926
saturationcoefficient,0.08361204013377926
clbody,0.08361204013377926
redcellplasmawaterpartitioncoefficient,0.08361204013377926
peakbileplasmaconcentrationratio,0.08361204013377926
meanresidencetimemrt0infinity,0.08361204013377926
minimumtherapeuticserumconcentrationofdrug,0.08361204013377926
areaundertheplasmaconcentrationtimeprofilecalculatedbetween0and168hauc0168,0.08361204013377926
observedmaximumctcconcentrationscmax,0.08361204013377926
initialvolume,0.08361204013377926
a50,0.08361204013377926
0interceptbetacurveb,0.08361204013377926
rateofeliminationfrombodyb,0.08361204013377926
halflifeeliminationfrombodyt12b,0.08361204013377926
w,0.08361204013377926
deepdistributionvolumev2,0.08361204013377926
timetoreach50,0.08361204013377926
rapideliminationhalflife,0.08361204013377926
sloweliminationhalflife,0.08361204013377926
tfi,0.08361204013377926
lengthofsurvival,0.08361204013377926
effectdelay,0.08361204013377926
maximalanti,0.08361204013377926
eliminationhalflifeoftheterminalpartoftheeliminationphaset12b,0.08361204013377926
depurationtime,0.08361204013377926
clearancem3g,0.08361204013377926
clearancem6g,0.08361204013377926
mrpl,0.08361204013377926
areaundercurveauc0a,0.08361204013377926
halflifeofradioactivity,0.08361204013377926
ae012,0.08361204013377926
maximummucoadhesiveforce,0.08361204013377926
auc010aucareaunderthecurve,0.08361204013377926
troughsupinedbp,0.08361204013377926
timetopeakfall,0.08361204013377926
bioavailabilityfrel,0.08361204013377926
peakplasmacilazaprilatconcentration,0.08361204013377926
apparentcilazaprilatclearance,0.08361204013377926
apparentsteadystatelevel,0.08361204013377926
timetoreachmaximumbloodconcentrationcmaxtmax,0.08361204013377926
peakplasmazonisamidecmax,0.08361204013377926
fractionofunbounddrug,0.08361204013377926
plasmacmaxatsteadystate,0.08361204013377926
maximumplasmazonisamideconcentration,0.08361204013377926
meanresidencetimemrt0a,0.08361204013377926
maximumtimeofpeakplasmaconcentrationtmax,0.08361204013377926
areasunderthecurvesaucs,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to72hoursauc072,0.08361204013377926
cshtsatsteadystate,0.08361204013377926
totalareaundertheconcentrationversustimecurve0hourstoinfinity,0.08361204013377926
areasundertheserumconcentrationtimecurveauc2425,0.08361204013377926
auc2425,0.08361204013377926
maximumpupildiameterchange,0.08361204013377926
distributionphasehalflifet12alpha,0.08361204013377926
ecp50ecp95,0.08361204013377926
plasmapartitioncoefficient,0.08361204013377926
maximumapparentinhibition,0.08361204013377926
t05ofelimination,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0tothelastsamplingtime,0.08361204013377926
weightadjustedclearance,0.08361204013377926
plasmaareaundertheconcentrationtimecurvefrom0to72hoursratio,0.08361204013377926
areaundertheeffectcurveaue,0.08361204013377926
aue,0.08361204013377926
relativepotencyratio,0.08361204013377926
serumoralclearance,0.08361204013377926
steadystatebioconcentrationfactor,0.08361204013377926
disappearanceraterapidphase,0.08361204013377926
relativeeffectivene,0.08361204013377926
dailyurineoutput,0.08361204013377926
maximumincreaseincwaterdeltacwatermax,0.08361204013377926
plasmameanresidencetimemrt,0.08361204013377926
bbbtransportclearance,0.08361204013377926
detectionlimitofdrug,0.08361204013377926
maximummorphineconcentrationscmax,0.08361204013377926
partitioninghalflife,0.08361204013377926
timestopeakbloodconcentration,0.08361204013377926
maximumreductionemax,0.08361204013377926
residuelevel,0.08361204013377926
coefficientsofelimination,0.08361204013377926
maximumbioaccumulationfactor,0.08361204013377926
totalamountofabsorbedlindane,0.08361204013377926
apparenthalflifeof,0.08361204013377926
minimummorphineconcentrationscmin,0.08361204013377926
volumeoffastinitialdistribution,0.08361204013377926
areaundertheplasmamelagatranconcentrationversustimecurve,0.08361204013377926
freewaterclearance,0.08361204013377926
timeofmaximumincrease,0.08361204013377926
urineoutputdose,0.08361204013377926
pretreatmentrecoveryrate,0.08361204013377926
clearancefclf,0.08361204013377926
volumeofdistributionfvdf,0.08361204013377926
biologicalhalflifetbeta12,0.08361204013377926
fastphase,0.08361204013377926
fastphaseofthedisappearancecurve,0.08361204013377926
ebapo,0.08361204013377926
ebappo,0.08361204013377926
overallrelativebioavailability,0.08361204013377926
freewaterreabsorption,0.08361204013377926
areaundertheplasmalzdconcentrationtimecurveauc24minimuminhibitoryconcentrationmic,0.08361204013377926
steadystateplasmaavtlevel,0.08361204013377926
pravp,0.08361204013377926
absorptionhalflifet12k,0.08361204013377926
totalu,0.08361204013377926
deliveryrateadjustedserumfentanylconcentration,0.08361204013377926
backgroundconcentration,0.08361204013377926
eliminationratebeta,0.08361204013377926
minimalplasmaconcentrationscmin,0.08361204013377926
timestothepeaklevel,0.08361204013377926
maximumbuprenorphineconcentration,0.08361204013377926
maximumnorbuprenorphineconcentration,0.08361204013377926
maximumbuprenorphineplasmaconcentration,0.08361204013377926
compartmentvolume,0.08361204013377926
residualamount,0.08361204013377926
overallventilatoryresponse,0.08361204013377926
timetomaximumeffecttmax,0.08361204013377926
maximumantinociceptiveeffectcmax,0.08361204013377926
peakplasmabuprenorphineconcentration,0.08361204013377926
timetomaximumplasmabuprenorphineconcentration,0.08361204013377926
areaundertheplasmaconcentrationtimecurveatsteadystateauctau,0.08361204013377926
residualtime,0.08361204013377926
rectalph,0.08361204013377926
motor,0.08361204013377926
durationofsensory,0.08361204013377926
terminaleliminationhalflifeofmeperidinet12beta,0.08361204013377926
ventricularcsfplasmaratio,0.08361204013377926
kef,0.08361204013377926
tmaxf,0.08361204013377926
concentrationsintheeffectcompartmentgeneratinghalfmaximalanalgesiaec50,0.08361204013377926
maximaleffectsemax,0.08361204013377926
hillcoefficientss,0.08361204013377926
maximumarterialbloodconcentration,0.08361204013377926
coronarysinusbloodconcentration,0.08361204013377926
maximumratesofuptakeinfluxes,0.08361204013377926
fractionofunboundpethi,0.08361204013377926
maximalcsfplasmaconcentrationratio,0.08361204013377926
maximumcsfnorpethidine,0.08361204013377926
timeaveragedextractionratio,0.08361204013377926
portionofthefreefraction,0.08361204013377926
fractionofunboundpethidine,0.08361204013377926
timetakentoreachthemaximumplasmaconcentration,0.08361204013377926
pwp,0.08361204013377926
timetofirstuse,0.08361204013377926
bloodconcentrationat50ofmaximumeffect,0.08361204013377926
peakconcentrationb,0.08361204013377926
reflexthreshold,0.08361204013377926
subjectivethreshold,0.08361204013377926
timeofpeakplasmamorphineconcentrationtmax,0.08361204013377926
apparentvolumesofdistributionatsteadystate,0.08361204013377926
totalvolume,0.08361204013377926
troughplasmasu0020concentration,0.08361204013377926
meanreleasetime,0.08361204013377926
tc50,0.08361204013377926
plasmaclearanceofunbounddrugclu,0.08361204013377926
volumeofdistributionofunbounddrugatsteadystatevuss,0.08361204013377926
maximumstriatumtocerebellumratio,0.08361204013377926
distributionvolumeratiodvr,0.08361204013377926
totaltroughconcentrationsctrough,0.08361204013377926
serumunboundconcentration,0.08361204013377926
acylationrateconstant,0.08361204013377926
maximumthermalthresholdtt,0.08361204013377926
t12c,0.08361204013377926
effectdelayhalflife,0.08361204013377926
terminalhalflifet12c,0.08361204013377926
maximalbloodconcentrationscmax,0.08361204013377926
steadystateplasmabuprenorphineconcentration,0.08361204013377926
halflifeofunbound,0.08361204013377926
concentrationbackextrapolatedtotimezero,0.08361204013377926
maximalobservedplasmaconcentrationofbuprenorphinecmax,0.08361204013377926
timeofthelastquantifiableconcentration,0.08361204013377926
secondorderrateconstantofreceptorassociationkon,0.08361204013377926
firstorderrateconstantofreceptordissociationkoff,0.08361204013377926
equilibriumdissociationconstantkdiss,0.08361204013377926
kdiss,0.08361204013377926
serumalbumin,0.08361204013377926
freebuprenorphine,0.08361204013377926
maximumincreaseintt,0.08361204013377926
t12koff,0.08361204013377926
thermalthresholdlatency,0.08361204013377926
peakcsfconcentrationtimetmaxf,0.08361204013377926
eliminationrateconstantkef,0.08361204013377926
c0cmin,0.08361204013377926
serumproteinbindingpercent,0.08361204013377926
maximumserumactivitycmax,0.08361204013377926
tissueplasmaconcentration,0.08361204013377926
maximumplasmadoxycyclineconcentration,0.08361204013377926
terminalslopehalflive,0.08361204013377926
plasmaotc,0.08361204013377926
eliminationperiod,0.08361204013377926
totalbodyclearanceoftheabsorbedfraction,0.08361204013377926
peakserumdoxycyclineconcentration,0.08361204013377926
synovialconcentration,0.08361204013377926
highesturineconcentration,0.08361204013377926
highestendometrialconcentration,0.08361204013377926
totalbrainconcentrationratio,0.08361204013377926
unboundbrainextracellularfluidconcentrationratio,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezero,0.08361204013377926
halflivest12lambdaz,0.08361204013377926
timetopeakserumdoxycyclineactivitytmax,0.08361204013377926
rateconstantbeta,0.08361204013377926
residue,0.08361204013377926
lymphlevel,0.08361204013377926
ventilatoryresponse,0.08361204013377926
m3gmorphineratio,0.08361204013377926
steadystatedcconcentration,0.08361204013377926
areaunderconcentrationversustimecurve,0.08361204013377926
ratiosofaverageconcentrationover48hcav048hmic,0.08361204013377926
areaundertheconcentrationtimecurveforthefreeunboundfractionofthedrug,0.08361204013377926
auclastmic,0.08361204013377926
fractionofsteadystateachieved,0.08361204013377926
distributionrateconstanta,0.08361204013377926
overallbodyclearance,0.08361204013377926
steadystateotcplasmalevel,0.08361204013377926
totalconcentrationratio,0.08361204013377926
areaundertheconcentrationtimecurveauc09days,0.08361204013377926
dosenormalizedareaunderthecurveaucd,0.08361204013377926
steadystateaverageplasmaconcentration,0.08361204013377926
maximumresiduelevel,0.08361204013377926
plasmaconcentrationattimezero,0.08361204013377926
critical,0.08361204013377926
totaldistributionvolumevdarea,0.08361204013377926
finaldistributionvolume,0.08361204013377926
serumconcentrationsafter24h,0.08361204013377926
unboundareaundertheconcentrationtimecurveaucuratio,0.08361204013377926
apparentlagtime,0.08361204013377926
peakserumtetracyclineconcentration,0.08361204013377926
timeofattainmentofpeakconcentration,0.08361204013377926
apparentfirstorderabsorptionhalflife,0.08361204013377926
apparentfirstordereliminationhalflife,0.08361204013377926
steadystatevolumedistribution,0.08361204013377926
maximalotcconcentration,0.08361204013377926
tissueplasmaconcentrationratiok12k21beta,0.08361204013377926
minimumplasmaconcentrationcpinfinityminmic,0.08361204013377926
timecorrespondingtocmaxtmax,0.08361204013377926
maximalplasmavalue,0.08361204013377926
maximumcysteamineplasmaconcentrationcmax,0.08361204013377926
distributionvolumeofthecentralcompartmentv1,0.08361204013377926
minimumotcconcentration,0.08361204013377926
plasmaexposureaucinf,0.08361204013377926
alphahalftimet12alpha,0.08361204013377926
aurc,0.08361204013377926
bioavailabilityauc0360min,0.08361204013377926
betaeliminationrateconstant,0.08361204013377926
timetoreachthecmax,0.08361204013377926
halflifeofthefirstphase,0.08361204013377926
penetrationfactor,0.08361204013377926
areaundertheconcentrationtimecurvefrom0toinfinitivetime,0.08361204013377926
peakmorphineconcentrationincsf,0.08361204013377926
betahalftimet12beta,0.08361204013377926
areaunderserumconcentrationtimecurveauc0micratio,0.08361204013377926
auc0micratio,0.08361204013377926
auc024hrmicratio,0.08361204013377926
areaundertheconcentrationtimecurveaucfromtimezerotoinfinityauc0,0.08361204013377926
finaleliminationhalflive,0.08361204013377926
areaundertheconcentrationtimecurvefrom0hrto,0.08361204013377926
distributionhalftimet12alpha,0.08361204013377926
steadystatefentanylconcentration,0.08361204013377926
dosenormalizedmaximumplasmaconcentration,0.08361204013377926
plasmaconcentrationtimecurve,0.08361204013377926
extractionfractionratioe,0.08361204013377926
effectivedoseequivalent,0.08361204013377926
secondhalflive,0.08361204013377926
serummorphineclearance,0.08361204013377926
steadystateoctreotideserumdruglevel,0.08361204013377926
skinequivalentdosedistribution,0.08361204013377926
areasunderthe,0.08361204013377926
timeofpeaktmax,0.08361204013377926
apparentvolumeofdistributionofthecentalcompartmentv1,0.08361204013377926
timevaluetopeakconcentration,0.08361204013377926
95inhibitoryconcentration,0.08361204013377926
mucosalextractionratio,0.08361204013377926
bioavailabilityf0infinity,0.08361204013377926
maximumincreaseinreactiontime,0.08361204013377926
weightnormalizedauc08,0.08361204013377926
timetopeakmidazolamconcentration,0.08361204013377926
timestothehalfmaximalmioticeffect,0.08361204013377926
serumhalflifeforthebetaphaset12beta,0.08361204013377926
fd,0.08361204013377926
suv,0.08361204013377926
apparentepoauc024,0.08361204013377926
apparentauc024,0.08361204013377926
cmaxomegaalpha,0.08361204013377926
aucomegaalpha,0.08361204013377926
dosenormalizedareaunderthecurvenlauc0infinity,0.08361204013377926
intervalofmaximum,0.08361204013377926
serumdistributionhalflife,0.08361204013377926
ess,0.08361204013377926
essmax,0.08361204013377926
dispositionresidencetime,0.08361204013377926
tumourtomuscleratio,0.08361204013377926
totalmorphinerescuedose,0.08361204013377926
totallocallybioavailable,0.08361204013377926
absorptionpeaktimetmax,0.08361204013377926
totalbodyeffectivedose,0.08361204013377926
timetotheprocedure,0.08361204013377926
clmet,0.08361204013377926
sedationduration,0.08361204013377926
percentageofunbounddruginplasma,0.08361204013377926
effectiveconcentrationtoattaina50maximalresponseec50,0.08361204013377926
halfmaximumconcentrationec50,0.08361204013377926
areaunderplasmalevelcurveofmidazolamaucmidazolamdose,0.08361204013377926
metabolicplasmaratioaucofalphaohmidazolamaucmidazolam,0.08361204013377926
peakplasmamidazolamconcentration,0.08361204013377926
timetoreachpeakplasmamidazolamconcentration,0.08361204013377926
timetoreachpeakplasmamidazolamlevel,0.08361204013377926
firstpasseffectf,0.08361204013377926
vfthreshold,0.08361204013377926
maximummorphineplasmaconcentrationcmax,0.08361204013377926
apparentvolumeoftheperipheralcompartmentv2,0.08361204013377926
areaunderthecurveratiosaucrs,0.08361204013377926
kvo,0.08361204013377926
areaundertheconcentrationtimecurveaucc,0.08361204013377926
concentrationmaximac,0.08361204013377926
metabolictransittime,0.08361204013377926
disappearancerateconstant,0.08361204013377926
intestinalextractionratioerg,0.08361204013377926
absorptionratetransitrateconstant,0.08361204013377926
maximummidazolamconcentration,0.08361204013377926
peakmidazolamserumconcentration,0.08361204013377926
intercompartmentalclearanceclq,0.08361204013377926
clq,0.08361204013377926
1ohmidazolammidazolamaucratio,0.08361204013377926
maximalchangeineffectmeasurefrombaselineemax,0.08361204013377926
interresponsetime,0.08361204013377926
aucinfratio,0.08361204013377926
durationofcontinuousin,0.08361204013377926
terminalhalflifeofmorphineelimination,0.08361204013377926
auc0lastratio,0.08361204013377926
peaklumbarcerebrospinalfluidlevel,0.08361204013377926
timetopeakcerebrospinalfluidmorphineconcentration,0.08361204013377926
peaksaccadicvelocity,0.08361204013377926
50ofeffectiveconcentration,0.08361204013377926
areaundertheeffectcurvetothelastobservationauec0last,0.08361204013377926
maximumreticulocytecount,0.08361204013377926
areaundertheserumconcentrationtimecurvefromtime0tothelastbloodsamplingtimeattimett,0.08361204013377926
areaundertheplasmaconcentrationtimeprofileauc,0.08361204013377926
rateofbiliaryelimination,0.08361204013377926
minimumconcentrationinserumcmin,0.08361204013377926
totalrecoveryofadministereddose,0.08361204013377926
totalamountsofradio,0.08361204013377926
maximalspecificerythrocytebindingcapacitybmaxrbc,0.08361204013377926
maximalspecificbindingcapacitytothetissuesbmaxtissue,0.08361204013377926
volumeofthecentralcompartmentvplasmatissuefluids,0.08361204013377926
totalintrinsiccl,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimeofadministrationto24hoursafterdosingauc024,0.08361204013377926
24hourpostdoseconcentrationc24,0.08361204013377926
final,0.08361204013377926
washouthalflifet12,0.08361204013377926
absorptionhalflifeta12cin,0.08361204013377926
ta12pip,0.08361204013377926
tb12cin,0.08361204013377926
totaldtg,0.08361204013377926
daystona,0.08361204013377926
ucin012h,0.08361204013377926
firstorderrateconstantk1,0.08361204013377926
cminunboundlevel,0.08361204013377926
cminunbound,0.08361204013377926
peakconcentrationtimetmax,0.08361204013377926
tumorbloodflowktrans,0.08361204013377926
timeto50ccr5receptoroccupancy,0.08361204013377926
systemapparentclearanceclf,0.08361204013377926
volumeofapparentdistributionincenterv1f,0.08361204013377926
intercompartmentaltransferrateskcpkpc,0.08361204013377926
correctedlungplasmaratio,0.08361204013377926
terad,0.08361204013377926
timewhenplasmaconcentration,0.08361204013377926
aucsfromtimezerotoinfinity,0.08361204013377926
areaunderthecurvefrom0hto24hauc024h,0.08361204013377926
timestopeakvalue,0.08361204013377926
totalfirstpasseffect,0.08361204013377926
tb12pip,0.08361204013377926
upip012h,0.08361204013377926
carboxyterminalhydrolase,0.08361204013377926
ratiooftotalbodyclearance,0.08361204013377926
timetopeakbudesonideplasmaconcentrationtmax,0.08361204013377926
areaunderthetimevsplasmaconcentrationcurve04h,0.08361204013377926
relativedrugavailability,0.08361204013377926
troughamikacinconcentration,0.08361204013377926
q3hrelease,0.08361204013377926
maximumplasmaconcentrationoffexofenadinetmax,0.08361204013377926
terminaldistributionvolumevz,0.08361204013377926
metabolicclearancerateofamcra,0.08361204013377926
mcra,0.08361204013377926
placentalclearancerate,0.08361204013377926
areaundercurvesauc0t,0.08361204013377926
accumulationfactoraucssauc0t,0.08361204013377926
peakarea,0.08361204013377926
dte,0.08361204013377926
timeatwhichcmaxwasreachedtmax,0.08361204013377926
viscositie,0.08361204013377926
peakinspiratoryflowrate,0.08361204013377926
timetoreachmaximumplasmaconcentrationscmax,0.08361204013377926
peakplasmabudesonidelevel,0.08361204013377926
maximumantagonizingeffect,0.08361204013377926
totalobjectiveresponserate,0.08361204013377926
totalfirstpasseffectegitliver,0.08361204013377926
totalrecoveryinexcreta,0.08361204013377926
maximalextent,0.08361204013377926
maximumdrugconcentrationinserumcmax,0.08361204013377926
centralvolumeofdistributionvcentr,0.08361204013377926
firsteliminationhalflifet12alpha,0.08361204013377926
secondeliminationhalflifet12beta,0.08361204013377926
timetoproteinadjusted90inhibitoryconcentration,0.08361204013377926
dosenormalizedareaundertheplasmacarboplatinconcentrationversustimecurveauc,0.08361204013377926
bloodclearancecl,0.08361204013377926
cmaxauci,0.08361204013377926
fractionofmorphineabsorbed,0.08361204013377926
pulmonarydeposition,0.08361204013377926
eliminationhalflifec,0.08361204013377926
volumeofdistributioninthebetaphasevdbeta,0.08361204013377926
areaunderthecurvefrom0to60minafteradministration,0.08361204013377926
timestoonsetofanalgesia,0.08361204013377926
plasmaconcentrationsratio,0.08361204013377926
minuteventilation,0.08361204013377926
meanabsorptionlagtimetlag,0.08361204013377926
auc0lloq,0.08361204013377926
peakcfen,0.08361204013377926
cfen,0.08361204013377926
timetopeakabsorption,0.08361204013377926
durationsofeffect,0.08361204013377926
fractionremoval,0.08361204013377926
areaunderthecurveextrapolatedtoinfinity,0.08361204013377926
achieved,0.08361204013377926
spo2,0.08361204013377926
clearance3,0.08361204013377926
areaunderthecurvefrom0to60hauc060,0.08361204013377926
auc060pd,0.08361204013377926
maintenancedose,0.08361204013377926
tubularsecretionclearanceclt,0.08361204013377926
apparenttotalclearanceafteroraladministrationclf,0.08361204013377926
maximumlatency,0.08361204013377926
fractionaloralbioavailabilityf,0.08361204013377926
observedtroughconcentration,0.08361204013377926
entrapmentyield,0.08361204013377926
renaltissuetoplasmaconcentrationratio,0.08361204013377926
vitaminb12,0.08361204013377926
secretionclearance,0.08361204013377926
floatingdurationtime,0.08361204013377926
oralavailabilityf,0.08361204013377926
clnrf,0.08361204013377926
maximumpeakconcentration,0.08361204013377926
steadystatemaximumplasmaconcentrationscmaxss,0.08361204013377926
steadystateareasundertheconcentrationtimecurvesduringthedoseintervalauctss,0.08361204013377926
detectionlimitpeakarea,0.08361204013377926
chromatographicrunningtime,0.08361204013377926
eliminationhalflifefromplasma,0.08361204013377926
peakmorphineconcentration,0.08361204013377926
timeaveragedbioavailability,0.08361204013377926
serumfentanylconcentration,0.08361204013377926
areaunderconcentrationtimecurveauc024,0.08361204013377926
rateoffentanylabsorption,0.08361204013377926
meanabsorptionrate,0.08361204013377926
mm6gratio,0.08361204013377926
maximumobservedserumfentanylconcentration,0.08361204013377926
areaunderthecurveauctau,0.08361204013377926
totalsteadystateplasmaconcentration,0.08361204013377926
rateoftransdermaldelivery,0.08361204013377926
areaundertheserumfentanylconcentrationtimecurve072h,0.08361204013377926
totalvolumeofdistributionvarea,0.08361204013377926
halflifeduringthetissueuptakephase,0.08361204013377926
maximumconcentrationproduced,0.08361204013377926
minimumanalgesicbloodconcentration,0.08361204013377926
peripheralcompartmentsv2,0.08361204013377926
steadystateconc,0.08361204013377926
cmaxmaximumserumconcentration,0.08361204013377926
tmaxtimetomaximumserumconcentration,0.08361204013377926
m6gmorphine,0.08361204013377926
apparentreleaseflux,0.08361204013377926
correctedauc05,0.08361204013377926
dosenormalizedbioavailability,0.08361204013377926
clearance2,0.08361204013377926
clearance1,0.08361204013377926
firstdetectableplasmafentanylconcentrationtime,0.08361204013377926
partitioncoefficientforunbounddrugkpuu,0.08361204013377926
meanabsorption,0.08361204013377926
areaunderthecurveforplasmafentanylconcentration0144h,0.08361204013377926
buccaldwelltime,0.08361204013377926
dosenormalizedauc0tmax,0.08361204013377926
timestodetectableconcentration,0.08361204013377926
metabolicclearancecl,0.08361204013377926
maximumlumbarcsfconcentration,0.08361204013377926
timeassociatedwith,0.08361204013377926
totalapparentvolumeofdistributionvbeta,0.08361204013377926
zerotimeplasmafentanylconcentration,0.08361204013377926
areaundertheplasmafentanylconcentrationvstimecurve,0.08361204013377926
kidneyplasmaratio,0.08361204013377926
troughsteadystatemetforminplasmaconcentration,0.08361204013377926
troughmetforminconcentration,0.08361204013377926
bispectralindexic50,0.08361204013377926
oraltransittimemtt,0.08361204013377926
timetoattaincmaxtmax,0.08361204013377926
biologicalhalflifeintheterminalphasebeta,0.08361204013377926
areaundertheconcentrationtimecurvefromzerotoinfinityauc0,0.08361204013377926
plasmaconcentrationsec50,0.08361204013377926
clfunbound,0.08361204013377926
clrenalunbound,0.08361204013377926
clsecretionunbound,0.08361204013377926
plasmafreedrugfraction,0.08361204013377926
dissociationrateconstantki,0.08361204013377926
waitingtime,0.08361204013377926
50maximumeffectiveconcentration,0.08361204013377926
areaundertheconcentrationtimecurvefromzeroto24hafteradministrationauc024h,0.08361204013377926
auc06ratio,0.08361204013377926
fluctuationindice,0.08361204013377926
totaloralbioavailability,0.08361204013377926
maximumflowrate,0.08361204013377926
areaundertheconcentrationtimecurveextrapolatedtoinfinityauc,0.08361204013377926
concentrationgiving50,0.08361204013377926
relativemaximumeffect,0.08361204013377926
mreffectratio,0.08361204013377926
areaundertheconcentrationtimecurveaucinf,0.08361204013377926
peakabsorption,0.08361204013377926
oraleliminationhalflife,0.08361204013377926
accumulativeurinaryexcretion,0.08361204013377926
areaunderplasmaconcentrationcurveauc08h,0.08361204013377926
sedationtargetconcentration,0.08361204013377926
steadystateinfusionrate,0.08361204013377926
totalmorphineconsumption,0.08361204013377926
rectalbioavailability,0.08361204013377926
timestoonset,0.08361204013377926
timestolossofresponse,0.08361204013377926
intrinsicgutwallclearance,0.08361204013377926
eclmet,0.08361204013377926
apparentvolumeofdistributioninsteadystate,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauct0tinf,0.08361204013377926
troughserummetforminconcentration,0.08361204013377926
maximumspecificactivity,0.08361204013377926
halfofmaximumbindingcapacity,0.08361204013377926
ocularhalflifet12,0.08361204013377926
suppressionduration,0.08361204013377926
slopecoefficient,0.08361204013377926
bbbpermeabilitysurfaceareaproduct,0.08361204013377926
distributionvolumeplasma,0.08361204013377926
timeaveragednonrenalclearance,0.08361204013377926
areaundertheconcentrationtimecurvefromdosingto12hourspostdoseauc012h,0.08361204013377926
halfmaximalefficaciousauc,0.08361204013377926
netsecretionclearance,0.08361204013377926
bloodtoplasmapartitionratiobp,0.08361204013377926
intrinsicequilibriumbp,0.08361204013377926
plasmarenalextractionratio,0.08361204013377926
renaleliminationrateconstant,0.08361204013377926
hydrodynamicdiameter,0.08361204013377926
intraoculareliminationhalflife,0.08361204013377926
areaundercurvefromtime0totheendpointauclast,0.08361204013377926
auct0tinf,0.08361204013377926
areaunderthecurveauc0last,0.08361204013377926
plasmameanresidencetime,0.08361204013377926
relativebioavailabilityfpgs,0.08361204013377926
apparentvolumeofdistributionofunbounddrugsteadystatevu,0.08361204013377926
redbloodcellplasmawaterconcentrationratio,0.08361204013377926
surfaceundertheserumconcentrationcurve,0.08361204013377926
timetoreachpeakleveltmax,0.08361204013377926
maximumplasmaprazosinconcentration,0.08361204013377926
urinet12beta,0.08361204013377926
distributionalhalflifet12alpha,0.08361204013377926
terminalphaseeliminationhalflifet12z,0.08361204013377926
plasmaconcentrationof,0.08361204013377926
initialmeanconcentration,0.08361204013377926
levelofunboundvegfa,0.08361204013377926
areaunderthecurvefromtime0totheendpoint,0.08361204013377926
relativemolarbindingactivitie,0.08361204013377926
deacylationrateconstant,0.08361204013377926
clmat50,0.08361204013377926
enhancementratiosser,0.08361204013377926
rateofsecretion,0.08361204013377926
drgp,0.08361204013377926
mtcontent,0.08361204013377926
releasehalflivest50,0.08361204013377926
zeroorderreleaserate,0.08361204013377926
peakendogenousmelatoninconcentration,0.08361204013377926
maximumnacetyltransferaseactivity,0.08361204013377926
eliminationconstantke1,0.08361204013377926
durationofsecretion,0.08361204013377926
maximumseruminsulinconcentrationcmaxins,0.08361204013377926
extractedfraction,0.08361204013377926
areaunderthenicotineconcentrationtimecurveauc,0.08361204013377926
maximumplasmanicotineconcentration,0.08361204013377926
timetothemaximumnicotineconcentration,0.08361204013377926
timetopartialresponse,0.08361204013377926
peaktotroughasenapineplasmaconcentrationratio,0.08361204013377926
maximumdrugdiffusion,0.08361204013377926
maximumplasmamltconcentrationcmax,0.08361204013377926
apparentterminalhalflifet12z,0.08361204013377926
amplitudeofsecretoryburst,0.08361204013377926
massofmelatoninreleased,0.08361204013377926
vdfapparentvolume,0.08361204013377926
daysopen,0.08361204013377926
halfabsorptiontime,0.08361204013377926
halfeliminationtime,0.08361204013377926
areaunderthecurvein24hour,0.08361204013377926
signalnoiseratio,0.08361204013377926
percentageofrenalclearanceclrcltotal,0.08361204013377926
steadystatebloodnicotineconcentration,0.08361204013377926
braindistributionspace,0.08361204013377926
clearanceofglucosefrombloodtobraink1,0.08361204013377926
fractionalclearanceofglucosefrombraintobloodk2,0.08361204013377926
peakplasmamelatoninlevel,0.08361204013377926
halflifeoftheabsorbedmelatonint12elimination,0.08361204013377926
dosenormalizedoralbioavailability,0.08361204013377926
nocturnalsleeptime,0.08361204013377926
ctc50,0.08361204013377926
areasundertheconcentrationversustimecurve012hauc012,0.08361204013377926
timerequiredtoreachmaximumbrainconcentration,0.08361204013377926
kglucose,0.08361204013377926
apparentni,0.08361204013377926
separationefficiency,0.08361204013377926
timetomaximumglucoseinfusionrate,0.08361204013377926
tissuetobloodpartitioncoefficient,0.08361204013377926
uer,0.08361204013377926
glucosehalflife,0.08361204013377926
aaurnet,0.08361204013377926
peakserumv,0.08361204013377926
voutput,0.08361204013377926
serumtobloodvratio,0.08361204013377926
glucosepeak,0.08361204013377926
maximumseruminsulinlevelscmax,0.08361204013377926
areaunderthecurvefrom0to120min,0.08361204013377926
maximummetaboliceffect,0.08361204013377926
timetopeakgirtmaxgir,0.08361204013377926
kitt,0.08361204013377926
t12glucose,0.08361204013377926
sweatchlorideconcentration,0.08361204013377926
lipemia,0.08361204013377926
maximumvoluntaryventilation,0.08361204013377926
fractionofunchangeddrugexcretedinurine,0.08361204013377926
baselinecorrectedcmax,0.08361204013377926
timetomaximalmetaboliceffectmaximumglucoseinfusionrategirmax,0.08361204013377926
timetohalfmaximaleffect,0.08361204013377926
glucoseconsumption,0.08361204013377926
insulinauc240480,0.08361204013377926
auc240480,0.08361204013377926
get,0.08361204013377926
auc120h,0.08361204013377926
tissuebloodpartitioncoefficient,0.08361204013377926
systemiceliminationhalftime,0.08361204013377926
initialhalftimeofabsorption,0.08361204013377926
totalextractionrecovery,0.08361204013377926
clearanceofglucose,0.08361204013377926
clfapparentclearance,0.08361204013377926
totaldrugexposureareaunderthecurve,0.08361204013377926
tissuemediumratio,0.08361204013377926
tmaxdcmi,0.08361204013377926
mrth,0.08361204013377926
plasmaclomipramineclearance,0.08361204013377926
relativeciclearance,0.08361204013377926
totaldistributionvolumevd,0.08361204013377926
relativevolumeofdistributiondelta,0.08361204013377926
auc15,0.08361204013377926
halflifeofapparentterminaldisposition,0.08361204013377926
tgconcentration,0.08361204013377926
timetoplasmapeaktmax,0.08361204013377926
halflifet12lambdaz,0.08361204013377926
plasmafinalhalflife,0.08361204013377926
overallprocessefficiency,0.08361204013377926
peakplasmaaraclevelsat3hcp3h,0.08361204013377926
renalclearancerc,0.08361204013377926
cp3h,0.08361204013377926
cdc,0.08361204013377926
tmaxcmi,0.08361204013377926
peakmeancsfconcentration,0.08361204013377926
hillcoefficientgamma,0.08361204013377926
biodegradabilityrate,0.08361204013377926
bloodflowrateqb,0.08361204013377926
plasmaarterialalendronateconcentration,0.08361204013377926
totalapparentvolumeofdistributionvz,0.08361204013377926
maximumbisoprololconcentration,0.08361204013377926
clogp,0.08361204013377926
firsthalflife,0.08361204013377926
brainextractionratio,0.08361204013377926
tmaxt12,0.08361204013377926
fub,0.08361204013377926
oralbioavailabityf,0.08361204013377926
peakserumcortisollevel,0.08361204013377926
apparentdistribution,0.08361204013377926
totalbodyclearanceofacthclb,0.08361204013377926
apparenteliminationrateconstantkel,0.08361204013377926
24hurine,0.08361204013377926
peakcaconcentration,0.08361204013377926
1arauratio,0.08361204013377926
bloodtobraintransferconstant,0.08361204013377926
areaunderthecurveaucivlast,0.08361204013377926
minimumplasmaaracconcentration,0.08361204013377926
arauaracratio,0.08361204013377926
eliminationhalfliket12,0.08361204013377926
arac,0.08361204013377926
halflifeofeliminationt12el,0.08361204013377926
electro,0.08361204013377926
peakaraclevel,0.08361204013377926
areaundertheconcentrationtimecurvetolastmeasurableconcentration,0.08361204013377926
plasmabioavailabilityf,0.08361204013377926
minimumdetectableamount,0.08361204013377926
peaklumbarcsflevel,0.08361204013377926
peaklumbararaulevel,0.08361204013377926
interassayrecovery,0.08361204013377926
secondphasehalflifet12beta,0.08361204013377926
ratelossconstant,0.08361204013377926
betaplasmahalflive,0.08361204013377926
ca1,0.08361204013377926
terminalhalflifet50,0.08361204013377926
ca8,0.08361204013377926
partitioncoefficientdec,0.08361204013377926
fractionfb,0.08361204013377926
apparentsteadystateplasmalevel,0.08361204013377926
maximumdmdcplasmaconcentration,0.08361204013377926
livertargetindex,0.08361204013377926
timetoreachthepeaklevel,0.08361204013377926
halflivesoftheinitialphaset12alpha,0.08361204013377926
secondphaset12beta,0.08361204013377926
minimalcytotoxiclevel,0.08361204013377926
concentrationmax,0.08361204013377926
secondhalflife,0.08361204013377926
t12ofthesecondphase,0.08361204013377926
steadystateplasmaaracconcentration,0.08361204013377926
percentageofincorporationefficiency,0.08361204013377926
interpuffinterval,0.08361204013377926
concentrationmaximumscmax,0.08361204013377926
tumortobrainratio,0.08361204013377926
halfmaximumeffectiveconcentrationec50,0.08361204013377926
ngttoigtratio,0.08361204013377926
areaundercurveaucofinsulinconcentration,0.08361204013377926
peakplasmanicotineconcentration,0.08361204013377926
recoveryoftracerinurine,0.08361204013377926
intestinalpermeabilitycoefficient,0.08361204013377926
totalfractionofinsulindoseabsorbedfa,0.08361204013377926
peakofglucose,0.08361204013377926
peakofnicotineconcentration,0.08361204013377926
concentrationtimemaximum,0.08361204013377926
maximumnicotinelevel,0.08361204013377926
maximumplasmanicotineconcentrationcmax,0.08361204013377926
transdermalclearance,0.08361204013377926
maximumtnratio,0.08361204013377926
maximummeasuredinsulinconcentration,0.08361204013377926
areaundertheplasmaconcentrationcurveforsteadystate24hintervalauc024,0.08361204013377926
nonhepaticglucoseuptake,0.08361204013377926
earlyt50,0.08361204013377926
camax,0.08361204013377926
instmax,0.08361204013377926
totalmetaboliceffectaucgir010h,0.08361204013377926
igf1,0.08361204013377926
extracteddose,0.08361204013377926
areasundertheinsulinconcentrationcurve,0.08361204013377926
timetopeakaction,0.08361204013377926
areaundertheplasmaconcentrationtimecurveduringdosingintervalauctau,0.08361204013377926
cmaxx,0.08361204013377926
areaundertheexogenousseruminsulincurvefrom0to6h,0.08361204013377926
maximalserumconcentrationofinsulincmax,0.08361204013377926
timetomaximalserumconcentrationofinsulintmax,0.08361204013377926
auc910,0.08361204013377926
auc1112,0.08361204013377926
cravingscore,0.08361204013377926
plasmaclearanceoverbioavailabilityratioclf,0.08361204013377926
timetoreach10of,0.08361204013377926
timetomaximalmetaboliceffecttmaxgir,0.08361204013377926
volumeaerodynamicdiameter,0.08361204013377926
hemoperfusionclearance,0.08361204013377926
renalmeprobamateclearance,0.08361204013377926
maximaldrugconcentrationcmax,0.08361204013377926
areavdarea,0.08361204013377926
observedminimalplasmaconcentration,0.08361204013377926
minimalsteadystateconcentration,0.08361204013377926
initialhalflifet12lambda1,0.08361204013377926
auc06hss,0.08361204013377926
mhmz,0.08361204013377926
terminalharmonicmeanhalflife,0.08361204013377926
physicalhalflifet12,0.08361204013377926
peakserumcyclophosphamidelevel,0.08361204013377926
maximumplasmabevantololconcentration,0.08361204013377926
aucroflumilastnoxideaucroflumilastratio,0.08361204013377926
rateofdrugabsorptiontmax,0.08361204013377926
peakconcentrationattmaxcmax,0.08361204013377926
timetothemaximumconcentrationcmaxofroflumilasttmax,0.08361204013377926
accumulationindexrac,0.08361204013377926
fluidsplasmaauclastratio,0.08361204013377926
minimaltherapeuticlevel,0.08361204013377926
plasmaresidue,0.08361204013377926
absorptionratconstant,0.08361204013377926
residualbloodlevel,0.08361204013377926
timeofoccurrenceofthepeakplasmalevel,0.08361204013377926
biologicaleliminationhalflife,0.08361204013377926
maximalpbzconcentration,0.08361204013377926
timeofmaximumdrugconcentrationtmax,0.08361204013377926
plasmaproteinbindingquota,0.08361204013377926
peakserumnicotineconcentration,0.08361204013377926
peakpbzplasmaconcentration,0.08361204013377926
peakfmconcentration,0.08361204013377926
peakplasmapbzconcentration,0.08361204013377926
terminalexponentialconstant,0.08361204013377926
halfthemaximumeffect,0.08361204013377926
c1b,0.08361204013377926
milkclearance,0.08361204013377926
aucs0loq,0.08361204013377926
durationoftherapy,0.08361204013377926
s05,0.08361204013377926
effectivetroughconcentration,0.08361204013377926
aucinsulin0360,0.08361204013377926
maximumarterialplasmanicotineconcentrationscmax,0.08361204013377926
arterialplasmanicotineconcentration,0.08361204013377926
volumeofdistributionintheperipheralcompartment,0.08361204013377926
maximalglucoseinfusionrategirmax,0.08361204013377926
aucpg05h,0.08361204013377926
areaunderthe24hourconcentrationtimecurve,0.08361204013377926
timewhenminimumplasmaglucoselevelappearedtmin,0.08361204013377926
relativepharmacologicalavailabilitie,0.08361204013377926
volumeofdistributioninthebetaphase,0.08361204013377926
troughpasireotideconcentration,0.08361204013377926
availableenergy,0.08361204013377926
peakinsulinconcentrationscmax,0.08361204013377926
bioeffect,0.08361204013377926
auc045min,0.08361204013377926
peakplasmabyl719,0.08361204013377926
percentminimumbloodglucoselevel,0.08361204013377926
areaundertheglucosecurveauc,0.08361204013377926
timetominimumplasma,0.08361204013377926
incl,0.08361204013377926
areaunderthecurvefrom0to360minute,0.08361204013377926
puff,0.08361204013377926
areaoverthecurve,0.08361204013377926
peakarteriallevel,0.08361204013377926
hairurineconcentrationratio,0.08361204013377926
extentofbioavailability,0.08361204013377926
reachingsystemiccirculation,0.08361204013377926
trans3hydroxycotininetocotinine,0.08361204013377926
timeforreachingcmaxtmax,0.08361204013377926
maximalgirgirmax,0.08361204013377926
timeforreachinggirmaxtgirmax,0.08361204013377926
bioefficacy,0.08361204013377926
aucgir,0.08361204013377926
cumulativeexcretionrate,0.08361204013377926
timetomaximalinsulinconcentrationtimemax,0.08361204013377926
timetomaximuminsulinconcentrationinserumtmax,0.08361204013377926
tgmin,0.08361204013377926
areaundertheplasmacotinineconcentrationtimecurvefrom0to8hour,0.08361204013377926
adsorptionporewidth,0.08361204013377926
forcedexpiratoryvolumein1secondfev1,0.08361204013377926
peakinsulincmax,0.08361204013377926
insulin,0.08361204013377926
exposurefromtime0to240minauc0240,0.08361204013377926
fractionalinsulinlossrate,0.08361204013377926
relativeretention,0.08361204013377926
timetomaximumglucagonconcentration,0.08361204013377926
peakplasmainsulinconcentration,0.08361204013377926
plasmaapparentsystemicclearance,0.08361204013377926
insulinloadingcapacity,0.08361204013377926
maximumadsorption,0.08361204013377926
deltaglucoseconcentration,0.08361204013377926
timetomaximumplasmanicotineconcentrationtmax,0.08361204013377926
normalizedrecovery,0.08361204013377926
timetomaximumplasmaconcentrationcmaxtmax,0.08361204013377926
influxrate,0.08361204013377926
timetopeakmetaboliceffecttgirmax,0.08361204013377926
serumminimumconcentration,0.08361204013377926
timetopeakinsulinconcentrationtmax,0.08361204013377926
auc0360ratio,0.08361204013377926
minimumeffectiveactiveglp1concentration,0.08361204013377926
oralbioavailabilityforal,0.08361204013377926
nethepaticglucoseuptake,0.08361204013377926
steadystateaverageplasmanicotineconcentration,0.08361204013377926
cumulativeamountpermeated,0.08361204013377926
diameterofbasement,0.08361204013377926
drugloadedspace,0.08361204013377926
insulincontent,0.08361204013377926
timewhentheminimumplasmaglucoselevelwasobtained,0.08361204013377926
relativephysiologicalavailabilitie,0.08361204013377926
recoveredpercentage,0.08361204013377926
halflifeofitselimination,0.08361204013377926
halflifeofformation,0.08361204013377926
biopotency,0.08361204013377926
ae0t,0.08361204013377926
ae048,0.08361204013377926
ae036,0.08361204013377926
areasunder6hourconcentrationversustimecurve,0.08361204013377926
peakdigoxinconcentration,0.08361204013377926
serumaccumulationratio,0.08361204013377926
maximumflutamideplasmaconcentration,0.08361204013377926
volumesofdistributionvz,0.08361204013377926
maximumserumbromideconcentration,0.08361204013377926
maximalplasmaphenobarbitalconcentration,0.08361204013377926
c1f,0.08361204013377926
steadystatevolumeofdistributionvdssf,0.08361204013377926
intrinsicabilityclin,0.08361204013377926
extentoforalabsorption,0.08361204013377926
meanresidencetimefororalabsorptionmrtabs,0.08361204013377926
tissuetoplasmaratiosofradioactivity,0.08361204013377926
peaksteadystateplasmaphenobarbitoneconcentration,0.08361204013377926
peakphenobarbitalserumconcentration,0.08361204013377926
steadystateserumphenobarbitalconcentration,0.08361204013377926
clpb,0.08361204013377926
serumareaunderthecurvefor24hour,0.08361204013377926
halflifeofinhibition,0.08361204013377926
apparentunboundclearancecluf,0.08361204013377926
cerebralconcentration,0.08361204013377926
saturableeliminationkm,0.08361204013377926
tumourbackgroundratiostbrs,0.08361204013377926
tbr,0.08361204013377926
nh3auc024hr,0.08361204013377926
timenormalizedauc,0.08361204013377926
plasmac,0.08361204013377926
drugdistributioncoefficient,0.08361204013377926
initialapparenthalflive,0.08361204013377926
saturablebinding,0.08361204013377926
timestothepeakplasmaconcentration,0.08361204013377926
aud024h,0.08361204013377926
auc12hr,0.08361204013377926
maximaldegreeof,0.08361204013377926
samplerecovery,0.08361204013377926
csfplasmaunboundratio,0.08361204013377926
maximumvelocityofmetabolism,0.08361204013377926
totalbodyclearance100nonrenal,0.08361204013377926
steadystatetroughserumlevel,0.08361204013377926
deltahr,0.08361204013377926
halftimet05beta,0.08361204013377926
halflifeinthesecondphase,0.08361204013377926
maximallplactivity,0.08361204013377926
eliminationtimeh,0.08361204013377926
totalregionallybioavailablehe,0.08361204013377926
polarizationrate,0.08361204013377926
betahalflifetime,0.08361204013377926
plasmaticbioavailability,0.08361204013377926
maximumplasmaheparinactivitie,0.08361204013377926
terminalhalflifetimet50,0.08361204013377926
maximumloading,0.08361204013377926
longcirculatinghalflife,0.08361204013377926
peakplasmaheparinconcentration,0.08361204013377926
timetopeakplasmaheparinconcentration,0.08361204013377926
peakactivatedpartialthromboplastintime,0.08361204013377926
serummorphineconcentration,0.08361204013377926
apparentclearancefromthecentralcompartmentclf,0.08361204013377926
overallefficiency,0.08361204013377926
apparentvolumeofdistributionofthecentralv1f,0.08361204013377926
timetoobservedmaximumconcentrationtmax,0.08361204013377926
exchangetime,0.08361204013377926
volumevd,0.08361204013377926
m6gm,0.08361204013377926
effectivemconcentration,0.08361204013377926
maximumphenobarbitalserumconcentration,0.08361204013377926
partitioncoefficientpb,0.08361204013377926
timetonormalization,0.08361204013377926
apparentremacemideclearanceclf,0.08361204013377926
thresholdcerebrospinalfluidconcentration,0.08361204013377926
peakplasmacyclopentolateconcentration,0.08361204013377926
maximumreceptoroccupancy,0.08361204013377926
apparentbiliaryclearance,0.08361204013377926
apparentmichaelismentenconstantkmapp,0.08361204013377926
apparentvolumeofmdistribution,0.08361204013377926
difference,0.08361204013377926
amountoflabelrecovered,0.08361204013377926
kbeta,0.08361204013377926
boronconcentration,0.08361204013377926
peakglucoseconcentration,0.08361204013377926
plasmaterminalphasehalflifet12,0.08361204013377926
areaundertheplasmaconcentrationtimecurvecxt,0.08361204013377926
cxtratio,0.08361204013377926
perfusatetoplasmadrugleakage,0.08361204013377926
durationofinfieldresponse,0.08361204013377926
timetoinfieldprogression,0.08361204013377926
minimumeffectivetumorboronconcentration,0.08361204013377926
maximumtumorconcentration,0.08361204013377926
tumorbrainratio,0.08361204013377926
plasmat05alpha,0.08361204013377926
peakplasmaenrichmentlevel,0.08361204013377926
netproteinbalance,0.08361204013377926
tumortobloodtbboronratio,0.08361204013377926
ked,0.08361204013377926
boronratio,0.08361204013377926
betaparticleenergie,0.08361204013377926
peakmelphalanconcentration,0.08361204013377926
apparentplasmaeliminationhalflifet12,0.08361204013377926
local,0.08361204013377926
regionalrecurrencerate,0.08361204013377926
perfusateplasmaareaunderthecurvefrom0to60minutesratio,0.08361204013377926
fractionunboundinplasma,0.08361204013377926
unboundmelpha,0.08361204013377926
cbefactor,0.08361204013377926
maximalratiovsblood,0.08361204013377926
maximalratio,0.08361204013377926
peak10bconcentration,0.08361204013377926
availabilityto,0.08361204013377926
overallfilterefficiency,0.08361204013377926
biologichalftime,0.08361204013377926
tumorgrowthrate,0.08361204013377926
tumorbloodboronconcentrationratio,0.08361204013377926
perfusionbloodflowrate,0.08361204013377926
proteinsynthesisrate,0.08361204013377926
totaltumorphysicaldose,0.08361204013377926
flankratio,0.08361204013377926
steadystateserumconcentrationsoforaldigoxinauc024zeta,0.08361204013377926
tumorto,0.08361204013377926
systemicleakage,0.08361204013377926
peakrate,0.08361204013377926
absolutenasalbioavailability,0.08361204013377926
ratioofaucaauc,0.08361204013377926
tissueplasmatmax,0.08361204013377926
apparentmeanbloodtotissuetransportk,0.08361204013377926
kinv,0.08361204013377926
areaunderthecurveauc07h,0.08361204013377926
plasmaammonialevel,0.08361204013377926
wholebodyhalflife,0.08361204013377926
peakplasmaglutamineconcentration,0.08361204013377926
troughserumactivitie,0.08361204013377926
tumortohealthybrainregionratio,0.08361204013377926
tumortomuscle,0.08361204013377926
polar,0.08361204013377926
brainplasmaconcentrationintegralratio,0.08361204013377926
overalleliminationconstantke1,0.08361204013377926
skintobloodratio,0.08361204013377926
terminalmelphalan,0.08361204013377926
timetom3gpeakconcentration,0.08361204013377926
fractionreachingthesystemiccirculation,0.08361204013377926
aucratiosaucperitonealfluidaucplasma,0.08361204013377926
tumorresponseratecompletepartialresponse,0.08361204013377926
timetolocaldiseaseprogression,0.08361204013377926
pressure,0.08361204013377926
timeforattainingthepeakconcentration,0.08361204013377926
perfusedtissuevolume,0.08361204013377926
peakperfusatemelphalanconcentration,0.08361204013377926
peaksystemictnfalphalevel,0.08361204013377926
tumortobloodtbratio,0.08361204013377926
ld50concentration,0.08361204013377926
extinctioncoefficient,0.08361204013377926
halflifeforgastricemptying,0.08361204013377926
timetopeakactivatedpartialthromboplastintime,0.08361204013377926
activated,0.08361204013377926
protaminetoheparin,0.08361204013377926
firstpasselimination,0.08361204013377926
bioavailabilityauc024,0.08361204013377926
auc04800,0.08361204013377926
auc01440,0.08361204013377926
volumeofdistributionatsteadystatevdbeta,0.08361204013377926
maximummeasuredplasmabetamethasoneconcentration,0.08361204013377926
peakfetalbetamethasoneconcentration,0.08361204013377926
effluxrateper,0.08361204013377926
highestserumconcentrationcmax,0.08361204013377926
totalflow,0.08361204013377926
timestomaximumplasmaconcentrationtmax,0.08361204013377926
areasundertheplasmaconcentrationtimecurveauc024,0.08361204013377926
absorptionduration,0.08361204013377926
maximumconcentrationofvgbcmax,0.08361204013377926
peakch1418plasmaconcentration,0.08361204013377926
steadystateserummorphineconcentration,0.08361204013377926
peakconcentrationtmax,0.08361204013377926
firstpassfractioneliminated,0.08361204013377926
urinaryrecoveryatsteadystate,0.08361204013377926
csfplasma,0.08361204013377926
percentagebiliary,0.08361204013377926
urinaryextraction,0.08361204013377926
peakgentamicinconcentration,0.08361204013377926
absorptionrateconstantske,0.08361204013377926
eliminationrateske,0.08361204013377926
radioactivitie,0.08361204013377926
maximalresponseemax,0.08361204013377926
eliminationhalflivesbeta,0.08361204013377926
peaksynovialmorphineconcentration,0.08361204013377926
terminalbiologicalhalftime,0.08361204013377926
bgmax,0.08361204013377926
aucrtb,0.08361204013377926
plasmamorphineclearance,0.08361204013377926
painintensityrating,0.08361204013377926
steadystatemorphineconcentration,0.08361204013377926
minimumserummorphineconcentration,0.08361204013377926
rscitratio,0.08361204013377926
releaselagtime,0.08361204013377926
percenturinaryrecovery,0.08361204013377926
areaunderthebloodconcentrationtimecurveauc0t,0.08361204013377926
areaunderthebloodconcentrationtimecurvefrom0infauc0inf,0.08361204013377926
steadystateof,0.08361204013377926
rsenantiomericratio,0.08361204013377926
hydrolysi,0.08361204013377926
metabolicratiorm,0.08361204013377926
matpo,0.08361204013377926
pancreastoliverratio,0.08361204013377926
peakplasmaalendronateconcentration,0.08361204013377926
eliminationrateconstantskurine,0.08361204013377926
knonur,0.08361204013377926
apparentuptakeclearanceclup,0.08361204013377926
aeinfinity,0.08361204013377926
relativeaeinfinityratio,0.08361204013377926
areasundertheplasmaconcentrationtimecurvesfromtime0tothelasttimepointauc0t,0.08361204013377926
areaundertheconcentrationcurvesauc,0.08361204013377926
redbloodcellstoserumfreedrugconcentrationratio,0.08361204013377926
steadystatecitalopramlevel,0.08361204013377926
peakserumtotalmexiletineconcentration,0.08361204013377926
sraucratio,0.08361204013377926
concentrationsratio,0.08361204013377926
responseratesdeltahamilton,0.08361204013377926
fluxrate,0.08361204013377926
areaundertheplasmaconcentrationtimeprofilesaucot,0.08361204013377926
lcst,0.08361204013377926
peaktimololconcentration,0.08361204013377926
observedpeaktime,0.08361204013377926
50inhibitoryic50concentration,0.08361204013377926
kakd,0.08361204013377926
maximumintraocularpressureiop,0.08361204013377926
totalvolumeofdistributionvdtot,0.08361204013377926
maximumofconcentrationcmax,0.08361204013377926
oraltotalbodyclearancecl,0.08361204013377926
extentofconjugation,0.08361204013377926
specificquantumyield,0.08361204013377926
hepaticefficiency,0.08361204013377926
dosingratio,0.08361204013377926
apttratio,0.08361204013377926
peakact,0.08361204013377926
concentrationatthepeak,0.08361204013377926
areaunderthecurvetoinfinityauc,0.08361204013377926
totalclearence,0.08361204013377926
maximalantifxaactivity,0.08361204013377926
fractionalcatabolicrate,0.08361204013377926
tct,0.08361204013377926
finalamount,0.08361204013377926
ratioofplasmaauc0infinity,0.08361204013377926
halflifein,0.08361204013377926
residualactivity,0.08361204013377926
vesselmuscleratio,0.08361204013377926
fastcompartmentvolume,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucfrom0htoinfinitypostdoseauc,0.08361204013377926
mravg,0.08361204013377926
plasmaaxaactivity,0.08361204013377926
clintr,0.08361204013377926
deformability,0.08361204013377926
targetingtime,0.08361204013377926
activatedcoagulationtimedact,0.08361204013377926
clottingtimect,0.08361204013377926
arterialmagnesiumconcentration,0.08361204013377926
ff,0.08361204013377926
renalclearanceduetofiltration,0.08361204013377926
maximumantifactorxaactivity,0.08361204013377926
antifactorxaactivity,0.08361204013377926
poolofbindingsite,0.08361204013377926
regenerationrate,0.08361204013377926
teralb,0.08361204013377926
album,0.08361204013377926
surfacecharge,0.08361204013377926
substitutionrate,0.08361204013377926
fragmentf12,0.08361204013377926
maximumloadingcontent,0.08361204013377926
specific,0.08361204013377926
antixamax,0.08361204013377926
hepaticclearanceofblood,0.08361204013377926
peakantifactorxalevel,0.08361204013377926
areaunderthetimeresponsecurvesauc,0.08361204013377926
minimumquantifiablelimit,0.08361204013377926
maximalaptt,0.08361204013377926
apparentredbloodcellplasmapartitioncoefficient,0.08361204013377926
drivingflowrate,0.08361204013377926
jetne,0.08361204013377926
plasmafiltratevolume,0.08361204013377926
intravascularfraction,0.08361204013377926
absolutecatabolicrate,0.08361204013377926
timeofviability,0.08361204013377926
timetotherapeuticrange,0.08361204013377926
auc096hareaunderthecurve,0.08361204013377926
heparintoprotamine,0.08361204013377926
activatedclottingtimeactratio,0.08361204013377926
apparentcompartmentalvolumesofdistribution,0.08361204013377926
molarpotencyratio,0.08361204013377926
timetopassthreshold,0.08361204013377926
lastdetectableplasmaconcentrationtmax,0.08361204013377926
phofmaximumstability,0.08361204013377926
dryfaecalconcentration,0.08361204013377926
attenuation,0.08361204013377926
maximumactivatedpartialthromboplastintime,0.08361204013377926
apparentvolumesofdistributionvdf,0.08361204013377926
bolushalflife,0.08361204013377926
axaactivity,0.08361204013377926
antithrombinactivity,0.08361204013377926
bloodelimination,0.08361204013377926
ciadult,0.08361204013377926
clgriii,0.08361204013377926
vh,0.08361204013377926
relativeauc,0.08361204013377926
molaraucratio,0.08361204013377926
totaleliminationtime,0.08361204013377926
maximalantifxaeffect,0.08361204013377926
totaldistributionvolumeduringtheterminalslope,0.08361204013377926
bleedingepisode,0.08361204013377926
apparenthalflivesoftheabsorption,0.08361204013377926
urinaryrecoverylevel,0.08361204013377926
eliminatedquantitie,0.08361204013377926
maximumcsfconcentrationcmax,0.08361204013377926
concentrationrequiredfor50emaxec50,0.08361204013377926
areaundertheplasmaconcentrationtimecurvebetweentime0and24h,0.08361204013377926
auc4872h,0.08361204013377926
peakdeltadeltaqtc,0.08361204013377926
areaundertheserumconcentrationtimecurveofthe24hdosingintervalauc024,0.08361204013377926
peritonealfluidtoplasmaratio,0.08361204013377926
areaundertheconcentrationtimecurveover48hour,0.08361204013377926
volumeofdistributionofcentralcompartmentvcf,0.08361204013377926
distributionalclearanceinplasmaq,0.08361204013377926
volumeofdistributionofperipheralcompartmentvpf,0.08361204013377926
maximumconcentrationinpfcmaxpf,0.08361204013377926
cmaxpf,0.08361204013377926
bloodradioactivity,0.08361204013377926
areaundertheconcentrationtimecurveauc0inf,0.08361204013377926
standardizeduptakevaluessuvs,0.08361204013377926
areaunderthetimeconcentrationcurvefromdosinguntil24hpostdoseauc024,0.08361204013377926
placebocorrectedchangefrombaselineddqtcf,0.08361204013377926
areasundertheconcentrationtimecurvesaucsfrom0to8hauc08s,0.08361204013377926
ratiosoftheaucsfrom0to24h,0.08361204013377926
concentrationsconcentration,0.08361204013377926
concentrationplasmaconcentrationratio,0.08361204013377926
timefromstartingtheinfusionpumptosteadystateflow,0.08361204013377926
targetattainmentrate,0.08361204013377926
maximumplasmamoxifloxacinconcentration,0.08361204013377926
aqueousconcentration,0.08361204013377926
pcta,0.08361204013377926
dcmax,0.08361204013377926
timetoattainmaximumconcentration,0.08361204013377926
intracellularpersistingfraction,0.08361204013377926
intracellularconcentrationtoextracellularconcentrationratio,0.08361204013377926
auc24pf,0.08361204013377926
maximumconcentrationofdruginserummic,0.08361204013377926
timeuntilcmaxtmax,0.08361204013377926
areaundertheconcentrationtimecurveauc024tomicratio,0.08361204013377926
cmax3,0.08361204013377926
areaundertheinhibitorycurveauic,0.08361204013377926
peakmoxifloxacinlevel,0.08361204013377926
auc112,0.08361204013377926
areaundertheinhibitoryconcentrationcurveauic,0.08361204013377926
minimumbactericidalconcentration,0.08361204013377926
susceptibilitybreakpoint,0.08361204013377926
auc2436,0.08361204013377926
enteralbioavailability,0.08361204013377926
areasunderthecurveauc12h,0.08361204013377926
concentration12hafterthestartofinfusioncmin,0.08361204013377926
proteinbindingpercent,0.08361204013377926
ofmaximumconcentrationcmax,0.08361204013377926
ejaculateplasmaratio,0.08361204013377926
unboundareaundertheplasmaconcentrationtimecurveminimuminhibitoryconcentrationmictarget,0.08361204013377926
areaunderthecurvemic90ratio,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to24hmic,0.08361204013377926
troughminimumconcentration,0.08361204013377926
miccipmic,0.08361204013377926
hepaticextractionratioe,0.08361204013377926
ratiocmaxmic,0.08361204013377926
troughserummoxifloxacinconcentration,0.08361204013377926
clearanceofhaemofiltration,0.08361204013377926
tonsillartissueplasmaconcentrationratio,0.08361204013377926
aqueoushumorconcentrationcmax,0.08361204013377926
maximumconcentrationmic90ratio,0.08361204013377926
areaundertheaqueoushumorconcentrationversustimecurveauc08h,0.08361204013377926
peakconcentrationinserum,0.08361204013377926
areasundertheplasmaconcentrationtimecurveextrapolatedtoinfinityauc,0.08361204013377926
escharconcentration,0.08361204013377926
fractionofmoxifloxacinclearanceto,0.08361204013377926
bronchialtoplasmaexposureratio,0.08361204013377926
zerodrugdeliverytime,0.08361204013377926
maximumplasmaepinephrineconcentration,0.08361204013377926
proteinbindinglevel,0.08361204013377926
braintoplasmaconcentrationratiokpapp,0.08361204013377926
areaunderthecurveauc0tlast,0.08361204013377926
plasmaepinephrineconcentration,0.08361204013377926
maximumpossibletreatmentrelatedeffect,0.08361204013377926
plasmaareasundertheconcentrationtimecurve,0.08361204013377926
peakarterialbloodconcentration,0.08361204013377926
peakplasmaepinephrinelevel,0.08361204013377926
areaunderthecurveplasmaconcentrationversustimeauc,0.08361204013377926
threshold,0.08361204013377926
t12ka2,0.08361204013377926
t02,0.08361204013377926
halflifeoftheslowerdistributiont12alpha,0.08361204013377926
areasundertheserumconcentrationcurvesoftramadolhydrochlorideauc,0.08361204013377926
vas2h,0.08361204013377926
firsttramadolconcentration,0.08361204013377926
areaundertheinsulinconcentrationcurve,0.08361204013377926
percentofdosesystemicallyabsorbed,0.08361204013377926
maximumconcentrationsofmoxifloxacininplasmacmax,0.08361204013377926
steadystatecsfconcentration,0.08361204013377926
csfplasmacssratio,0.08361204013377926
constantinfusionratei,0.08361204013377926
areaunderthecurveplasmaconcentration,0.08361204013377926
maximumlevelofradioactivity,0.08361204013377926
halflifet12betaphase,0.08361204013377926
dyspneaindex,0.08361204013377926
steadystatecsfplasmaratio,0.08361204013377926
bo,0.08361204013377926
cmaxc,0.08361204013377926
auc024c,0.08361204013377926
auc190,0.08361204013377926
areaundertheconcentrationtimecurveupto24h,0.08361204013377926
excretionindex,0.08361204013377926
halflifeofdecline,0.08361204013377926
tramadolconcentration,0.08361204013377926
therapeuticthresholdconcentration,0.08361204013377926
concentrationsatthetimeofbirtht0,0.08361204013377926
plasmaabsolutebioavailability,0.08361204013377926
oraladsorptionf,0.08361204013377926
visualantimode,0.08361204013377926
lockouttime,0.08361204013377926
plasmatlevel,0.08361204013377926
relativesystemicavailabilitie,0.08361204013377926
t12l,0.08361204013377926
formationclearancecl2m1,0.08361204013377926
serumm1concentration,0.08361204013377926
areaunderthecurvem1tramadolratio,0.08361204013377926
hwrl,0.08361204013377926
strl,0.08361204013377926
maximalmeasuredplasmatramadolconcentration,0.08361204013377926
maximalmeasuredplasmaconcentration,0.08361204013377926
percentageoftimeabovemic,0.08361204013377926
aucareaunderblooddrugconcentrationcurve,0.08361204013377926
tmaxtimerequiredtoattainmaximumblooddruglevel,0.08361204013377926
cmaxmaximumblooddruglevel,0.08361204013377926
accumulationindexe,0.08361204013377926
minimumplasmaconcentrationscmin,0.08361204013377926
tgd,0.08361204013377926
timetoreachpeaktram,0.08361204013377926
auc16,0.08361204013377926
areaundertheconcentrationtimecurveatthefirstdoseintervalauc16,0.08361204013377926
urinarydetectiontime,0.08361204013377926
maximalplasmatramadolconcentrationcmax,0.08361204013377926
areaundertheconcentrationvstimecurveauc0infinity,0.08361204013377926
peakepinephrineconcentration,0.08361204013377926
m1gm1total,0.08361204013377926
kpuucsf0,0.08361204013377926
kpuucsf0360,0.08361204013377926
apparentvolumesofdistributionofthecentralcompartment,0.08361204013377926
areaunderthecurvefrom08hoursauc08,0.08361204013377926
correctedqtinterval,0.08361204013377926
ctr,0.08361204013377926
tmsw,0.08361204013377926
halfofemax,0.08361204013377926
peakclozapine,0.08361204013377926
norclozapineconcentration,0.08361204013377926
peritonealeffluentconcentration,0.08361204013377926
intervalfromoraladministrationuntilmaximumconcentration,0.08361204013377926
equilibriumstateconcentrationratio,0.08361204013377926
totalbodyplasmaclearancecltot,0.08361204013377926
constantofabsorptionrate,0.08361204013377926
apparentvolumeofdistributionavdbeta,0.08361204013377926
apparentfirstorderformationrateconstantki,0.08361204013377926
firstorderabsorptionrateconstantska,0.08361204013377926
totalbodydrugclearancetcl,0.08361204013377926
areaunderthecurveuntilthelastmeasurableconcentrationauclast,0.08361204013377926
ratioofperipheraltocentrallungdeposition,0.08361204013377926
auc50cauc50,0.08361204013377926
clzdosenormalizedc0dratio,0.08361204013377926
apparentmaximumcapacityforrenaluptakevmax,0.08361204013377926
clearancesclf,0.08361204013377926
cpavecpave,0.08361204013377926
partition,0.08361204013377926
totalplasmadrugclearance,0.08361204013377926
firstpassextractionratioeg,0.08361204013377926
eg,0.08361204013377926
minimuminjectionvolume,0.08361204013377926
eliminationrateconstantsfromcompartments1,0.08361204013377926
rbcplasmaconcentrationratio,0.08361204013377926
k20,0.08361204013377926
apparentclearanceofclozapineclf,0.08361204013377926
peaksputumconcentration,0.08361204013377926
t12m3,0.08361204013377926
terminalhalflivest12lz,0.08361204013377926
cmaxtominimuminhibitoryconcentrationratio,0.08361204013377926
apparentmaximumcapacityoftransportvmax,0.08361204013377926
nonsaturableuptakerateconstantk4,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityaucinfinty,0.08361204013377926
inhibitoryquotientiqcmaxmic,0.08361204013377926
areaundertheconcentrationversusthetimecurvefrom0tothelastsamplingpointauc0t,0.08361204013377926
aucmilkplasmaratio,0.08361204013377926
plasmadistributionhalflifet12alpha,0.08361204013377926
volumeofdistributionareamethod,0.08361204013377926
maximumacceptablelevel,0.08361204013377926
totalaucmic,0.08361204013377926
timeofthemaximumconcentrationtmax,0.08361204013377926
concentrationratioswwwv,0.08361204013377926
accumulatedelimination,0.08361204013377926
earlyplasmapeak,0.08361204013377926
faecalclearance,0.08361204013377926
absorptionconstantska,0.08361204013377926
topic,0.08361204013377926
plasmaeliminationhalflifet12z,0.08361204013377926
eliminationhalflifet12elim,0.08361204013377926
timeofclearance,0.08361204013377926
maximumconcentrationattained,0.08361204013377926
highestdetectedconcentration,0.08361204013377926
serumconcentrationatsteadystate,0.08361204013377926
tubularsecretoryintrinsicclearancevmaxkm,0.08361204013377926
apparentdissociationconstantkd,0.08361204013377926
bindingcapacitynp,0.08361204013377926
maximumtransportcapacityvmax,0.08361204013377926
auc24mpc,0.08361204013377926
milktoplasmaaucratio,0.08361204013377926
lethalconcentration,0.08361204013377926
fractionofdoserecoveredinmilk,0.08361204013377926
maximumresiduallevel,0.08361204013377926
weightadjustedclf,0.08361204013377926
systemicdisposition,0.08361204013377926
apparentvolumeofdistributionofthecentralcompartmentvd1,0.08361204013377926
areaundertheplasmaconcentrationcurveversustime,0.08361204013377926
deltacpave,0.08361204013377926
transittimesthroughthesystemiccirculationts,0.08361204013377926
extractionratiosthroughthesystemiccirculationes,0.08361204013377926
relativerecoveryrate,0.08361204013377926
minimuminhibitoryconcentrationsmic,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0untilthelastquantifiableplasmaconcentrationauc024h,0.08361204013377926
mic90minimuminhibitoryconcentrationrequiredtoinhibit,0.08361204013377926
freelungtissueconcentration,0.08361204013377926
freetissuefreeserumconcentrationratio,0.08361204013377926
peakmuscleconcentrationcmax,0.08361204013377926
ratioscmaxmic,0.08361204013377926
maximallungconcentrationscmax,0.08361204013377926
peak2r4r,0.08361204013377926
exudateplasmalevel,0.08361204013377926
initialantibioticconcentration,0.08361204013377926
peakconcentrationattheendofmoxifloxacininfusioncmax,0.08361204013377926
areaundertheconcentrationtimecurveextrapolatedtoinfinityauc0,0.08361204013377926
pan,0.08361204013377926
ratiooftheauclung,0.08361204013377926
steadystatemoxifloxacinratio,0.08361204013377926
meantransittimesthroughthepulmonarycirculationtp,0.08361204013377926
proteinbindingfu,0.08361204013377926
maximalresiduelimit,0.08361204013377926
clearanceofhaemodiafiltration,0.08361204013377926
auc02areaundertheconcentrationtimecurvefrom0to2hours,0.08361204013377926
initialmaximumconcentration,0.08361204013377926
probabilityoftargetattainmentpta,0.08361204013377926
intervalfrominjectionuntilmaximumconcentration,0.08361204013377926
minimuminhibitoryconcentrationfor90oforganismsmic90,0.08361204013377926
peritonealfluidserumconcentrationratio,0.08361204013377926
plasmaproteinbindingpercent,0.08361204013377926
fauc024mic90ratio,0.08361204013377926
skinplasmaratio,0.08361204013377926
faucserummic,0.08361204013377926
aucbonemic,0.08361204013377926
abscessfluidplasmaconcentrationratio,0.08361204013377926
minimumplasmaciprofloxacinconcentration,0.08361204013377926
eliminationphaseapparentdistributionvolumecoefficientdeltadarea,0.08361204013377926
micbreakpoint,0.08361204013377926
minimumplasmaconcentrationduringsteadystate,0.08361204013377926
ratiosofabsorptionrateconstant,0.08361204013377926
mhratio,0.08361204013377926
totalmetoprololclearance,0.08361204013377926
fractionofthedrugavailable,0.08361204013377926
maximalbeta1blockingeffectemax,0.08361204013377926
emaxc50,0.08361204013377926
mpcmicratio,0.08361204013377926
areaunderthecurve12,0.08361204013377926
cllung,0.08361204013377926
lungpenetrationfactor,0.08361204013377926
systemicbioavailabilitiesf,0.08361204013377926
interfaceflowrate,0.08361204013377926
areaunderplasmaconcentrationcurvesauc,0.08361204013377926
extractionratiothroughthepulmonarycirculationep,0.08361204013377926
emin,0.08361204013377926
clodoseoaucs,0.08361204013377926
areaunderthebloodconcentrationvstimecurve,0.08361204013377926
initialin,0.08361204013377926
steadystatedistributionvolumesvdss,0.08361204013377926
halftimeofabsorptiont12ka,0.08361204013377926
halftimeofeliminationt12ke,0.08361204013377926
halfmaximum,0.08361204013377926
timelagtlag,0.08361204013377926
clwomen,0.08361204013377926
clmen,0.08361204013377926
fractionoftheoraldosesystemicallyavailable,0.08361204013377926
ratioforauctominimuminhibitoryconcentration,0.08361204013377926
areaunderthedrugconcentrationtimecurvesauc,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezerototimet,0.08361204013377926
dpdtmax,0.08361204013377926
overallpenetrationintotheinflammatoryfluid,0.08361204013377926
maximumtargetoccupancie,0.08361204013377926
auc048ratio,0.08361204013377926
initialamount,0.08361204013377926
csfserumdrugratio,0.08361204013377926
peripheralconcentration,0.08361204013377926
secondphasebiologicalhalflivest12beta,0.08361204013377926
tdflux,0.08361204013377926
areaunderthedrugconcentrationtimecurvesauc024hr,0.08361204013377926
ratioauctonsilaucplasma,0.08361204013377926
ratesofmetabolism,0.08361204013377926
aucmtx,0.08361204013377926
imaxd,0.08361204013377926
centraldistributionofvolume,0.08361204013377926
ktc,0.08361204013377926
50growthinhibitoryconcentration,0.08361204013377926
clfilt,0.08361204013377926
volumedoublingtime,0.08361204013377926
peakplasmadampaconcentration,0.08361204013377926
ic50d,0.08361204013377926
maximumpercutaneousuptake,0.08361204013377926
effectiveconcentrationceff,0.08361204013377926
biliaryexcretionconstant,0.08361204013377926
troughinclearance,0.08361204013377926
renalvenousarterialreninratio,0.08361204013377926
peakfourthventriclecsfmethotrexatelevel,0.08361204013377926
totalplasmaclearanceofthe,0.08361204013377926
troughplasmaconcentrationctroughratio,0.08361204013377926
urinaryexcretionconstant,0.08361204013377926
totalareaundertheserumconcentrationvstimecurve,0.08361204013377926
plasmaclearancec1p,0.08361204013377926
maximumserummtxconcentrationcmax,0.08361204013377926
vlambda,0.08361204013377926
pulmonaryarteryconcentration,0.08361204013377926
initialdruglevel,0.08361204013377926
halflifeofdrugrelease,0.08361204013377926
rateofbiliaryexcretion,0.08361204013377926
kct,0.08361204013377926
ceff,0.08361204013377926
minimumdetectablequantitie,0.08361204013377926
tumorcortexratio,0.08361204013377926
areaundertheinterstitialfluidconcentrationtimecurveauc,0.08361204013377926
eqm,0.08361204013377926
areaunderthecurvevaluesonday13auc13day,0.08361204013377926
salivaserumlevelratio,0.08361204013377926
influxrateconstant,0.08361204013377926
concentrationxtime,0.08361204013377926
timetoreachthepeakdrugconcentrationtmax,0.08361204013377926
peakmtxconcentration,0.08361204013377926
tissueplasmaaucratio,0.08361204013377926
apparentvolumeofdistributionatsteadystatev,0.08361204013377926
boundpercentage,0.08361204013377926
totalbindingcapacitie,0.08361204013377926
tissuereflectioncoefficientss,0.08361204013377926
areaundertheserumconcentrationtimecurvefromtimezerotoinfinityauc0infinity,0.08361204013377926
ultrafilt,0.08361204013377926
halfmaximaleffectconcentration,0.08361204013377926
durationoffever,0.08361204013377926
nong,0.08361204013377926
minimumauc,0.08361204013377926
clfmtx,0.08361204013377926
timestoreachsteadystate,0.08361204013377926
halflifeofaccumulation,0.08361204013377926
transferconstantq,0.08361204013377926
dosenormalizedareaunderthecurveaucdn,0.08361204013377926
fractionofabsorbeddosef,0.08361204013377926
fractionoforalmethotrexate,0.08361204013377926
peakplasmaradioactivityconcentrationcmax,0.08361204013377926
iontransitionsmz,0.08361204013377926
peakserummtxconcentration,0.08361204013377926
plateauserummtxconcentration,0.08361204013377926
clcl,0.08361204013377926
maximummtxconcentration,0.08361204013377926
tumoraccumulationrate,0.08361204013377926
clearancecl7oh,0.08361204013377926
clearanceclmtx,0.08361204013377926
photoncount,0.08361204013377926
timeintervalofmaximalp,0.08361204013377926
clearanceviacapdcl,0.08361204013377926
totalserumclearancecltot,0.08361204013377926
renaldrugclearance,0.08361204013377926
maximalppixconcentration,0.08361204013377926
thcratio,0.08361204013377926
boweltobladderconcentration,0.08361204013377926
plasmaareaundertheplasmaconcentrationtimecurvefromtime0toinfinity,0.08361204013377926
timeofmaximumexcretionrate,0.08361204013377926
tumornormalbladderratio,0.08361204013377926
terminalurinaryeliminationt12,0.08361204013377926
timesofthelastdetectablelevel,0.08361204013377926
administrationtime,0.08361204013377926
bodyswayeyesclosed,0.08361204013377926
proteinunboundfreefraction,0.08361204013377926
skeletalretention,0.08361204013377926
anchoringefficiency,0.08361204013377926
troughplasmaconcentrationsatsteadystate,0.08361204013377926
tlagtime,0.08361204013377926
timeneededtoreachcmaxtmax,0.08361204013377926
initialabsorption,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefromthetimeofadministrationofthelastdoseto24hoursafterthattime,0.08361204013377926
halflifet12lz,0.08361204013377926
oraldisintegrationtime,0.08361204013377926
ratioofdrugconcentration,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc036,0.08361204013377926
bodyextractionratio,0.08361204013377926
rateofdrugabsorption,0.08361204013377926
equilibriumdissociationconstantskd,0.08361204013377926
areaunderthecurvetothelastmeasuredconcentration,0.08361204013377926
toxic,0.08361204013377926
areaunderthecurvefordrugconcentrationinplasmaxtimeat024hour,0.08361204013377926
cooh,0.08361204013377926
inhalationholdingtimeratio,0.08361204013377926
timestomaximumconcentrationtmax,0.08361204013377926
circulatoryhalflife,0.08361204013377926
plasmacmaxincrease,0.08361204013377926
finh,0.08361204013377926
appx,0.08361204013377926
auc08hdose,0.08361204013377926
oralfluidtoserumratio,0.08361204013377926
rateoflo,0.08361204013377926
peakintra,0.08361204013377926
inactivationefficiencieskinactkiu,0.08361204013377926
csfmtx,0.08361204013377926
minimumcsfmtx,0.08361204013377926
effectivebloodvolume,0.08361204013377926
peakabsoluteincrease,0.08361204013377926
boneuptake,0.08361204013377926
percentageboneuptake,0.08361204013377926
fatplasmaratio,0.08361204013377926
cdmirlevel,0.08361204013377926
apparentoverallvolume,0.08361204013377926
metabolicclearanceofdrug,0.08361204013377926
oralfluidserumratio,0.08361204013377926
acutephaseeliminationhalflife,0.08361204013377926
terminalphasebetaphaseplasmahalflife,0.08361204013377926
sensitivityofdetection,0.08361204013377926
peakplasmafreethc,0.08361204013377926
fluorescenceintensity,0.08361204013377926
initialapparentvolumeofdistribution,0.08361204013377926
later,0.08361204013377926
plasmaauc24h,0.08361204013377926
totalmetabolicbloodclearance,0.08361204013377926
timetothefirstmeasurableconcentration,0.08361204013377926
thc,0.08361204013377926
glucuronideconcentration,0.08361204013377926
tissueplasmaareaundertheconcentrationcurveaucratio,0.08361204013377926
steadystatepredoseserumconcentration,0.08361204013377926
molarfabtodmiratio,0.08361204013377926
overallexposure,0.08361204013377926
p8h,0.08361204013377926
totalporosity,0.08361204013377926
bulkdensity,0.08361204013377926
peakserumpenbutololconcentration,0.08361204013377926
maximumof4,0.08361204013377926
maximalmeanconcentration,0.08361204013377926
unboundfractioninplasma,0.08361204013377926
areaundertheserumconcentrationcurve,0.08361204013377926
bronchialconcentration,0.08361204013377926
tissuetoserumratio,0.08361204013377926
excretoryfluidplasmaareaundertheconcentrationtimecurveratio,0.08361204013377926
peaksputumconcentrationatsteadystate,0.08361204013377926
timestoreachpeakconcentrationtmax,0.08361204013377926
areaundertheplasmatimeconcentrationcurveaucfrom0to12h,0.08361204013377926
p1h,0.08361204013377926
redbloodcelleplasmapartitionratio,0.08361204013377926
peakbronchialsecretionlevel,0.08361204013377926
recoveryoftotalradioactivity,0.08361204013377926
maximumquinidineconcentration,0.08361204013377926
fractionofunboundquin,0.08361204013377926
apparenteliminationrateconstantk2,0.08361204013377926
quin,0.08361204013377926
encapsulationefficienciesees,0.08361204013377926
unboundquinidinefraction,0.08361204013377926
timetomaximalplasmaradioactivity,0.08361204013377926
timetoachievepeakplasmaquinidineconcentration,0.08361204013377926
terminaleliminationhalflifeofradioactivity,0.08361204013377926
renalquinidineclearance,0.08361204013377926
totalapparentvolumeofdistributionvdbeta,0.08361204013377926
overallapparentvolumeofdistribution,0.08361204013377926
048auc,0.08361204013377926
qrsduration,0.08361204013377926
peakpenbutololconcentration,0.08361204013377926
peakenoxacinconcentration,0.08361204013377926
timesofformation,0.08361204013377926
maximumpercentcumulativedrugrelease,0.08361204013377926
maximumplasmaconcentrationofradioactivity,0.08361204013377926
concentrationofradioactivity,0.08361204013377926
totalclearanceofdmicldmi,0.08361204013377926
fpxloading,0.08361204013377926
peakplasmaantifactorxaactivitie,0.08361204013377926
molarratioof,0.08361204013377926
auct96120hours,0.08361204013377926
areaundertheconcentrationtimecurvefromzerotolastmeasurableconcentration,0.08361204013377926
areasundertheplasmaconcentrationtimecurveswithindosingintervalsauct,0.08361204013377926
timeofmaximaltoxicity,0.08361204013377926
sdc,0.08361204013377926
oralplasmaclearanceclp,0.08361204013377926
areaundertheplasmaconcentrationtimecurve0168hours,0.08361204013377926
maximumplasmabepridilconcentration,0.08361204013377926
initialplasmaeliminationhalflife,0.08361204013377926
areaunderthecurvevaluesover12hauc012h,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to12h,0.08361204013377926
percententrapmentefficienciesee,0.08361204013377926
peakenoxacinserumconcentration,0.08361204013377926
sfv,0.08361204013377926
totalrecoveryofdruginmilk,0.08361204013377926
cumulativedelivery,0.08361204013377926
q5min,0.08361204013377926
theresidencetime,0.08361204013377926
auc030minute,0.08361204013377926
painfreerate,0.08361204013377926
timetoinitialdisintegration,0.08361204013377926
drugdelivery,0.08361204013377926
eliminationhalflifeafter,0.08361204013377926
timestofirstmeasurableplasmaconcentration,0.08361204013377926
percentagecmax,0.08361204013377926
maximummeanserumconcentration,0.08361204013377926
ex2,0.08361204013377926
clearanceclq,0.08361204013377926
totalbodyserumclearancecltot,0.08361204013377926
areaunderplasmaconcentrationversustimecurveauc,0.08361204013377926
lymphplasmamtxratio,0.08361204013377926
peakplasmamethotrexateconcentration,0.08361204013377926
clearanceofcentralcompartmentcl1,0.08361204013377926
apparentvolumeofdistributionofcentralcompartmentv1,0.08361204013377926
clearancebetweencentralandperipheralcompartmentcl2,0.08361204013377926
apparentvolumeofdistributionofperipheralcompartmentv2,0.08361204013377926
peakmtxlevel,0.08361204013377926
areaundercurvein120minauc0120,0.08361204013377926
endogenousinput,0.08361204013377926
affinityconstantka,0.08361204013377926
lowestdetectablelevel,0.08361204013377926
maximumclearancecapacity,0.08361204013377926
steadylevel,0.08361204013377926
peakcsfmtxconcentration,0.08361204013377926
concentrationratioslymph,0.08361204013377926
rmse,0.08361204013377926
formationrateconstantkmf,0.08361204013377926
amountofmtxexcretedinurinexu,0.08361204013377926
ratesofformation,0.08361204013377926
bioavailabilityof,0.08361204013377926
halflifeoftheearlyphase,0.08361204013377926
cmaxmaximummtxconcentration,0.08361204013377926
totalareaundercurve,0.08361204013377926
areaunderthecurveofplasmainsulinconcentration,0.08361204013377926
endofinfusionconcentration,0.08361204013377926
observedhalflive,0.08361204013377926
steadystatetotalplasmaclearance,0.08361204013377926
auc2436h,0.08361204013377926
iondiffusivity,0.08361204013377926
the,0.08361204013377926
intrinsicmeanresidencetime,0.08361204013377926
steadystatemxconcentration,0.08361204013377926
totaldrugloadingrate,0.08361204013377926
cp24h,0.08361204013377926
sfac,0.08361204013377926
firstintercompartmentalclearance,0.08361204013377926
firstorderabsorptionhalflive,0.08361204013377926
minimummaximum,0.08361204013377926
volumeofdistributionofnaloxonevd,0.08361204013377926
betarateconstantofelimination,0.08361204013377926
firstperipheralcompartmentvolume,0.08361204013377926
secondperipheralcompartmentvolume,0.08361204013377926
secondintercompartmentalclearance,0.08361204013377926
tumortobonemarrowratio,0.08361204013377926
kmf,0.08361204013377926
eliminationrateconstantkmu,0.08361204013377926
volumeofdistributionvm,0.08361204013377926
lipidwaterpartitioncoefficient,0.08361204013377926
surfaceareasa,0.08361204013377926
areaunderthecurvefromadministrationtolastmeasuredconcentrationauc0last,0.08361204013377926
auc046h,0.08361204013377926
maximumconcentrationlevelscmax,0.08361204013377926
peakconcentrations,0.08361204013377926
absorptionrateconstantofdigoxinka,0.08361204013377926
peakplasmadigoxin,0.08361204013377926
doseeliminatedinurine,0.08361204013377926
maximaldruglevel,0.08361204013377926
maturationtime,0.08361204013377926
intrinsiceffluxclearance,0.08361204013377926
fractionofabsorptionofmethotrexatefafg,0.08361204013377926
peakmtxplasmaconcentration,0.08361204013377926
vpl,0.08361204013377926
timeaveragedclearance,0.08361204013377926
areaunderconcentrationtimecurveauc048h,0.08361204013377926
meanresidencetimemrt072h,0.08361204013377926
intermediaryhalflife,0.08361204013377926
totalradioactivitydose,0.08361204013377926
dermalabsorption,0.08361204013377926
areaundertheplasmaconcentrationcurveovertimeauc,0.08361204013377926
plasmaresidencetimesmrt,0.08361204013377926
fluidvolume,0.08361204013377926
ratioofbr,0.08361204013377926
fractionnot,0.08361204013377926
maximumvelocityofmetabolismofethanolvm,0.08361204013377926
viablebacteriumcount,0.08361204013377926
diameterszaverage,0.08361204013377926
timetakentoreachpeakplasmaconcentration,0.08361204013377926
plasmawholebloodratio,0.08361204013377926
particlesizemps,0.08361204013377926
rateofethanoldisappearancefrombloodbetaslope,0.08361204013377926
50effectivedosesed50s,0.08361204013377926
apparentdrugentrapmentefficiency,0.08361204013377926
halflifefordermalabsorption,0.08361204013377926
terminalexcretionhalflive,0.08361204013377926
filterclearance,0.08361204013377926
45minuteto5minuteratio,0.08361204013377926
eliminationfromthecentralcompartmentkel,0.08361204013377926
eliminationofethanolfromthebodyvxko,0.08361204013377926
peripheralbloodethanolconcentrationkm,0.08361204013377926
meanresidualtime,0.08361204013377926
tilde,0.08361204013377926
skinretentionpermeationratio,0.08361204013377926
aucskin012h,0.08361204013377926
aucplasma012h,0.08361204013377926
maximumrateofeliminationofethanoleliminationcapacityor,0.08361204013377926
bloodexpiredairratio,0.08361204013377926
fromtheperipheraltocentralcompartmentk21,0.08361204013377926
breathclearance,0.08361204013377926
sweatclearance,0.08361204013377926
ethanolconcentrationinmilkat,0.08361204013377926
mutantselectionwindowmsw,0.08361204013377926
clearanceofinfluxintolungtissue,0.08361204013377926
transferrateconstantsfromthecentraltoperipheralcompartmentk12,0.08361204013377926
distributionvolumeofethanolv,0.08361204013377926
peakplasmapggconcentrationscmax,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc08h,0.08361204013377926
areaundertheethanolconcentrationtimecurveauc,0.08361204013377926
corticalboneplasmaconcentrationratio,0.08361204013377926
tmaxh,0.08361204013377926
break,0.08361204013377926
clumday7,0.08361204013377926
maximalrateofclearance,0.08361204013377926
halfmaximalclearance,0.08361204013377926
areaundertheconcentrationtimecurveover24hinthesteadystatedividedbythemicaucmic,0.08361204013377926
timetoachievecmaxtmax,0.08361204013377926
selfemulsificationtime,0.08361204013377926
peakbloodalcoholconcentrationsbac,0.08361204013377926
areasundertheconcentrationtimeprofilesauc,0.08361204013377926
areasundertheplasmaconcentrationtimecurvefrom0htoinfinityauc0s,0.08361204013377926
beta60,0.08361204013377926
totalcount,0.08361204013377926
peakplasmaorbifloxacinconcentration,0.08361204013377926
areaundertheplasmaconcentrationovertimecurveauc,0.08361204013377926
peaksc,0.08361204013377926
areasundertheeffectversustimecurve,0.08361204013377926
clearanceratesfromblood,0.08361204013377926
maximumbloodethanolconcentration,0.08361204013377926
flowratesqd,0.08361204013377926
steadystateethanolconcentration,0.08361204013377926
timetopeakethanolplasmaconcentration,0.08361204013377926
ethanoloralclearanceclf,0.08361204013377926
relativeeliminationhalflifet12re,0.08361204013377926
areaundertheplasmaconcentrationovertimecurvetominimuminhibitoryconcentrationratio,0.08361204013377926
absoluteeliminationhalflifet12ab,0.08361204013377926
t12re,0.08361204013377926
hepaticbloodflowrate,0.08361204013377926
totalaucproduced,0.08361204013377926
areaunderthecurveauc048h,0.08361204013377926
timetoreachmaximalbloodlevel,0.08361204013377926
areaundertheconcentrationtimecurvetothelastmeasurableconcentration,0.08361204013377926
withdrawtime,0.08361204013377926
peakbal,0.08361204013377926
eliminationrateconstantsk12,0.08361204013377926
areaunderthetotaligficoncentrationcurve,0.08361204013377926
intracellulartoextracellularconcentrationratiocintracextra,0.08361204013377926
ratioofauc0,0.08361204013377926
biologicpotency,0.08361204013377926
coefficientsa,0.08361204013377926
rateconstantsalpha,0.08361204013377926
capillaryplasmaconcentration,0.08361204013377926
apparentvolumeofdistributionofethanolvz,0.08361204013377926
rateconstantk3,0.08361204013377926
areaundertheintravenouscurveauciv,0.08361204013377926
cmaxper,0.08361204013377926
edi,0.08361204013377926
extracellularpeakconcentrationcmax,0.08361204013377926
plasmaritanserinconcentration,0.08361204013377926
tbw,0.08361204013377926
peakintraocularconcentration,0.08361204013377926
inhibitoryrateoftumorirt,0.08361204013377926
peaktopeakinterval,0.08361204013377926
steadystateaac,0.08361204013377926
timestoparasiteclearance,0.08361204013377926
feverclearance,0.08361204013377926
halflifeofclearancet12beta,0.08361204013377926
respirablefraction,0.08361204013377926
serumethanolclearancerate,0.08361204013377926
maximumethanoleliminationrate,0.08361204013377926
finalreversibility,0.08361204013377926
effectivehalflive,0.08361204013377926
absorbedamount,0.08361204013377926
distributionvolumevdarea,0.08361204013377926
serumb,0.08361204013377926
areaunderthecurveaucauc0264,0.08361204013377926
clearanceforthelinearfirstorderelimination,0.08361204013377926
timetoreachzerobac,0.08361204013377926
fractionofadoseofethanolconvertedtoacetatefaca,0.08361204013377926
distributiont12a,0.08361204013377926
pseudozeroordereliminationrateconstantbeta,0.08361204013377926
auc0approximatelyinfinityratio,0.08361204013377926
micsusceptibility,0.08361204013377926
steadystatebenzeneconcentration,0.08361204013377926
peakbloodalcohol,0.08361204013377926
beta60min,0.08361204013377926
beta60max,0.08361204013377926
ratiosoftheareaundertheconcentrationtimecurveauctothemic,0.08361204013377926
halflifeofabsorptiont12abs,0.08361204013377926
inhibitoryquotient,0.08361204013377926
d7lum,0.08361204013377926
aucd728,0.08361204013377926
maximaleliminationvelocityvmax,0.08361204013377926
apparentvolumesofdistributionv1,0.08361204013377926
maximumwaitingtimeforblooddraw,0.08361204013377926
rateconstantfortheeliminationphase,0.08361204013377926
apparentfirstorderhalflive,0.08361204013377926
urinaryrate,0.08361204013377926
maximumenfconcentrationcmax,0.08361204013377926
maximumbec,0.08361204013377926
maximalresiduelimitmrl,0.08361204013377926
maximumconcentrationminimuminhibitoryconcentrationcmaxmic,0.08361204013377926
hazardindex,0.08361204013377926
maximalalcoholconcentrationinblood,0.08361204013377926
minimummeasurablelevel,0.08361204013377926
totaldrugloading,0.08361204013377926
c0breathalcoholconcentration,0.08361204013377926
areaundercurveminimuminhibitoryconcentrationaucmic,0.08361204013377926
percentresistance,0.08361204013377926
peakoleuropeinconcentration,0.08361204013377926
totalbodyclearanceofdrug,0.08361204013377926
maximumggaplasmaconcentrationcmax,0.08361204013377926
growthinhibitionic50,0.08361204013377926
maximumethanolconcentration,0.08361204013377926
aucmilkaucplasmaratio,0.08361204013377926
peakplasmacamplevel,0.08361204013377926
bioavailabilitiesfabs,0.08361204013377926
peakserumciprofloxacinconcentration,0.08361204013377926
50clearancetime,0.08361204013377926
timetoreachmaximumpeakplasmaconcentrationfollowingdrugadministrationtmax,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefromtimezerotoinfinite,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefromtimezerotothelastquantifiableconcentration,0.08361204013377926
meansamplingtime,0.08361204013377926
oraldrugbioavailability,0.08361204013377926
exchangevolume,0.08361204013377926
exchangerate,0.08361204013377926
intravascularhalflife,0.08361204013377926
totalrenalelimination,0.08361204013377926
auc0300,0.08361204013377926
percentageexcretion,0.08361204013377926
absorptionrateconstantsalpha,0.08361204013377926
mucoadhesivestrength,0.08361204013377926
auc2448,0.08361204013377926
qp,0.08361204013377926
cmaxtomicratio,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucminimuminhibitoryconcentrationmicratio,0.08361204013377926
apparentvolumeofdistributionatsteadystatebioavailability,0.08361204013377926
intracellularserumratio,0.08361204013377926
auc24hrmic,0.08361204013377926
aucminimuminhibitoryconcentrationmicratio,0.08361204013377926
eliminationhalflifefromblisterfluid,0.08361204013377926
gellingpoint,0.08361204013377926
solgeltransitiontemperature,0.08361204013377926
mucociliarytransporttime,0.08361204013377926
totalvolumeatsteadystate,0.08361204013377926
drugtargetingefficiencyindex,0.08361204013377926
directtransportpercentindex,0.08361204013377926
maximumconcentrationtmax,0.08361204013377926
totalendogenouspyridoxal,0.08361204013377926
netcmax,0.08361204013377926
maximummesnaconcentration,0.08361204013377926
plasmaintrinsicclearanceforunbounddtzcli,0.08361204013377926
pulsedreleasetimetrm10,0.08361204013377926
delayedreleasetime,0.08361204013377926
pulsedreleasetime,0.08361204013377926
peakserumdiltiazemlevel,0.08361204013377926
minimalinhibitoryenrofloxacinconcentration,0.08361204013377926
distributionalclearancebetweenthecentralandperipheralcompartment,0.08361204013377926
peaksputumlevel,0.08361204013377926
delayedreleasetimet10,0.08361204013377926
90cl,0.08361204013377926
areaunderthecurveofserumconcentrationversustime,0.08361204013377926
peakaqueousconcentration,0.08361204013377926
maximumciprofloxacinconcentration,0.08361204013377926
totalareaundertheconcentrationtimecurveauc0infinity,0.08361204013377926
biologicaleliminationt12,0.08361204013377926
maximumreleasetimetrm,0.08361204013377926
timetopeakplasmadiltiazemconcentration,0.08361204013377926
basalplasmaplpconcentration,0.08361204013377926
t05el,0.08361204013377926
basalplasmaplconcentration,0.08361204013377926
areaunderconcentrationtimecurveauc0300,0.08361204013377926
serumclearancerate,0.08361204013377926
peakbronchialconcentration,0.08361204013377926
cumulativelevelsofrenalexcretion,0.08361204013377926
t05ab,0.08361204013377926
eliminationhalflivest05a,0.08361204013377926
t12deg,0.08361204013377926
maximumconcentrationsofdruginserum,0.08361204013377926
cminconcentration,0.08361204013377926
pqinterval,0.08361204013377926
areasundertheconcentrationtimecurvefrom0htoinfinity,0.08361204013377926
bloodplasmadistributionratio,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvesauc0infinity,0.08361204013377926
auc12htomicratio,0.08361204013377926
peakdialysatelevel,0.08361204013377926
cmaxd,0.08361204013377926
areaunderthebractimecurve,0.08361204013377926
polydispersionindex,0.08361204013377926
areaundertheconcentrationvstimecurvesauc,0.08361204013377926
areaunderthecurvein04h,0.08361204013377926
plasmafreedrugconcentration,0.08361204013377926
releaserateconstant,0.08361204013377926
micsmic50,0.08361204013377926
fllc12,0.08361204013377926
logapparentoctanolwaterpartitioncoefficient,0.08361204013377926
pseudosteadystatebreathalcoholconcentrationbrac,0.08361204013377926
totalbodyclearancesclb,0.08361204013377926
plateauslilevel,0.08361204013377926
s1recoverie,0.08361204013377926
halflifeforretention,0.08361204013377926
doublingtimefortumoraccumulation,0.08361204013377926
energiesofactivation,0.08361204013377926
kmtheapparentinvivomichaelisconstant,0.08361204013377926
cmax500,0.08361204013377926
albuminboundfraction,0.08361204013377926
maximumdimesnaconcentration,0.08361204013377926
peakmesnaconcentration,0.08361204013377926
peakdimesnaconcentration,0.08361204013377926
uroprotectiveconcentration,0.08361204013377926
transferconstant,0.08361204013377926
distributionconstant,0.08361204013377926
overallfractionalattainment,0.08361204013377926
areaundertheconcentrationtimecurvesauc024h,0.08361204013377926
rateofethanoleliminationfromblood,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to24hauc024micratio,0.08361204013377926
maximumconcentrationsinplasmacmax,0.08361204013377926
areasundertheconcentrationtimecurvesfromtimezerotothetimeofthelast,0.08361204013377926
voidvolumevo,0.08361204013377926
retentiontimestr,0.08361204013377926
maximalethyleneglycolglycolateconcentration,0.08361204013377926
timetopeakbrac,0.08361204013377926
areaunderthebloodethanoltimecurveauc,0.08361204013377926
vtau,0.08361204013377926
eliminationofalcoholfrombreath,0.08361204013377926
auc012750,0.08361204013377926
auc012500,0.08361204013377926
areasundertheconcentrationtimecurveauc0,0.08361204013377926
concentrationsofschi,0.08361204013377926
tleg,0.08361204013377926
steadybloodalcoholconcentrationsbac,0.08361204013377926
betaphaseconstant,0.08361204013377926
steadystatebac,0.08361204013377926
firstordereliminationrate,0.08361204013377926
rateconstantfortransportto,0.08361204013377926
freetotaltiagabine,0.08361204013377926
maximumeegeffect,0.08361204013377926
cmax750,0.08361204013377926
aucmicatmic,0.08361204013377926
rhofactor,0.08361204013377926
betaslope,0.08361204013377926
initialmucosalpeak,0.08361204013377926
extension,0.08361204013377926
hepatickm,0.08361204013377926
mucosaserumratio,0.08361204013377926
peakalcoholconcentration,0.08361204013377926
milktoplasmaratiosmp,0.08361204013377926
q055,0.08361204013377926
q040,0.08361204013377926
1kappa,0.08361204013377926
pleuralplasmaratio,0.08361204013377926
rst,0.08361204013377926
fractionofmetabolism,0.08361204013377926
pleuralfluidplasmaratio,0.08361204013377926
steadystateciprofloxacinconcentration,0.08361204013377926
absolutebioavailabiltiy,0.08361204013377926
maximumciprofloxacinplasmaconcentration,0.08361204013377926
peakbloodacetaldehydeconcentration,0.08361204013377926
areasunderthedrugconcentrationtimecurve,0.08361204013377926
inhibitoryratioir,0.08361204013377926
apparentvolumeofdistributionduringterminalphase,0.08361204013377926
retardquotientdeltar,0.08361204013377926
overalldrugrecovery,0.08361204013377926
areaunderthetimeplasmaconcentrationcurveauc,0.08361204013377926
percentagebioinversion,0.08361204013377926
percentbioinversion,0.08361204013377926
aucmicratioauic,0.08361204013377926
areaundertheconcentrationtimecurve024h,0.08361204013377926
halflifeofeliminationkelt12,0.08361204013377926
kelt12,0.08361204013377926
earlypeaklevel,0.08361204013377926
auc0areaundertheconcentrationtimecurvefromtimezerotoinfinity,0.08361204013377926
tmaxpeaktime,0.08361204013377926
cmaxcminratioatsteadystateconcentration,0.08361204013377926
peaklevelsofdrug,0.08361204013377926
apparentcornealpermeabilitycoefficient,0.08361204013377926
percentmetaboliteconversionratio,0.08361204013377926
aucsareasundertheconcentrationvstimecurve,0.08361204013377926
aucaucratio,0.08361204013377926
apparentdrugdistributionvolumevdlambdazf,0.08361204013377926
maximumplasmaaripiprazoleconcentration,0.08361204013377926
total7dayrecovery,0.08361204013377926
areaundertheserumcipconcentrationtimecurveaucfromtimezerotoinfinity,0.08361204013377926
volumeofdistributionvdareaf,0.08361204013377926
areaundertheplasmaconcentrationtimecurveoveronedosingintervaltau012hafterdrugadministrationauctau,0.08361204013377926
vsskg,0.08361204013377926
peakaqueou,0.08361204013377926
timetomaximumconcentrationofdrug,0.08361204013377926
auc0htz,0.08361204013377926
timetoreachmeasuredmaximumplasmaconcentrationaftermultipleadministrationstmaxss,0.08361204013377926
maximumplasmaconcentrationaftermultipleadministrationscmaxss,0.08361204013377926
timetomaximaltemperaturereduction,0.08361204013377926
peakibuprofenconcentration,0.08361204013377926
peakbloodethanolconcentrationsbec,0.08361204013377926
areaunderthe24hourinhibitoryconcentrationcurveauic24,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimezerotothetimeoflastquantifiableconcentrationauc0t,0.08361204013377926
rateconstantfordrugdistribution,0.08361204013377926
accumulationindexai,0.08361204013377926
ductalclosurerate,0.08361204013377926
remedicationtime,0.08361204013377926
timetomeaningfulpainrelief,0.08361204013377926
gastricretentiontime,0.08361204013377926
maximumtotaldrugconcentrationcmax,0.08361204013377926
areaunderthecurvefor024hour,0.08361204013377926
timetoachieveapparentmaximumibuprofenconcentrationtmax,0.08361204013377926
peakplasmaibuprofenconcentration,0.08361204013377926
viablebacterialcount,0.08361204013377926
overallinversionefficiency,0.08361204013377926
areaundertimeconcentrationcurveforibuprofenauc0360,0.08361204013377926
rateconstantfordrugdistributionfromtheperipheral,0.08361204013377926
matureclearance,0.08361204013377926
totalibuprofenconcentrationinthecsfversu,0.08361204013377926
ratiobetweentheauc,0.08361204013377926
auc06hr,0.08361204013377926
completiontimeof,0.08361204013377926
relativebioavailabilityindex,0.08361204013377926
areaunderthecurveoftheplasmaconcentrationtimecurveauc,0.08361204013377926
auc1d,0.08361204013377926
auc3d,0.08361204013377926
ss,0.08361204013377926
systemicplasmaclearancecltot,0.08361204013377926
auc0n,0.08361204013377926
maximumsteadystatedrugconcentration,0.08361204013377926
areaundertheconcentrationcurvefromtime0,0.08361204013377926
eliminationrateconstantfromtheeffectcompartment,0.08361204013377926
halflifeofdrugintheeffectcompartment,0.08361204013377926
areaundertheconcentrationtimecurveauc0n,0.08361204013377926
areasundertheconcentrationtimecurvesaucsfrom0to9h,0.08361204013377926
midpoint,0.08361204013377926
aucss08ratio,0.08361204013377926
timeabovethelethalconcentration50lc50,0.08361204013377926
totalfractionofthedoserecovered,0.08361204013377926
totalfraction,0.08361204013377926
timetothemaximumobservedamifloxacinconcentration,0.08361204013377926
overallclb,0.08361204013377926
overallvdss,0.08361204013377926
maximumobservedamifloxacinconcentration,0.08361204013377926
amountofdrugrecovered,0.08361204013377926
timeabovelc50,0.08361204013377926
systemicareaunderthecurveauc,0.08361204013377926
ratioofaucmilkplasma,0.08361204013377926
maximalresiduelevelvaluemrl,0.08361204013377926
areaunderthecurveauctot,0.08361204013377926
bioconcentrationfactor,0.08361204013377926
apparentpopulationclearance,0.08361204013377926
truene,0.08361204013377926
timeabovethelc50,0.08361204013377926
apparentclearanceclfm,0.08361204013377926
mrtfaece,0.08361204013377926
plasmabioavailabilitiesauc,0.08361204013377926
halflivesofthedistribution,0.08361204013377926
aumc0last,0.08361204013377926
apparentclearanceofthebioavailablefractionclf,0.08361204013377926
aucmilkplasma,0.08361204013377926
aucfaece,0.08361204013377926
maximumdungconcentration,0.08361204013377926
ratioofaucmilk,0.08361204013377926
noobservedeffectconcentration,0.08361204013377926
peakfecalconcentrationfcmax,0.08361204013377926
terminalamifloxacinhalflife,0.08361204013377926
plasmameanresidencetimesmrt,0.08361204013377926
skinmrt,0.08361204013377926
peakvaluescmax,0.08361204013377926
systemicbodyclearanceclb,0.08361204013377926
slopeoftheterminalphase,0.08361204013377926
apparentabsorptionrate,0.08361204013377926
maximalplasmadrugconcentrationcmax,0.08361204013377926
maximumresidue,0.08361204013377926
areaundertheconcentrationtimecurvesauc,0.08361204013377926
fflu,0.08361204013377926
amountexcretedae,0.08361204013377926
plasmaconcentrationtimeareaunderthecurveauc024,0.08361204013377926
aeratio,0.08361204013377926
timetopeakdrugconcentrationtmax,0.08361204013377926
drugcarrierratio,0.08361204013377926
ratioofthefaecalauc,0.08361204013377926
areaundertheconcentrationovertimecurve,0.08361204013377926
systemicexposureauc,0.08361204013377926
maximumconcentrationsmeancmax,0.08361204013377926
basaltoapicalflux,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucss08,0.08361204013377926
minimummeanconcentration,0.08361204013377926
timepointofmaximumplasmaconcentrationtp,0.08361204013377926
areasunderthecurve0to12h,0.08361204013377926
peaksofserumconcentrationcmax,0.08361204013377926
50ofmaximumeffect,0.08361204013377926
peakexcretionlevel,0.08361204013377926
distributionrateconstantalpha,0.08361204013377926
plasmaresidencetimemrt,0.08361204013377926
lastdetectableplasmaconcentrationtlast,0.08361204013377926
fecrt,0.08361204013377926
timedur4,0.08361204013377926
timedur3,0.08361204013377926
areaunderthefaecalconcentrationtimecurve,0.08361204013377926
ratioofarea,0.08361204013377926
lambtoewe,0.08361204013377926
overallconcentration,0.08361204013377926
areasundertheplasmaconcentrationversustimecurve,0.08361204013377926
maximumpreoperativeplasmaconcentration,0.08361204013377926
adultclearance,0.08361204013377926
cmaxecmic90,0.08361204013377926
peakacetoneconcentration,0.08361204013377926
abac,0.08361204013377926
vbac,0.08361204013377926
brac,0.08361204013377926
disappearancerateofethanol,0.08361204013377926
distributionvdlambdazf,0.08361204013377926
mbec,0.08361204013377926
eliminationhalflifest12l,0.08361204013377926
maximumplasmalevelsreached,0.08361204013377926
maximumbac,0.08361204013377926
peakbrac,0.08361204013377926
methanolconcentration,0.08361204013377926
aqueouspeak,0.08361204013377926
liverterminalhalflifet12,0.08361204013377926
t12oftheterminaldecayphase,0.08361204013377926
ethanoltoetgratio,0.08361204013377926
bloodalcohollevel,0.08361204013377926
carriercellrecovery,0.08361204013377926
t05b,0.08361204013377926
populationabsorptionhalflife,0.08361204013377926
peakplasmalumefantrineconcentration,0.08361204013377926
dosegivingmaximumpolarization,0.08361204013377926
eliminationhalflifefromthemembranefraction,0.08361204013377926
maximumdecrease,0.08361204013377926
auc0300min,0.08361204013377926
ratioofaucglucuronidesulfateaucaglycone,0.08361204013377926
timetakenformaximumplasmalevelstobereached,0.08361204013377926
areasundertheconcentrationcurvesaucs,0.08361204013377926
biotransformationratio,0.08361204013377926
cssmaxmic,0.08361204013377926
cmax1mic,0.08361204013377926
rateofdeclineoftheplasmaethanolconcentrationk0,0.08361204013377926
tissueversusplasmaconcentrationratio,0.08361204013377926
eliminationhalflifet05el,0.08361204013377926
serumareaundertheconcentrationtimecurveauc,0.08361204013377926
initialhalflifeforbiliaryelimination,0.08361204013377926
numberofrespiratoryeventsper,0.08361204013377926
convectiveclearance,0.08361204013377926
diffusiveclearance,0.08361204013377926
totalciprofloxacinclearance,0.08361204013377926
dialysatefluxqd,0.08361204013377926
interstitiumtoserumconcentrationratio,0.08361204013377926
peakbloodalcohollevel,0.08361204013377926
apneaindex,0.08361204013377926
ueg,0.08361204013377926
minimumsao2,0.08361204013377926
flowratefor,0.08361204013377926
maximalkill,0.08361204013377926
rateofzeroorderethanolelimination,0.08361204013377926
areaundertheconcentrationtimecurvesfrom0hto24hauc024h,0.08361204013377926
timetakentoachievepeakplasmaconcentrationtmax,0.08361204013377926
totalamikacinclearance,0.08361204013377926
areaundertheethanolconcentrationtimecurve,0.08361204013377926
peakbloodethanol,0.08361204013377926
maxvelocityofmetabolizing,0.08361204013377926
overalldrugtargetingefficiency,0.08361204013377926
selfmicroemulsifyingtime,0.08361204013377926
dropsize,0.08361204013377926
fpm,0.08361204013377926
betapac,0.08361204013377926
kalphapac,0.08361204013377926
betaaac,0.08361204013377926
kalphaaac,0.08361204013377926
highestmeanurineconcentration,0.08361204013377926
logoctanolwaterpartitioncoefficient,0.08361204013377926
resolutionfactorr,0.08361204013377926
separationfactoralpha,0.08361204013377926
endometrialconcentration,0.08361204013377926
kform,0.08361204013377926
encapsulationyield,0.08361204013377926
braintargetingindex,0.08361204013377926
peakplasmaconcentrationatsteadystate,0.08361204013377926
plasmaalfaxalone,0.08361204013377926
drugexposureauc024,0.08361204013377926
timetoreachmaximumplasmaconcentrationstmax,0.08361204013377926
eliminationterminalhalflife,0.08361204013377926
hepaticfirstpassextraction,0.08361204013377926
gutextractionratio,0.08361204013377926
areaunderconcentrationtimecurvemeasuredinsteadystateupto24hafterdosingauc024h,0.08361204013377926
peakenrofloxacinconcentration,0.08361204013377926
totalfetalclearance,0.08361204013377926
totalmaternalclearance,0.08361204013377926
transplacentalclearance,0.08361204013377926
minimumsteadystateconcentrationscmin,0.08361204013377926
areaundertheconcentrationtimecurveat24hauc24,0.08361204013377926
clarea,0.08361204013377926
peakhemolymphconcentrationcmax,0.08361204013377926
peakenrofloxacinplasmaconcentration,0.08361204013377926
t2max,0.08361204013377926
firstorderrateconstantofdegradation,0.08361204013377926
volumeofdistributionofthecentralcompartmentvdc,0.08361204013377926
ratiosaucecmic90,0.08361204013377926
terminalkinetichalflive,0.08361204013377926
oralbioavailabilityauc0t,0.08361204013377926
timetoreachmaximumdrugconcentrationtmax,0.08361204013377926
maximuminhibitionofthezeroordersynthesisrate,0.08361204013377926
halflifeduringtheterminaleliminationphaset12lambda,0.08361204013377926
timetomaximumaccumulation,0.08361204013377926
meanresidencetimebetween0and24h,0.08361204013377926
samplingtimeafteradose,0.08361204013377926
clpxf,0.08361204013377926
cohpxsscpxss,0.08361204013377926
nasalsecretoryconcentration,0.08361204013377926
steadystatesalivary,0.08361204013377926
clareaf,0.08361204013377926
maximumsteadystateconcentrationscmax,0.08361204013377926
minimalquantifiableconcentration,0.08361204013377926
maximuminflammatoryfluidlevel,0.08361204013377926
peaklomefloxacinconcentration,0.08361204013377926
reaching,0.08361204013377926
bone,0.08361204013377926
bonetoplasmaratio,0.08361204013377926
auc24hmicratio,0.08361204013377926
maximumurinaryexcretionratermax,0.08361204013377926
percentageofthe,0.08361204013377926
plasmacmaxmicratio,0.08361204013377926
areasunderthedrugconcentrationcurve,0.08361204013377926
tissuepenetrationfactor,0.08361204013377926
timeoftissueextraction,0.08361204013377926
prostatetissueconcentration,0.08361204013377926
maximumconcentrationofdruginserum,0.08361204013377926
eliminationhalflifefromserum,0.08361204013377926
apparentvolumeofdistributionassociatedwiththeterminalphase,0.08361204013377926
timeofoccurrenceofthemaximumconcentration,0.08361204013377926
maximumplasmalomefloxacinconcentration,0.08361204013377926
bacterialkillingandregrowthcurve,0.08361204013377926
bronchialmucosalconcentration,0.08361204013377926
auc024hmicratio,0.08361204013377926
auc24mpcratio,0.08361204013377926
overallserumeliminationhalflife,0.08361204013377926
percentagepenetrationintotheinflammatorycompartment,0.08361204013377926
serumconcentrationversustimecurve,0.08361204013377926
plasmaconcentrationratior,0.08361204013377926
potencyratioic50,0.08361204013377926
cumulativeexcretionofradioactivity,0.08361204013377926
terminalhalflifet12lambda,0.08361204013377926
steadystatemaximumcmax,0.08361204013377926
80inhibitoryconcentrationic80,0.08361204013377926
lzhl,0.08361204013377926
totalplasmameloxicamconcentrationsauc,0.08361204013377926
1ke,0.08361204013377926
totalapparentbodyclearanceclf,0.08361204013377926
reabsorbedfractionofbioavailabledose,0.08361204013377926
areaunderthecurvevaluesfor72hoursauc072,0.08361204013377926
peakplasmachlorzoxazoneconcentration,0.08361204013377926
terminalhalflifeofdrug,0.08361204013377926
timetopeakcande,0.08361204013377926
areaundertheconcentrationtimecurveover24hoursieonedosingintervalauctau,0.08361204013377926
cumulationhalflifet12beta,0.08361204013377926
freeintrinsicserumclearance,0.08361204013377926
bioavailabilitycoefficientsfauc,0.08361204013377926
tpc,0.08361204013377926
sexratio,0.08361204013377926
unboundvpaclearance,0.08361204013377926
totalvpa,0.08361204013377926
totalvpaconcentration,0.08361204013377926
peakplasmavpaconcentrationcmax,0.08361204013377926
tirstumorinhibitionrate,0.08361204013377926
eliminationhalflivest12z,0.08361204013377926
timetoattainapeakserumconcentration,0.08361204013377926
peakthpplasmaconcentration,0.08361204013377926
serumproteinboundfraction,0.08361204013377926
maximumserumconcentrationc0p,0.08361204013377926
ratioofthedrug,0.08361204013377926
rateoftransferofdrugfromthecentraltotheperipheralcompartmentk12,0.08361204013377926
areaundertheconcentrationtimecurvefromzerotoinfinite,0.08361204013377926
flowratesqdi,0.08361204013377926
areaundertheconcentrationtimecurvewithinadosingintervalauctau,0.08361204013377926
aucfrom0to48h,0.08361204013377926
minimumobservedconcentrationcmin,0.08361204013377926
timetoreachmaximumobservedconcentrationcmax,0.08361204013377926
totalbloodclearanceci,0.08361204013377926
terminalt12betahalflive,0.08361204013377926
initialt12alpha,0.08361204013377926
redispersibilityindex,0.08361204013377926
cellplasmaconcentrationratio,0.08361204013377926
zeroorderabsorptionrate,0.08361204013377926
extentofabsorptionareaundertheconcentrationtimecurve,0.08361204013377926
clpop,0.08361204013377926
plasmaunboundfractionfu,0.08361204013377926
period,0.08361204013377926
bioavailabilityareaundertheconcentrationtimecurveaucratio,0.08361204013377926
percenttargetattainment,0.08361204013377926
brainuptake,0.08361204013377926
ic50pop,0.08361204013377926
vdpop,0.08361204013377926
steadystatefetalmaternalunboundvpaplasmaconcentrationratio,0.08361204013377926
kapop,0.08361204013377926
timelagbeforeabsorption,0.08361204013377926
halflifeofeliminationt05beta,0.08361204013377926
bindingsitesn,0.08361204013377926
dissociationconstantk,0.08361204013377926
kem,0.08361204013377926
ultrafiltration,0.08361204013377926
peakleukemiccelldaunomycinoldnmolconcentration,0.08361204013377926
durationofdrugabsorption,0.08361204013377926
intrinsicformationclearanceclf,0.08361204013377926
terminalfetalmaternalratiosofbloodconcentration,0.08361204013377926
auc050h,0.08361204013377926
clfree,0.08361204013377926
cfree,0.08361204013377926
totalvpaclearancecltotal,0.08361204013377926
ctotal,0.08361204013377926
mobilityspeed,0.08361204013377926
peakleukemiccelldnmconcentration,0.08361204013377926
durationofretention,0.08361204013377926
maximumdnrconcentration,0.08361204013377926
leveldoseratio,0.08361204013377926
unboundvpa,0.08361204013377926
peakplasmadnmlevel,0.08361204013377926
terminalplasma,0.08361204013377926
intervalfromadministrationuntilmaximumconcentrationtmax,0.08361204013377926
peritoneumplasmaconcentrationratio,0.08361204013377926
maximumnontoxicdosage,0.08361204013377926
braintoplasmaratiokbrainplasma,0.08361204013377926
compartmentalvolumeofdistributionatsteadystatevss,0.08361204013377926
maximumnetplasmaconcentrationcmax,0.08361204013377926
ed25,0.08361204013377926
areaundertheplasmaconcentrationtimecurvesauclast,0.08361204013377926
bei,0.08361204013377926
absoluteoralbioavailibility,0.08361204013377926
areaundertheconcentrationtimecurvetoinfinity,0.08361204013377926
peaklevamisoleplasmalevel,0.08361204013377926
timetoachievethecmaxtmax,0.08361204013377926
concentrationrequired,0.08361204013377926
ratiooftumortoplasmaconcentration,0.08361204013377926
stsp,0.08361204013377926
volumeofdistributionduringtheeliminationphasevdb,0.08361204013377926
totalsalivaryconcentration,0.08361204013377926
fractionabsorbedf,0.08361204013377926
biologicalhalflivesforelimination,0.08361204013377926
auchalftimeofelimination,0.08361204013377926
amnioticfluidfetalbloodratio,0.08361204013377926
arterialtension,0.08361204013377926
vzbeta,0.08361204013377926
effectcompartmentclearance,0.08361204013377926
cissrf,0.08361204013377926
aucsst,0.08361204013377926
tissueeliminationhalflife,0.08361204013377926
unboundnonrenalclearance,0.08361204013377926
apparentclearancerateclf,0.08361204013377926
radiolabeling,0.08361204013377926
oc50,0.08361204013377926
steadystatemilktoplasma,0.08361204013377926
apparentoralclearanceclssf,0.08361204013377926
halflifeassociatedwithbetaphaset12beta,0.08361204013377926
ultrafiltrationefficiencyof,0.08361204013377926
accumulationfactorr,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucvalue,0.08361204013377926
maximumtolerateddosesmtd,0.08361204013377926
timetoatofratio,0.08361204013377926
tgt,0.08361204013377926
cumulativeurinaryexcretionsigmaxusr,0.08361204013377926
areaundertheconcentrationtimecurveauc033h,0.08361204013377926
tmx,0.08361204013377926
apparentvdkg,0.08361204013377926
plasmaeliminationhalflifet12el,0.08361204013377926
steadystateplasmaconcentrationelicitinghalfofmaximume,0.08361204013377926
maximumfoldofinductionemax,0.08361204013377926
cess50,0.08361204013377926
durationtoatofratio,0.08361204013377926
areaundertheplasmaconcentrationtimecurve0infinity,0.08361204013377926
areasundertheconcentrationversustimecurvesaucs,0.08361204013377926
eliminationphasedispositionhalflifet12beta,0.08361204013377926
necroticpancreatictissueserumconcentrationratio,0.08361204013377926
slowhalflive,0.08361204013377926
fractionofacebutololunboundtoplasmaprotein,0.08361204013377926
halllife,0.08361204013377926
areaoftheplasmaleveltimecurveauc,0.08361204013377926
absoluteavailabilitie,0.08361204013377926
lagtimesbeforeonsetofabsorption,0.08361204013377926
lungbloodconcentrationratio,0.08361204013377926
lungbloodratio,0.08361204013377926
peakrpqconcentration,0.08361204013377926
equilibriumer,0.08361204013377926
peakspqconcentration,0.08361204013377926
accura,0.08361204013377926
areasunderthecurveto4hr,0.08361204013377926
slopeparameter,0.08361204013377926
clearancebydial,0.08361204013377926
eliminationhalflifeofthebetaphase,0.08361204013377926
t12ofthebetaphase,0.08361204013377926
vclbf,0.08361204013377926
unboundvpaconcentration,0.08361204013377926
steadystateminimumplasmaconcentration,0.08361204013377926
peakvalueofmaximumplasma8mopconcentrationstmaxcmax,0.08361204013377926
areaunderthecurve0120h,0.08361204013377926
totalquantity,0.08361204013377926
maximumserumvalproateconcentration,0.08361204013377926
gamma1,0.08361204013377926
td2,0.08361204013377926
td1,0.08361204013377926
gammashape,0.08361204013377926
auc8tau9tau,0.08361204013377926
clbcecf,0.08361204013377926
clecfbc,0.08361204013377926
qbcb,0.08361204013377926
areaunderthecurvefrom0toinfinity,0.08361204013377926
peakmetoclopramideconcentration,0.08361204013377926
qbbb,0.08361204013377926
peakplasmaghlevel,0.08361204013377926
ratioofmeanresidencetime,0.08361204013377926
cbccecf,0.08361204013377926
daystoinitiationoftesting,0.08361204013377926
distributionvolumeatthesteadystate,0.08361204013377926
plasmaammonian,0.08361204013377926
maximumcmaxconcentration,0.08361204013377926
maximumvpaconcentration,0.08361204013377926
wholebodyturnovertime,0.08361204013377926
daystotaskmastery,0.08361204013377926
lowestdetectionlimit,0.08361204013377926
volumesofdistributionvdlambdaz,0.08361204013377926
areaundertheconcentrationvstimecurveauc0,0.08361204013377926
timetoreachthepeakplasmaconcentration,0.08361204013377926
areasundertheserumconcentrationtimecurvesauc0infinity,0.08361204013377926
relativebioavailabilityf024,0.08361204013377926
f0,0.08361204013377926
clutb,0.08361204013377926
cubccecf,0.08361204013377926
retentionindex,0.08361204013377926
maximumtotal,0.08361204013377926
biologicalt12,0.08361204013377926
fetaltomaternalconcentrationratio,0.08361204013377926
cavgt,0.08361204013377926
timepeak,0.08361204013377926
initialbioavailability,0.08361204013377926
cue48,0.08361204013377926
aucfromtimezerotothetimeofthelastmeasurableconcentrationauclast,0.08361204013377926
absorptionoforaldose,0.08361204013377926
plasmaconcentrationscavgt,0.08361204013377926
maximuminitialdose,0.08361204013377926
timesofpeakconcentration,0.08361204013377926
vcmean,0.08361204013377926
halflifeofthealphaphaseofdistribution,0.08361204013377926
absorptionhalflifest12s,0.08361204013377926
cyclinginterruptedclearance,0.08361204013377926
eliminationhalflifepostdistribution,0.08361204013377926
percentagerecoveryof,0.08361204013377926
areaundertheplasmametoclopramideleveltimecurveauc,0.08361204013377926
durationofthezeroorderabsorptiontk0,0.08361204013377926
cbcecf,0.08361204013377926
steadystatemetoclopramideconcentrationmcpss,0.08361204013377926
concentrationdose,0.08361204013377926
rectalretentionforce,0.08361204013377926
cmax04h,0.08361204013377926
specificsurface,0.08361204013377926
latencytimetlag,0.08361204013377926
gmax,0.08361204013377926
sustainedplasmaconcentration,0.08361204013377926
areaundertheserumconcentrationtimecurveauc0infinity,0.08361204013377926
steadystatepeaklevelsofdigoxincmaxss,0.08361204013377926
distance,0.08361204013377926
daucgluc,0.08361204013377926
aucgluc,0.08361204013377926
totalapparentplasmaclearance,0.08361204013377926
plasmacarnitineclearance,0.08361204013377926
aucinfinityfaaucinfinityma,0.08361204013377926
tec50,0.08361204013377926
nf,0.08361204013377926
cumulativeamountabsorbeduptotime6h,0.08361204013377926
totalamountsaucpxcliv,0.08361204013377926
rateofdrugadministration,0.08361204013377926
ec50a,0.08361204013377926
ec50b,0.08361204013377926
maximumconcentrationf,0.08361204013377926
peakglyceryltrinitrateplasmalevel,0.08361204013377926
arterialt12,0.08361204013377926
arterialvenousextraction,0.08361204013377926
dinitrateratio,0.08361204013377926
apparenterythrocyteplasmapartitioncoefficient,0.08361204013377926
objectivefunction,0.08361204013377926
areaundertheplasmaconcentrationtimecurveto48hauc048h,0.08361204013377926
activesurfacearea,0.08361204013377926
aucotlast,0.08361204013377926
totalradioactivemetabolitesexcreted,0.08361204013377926
apparentvolumeofdistributionwasvdbeta,0.08361204013377926
orderofassociationconstantk,0.08361204013377926
lp,0.08361204013377926
s50app,0.08361204013377926
vmaxapp,0.08361204013377926
hillcoefficientn,0.08361204013377926
distributionvolumeatsteadystatewasv,0.08361204013377926
minimumvalproicacidconcentration,0.08361204013377926
areasunderthecurvefromtime0tothelast,0.08361204013377926
bindingcapacitybmax1,0.08361204013377926
venousplasmaclearance,0.08361204013377926
clearanceofthefreedrugintrinsicclearance,0.08361204013377926
absorptionratekr,0.08361204013377926
halflifeoft12,0.08361204013377926
peaknitroglycerinconcentration,0.08361204013377926
peakplasmagtnlevel,0.08361204013377926
timestoreachhalfpeakplasmagtnlevel,0.08361204013377926
peakno3level,0.08361204013377926
t12betaoftheeliminationphasebeta,0.08361204013377926
netlosse,0.08361204013377926
encapsulationefficiencypercentage,0.08361204013377926
absolutebioavailabilitybioav,0.08361204013377926
bioav,0.08361204013377926
renalexcretoryclearancetogfrratio,0.08361204013377926
renalexcretoryclearance,0.08361204013377926
plasmacarnitine,0.08361204013377926
peakno2level,0.08361204013377926
total24hexcretion,0.08361204013377926
reachedsteadystatelevel,0.08361204013377926
totalplasmacarnitineconcentration,0.08361204013377926
volumesofdistributionatsteadystatevdssofthecentralcompartment,0.08361204013377926
equilibriumassociationconstant,0.08361204013377926
accumulatedurinaryexcretion,0.08361204013377926
eliminationper,0.08361204013377926
concentrationsscac,0.08361204013377926
plasmaconcentrationat10minutesafterdosingc10,0.08361204013377926
areaunderthecurvefromtime0tothelastquantifiablesampleauc0tlast,0.08361204013377926
maximalbloodplasmaconcentration,0.08361204013377926
amountofdrugnotabsorbed,0.08361204013377926
arteriovenousextraction,0.08361204013377926
clappm2,0.08361204013377926
clappm1,0.08361204013377926
v0f,0.08361204013377926
totalamountofntgtransdermallyabsorbedaucxcl,0.08361204013377926
clvpa,0.08361204013377926
normalizedareasunderthecurve,0.08361204013377926
peakmalotilateplasmaconcentration,0.08361204013377926
volumesofdistributionvcf,0.08361204013377926
kf2,0.08361204013377926
kf1,0.08361204013377926
urinaryhalflife,0.08361204013377926
centralbloodvolume,0.08361204013377926
totalbloodvolume,0.08361204013377926
percentsrecovery,0.08361204013377926
totalbodyclearanceclbf,0.08361204013377926
cmaxpeakdrugconcentration,0.08361204013377926
oralapparentvolumeofdistribution,0.08361204013377926
peakplasmasdzconcentration,0.08361204013377926
peakplasmatmpconcentration,0.08361204013377926
distributionofthemic,0.08361204013377926
peakmeanserumconcentration,0.08361204013377926
freeauc024mic,0.08361204013377926
serumminimum,0.08361204013377926
tmp,0.08361204013377926
freesmz,0.08361204013377926
totalsmz,0.08361204013377926
proportionseliminated,0.08361204013377926
penetrationintoperipheral,0.08361204013377926
meanresiduetimemrt,0.08361204013377926
minimumtherapeuticserumconcentration,0.08361204013377926
degreeofpenetrationintoblisterfluid,0.08361204013377926
peaktmplevel,0.08361204013377926
tubularsecretoryclearance,0.08361204013377926
tubulartransportmaximum,0.08361204013377926
apparentmichaelismentenconstantfortubularsecretion,0.08361204013377926
serumhalflifevaluest12,0.08361204013377926
stratio,0.08361204013377926
csftoserumconcentrationratio,0.08361204013377926
aucfrom08hour,0.08361204013377926
fngt,0.08361204013377926
timetoreachthepeaktmax,0.08361204013377926
aucsbfaucspercentratio,0.08361204013377926
tissuetobloodconcentrationratio,0.08361204013377926
volumeofdistributionincentralvcf,0.08361204013377926
vbf,0.08361204013377926
vlf,0.08361204013377926
maximumsulfamethoxazoleconcentration,0.08361204013377926
maximumtrimethoprimconcentration,0.08361204013377926
fractionalconcentrationofinspiredoxygenf1o2,0.08361204013377926
poresize,0.08361204013377926
peritonealdialysance,0.08361204013377926
peaktheophylline,0.08361204013377926
throughplasmalevel,0.08361204013377926
apparentvolumeofdistributionvbetaf,0.08361204013377926
totalplasmaclearanceclsf,0.08361204013377926
troughvancomycinconcentration,0.08361204013377926
peakserumtheophyllineconcentration,0.08361204013377926
percentageofthedosereleased,0.08361204013377926
volumeofdistributionbasedonterminalphasevdz,0.08361204013377926
peaknonfastinglevel,0.08361204013377926
penetrationindexe,0.08361204013377926
plasmaclearence,0.08361204013377926
apparentvolumesofdistributionduringthebetaphasevdbeta,0.08361204013377926
cssmaxd,0.08361204013377926
maximalconccmax,0.08361204013377926
distributioncoefficientvdarea,0.08361204013377926
totalclearancef,0.08361204013377926
totalunboundclearance,0.08361204013377926
maximumserumtheophyllineconcentration,0.08361204013377926
peaktrough,0.08361204013377926
distributionvolumesvarea,0.08361204013377926
volumeofdistributiondividedbybioavailabilityvf,0.08361204013377926
vdtd,0.08361204013377926
c1serumconcentration,0.08361204013377926
clearancefromplasmadividedbybioavailabilityclf,0.08361204013377926
smxa,0.08361204013377926
milkplasmaquotient,0.08361204013377926
halflifeateliminationphase,0.08361204013377926
cardiac,0.08361204013377926
ren,0.08361204013377926
absorptionration,0.08361204013377926
peritonealdialysateconcentration,0.08361204013377926
maximumsecretorycapacitytmpah,0.08361204013377926
apparentaffinitykm,0.08361204013377926
filtrationefficiency,0.08361204013377926
peakcimetidinelevel,0.08361204013377926
overalleliminationrateconstantk,0.08361204013377926
peakmeanserumtmpconcentration,0.08361204013377926
amountofdrugexcretedintheurineae01,0.08361204013377926
recommendedmaintenancedose,0.08361204013377926
mrtpregnant,0.08361204013377926
mrtlactating,0.08361204013377926
eliminationhalflifeinserumduringsteadystate,0.08361204013377926
fourhourconcentration,0.08361204013377926
peakconcentrationsatsteadystate,0.08361204013377926
aucfrom0to12hour,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucfrom0to24hour,0.08361204013377926
gammadistributionrateconstantktrpo,0.08361204013377926
drugclearancec,0.08361204013377926
peakserumtmplevel,0.08361204013377926
apparentrateconstantforabsorptionka,0.08361204013377926
concentrationscausing50inhibition,0.08361204013377926
areaunderthebloodconcentrationcurveauc0,0.08361204013377926
peakserumcimetidineconcentration,0.08361204013377926
steadystatemsratio,0.08361204013377926
systemicdiseasecl,0.08361204013377926
totalbodyclearancecltotal,0.08361204013377926
serumconcentrationsc88,0.08361204013377926
timethattheserumcimetidine,0.08361204013377926
bioavailabilityaucpoauciv,0.08361204013377926
halflifeofabsorptiont05ab,0.08361204013377926
slopeks,0.08361204013377926
clccll,0.08361204013377926
m8clearance,0.08361204013377926
peakgoal,0.08361204013377926
fractionoforaldoseabsorbedfa,0.08361204013377926
apparentvolumeofdistributionvs,0.08361204013377926
systemicor,0.08361204013377926
residualclearance,0.08361204013377926
ap,0.08361204013377926
morningplasmaconcentration,0.08361204013377926
fractioneliminatedunchangedin,0.08361204013377926
t12eliminationhalflife,0.08361204013377926
cmaxthemaximumplasmaconcentration,0.08361204013377926
absorptionconstantrateka,0.08361204013377926
cumulativedissolutionrate,0.08361204013377926
apparentvolumeofdistributioninthecentralcompartmentbasedontheareaundertheplasmaconcentrationtimecurve,0.08361204013377926
areasundertherespectiveconcentrationvstimecurvesauc,0.08361204013377926
peakplasmafamotidineconcentration,0.08361204013377926
clearanceclhda,0.08361204013377926
areaunderthefamotidineplasmaconcentrationcurve,0.08361204013377926
initialplasmaconcentrationc0,0.08361204013377926
sul,0.08361204013377926
proteinbindingratio,0.08361204013377926
totalplasmacl,0.08361204013377926
90maximumeffectec90,0.08361204013377926
areaundercurveofplasmaconcentrationuntilthelastconcentrationobserved,0.08361204013377926
auc0infininty,0.08361204013377926
minimumeffectiveplasmaconcentration,0.08361204013377926
maximumserumdrugconcentration,0.08361204013377926
peaksulfamethoxazole,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to24hmicratio,0.08361204013377926
peakblisterfluidconcentration,0.08361204013377926
peaksofthemeanconcentrationcurve,0.08361204013377926
withdrawaltimewdt,0.08361204013377926
troughplasmavrczconcentration,0.08361204013377926
minimumurinaryconcentration,0.08361204013377926
cior,0.08361204013377926
meanresidencetimeforabsorption,0.08361204013377926
urina,0.08361204013377926
toccrratio,0.08361204013377926
totalamountofcimetidineeliminated,0.08361204013377926
clhda,0.08361204013377926
cssmaxcssmin,0.08361204013377926
stc,0.08361204013377926
peakflow,0.08361204013377926
evening,0.08361204013377926
maximaltissuelevelscmax,0.08361204013377926
absolutebioavailabilityfa,0.08361204013377926
clearancefromthebodycl,0.08361204013377926
percentagesofmoisturecontent,0.08361204013377926
areasunderplasmacurve,0.08361204013377926
volumeofdistributionbeta,0.08361204013377926
tv,0.08361204013377926
maximalmeanserumconcentration,0.08361204013377926
invivodissolutiontimetdissvivo,0.08361204013377926
timeafteroraladministration,0.08361204013377926
amplitudesof,0.08361204013377926
maximumplasmafolateresponse,0.08361204013377926
fractionofdrugremoved,0.08361204013377926
0htoinfinityauc0inf,0.08361204013377926
netabsorption,0.08361204013377926
periodoftimetobeplacedonoral,0.08361204013377926
maximumsulfadoxine,0.08361204013377926
timesto50,0.08361204013377926
areasundertheconcentrationtimecurvesaucsfrom0toinfinity,0.08361204013377926
timetakentoreachmaximumconcentrationtmax,0.08361204013377926
peaktroughfluctuationdeltapt,0.08361204013377926
oralabsorptionrateconstantka,0.08361204013377926
apparentvolumeofdistributionafteroraldosingvdf,0.08361204013377926
relativeextentsofabsorption,0.08361204013377926
maximumtheophyllineserumconcentration,0.08361204013377926
distributionclearancebetweencentraland2ndcompartment,0.08361204013377926
halflifeofserumelimination,0.08361204013377926
maximalplasmaconcentrationcbmax,0.08361204013377926
associationequilibriumconstantka,0.08361204013377926
separationfactor,0.08361204013377926
2ndperipheralcompartmentvolume,0.08361204013377926
3rdperipheralcompartmentvolume,0.08361204013377926
areasundertheplasmaconcentrationtimecurveaucfrom024hpostdoseauc024,0.08361204013377926
steadystateserumtheophyllineconcentrationsstcs,0.08361204013377926
totalvolumeof,0.08361204013377926
cox1cox2ratio,0.08361204013377926
terminaleliminationphaset12beta,0.08361204013377926
maximumnontoxicdose,0.08361204013377926
halflivesduringthedistributionphaset12alpha,0.08361204013377926
rmin,0.08361204013377926
synovia,0.08361204013377926
peakplasmatissueratio,0.08361204013377926
areaundertheplasmasertralineconcentrationtimecurveaucfrom0toinfinity,0.08361204013377926
tissueintracellularwaterpartitioncoefficient,0.08361204013377926
fractionrecoveredinurine,0.08361204013377926
overallkm,0.08361204013377926
milkproduction,0.08361204013377926
auc0105,0.08361204013377926
sonicationtimest,0.08361204013377926
dissociationconstantpka,0.08361204013377926
areaunderthecurvefrom0to36h,0.08361204013377926
halflifeduringtheeliminationphase,0.08361204013377926
peakserumdoxofyllineconcentration,0.08361204013377926
peakbiliaryexcretion,0.08361204013377926
apparentvolumesofdistributionduringtheeliminatorybetaphasevdbeta,0.08361204013377926
peaktotroughconcentrationratio,0.08361204013377926
timestomaximumtheophyllineconcentration,0.08361204013377926
fractionalturnoverrate,0.08361204013377926
maximaleosinopenic,0.08361204013377926
peaktheophyllineconcentrationcmax,0.08361204013377926
renalclearance02h,0.08361204013377926
totalclearanceatsteadystate,0.08361204013377926
peaktroughfluctuationinthesteadystate,0.08361204013377926
releaseamount,0.08361204013377926
icgr15,0.08361204013377926
areaunderconcentrationversustimecurveauc,0.08361204013377926
rootmeansquaredpredictionerror,0.08361204013377926
peakserumtryptophanlevel,0.08361204013377926
intrahepaticconcentrationofunchanged,0.08361204013377926
timeofpeakabsorption,0.08361204013377926
totalamountofsleep,0.08361204013377926
bloodclearancerate,0.08361204013377926
maintenancedoserate,0.08361204013377926
oesoduodenaltransittime,0.08361204013377926
milktoserumconcentrationratio,0.08361204013377926
apparentbreastmilkclearance,0.08361204013377926
apparentmaximumvelocityvmax,0.08361204013377926
continuousflux,0.08361204013377926
eliminationrateconstantlambda,0.08361204013377926
cumulativepermeationamount,0.08361204013377926
troughtheop,0.08361204013377926
oralbloavailability,0.08361204013377926
rebound,0.08361204013377926
timecmaxwasachievedtmax,0.08361204013377926
kmforoverallelimination,0.08361204013377926
areaunderthecurvefromtime0toa,0.08361204013377926
intrinsicnonrenalclearance,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefrom0htoinfinityauc0,0.08361204013377926
aucsfromzeroto15minute,0.08361204013377926
maximumserumconcentrationattained,0.08361204013377926
plateautimest75cmax,0.08361204013377926
overalleliminationrateconstantlambdaz,0.08361204013377926
postinjectiontimetmax,0.08361204013377926
bioavailabilityt,0.08361204013377926
cerebrallevel,0.08361204013377926
areaunderthecpvstimecurve,0.08361204013377926
maximumserumzolpidemconcentration,0.08361204013377926
doserequired,0.08361204013377926
plasmaconcentrationsat,0.08361204013377926
maximumzpcaconcentration,0.08361204013377926
maximumzolpidemconcentration,0.08361204013377926
distributional,0.08361204013377926
interresponsetimesirts,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimezerotothelastquantifiableplasmaconcentrationauc012,0.08361204013377926
cumulativeamountsexcreted,0.08361204013377926
areaundertheconcentrationvstimecurveaucfromtime0to24hoursaucun,0.08361204013377926
apparentpampap,0.08361204013377926
maximumconcentrationat12hour,0.08361204013377926
serumtheophyllineconcentrationstc,0.08361204013377926
timewhenthepeak,0.08361204013377926
maximumtheophyllinaemiacmax,0.08361204013377926
minimumplasmatheophyllineconcentration,0.08361204013377926
salivaplasmadd,0.08361204013377926
plateautimet75cmax,0.08361204013377926
aucfromtime0toinfinityaucex,0.08361204013377926
areaunderthecurveauc048,0.08361204013377926
steadystatepeakserumlevel,0.08361204013377926
steadystateserumtheophyllineconcentration,0.08361204013377926
minimuminhibitionconcentrationmic,0.08361204013377926
serumconcentrationsc,0.08361204013377926
auc0tlqc,0.08361204013377926
timeofmaximumserumconcentrationtmax,0.08361204013377926
areaunderthecurves08h,0.08361204013377926
percentageofresidualconcentration,0.08361204013377926
maximumpyrimethamineconcentration,0.08361204013377926
austyn,0.08361204013377926
interferonlevel,0.08361204013377926
areaundertheplasmapqconcentrationtimecurveauc0,0.08361204013377926
peakflowrate,0.08361204013377926
pqratio,0.08361204013377926
maximummilkintake,0.08361204013377926
momenthalflifetimetm12,0.08361204013377926
zerohalflifetimet12,0.08361204013377926
initialeliminationof14c,0.08361204013377926
auc0288,0.08361204013377926
steadystatetroughserumconcentration,0.08361204013377926
timetopositiveparasitemia,0.08361204013377926
terminaleliminationrateconstantkel,0.08361204013377926
maximumlorazepamconcentrationachievedduringsteadystate,0.08361204013377926
vd3,0.08361204013377926
timetomaximumplasmame,0.08361204013377926
recoveredradioactive,0.08361204013377926
peaktemozolomideconcentration,0.08361204013377926
timetoreachpeaklevel,0.08361204013377926
stablediseaserate,0.08361204013377926
phvalue,0.08361204013377926
nanoenc,0.08361204013377926
tph,0.08361204013377926
eliminationhalflifeofterminalexcretionphaset12lambdaz,0.08361204013377926
aucfromtimezeroextrapolatedtoinfinityaucinfinity,0.08361204013377926
columnlife,0.08361204013377926
volumeofthecentralcompartmentofvc,0.08361204013377926
apparentvolumeofdistributionvb,0.08361204013377926
systemicclearancerateclsf,0.08361204013377926
rateofspontaneousdetoxification,0.08361204013377926
transferratefromplasmatocsfkplasmacsf,0.08361204013377926
cc,0.08361204013377926
areaundertheplasmaconcentrationcurveaucfromtimezerotothetimeoflastquantifiableconcentrationauclast,0.08361204013377926
peakcsftemozolomideconcentration,0.08361204013377926
timetomycologicalcure,0.08361204013377926
halflifet12d,0.08361204013377926
timetomaximumconcentrationtmaxd,0.08361204013377926
terminalgammaphase,0.08361204013377926
finalelimination,0.08361204013377926
mycologicalcurerate,0.08361204013377926
completecurerate,0.08361204013377926
timetocompletecure,0.08361204013377926
maximumplasmaolopatadineconcentration,0.08361204013377926
maximumterbinafinelevel,0.08361204013377926
overallclinicalimprovementrate,0.08361204013377926
overallfungaleradicationrate,0.08361204013377926
initialterminalhalflifet12,0.08361204013377926
tissueterminalhalflife,0.08361204013377926
mlc,0.08361204013377926
backwardsrate,0.08361204013377926
areasunderthetemozolomideconcentrationtimecurve,0.08361204013377926
areaundercurveduringdosingintervalatsteadystate,0.08361204013377926
salivarylevel,0.08361204013377926
plasmasteadystatetroughvoriconazolelevel,0.08361204013377926
uvdetectionwavelength,0.08361204013377926
otherroute,0.08361204013377926
bloodplasma,0.08361204013377926
cl0120app,0.08361204013377926
sal,0.08361204013377926
salivaryhalflive,0.08361204013377926
peaktrfconcentration,0.08361204013377926
systemicwholebloodclearance,0.08361204013377926
fractionalavailability,0.08361204013377926
medicationpossessionratio,0.08361204013377926
timeformaximalserumconcentration,0.08361204013377926
plasmaconcentrationofdrug,0.08361204013377926
areaundertheconcentrationtimecurveextrapolatedtosteadystateaucss,0.08361204013377926
peaklcflevel,0.08361204013377926
auc0672h,0.08361204013377926
marrowrequiringdose,0.08361204013377926
eliminationrateconstantsfromtheeffectsite,0.08361204013377926
timestonadir,0.08361204013377926
timetorecover50ofthemaximumdrugeffectrt50,0.08361204013377926
peakzincconcentration,0.08361204013377926
maximalglibenclamideplasmaconcentration,0.08361204013377926
timetopeakglyburideconcentrationstmax,0.08361204013377926
peakplasmaglibenclamideconcentration,0.08361204013377926
redispersibilityindice,0.08361204013377926
auc0672,0.08361204013377926
timeofmaximumbloodglucoseresponse,0.08361204013377926
timeofmaximumresponse,0.08361204013377926
apparentvolumeofdistributioninthebetaphase,0.08361204013377926
systemicdrugclearance,0.08361204013377926
areasunderthebloodconcentrationtimecurvesauc0infinity,0.08361204013377926
metabolicdebtrepayment,0.08361204013377926
areaunderthecurveaucfromtime0to24h,0.08361204013377926
terminaldepositionhalflife,0.08361204013377926
drugdetention,0.08361204013377926
areaunderthecurvefor6hour,0.08361204013377926
molardosefraction,0.08361204013377926
areaunderthecurvefromtimezerototimeoflastquantifiableconcentrationauc0t,0.08361204013377926
halfemptyingtime,0.08361204013377926
totallarvalvolume,0.08361204013377926
peakblood14cformateconcentration,0.08361204013377926
enter,0.08361204013377926
apparentauc,0.08361204013377926
gastricemptyinghalftime,0.08361204013377926
halflivesofdistributiont12a,0.08361204013377926
braintoplasmaauc0240ratio,0.08361204013377926
ciiso,0.08361204013377926
druguptake,0.08361204013377926
centralvolumev2foral,0.08361204013377926
peripheralvolumeofdistributionv3foral,0.08361204013377926
cliot,0.08361204013377926
nonrenalelimination,0.08361204013377926
accumulatedpermeation,0.08361204013377926
motilityindex,0.08361204013377926
totalamountsofurinaryexcretion,0.08361204013377926
timetoreach90ofthesteadystateconcentration,0.08361204013377926
availabilityafterthefirstpasshepaticextraction,0.08361204013377926
apparentavailabilitie,0.08361204013377926
numberofcontraction,0.08361204013377926
amplitudeofcontraction,0.08361204013377926
timetoreachthepeakacetaminophenconcentration,0.08361204013377926
clearancenormalizedforbioavailabilityf,0.08361204013377926
maximalacetaminophenconcentration,0.08361204013377926
areaundertheconcentrationtimecurveat60min,0.08361204013377926
peaktroughfluctuation,0.08361204013377926
fbioavailability,0.08361204013377926
initialarterialtovenousconcentrationratio,0.08361204013377926
targeteffectcompartmentconcentration,0.08361204013377926
intercompartmentclearanceqforal,0.08361204013377926
tmaxtimetoreachmaximumplasmaconcentration,0.08361204013377926
bk1,0.08361204013377926
totalareaundertheconcentrationversustimecurvesauc,0.08361204013377926
timestopeakplasmalevel,0.08361204013377926
ratiocsfplasmaconcentration,0.08361204013377926
tissueplasmapartitioncoefficientkp,0.08361204013377926
unboundtotalclearance,0.08361204013377926
unboundsteadystatedistributionvolume,0.08361204013377926
uae,0.08361204013377926
peakstreptozotocinconcentration,0.08361204013377926
freesulfateconcentration,0.08361204013377926
firstorderreactionconstant,0.08361204013377926
clbile,0.08361204013377926
areaunderthecurveauc048hrs,0.08361204013377926
integratedgastricacidity,0.08361204013377926
areaunderthecurvefromtime0to24h,0.08361204013377926
sclevel,0.08361204013377926
plasmahalflivesofdistribution,0.08361204013377926
volumeofdistributionvalpha,0.08361204013377926
steadystateareaunderthecurveauc,0.08361204013377926
faecalrecoverie,0.08361204013377926
kpaucbrainaucplasma,0.08361204013377926
tsolgel,0.08361204013377926
cssmean,0.08361204013377926
steadystateparacetamolconcentrationcssmean,0.08361204013377926
fgfrate,0.08361204013377926
totalbodyclearancecif,0.08361204013377926
relativeextractionratio,0.08361204013377926
concentrationscav,0.08361204013377926
sulphationclearance,0.08361204013377926
glucuronidesulphateratio,0.08361204013377926
areaunderthecurveconcentrationtime,0.08361204013377926
absolutemetabolicclearance,0.08361204013377926
absolutevolumeofdistributionvd,0.08361204013377926
areaunderplasmaconcentrationstimecurve,0.08361204013377926
areaundercurvebetweenzeroandinfinity,0.08361204013377926
timetoreachmaximalconcentration,0.08361204013377926
apparentmaximumplasmaconcentrationscmax,0.08361204013377926
levelsatsteadystate,0.08361204013377926
slowdispositionhalflifevaluest12beta,0.08361204013377926
weightadjustedmaximumconcentrationcmax,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0to12hoursauc12,0.08361204013377926
fromtime0toinfinityaucinfinity,0.08361204013377926
relativebioavailabilityauc024h,0.08361204013377926
apparentplasmadisappearancehalflivest12,0.08361204013377926
fetaltomaternalbloodratio,0.08361204013377926
percentageentrapment,0.08361204013377926
mostprobablesize,0.08361204013377926
clearanceg,0.08361204013377926
trougha,0.08361204013377926
firstdosepeak,0.08361204013377926
maternalinfant,0.08361204013377926
peaktotroughconcentrationratiocmaxcmin,0.08361204013377926
distributionvolumel,0.08361204013377926
total48hurinaryrecovery,0.08361204013377926
id30,0.08361204013377926
diseaseduration,0.08361204013377926
intertissueclearance,0.08361204013377926
auc024concentration,0.08361204013377926
timeof,0.08361204013377926
volumesofdistributionin,0.08361204013377926
postplasmaconcentration,0.08361204013377926
stableplasmatroughconcentration,0.08361204013377926
chromatographictime,0.08361204013377926
icrcl,0.08361204013377926
ccrit,0.08361204013377926
criticalareaunderthecurvein24hoursatsteadystate,0.08361204013377926
percentdoserecovered,0.08361204013377926
maximumacyclovirconcentration,0.08361204013377926
auc12areaundertheconcentrationtimecurveovera12h,0.08361204013377926
50growthinhibitoryconcentrationsic50,0.08361204013377926
eliminationhalflivest12k10,0.08361204013377926
areaunderthefreecarboplatinplasmaconcentrationversustimecurve,0.08361204013377926
timeforsecondpeakconcentrationtmax2,0.08361204013377926
terminalphaseeliminationrateconstantkel,0.08361204013377926
apparentfirstorderabsorptionka,0.08361204013377926
areaundertheblooddrugconcentrationtimecurveauc,0.08361204013377926
apparentfirstorderrate,0.08361204013377926
apparentfirstorderintercompartmentaltransferrateconstantsk10,0.08361204013377926
areaunderthecurvefromzerotoinfinityauc072,0.08361204013377926
freeauc0infinity,0.08361204013377926
midminimumdose,0.08361204013377926
freecmax,0.08361204013377926
fractionunbounddrug,0.08361204013377926
dominanthalflifeofelimination,0.08361204013377926
plasmat12z,0.08361204013377926
volumeofdistributionatterminalphasevz,0.08361204013377926
t11beta,0.08361204013377926
timetofirstoccurrenceofcmaxtmax,0.08361204013377926
rateconstantfromtheperipheraltothecentralcompartment,0.08361204013377926
expo,0.08361204013377926
peakplasmaacvconcentration,0.08361204013377926
peakbreastmilkconcentration,0.08361204013377926
t85,0.08361204013377926
apparentmaximumunboundconcentration,0.08361204013377926
troughprefilter,0.08361204013377926
steadystatevalue,0.08361204013377926
timecorrespondingto80dissolutiont80,0.08361204013377926
timetomaximumserumdrugconcentration,0.08361204013377926
rateconstantfromthecentraltotheperipheralcompartment,0.08361204013377926
timetopeakserumganciclovirconcentration,0.08361204013377926
maximumtearfamciclovirconcentration,0.08361204013377926
maximumtearpenciclovirconcentration,0.08361204013377926
peakacyclovirplasmalevel,0.08361204013377926
clearancefor,0.08361204013377926
peakplasmaganciclovirconcentration,0.08361204013377926
aumc0,0.08361204013377926
timetoreachmaximumconcentrationofdrug,0.08361204013377926
minimumsteadystateconcentrationcmin,0.08361204013377926
auctm,0.08361204013377926
reverse,0.08361204013377926
steadystateplasmalactoneconcentration,0.08361204013377926
steadystateconcentrationsoftopotecancss,0.08361204013377926
csstot,0.08361204013377926
ventricularlactoneconcentration,0.08361204013377926
ipauc,0.08361204013377926
aucoftheclosedringformaucclosed,0.08361204013377926
maximumaqueoushumorconcentrationcmax,0.08361204013377926
aucoftheringopenedformaucopen,0.08361204013377926
maximumtotaltopotecanconcentration,0.08361204013377926
apparentvss,0.08361204013377926
t12formation,0.08361204013377926
relativetumoruptakeratio,0.08361204013377926
slp,0.08361204013377926
forward,0.08361204013377926
lactoneclearance,0.08361204013377926
0to24h,0.08361204013377926
secondphasehalflive,0.08361204013377926
opticnervetoplasmaratio,0.08361204013377926
ecftoplasmadistributionratio,0.08361204013377926
observedauc,0.08361204013377926
volumeofdistributionvdatsteadystate,0.08361204013377926
oralbioavailablity,0.08361204013377926
maximumtotalplasmatopotecanconcentration,0.08361204013377926
totalplasmatopotecan,0.08361204013377926
timetomaximumplasmaconcentrationafteroraladministrationtmax,0.08361204013377926
halflifeoftheterminalpartofthecurve,0.08361204013377926
clearancefromventricularcsf,0.08361204013377926
peaklumbarconcentration,0.08361204013377926
volumevcf,0.08361204013377926
peaksecretion,0.08361204013377926
cumulativeefflux,0.08361204013377926
timeneededtoreachmaximalplasmalevel,0.08361204013377926
betahalflivesofelimination,0.08361204013377926
fetalplasmacmax,0.08361204013377926
areaunderthecurveat024hoursauc024,0.08361204013377926
timerequiredtoreachcmaxtmax,0.08361204013377926
acc,0.08361204013377926
percentdrugentrapmentefficiency,0.08361204013377926
releaseof,0.08361204013377926
totalturnaroundtime,0.08361204013377926
peakacyclovirlevel,0.08361204013377926
steadystateaverageserumconcentration,0.08361204013377926
peakacvlevel,0.08361204013377926
overallhalflivesofeliminationfromthecentralcompartmentt12,0.08361204013377926
areaundertheplasmaconcentrationvstimecurvesfromtime0to24hauc024,0.08361204013377926
timetoreachthemaximumplasmaconcentrationstmax,0.08361204013377926
inhibitorydoses50id50,0.08361204013377926
areaunderthedrugconcentrationtimecurveauctarget,0.08361204013377926
clearancefromtheaqueoushumour,0.08361204013377926
peakacyclovirconcentration,0.08361204013377926
circulatingplasmaconcentrationcmax,0.08361204013377926
peakacyclovirplasmaconcentration,0.08361204013377926
observedmaximumserumganciclovirconcentration,0.08361204013377926
auc0brainauc0plasmaratio,0.08361204013377926
timetoviralclearance,0.08361204013377926
timetoreachtargetauc,0.08361204013377926
areaundertheconcentrationtimecurvefromdrugadministrationtolastobservedconcentrationafter12hoursauc012,0.08361204013377926
halflifeoftherapideliminationphase,0.08361204013377926
maximummeanplasmaconcentrationscmax,0.08361204013377926
effectivedrugconcentration,0.08361204013377926
observedmaximumserumacvconcentrationcmax,0.08361204013377926
extractioncoefficient,0.08361204013377926
peakganciclovirconcentration,0.08361204013377926
halflifeofitsbetaphaseofelimination,0.08361204013377926
volumeofdistributionbioavailabilityvdf,0.08361204013377926
apparenttotalsystemicclearanceclf,0.08361204013377926
oxidation,0.08361204013377926
sulfation,0.08361204013377926
er50,0.08361204013377926
peakseruminterferonconcentration,0.08361204013377926
uar,0.08361204013377926
toplasmacmaxpeakconcentrationratio,0.08361204013377926
peakplasmaprednisoloneconcentration,0.08361204013377926
timetopeakconcentrationtmaxss,0.08361204013377926
areaunderconcentrationtimecurvefromzerototimeoflast,0.08361204013377926
tototalserumconcentrationratio,0.08361204013377926
penetrationhalftime,0.08361204013377926
maximumltgconcentration,0.08361204013377926
csftototalserumconcentrationratio,0.08361204013377926
penetrationhalftimeintocsf,0.08361204013377926
maximumplasmaprednisoloneconcentration,0.08361204013377926
apparentltgclearanceclf,0.08361204013377926
intolerability,0.08361204013377926
rateoftotalbodyclearance,0.08361204013377926
salivaserumconcentrationratio,0.08361204013377926
maximummeasuredplasmaisoflupredoneconcentration,0.08361204013377926
overallplasmaeliminationt12,0.08361204013377926
vdvt,0.08361204013377926
t13,0.08361204013377926
areaunderthecurvefrom0toinfinityauc0infinity,0.08361204013377926
nitricoxideuptake,0.08361204013377926
pao2fio2,0.08361204013377926
dynamiclungcompliancecdyn,0.08361204013377926
pulmonaryvascularresistanceindexpvri,0.08361204013377926
halflifeforliverretention,0.08361204013377926
aucunboundprednisolone,0.08361204013377926
peaknitricoxidemetabolitesconcentration,0.08361204013377926
clearanceperfractionofdoseabsorbed,0.08361204013377926
peakplasmabutorphanolconcentration,0.08361204013377926
timetopeakplasmadrugconcentrationtmax,0.08361204013377926
adma,0.08361204013377926
plasmaproteinbindingatsteadystate,0.08361204013377926
areaunderthedrugconcentrationinaqueoushumorvstimecurve,0.08361204013377926
totalurinaryrecoveryofdrug,0.08361204013377926
urinaryexcretionrateofdrug,0.08361204013377926
apparentdailyclearance,0.08361204013377926
supplyrate,0.08361204013377926
capacityfactork,0.08361204013377926
numberoftheoreticalplate,0.08361204013377926
brainpenetrationhalftime,0.08361204013377926
apparenthalflifeoftheterminalphase,0.08361204013377926
percenturinaryexcretion,0.08361204013377926
firstdose,0.08361204013377926
volumesofthecentral,0.08361204013377926
renalclearanceclt,0.08361204013377926
volumeofdistributionvcvolumeofdistributionofcentralcompartment,0.08361204013377926
halflifeofdistributionphase,0.08361204013377926
maximumrise,0.08361204013377926
serumthiopentalconcentration,0.08361204013377926
maximumarterialplasmathiopentalconcentration,0.08361204013377926
permeabilityflowratio,0.08361204013377926
maximumrateofeliminationvm,0.08361204013377926
plasmaconcentrationratio2nglucltg,0.08361204013377926
apparentlamotrigineoralclearance,0.08361204013377926
doseplasmaconcentrationratiodc,0.08361204013377926
metabolismrateconstantskmblood,0.08361204013377926
rateofpartialseizuresper,0.08361204013377926
kabs,0.08361204013377926
oralbodyclearanceclf,0.08361204013377926
logoctanolwaterpartitioncoefficientslogpvalues,0.08361204013377926
ratioofmilktoplasmaconcentration,0.08361204013377926
absolutebioavailabilityfraction,0.08361204013377926
clfs,0.08361204013377926
halftimeoftheinitialphase,0.08361204013377926
timefordisappearance,0.08361204013377926
systemicplasmaclearanceclp,0.08361204013377926
initialdistributionvolumev1,0.08361204013377926
hepaticenzymesaturation,0.08361204013377926
areaundertheconcentrationversustimecurveaucfromtimezerotoinfinityauc0infinity,0.08361204013377926
aucfromtimezerotothedosingintervalauc0tau,0.08361204013377926
residualm,0.08361204013377926
drugexposure,0.08361204013377926
volumesofdistributioninthecentralcompartmentv1,0.08361204013377926
apparentfirstorderhalflife,0.08361204013377926
caucendoscopy,0.08361204013377926
dissociationconstantkss,0.08361204013377926
t12lambda1oral,0.08361204013377926
fel,0.08361204013377926
mrt01,0.08361204013377926
steadystatelorazepamlevel,0.08361204013377926
saccadiclatency,0.08361204013377926
sauc,0.08361204013377926
kint,0.08361204013377926
peakplasmathcconcentration,0.08361204013377926
troughifxlevel,0.08361204013377926
apparentvolumesofdistributioninthecentralv1,0.08361204013377926
baselineclearance,0.08361204013377926
maximumpredictedeffectemax,0.08361204013377926
timetohalfrecovery,0.08361204013377926
areaunderthecurveratioaucr,0.08361204013377926
hepaticbloodclearance,0.08361204013377926
steadystatebloodvolumeofdistribution,0.08361204013377926
plasmadrugconcentrationproducing50ofmaximaleffectec50,0.08361204013377926
timetoreachthemaximaldrugconcentration,0.08361204013377926
timetopeakplasmaconcentrationsatsteadystate,0.08361204013377926
apparentcomparablehalflife,0.08361204013377926
overallresponseratesorrs,0.08361204013377926
initialhalflivest12alpha,0.08361204013377926
timeneededtoreachthepeakconcentration,0.08361204013377926
halflivesareaunderthecurve,0.08361204013377926
aucfigure,0.08361204013377926
apparentvolumeofdistributionderivedfromauc,0.08361204013377926
halflifeoftheinitialalphaphaseofdistribution,0.08361204013377926
terminalbiologicalhalflife,0.08361204013377926
troughseruminfliximabconcentration,0.08361204013377926
withdrawal,0.08361204013377926
volumeofdistributionn,0.08361204013377926
formationrateconstantka,0.08361204013377926
totsil,0.08361204013377926
lowerlimitofdetectionllod,0.08361204013377926
timeofmaximumobservedconcentrationtmax,0.08361204013377926
oralbioavailabilityfpo,0.08361204013377926
normalizedareaunderthecurvefor8hauc08,0.08361204013377926
aucdn,0.08361204013377926
pulmonaryvascularresistance,0.08361204013377926
aucat168h,0.08361204013377926
aucs024h,0.08361204013377926
fractionalclearancerate,0.08361204013377926
timetoachievethispeak,0.08361204013377926
halflifeoftheterminalslope,0.08361204013377926
cmaxofradioactivity,0.08361204013377926
feno,0.08361204013377926
teac,0.08361204013377926
selfdispersiontime,0.08361204013377926
rateconstantfromthecentraltoperipheralcompartment,0.08361204013377926
auctdn,0.08361204013377926
poreradiusdvr,0.08361204013377926
maximaltime,0.08361204013377926
span,0.08361204013377926
weightadjustedapparentvolumeofdistributionvdf,0.08361204013377926
weightadjustedapparenttotalbodyclearanceclf,0.08361204013377926
q6h,0.08361204013377926
electricalconductivity,0.08361204013377926
aucmetaboliteatvratio,0.08361204013377926
areaundertheconcentrationtimecurvefromtime0toinfinityauc0infinity,0.08361204013377926
glucoseinfusionrate,0.08361204013377926
totalglucoseinfusion,0.08361204013377926
partial,0.08361204013377926
populationdistribution,0.08361204013377926
ta12,0.08361204013377926
timetoreachearlyburstsuppression,0.08361204013377926
effectivethiopentalconcentration,0.08361204013377926
c45,0.08361204013377926
maximumserumacetaminophenconcentration,0.08361204013377926
timetomaximumserumacetaminophenconcentration,0.08361204013377926
unboundfractionatsteadystate,0.08361204013377926
plasmaconcentrationtc,0.08361204013377926
hepaticmetabolicclearance,0.08361204013377926
gastricemptyingt12,0.08361204013377926
timetoachieve50ofsteadystatelevel,0.08361204013377926
biologicalhalflifeofrapiddistributiont12alpha,0.08361204013377926
peaktotalvenousdpconcentration,0.08361204013377926
maximumparacetamolplasmaconcentrationscmax,0.08361204013377926
truerelativebioavailability,0.08361204013377926
cmaxmaximumcomcentration,0.08361204013377926
auc0tareaundertheconcentrationtimecurve,0.08361204013377926
t12keleliminationhalflife,0.08361204013377926
timeforinput,0.08361204013377926
totalclearanceofpclt,0.08361204013377926
formationclearanceratio,0.08361204013377926
aucfree09,0.08361204013377926
affinityconstantkm,0.08361204013377926
areaunderconcentrationcurve,0.08361204013377926
totalbodyclearancescl,0.08361204013377926
terminaleliminationrateconstantofunbounddrug,0.08361204013377926
halflivesofhepaticuptake,0.08361204013377926
halflifeofhepaticuptake,0.08361204013377926
24hserumconcentration,0.08361204013377926
timeofpeakserumconcentration,0.08361204013377926
maximumentrapment,0.08361204013377926
intrinsicclearanceievmaxkm,0.08361204013377926
dosenormalizedauc0t,0.08361204013377926
logpow,0.08361204013377926
troughplasmaconcentrationcmin,0.08361204013377926
formationclearanceof,0.08361204013377926
apparentrelativebioavailability,0.08361204013377926
totalrenalexcretionrate,0.08361204013377926
plasmahalflifebetat2,0.08361204013377926
eliminationphasekineticparameter,0.08361204013377926
maximumpainreliefscore,0.08361204013377926
effectcompartmentconcentrationat50maximum,0.08361204013377926
cmaxhaparatio,0.08361204013377926
hydrolyzedplasmaconcentration,0.08361204013377926
oxidationclearance,0.08361204013377926
timeofdrugdisappearance,0.08361204013377926
kelt12el,0.08361204013377926
terminalplasmaeliminationhalflifet12beta,0.08361204013377926
timesrequiredtoreachthemaximumconcentrationtmax,0.08361204013377926
steadystateconcentrationcssmean,0.08361204013377926
aumc5,0.08361204013377926
apparentparacetamolclearance,0.08361204013377926
analysistimeperinjection,0.08361204013377926
maximalfractionalsodiumexcretion,0.08361204013377926
rateconstantfortheelimination,0.08361204013377926
urinetoplasmapara,0.08361204013377926
halflifel,0.08361204013377926
minimalczplevel,0.08361204013377926
maximummeasuredplasmaconcentrationtmax,0.08361204013377926
iauc,0.08361204013377926
oralextractionratio,0.08361204013377926
activatedcharcoaldrugratio,0.08361204013377926
auc000,0.08361204013377926
epa,0.08361204013377926
timetoattainthispeak,0.08361204013377926
eliminationhalflifeofunboundconcentration,0.08361204013377926
eliminationrateconstantskes,0.08361204013377926
totalplasmaacetaminophenclearance,0.08361204013377926
clufunboundclearancedividedbybioavailability,0.08361204013377926
unboundsteadystatevolumeofdistribution,0.08361204013377926
gastrictransittime,0.08361204013377926
cmaxtotroughconcentrationratio,0.08361204013377926
urineclearance,0.08361204013377926
steadystatethiopentalconcentration,0.08361204013377926
measurablelowestconcentration,0.08361204013377926
fractionofthiopentallossfromthecentralcompartment,0.08361204013377926
minimumsalivaflow,0.08361204013377926
timeduration,0.08361204013377926
lengthof,0.08361204013377926
maximalatropineconcentrationcmax,0.08361204013377926
eliminationt12betahalflife,0.08361204013377926
t123,0.08361204013377926
constantratevalue,0.08361204013377926
varead,0.08361204013377926
total14crecovery,0.08361204013377926
cumulative14cradioactivityexcreted,0.08361204013377926
eliminationhalflifet123,0.08361204013377926
apparentserumclearance,0.08361204013377926
physicalhalflife,0.08361204013377926
effectsiterateconstant,0.08361204013377926
halflifeoftheelimination,0.08361204013377926
bioavailabilityover6hoursauc06,0.08361204013377926
peakplasmaatropineconcentration,0.08361204013377926
terminalhalflifewast12beta,0.08361204013377926
timetomaximumplasmahi6concentrationtmax,0.08361204013377926
absorptionhalflifet2a,0.08361204013377926
apparenteliminationhalflifet2e,0.08361204013377926
urinaryexcretionofunchangeddrug,0.08361204013377926
maximalratiosoftotaltononspecificuptake,0.08361204013377926
percentagebound,0.08361204013377926
protection,0.08361204013377926
peakserumatropineconcentration,0.08361204013377926
peakconcentrationscmaxobs,0.08361204013377926
steadystatetroughplasmaconcentrationcminobs,0.08361204013377926
maximumrateofeliminationvmax,0.08361204013377926
lct50,0.08361204013377926
meansurvivaltime,0.08361204013377926
lnratio,0.08361204013377926
apparentterminaleliminationrateconstant,0.08361204013377926
retainedma,0.08361204013377926
timetoreacht025m,0.08361204013377926
totalfluorescence,0.08361204013377926
minimumsteadystatelevel,0.08361204013377926
maximumcanrenoneplasmalevel,0.08361204013377926
capillarypermeabilityareaproduct,0.08361204013377926
apparentmedianterminaleliminationrateconstantsassociatedhalflives,0.08361204013377926
minimalparasiticidalconcentration,0.08361204013377926
onsetofgastricemptying,0.08361204013377926
24houraucratio,0.08361204013377926
clearanceiv,0.08361204013377926
apparentclearancesc,0.08361204013377926
t12iv,0.08361204013377926
halftimeofaneffectcompartment,0.08361204013377926
plasmaconcentrationcavg,0.08361204013377926
formationrate,0.08361204013377926
transportefficiency,0.08361204013377926
totaldelivery,0.08361204013377926
apparentfirstorderrateconstantskobs,0.08361204013377926
sodiumpotassiumratio,0.08361204013377926
poststeadystateeliminationhalflifet12,0.08361204013377926
maximumaveragepeakconcentrationcmax,0.08361204013377926
maximumaverage,0.08361204013377926
maximumaveragecmax,0.08361204013377926
maximumaverageplasmaconcentration,0.08361204013377926
areasunderthecurvewithin72hour,0.08361204013377926
maximumeliminationratevmax,0.08361204013377926
cma2,0.08361204013377926
areaundertheconcentrationcurvefrom0to6hoursauc06,0.08361204013377926
areaunderthedocetaxelplasmaconcentrationtimecurveextrapolatedtoinfinityauc,0.08361204013377926
concentrationathalfofthevmaxkm,0.08361204013377926
auc0max,0.08361204013377926
peaksofplasmaconcentrationcmax,0.08361204013377926
eliminationratekel,0.08361204013377926
aucmic90,0.08361204013377926
bioavailablelng,0.08361204013377926
areasunderdrugconcentrationtimecurveaucratio,0.08361204013377926
auc07day,0.08361204013377926
volumeinfused,0.08361204013377926
areaunderthe8c2plasmaconcentrationtimecurveforthelengthofthestudyauc014d,0.08361204013377926
thirdcompartmentph,0.08361204013377926
eliminationhalflivest12s,0.08361204013377926
troughverapamilconcentrationscmin,0.08361204013377926
populationoralclearance,0.08361204013377926
troughplasmaaatlevel,0.08361204013377926
distributionhalflifealpha,0.08361204013377926
globalextractionratio,0.08361204013377926
salivaplasmaspratio,0.08361204013377926
dmotmoratio,0.08361204013377926
ovulationrate,0.08361204013377926
maximalserumprogesteronelevel,0.08361204013377926
plasmahalflifetimeofclearancet12,0.08361204013377926
ce05,0.08361204013377926
areaundertheplasmaconcentrationtimecurveinsteadystateaucss,0.08361204013377926
maximumaminoguanidineconcentrationcmax,0.08361204013377926
percentageofdoseexcretedin,0.08361204013377926
totalverapamil,0.08361204013377926
sustained,0.08361204013377926
peakplasma17aagconcentration,0.08361204013377926
transepithelialpermeabilityratio,0.08361204013377926
emaxdpressure,0.08361204013377926
timetoreachmaximumplasmaconcentrationfollowingdrugadministrationtmax,0.08361204013377926
maximalsverapamilconcentration,0.08361204013377926
effectivet12,0.08361204013377926
biovailabilitynormalizedclearance,0.08361204013377926
totalmeanabsorptiontime,0.08361204013377926
clearanceofdarbe,0.08361204013377926
absorptionrateieka,0.08361204013377926
halflifeofdarbepoetint12,0.08361204013377926
accumulationfactorrac,0.08361204013377926
e1,0.08361204013377926
pmax,0.08361204013377926
vmaxsec,0.08361204013377926
kmsec,0.08361204013377926
peakserumprogesteroneconcentration,0.08361204013377926
serumprogesteroneconcentration,0.08361204013377926
t12ofthedistributionphase,0.08361204013377926
vdofthecentralcompartmentvda,0.08361204013377926
vdintheperipheralcompartmentvdb,0.08361204013377926
auc0tauc0,0.08361204013377926
apparentvolumeofdistributionofthemetabolitecompartmentv3f,0.08361204013377926
steadystateplasmaconcentrationscmax,0.08361204013377926
tissuearterialbloodratio,0.08361204013377926
kmmet2,0.08361204013377926
vmaxmet2,0.08361204013377926
kmmet1,0.08361204013377926
maximumprogesteroneconcentrationcmax,0.08361204013377926
apparentclearanceofthemetaboliteclmf,0.08361204013377926
apparentintercompartmentalclearanceqf,0.08361204013377926
drugloadingcapability,0.08361204013377926
areaunderthecurveauc0720min,0.08361204013377926
timetoreachpeakbloodleveltmax,0.08361204013377926
bodyclearancec1b,0.08361204013377926
areasunderthesalivaryprogesteronecurveauc024h,0.08361204013377926
maximumconcentrationsofvilaprisancmax,0.08361204013377926
exposuretovilaprisanauc,0.08361204013377926
auc024mdauc024,0.08361204013377926
auc0720,0.08361204013377926
apparentvolumeofdistributionforthecentralcompartmentv2f,0.08361204013377926
timetomaximumsalivaconcentrationstmax,0.08361204013377926
aucestradiol,0.08361204013377926
fastcomponenthalflife,0.08361204013377926
aucvaucmratioaucr,0.08361204013377926
hepaticclearanceofverapamilcllver,0.08361204013377926
steadystatemaximumconcentrationcmax,0.08361204013377926
areaundertheconcentrationtimecurvefrom021hoursauc021,0.08361204013377926
timestopeakincrease,0.08361204013377926
apparentoralclearanceclo,0.08361204013377926
maximaleffectec50,0.08361204013377926
areaundertheplasmaconcentrationtimecurveduringthe12hdoseintervalauc012h,0.08361204013377926
peakprilocaineconcentration,0.08361204013377926
druginputrate,0.08361204013377926
activityfactor,0.08361204013377926
absorptivepapp,0.08361204013377926
maximaleffectinloweringtheiopemax,0.08361204013377926
fluidtoultrafiltrate,0.08361204013377926
talpha12,0.08361204013377926
chloride,0.08361204013377926
fractionalfreewaterclearance,0.08361204013377926
osmolarity,0.08361204013377926
ultrafiltrateconcentration,0.08361204013377926
areaunderthepercentchangeinprvstimecurve,0.08361204013377926
timetomaximalprolongation,0.08361204013377926
tabs12,0.08361204013377926
maximalprilocaineserumlevel,0.08361204013377926
eliminationoft12z,0.08361204013377926
areaundertheconcentrationtimecurvefromzerotoinfinityauc0inf,0.08361204013377926
ex130,0.08361204013377926
percentageofmaximaldecline,0.08361204013377926
mbobs,0.08361204013377926
gelationtime,0.08361204013377926
peakprprolongation,0.08361204013377926
peakbpreduction,0.08361204013377926
totalareaundertheplasmaconcentrationtimecurvefromzerotoinfinityauc,0.08361204013377926
plasmaclearancew,0.08361204013377926
halflifeforthedistributionphaset12a,0.08361204013377926
areaunderthetimeconcentrationcurve0to12hours,0.08361204013377926
plasmameanhalflife,0.08361204013377926
particlediameter,0.08361204013377926
timeofdefecation,0.08361204013377926
maximumplasmaconcentrationofmesalazinecmax,0.08361204013377926
sfserumconcentrationratio,0.08361204013377926
percentageproteinbinding,0.08361204013377926
totalthroughnaproxenconcentration,0.08361204013377926
freefractionsrfxratio,0.08361204013377926
place,0.08361204013377926
pappab,0.08361204013377926
steadystateflx,0.08361204013377926
norflx,0.08361204013377926
minimumplasmaticconcentration,0.08361204013377926
auc0192h,0.08361204013377926
totalverapamilclearance,0.08361204013377926
plasmaconcentrationcave,0.08361204013377926
rfbinh,0.08361204013377926
plasmaexposuresauc,0.08361204013377926
vascularinterstitialpermeabilitysurfaceareaproduct,0.08361204013377926
halflifeofendogenousproteinturnover,0.08361204013377926
steadystatedistributionvolumevssf,0.08361204013377926
relativebioavailabilityaucsraucc,0.08361204013377926
metabolitetodrugratio,0.08361204013377926
pappba,0.08361204013377926
timereachmaximumconcentrationtmax,0.08361204013377926
ventricularrateatpeakplasmaverapamilconcentration,0.08361204013377926
peakverapamilserumconcentration,0.08361204013377926
minimumthreshold,0.08361204013377926
notbound,0.08361204013377926
distributionvolumesatequilibrium,0.08361204013377926
volumeofdistributionduringtheterminaleliminationphasevdbeta,0.08361204013377926
plasmahalflifeofthebetaphase,0.08361204013377926
timefor70dissolutiont70,0.08361204013377926
areaauc0infinityundertheplasmaconcentrationtimecurve,0.08361204013377926
timetmaxtoreachpeakconcentration,0.08361204013377926
aucu012,0.08361204013377926
steadystateunboundplasmadrugconcentration,0.08361204013377926
unboundclearancebioavailability,0.08361204013377926
totalplasmaclearancebioavailabilityclf,0.08361204013377926
areaunderthecurveauc0720,0.08361204013377926
vmaxmet1,0.08361204013377926
logpbutanolwater,0.08361204013377926
cls1,0.08361204013377926
eliminationrateperminute,0.08361204013377926
plasmaticcmax,0.08361204013377926
regressionoftolerance,0.08361204013377926
tissuebloodconcentrationratio,0.08361204013377926
semenbloodconcentrationratio,0.08361204013377926
areaundertheserumcaffeineconcentrationtimecurveauc0infinity,0.08361204013377926
vs1,0.08361204013377926
plasmatg,0.08361204013377926
last,0.08361204013377926
eliminationhalflifet12lambda,0.08361204013377926
effectiverate,0.08361204013377926
bacteriaclearancerate,0.08361204013377926
overallbreastmilkplasmaratio,0.08361204013377926
plasmatimetopeak,0.08361204013377926
aucareaunderthecurveaboveminimumeffectiveconcentration,0.08361204013377926
apparentfirstordereliminationrateconstant,0.08361204013377926
mediummaintenanceresidualrate,0.08361204013377926
concentrationsincsf,0.08361204013377926
areasundertheenrichmenttimecurve,0.08361204013377926
lagtimeafteroraladministration,0.08361204013377926
overallbloodeliminationhalflife,0.08361204013377926
fatox,0.08361204013377926
oxygenconsumption,0.08361204013377926
freefractionfp,0.08361204013377926
ke1,0.08361204013377926
maximumofloxacinconcentration,0.08361204013377926
peakserumofloxacinconcentration,0.08361204013377926
fractionexcretedunchangedinurine,0.08361204013377926
auc115,0.08361204013377926
areaundertheserumconcentrationtimecurvexeliminationrateconstantaucxke,0.08361204013377926
dosenormalizedareaundertheplasmaconcentrationversu,0.08361204013377926
areaundertheplasmaegcgconcentrationtimecurveauc,0.08361204013377926
timetopeakconcentrationofofloxacininserumcmax,0.08361204013377926
mediumloadingresidualrate,0.08361204013377926
auc0to720,0.08361204013377926
serumofloxacinconcentrationpeak,0.08361204013377926
timetoreachthatpeaktmax,0.08361204013377926
salivatoplasmaconcentrationratiocscp,0.08361204013377926
timetopeakanc,0.08361204013377926
apparentatsteadystate,0.08361204013377926
peakvitreouslevel,0.08361204013377926
peakaqueoushumorlevel,0.08361204013377926
volumeofdistributionf,0.08361204013377926
serumconcentrationscmax,0.08361204013377926
timetoleukocyterecovery,0.08361204013377926
hill,0.08361204013377926
timetomaximumconcentrationofdruginserum,0.08361204013377926
term,0.08361204013377926
systemclearancecl,0.08361204013377926
apparentvolumeofdistributionrelatedtoweightv,0.08361204013377926
fastingplasmaconcentration,0.08361204013377926
mrtti,0.08361204013377926
maximaltroughcaffeineconcentration,0.08361204013377926
volumeofdistributionbodyweight,0.08361204013377926
salivary,0.08361204013377926
serumca,0.08361204013377926
areaunderthetimecurvemicratio,0.08361204013377926
braint12,0.08361204013377926
timeresolution,0.08361204013377926
apparentvolumeofdistributionbodyweight,0.08361204013377926
recoverypercent,0.08361204013377926
maximumconcentrationintheblood,0.08361204013377926
infectionresolutionrate,0.08361204013377926
hospitalsurvivalrate,0.08361204013377926
tonsilserumratio,0.08361204013377926
peakoxygenconsumptionvo2peak,0.08361204013377926
firstserumconcentration,0.08361204013377926
vo2,0.08361204013377926
cpdr,0.08361204013377926
maximumconcentrationinbonecmax,0.08361204013377926
bonebioavailability,0.08361204013377926
areaunderlocalconcentrationtimecurve,0.08361204013377926
maximaltimeconcentration,0.08361204013377926
timetoreachdoxepinmaximumplasmaconcentrationtmax,0.08361204013377926
areaunderthecurve048h,0.08361204013377926
volumeofdistributionbytheareamethodvarea,0.08361204013377926
volumeofdistributionoftheplasmacompartment,0.08361204013377926
areasundertheserumconcentrationtimecurvesauc028,0.08361204013377926
c1csratio,0.08361204013377926
halflivesoftheterminalbetaphase,0.08361204013377926
aucs024,0.08361204013377926
aucs024s,0.08361204013377926
totalplasmaclearancedividedbyavailability,0.08361204013377926
volumeofdistributiondividedbyavailability,0.08361204013377926
flowinjection,0.08361204013377926
bodyclearancerate,0.08361204013377926
percentageoftotaldoserecovered,0.08361204013377926
limitofmsdetection,0.08361204013377926
peakofloxacinlevel,0.08361204013377926
prb,0.08361204013377926
sustain,0.08361204013377926
vmaternalf,0.08361204013377926
mothertocordrateconstant,0.08361204013377926
totalmeanresidencetime,0.08361204013377926
peakplasmapconcentration,0.08361204013377926
mcrb,0.08361204013377926
aucssday10,0.08361204013377926
limitofuvdetection,0.08361204013377926
totalurinaryexcretion024h,0.08361204013377926
overallmeanrenalclearance,0.08361204013377926
normalizedurinaryrecovery,0.08361204013377926
areaundertheplasmaconcentrationtimecurveatsteadystate,0.08361204013377926
maximumplasmadiflunisalconcentration,0.08361204013377926
transitrateconstant,0.08361204013377926
prostateplasmaratio,0.08361204013377926
peritonealdrugconcentration,0.08361204013377926
fractionalinhibitoryconcentration,0.08361204013377926
maximumaptt,0.08361204013377926
reabsorptionfractionfb,0.08361204013377926
db,0.08361204013377926
percentunboundpiroxicam,0.08361204013377926
inc,0.08361204013377926
aud024aptt,0.08361204013377926
clearanceper,0.08361204013377926
betahalflifeofelimination,0.08361204013377926
areaabovethe,0.08361204013377926
alphahalflifeofdistribution,0.08361204013377926
penetrationinto,0.08361204013377926
ratesofabsorption,0.08361204013377926
areasunderthecurvefromzerotoinfinityauc0infinity,0.08361204013377926
maximumuptake,0.08361204013377926
bonebloodratio,0.08361204013377926
cmedss,0.08361204013377926
troughsteadystatelevel,0.08361204013377926
maximumaverageboneconcentration,0.08361204013377926
intercompartmentalt12,0.08361204013377926
excretionmetabolisationt12,0.08361204013377926
totalauc24hmicratio,0.08361204013377926
troughserumofxconcentration,0.08361204013377926
mic70,0.08361204013377926
peakserumpiroxicamconcentration,0.08361204013377926
aucsaaucpl,0.08361204013377926
systemicauc,0.08361204013377926
14c,0.08361204013377926
t12hd,0.08361204013377926
overallcurerate,0.08361204013377926
totalamountlost,0.08361204013377926
timestomaximalserumconcentrationtmax,0.08361204013377926
steadystateplasmapiroxicamconcentration,0.08361204013377926
ex4,0.08361204013377926
activityindex,0.08361204013377926
peakplasmaclzconcentrationcmax,0.08361204013377926
tbcf,0.08361204013377926
maximaldrugplasmaconcentration,0.08361204013377926
peakmebendazoleconcentration,0.08361204013377926
lognumber,0.08361204013377926
peakfetalplasmaconcentration,0.08361204013377926
apparentfetaleliminationhalflife,0.08361204013377926
halflivesoftheabsorption,0.08361204013377926
auctau0,0.08361204013377926
aucmilkaucplasma,0.08361204013377926
aucrraucssratio,0.08361204013377926
areaundertheconcentrationtimecurveaucdosex1000,0.08361204013377926
dosecorrectedaucaucdosex1000,0.08361204013377926
clmp,0.08361204013377926
clmn,0.08361204013377926
auc48hours,0.08361204013377926
braintoplasmabpratio,0.08361204013377926
areaunderthedrugconcentrationtimecurveauc0,0.08361204013377926
ratioofaucfrom0to24hour,0.08361204013377926
effectiveplasmahalflifeofaccumulationatsteadystate,0.08361204013377926
bloodcelltoplasmapartitioning,0.08361204013377926
phasetransitiontemperature,0.08361204013377926
plasmaclearancedpc,0.08361204013377926
retentiontimefrom0totimemrt0t,0.08361204013377926
processefficiencie,0.08361204013377926
freefractionofdrugf,0.08361204013377926
percentageofinjecteddose,0.08361204013377926
apparenttotalbiliaryclearance,0.08361204013377926
auc0loq,0.08361204013377926
noael,0.08361204013377926
absorptionhalflifek01hl,0.08361204013377926
eliminationhalflivesk10hl,0.08361204013377926
phpeakactivity,0.08361204013377926
apparentrateofclearance,0.08361204013377926
auc42hours,0.08361204013377926
maximumconcentrationratio,0.08361204013377926
clbi,0.08361204013377926
halftimeln2ke0,0.08361204013377926
areasundertheconcentrationtimecurvesfrom0toinfinityaucinfinity,0.08361204013377926
plasmabound,0.08361204013377926
k11,0.08361204013377926
totaldrug,0.08361204013377926
maximalle,0.08361204013377926
tearfluidconcentration,0.08361204013377926
cmaxpeakconcentration,0.08361204013377926
redbloodcellplasmadistributioncoefficient,0.08361204013377926
aucareaunderthecurvefromtime0toinfinity,0.08361204013377926
peakplasmalsconcentration,0.08361204013377926
peakdexamethasoneconcentration,0.08361204013377926
tmaxtimeofoccurrenceofcmax,0.08361204013377926
timetoreachmaximumplasmalevel,0.08361204013377926
areasundertheconcentrationtimecurvefromtime0tothelastmeasurabletimepointauc0t,0.08361204013377926
timesfor,0.08361204013377926
plasmaredbloodcellconcentrationratio,0.08361204013377926
maximumconcentrationpeak,0.08361204013377926
drugdiffusioncoefficient,0.08361204013377926
rbcrecovery,0.08361204013377926
halftimeofitsdisappearance,0.08361204013377926
steadyconcentration,0.08361204013377926
maximumofconcentration,0.08361204013377926
drugclearancehalftime,0.08361204013377926
roundwindowpermeability,0.08361204013377926
apparentmetaboliteclearance,0.08361204013377926
vssivt,0.08361204013377926
overallconversion,0.08361204013377926
blank,0.08361204013377926
criticalsolutiontemperature,0.08361204013377926
maximalvenousblooddrugconcentration,0.08361204013377926
auc0infinityh,0.08361204013377926
apparenthexanewaterpartitioncoefficient,0.08361204013377926
dailydoserequirement,0.08361204013377926
mrtliver,0.08361204013377926
timetoachievethefirsttherapeuticinr,0.08361204013377926
bioadhesionforce,0.08361204013377926
timetoreachthemaximumleveltmax,0.08361204013377926
maximumcycloguanilconcentration,0.08361204013377926
areasundertheplasmadrugconcentrationtimecurve,0.08361204013377926
k10halflife,0.08361204013377926
maximumplasmaproguanilconcentration,0.08361204013377926
steadystatedeliveryrate,0.08361204013377926
areaundertheplasmaconcentrationvstimecurvefromtimezerotothelastmeasurableconcentration,0.08361204013377926
vmfm,0.08361204013377926
csfpenetrationratio,0.08361204013377926
maximumadministereddosemad,0.08361204013377926
timetorepeatbolu,0.08361204013377926
activityclearance,0.08361204013377926
effectivehalflifeclearance,0.08361204013377926
absorbedselfdose,0.08361204013377926
timetoreachthemaximalconcentrationtmax,0.08361204013377926
v1sactivity,0.08361204013377926
ratioofthetotaldrugconcentration,0.08361204013377926
peakcycloguanilconcentration,0.08361204013377926
particlesizezavg,0.08361204013377926
steadystatesaserumconcentration,0.08361204013377926
relativecumulativeurinaryexcretion,0.08361204013377926
releaserateenhancement,0.08361204013377926
crystallitesize,0.08361204013377926
ratioofprogua,0.08361204013377926
rateconstantsofelimination,0.08361204013377926
salivaplasmaproguanil,0.08361204013377926
areaundertheconcentrationversuscurveat24hauc024,0.08361204013377926
duinfinity,0.08361204013377926
maximumexcretionrateddudtmax,0.08361204013377926
maximumunbounddapsoneconcentration,0.08361204013377926
maximumunboundchlorcycloguanilconcentration,0.08361204013377926
steadystatemeanpeakconcentration,0.08361204013377926
progressionfreesurvivialpfs,0.08361204013377926
cd19,0.08361204013377926
timetoundetectablerituximab,0.08361204013377926
timeofobservedcmax,0.08361204013377926
salivavsplasmaspratio,0.08361204013377926
salivavs,0.08361204013377926
plasmaproteinunboundfractionspfratio,0.08361204013377926
absorptionauc0tlast,0.08361204013377926
aucpt0168h,0.08361204013377926
maximumcapacity,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezerotothetimeoflastnonzeroconcentrationauc0t,0.08361204013377926
das28,0.08361204013377926
capacityimax,0.08361204013377926
srratiosofauc,0.08361204013377926
cmaxpo,0.08361204013377926
clpou,0.08361204013377926
aucinrratio,0.08361204013377926
livertoserumtotalwarfarin,0.08361204013377926
adversereaction,0.08361204013377926
adversereactionrate,0.08361204013377926
elap,0.08361204013377926
terminalphasehalflifet12beta,0.08361204013377926
unboundmetabolicclearance,0.08361204013377926
rateofk12,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezerotothelasttimepointauclast,0.08361204013377926
potencyfactor,0.08361204013377926
renalfecalexcretionratio,0.08361204013377926
maximalheartrateincrease,0.08361204013377926
rat,0.08361204013377926
hearinglo,0.08361204013377926
overalltissuetoplasmapartitioncoefficient,0.08361204013377926
clearancefromtheaqueoushumor,0.08361204013377926
targetmediatedeliminationrateconstant,0.08361204013377926
effectiveradiationdose,0.08361204013377926
rateofcompletebonemarrowresponse,0.08361204013377926
maximumplasmavareniclineconcentrationcmax,0.08361204013377926
clrpo,0.08361204013377926
overalldistributionvolume,0.08361204013377926
oralplasmaclearanceclf,0.08361204013377926
encapsulationcapacitie,0.08361204013377926
clearancerateofelimination,0.08361204013377926
maximaldosage,0.08361204013377926
timetoreachthemaximumbloodconcentrationtmax,0.08361204013377926
apc,0.08361204013377926
therapeuticsteadystateconcentration,0.08361204013377926
cumulativeexcretionpercentage,0.08361204013377926
urineexcretionofunchangedform,0.08361204013377926
xu024,0.08361204013377926
apparenthalflifeofitsformation,0.08361204013377926
timelapsetopeakconcentration,0.08361204013377926
cmaxsrratio,0.08361204013377926
peakblood,0.08361204013377926
pulmonaryperfusionclearance,0.08361204013377926
firstpeakplasmacmax,0.08361204013377926
unboundoralclearancecloral,0.08361204013377926
recirculationrate,0.08361204013377926
halflifet12a,0.08361204013377926
relativeextentofavailability,0.08361204013377926
maximumhr,0.08361204013377926
recoveryof3hradioactivity,0.08361204013377926
totalintrinsicclearance,0.08361204013377926
rateofeliminationconstant,0.08361204013377926
terminalt12gamma,0.08361204013377926
proteinbindingdegree,0.08361204013377926
clearancethroughglucuronidation,0.08361204013377926
maximalmetabolicratevm,0.08361204013377926
brainblood,0.08361204013377926
distributioncoefficientdelta,0.08361204013377926
clearancethrough,0.08361204013377926
apparentvolumeofdistributionforthecentralcompartmentv1,0.08361204013377926
clearancethroughsidechainoxidation,0.08361204013377926
ratiok12k21,0.08361204013377926
plasmapeakconcentrationofradioactivity,0.08361204013377926
excretionrateconstant,0.08361204013377926
steadystatevolumevssofdistribution,0.08361204013377926
lagtimebeforedrugabsorption,0.08361204013377926
minimalsteadystate,0.08361204013377926
volumeofdistributionduringthedistributionphase,0.08361204013377926
intrinsicplasmaclearancecli,0.08361204013377926
ratiosatsteadystate,0.08361204013377926
maximalconcentrationsinplasmacmin,0.08361204013377926
semihydrolysistime,0.08361204013377926
prola,0.08361204013377926
drugpermeationrate,0.08361204013377926
auc28,0.08361204013377926
steadystateauc28,0.08361204013377926
halflifeoft12alpha,0.08361204013377926
disin,0.08361204013377926
overalloralbioavailability,0.08361204013377926
maximumselfotellevel,0.08361204013377926
steadystateeffectiveplasmaha,0.08361204013377926
rateofdrugadministrationtothesystemic,0.08361204013377926
initialeliminationhalflive,0.08361204013377926
totalradiolabelrecovered,0.08361204013377926
troughreduction,0.08361204013377926
accumulationpotentialeacc,0.08361204013377926
areaauc016h,0.08361204013377926
percentagefree,0.08361204013377926
auc05hour,0.08361204013377926
totalfloatingtime,0.08361204013377926
steadystateconcentrationratio,0.08361204013377926
hepaticvenouspressuregradient,0.08361204013377926
repetitiontimetr,0.08361204013377926
t1time,0.08361204013377926
totalbloodclearanceatsteadystate,0.08361204013377926
areaundertheserumdrugconcentrationtimecurve,0.08361204013377926
plasmanla,0.08361204013377926
clearancecl0,0.08361204013377926
centralcompartmentvc,0.08361204013377926
myocardialtoplasmaconcentrationratio,0.08361204013377926
timeofadministration,0.08361204013377926
steadystatepeakconcentrationcmax,0.08361204013377926
membranepermeabilitypapp,0.08361204013377926
ck,0.08361204013377926
areasundertheconcentrationcurvesaucfrom0to12h,0.08361204013377926
ratioaucauc,0.08361204013377926
tcl,0.08361204013377926
maximumctrough,0.08361204013377926
timeauc,0.08361204013377926
initialmaintenancedose,0.08361204013377926
totalareaunderthecurveuptothelastmeasurableconcentrationauclast,0.08361204013377926
totalareaunderthecurveaucinf,0.08361204013377926
apparenttruebiliaryclearanceratio,0.08361204013377926
maximalintrinsicclearance,0.08361204013377926
apparentsteadystatecondition,0.08361204013377926
areaundertheconcentrationtimecurveauc048h,0.08361204013377926
areaunderthecurveofbloodconcentration,0.08361204013377926
terminalbloodhalflife,0.08361204013377926
lowerlimitsofdetectionllod,0.08361204013377926
apparentoverallvolumesofdistribution,0.08361204013377926
apparenthalflivesoffirstorderabsorption,0.08361204013377926
lagtimesofabsorption,0.08361204013377926
apparenthalflifeoffirstorderinvasion,0.08361204013377926
masstransitionion,0.08361204013377926
dosecorrectedauc024,0.08361204013377926
gammaeliminationhalflifet12gamma,0.08361204013377926
cumulativebiliaryexcretionrate,0.08361204013377926
halflifeofalphaphase,0.08361204013377926
rhhepaticrecoveryratio,0.08361204013377926
uptakeclearancecluptake,0.08361204013377926
areaundercurvefromzerotoinfinityauc,0.08361204013377926
bioaccessibilitie,0.08361204013377926
forcesofdetachment,0.08361204013377926
hepaticinflowconcentrationscin,0.08361204013377926
systemictotalclearance,0.08361204013377926
auc045h,0.08361204013377926
areaunderplasmaconcentrationtimecurveforthesteadystate,0.08361204013377926
permeabilitypeff,0.08361204013377926
troughgefitiniblevel,0.08361204013377926
areaunderthecurveauct,0.08361204013377926
totalsteadystatematernalplasmapropranololconcentration,0.08361204013377926
troughgefitinibplasmaconcentrationcmin,0.08361204013377926
tissuetoplasmapartitioncoefficientskpt,0.08361204013377926
steadystatematernaltotaldrugconcentration,0.08361204013377926
clearancevaluesclf,0.08361204013377926
timetoprogressionofbrainlesion,0.08361204013377926
peakgefitinibplasmaconcentration,0.08361204013377926
d8d2ratio,0.08361204013377926
apparentvolumeofdistributionbeta,0.08361204013377926
areasundertheconcentrationtimecurveauc096,0.08361204013377926
timetoreachthemaximumconcentrationstmax,0.08361204013377926
accumulationratiosaucsteadystate024haucsingledose0infinity,0.08361204013377926
gastricemptyingt90,0.08361204013377926
troughplasmaconcentrationc0,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to24hoursauc024,0.08361204013377926
timefromfirsttosecondtransplantation,0.08361204013377926
aucphase2aucphase1,0.08361204013377926
maximalinhibitoryeffect,0.08361204013377926
pulmonarytransittime,0.08361204013377926
timetoemax,0.08361204013377926
areaundertheeffecttimecurvefromtimezeroto72h,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtimezerotothelastquantifiabletimepointauclast,0.08361204013377926
overallpatientresponserate,0.08361204013377926
cmaxmaximumobservedplasmaconcentration,0.08361204013377926
steadystatereservoir,0.08361204013377926
hepaticuptakeratio,0.08361204013377926
excretedintotheurinefromtime0to12hoursae012,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefromtime0to6hoursauc06,0.08361204013377926
articularcartilageconcentration,0.08361204013377926
eauc,0.08361204013377926
serumantiviralactivityauc,0.08361204013377926
90maximumclearance,0.08361204013377926
maximumdeltaf,0.08361204013377926
ec98,0.08361204013377926
volumeofdistributionofcompartment1,0.08361204013377926
volumeofdistributionofcompartment2,0.08361204013377926
volumeofdistributionofcompartment3,0.08361204013377926
volumeofdistributionofcompartment4,0.08361204013377926
tissuestore,0.08361204013377926
mt,0.08361204013377926
rateofaccumulation,0.08361204013377926
storage,0.08361204013377926
cthdlratio,0.08361204013377926
halflifeofdruginblood,0.08361204013377926
rs,0.08361204013377926
clearanceofunboundteniposide,0.08361204013377926
maximumdeltat,0.08361204013377926
areaundertheconcentrationtimecurvetotheendofthedosingperiodauctau,0.08361204013377926
tissuehalflive,0.08361204013377926
primaryhalflifet12,0.08361204013377926
weightadjustedplasmaclearance,0.08361204013377926
betaphaseplasmahalflive,0.08361204013377926
mmr,0.08361204013377926
eliminationhalflifeinthebetaphase,0.08361204013377926
painthreshold,0.08361204013377926
maximalrateofdecline,0.08361204013377926
chronict12,0.08361204013377926
salivatoplasmamethadone,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucfromtimezeroto72hoursauc72,0.08361204013377926
unboundcmin,0.08361204013377926
semenblooddrugconcentrationratio,0.08361204013377926
peakdruglevelinblood,0.08361204013377926
troughsmethadoneplasmalevel,0.08361204013377926
dosecorrectedpeakplasmaconcentrationcmax,0.08361204013377926
50maximumclearance,0.08361204013377926
maximumgemcitabineconcentration,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefrom0to270minute,0.08361204013377926
maximumgemcitabineplasmaconcentrationcmax,0.08361204013377926
plasmaeliminationhalflifelambdazhalflife,0.08361204013377926
relativebraindistributioncoefficientaucbrainecfaucplasma,0.08361204013377926
relativebraindistributioncoefficient,0.08361204013377926
totalradiationdose,0.08361204013377926
oralbioavailabilty,0.08361204013377926
areaundertheconcentrationtimecurve051hour,0.08361204013377926
tumoraccumulationratio,0.08361204013377926
areaunderthecurvet0168hours,0.08361204013377926
tumoraucratio,0.08361204013377926
combinedresponserate,0.08361204013377926
timeresponsetoprogression,0.08361204013377926
mediansurvivaltime,0.08361204013377926
qualifiedresponserate,0.08361204013377926
steadystatetumorplasma,0.08361204013377926
peakventricularcsfgemcitabineconcentration,0.08361204013377926
tumorgrowthcontrolrate,0.08361204013377926
steadystateplasmadfdclevel,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezeroto24hauc024h,0.08361204013377926
maximaltolerabledose,0.08361204013377926
peripheralcompartmentv2,0.08361204013377926
steadystatedfdclevel,0.08361204013377926
circulation,0.08361204013377926
peakplasmacurcuminlevel,0.08361204013377926
intercompartmentalclearancesq2,0.08361204013377926
sat,0.08361204013377926
lengthofinfusion,0.08361204013377926
overallclinicalresponserate,0.08361204013377926
volumeofdistributionduringtheeliminationphase,0.08361204013377926
interval,0.08361204013377926
fdr,0.08361204013377926
cendofinfusion,0.08361204013377926
auc0areaundercurve,0.08361204013377926
painreliefscore,0.08361204013377926
apparentvolumeofdistributioncorrectedforbioavailability,0.08361204013377926
totalbodyclearancecorrectedforbioavailability,0.08361204013377926
troughlevelatsteadystate,0.08361204013377926
infusionduration,0.08361204013377926
initialbloodclearancet12earlyphase,0.08361204013377926
maximumtoleratedinfusionrate,0.08361204013377926
steadystatecl,0.08361204013377926
totalatlglevel,0.08361204013377926
intercompartmentalclearanceq2f,0.08361204013377926
annualizedinfectionsrate,0.08361204013377926
seriousinfectionrate,0.08361204013377926
cerebrovascularpermeabilitysurfaceareapa,0.08361204013377926
permeabilityxcapillarysurfacearea,0.08361204013377926
areasundertheconcentrationvstimecurvesauc010days,0.08361204013377926
timetopeakplasmafab2,0.08361204013377926
aucim,0.08361204013377926
vssim,0.08361204013377926
troughiggconcentration,0.08361204013377926
timeofrecoveryto50,0.08361204013377926
totallo,0.08361204013377926
peakiggconcentration,0.08361204013377926
totalactivity,0.08361204013377926
maximumabsorbeddose,0.08361204013377926
tumourbackgroundratio,0.08361204013377926
serumt12b,0.08361204013377926
urinarydigoxinrecovery,0.08361204013377926
absorbeddosestonormalorgan,0.08361204013377926
maximumcytolysi,0.08361204013377926
timetomaximumobservedserumconcentration,0.08361204013377926
peakheightratiotamis,0.08361204013377926
endotrachealaspirateserumconcentrationratio,0.08361204013377926
concentrationatasteadystate,0.08361204013377926
maximummeanserumatezolizumabconcentration,0.08361204013377926
totalareaundertheserumconcentrationtimecurve,0.08361204013377926
troughimmunoglobulingconcentration,0.08361204013377926
fimvss,0.08361204013377926
timetotheresolutionoffever,0.08361204013377926
lineareliminationhalflife,0.08361204013377926
intercompartmentclearancesq2,0.08361204013377926
maximumplasmamethadoneconcentration,0.08361204013377926
coldpainthreshold,0.08361204013377926
paintolerancetime,0.08361204013377926
rid,0.08361204013377926
minimalplasmaticconcentration,0.08361204013377926
rectalabsorptioncondition,0.08361204013377926
plasmaconcentrationinastablestate,0.08361204013377926
tlr,0.08361204013377926
maximumdexmedetomidineinfusiondose,0.08361204013377926
areaundertheeffecttimecurveauce0120,0.08361204013377926
maximumobservedeffectparameteremax,0.08361204013377926
concentrationelicitinghalfofemaxec50,0.08361204013377926
hillrelatedexponentgamma,0.08361204013377926
dialysateclearance,0.08361204013377926
timetoreachpeakserumconcentrationofdextmax,0.08361204013377926
maximumdoserate,0.08361204013377926
observedmethadoneconcentration,0.08361204013377926
secondaryphasehalflife,0.08361204013377926
primaryphasehalflife,0.08361204013377926
areaunderthemethadoneconcentrationcurve024hauc024h,0.08361204013377926
teru50,0.08361204013377926
maximuminhibitionoflossofresponseimax,0.08361204013377926
bodyweightnormalizedareaundertheconcentrationtimecurve,0.08361204013377926
ae08h,0.08361204013377926
totalamountofunchangedtorasemideexcretedin,0.08361204013377926
disappearanceclearanceclint,0.08361204013377926
maximumurinarysodiumexcretionrate,0.08361204013377926
areaundertheplasmadrugconcentrationovertimecurveauc,0.08361204013377926
maximumobservedserumconcentrationcmax,0.08361204013377926
rateofmildormoderateinfectionepisode,0.08361204013377926
troughserumigglevel,0.08361204013377926
tumorturnovertimeconstant,0.08361204013377926
pseudofirstorderrateconstant,0.08361204013377926
capacityfactorsmax,0.08361204013377926
ubratio,0.08361204013377926
peakplasmarhghlevel,0.08361204013377926
halflivesoftheinitialdistributionphasealpha,0.08361204013377926
lbratio,0.08361204013377926
lungtobloodtransferrateconstant,0.08361204013377926
peakserumghlevel,0.08361204013377926
lineardisappearancerate,0.08361204013377926
stokesradiu,0.08361204013377926
halftimet12,0.08361204013377926
initialdegradationrate,0.08361204013377926
integratedconcentrationofgrowthhormone,0.08361204013377926
peakgrowthhormonelevel,0.08361204013377926
timetopeakgrowthhormonelevel,0.08361204013377926
constantofelimination,0.08361204013377926
integratedconcentration,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to48hour,0.08361204013377926
rateofproduction,0.08361204013377926
halfmaximumabsorptionratekma,0.08361204013377926
clearanceclfss,0.08361204013377926
areaunderthecurveforthegivendoseintervalauctau,0.08361204013377926
dfi,0.08361204013377926
insulinclearancerate,0.08361204013377926
peakserumrapamycinconcentration,0.08361204013377926
minimumlanreotideconcentrationscminatsteadystate,0.08361204013377926
halfoftheemaxec50,0.08361204013377926
vzfss,0.08361204013377926
proteinloading,0.08361204013377926
peaksirolimuslevel,0.08361204013377926
peakplasmagrowthhormoneconcentrationscmax,0.08361204013377926
plasmastability,0.08361204013377926
beta12,0.08361204013377926
totalrestenosisrate,0.08361204013377926
apparentclearancefromblood,0.08361204013377926
maximumabsorptionratevma,0.08361204013377926
maximumeliminationratevm,0.08361204013377926
cl1systemicclearance,0.08361204013377926
hydroxyl,0.08361204013377926
bodyclearancerateclb,0.08361204013377926
lategainlo,0.08361204013377926
laterestenosisrate,0.08361204013377926
observedclearance,0.08361204013377926
intrinsicrate,0.08361204013377926
imprintingfactor,0.08361204013377926
024hour,0.08361204013377926
t12eff,0.08361204013377926
maximumcarprofenconcentration,0.08361204013377926
halflifeoflz,0.08361204013377926
phasichalflive,0.08361204013377926
curvefittedec50,0.08361204013377926
areaundertheplasmaconcentrationversustimecurvefromtime0to24hauc024,0.08361204013377926
lexclemiss,0.08361204013377926
distributionvolumerate,0.08361204013377926
peakoccupancytimepot,0.08361204013377926
halfmaximumeliminationrate,0.08361204013377926
maximummeaninhibinblevel,0.08361204013377926
associationconstantska,0.08361204013377926
volumetricproductivity,0.08361204013377926
concentrationsc50,0.08361204013377926
maximalghproductionrate,0.08361204013377926
neo,0.08361204013377926
maximumserumfshctpconcentration,0.08361204013377926
bloodbrainbarrierpermeability,0.08361204013377926
accumulationratiorac,0.08361204013377926
totalareaundertheplasmaconcentrationtimecurvefromtimezeroto8hrauc08hr,0.08361204013377926
annualizedrelapserate,0.08361204013377926
lagtimesfor,0.08361204013377926
doseconcentrationratiodcratio,0.08361204013377926
dcratio,0.08361204013377926
nebulizer,0.08361204013377926
renalfraction,0.08361204013377926
areaunderthecurveover24h,0.08361204013377926
troughserumgrowthhormone,0.08361204013377926
heartplasmaaucratio,0.08361204013377926
absoluteabsorption,0.08361204013377926
amountofabsorbed,0.08361204013377926
brainexposure,0.08361204013377926
apparentoraldoseclearanceclf,0.08361204013377926
wholebloodterminaldispositionhalflifet12,0.08361204013377926
accumulationhalftime,0.08361204013377926
maximumqtcintervalprolongation,0.08361204013377926
vdatsteadystate,0.08361204013377926
thrombosisrate,0.08361204013377926
ratiosofauc0infinity,0.08361204013377926
volumeofcompartmentonev1,0.08361204013377926
distributionalclearancecld,0.08361204013377926
volumeofcompartmenttwov2,0.08361204013377926
lymphatictransport,0.08361204013377926
bloodhalflifeduringthebetaphase,0.08361204013377926
gastricretention,0.08361204013377926
wholebloodoralclearance,0.08361204013377926
areasunderthebloodconcentrationtimecurve,0.08361204013377926
ramsaysedationscorerss,0.08361204013377926
sur,0.08361204013377926
a2a1ratio,0.08361204013377926
timeoflastdetection,0.08361204013377926
volumeofdistributionvssf,0.08361204013377926
peakcaptoprilconcentration,0.08361204013377926
yieldof,0.08361204013377926
apparentplasmahalftime,0.08361204013377926
rpf,0.08361204013377926
minimumbioavailability,0.08361204013377926
timeofmaximalplasmaconcentrationtmax,0.08361204013377926
coefficienta,0.08361204013377926
terminalhalflifet12alpha,0.08361204013377926
areaundertheconcentrationtimecurveto24h,0.08361204013377926
areaundertheconcentrationtimecurveaucupto8h,0.08361204013377926
areaundertheplasmatriazolamconcentrationtimecurveauc0,0.08361204013377926
oralvolumeofdistributionvd,0.08361204013377926
biologicalbioavailability,0.08361204013377926
areaundertheghcurve,0.08361204013377926
areaunderdrugconcentrationtimecurve,0.08361204013377926
serummeanresidencetime,0.08361204013377926
systemiccirculationauc024,0.08361204013377926
infusion,0.08361204013377926
infusionhalflife,0.08361204013377926
cycle,0.08361204013377926
observedpeakplasmaconcentration,0.08361204013377926
timeshiftacrophase,0.08361204013377926
remaintimemrt,0.08361204013377926
aucofblooddrugconcentrationtimecurve,0.08361204013377926
halftimeofdistributiont12alpha,0.08361204013377926
halftimeofremovalt12beta,0.08361204013377926
peakigficoncentration,0.08361204013377926
peaksirolimusconcentration,0.08361204013377926
peakwholebloodconcentrationcmax,0.08361204013377926
maximalcm,0.08361204013377926
minimalplasmaconcentrationctroug,0.08361204013377926
a9concentration,0.08361204013377926
accumulationratioforauc024hr,0.08361204013377926
analyticaltime,0.08361204013377926
apparentvolumeofdistributionintheterminalphase,0.08361204013377926
maintenancetroughlevel,0.08361204013377926
timetoradiologicalprogression,0.08361204013377926
peaklocaltissuesirolimuslevel,0.08361204013377926
leveldoseratioldr,0.08361204013377926
wholebloodtoplasmabpconcentrationratio,0.08361204013377926
decelerationrate,0.08361204013377926
maximumplasmamianserinconcentrationcmax,0.08361204013377926
kineticvolumeofdistribution,0.08361204013377926
peakserumtriazolamconcentration,0.08361204013377926
extracellularfluidvolume,0.08361204013377926
bloodbrainbarrierpermeabilitysurfaceareaproduct,0.08361204013377926
terminalhalflifeincirculation,0.08361204013377926
circulatingtotalmmiconcentration,0.08361204013377926
basalconcentrationc0,0.08361204013377926
apparentserumhalflife,0.08361204013377926
halflifeforreachingequilibrium,0.08361204013377926
constantmobilephaseflowrate,0.08361204013377926
auc08ratio,0.08361204013377926
minimaldetectionlimit,0.08361204013377926
tran,0.08361204013377926
cltsratio,0.08361204013377926
halflifeofthedistributionphaset12alpha,0.08361204013377926
slowerphaset12beta,0.08361204013377926
maximumserummmiconcentrationscmax,0.08361204013377926
timetoreachthesteadystateconcentration,0.08361204013377926
clearancerateconstantkmono,0.08361204013377926
kmono,0.08361204013377926
salinetoglucoseabsorptionratio,0.08361204013377926
overallabsorption,0.08361204013377926
ratiosforauc,0.08361204013377926
areaundertheactivitycurveauac024h,0.08361204013377926
noncompartmentalhalflive,0.08361204013377926
biologicalhalflifetime,0.08361204013377926
relativemobilitiesmr,0.08361204013377926
halflifeceiling,0.08361204013377926
totalfactorconsumption,0.08361204013377926
areaunderthecurveuntildrugremoval,0.08361204013377926
auac024h,0.08361204013377926
areaunderthempaconcentrationversustimecurveupto360min,0.08361204013377926
halflifeextensionratio,0.08361204013377926
minimumhalflifeextensionratio,0.08361204013377926
intrinsicaffinitie,0.08361204013377926
apparentclearancefromthecentralclc,0.08361204013377926
terminaleliminationhalflifetimet12,0.08361204013377926
topeakplasmalevelscmax,0.08361204013377926
pdratio,0.08361204013377926
turnoverrate,0.08361204013377926
maximalantihbsconcentration,0.08361204013377926
oralclearancerateclf,0.08361204013377926
tt4concentration,0.08361204013377926
maximaltt4concentration,0.08361204013377926
tt4,0.08361204013377926
areasundertheserumt4concentrationversustimecurvefrom0to8hauc,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to2h,0.08361204013377926
peakserumradioactivity,0.08361204013377926
dosenormalizedpeakconcentrationcmax,0.08361204013377926
maximalprolactinresponse,0.08361204013377926
dosenormalizedareaundertheconcentrationtimecurvefromtime0to120hour,0.08361204013377926
halflifeoftheterminaldistributionphase,0.08361204013377926
distributionhalftimet12lambda1,0.08361204013377926
t4,0.08361204013377926
metabolicclearancerateof,0.08361204013377926
peakleveltmax,0.08361204013377926
overalllevel,0.08361204013377926
tsh,0.08361204013377926
sustainedeffectiveplasmaconcentration,0.08361204013377926
unboundhydroquininefraction,0.08361204013377926
receptorsaturation,0.08361204013377926
tumorpenetration,0.08361204013377926
areaunderthemomentcurve,0.08361204013377926
concentrationsversustimeaucratio,0.08361204013377926
gelstrength,0.08361204013377926
irreversiblebinding,0.08361204013377926
dispositionrateconstantalpha,0.08361204013377926
areasunderthecurveauc08h,0.08361204013377926
totalvolumesofdistribution,0.08361204013377926
timetothelastdetectable,0.08361204013377926
timetothemaximumconcentrationofdrug,0.08361204013377926
plasmathyroxineconcentration,0.08361204013377926
timetopeakbloodlevel,0.08361204013377926
areaundertheconcentrationversustimecurveupto6hour,0.08361204013377926
timetoreachaminimumtherapeuticthreshold,0.08361204013377926
areasunderthemiso,0.08361204013377926
annualjointbleed,0.08361204013377926
ivr,0.08361204013377926
bleedingrate,0.08361204013377926
rateofsynthesi,0.08361204013377926
decayrate,0.08361204013377926
rateofdecay,0.08361204013377926
timetotrough,0.08361204013377926
peakfviiic,0.08361204013377926
peakheighttph,0.08361204013377926
timeto1i,0.08361204013377926
potentialtp,0.08361204013377926
troughlevelstl,0.08361204013377926
troughactivity,0.08361204013377926
associationrateconstantkon,0.08361204013377926
annualizedspontaneousbleedingrate,0.08361204013377926
timeofthemaximummeasuredplasmaconcentration,0.08361204013377926
timespent,0.08361204013377926
timetoachievemaximuminhibition,0.08361204013377926
halfliferatio,0.08361204013377926
lequesnesindex,0.08361204013377926
serummaximalconcentration,0.08361204013377926
dosenormalizedmaximumplasmagsconcentration,0.08361204013377926
maximalplasmagsconcentrationsoccurred,0.08361204013377926
partitioncoefficientofipka,0.08361204013377926
maximalsf,0.08361204013377926
glucosaminelevel,0.08361204013377926
tmaxtimetoachievemaximumplasmaconcentrations,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucfromtimezerotothetimeofthelastquantifiableconcentrationauclast,0.08361204013377926
timedelayforthepeakresponse,0.08361204013377926
apparentrateofelimination,0.08361204013377926
cmaxmaximumplasmaconcentrations,0.08361204013377926
auc048areaunderthecurve,0.08361204013377926
quasisteadystateconstant,0.08361204013377926
occupancyatsteadystate,0.08361204013377926
annualbleedingrate,0.08361204013377926
annualizedbleedingrate,0.08361204013377926
durationofbleeding,0.08361204013377926
apparenttotalbodyclearancecl,0.08361204013377926
annualizedbleedingrateabr,0.08361204013377926
inductionabortioninterval,0.08361204013377926
invivohalflife,0.08361204013377926
invivoincrementalrecovery,0.08361204013377926
tat,0.08361204013377926
peakfviiiconcentration,0.08361204013377926
timetoreach1,0.08361204013377926
peakfviiilevel,0.08361204013377926
totalareaundertheplasmaconcentrationcurveauc0infinity,0.08361204013377926
serumconcentrationareaunderthecurveat5hour,0.08361204013377926
troughvwfrco,0.08361204013377926
areasundermisoprostolconcentrationversustimecurvesupto5h,0.08361204013377926
maximummeanauc0,0.08361204013377926
onestagechromogenicratio,0.08361204013377926
terminalhalflifeofradioactivityelimination,0.08361204013377926
timetomaintainf,0.08361204013377926
timetomaintainfviiilevel,0.08361204013377926
troughfviii,0.08361204013377926
troughfviiilevel,0.08361204013377926
dosingfrequency,0.08361204013377926
maximumrateofsubstrateconversion,0.08361204013377926
bloodratio,0.08361204013377926
overallcompleteabortionrate,0.08361204013377926
overallratesofhealing,0.08361204013377926
completeabortionrate,0.08361204013377926
firstphaset12,0.08361204013377926
timeto005i,0.08361204013377926
c2c6ratio,0.08361204013377926
totalrfviiaclearance,0.08361204013377926
fviiac,0.08361204013377926
coagulantactivityfviic,0.08361204013377926
auecratio,0.08361204013377926
tcav,0.08361204013377926
aucauecratio,0.08361204013377926
apparentclearanceoforalquinineclf,0.08361204013377926
plasmatobloodratiooftotalradioactivityconcentration,0.08361204013377926
areaundertheplasmaconcentrationtimecurveaucfromtime0toinfinityauc,0.08361204013377926
aucduringthedosingintervaltatsteadystateauctss,0.08361204013377926
clearanceplasmaconcentration,0.08361204013377926
fluidflowrate,0.08361204013377926
maximalplasmaquinineconcentration,0.08361204013377926
milkmaternalserumconcentrationratio,0.08361204013377926
totalareaundertheconcentrationversustimecurve,0.08361204013377926
yintercept,0.08361204013377926
peakconcentrationatsteadystate,0.08361204013377926
timetoachievepeakconcentration,0.08361204013377926
troughsteadystateserumconcentration,0.08361204013377926
serumtroughsteadystateconcentrationcminss,0.08361204013377926
interdialyticeliminationhalflife,0.08361204013377926
limitsofdetectionslods,0.08361204013377926
te,0.08361204013377926
cu,0.08361204013377926
hemofiltrateclearance,0.08361204013377926
peakvenousplasmalevel,0.08361204013377926
timetothepeakserumconcentrationtmax,0.08361204013377926
maximumflecainideplasmalevel,0.08361204013377926
timeaboveic50,0.08361204013377926
milktoplasmaflecainide,0.08361204013377926
peakflecainideacetateconcentration,0.08361204013377926
troughatsteadystate,0.08361204013377926
timetoseizureoccurrence,0.08361204013377926
totalinstrumentalruntime,0.08361204013377926
serumlevetiracetamconcentration,0.08361204013377926
troughserumlevetiracetamconcentration,0.08361204013377926
transferrateconstraint,0.08361204013377926
vda,0.08361204013377926
recoveryfromurine,0.08361204013377926
serumfreetotalserumlevetiracetam,0.08361204013377926
concentrationratiofreefraction,0.08361204013377926
bioavailabilityaucratio,0.08361204013377926
rateofseriousbacterialinfection,0.08361204013377926
isolationtime,0.08361204013377926
excretedunchangeddu,0.08361204013377926
auc0tiv,0.08361204013377926
auc0tsc,0.08361204013377926
troughigglevel,0.08361204013377926
annualizedrateofinfection,0.08361204013377926
criticalthresholdconcentration,0.08361204013377926
auc480h,0.08361204013377926
maximumtumouruptake,0.08361204013377926
fractionavailablef,0.08361204013377926
peakserumantibodyconcentration,0.08361204013377926
tumortoblood,0.08361204013377926
tumortoliveruptakeratio,0.08361204013377926
increaseinserumiggdeltaigg,0.08361204013377926
overallhalflifet12,0.08361204013377926
schoolmissed,0.08361204013377926
troughserumiggconcentration,0.08361204013377926
timetoreachtroughantihbslevel,0.08361204013377926
maximumexcretionratesddudtmax,0.08361204013377926
totaligg,0.08361204013377926
seriousbacterialinfectionrate,0.08361204013377926
maximume,0.08361204013377926
areasundertheplasmaconcentrationvstimecurvesauc010days,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to360day,0.08361204013377926
recrudescencerate,0.08361204013377926
troughantibodytiter,0.08361204013377926
durationofhospitalization,0.08361204013377926
rateofhospitalizationsdue,0.08361204013377926
parasiteeliminationhalflife,0.08361204013377926
observedsteadystatepredosetocilizumabconcentration,0.08361204013377926
cumulativeareaunderthecurve,0.08361204013377926
steadystatequinineplasmaconcentration,0.08361204013377926
admissionplasmaconcentration,0.08361204013377926
apparentfirstorderrateconstant,0.08361204013377926
troughfixactivity,0.08361204013377926
timeabovefix,0.08361204013377926
overallannualizedbleedingrateabr,0.08361204013377926
clearancemrt,0.08361204013377926
annualbleedrate,0.08361204013377926
overallspontaneousbleedingrate,0.08361204013377926
halflifehl,0.08361204013377926
clearencecl,0.08361204013377926
annualisedspontaneousbleedingrate,0.08361204013377926
incrementalrecoveryir,0.08361204013377926
steadystatefixtroughlevel,0.08361204013377926
ratioofhalflife,0.08361204013377926
tenminuteplasmarecovery,0.08361204013377926
t12betaphaseelimination,0.08361204013377926
maximumrelativeactivatedpartialthromboplastintime,0.08361204013377926
activityincrease,0.08361204013377926
clmi,0.08361204013377926
aucooo,0.08361204013377926
asbr,0.08361204013377926
absorptionka,0.08361204013377926
eliminationkd,0.08361204013377926
fractionofdose,0.08361204013377926
areaundertheplasmaconcentrationtimecurvefor24hatsteadystateauctss,0.08361204013377926
areaundertheconcentrationversustimecurveaucinf,0.08361204013377926
activityterminalt12,0.08361204013377926
fixactivity,0.08361204013377926
mrtmi,0.08361204013377926
troughexogenousfixactivitylevel,0.08361204013377926
thirdorderassociationrateconstant,0.08361204013377926
fix,0.08361204013377926
invivoresponse,0.08361204013377926
fixcplasmalevel,0.08361204013377926
fixc,0.08361204013377926
timeneededtoachievethi,0.08361204013377926
peakrecovery,0.08361204013377926
maximumpeakthrombingenerationptg,0.08361204013377926
netdialysisclearance,0.08361204013377926
totalanalysistimepersample,0.08361204013377926
degradationhalftime,0.08361204013377926
fluideliminationhalflive,0.08361204013377926
totaleliminationhalflife,0.08361204013377926
durationoftreatment,0.08361204013377926
plasmaclearancerelativetobioavailabilityclpf,0.08361204013377926
totalapparentvolumeofdistributionv,0.08361204013377926
factorconsumption,0.08361204013377926
maximumconcentrationofroxithromycincmax,0.08361204013377926
skinconcentration,0.08361204013377926
skin,0.08361204013377926
gradientelutionatflowrate,0.08361204013377926
tissueplasmatpratio,0.08361204013377926
combinedeliminationconstantkel,0.08361204013377926
eliminationhalftimet12z,0.08361204013377926
totaleliminationrateconstantk,0.08361204013377926
excretiveratio,0.08361204013377926
tissueserumconcentrationratio,0.08361204013377926
totaleliminationratio,0.08361204013377926
sampleefficiency,0.08361204013377926
tissuepeakconcentration,0.08361204013377926
troughgentamicinconcentration,0.08361204013377926
peak3hlevel,0.08361204013377926
pulmonaryintrinsicclearance,0.08361204013377926
ep,0.08361204013377926
pulmonaryextractionratioep,0.08361204013377926
pulmonaryarterial,0.08361204013377926
salivaplasmaquinine,0.08361204013377926
areaunderthecurveauc12hours,0.08361204013377926
amountofcumulativedrugreleased,0.08361204013377926
iii,0.08361204013377926
ida,0.08361204013377926
rateofhe,0.08361204013377926
relativeurinaryexcretion,0.08361204013377926
diffusionrateconstantkie,0.08361204013377926
areundertheconcentrationtimecurveat06h,0.08361204013377926
timetoreachmaximumphenytoinserumconcentration,0.08361204013377926
timetoreachaplasmaconcentration,0.08361204013377926
timetoreachthe,0.08361204013377926
absorptionrateconstanth,0.08361204013377926
absoluteenteralbioavailability,0.08361204013377926
tratscore,0.08361204013377926
vmaxinfinity,0.08361204013377926
bwt6096,0.08361204013377926
timetoonsetofinduction,0.08361204013377926
maximummetabolicrate,0.08361204013377926
buclcbw,0.08361204013377926
peakphenytoinserumlevel,0.08361204013377926
steadystatephenytoinconcentration,0.08361204013377926
oralresidencehalftime,0.08361204013377926
kind,0.08361204013377926
kmax,0.08361204013377926
portalveinclearance,0.08361204013377926
totalareasundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc,0.08361204013377926
totalalphalevel,0.08361204013377926
exponentn,0.08361204013377926
coefficientb,0.08361204013377926
freepeakplasmalevel,0.08361204013377926
timetoreachtotal,0.08361204013377926
peakfreedruglevel,0.08361204013377926
saturatedeliminationratevxvmax,0.08361204013377926
peakserumdphconcentration,0.08361204013377926
areasundertheserumdphconcentrationtimecurvesauc,0.08361204013377926
bodyclearanceclf,0.08361204013377926
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityaucinf,0.08361204013377926
firstordereliminationrateconstantke,0.08361204013377926
seizurefrequency,0.08361204013377926
exsorptionrate,0.08361204013377926
relativedegreeofbioavailability,0.08361204013377926
tmax04,0.08361204013377926
apparentclearancedosescauc,0.08361204013377926
totalbraintissueconcentration,0.08361204013377926
halflifeoftheterminalportion,0.08361204013377926
intracellular,0.08361204013377926
plasmactrough,0.08361204013377926
areaundertheconcentrationtimecurvetime0tolastquantifiableconcentration,0.08361204013377926
injectionsitepainscore,0.08361204013377926
overalltreatmentsuccessrate,0.08361204013377926
peakeelevel,0.08361204013377926
firstdosetroughlevelcmin1,0.08361204013377926
apparentvolumeofdistributionofatgv,0.08361204013377926
absolutelymphocytecount,0.08361204013377926
areaunderthecurvetothelastmeasurableobservationauc0t,0.08361204013377926
auc0tdose,0.08361204013377926
areaundertheplasmaconcentrationvstimecurveauc0t,0.08361204013377926
halfmaximalconcentration,0.08361204013377926
halflifeofunchanged,0.08361204013377926
partialpressureofcarbondioxidepaco2,0.08361204013377926
massbalancefactor,0.08361204013377926
partialpressurepaofoxygen,0.08361204013377926
peritonealmasstransfer,0.08361204013377926
maximaleliminationrate,0.08361204013377926
rapiddecayconstant,0.08361204013377926
slowdecayconstant,0.08361204013377926
constanttrough,0.08361204013377926
maximalphenytoinplasmaconcentration,0.08361204013377926
halflifeoftotalradioactivityelimination,0.08361204013377926
90fractionalabsorption,0.08361204013377926
timeto50fractionalabsorption,0.08361204013377926
biocon,0.08361204013377926
maximumfolliculardiameter,0.08361204013377926
maximalgestodenelevel,0.08361204013377926
steadystateserumphenytoinconcentration,0.08361204013377926
maximalurinaryexcretion,0.08361204013377926
maximumrate,0.08361204013377926
peakc,0.08361204013377926
timetopeakconcentrationstmax,0.08361204013377926
vmaxdelta,0.08361204013377926
measurabletrough,0.08361204013377926
areasunderthecurvesauc0infinity,0.08361204013377926
minimaltherapeuticplasmalevel,0.08361204013377926
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinity,0.08361204013377926
apparentvolumeofdistributionincentralcompartment,0.08361204013377926
timesoffirstnifedipineappearancetfa,0.08361204013377926
apparentvolumeofdistributionofthecentralcompartmentvce,0.08361204013377926
auc072hr,0.08361204013377926
vmaxinduced,0.08361204013377926
vmaxbaseline,0.08361204013377926
clintliver0,0.08361204013377926
clintliver,0.08361204013377926
terminaleliminationphasebeta,0.08361204013377926
vmaxb,0.08361204013377926
brainbloodconcentrationratio,0.08361204013377926
initialfreep,0.08361204013377926
areasunderthecurvesauc010h,0.08361204013377926
eliminationhalflifevaluest12beta,0.08361204013377926
peakperitonealfluid,0.08361204013377926
tmaxatsteadystate,0.08361204013377926
ratioofauc08hsteadystateauc08h,0.08361204013377926
peakplasmanifedipineconcentration,0.08361204013377926
maximalnifedipineplasmaconcentrationscmax,0.08361204013377926
unboundropivacaine,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc06,0.08361204013377926
plasmadigoxinconcentration,0.08361204013377926
halflifedrug,0.08361204013377926
kidneyclearance,0.08361204013377926
oxidationactivity,0.08361204013377926
p450content,0.08361204013377926
areaunderthecurveofthedrugconcentrationsintime,0.08361204013377926
kaalpharelationship,0.08361204013377926
kaalpha,0.08361204013377926
totalsystemicresistance,0.08361204013377926
areaunderthecurvefromtime0toinfinityauc0,0.08361204013377926
peakpregabalinconcentration,0.08361204013377926
timeabovetheminimumtherapeuticconcentration,0.08361204013377926
timetopeakpregabalinconcentration,0.08361204013377926
peakbrainlevel,0.08361204013377926
areaundertheplasmaconcentrationtimeprofileareaunderthecurve,0.08361204013377926
aucsub0inf,0.08361204013377926
wholeplasmaclearance,0.08361204013377926
timetopeaknifedipineconcentration,0.08361204013377926
biologichalflifeintheeliminationphase,0.08361204013377926
ca,0.08361204013377926
maximalpossiblebioavailability,0.08361204013377926
concentrationat2hpostinfusionc2h,0.08361204013377926
distributionrateconstantsalpha,0.08361204013377926
volumeofcentralcompartmentisvc,0.08361204013377926
aucsub0lastsub,0.08361204013377926
unboundphenytoinfraction,0.08361204013377926
sssc,0.08361204013377926
maximalsteadystateplasmaconcentration,0.08361204013377926
cmaxtooccur,0.08361204013377926
timeover,0.08361204013377926
areaunderthecurvefromtime0to36hour,0.08361204013377926
intrinsicp,0.08361204013377926
maximaleliminationratesvmax,0.08361204013377926
intrinsicmetabolicactivityvmaxkm,0.08361204013377926
totalprocessingtime,0.08361204013377926
apparentv,0.08361204013377926
cmaxsst,0.08361204013377926
auc0tausst,0.08361204013377926
drugloadedamount,0.08361204013377926
areaunderthecurvefromtimezerotothelastsamplingtimeauc0t,0.08361204013377926
areaunderthecurvefrom0to6hour,0.08361204013377926
areasundertheplasmaleveltimecurve,0.08361204013377926
peakplasmaconcentrationcmaxabs,0.08361204013377926
halfeliminationperiod,0.08361204013377926
24htroughlevel,0.08361204013377926
areaunderthebloodconcentrationtimecurvefromtime0totimeinfinity,0.08361204013377926
vfvolumeofdistribution,0.08361204013377926
hepatobiliaryexcretionratio,0.08361204013377926
timeabovethemic,0.08361204013377926
areasundertheconcentrationcurveaucs,0.08361204013377926
hepatobiliaryclearance,0.08361204013377926
24hareaunderthecurveauc,0.08361204013377926
areundertheconcentrationtimecurvetoinfinityauc0infinity,0.08361204013377926
areaundertheconcentrationvstimecurvefrom0to24hr,0.08361204013377926
maintenancelevel,0.08361204013377926
stomachdeposition,0.08361204013377926
totaldepositeddose,0.08361204013377926
maximumdrugload,0.08361204013377926
terminalfirstorderrateconstantbeta,0.08361204013377926
amountabsorbed,0.08361204013377926
areaunderthewholebloodconcentrationversustimecurvefrom012hauc012,0.08361204013377926
eliminationhalflivest12lambdaz,0.08361204013377926
intercompartmentalclearanceafteroraladministrationqf,0.08361204013377926
bindingaffinityconstant,0.08361204013377926
percentageentrapmentefficiencie,0.08361204013377926
endogenoussecretionrate,0.08361204013377926
glomerularfiltrationrategfr,0.08361204013377926
effectiverenalplasmaflowerpf,0.08361204013377926
restingplasmaanflevel,0.08361204013377926
centralvolumeofdistributionafteroraladministrationv1f,0.08361204013377926
apparenturinarycsaclearance,0.08361204013377926
clfss,0.08361204013377926
apparentdurationofeffect,0.08361204013377926
clearanceofunboundtemazepam,0.08361204013377926
peakplasmatemazepamconcentration,0.08361204013377926
distributiona,0.08361204013377926
eliminationbeta,0.08361204013377926
intermediatet12,0.08361204013377926
durationofdrugabsorptiont,0.08361204013377926
weightadjustedmaximumplasmaconcentrationcmax,0.08361204013377926
percentageofdose,0.08361204013377926
areaunderthetimeconcentrationcurvefrom0to12h,0.08361204013377926
peakplasmacialevel,0.08361204013377926
lymphaticavailability,0.08361204013377926
maximumlymphcialevel,0.08361204013377926
timestoreachmaximumeffect,0.08361204013377926
absoluteintranasalbioavailability,0.08361204013377926
totaldrugreleased,0.08361204013377926
rateofmeandrugclearance,0.08361204013377926
sloweliminationphaset12beta,0.08361204013377926
percentagesrecovered,0.08361204013377926
percentagesofdoserecovered,0.08361204013377926
timetopeakplasmamoricizineconcentration,0.08361204013377926
peakplasmamoricizineconcentration,0.08361204013377926
maximalmoricizineconcentration,0.08361204013377926
maximalplasmaunboundpropiverineequivalentscmax,0.08361204013377926
areasunderplasmaconcentrationtimecoursecurvesauc,0.08361204013377926
bloodtobiledistributionratiok,0.08361204013377926
apparenttransbuccalmucosalpermeabilitycoefficient,0.08361204013377926
rectalsystemicavailabilitie,0.08361204013377926
maximalrateofabsorption,0.08361204013377926
timeatwhichthi,0.08361204013377926
halflifeofthealphaphase,0.08361204013377926
maximalserumetomidateconcentration,0.08361204013377926
timetoreachmaximalserumconcentration,0.08361204013377926
volumeforthecentralcompartment,0.08361204013377926
mrt012h,0.08361204013377926
osmoticpressure,0.08361204013377926
volumesofdistributionatcentral,0.08361204013377926
clearancesatsteadystate,0.08361204013377926
halflifegamma,0.08361204013377926
logbb,0.08361204013377926
peakplasmascopolamineconcentration,0.08361204013377926
c3,0.08361204013377926
c4,0.08361204013377926
auc06hours,0.08361204013377926
polydispersibility,0.08361204013377926
peakplasmaatralevel,0.08361204013377926
timetoreachthismaximum,0.08361204013377926
areasundertheconcentrationtimecurveconcentrationinplasmaversustime,0.08361204013377926
timerequiredtoreachthepeakplasmalevel,0.08361204013377926
pexcretion,0.08361204013377926
peakplasmaticconcentration,0.08361204013377926
embryomaternalplasmaratio,0.08361204013377926
percentdissolution,0.08361204013377926
pulmonaryhalflife,0.08361204013377926
liverlevel,0.08361204013377926
areaunderthedrugtimecurveauc,0.08361204013377926
auc0infinityserum,0.08361204013377926
tissueplasmaretinamideratio,0.08361204013377926
maximalvelocityofelimination,0.08361204013377926
volumeofskinblister,0.08361204013377926
areaundertheplasmadrugconcentrationvstimecurvefrom0to4h,0.08361204013377926
bmax2,0.08361204013377926
peakmpconcentration,0.08361204013377926
timetoachieveascendingplasmamphconcentration,0.08361204013377926
apparentalphahalflife,0.08361204013377926
apparentbetahalflife,0.08361204013377926
urinaryclearancetime,0.08361204013377926
oralfluidpeakconcentration,0.08361204013377926
oralfluidtoplasmamphratio,0.08361204013377926
peakmphconcentration,0.08361204013377926
auc4,0.08361204013377926
oralfluidconcentration,0.08361204013377926
sleeplatency,0.08361204013377926
minimumtransportarea,0.08361204013377926
mobility,0.08361204013377926
initialpeakplasmaconcentration,0.08361204013377926
initialplateauconcentration,0.08361204013377926
constantkme,0.08361204013377926
maximalvelocityofabsorption,0.08361204013377926
initialpeakatra,0.08361204013377926
areaundertheconcentrationtimecurvefromzerotothetimepointwiththelastmeasurableconcentrationauclast,0.08361204013377926
normalizedareasundertheplasmaconcentrationtimecurve,0.08361204013377926
maximalcsaplasmalevel,0.08361204013377926
troughcsabloodlevel,0.08361204013377926
cvauc,0.08361204013377926
solubilization,0.08361204013377926
auco4,0.08361204013377926
timetoclinicalremission,0.08361204013377926
maximalplasmaconcentrationcpmax,0.08361204013377926
totalvolumeofdistributionatsteadystate,0.08361204013377926
apparentin,0.08361204013377926
fluidtobloodratio,0.08361204013377926
fluidtobloodaucratio,0.08361204013377926
bmax1,0.08361204013377926
kd2,0.08361204013377926
apparentvolumeofdistributionforthecentralcompartmentvdf,0.08361204013377926
areaundertheconcentrationtimecurveoverthefirst4hourspostdoseauc04h,0.08361204013377926
auc05,0.08361204013377926
t12g,0.08361204013377926
gastrichalflifet12g,0.08361204013377926
effectivenesstroughlevelsctrough,0.08361204013377926
nonresponse,0.08361204013377926
auclimit,0.08361204013377926
snaareaundertheconcentrationtimecurve,0.08361204013377926
overallexcretion,0.08361204013377926
firstorderterminalhalflife,0.08361204013377926
turnovertimes1kel,0.08361204013377926
areaunderraconcentrationovertimecurve,0.08361204013377926
plasmapeaktime,0.08361204013377926
volumeofperipheralcompartmentvp,0.08361204013377926
volumeofdistributionatthesteadystatevss,0.08361204013377926
logpcoct,0.08361204013377926
peaktotalconcentration,0.08361204013377926
percentageofdrugboundto,0.08361204013377926
peakserumdrugconcentration,0.08361204013377926
inductiontarget,0.08361204013377926
timestoinductionofan,0.08361204013377926
wakingtime,0.08361204013377926
timetoinduction,0.08361204013377926
firstexponentialphasehalflife,0.08361204013377926
thirdexponentialphasehalflife,0.08361204013377926
bloodconcentrationcp,0.08361204013377926
lossrate,0.08361204013377926
halftimeofdistributionphase,0.08361204013377926
areasundertheplasmavstimeconcentrationcurvein24hauc024,0.08361204013377926
auc024mic90,0.08361204013377926
recoveryfromsedation,0.08361204013377926
clinicalrecoverytimepostsedationresponsiveness,0.08361204013377926
timetoeradication,0.08361204013377926
maximalva,0.08361204013377926
passivetransdermalflux,0.08361204013377926
intercompartmentalrateconstant,0.08361204013377926
cerebralbloodflowvelocity,0.08361204013377926
areaunderthecurvefrom0to24hrauc024minimuminhibitoryconcentrationmicratio,0.08361204013377926
centralcompartmentdistributionvolumevc,0.08361204013377926
distributionphasehalftimet12alpha,0.08361204013377926
amtoplasmaratio,0.08361204013377926
ctci,0.08361204013377926
peakplasmaconcentrationsmic,0.08361204013377926
areaunderthecurvefromthetimeofdosingto24hrminimalinhibitoryconcentrationmic,0.08361204013377926
cip,0.08361204013377926
peakciprofloxacinconcentration,0.08361204013377926
clearancesofthecentralcl1,0.08361204013377926
steadystateplasmapropofolconcentration,0.08361204013377926
halflifet12ke0,0.08361204013377926
totalbodyclearanceincrease,0.08361204013377926
halftimet12ke0,0.08361204013377926
apparenteffectsiteconcentration,0.08361204013377926
compartmentclearanceq,0.08361204013377926
cpred50,0.08361204013377926
terminalhalflifet12tbeta,0.08361204013377926
peakplasmaclonidineconcentration,0.08361204013377926
apparentke0,0.08361204013377926
volumeofdistributionv1clearancecl,0.08361204013377926
awakening,0.08361204013377926
recoveryfromblood,0.08361204013377926
halflifeoftheadditionalinitialdistributionphaset12lambda1,0.08361204013377926
terminalhalflifet12lambda2,0.08361204013377926
initialtargetconcentration,0.08361204013377926
maximalcsfconcentration,0.08361204013377926
timetolossofresponsivenesslor,0.08361204013377926
hydroxylase,0.08361204013377926
freefractioninblood,0.08361204013377926
venousserumpropofolconcentration,0.08361204013377926
clnonorgan,0.08361204013377926
clorgan,0.08361204013377926
sedationconcentration,0.08361204013377926
timetoachievemaximumplasmaconcentration,0.08361204013377926
effectsiteconcentrationce50,0.08361204013377926
bispectralindexbis,0.08361204013377926
totalsedationrelatedadverseeventrate,0.08361204013377926
timetopeakeffecttpeak,0.08361204013377926
onsetofanal,0.08361204013377926
maximalclonidineconcentration,0.08361204013377926
ocularclearanceqe,0.08361204013377926
apparentsteadystatevolumeofdistributionv,0.08361204013377926
ratioofbrainplasmaareaunderthecurve,0.08361204013377926
finalphasehalflife,0.08361204013377926
meanresidencetimemrtd,0.08361204013377926
cornealabsorptionrateconstantka,0.08361204013377926
targetconcentrationtc,0.08361204013377926
volumeofdistributionbasedontheterminalphasev,0.08361204013377926
effectsiteconcentrationatlossofconsciousne,0.08361204013377926
effectsiteconcentrationatrecoveryofconsciousne,0.08361204013377926
elftoplasmaratio,0.08361204013377926
ultrafiltrateflowrateufr,0.08361204013377926
boneconcentration,0.08361204013377926
prostatebloodratio,0.08361204013377926
milkeliminationhalflive,0.08361204013377926
totalbiliaryelimination,0.08361204013377926
minimuminhibitoryconcentrationmicaucmic,0.08361204013377926
gastricresidenceperiod,0.08361204013377926
constantplasmabloodconcentrationratio,0.08361204013377926
prostateconcentration,0.08361204013377926
peakplasmadoxylamineconcentrationcmax,0.08361204013377926
distributiont12t12,0.08361204013377926
auctnormal,0.08361204013377926
toreachpeakconcentration,0.08361204013377926
clearanceofcentralcompartment,0.08361204013377926
clearanceofintercompartment,0.08361204013377926
intervalfromoraladministrationuntilmaximalconcentration,0.08361204013377926
minimumtroughplasmamodafinilconcentration,0.08361204013377926
eliminationt12t12beta,0.08361204013377926
rateconstantsk12,0.08361204013377926
transformationrate,0.08361204013377926
steadystateplasmalevelsc,0.08361204013377926
steadystatediltiazemconcentration,0.08361204013377926
areasundertheconcentrationcurvesauc12h,0.08361204013377926
areaunderthecurveauctomicratio,0.08361204013377926
lagtimet10,0.08361204013377926
totalareaunderthecurveauc0oo,0.08361204013377926
cumulatedrenalexcretion,0.08361204013377926
time0tothelastquantifiablesampleauc0tlast,0.08361204013377926
volumeofdistributionareavarea,0.08361204013377926
cumulatedrecovery,0.08361204013377926
kt0,0.08361204013377926
halftimesofinitial,0.08361204013377926
terminaldrugaccumulationphase,0.08361204013377926
minimumdecreasemaximumdecreaseratio,0.08361204013377926
areaunderthecurveaucratioauc,0.08361204013377926
relativeconversionfraction,0.08361204013377926
pseudosteadystatetargetconcentration,0.08361204013377926
meanrecoverytime,0.08361204013377926
dilutionrate,0.08361204013377926
effectsiteconcentrationsces,0.08361204013377926
areaunderconcentrationtimecurvemicratiosauc024hmic,0.08361204013377926
minimalbactericidalconcentrationmbc,0.08361204013377926
tci,0.08361204013377926
timewhenthemaximumconcentrationreachedtmax,0.08361204013377926
fractionofdrugeliminatedduringtheterminalphase,0.08361204013377926
totalareaunderthecurveaucoalpha,0.08361204013377926
eliminationhalflivest12b,0.08361204013377926
maximumdialysateconcentration,0.08361204013377926
clearanceclstd,0.08361204013377926
peripheralvolume1,0.08361204013377926
peripheralvolume2,0.08361204013377926
steadystatemaximumserumconcentration,0.08361204013377926
areaunderthetimecurvefrom012h,0.08361204013377926
slowdistributionclearancecl3,0.08361204013377926
rapiddistributionclearancecl2,0.08361204013377926
slowdistributioncompartmentv3,0.08361204013377926
rapiddistributioncompartmentv2,0.08361204013377926
cpmaxmic,0.08361204013377926
percentabsolutebioavailability,0.08361204013377926
sputumlevel,0.08361204013377926
respiratory,0.08361204013377926
apparenttimelagbeforeabsorption,0.08361204013377926
eliminationphasedistributionvolume,0.08361204013377926
peakdose,0.08361204013377926
areaundertheconcentrationtimecurveaucdose,0.08361204013377926
timestocessation,0.08361204013377926
blood14cconcentration,0.08361204013377926
durationofsleep,0.08361204013377926
cppl,0.08361204013377926
cpg,0.08361204013377926
eliminationfromtheeffectcompartment,0.08361204013377926
halflivesofuptakeinto,0.08361204013377926
concentrationsatapparentsteadystate,0.08361204013377926
t12a2,0.08361204013377926
volumesofdistributionatsteadystatevd,0.08361204013377926
maximumclpinhibitionimax,0.08361204013377926
imaxi50,0.08361204013377926
maximumpossibleeffectae90,0.08361204013377926
effectsiteamount,0.08361204013377926
correctedrenaldrugclearance,0.08361204013377926
totalclearanceofthedrugfromserum,0.08361204013377926
clearancesclp,0.08361204013377926
apparentareavolumeofdistributionvdarea,0.08361204013377926
peakserumdrugconcentrationcmax,0.08361204013377926
areaundertheconcentrationversustimecurvefrom0to24h,0.08361204013377926
maximumfreeropivacaineconcentration,0.08361204013377926
subcutaneousbioavailabilitie,0.08361204013377926
halflivesoftheterminaleliminationphase,0.08361204013377926
biologicalhalflivesateliminationphaset12,0.08361204013377926
serumproteinbindingrate,0.08361204013377926
initialuptakeclearance,0.08361204013377926
maximumcidofovirplasmaconcentration,0.08361204013377926
bioavailablef,0.08361204013377926
peakampicillinplasmaconcentration,0.08361204013377926
maximumfreefraction,0.08361204013377926
maximalrateofeliminationvm,0.08361204013377926
unboundmichaelismentenconstantkmu,0.08361204013377926
unboundvolumeofdistributionofthecentralcompartmentvcu,0.08361204013377926
overalldispositionhalflife,0.08361204013377926
urinaryrecoveriesur,0.08361204013377926
arterialbloodconcentration,0.08361204013377926
penetrationpercentage,0.08361204013377926
fractionexcreted,0.08361204013377926
urinaryrecoveryin24h,0.08361204013377926
steepnessparameter,0.08361204013377926
ke0halflife,0.08361204013377926
plasmaproteinbindingfp,0.08361204013377926
michaelismentenconstantconstant,0.08361204013377926
fmugt,0.08361204013377926
90minimalinhibitoryconcentration,0.08361204013377926
renalclearanceoftheunbounddrug,0.08361204013377926
peaktotalplasmaconcentrationscmax,0.08361204013377926
absorptionratek12,0.08361204013377926
minimalinhibitoryconcentrationmic90,0.08361204013377926
renalexcretionratetime,0.08361204013377926
eliminationofhalflifet12beta,0.08361204013377926
totalbodyclearancecib,0.08361204013377926
clearanceratiorenalclearanceglomerularfiltrationrate,0.08361204013377926
halflifeofabsorptiont12ab,0.08361204013377926
uic50,0.08361204013377926
apparentcentralvolumevf,0.08361204013377926
maximumdetectedconcentration,0.08361204013377926
ultimateserumhalflife,0.08361204013377926
totalsystemicclearanceclts,0.08361204013377926
unboundplasmaconcentrationsatcmax,0.08361204013377926
intrinsict12,0.08361204013377926
peakvenousplasmaconcentrationscmax,0.08361204013377926
plasmadrughalflife0693vmkm,0.08361204013377926
vmkmratio,0.08361204013377926
plasmadrughalflife,0.08361204013377926
peakprobenecidlevel,0.08361204013377926
halflifeinserum,0.08361204013377926
urinaryrecoveryofadministereddose,0.08361204013377926
decay,0.08361204013377926
timestomaximumplasmaropivacaineconcentrationtmax,0.08361204013377926
volumeofdistributionduringtheterminalexponentialphaseofdrugelimination,0.08361204013377926
serumhalflivest12s,0.08361204013377926
ratiosr,0.08361204013377926
apparentvolumeofdistributionatthesteadystatevdss,0.08361204013377926
ratioofmeropenem,0.08361204013377926
renalcortexplasmaconcentrationratio,0.08361204013377926
totalmeanclearance,0.08361204013377926
mz275,0.08361204013377926
halflike,0.08361204013377926
totaldistributionvolumevarea,0.08361204013377926
plasmatarget,0.08361204013377926
steadystateplasmaclearanceclss,0.08361204013377926
maximuminfusionrateduringsteadystatecondition,0.08361204013377926
effectsitepeak,0.08361204013377926
plasmaconcentrationovershoot,0.08361204013377926
dispositionrateapparentabsorption,0.08361204013377926
faecalrecovery,0.08361204013377926
thalfkeo,0.08361204013377926
slopeoftheeffectconcentrationrelationship,0.08361204013377926
operatingtime,0.08361204013377926
12,0.08361204013377926
firstorderrateconstantforabsorption,0.08361204013377926
apparentvdbeta,0.08361204013377926
volumeofdistributionvc,0.08361204013377926
terminalvolumeofdistributionvz,0.08361204013377926
clearancefromthesecondcompartmentcld2,0.08361204013377926
ultimatehalflife,0.08361204013377926
pulmonarytissuecompartment,0.08361204013377926
timetowalkingwithoutataxia,0.08361204013377926
doseperweight,0.08361204013377926
bloodconcentrationat,0.08361204013377926
pwrmax,0.08361204013377926
concentrationtoplasmaconcentrationratio,0.08361204013377926
trainoffourrecoveryratio,0.08361204013377926
pulmonaryfirstpasselimination,0.08361204013377926
tbetas12,0.08361204013377926
slowphase,0.08361204013377926
ni,0.08361204013377926
eliminationrateconstantke0,0.08361204013377926
rapidphase,0.08361204013377926
estimated,0.08361204013377926
timetoloc,0.08361204013377926
clearanceofunboundoxa,0.08361204013377926
minimaleffectiveconcentrationcmin,0.08361204013377926
durationoftherapeuticconcentrationdtc,0.08361204013377926
cumulativebiliaryexcretionamount,0.08361204013377926
timestotwosegmentregression,0.08361204013377926
maximumthoraciclevel,0.08361204013377926
dc0dt,0.08361204013377926
distributionserumhalflifet12alpha,0.08361204013377926
eliminationserumhalflifet12beta,0.08361204013377926
serumclearancescs,0.08361204013377926
biliaryclearanceclb,0.08361204013377926
peakpenicillinconcentration,0.08361204013377926
clearanceratiocsagfr,0.08361204013377926
csa,0.08361204013377926
renalexcretionrate,0.08361204013377926
maximalropivacaineconcentration,0.08361204013377926
heightoftheplateauvalue,0.08361204013377926
ultimatehalflifet12,0.08361204013377926
totaldurationsofsensoryblockade,0.08361204013377926
excretedhalflive,0.08361204013377926
totalburnsurfacearea,0.08361204013377926
expiredfraction,0.08361204013377926
intrathecalbioavailability,0.08361204013377926
serumrobenacoxibconcentrationat240minc240,0.08361204013377926
maximumserumconcentrationofrobenacoxibcmax,0.08361204013377926
transferconstantfromcompartment1tocompartment2k12,0.08361204013377926
timeto80block,0.08361204013377926
ratiooftoxictotherapeuticplasmaconcentration,0.08361204013377926
minimalantiarrhythmicplasmaconcentration,0.08361204013377926
maximumunboundfreeplasmaconcentration,0.08361204013377926
timetothefirstdemandforanalgesia,0.08361204013377926
peakfreeropivacaineconcentration,0.08361204013377926
peakfreeplasmaconcentration,0.08361204013377926
individualfreeplasmaconcentration,0.08361204013377926
peaktotalplasmaconcentration,0.08361204013377926
halfdistribution,0.08361204013377926
minimaltherapeuticplasmaethacyzineconcentration,0.08361204013377926
totalplasmamaximumconcentrationcmax,0.08361204013377926
steadystatemeanplasmaconcentration,0.08361204013377926
rateofigeproduction,0.08361204013377926
dissociationconstantforbinding,0.08361204013377926
fractionexcretedinbile,0.08361204013377926
fractionofeliminated,0.08361204013377926
totalperfusateclearance,0.08361204013377926
peakgemfibrozilconcentration,0.08361204013377926
association,0.08361204013377926
steadystateadductconcentration,0.08361204013377926
peakadinazolamplasmaconcentrationscmax,0.08361204013377926
apparentmetaboliteclearanceclmcfm,0.08361204013377926
freeintrinsicclearance,0.08361204013377926
relativeauc60min,0.08361204013377926
brainbodyexposureratio,0.08361204013377926
inhibitorydosesid50,0.08361204013377926
timetofirstasthmaexacerbation,0.08361204013377926
firstorderinternalizationrateconstant,0.08361204013377926
transferconstantfromthecentralcompartmenttotheoutsidek10,0.08361204013377926
areaundertheplasmaconcentrationtimecurveauc0tau,0.08361204013377926
hepaticclearanceofeviniferinvmaxkm,0.08361204013377926
overallzetapotential,0.08361204013377926
selfem,0.08361204013377926
t12ter,0.08361204013377926
troughcminconcentration,0.08361204013377926
steadystateconcentrationofdrug,0.08361204013377926
radioactivityexcreted,0.08361204013377926
maximalconcentrationofreceptor,0.08361204013377926
plasmaaucinf,0.08361204013377926
plasmaconcentrationsofnilcnil,0.08361204013377926
clqh,0.08361204013377926
steadystateareaundertheplasmaconcentrationtimecurveaucss,0.08361204013377926
overallorr,0.08361204013377926
x4,0.08361204013377926
residualdrugactivity,0.08361204013377926
braintosystemicexposureratio,0.08361204013377926
lc95,0.08361204013377926
feversubsidencetimefst,0.08361204013377926
maximumfreebrainconcentration,0.08361204013377926
totaldrugexposure,0.08361204013377926
minimumwholebloodmefloquineconcentration,0.08361204013377926
minimumconcentrationof,0.08361204013377926
totalinhaledbioavailability,0.08361204013377926
timefromdoseadministrationtopeakwholebloodmefloquineconcentration,0.08361204013377926
plasmamconcentration,0.08361204013377926
maximumbrain,0.08361204013377926
log10parasitereductionratio,0.08361204013377926
percentagef,0.08361204013377926
apparentperipheraldistributionvolume,0.08361204013377926
apparentdistributionclearance,0.08361204013377926
wholebloodhalflife,0.08361204013377926
erythrocytetoplasmaratio,0.08361204013377926
maximumwholebrainconcentration,0.08361204013377926
concentrationstaysabovea,0.08361204013377926
totaldruglevel,0.08361204013377926
timetakentocleartheparasitespct,0.08361204013377926
maximumserumibutilideconcentration,0.08361204013377926
areaundertheserumconcentrationtimecurvefromtimezeroextrapolatedtoinfinity,0.08361204013377926
tl2z,0.08361204013377926
terminalhalflivest12z,0.08361204013377926
parasitemiahalflifehalflife,0.08361204013377926
volumeofdistributionvdzf,0.08361204013377926
peakblooddrugconcentration,0.08361204013377926
timeartem,0.08361204013377926
pct50,0.08361204013377926
50inhibitionconcentrationsic50,0.08361204013377926
aucfromzerotimeto5day,0.08361204013377926
maximumbound,0.08361204013377926
unboundbrainlevel,0.08361204013377926
totalauccmax,0.08361204013377926
areaundertheserumconcentrationtimecurvefromzerotoinfinityauc0infinity,0.08361204013377926
livertargetingindex,0.08361204013377926
fractionofdrugabsorbed,0.08361204013377926
halflifefordistribution,0.08361204013377926
halflivesfordistribution,0.08361204013377926
areaundertheconcentrationxtimecurve,0.08361204013377926
totalbodyclearanceclpl,0.08361204013377926
active,0.08361204013377926
ppb,0.08361204013377926
peakplasmaflumazenilconcentration,0.08361204013377926
halftimeof,0.08361204013377926
eliminationhalflifet12m,0.08361204013377926
plasmaclearanceclel,0.08361204013377926
distributionalclearancecldist,0.08361204013377926
peakplasmadantroleneconcentration,0.08361204013377926
timetoprogressionsurvival,0.08361204013377926
totalplasmaplatinum,0.08361204013377926
percentagesofrelease,0.08361204013377926
transwellpermeabilityrate,0.08361204013377926
trougheculizumabconcentration,0.08361204013377926
aue04h,0.08361204013377926
eliminationhalflifet12k,0.08361204013377926
molarsubstitutionratio,0.08361204013377926
areaunderthecelecoxibplasmaconcentrationtimecurve,0.08361204013377926
maximuminjectiontime,0.08361204013377926
fractionofbounddrug,0.08361204013377926
percentdrugrelease,0.08361204013377926
maximumobservedplasmaconcentrationscmax,0.08361204013377926
halflivesofthebiexponentialeliminationt12alpha,0.08361204013377926
halfmaximaleffectivedoseed50,0.08361204013377926
eliminationhalflivest12k,0.08361204013377926
plasmacbconcentration,0.08361204013377926
timeformaximumconcentration,0.08361204013377926
maximumplasmaclenbuterolconcentration,0.08361204013377926
serumfreec5concentration,0.08361204013377926
freec5concentration,0.08361204013377926
firstordersrateconstant,0.08361204013377926
krel,0.08361204013377926
areaundertheconcentrationcurvein,0.08361204013377926
ratioofareaunderthecurve,0.08361204013377926
plasmadrugeliminationhalflife,0.08361204013377926
ic50concentrationofdrugrequiredtoachievehalfmaximalgrowthsuppression,0.08361204013377926
areaunderplasmaconcentrationtimecurveatsteadystate,0.08361204013377926
cumulativepercentagedrugrelease,0.08361204013377926
globulediameter,0.08361204013377926
aucfromtimezeroto48hoursauc48,0.08361204013377926
salivaoutput,0.08361204013377926
auc010d,0.08361204013377926
areaundertheplasmatimecoursecurve,0.08361204013377926
skinabsorption,0.08361204013377926
ratiofortheauc,0.08361204013377926
nonsaturableclearance,0.08361204013377926
urinet12,0.08361204013377926
halflifeofhydrolysi,0.08361204013377926
steadystateplasmappcconcentration,0.08361204013377926
integratedeffectauec0288h,0.08361204013377926
quicktime,0.08361204013377926
peakplasmaresveratrolconcentrationcmax,0.08361204013377926
extravascularlevel,0.08361204013377926
aucoomega,0.08361204013377926
clearancefraction,0.08361204013377926
meantransittimemtt0last,0.08361204013377926
absorptionlo,0.08361204013377926
progressionfreerate,0.08361204013377926
fractionexcretedunchangedinurinefe,0.08361204013377926
distributionvc,0.08361204013377926
residencemtt0last,0.08361204013377926
tmaxpredicted,0.08361204013377926
drugtargetingefficiencyte,0.08361204013377926
deathrate,0.08361204013377926
completeruntime,0.08361204013377926
lc5050lethalconcentration,0.08361204013377926
ltratio,0.08361204013377926
steadystatemcr,0.08361204013377926
mrnalevel,0.08361204013377926
overallratio,0.08361204013377926
peakplasmaconcentrationcmaxminimalinhibitoryconcentrationmicratio,0.08361204013377926
plasmaradioactivityconcentration,0.08361204013377926
lagtimeofreabsorptiont,0.08361204013377926
reabsorptionratera,0.08361204013377926
areaunderthecurverepresentingtheconcentrationofdiazepamovera24hourperiodauc024,0.08361204013377926
peakplasmadesmethyldiazepamconcentration,0.08361204013377926
overallhalflive,0.08361204013377926
k01hl,0.08361204013377926
k12hl,0.08361204013377926
k10hl,0.08361204013377926
maximumplasmadiazepamconcentration,0.08361204013377926
dzratio,0.08361204013377926
timeofthemaximalplasmaconcentration,0.08361204013377926
halflivesofdisappearance,0.08361204013377926
numberofsite,0.08361204013377926
ratesofdrugclearance,0.08361204013377926
precursortoproduction,0.08361204013377926
equilibriumplasmaconcentration,0.08361204013377926
serumdiazepamlevel,0.08361204013377926
inputrateintotheextravascularcompartment2,0.08361204013377926
plasmaappearancerate,0.08361204013377926
plasmane,0.08361204013377926
absorptionhalflifet12,0.08361204013377926
areaunderthescoretimecurvefrom0to8h,0.08361204013377926
freeplasmaclearance,0.08361204013377926
initialmaximum,0.08361204013377926
secondmaximum,0.08361204013377926
removalof,0.08361204013377926
maximumvenou,0.08361204013377926
lofl,0.08361204013377926
receptorbindingactivitie,0.08361204013377926
biologicalhalflifet2,0.08361204013377926
cmaxvalue,0.08361204013377926
maximumconcentrationobservedcmax,0.08361204013377926
logd7,0.08361204013377926
concentrationof,0.08361204013377926
inhibitoryquotientswgiq,0.08361204013377926
maximumplasmamaravirocconcentration,0.08361204013377926
areaundertheplasmaconcentrationtimecurveforthedosingintervalauctau,0.08361204013377926
totalmaravir,0.08361204013377926
concentrationscavg,0.08361204013377926
steadystatedruglevel,0.08361204013377926
bloodconcentrationpeakvalue,0.08361204013377926
areaundertheplasmaconcentrationtimecurvesfromtime0toinfinityauc0inf,0.08361204013377926
compartmenttoplasmaratio,0.08361204013377926
peakplasmasalicylatelevel,0.08361204013377926
auccellauctotgmratio,0.08361204013377926
areaunderthetimeconcentrationcurvefrom012hauc012,0.08361204013377926
constantplasmalevel,0.08361204013377926
peakmedianplasmabismuthconcentration,0.08361204013377926
intrinsicdissolutionratesidrs,0.08361204013377926
peakretentiontime,0.08361204013377926
amountofdrug,0.08361204013377926
dispersibility,0.08361204013377926
mma,0.08361204013377926
vdsslkg,0.08361204013377926
tolerability,0.08361204013377926
clearanceofunbounddiazepamintrinsicclearance,0.08361204013377926
depthofmicroprojectionpenetration,0.08361204013377926
fractionalrenalexcretion,0.08361204013377926
apparentbloodhalflife,0.08361204013377926
flexibility,0.08361204013377926
eliminationor,0.08361204013377926
amountsexcretedunchanged,0.08361204013377926
cumulativepenetrationamount,0.08361204013377926
concentrationscausing50inhibitioni50,0.08361204013377926
plasmaclearancehalflive,0.08361204013377926
volumeofdistributiononehalf,0.08361204013377926
lymphatic,0.08361204013377926
aucratioofunbounddrug,0.08361204013377926
peakvaluesofserumconcentration,0.08361204013377926
map,0.08361204013377926
intoxicationrate,0.08361204013377926
relativebioavalability,0.08361204013377926
differencefactorf1,0.08361204013377926
512beta,0.08361204013377926
percentage12hrenalelimination,0.08361204013377926
serumhalflivest12,0.08361204013377926
maximalapparentserumconcentration,0.08361204013377926
minimuminhibitionconcentration,0.08361204013377926
serumconcentrationat8hour,0.08361204013377926
areaderivedvolumeofdistributionvdarea,0.08361204013377926
renalclearancec1r,0.08361204013377926
ccsf0nor,0.08361204013377926
ccsfbasenorratio,0.08361204013377926
urinaryexcretionae0,0.08361204013377926
fabeliminationhalflife,0.08361204013377926
braintoblood,0.08361204013377926
bohavailability,0.08361204013377926
mz290,0.08361204013377926
productionvelocity,0.08361204013377926
areaundertheconcentrationtimecurvefromtimezerotothelastquantifiabletimeauc0t,0.08361204013377926
areaunderthedrugconcentrationintheahtimecurveauc,0.08361204013377926
areasunderthecurvefromtime0to360h,0.08361204013377926
024hareaunderthecurveauc024h,0.08361204013377926
totaldrugoutput,0.08361204013377926
steadystateplasmadigoxinconcentration,0.08361204013377926
steadystatevolumeofthedistribution,0.08361204013377926
excretoryhalflife,0.08361204013377926
timeforpeakabsorption,0.08361204013377926
massmedianaerodynamicdiametersmmads,0.08361204013377926
urineconcentrationt2,0.08361204013377926
cumulativerenalexeretion,0.08361204013377926
meanresidencetimeratiosmrt,0.08361204013377926
peakconcentrationsratiocmaxrumencmaxplasma,0.08361204013377926
aucrumenauc,0.08361204013377926
percentageofdrugabsorbed,0.08361204013377926
areaunderserumconcentrationtimecurvefrom0to4hafterinhalationauc04,0.08361204013377926
timetopeakterbutalineconcentration,0.08361204013377926
systemicmeanresidencetime,0.08361204013377926
timerequiredforcompletedegradation,0.08361204013377926
systemicbioavailabilityratio,0.08361204013377926
uptakehalftime,0.08361204013377926
uter05,0.08361204013377926
ed100,0.08361204013377926
maximalincreaseinfvc,0.08361204013377926
bileclearance,0.08361204013377926
eliminationconstantofthesecondphase,0.08361204013377926
maximumserumterbutalineconcentration,0.08361204013377926
inhaledflow,0.08361204013377926
timetomean,0.08361204013377926
maximumserumconcentrationofterbutalinecmax,0.08361204013377926
effectivebloodlevel,0.08361204013377926
serumconcentrationcurve,0.08361204013377926
fractionalmy,0.08361204013377926
peakplasmalevelsattained,0.08361204013377926
areaundertheserumconcentrationtimecurvewithinthefirst6h,0.08361204013377926
steadystateterminalhalflife,0.08361204013377926
intermediaryt12,0.08361204013377926
increasedbioavailability,0.08361204013377926
areasundertheserumconcentrationtimecurveauc0infinity,0.08361204013377926
areaundercurvefrom0to12hoursauc012,0.08361204013377926
stre,0.08361204013377926
bloodflowratio,0.08361204013377926
peaknorfloxacinconcentration,0.08361204013377926
areaunderplasmaconcentrationcurveauco12hr,0.08361204013377926
timetakentoachievemeanpeakplasmaconcentrationtmax,0.08361204013377926
finaldecayconstant,0.08361204013377926
totalmeanpercentrecovery,0.08361204013377926
entrapmentpercent,0.08361204013377926
sbet,0.08361204013377926
areasunderconcentrationcurve,0.08361204013377926
tgamma,0.08361204013377926
ratioofareaundercurve,0.08361204013377926
pdb,0.08361204013377926
terminaldispositionhalflifet12lambdaz,0.08361204013377926
expansionratio,0.08361204013377926
plasmatoperitonealfluidaucratio,0.08361204013377926
t12betaeliminationphase,0.08361204013377926
talpha,0.08361204013377926
maximumbiliaryconcentration,0.08361204013377926
t12betadistribution,0.08361204013377926
t12gammaelimination,0.08361204013377926
troughcsalevel,0.08361204013377926
t12alphaabsorption,0.08361204013377926
kdna,0.08361204013377926
tbeta,0.08361204013377926
concentrationcav,0.08361204013377926
peritonealpeakconcentration,0.08361204013377926
bloodconcentrationat2hpostdosec2,0.08361204013377926
timeofpeaktestosteroneconcentration,0.08361204013377926
peaktestosteroneconcentration,0.08361204013377926
intrinsiccyclosporinclearance,0.08361204013377926
bileelimination,0.08361204013377926
c2hour,0.08361204013377926
maximumleveloftestosteroneconcentration,0.08361204013377926
serumtequivalent,0.08361204013377926
volumeofdistributionofthebetaphase,0.08361204013377926
tl2gamma,0.08361204013377926
peakmitoxantronelevel,0.08361204013377926
wbc,0.08361204013377926
areaundertheplasmadisappearancecurveauc,0.08361204013377926
volumeofdistributionss,0.08361204013377926
plasmaplateauconcentration,0.08361204013377926
kmacro,0.08361204013377926
maximumtoleratedtotaldose,0.08361204013377926
vascularleakage,0.08361204013377926
boundtofreeratio,0.08361204013377926
tumorviability,0.08361204013377926
peakplasmalevelsofvtbcmax,0.08361204013377926
steadystateplasmaotconcentrationcss,0.08361204013377926
braintoperfusate,0.08361204013377926
inductiondeliveryintervalidi,0.08361204013377926
areaunderthebrainconcentrationtimecurveaucbrain,0.08361204013377926
peakatosibanconcentrationcmax,0.08361204013377926
maximalsilodosinconcentrationinplasmacmax,0.08361204013377926
plasmaoxytocin,0.08361204013377926
peakplasmaoxytocinlevel,0.08361204013377926
peakcyclosporineconcentration,0.08361204013377926
syx,0.08361204013377926
cellularaccumulationratio,0.08361204013377926
peakbloodcyclosporineconcentration,0.08361204013377926
accumulationratiooftheauc,0.08361204013377926
dosenormalizedc,0.08361204013377926
firstphasehalflife,0.08361204013377926
troughc0,0.08361204013377926
cumulativerenalelimination,0.08361204013377926
timeproduct,0.08361204013377926
peakplasmamitoxantroneconcentration,0.08361204013377926
ifngamma,0.08361204013377926
tissuehalftime,0.08361204013377926
2hc2,0.08361204013377926
areaunderthecurveofthefirst4hauc04,0.08361204013377926
bloodtolymphclearancerateofcyacllb,0.08361204013377926
initialplasmalevel,0.08361204013377926
peakbloodcsaconcentration,0.08361204013377926
measured,0.08361204013377926
sizeratio,0.08361204013377926
lymphconcentration,0.08361204013377926
plasmatolymphclearancerateof,0.08361204013377926
auc010hratio,0.08361204013377926
troughcyclosporineconcentration,0.08361204013377926
maximumserumtestosterone,0.08361204013377926
peaktroughflu,0.08361204013377926
timerequiredtoreachpeaklevel,0.08361204013377926
areaundertheserumlevelversustimecurve,0.08361204013377926
effectivehalflifeofplasmadecay,0.08361204013377926
equilibriumbloodcellplasmaratio,0.08361204013377926
plasmamagnesiumconcentration,0.08361204013377926
peakfreetestosteroneconcentration,0.08361204013377926
apparentclearanceofdistributionqf,0.08361204013377926
totalamountofradioactivityexcreted,0.08361204013377926
areaunderthecurvefrom012hauc012,0.08361204013377926
geldryingtime,0.08361204013377926
timetosteadystateserumttconcentration,0.08361204013377926
freetestosteroneindexfti,0.08361204013377926
halflifeoftestosteroneeliminationt12,0.08361204013377926
testosteroneconcentrationcave024,0.08361204013377926
peakfshconcentration,0.08361204013377926
oralvolumeofdistributionofthecentral,0.08361204013377926
levelc0,0.08361204013377926
steadystatetconcentration,0.08361204013377926
endogenou,0.08361204013377926
c0c2,0.08361204013377926
brainbloodexposureratio,0.08361204013377926
totaltestosteroneconcentration,0.08361204013377926
areaundertheconcentrationtimecurveduringoraladministrationaucpo,0.08361204013377926
steadystatementconcentration,0.08361204013377926
totalt,0.08361204013377926
oralintercompartmentalclearance,0.08361204013377926
cave024,0.08361204013377926
tdhtratio,0.08361204013377926
troughcyserumlevel,0.08361204013377926
dosenormalizedauc04,0.08361204013377926
peakcyaconcentration,0.08361204013377926
testosteroneconcentrationcavg,0.08361204013377926
ftcavg,0.08361204013377926
auc024vale,0.08361204013377926
set,0.08361204013377926
prehepaticextraction,0.08361204013377926
rateofrelease,0.08361204013377926
volumeofdistributionofcsaatsteadystatevdss,0.08361204013377926
terminaldispositionhalflifeof,0.08361204013377926
areaundertheconcentrationtimecurvefrom0to27hoursauc027,0.08361204013377926
maximumfrequency,0.08361204013377926
peakradioactivity,0.08361204013377926
prehepaticextractionratio,0.08361204013377926
esct,0.08361204013377926
c2concentration,0.08361204013377926
t6,0.08361204013377926
troughtconcentration,0.08361204013377926
effectiveconcentrationc50,0.08361204013377926
maximumcnainhibitionimax,0.08361204013377926
firstcompartmentvolumeofdistributionv1,0.08361204013377926
halfduration,0.08361204013377926
areaunderconcentrationtimecurveauc028,0.08361204013377926
overalldoseadjustedpredoseconcentrationc0dose,0.08361204013377926
overalldoseadjustedconcentrationc2dose,0.08361204013377926
overallc0dose,0.08361204013377926
steadystatetestosteroneconcentration,0.08361204013377926
serumtest,0.08361204013377926
c2dose,0.08361204013377926
unboundcyaconcentration,0.08361204013377926
areaundertheconcentrationtimecurveto12hour,0.08361204013377926
doseat,0.08361204013377926
cmax012h,0.08361204013377926
maximumserumtestosteroneconcentration,0.08361204013377926
skinpermeationrate,0.08361204013377926
bloodtobiledistributionratioskaucbileaucblood,0.08361204013377926
bileblooddistributionratio,0.08361204013377926
dosenormalizedareaunderthebloodconcentrationvstimecurveauc,0.08361204013377926
peakcsaconcentration,0.08361204013377926
radiationdosebed10,0.08361204013377926
parentfraction,0.08361204013377926
areaundertheplasmaleveltimecurveauc0infinity,0.08361204013377926
c0c2ratio,0.08361204013377926
ktransfer,0.08361204013377926
placentalclearanceindex,0.08361204013377926
c2doseratio,0.08361204013377926
clearanceapcl,0.08361204013377926
apcl,0.08361204013377926
transportfraction,0.08361204013377926
radioactivityconcentration,0.08361204013377926
peakclearanceindex,0.08361204013377926
tdelinabsorption,0.08361204013377926
bloodtotalbodyclearance,0.08361204013377926
abomasalbioavailability,0.08361204013377926
feverindex,0.08361204013377926
apparentterminaldispositionrateconstantk,0.08361204013377926
troughcsa,0.08361204013377926
fetaltransferrateftr,0.08361204013377926
apparentkd,0.08361204013377926
tf,0.08361204013377926
fractionabsorbedfabs,0.08361204013377926
apparentcyclosporinbindingcapacitybmax,0.08361204013377926
apparentcyclosporinbindingaffinitykd,0.08361204013377926
t12ofabsorption,0.08361204013377926
t12distribution,0.08361204013377926
livervolume,0.08361204013377926
kco2,0.08361204013377926
ctau,0.08361204013377926
clant,0.08361204013377926
tdoc12,0.08361204013377926
peakalprazolamlevel,0.08361204013377926
c2target,0.08361204013377926
p450level,0.08361204013377926
desaggregationtime,0.08361204013377926
tritiatedwaterspace,0.08361204013377926
fluidexce,0.08361204013377926
clfd,0.08361204013377926
timetomaximalbloodconcentration,0.08361204013377926
bestoverallresponserate,0.08361204013377926
orallybioavailability,0.08361204013377926
drugthroughlevel,0.08361204013377926
areaunderthedrugconcentrationtimecurvefrom0to4haftertreatmentauc04,0.08361204013377926
systemicallyavailable,0.08361204013377926
troughcsalevelc0,0.08361204013377926
minimumtoxicconcentration,0.08361204013377926
intra,0.08361204013377926
aucareaundertheconcentrationbloodcurve,0.08361204013377926
peakplasmafenoldopamlevel,0.08361204013377926
totalbloodclearancecltotal,0.08361204013377926
peakplasmatime,0.08361204013377926
dispositionratealpha,0.08361204013377926
apparentterminalplasmaeliminationratebeta,0.08361204013377926
day15day0ratio,0.08361204013377926
ratioofauc08h,0.08361204013377926
auc049d,0.08361204013377926
plasmabloodconcentrationratio,0.08361204013377926
assaytime,0.08361204013377926
peripheralcompartmentvd,0.08361204013377926
maintenancesteadystatetrough,0.08361204013377926
troughsgc,0.08361204013377926
sgc,0.08361204013377926
softeningtemperature,0.08361204013377926
clearanceassociatedwithmaternalfetaltransferofthedrugcldf,0.08361204013377926
aucimaucivratio,0.08361204013377926
feo,0.08361204013377926
criticalaggregationconcentrationcac,0.08361204013377926
resolutioncoefficient,0.08361204013377926
steadystatevolumesofdistributionvdss,0.08361204013377926
haliclife,0.08361204013377926
extraenergyexpenditure,0.08361204013377926
blood24hourtroughconcentration,0.08361204013377926
intracellulartoplasmaconcentrationratio,0.08361204013377926
minimumconcentrationatsteadystate,0.08361204013377926
influxconstant,0.08361204013377926
initialvolumeofdistributionv0,0.08361204013377926
timetotherelapseofinfection,0.08361204013377926
timeec90,0.08361204013377926
steadystatecy,0.08361204013377926
incorporationefficiencyie,0.08361204013377926
i50,0.08361204013377926
peripheralvolumeofdistributionf,0.08361204013377926
radioactivehalflife,0.08361204013377926
time0toinfinityauc0infinity,0.08361204013377926
timeofmaximumbloodconcentration,0.08361204013377926
dosenormalisedcmax,0.08361204013377926
dosenormalisedauc,0.08361204013377926
fluorescenceintensitie,0.08361204013377926
kic,0.08361204013377926
suvmean,0.08361204013377926
clff,0.08361204013377926
maximumadministereddose,0.08361204013377926
intracellulardistributionrateconstant,0.08361204013377926
clinicalhalflife,0.08361204013377926
totalbodyeliminationrateconstant,0.08361204013377926
areaunderthetimeconcentrationcurveovertheentire12hrdosageintervalauc012,0.08361204013377926
apparentoralcyclosporineclearance,0.08361204013377926
firsteliminationhalflife,0.08361204013377926
timetoachievetargetceruloplasmin,0.08361204013377926
areaundertheconcentrationtimecurveduringthefirst4hoursauc04,0.08361204013377926
aucpl,0.08361204013377926
logk,0.08361204013377926
recommendthroughconcentration,0.08361204013377926
cw,0.08361204013377926
absoluteplasmabioavailabilitie,0.08361204013377926
transitcompartmentrate,0.08361204013377926
ratiosoffluorescence,0.08361204013377926
apparentmeaneliminationhalflife,0.08361204013377926
totalexcretionrecovery,0.08361204013377926
radioact,0.08361204013377926
wallpermeability,0.08361204013377926
ec50thehalfmaximaleffectiveconcentration,0.08361204013377926
spanfactor,0.08361204013377926
serumeliminationhalflifetime,0.08361204013377926
peakserumfluvastatinconcentrationcmax,0.08361204013377926
peakradioactivityconcentrationscmax,0.08361204013377926
bloodtroughc,0.08361204013377926
relativeurinaryrecoverie,0.08361204013377926
doseadjustedtroughcyclosporinebloodconcentration,0.08361204013377926
troughbloodconcentrationstbc,0.08361204013377926
areaunderthebloodconcentrationvstimecurveauc,0.08361204013377926
creq,0.08361204013377926
apparentfirstorderabsorptionrateconstant,0.08361204013377926
apparentcentralcompartmentvolumeofdistributionvff,0.08361204013377926
lungtissuebloodaucratio,0.08361204013377926
aucto24hour,0.08361204013377926
aucof04hoursauc04,0.08361204013377926
aucbrainaucblood,0.08361204013377926
areaunderthecyclosporineconcentrationtimecurve,0.08361204013377926
aucssblood,0.08361204013377926
auctaub,0.08361204013377926
auctaubssratio,0.08361204013377926
linearrejectionrate,0.08361204013377926
rejectionrate,0.08361204013377926
aucachieving50ofthemaximumeffecteauc50,0.08361204013377926
survivalday,0.08361204013377926
llq,0.08361204013377926
100serumequivalentcurve,0.08361204013377926
absolutescbioavailability,0.08361204013377926
apparentbasalvalue,0.08361204013377926
runtimeofanalysi,0.08361204013377926
areaundertheplasmadrugconcentrationcurve,0.08361204013377926
